PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ayvazian, LF				Ayvazian, LF			Endoscopy in its infancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Ayvazian, LF (corresponding author), 3 James Ave, Northampton, MA 01060 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 11	1999	340	10					772	772		10.1056/NEJM199903113401005	http://dx.doi.org/10.1056/NEJM199903113401005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	174KJ	10072412				2022-12-28	WOS:000079034100005
J	Goldbeck-Wood, S; Robinson, R				Goldbeck-Wood, S; Robinson, R			BMJ introduces a fast track system for papers - We will offer to publish exceptional papers within four weeks	BRITISH MEDICAL JOURNAL			English	Editorial Material																		Stearne MR, 1998, BMJ-BRIT MED J, V317, P703	1	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					620	620		10.1136/bmj.318.7184.620	http://dx.doi.org/10.1136/bmj.318.7184.620			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066184	Green Published			2022-12-28	WOS:000079089200005
J	Rosler, M; Anand, R; Cicin-Sain, A; Gauthier, S; Agid, Y; Dal-Bianco, P; Stahelin, HB; Hartman, R; Gharabawi, M				Rosler, M; Anand, R; Cicin-Sain, A; Gauthier, S; Agid, Y; Dal-Bianco, P; Stahelin, HB; Hartman, R; Gharabawi, M		B303 Exelon Study Grp	Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DOUBLE-BLIND; EXELON(TM) ENA-713; TACRINE; MULTICENTER; DETERIORATION; PREDICTORS; DEMENTIA; SCALE	Objectives To assess the effects of rivastigmine on the core domains of Alzheimer's disease. Design Prospective, randomised, multicentre, double blind, placebo controlled, parallel group trial. Patients received either placebo, 1-4 mg/day (lower dose) rivastigmine, or 6-12 mg/day (higher dose) rivastigmine. Doses were increased in one of two fixed dose ranges (1-4 mg/day or 6-12 mg/day) over the first 12 weeks with a subsequent assessment period of 14 weeks. Setting 45 centres in Europe and North America. Participants 725 patients with mild to moderately severe probable Alzheimer's disease diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, and the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association. Outcome measures Cognitive subscale of the Alzheimer's disease assessment scale, rating on the clinician interview based impression of change incorporating caregiver information scale, and the progressive deterioration scale. Results At the end of the study cognitive function had deteriorated among those in the placebo group. Scores on die Alzheimer's disease assessment scale improved in patients in the higher dose group when compared with patients taking placebo (P < 0.05). Significantly more patients in the higher dose group had improved by 4 points or more than had improved in the placebo group (24% (57/242) v 16% (39/238)), Global Function as rated by the clinician interview scale had significantly improved among tl-lose in the higher dose group compared with those taking placebo (P < 0.001), and significantly more patients in the higher dose group showed improvement than did in the placebo group (37% (80/219) v 20% (46/230)). Mean scores on the progressive deterioration scale improved From baseline in patients in the higher dose group but fell in the placebo group. Adverse events were predominantly gastrointestinal, of mild to moderate severity, transient, and occurred mainly during escalation of the dose. 23% (55/242) of those in the higher dose group, 7% (18/242) of those in the lower dose group, and 7% (16/239) of those in the placebo group discontinued treatment because of adverse events. Conclusions Rivastigmine is well tolerated and effective. It improves cognition, participation in activities of daily living, and global evaluation ratings in patients with mild to moderately severe Alzheimer's disease. This is the first treatment to show compelling evidence of efficacy in a predominantly European population.	Univ Wurzburg, Psychiat Klin, Sekt Gerontopsychiat, D-97080 Wurzburg, Germany; Novartis Pharmaceut, CNS Clin Res, E Hanover, NJ 07936 USA; Novartis Pharmaceut, CH-4002 Basel, Switzerland; McGill Ctr Studies Aging, Verdun, PQ H4H 1R3, Canada; Hop La Pitie Salpetriere, Federat Neurol, Dept Neurol, F-75013 Paris, France; Hop La Pitie Salpetriere, INSERM, U289, F-75013 Paris, France; Univ Vienna, Neurol Klin, A-1090 Vienna, Austria; Univ Basel, Kantonsspital, Geriatr Klin, CH-4031 Basel, Switzerland	University of Wurzburg; Novartis; Novartis; McGill University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Vienna; Kantonsspital Aarau AG (KSA); University of Basel	Rosler, M (corresponding author), Univ Wurzburg, Psychiat Klin, Sekt Gerontopsychiat, Fuchsleinstr 15, D-97080 Wurzburg, Germany.	roesler@rzbox.uni-wuerzburg.de						American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Anand R, 1996, J DRUG DEV CLIN PR, V8, P117; Anand R, 1996, J DRUG DEV CLIN PR, V8, P109; ANTUONO PG, 1995, ARCH INTERN MED, V155, P1766, DOI 10.1001/archinte.155.16.1766; COREYBLOOM J, 1998, INT J GERIATR PSYCHO, V1, P55; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; DEJONG R, 1989, CLIN THER, V11, P545; Enz A, 1996, ALZHEIMERS DIS MOL B, P211; FARLOW M, 1992, JAMA-J AM MED ASSOC, V268, P2523, DOI 10.1001/jama.268.18.2523; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; *FOOD DRUG COSM RE, 1992, FDA GUID ALZ DRUG DI, P13; KNAPP MJ, 1994, JAMA-J AM MED ASSOC, V271, P985, DOI 10.1001/jama.271.13.985; MCDOWELL I, 1994, CAN J AGING, V13, P470; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MITTELMAN MS, 1993, GERONTOLOGIST, V33, P730, DOI 10.1093/geront/33.6.730; Reisberg B, 1997, ALZ DIS ASSOC DIS, V11, P8; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; RITER RN, 1992, GERONTOLOGIST, V32, P184, DOI 10.1093/geront/32.2.184; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Rogers SL, 1996, DEMENTIA, V7, P293, DOI 10.1159/000106895; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Solomon PR, 1996, LANCET, V348, P275, DOI 10.1016/S0140-6736(05)65594-8; Sramek JJ, 1996, LIFE SCI, V58, P1201, DOI 10.1016/0024-3205(96)00081-1; STERN RG, 1994, AM J PSYCHIAT, V151, P390; Thal LJ, 1996, NEUROLOGY, V47, P705, DOI 10.1212/WNL.47.3.705	25	748	770	0	60	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 6	1999	318	7184					633	638		10.1136/bmj.318.7184.633	http://dx.doi.org/10.1136/bmj.318.7184.633			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066203	Green Submitted, Green Published, Green Accepted, Bronze			2022-12-28	WOS:000079089200025
J	Wallace, DC				Wallace, DC			Mitochondrial diseases in man and mouse	SCIENCE			English	Review							HEREDITARY OPTIC NEUROPATHY; KEARNS-SAYRE SYNDROME; CYTOCHROME-C-OXIDASE; DNA DELETION LEVELS; SUPEROXIDE-DISMUTASE; SKELETAL-MUSCLE; POINT MUTATION; HUMAN BRAIN; NUCLEOTIDE PAIR-14459; ALZHEIMER-DISEASE	Over the past 10 years, mitochondrial defects have been implicated in a wide variety of degenerative diseases, aging, and cancer. Studies on patients with these diseases have revealed much about the complexities of mitochondrial genetics, which involves an interplay between mutations in the mitochondrial and nuclear genomes. However, the pathophysiology of mitochondrial diseases has remained perplexing. The essential role of mitochondrial oxidative phosphorylation in cellular energy production, the generation of reactive oxygen species, and the initiation of apoptosis has suggested a number of novel mechanisms for mitochondrial pathology. The importance and interrelationship of these functions are now being studied in mouse models of mitochondrial disease.	Emory Univ, Ctr Mol Med, Atlanta, GA 30322 USA	Emory University	Wallace, DC (corresponding author), Emory Univ, Ctr Mol Med, 1462 Clifton Rd,Suite 420, Atlanta, GA 30322 USA.	dwallace@gmm.gen.emory.edu			NHLBI NIH HHS [HL45572] Funding Source: Medline; NIA NIH HHS [AG13154] Funding Source: Medline; NINDS NIH HHS [NS21328] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013154] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BALLINGER SW, 1994, NAT GENET, V7, P458, DOI 10.1038/ng0894-458; BLANC H, 1981, P NATL ACAD SCI-BIOL, V78, P3789, DOI 10.1073/pnas.78.6.3789; BODNAR AG, 1993, AM J HUM GENET, V53, P663; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; BUNN CL, 1974, P NATL ACAD SCI USA, V71, P1681, DOI 10.1073/pnas.71.5.1681; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CORRALDEBRINSKI M, 1992, MUTAT RES, V275, P169, DOI 10.1016/0921-8734(92)90021-G; CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; DAS DK, 1989, BIOCHEM BIOPH RES CO, V165, P1004, DOI 10.1016/0006-291X(89)92702-2; DiMauro S, 1997, MOL GENETIC BASIS NE, P201; Earnshaw WC, 1999, NATURE, V397, P387, DOI 10.1038/17015; ESPOSITO L, IN PRESS P NATL ACAD; GERBITZ KD, 1995, BBA-MOL BASIS DIS, V1271, P253, DOI 10.1016/0925-4439(95)00036-4; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; GOTO Y, 1995, MUSCLE NERVE, pS107; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Habano W, 1998, ONCOGENE, V17, P1931, DOI 10.1038/sj.onc.1202112; HEDDI A, 1994, BBA-MOL BASIS DIS, V1226, P206, DOI 10.1016/0925-4439(94)90030-2; HEDDI A, 1993, J BIOL CHEM, V268, P12156; Hirano M, 1997, P NATL ACAD SCI USA, V94, P14894, DOI 10.1073/pnas.94.26.14894; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; HOLT IJ, 1990, AM J HUM GENET, V46, P428; HORTON TM, 1995, NEUROLOGY, V45, P1879, DOI 10.1212/WNL.45.10.1879; Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z; HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892; Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93; Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146; Jun AS, 1996, MOL CELL BIOL, V16, P771; JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LEVY S, IN PRESS TRANSGENIC; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154; LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637; MASUCCI JP, 1995, MOL CELL BIOL, V15, P2872; MATTHEWS PM, 1993, ANN NEUROL, V33, P652, DOI 10.1002/ana.410330616; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; Meirelles FV, 1998, GENETICS, V148, P877; Meirelles FV, 1997, GENETICS, V145, P445; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; Melov S, 1997, NUCLEIC ACIDS RES, V25, P974, DOI 10.1093/nar/25.5.974; MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; MITA S, 1989, P NATL ACAD SCI USA, V86, P9509, DOI 10.1073/pnas.86.23.9509; MORAES CT, 1991, AM J HUM GENET, V48, P492; MULLERHOCKER J, 1992, MUTAT RES, V275, P115, DOI 10.1016/0921-8734(92)90016-I; MURDOCK D, IN PRESS J BIOL CHEM; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; NOVOTNY EJ, 1986, NEUROLOGY, V36, P1053, DOI 10.1212/WNL.36.8.1053; OHKOSHI N, 1995, MUSCLE NERVE, V18, P1265, DOI 10.1002/mus.880181108; ORTIZ RG, 1993, ARCH OPHTHALMOL-CHIC, V111, P1525, DOI 10.1001/archopht.1993.01090110091031; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; Pinkert CA, 1997, TRANSGENIC RES, V6, P379, DOI 10.1023/A:1018431316831; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; ROTIG A, 1989, LANCET, V1, P902; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; SHOFFNER JM, 1995, ANN NEUROL, V38, P163, DOI 10.1002/ana.410380207; SHOFFNER JM, 1992, NEUROLOGY, V42, P2168, DOI 10.1212/WNL.42.11.2168; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299; SHOFFNER JM, 1995, METABOLIC MOL BASES, P1535; SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A; SOONG NW, 1992, NAT GENET, V2, P318; SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TATUCH Y, 1992, AM J HUM GENET, V50, P852; Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150; TROUNCE I, 1994, P NATL ACAD SCI USA, V91, P8334, DOI 10.1073/pnas.91.18.8334; TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716; WALLACE DC, 1982, MICROBIOL REV, V46, P208, DOI 10.1128/MMBR.46.2.208-240.1982; WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8; Wallace DC, 1997, P NATL ACAD SCI USA, V94, P14900, DOI 10.1073/pnas.94.26.14900; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; WALLACE DC, 1975, J CELL BIOL, V67, P174, DOI 10.1083/jcb.67.1.174; WALLACE DC, 1996, EMERY RIMOINS PRINCI, V1, P277; WALLACE DC, 1997, MOL GENETIC BASIS NE, P237; WALLACE DC, 1982, TECHNIQUES SOMATIC C, V12, P159; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089; WATANABE T, 1978, P NATL ACAD SCI USA, V75, P5113, DOI 10.1073/pnas.75.10.5113; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510; ZEVIANI M, 1995, BBA-MOL BASIS DIS, V1271, P153, DOI 10.1016/0925-4439(95)00022-V; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	101	2396	2523	8	323	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 5	1999	283	5407					1482	1488		10.1126/science.283.5407.1482	http://dx.doi.org/10.1126/science.283.5407.1482			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066162	Green Submitted			2022-12-28	WOS:000078959200034
J	Grimbacher, B; Holland, SM; Gallin, JI; Greenberg, F; Hill, SC; Malech, HL; Miller, JA; O'Connell, AC; Puck, JM				Grimbacher, B; Holland, SM; Gallin, JI; Greenberg, F; Hill, SC; Malech, HL; Miller, JA; O'Connell, AC; Puck, JM			Hyper-IgE syndrome with recurrent infections - An autosomal dominant multisystem disorder	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPERIMMUNOGLOBULINEMIA-E SYNDROME; INTERFERON-GAMMA PRODUCTION; JOBS SYNDROME; CLEIDOCRANIAL DYSPLASIA; T-CELLS; INTERLEUKIN-4; ASSOCIATION; DEFICIENCY; LYMPHOMA; OSTEOPOROSIS	Background The hyper-IgE syndrome with recurrent infections is a rare immunodeficiency characterized by recurrent skin and pulmonary abscesses and extremely elevated levels of IgE in serum. Associated facial and skeletal features have been recognized, but their frequency is unknown, and the genetic basis of the hyper-IgE syndrome is poorly understood. Methods We studied 30 patients with the hyper-IgE syndrome and 70 of their relatives. We took histories, reviewed records, performed physical and dental examinations, took anthropometric measurements, and conducted laboratory studies. Results Nonimmunologic features of the hyper-IgE syndrome were present in all patients older than eight years. Seventy-two percent had the previously unrecognized feature of failure or delay of shedding of the primary teeth owing to lack of root resorption. Common findings among patients were recurrent fractures (in 57 percent of patients), hyperextensible joints (in 68 percent), and scoliosis tin 76 percent of patients 16 years of age or older). The classic triad of abscesses, pneumonia, and an elevated IgE level was identified in 77 percent of all patients and in 85 percent of those older than eight. In 6 of 23 adults (26 percent), IgE levels declined over time and came closer to or fell within the normal range. Autosomal dominant transmission of the hyper-IgE syndrome was found, but with variable expressivity. Of the 27 relatives at risk for inheriting the hyper-IgE syndrome, 10 were fully affected, 11 were unaffected, and 6 had combinations of mild immunologic, dental, and skeletal features of the hyper-IgE syndrome. Conclusions The hyper-IgE syndrome is a multisystem disorder that affects the dentition, the skeleton, connective tissue, and the immune system. It is inherited as a single-locus autosomal dominant trait with variable expressivity. (N Engl J Med 1999;340:692-702.) (C) 1999, Massachusetts Medical Society.	NIH, Natl Human Genome Res Inst, Genet & Mol Biol Branch, Immunol Genet Sect, Bethesda, MD 20892 USA; NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; NIH, Warren Grant Magnuson Clin Ctr, Dept Radiol, Bethesda, MD 20892 USA; NIDCR, NIH, Bethesda, MD 20892 USA; NIH, Natl Human Genome Res Inst, Genet Dis Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Puck, JM (corresponding author), NIH, Natl Human Genome Res Inst, Genet & Mol Biol Branch, Immunol Genet Sect, Bldg 49,Rm 3A14,40 Convent Dr, Bethesda, MD 20892 USA.	jpuck@nhgri.nih.gov		O'Connell, Anne C/0000-0002-1495-3983; Malech, Harry/0000-0001-5874-5775	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000644, Z01AI000646, ZIAAI000644, ZIAAI000646] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDRICH MP, 1993, CLIN NUCL MED, V18, P153, DOI 10.1097/00003072-199302000-00017; BALE JF, 1977, CANCER, V39, P2386, DOI 10.1002/1097-0142(197706)39:6<2386::AID-CNCR2820390612>3.0.CO;2-X; BANNATYNE RM, 1969, J PEDIATR-US, V75, P236, DOI 10.1016/S0022-3476(69)80394-X; Belohradsky B H, 1987, Ergeb Inn Med Kinderheilkd, V55, P1; BLUM R, 1977, J PEDIATR-US, V90, P607, DOI 10.1016/S0022-3476(77)80380-6; Borges WG, 1998, J PEDIATR-US, V133, P303, DOI 10.1016/S0022-3476(98)70243-4; BRESTEL EP, 1982, AM J DIS CHILD, V136, P774, DOI 10.1001/archpedi.1982.03970450016003; BUCKLEY R H, 1991, Journal of Allergy and Clinical Immunology, V87, P313, DOI 10.1016/0091-6749(91)91978-3; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; BUCKLEY RH, 1981, CLIN IMMUNOLOGY UPDA, P147; BUNCH WH, 1989, SCOLIOSIS MAKING CLI, P44; CLAASSEN JJ, 1991, J ALLERGY CLIN IMMUN, V88, P713, DOI 10.1016/0091-6749(91)90177-P; Cohen M M Jr, 1988, Am J Med Genet Suppl, V4, P99; DAUMLING S, 1980, INFECTION, V8, P248; DAVIS SD, 1966, LANCET, V1, P1013; DEMIRJIAN A, 1973, HUM BIOL, V45, P211; DONABEDIAN H, 1983, MEDICINE, V62, P195, DOI 10.1097/00005792-198307000-00001; DRESKIN SC, 1987, J CLIN INVEST, V79, P1764, DOI 10.1172/JCI113017; DRESKIN SC, 1985, J CLIN INVEST, V75, P26, DOI 10.1172/JCI111683; DRESKIN SC, 1987, J ALLERGY CLIN IMMUN, V80, P746, DOI 10.1016/0091-6749(87)90297-1; DRESKIN SC, 1987, J ALLERGY CLIN IMMUN, V79, P515, DOI 10.1016/0091-6749(87)90370-8; Driscoll DA, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P198; EINSELE H, 1990, DEUT MED WOCHENSCHR, V115, P1141, DOI 10.1055/s-2008-1065133; FARKAS LG, 1994, ANTHROPOMETRY HEAD F, P242; GAHR M, 1987, MONATSSCHR KINDERH, V135, P329; GAHR M, 1987, HELV PAEDIATR ACTA, V42, P185; Geha R S, 1989, Immunodefic Rev, V1, P155; GEHA RS, 1981, J CLIN INVEST, V68, P783, DOI 10.1172/JCI110315; GORIN LJ, 1989, J ALLERGY CLIN IMMUN, V83, P5, DOI 10.1016/0091-6749(89)90471-5; Gottlieb S, 1997, AM J HUM GENET, V60, P1194; Grimbacher B, 1998, NEW ENGL J MED, V338, P1073; HALL RA, 1995, ANN THORAC SURG, V59, P759, DOI 10.1016/0003-4975(94)00730-6; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; HILL HR, 1974, LANCET, V2, P617; HILL HR, 1974, LANCET, V1, P183; HOCHREUTENER H, 1991, DERMATOLOGICA, V182, P7, DOI 10.1159/000247728; HOGER PH, 1985, EUR J PEDIATR, V144, P414, DOI 10.1007/BF00441793; HOLLAND SM, 1998, HARRISONS PRINCIPLES, V1, P351; HURME V O, 1949, J Dent Child, V16, P11; JACOBS DH, 1984, GASTROENTEROLOGY, V87, P201; JENSEN BL, 1990, J ORAL PATHOL MED, V19, P89, DOI 10.1111/j.1600-0714.1990.tb00803.x; KIMATA H, 1995, J ALLERGY CLIN IMMUN, V95, P771, DOI 10.1016/S0091-6749(95)70185-0; KING CL, 1989, P NATL ACAD SCI USA, V86, P10085, DOI 10.1073/pnas.86.24.10085; KIRCHNER SG, 1985, RADIOLOGY, V156, P362, DOI 10.1148/radiology.156.2.4011897; LALLEMAND D, 1979, ANN RADIOL, V22, P108; LEUNG DYM, 1988, J IMMUNOL, V140, P84; LEWIS DB, 1993, P NATL ACAD SCI USA, V90, P11618, DOI 10.1073/pnas.90.24.11618; McKusick V.A., 1998, MENDELIAN INHERITANC; MERTEN DF, 1979, RADIOLOGY, V132, P71, DOI 10.1148/132.1.71; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; OHTSUKA Y, 1988, SPINE, V13, P1251, DOI 10.1097/00007632-198811000-00008; PAGANELLI R, 1991, CLIN EXP IMMUNOL, V84, P28; ROUSSET F, 1991, J ALLERGY CLIN IMMUN, V87, P58, DOI 10.1016/0091-6749(91)90213-8; SCHOPFER K, 1983, BRIT MED J, V287, P524, DOI 10.1136/bmj.287.6391.524; SMITHWICK EM, 1978, LANCET, V1, P826; Soucacos PN, 1997, J BONE JOINT SURG AM, V79A, P1498, DOI 10.2106/00004623-199710000-00006; STIEHM ER, 1996, IMMUNOLOGIC DISORDER, P413; VANEPPS DE, 1983, CLIN EXP IMMUNOL, V53, P678; VANSCOY RE, 1975, ANN INTERN MED, V82, P766, DOI 10.7326/0003-4819-82-6-766; VERCELLI D, 1990, J CLIN INVEST, V85, P1666, DOI 10.1172/JCI114618; WRIGHT BA, 1978, ORAL SURG ORAL MED O, V46, P806, DOI 10.1016/0030-4220(78)90312-2	62	510	536	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1999	340	9					692	702		10.1056/NEJM199903043400904	http://dx.doi.org/10.1056/NEJM199903043400904			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172ZB	10053178	Bronze			2022-12-28	WOS:000078955200004
J	Bauer, IS				Bauer, IS			Star treatment	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Bauer, IS (corresponding author), 82 W 12th St, New York, NY 10011 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	1999	130	5					447	449		10.7326/0003-4819-130-5-199903020-00019	http://dx.doi.org/10.7326/0003-4819-130-5-199903020-00019			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172AA	10068423				2022-12-28	WOS:000078898100012
J	West, KP; Katz, J; Khatry, SK; LeClerq, SC; Pradhan, EK; Shrestha, SR; Conner, PB; Dali, SR; Christian, P; Pokhrel, RP; Sommer, A				West, KP; Katz, J; Khatry, SK; LeClerq, SC; Pradhan, EK; Shrestha, SR; Conner, PB; Dali, SR; Christian, P; Pokhrel, RP; Sommer, A		NNIPS-2 Study Grp	Double blind, cluster randomised trial of low dose supplementation with vitamin A or beta carotene on mortality related to pregnancy in Nepal	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LIPID-PEROXIDATION; ANTIOXIDANT	Objective To assess the impact on mortality related to pregnancy of supplementing women of reproductive age each. week with a recommended dietary allowance of vitamin A, either preformed or as beta carotene, Design Double blind, cluster randomised, placebo controlled field trial Setting Rural southeast central plains of Nepal (Sarlahi district). Subjects 44 646 married women, of whom 20 119 became pregnant 22 189 times. Intervention 270 wards randomised to 3 groups of 90 each for women to receive weekly a single oral supplement of placebo, vitamin A (7000 mu g retinol equivalents) or beta carotene (42 mg, or 7000 mu g retinol equivalents) for over 3 1/3 years. Main outcome measures All cause mortality in women during pregnancy up to 12 weeks post partum (pregnancy related mortality) and mortality during pregnancy to 6 weeks postpartum, excluding deaths apparently related to injury (maternal mortality). Results, Mortality related to pregnancy in the placebo, vitamin A, and beta carotene groups was 704, 426, and 361 deaths per 100 000 pregnancies, yielding relative risks (95% confidence intervals) of 0.60 (0.37 to 0.97) and 0.51 (0.30 to 0.86). This represented reductions of 40% (P < 0.04) and 49% (P < 0.01) among those who received vitamin A and 6 carotene. Combined, vitamin A or beta carotene lowered mortality by 44% (0.56 (0.37 to 0.84), P < 0.005) and reduced the maternal mortality ratio from 645 to 385 deaths per 100 000 live births, or by 40% (P < 0.02). Differences in cause of death could not be reliably distinguished between supplemented and placebo groups. Conclusion Supplementation of women with either vitamin A or beta carotene at recommended dietary amounts during childbearing years can lower mortality related to pregnancy in rural, undernourished populations of south Asia.	Johns Hopkins Sch Hyg & Publ Hlth, Div Human Nutr, Baltimore, MD 21205 USA; Nepal Netra Jyoti Sangh, NNIPS, Kathmandu, Nepal	Johns Hopkins University	West, KP (corresponding author), Johns Hopkins Sch Hyg & Publ Hlth, Div Human Nutr, Room 2041,615 N Wolfe St, Baltimore, MD 21205 USA.	kwest@jhsph.edu		Katz, Joanne/0000-0002-5997-7823				ALLARD JP, 1994, AM J CLIN NUTR, V59, P884, DOI 10.1093/ajcn/59.4.884; Anker M, 1997, INT J EPIDEMIOL, V26, P1090, DOI 10.1093/ije/26.5.1090; BASU R J S, 1973, Indian Journal of Medical Research, V61, P589; Beard JL, 1998, AM J CLIN NUTR, V68, P209, DOI 10.1093/ajcn/68.2.209; BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156; Christian P, 1998, J NUTR, V128, P1458, DOI 10.1093/jn/128.9.1458; Christian P, 1998, AM J CLIN NUTR, V67, P1237, DOI 10.1093/ajcn/67.6.1237; Christian P, 1998, INT J EPIDEMIOL, V27, P231, DOI 10.1093/ije/27.2.231; Crabtree DV, 1997, MED HYPOTHESES, V48, P183, DOI 10.1016/S0306-9877(97)90286-3; DAVIDGE ST, 1992, OBSTET GYNECOL, V79, P897; Dimenstein R, 1996, BIOL NEONATE, V69, P230, DOI 10.1159/000244315; Fawzi WW, 1998, LANCET, V351, P1477, DOI 10.1016/S0140-6736(98)04197-X; Green HN, 1931, BMJ-BRIT MED J, V1931, P595, DOI 10.1136/bmj.2.3691.595; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; HUBEL CA, 1989, AM J OBSTET GYNECOL, V161, P1025, DOI 10.1016/0002-9378(89)90778-3; Jayasekera J P, 1991, Asia Oceania J Obstet Gynaecol, V17, P217; Kahn HA, 1989, STAT METHODS EPIDEMI; KATZ J, 1988, INT J EPIDEMIOL, V17, P865, DOI 10.1093/ije/17.4.865; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; MORSE EH, 1975, AM J CLIN NUTR, V28, P1000, DOI 10.1093/ajcn/28.9.1000; MUHILAL, 1988, AM J CLIN NUTR, V48, P1271, DOI 10.1093/ajcn/48.5.1271; *NAT RES COUNC, 1989, REC DIET ALL, P78; PANTH M, 1990, BRIT J NUTR, V64, P351, DOI 10.1079/BJN19900037; Ronsmans C, 1998, INT J EPIDEMIOL, V27, P660, DOI 10.1093/ije/27.4.660; SEMBA RD, 1994, CLIN INFECT DIS, V19, P489, DOI 10.1093/clinids/19.3.489; SHAH RS, 1987, BRIT J NUTR, V58, P181, DOI 10.1079/BJN19870085; SHARMA SC, 1986, INT J VITAM NUTR RES, V56, P3; Sivakumar B, 1997, INT J VITAM NUTR RES, V67, P232; Sommer A., 1996, VITAMIN A DEFICIENCY, P19; Tee ES, 1998, NUTR REV, V56, pS10; UNDERWOOD BA, 1994, AM J CLIN NUTR, V59, p517S, DOI 10.1093/ajcn/59.2.517S; WEST KP, 1997, MATERNAL NIGHT BLIND; Ziari SA, 1996, AM J PERINAT, V13, P287, DOI 10.1055/s-2007-994343	33	333	336	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 27	1999	318	7183					570	575		10.1136/bmj.318.7183.570	http://dx.doi.org/10.1136/bmj.318.7183.570			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037634	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000078966300029
J	Hanssen, RF; Weckwerth, TM; Zebker, HA; Klees, R				Hanssen, RF; Weckwerth, TM; Zebker, HA; Klees, R			High-resolution water vapor mapping from interferometric radar measurements	SCIENCE			English	Article							SYNTHETIC-APERTURE RADAR; GLOBAL POSITIONING SYSTEM; PLANETARY BOUNDARY-LAYER; EARTHS ATMOSPHERE; TOPOGRAPHIC MAPS; INTERFEROGRAMS	Spaceborne radar interferometric delay measurements were used to infer high-resolution maps of integrated atmospheric water vapor, which can be readily related to meteorological phenomena. Maps of the water vapor distribution associated with a precipitating cloud, a partly precipitating cold front, and horizontal convective rolls reveal quantitative measures that are not observed with conventional methods, and suggest that such radar observations can be used for forecasting and to study atmospheric dynamics.	Delft Univ Technol, Delft Inst Earth Oriented Space Res, NL-2629 JA Delft, Netherlands; Natl Ctr Atmospher Res, Boulder, CO 80307 USA; Stanford Univ, Dept Geophys, Stanford, CA 94305 USA; Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA	Delft University of Technology; National Center Atmospheric Research (NCAR) - USA; Stanford University; Stanford University	Hanssen, RF (corresponding author), Delft Univ Technol, Delft Inst Earth Oriented Space Res, Thijsseweg 11, NL-2629 JA Delft, Netherlands.	hanssen@geo.tudelft.nl	Hanssen, Ramon/M-7662-2013; Hanssen, Ramon/O-8118-2019; Klees, Roland/I-3574-2013	Hanssen, Ramon/0000-0002-6067-7561; Klees, Roland/0000-0002-0670-2607; zebker, howard/0000-0001-9931-5237				BEVIS M, 1992, J GEOPHYS RES-ATMOS, V97, P15787, DOI 10.1029/92JD01517; BROWN RA, 1980, REV GEOPHYS, V18, P683, DOI 10.1029/RG018i003p00683; Crook NA, 1996, MON WEATHER REV, V124, P1767, DOI 10.1175/1520-0493(1996)124<1767:SOMCFB>2.0.CO;2; ELGERED GK, 1982, IEEE T ANTENN PROPAG, V30, P502, DOI 10.1109/TAP.1982.1142808; EMANUEL K, 1995, B AM METEOROL SOC, V76, P1194; GABRIEL AK, 1988, INT J REMOTE SENS, V9, P857, DOI 10.1080/01431168808954901; GABRIEL AK, 1989, J GEOPHYS RES-SOLID, V94, P9183, DOI 10.1029/JB094iB07p09183; GOLDSTEIN R, 1995, GEOPHYS RES LETT, V22, P2517, DOI 10.1029/95GL02475; Hanssen R. F., 1998, ATMOSPHERIC HETEROGE; JUST D, 1994, APPL OPTICS, V33, P4361, DOI 10.1364/AO.33.004361; KUETTNER JP, 1971, TELLUS, V23, P404, DOI 10.1111/j.2153-3490.1971.tb00585.x; Kursinski ER, 1997, J GEOPHYS RES-ATMOS, V102, P23429, DOI 10.1029/97JD01569; LEMONE MA, 1973, J ATMOS SCI, V30, P1077, DOI 10.1175/1520-0469(1973)030<1077:TSADOH>2.0.CO;2; LEMONE MA, 1976, MON WEATHER REV, V104, P524, DOI 10.1175/1520-0493(1976)104<0524:TROTWC>2.0.CO;2; MASSONNET D, 1995, GEOPHYS RES LETT, V22, P1537, DOI 10.1029/95GL00711; MASSONNET D, 1993, NATURE, V364, P138, DOI 10.1038/364138a0; MUELLER CK, 1993, WEATHER FORECAST, V8, P132, DOI 10.1175/1520-0434(1993)008<0132:TUOSAM>2.0.CO;2; PARSONS DB, 1992, J ATMOS SCI, V49, P1810, DOI 10.1175/1520-0469(1992)049<1810:AEFIFU>2.0.CO;2; RIND D, 1991, NATURE, V349, P500, DOI 10.1038/349500a0; Saastamoinen, 1973, B GEOD, V106, P383, DOI [10.1007/BF02522083, DOI 10.1007/BF02522083]; Simpson J. E., 1994, SEA BREEZE LOCAL WIN; Tarayre H, 1996, GEOPHYS RES LETT, V23, P989, DOI 10.1029/96GL00622; Weckwerth TM, 1996, MON WEATHER REV, V124, P769, DOI 10.1175/1520-0493(1996)124<0769:TVWTCB>2.0.CO;2; ZEBKER HA, 1986, J GEOPHYS RES-SOLID, V91, P4993, DOI 10.1029/JB091iB05p04993; Zebker HA, 1997, J GEOPHYS RES-SOL EA, V102, P7547, DOI 10.1029/96JB03804; ZEBKER HA, 1994, IEEE T GEOSCI REMOTE, V32, P823, DOI 10.1109/36.298010; ZEBKER HA, 1992, IEEE T GEOSCI REMOTE, V30, P950, DOI 10.1109/36.175330	28	132	143	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 26	1999	283	5406					1297	1299		10.1126/science.283.5406.1297	http://dx.doi.org/10.1126/science.283.5406.1297			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037594				2022-12-28	WOS:000078839900033
J	Yuan, LL; Ganetzky, B				Yuan, LL; Ganetzky, B			A glial-neuronal signaling pathway revealed by mutations in a neurexin-related protein	SCIENCE			English	Article							DROSOPHILA; CELLS; CHANNELS; LOCUS; INHIBITOR; PEPTIDE; SWITCH; GENES	In the nervous system, glial cells greatly outnumber neurons but the full extent of their role in determining neural activity remains unknown. Here the axotactin (axo) gene of Drosophila was shown to encode a member of the neurexin protein superfamily secreted by glia and subsequently localized to axonal tracts, Null mutations of axo caused temperature-sensitive paralysis and a corresponding blockade of axonal conduction. Thus, the AXO protein appears to be a component of a glial-neuronal signaling mechanism that helps to determine the membrane electrical properties of target axons.	Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ganetzky, B (corresponding author), Univ Wisconsin, Neurosci Training Program, 445 Henry Mall, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015390] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43100] Funding Source: Medline; NINDS NIH HHS [NS15390] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHBURNER M, 1989, DROSOPHILA LAB HDB, P207; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BARRES BA, 1991, J NEUROSCI, V11, P3685; Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; Bellen HJ, 1998, TRENDS NEUROSCI, V21, P444, DOI 10.1016/S0166-2236(98)01267-3; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; Einheber S, 1997, J CELL BIOL, V139, P1495, DOI 10.1083/jcb.139.6.1495; FENG GP, 1995, CELL, V82, P1001, DOI 10.1016/0092-8674(95)90279-1; GHO M, 1992, SCIENCE, V258, P313, DOI 10.1126/science.1384131; Goodman Corey S., 1993, P1131; HONG CS, 1994, J NEUROSCI, V14, P5160; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; ITO K, 1995, ROUX ARCH DEV BIOL, V204, P284, DOI 10.1007/BF02179499; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; Kaplan MR, 1997, NATURE, V386, P724, DOI 10.1038/386724a0; KERNAN MJ, 1991, CELL, V66, P949, DOI 10.1016/0092-8674(91)90440-A; Kunitz M, 1936, J GEN PHYSIOL, V19, P991, DOI 10.1085/jgp.19.6.991; LITTLETON JT, 1997, J CELL BIOL, V137; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; LUCCHESI KJ, 1991, J GEN PHYSIOL, V97, P1295, DOI 10.1085/jgp.97.6.1295; Menegoz M, 1997, NEURON, V19, P319, DOI 10.1016/S0896-6273(00)80942-3; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; ORDWAY RW, 1994, P NATL ACAD SCI USA, V91, P5715, DOI 10.1073/pnas.91.12.5715; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684; SCHWEITZ H, 1994, P NATL ACAD SCI USA, V91, P878, DOI 10.1073/pnas.91.3.878; Titus SA, 1997, J NEUROSCI, V17, P875; Wang XJ, 1997, J NEUROSCI, V17, P882; WU CF, 1978, P NATL ACAD SCI USA, V75, P4047, DOI 10.1073/pnas.75.8.4047; WU RL, 1994, J NEUROSCI, V14, P1677, DOI 10.1523/JNEUROSCI.14-03-01677.1994	30	53	54	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1343	1345		10.1126/science.283.5406.1343	http://dx.doi.org/10.1126/science.283.5406.1343			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037607				2022-12-28	WOS:000078839900046
J	Katayama, I; Kayano, H				Katayama, I; Kayano, H			Yolk sac with blood island	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Saitama Med Sch, Moroyama, Saitama 35004, Japan	Saitama Medical University	Katayama, I (corresponding author), Saitama Med Sch, Moroyama, Saitama 35004, Japan.								0	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1999	340	8					617	617		10.1056/NEJM199902253400805	http://dx.doi.org/10.1056/NEJM199902253400805			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	169NP	10029646				2022-12-28	WOS:000078755700005
J	Gaede, P; Vedel, P; Parving, HH; Pedersen, O				Gaede, P; Vedel, P; Parving, HH; Pedersen, O			Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study	LANCET			English	Article							BLOOD-GLUCOSE CONTROL; MICROVASCULAR COMPLICATIONS; METABOLIC CONTROL; INSULIN-TREATMENT; GLYCEMIC CONTROL; RETINOPATHY; PROGRESSION; NEPHROPATHY; MORTALITY; PROTEINURIA	Background In type 2 diabetes mellitus the aetiology of long-term complications is multifactorial, We carried out a randomised trial of stepwise intensive treatment or standard treatment of risk factors in patients with microalbuminuria. Methods In this open, parallel trial patients were allocated standard treatment (n=80) or intensive treatment (n=80). Standard treatment followed Danish guidelines. Intensive treatment was a stepwise implementation of behaviour modification, pharmacological therapy targeting hyperglycaemia, hypertension, dyslipidaemia, and microalbuminuria. The primary endpoint was the development of nephropathy (median albumin excretion rate >300 mg per 24 h in at least one of the two-yearly examinations). Secondary endpoints were the incidence or progression of diabetic retinopathy and neuropathy. Findings The mean age was 55.1 years (SD 7.2) and patients were followed up for 3.8 years (0.3). Patients in the intensive group had significantly lower rates of progression to nephropathy (odds ratio 0.27 [95% CI 0.10-0.75]), progression of retinopathy (0.45 [0.21-0.95]), and progression of autonomic neuropathy (0.32 [0.12-0.78]) than those in the standard group. Interpretation Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria slows progression to nephropathy, and progression of retinopathy and autonomic neuropathy, However, further studies are needed to establish the effect of intensified multifactorial treatment on macrovascular complications and mortality.	Steno Diabet Ctr, DK-2820 Gentofte, Denmark	Steno Diabetes Center	Pedersen, O (corresponding author), Steno Diabet Ctr, Niels Steensens Vej 2, DK-2820 Gentofte, Denmark.		Pedersen, Oluf/AAG-8015-2020	Gaede, Peter/0000-0002-1457-2742				ABRAIRA C, 1995, DIABETES CARE, V18, P1113, DOI 10.2337/diacare.18.8.1113; ALDINGTON SJ, 1995, DIABETOLOGIA, V38, P437, DOI 10.1007/BF00410281; BANGSTAD HJ, 1994, DIABETOLOGIA, V37, P483, DOI 10.1007/s001250050136; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; BLOOM S, 1984, BRIT MED J, V288, P1793, DOI 10.1136/bmj.288.6433.1793; Boner G, 1996, DIABETOLOGIA, V39, P587; Chaturvedi N, 1998, LANCET, V351, P28, DOI 10.1016/S0140-6736(97)06209-0; CLOSE CF, 1995, BMJ-BRIT MED J, V311, P973; DAHLJORGENSEN K, 1985, BRIT MED J, V290, P811, DOI 10.1136/bmj.290.6471.811; *DANSK SELSK INT M, 1988, IKK INS DIAB MELL; Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FELDTRASMUSSEN B, 1991, DIABETOLOGIA, V34, P164, DOI 10.1007/BF00418270; FRIER BM, 1977, DIABETES, V26, P369; GALL MA, 1995, DIABETES, V44, P1303, DOI 10.2337/diabetes.44.11.1303; HANSEN HP, 1995, KIDNEY INT, V47, P1726, DOI 10.1038/ki.1995.238; HILSTED J, 1982, DIABETES, V31, P730, DOI 10.2337/diab.31.8.730; KNATTERUD GL, 1978, JAMA-J AM MED ASSOC, V240, P37, DOI 10.1001/jama.240.1.37; LAURITZEN T, 1985, DIABETES, V34, P74, DOI 10.2337/diab.34.3.S74; LAURITZEN T, 1983, LANCET, V1, P200; MASAOKA S, 1985, DIABETES CARE, V8, P64, DOI 10.2337/diacare.8.1.64; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; NIELSEN PE, 1972, SCAND J CLIN LAB INV, V29, P371, DOI 10.3109/00365517209080253; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Parving HH, 1998, DIABETOLOGIA, V41, P745, DOI 10.1007/s001250050983; PARVING HH, 1996, KIDNEY, P1864; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y	32	674	698	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 20	1999	353	9153					617	622		10.1016/S0140-6736(98)07368-1	http://dx.doi.org/10.1016/S0140-6736(98)07368-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QU	10030326				2022-12-28	WOS:000078818200010
J	Gerstein, HC				Gerstein, HC			Preventive medicine in a diabetes clinic: an opportunity to make a difference	LANCET			English	Editorial Material							MELLITUS; MORTALITY; DISEASE; RISK		McMaster Univ, Dept Med, Div Endocrinol & Metab, Hamilton, ON L8N 3Z5, Canada; Hamilton Hlth Sci Corp, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	Gerstein, HC (corresponding author), McMaster Univ, Dept Med, Div Endocrinol & Metab, Hamilton, ON L8N 3Z5, Canada.		Gerstein, Hertzel C/B-1235-2013; Gerstein, Hertzel/ABB-8781-2020	Gerstein, Hertzel C/0000-0001-8072-2836; Gerstein, Hertzel/0000-0001-8072-2836				Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; Dinneen SF, 1997, ARCH INTERN MED, V157, P1413, DOI 10.1001/archinte.157.13.1413; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Ravid M, 1996, ARCH INTERN MED, V156, P286, DOI 10.1001/archinte.156.3.286; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6	11	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 20	1999	353	9153					606	608		10.1016/S0140-6736(98)00366-3	http://dx.doi.org/10.1016/S0140-6736(98)00366-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QU	10030322				2022-12-28	WOS:000078818200004
J	Pal, B				Pal, B			Questionnaire survey of advice given to patients with fractures	BRITISH MEDICAL JOURNAL			English	Article									Withington Hosp, Univ S Manchester Hosp NHS Trust, Manchester M20 2LR, Lancs, England		Pal, B (corresponding author), Withington Hosp, Univ S Manchester Hosp NHS Trust, Manchester M20 2LR, Lancs, England.							BARLOW DM, 1994, ADVISORY GROUP OSTEO; Ekman A, 1997, LANCET, V350, P563, DOI 10.1016/S0140-6736(05)63140-6; *ROYAL COLL PHYS, 1995, J R COLL PHYS LOND, V23, P8; Scheiber LB, 1998, SEMIN ARTHRITIS RHEU, V27, P245, DOI 10.1016/S0049-0172(98)80004-8; Van Staa TP, 1998, BRIT J RHEUMATOL, V37, P87	5	63	63	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1999	318	7182					500	501		10.1136/bmj.318.7182.500	http://dx.doi.org/10.1136/bmj.318.7182.500			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QT	10024257	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000078818100026
J	Benbadis, SR; Mascha, E; Perry, MC; Wolgamuth, BR; Smolley, LA; Dinner, DS				Benbadis, SR; Mascha, E; Perry, MC; Wolgamuth, BR; Smolley, LA; Dinner, DS			Association between the Epworth Sleepiness Scale and the multiple sleep latency test in a clinical population	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Associated-Professional-Sleep-Societies 11th Annual Meeting	JUN 03, 1997	SAN FRANCISCO, CA	Assoc Profess Sleep Soc			DAYTIME SLEEPINESS	Background: Excessive daytime sleepiness can be evaluated with both subjective and objective tests. Objective: To examine the association between Epworth Sleepiness Scale scores and sleep latency on the multiple sleep latency test. Design: Case series. Setting: Referral sleep disorders center. Patients: 102 consecutive patients evaluated for excessive daytime sleepiness. Measurements: Epworth Sleepiness Scale scores and mean sleep latency on the multiple sleep latency test. Results: No significant association was seen between Epworth scores and mean sleep latency (Pearson correlation, -0.17 [95% CI, -0.35 to 0.03]; P = 0.09) (analysis of variance, P = 0.13). The mean Epworth score did not differ in three groups of patients who were defined by mean sleep latency as having normal sleep latency (>10 minutes), moderate sleep latency (5 to 10 minutes), or severe sleep latency (<5 minutes) (analysis of variance, P = 0.13). Conclusions: No statistically or clinically significant association was seen between Epworth scores and mean sleep latency. The subjective Epworth Sleepiness Scale and the objective multiple sleep latency test may evaluate different, complementary aspects of sleepiness.	Cleveland Clin, Dept Pulm Med, Ft Lauderdale, FL 33309 USA; Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Biostat, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Benbadis, SR (corresponding author), Univ S Florida, Coll Med, Dept Neurol, Harbourside Med Tower,4 Columbia Dr,Suite 730, Tampa, FL 33606 USA.	sbenbadi@com1.med.usf.edu						*AM EL SOC, 1994, J CLIN NEUROPHYSIOL, V11, P116; Benbadis SR, 1996, SLEEP, V19, P632; Briones B, 1996, SLEEP, V19, P583, DOI 10.1093/sleep/19.7.583; Broughton RJ, 1997, NEUROLOGY, V49, P444, DOI 10.1212/WNL.49.2.444; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Chervin RD, 1997, J PSYCHOSOM RES, V42, P145, DOI 10.1016/S0022-3999(96)00239-5; GREENLAND S, 1986, AM J EPIDEMIOL, V123, P203, DOI 10.1093/oxfordjournals.aje.a114229; HARNISH MJ, 1996, SLEEP RES, V25, P492; HOCH CC, 1992, NEUROBIOL AGING, V13, P353, DOI 10.1016/0197-4580(92)90049-4; JOHNS MW, 1994, SLEEP, V17, P703, DOI 10.1093/sleep/17.8.703; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Mitler MM, 1998, ANN NEUROL, V43, P88; PRESSMAN MR, 1989, SLEEP, V12, P239, DOI 10.1093/sleep/12.3.239; Rechtschaffen A, 1968, BRAIN INF SERV; SANDER AM, 1996, SLEEP RES, V25, P355; Sangal R, 1997, SLEEP RES, V26, P492; SANGAL RB, 1997, SLEEP RES, V26, P493; SEIDEL WF, 1984, SLEEP, V7, P230, DOI 10.1093/sleep/7.3.230; Smolley LA, 1993, SLEEP RES, V22, P389; THORPY MJ, 1992, SLEEP, V15, P268	20	132	138	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	1				289	292		10.7326/0003-4819-130-4-199902160-00014	http://dx.doi.org/10.7326/0003-4819-130-4-199902160-00014			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	166PY	10068387				2022-12-28	WOS:000078587200006
J	Bronkhorst, AW; Houtgast, T				Bronkhorst, AW; Houtgast, T			Auditory distance perception in rooms	NATURE			English	Article							REVERBERATION	The perceived distance of a sound source in a room has been shown to depend on the ratio of the energies of direct and reflected sound(1). Although this relationship was verified in later studies(2-4), the research has never led to a quantitative model. The advent of techniques for the generation of virtual sound sources(5,6) has made it possible to study distance perception using controlled, deterministic stimuli. Here we present two experiments that make use of such stimuli and we show that a simple model, based on a modified direct-to-reverberant energy ratio, can accurately predict the results and also provide an explanation for the 'auditory horizon' in distance perception. The modification of the ratio consists of the use of an integration time of 6 milliseconds in the calculation of the energy of the direct sound. This time constant seems to be important in spatial hearing-the precedence effect is also based on a similar integration window(7).	TNO, Human Factors Res Inst, NL-3769 ZG Soesterberg, Netherlands	Netherlands Organization Applied Science Research	Bronkhorst, AW (corresponding author), TNO, Human Factors Res Inst, POB 23, NL-3769 ZG Soesterberg, Netherlands.							BEGAULT DR, 1992, J AUDIO ENG SOC, V40, P895; Blauert J., 1997, SPATIAL HEARING PSYC, DOI [10.7551/mitpress/6391.001.0001, DOI 10.7551/MITPRESS/6391.001.0001]; BRONKHORST AW, 1995, J ACOUST SOC AM, V98, P2542, DOI 10.1121/1.413219; COLEMAN PD, 1963, PSYCHOL BULL, V60, P302, DOI 10.1037/h0045716; COLEMAN PD, 1962, J ACOUST SOC AM, V34, P345, DOI 10.1121/1.1928121; HOUTGAST T, 1994, HEARING RES, V72, P29, DOI 10.1016/0378-5955(94)90202-X; Kuttruff H., 1973, ROOM ACOUSTICS, V4th; MERSHON DH, 1979, PERCEPTION, V8, P311, DOI 10.1068/p080311; MERSHON DH, 1975, PERCEPT PSYCHOPHYS, V18, P409, DOI 10.3758/BF03204113; MOLLER H, 1995, J AUDIO ENG SOC, V43, P300; MOORE BCJ, 1988, J ACOUST SOC AM, V83, P1102, DOI 10.1121/1.396055; NIELSEN SH, 1993, J AUDIO ENG SOC, V41, P755; von Bekesy G., 1938, AKUST Z, V3, P21; WETTSCHURECK R, 1973, ACUSTICA, V29, P260; WIGHTMAN FL, 1989, J ACOUST SOC AM, V85, P868, DOI 10.1121/1.397558	15	168	170	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 11	1999	397	6719					517	520		10.1038/17374	http://dx.doi.org/10.1038/17374			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KN	10028966				2022-12-28	WOS:000078574900048
J	Roorda, A; Williams, DR				Roorda, A; Williams, DR			The arrangement of the three cone classes in the living human eye	NATURE			English	Article							COLOR-VISION; BLUE; SENSITIVITY; PIGMENTS	Human colour vision depends on three classes of receptor, the short- (S), medium- (M), and long- (L) wavelength-sensitive cones. These cone classes are interleaved in a single mosaic so that, at each point in the retina, only a single class of cone samples the retinal image. As a consequence, observers with normal trichromatic colour vision are necessarily colour blind on a local spatial scale(1). The limits this places on vision depend on the relative numbers and arrangement of cones. Although the topography of human S cones is known(2,3), the human L- and M-cone submosaics have resisted analysis. Adaptive optics, a technique used to overcome blur in ground-based telescopes(4), can also overcome blur in the eye, allowing the sharpest images ever taken of the living retina(5). Were we combine adaptive optics and retinal densitometry(6) to obtain what are, to our knowledge, the first. images of the arrangement of S, M and L cones in the living human eye. The proportion of L to M cones is strikingly different in two male subjects, each of whom has normal colour vision. The mosaics of both subjects have large patches in which either M or L cones are missing. This arrangement reduces the eye's ability to recover colour variations of high spatial frequency in the environment but may improve the recovery of luminance variations of high spatial frequency.	Univ Rochester, Ctr Visual Sci, Rochester, NY 14627 USA	University of Rochester	Roorda, A (corresponding author), Univ Houston, Coll Optometry, Houston, TX 77204 USA.	aroorda@popmail.opt.uh.edu		Williams, David R/0000-0003-3227-8333				Babcock H.W., 1953, PUBL ASTRON SOC PAC, V65, P229, DOI [10.1086/126606, DOI 10.1086/126606]; BOWMER TN, 1980, MAKROMOL CHEM-RAPID, V1, P1; BREWSTER D, 1832, LONDON EDINBURGH PHI, V1, P169; CAMPBELL FW, 1955, J PHYSIOL-LONDON, V130, P131, DOI 10.1113/jphysiol.1955.sp005399; CICERONE CM, 1989, VISION RES, V29, P115, DOI 10.1016/0042-6989(89)90178-8; CURCIO CA, 1991, J COMP NEUROL, V312, P610, DOI 10.1002/cne.903120411; DARTNALL HJA, 1983, PROC R SOC SER B-BIO, V220, P115, DOI 10.1098/rspb.1983.0091; Diggle PJ, 1983, STAT ANAL SPATIAL PO; Hagstrom SA, 1998, NEUROREPORT, V9, P1963, DOI 10.1097/00001756-199806220-00009; Holmgren F., 1884, COMP REND C PERIOD I, V1, P80; Jacobs GH, 1997, VISUAL NEUROSCI, V14, P921, DOI 10.1017/S0952523800011639; Jacobs GH, 1993, COLOUR VISION DEFICI, VXI, P107; KRAUSKOPF J, 1964, J OPT SOC AM, V54, P1171, DOI 10.1364/JOSA.54.001171; Liang JZ, 1997, J OPT SOC AM A, V14, P2884, DOI 10.1364/JOSAA.14.002884; Miyahara E, 1998, VISION RES, V38, P601, DOI 10.1016/S0042-6989(97)88334-4; MOLLON JD, 1989, J EXP BIOL, V146, P21; MOLLON JD, 1992, NATURE, V360, P677, DOI 10.1038/360677a0; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; Packer OS, 1996, J NEUROSCI, V16, P2251; POKORNY J, 1991, NATO ADV SCI I A-LIF, V203, P23; RUSHTON WAH, 1964, VISION RES, V4, P75, DOI 10.1016/0042-6989(64)90034-3; SEKIGUCHI N, 1993, J OPT SOC AM A, V10, P2118, DOI 10.1364/JOSAA.10.002118; VIMAL RLP, 1989, VISION RES, V29, P61, DOI 10.1016/0042-6989(89)90174-0; WILLIAMS DR, 1981, VISION RES, V21, P1357, DOI 10.1016/0042-6989(81)90242-X; WILLIAMS DR, 1991, NATO ADV SCI I A-LIF, V203, P11; WILLIAMS DR, 1990, ADVANCES IN PHOTORECEPTION, P135; Yamaguchi T, 1997, HUM MOL GENET, V6, P981, DOI 10.1093/hmg/6.7.981	27	641	660	1	111	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 11	1999	397	6719					520	522		10.1038/17383	http://dx.doi.org/10.1038/17383			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KN	10028967				2022-12-28	WOS:000078574900049
J	Herwaldt, BL; Beach, MJ				Herwaldt, BL; Beach, MJ		Cyclospora Working Grp	The return of Cyclospora in 1997: Another outbreak of cyclosporiasis in North America associated with imported raspberries	ANNALS OF INTERNAL MEDICINE			English	Article							FOREIGN RESIDENTS; EPIDEMIOLOGY; FOOD; INFECTIONS; TRAVELERS; DIARRHEA; PATHOGEN; LESSONS; DISEASE; NEPAL	Background: In the spring of 1996, an outbreak of cyclosporiasis associated with fresh Guatemalan raspberries occurred in the United States and Canada. Another multistate outbreak of cyclosporiasis occurred in North America in the spring of 1997. Objective: To identify the vehicle of the outbreak that occurred in the spring of 1997. Design: Retrospective cohort studies of clusters of cases associated with events (such as banquets) and traceback investigations of sources of implicated produce. Setting: United States and Canada. Patients: Persons who attended events associated with clusters of cases of cyclosporiasis. Measurements: identification of clinically defined or laboratory-confirmed cases of cyclosporiasis and risk factors for infection. Results: 41 clusters of cases were reported in association with events held from 1 April through 26 May in 13 U.S. states, the District of Columbia, and 1 Canadian province. The clusters comprised 762 cases of cyclosporiasis, 192 (25.2%) of which were laboratory confirmed. In addition, 250 laboratory-confirmed sporadic cases were reported in persons who developed gastrointestinal symptoms from April through 15 June, for a total of 1012 cases. Fresh raspberries were the only food common to all 41 events and were the only type of berry served at 9 events (22.0%). Statistically significant associations between consumption of raspberry-containing items and cyclosporiasis were documented for 15 events (40.5% of 37), For 31 of the 33 events with well-documented traceback data, the raspberries either definitely came from Guatemala (8 events) or could have come from Guatemala (23 events). The mode of contamination of the raspberries remains unknown. The outbreak ended shortly after the exportation of fresh raspberries from Guatemala was voluntarily suspended at the end of May 1997. Conclusions: Similar multistate, multicluster outbreaks of cyclosporiasis associated with consumption of Guatemalan raspberries have occurred in consecutive years. These outbreaks highlight the need for better understanding of the biology and epidemiology of Cyclospora cayetanensis and for stronger prevention and control measures to ensure the safety of produce eaten raw.	Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Herwaldt, BL (corresponding author), Ctr Dis Control & Prevent, Div Parasit Dis, 4770 Buford Highway NE,Mailstop F22, Atlanta, GA 30341 USA.							Barriga O. O., 1997, Parasitologia al Dia, V21, P122; Blaser MJ, 1996, NEW ENGL J MED, V334, P1324, DOI 10.1056/NEJM199605163342009; CONNOR BA, 1993, ANN INTERN MED, V119, P377, DOI 10.7326/0003-4819-119-5-199309010-00005; DeGraw E., 1997, Morbidity and Mortality Weekly Report, V46, P521; Dubey JP, 1998, INT J PARASITOL, V28, P369, DOI 10.1016/S0020-7519(97)83432-7; Eberhard ML, 1997, ARCH PATHOL LAB MED, V121, P792; FITZGERALD PR, 1968, J PARASITOL, V54, P233, DOI 10.2307/3276927; GARCIA LS, 1997, DIAGNOSTIC MED PARAS, P66; GarciaLopez HL, 1996, EMERG INFECT DIS, V2, P356, DOI 10.3201/eid0204.960414; HEDBERG CW, 1994, CLIN INFECT DIS, V18, P671, DOI 10.1093/clinids/18.5.671; Herwaldt BL, 1997, NEW ENGL J MED, V336, P1548, DOI 10.1056/NEJM199705293362202; Herwaldt BL, 1997, NEW ENGL J MED, V337, P1171; HOGE CW, 1995, LANCET, V345, P691, DOI 10.1016/S0140-6736(95)90868-4; HOGE CW, 1993, LANCET, V341, P1175, DOI 10.1016/0140-6736(93)91002-4; HUANG P, 1995, ANN INTERN MED, V123, P409, DOI 10.7326/0003-4819-123-6-199509150-00002; Koumans EHA, 1998, AM J TROP MED HYG, V59, P235, DOI 10.4269/ajtmh.1998.59.235; Madico G, 1997, CLIN INFECT DIS, V24, P977, DOI 10.1093/clinids/24.5.977; Ortega YR, 1997, AM J TROP MED HYG, V57, P683, DOI 10.4269/ajtmh.1997.57.683; ORTEGA YR, 1993, NEW ENGL J MED, V328, P1308, DOI 10.1056/NEJM199305063281804; Osterholm MT, 1997, NEW ENGL J MED, V336, P1597, DOI 10.1056/NEJM199705293362210; Pieniazek NJ, 1997, EMERG INFECT DIS, V3, P381, DOI 10.3201/eid0303.970319; Relman DA, 1996, J INFECT DIS, V173, P440, DOI 10.1093/infdis/173.2.440; Smith HV, 1996, VET REC, V138, P528; Soave R, 1998, INFECT DIS CLIN N AM, V12, P1, DOI 10.1016/S0891-5520(05)70404-9; Soave R, 1996, CLIN INFECT DIS, V23, P429, DOI 10.1093/clinids/23.3.429; Tauxe R, 1997, J FOOD PROTECT, V60, P1400, DOI 10.4315/0362-028X-60.11.1400; Tauxe RV, 1996, BMJ-BRIT MED J, V313, P1093, DOI 10.1136/bmj.313.7065.1093; U. S. Environmental Protection Agency (USEPA) U. S. Department of Agriculture Department of Health and Human Services, 1997, FOOD SAF FARM TABL N; Visvesvara GS, 1997, J CLIN MICROBIOL, V35, P730, DOI 10.1128/JCM.35.3.730-733.1997; ZERPA R, 1995, J TROP MED HYG, V98, P325; 1997, MMWR MORB MORTAL WKL, V46, P689; 1997, MMWR MORB MORTAL WKL, V46, P461; 1997, MMWR MORB MORTAL WKL, V46, P451; 1998, MMWR MORB MORTAL WKL, V47, P782; 1998, MMWR MORB MORTAL WKL, V47, P806	35	97	103	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 2	1999	130	3					210	+		10.7326/0003-4819-130-3-199902020-00006	http://dx.doi.org/10.7326/0003-4819-130-3-199902020-00006			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	162PD	10049199				2022-12-28	WOS:000078355000005
J	Spencer, JM				Spencer, JM			Nail-apparatus melanoma	LANCET			English	Editorial Material							SUBUNGUAL MALIGNANT-MELANOMA		CUNY, Mt Sinai Med Ctr, Div Dermatol Surg, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Spencer, JM (corresponding author), CUNY, Mt Sinai Med Ctr, Div Dermatol Surg, New York, NY 10029 USA.							Banfield CC, 1998, BRIT J DERMATOL, V139, P276; DAWBER RPR, 1991, SEMIN DERMATOL, V10, P82; FINLEY RK, 1994, SURGERY, V116, P96; HEATON KM, 1994, ANN SURG, V219, P197, DOI 10.1097/00000658-199402000-00012; KOPF AW, 1977, J DERMATOL SURG ONC, V3, P49; PACK GT, 1967, SURG GYNECOL OBSTETR, V124, P571; PATTERSON RH, 1980, CANCER-AM CANCER SOC, V46, P2074, DOI 10.1002/1097-0142(19801101)46:9<2074::AID-CNCR2820460928>3.0.CO;2-K; SAIDA T, 1989, CANCER, V63, P556, DOI 10.1002/1097-0142(19890201)63:3<556::AID-CNCR2820630326>3.0.CO;2-Q; SAIDA T, 1992, BRIT J DERMATOL, V126, P529, DOI 10.1111/j.1365-2133.1992.tb11836.x	9	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 9	1999	353	9147					84	85		10.1016/S0140-6736(05)76149-3	http://dx.doi.org/10.1016/S0140-6736(05)76149-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023888				2022-12-28	WOS:000078087200004
J	Ritchie, A; Griffiths, G; Parmar, M; Fossa, SD; Selby, PJ; Cornbleet, MA; Sibley, G; Mead, GM; Kaye, S; Owen, JR; Oliver, RTD; Smith, PH; Whelan, P; Cook, PA; Fayers, PM; Cook, P; Webb, J; Whitehead, J; Lamont, A				Ritchie, A; Griffiths, G; Parmar, M; Fossa, SD; Selby, PJ; Cornbleet, MA; Sibley, G; Mead, GM; Kaye, S; Owen, JR; Oliver, RTD; Smith, PH; Whelan, P; Cook, PA; Fayers, PM; Cook, P; Webb, J; Whitehead, J; Lamont, A		Med Res Counc Renal Canc Collaborators	Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial	LANCET			English	Article							CELL CARCINOMA; CANCER	Background Metastatic renal carcinoma has a 2-year survival of around 20% and is largely resistant to chemotherapy. The use of interferons in the treatment of metastatic renal carcinoma remains controversial. Although non-randomised studies suggest that biological therapy with interferons produces a small number of tumour responses, most clinicians judge such treatment to be ineffective. We have investigated the effect of treatment with interferon-alpha on survival inpatients with metastatic renal carcinoma. Methods In a multicentre, randomised trial, patients with metastatic renal carcinoma were randomly assigned subcutaneous interferon-alpha (three doses-5 MU, 5 MU, 10 MU-for the first week, then 10 MU three times per week for a further 11 weeks; n=174) or oral medroxyprogesterone acetate (MPA; 300 mg once daily for 12 weeks; n=176); The primary endpoint was overall survival. Analysis was by intention to treat. The trial used a triangular sequential design for early termination as soon as results were conclusive. The trial was stopped in November, 1997, when data were available for 335 patients (167 interferon-alpha, 168 MPA). Findings A total of 111 patients have died in the interferon-a group, and 125 patients have died in the MPA group. There was a 28% reduction in the risk of death in the interferon-alpha group (hazard ratio 0.72 [95% CI 0.55-0.94], p=0.017). Interferon-ol gave an improvement in 1-year survival of 12% (MPA 31% survival, interferon-alpha 43%), and an improvement in median survival of 2.5 months (MPA 6 months, interferon-alpha 8.5 months). Interpretation The benefit of treatment with interferon-oc should be weighed against the drug's toxic effects. Combination regimens of biological therapy and chemotherapy should now be compared with interferon-ce monotherapy in randomised controlled trials.	MRC, Canc Trials Off, RE01 Trial, Cambridge CB2 2BW, England; Glasgow Beatson Oncol Ctr, Glasgow, Lanark, Scotland; Birmingham City Hosp, Birmingham, W Midlands, England; Derbyshire Royal Infirm, Derby, England; Aberdeen Royal Infirm, Aberdeen, Scotland; Leicester Royal Infirm, Leicester, Leics, England; Royal Lancaster Infirm, Lancaster, England; Pontefract Gen Infirm, Pontefract, England	Beatson Oncology Centre; University of Aberdeen; University of Leicester	Ritchie, A (corresponding author), MRC, Canc Trials Off, RE01 Trial, 5 Shaftesbury Rd, Cambridge CB2 2BW, England.		Fayers, Peter M/A-5999-2010	Griffiths, Gareth/0000-0002-9579-8021				ATZPODIEN J, 1997, P ASCO, V16, pA326; DEHAES JCJM, 1990, BRIT J CANCER, V62, P1034, DOI 10.1038/bjc.1990.434; FAYERS PM, 1994, STAT MED, V13, P2249, DOI 10.1002/sim.4780132106; FOSSA S, 1995, BRIT J UROL, V76, P286, DOI 10.1111/j.1464-410X.1995.tb07702.x; Gleave ME, 1998, NEW ENGL J MED, V338, P1265, DOI 10.1056/NEJM199804303381804; Henriksson R, 1998, BRIT J CANCER, V77, P1311, DOI 10.1038/bjc.1998.218; Negrier S, 1998, NEW ENGL J MED, V338, P1272, DOI 10.1056/NEJM199804303381805; NEGRIER S, 1997, P AN M AM SOC CLIN, V16, pA326; PARMAR M, 1995, SURVIVAL ANAL PRACTI; PYRHONAN S, 1996, P AN M AM SOC CLIN, V15, P614; RITCHIE AWS, 1987, SEMIN NEPHROL, V7, P131; Ritchie AWS, 1995, OXFORD TXB ONCOLOGY, P1480; SELLI C, 1983, CANCER, V52, P899, DOI 10.1002/1097-0142(19830901)52:5<899::AID-CNCR2820520526>3.0.CO;2-#; STEINECK G, 1990, ACTA ONCOL, V29, P155, DOI 10.3109/02841869009126537; Whitehead J, 1997, DESIGN ANAL SEQUENTI	15	502	510	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 2	1999	353	9146					14	17						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023944				2022-12-28	WOS:000077934800010
J	Beecham, L				Beecham, L			GPs will set up an English committee	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					675	675						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066228				2022-12-28	WOS:000079089200074
J	Shekelle, PG; Woolf, SH; Eccles, M; Grimshaw, J				Shekelle, PG; Woolf, SH; Eccles, M; Grimshaw, J			Developing guidelines	BRITISH MEDICAL JOURNAL			English	Article							DESIGN AFFECTS OUTCOMES; CONTROLLED TRIALS; APPROPRIATENESS; BIAS; LANGUAGE; THERAPY; RATINGS		W Los Angeles Vet Affairs Med Ctr, Hlth Serv Res & Dev Serv, Los Angeles, CA 90073 USA; Virginia Commonwealth Univ, Dept Family Practice, Fairfax, VA 22033 USA; Univ Newcastle Upon Tyne, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Univ Aberdeen, Hlth Serv Res Unit, Aberdeen AB9 2ZD, Scotland	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; Virginia Commonwealth University; Newcastle University - UK; University of Aberdeen	Shekelle, PG (corresponding author), W Los Angeles Vet Affairs Med Ctr, Hlth Serv Res & Dev Serv, 111G,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.		Eccles, Martin P/AAD-4029-2020; Schober, Otmar/A-8670-2008; Grimshaw, Jeremy/D-8726-2013	Grimshaw, Jeremy/0000-0001-8015-8243				*COCHR COLL, 1998, COCHR LIB, V4; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; COULTER I, 1995, HEALTH SERV RES, V30, P577; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; FEDER G, IN PRESS BMJ; GREGOIRE G, 1995, J CLIN EPIDEMIOL, V48, P159, DOI 10.1016/0895-4356(94)00098-B; Kahan JP, 1996, MED CARE, V34, P512, DOI 10.1097/00005650-199606000-00002; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; Leape L L, 1992, Qual Assur Health Care, V4, P151; MILLER JN, 1989, STAT MED, V8, P455, DOI 10.1002/sim.4780080409; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Shekelle PG, 1996, HEALTH SERV RES, V31, P453; Shekelle PG, 1998, INT J TECHNOL ASSESS, V14, P707, DOI 10.1017/S0266462300012022; SHEKELLE PG, IN PRESS HLTH SERVIC; WOOLF SH, 1994, AHCPR PUBLICATION, P105	17	813	839	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					593	596		10.1136/bmj.318.7183.593	http://dx.doi.org/10.1136/bmj.318.7183.593			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037645	Green Published			2022-12-28	WOS:000078966300039
J	Lu, PJ; Zhou, XZ; Shen, MH; Lu, KP				Lu, PJ; Zhou, XZ; Shen, MH; Lu, KP			Function of WW domains as phosphoserine- or phosphothreonine-binding modules	SCIENCE			English	Article							PROTEIN-PROTEIN RECOGNITION; SACCHAROMYCES-CEREVISIAE; SIGNALING PROTEINS; CDC25 PHOSPHATASE; TYROSINE KINASES; SH3 DOMAINS; M-PHASE; UBIQUITIN; PHOSPHORYLATION; DEGRADATION	Protein-interacting modules help determine the specificity of signal transduction events, and protein phosphorylation can modulate the assembly of such modules into specific signaling complexes. Although phosphotyrosine-binding modules have been well-characterized, phosphoserine- or phosphothreonine-binding modules have not been described. WW domains are small protein modules found in various proteins that participate in cell signaling or regulation, WW domains of the essential mitotic prolyl isomerase Pin1 and the ubiquitin ligase Nedd4 bound to phosphoproteins, including physiological substrates of enzymes, in a phosphorylation-dependent manner. The Pin1 WW domain functioned as a phosphoserine- or phosphothreonine-binding module, with properties similar to those of SRC homology 2 domains, Phosphoserine- or phosphothreonine-binding activity was required for Pin1 to interact with its substrates in vitro and to perform its essential function in vivo.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Lu, KP (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA.				NIGMS NIH HHS [R01GM58556, R01GM56230] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056230, R01GM058556] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; COPLEY RR, 1994, J MOL BIOL, V242, P321; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Hunter T, 1998, CELL, V92, P141, DOI 10.1016/S0092-8674(00)80906-X; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JANIN J, 1990, J BIOL CHEM, V265, P16027; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lu KP, 1996, NATURE, V380, P544; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Marchal C, 1998, MOL CELL BIOL, V18, P314, DOI 10.1128/MCB.18.1.314; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rotin D, 1998, CURR TOP MICROBIOL, V228, P115; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHMID FX, 1995, CURR BIOL, V5, P993, DOI 10.1016/S0960-9822(95)00197-7; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x; YOUNG L, 1994, PROTEIN SCI, V3, P717; Zhou X., UNPUB	53	579	596	2	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1325	1328		10.1126/science.283.5406.1325	http://dx.doi.org/10.1126/science.283.5406.1325			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037602				2022-12-28	WOS:000078839900041
J	Kuttner, R				Kuttner, R			The American health care system - Wall Street and health care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		*AM HOSP ASS, 1997, HOSP STAT 1996 1997; Blecher MB, 1998, HOSP HEALTH NETWORK, V72, P28; GORDON SS, 1999, BOSTON GLOBE    0108; Haugh R, 1998, HOSP HEALTH NETWORK, V72, P32; *HMO, 1998, INT HMO TREND REP 19; *HMO, 1998, 82 HMO INT, P59; Hudson T, 1998, HOSP HEALTH NETWORK, V72, P30; Pear Robert, 1998, NEW YORK TIMES  1226, pA20; 1998, MODERN HEALTHCA 1130, P6; 1998, BNAS MANAGED CA 1230, P1251; 1998, BUSINESS WEEK   1228, P156; 1998, BNAS MANAGED CA 1104, P1086; 1999, HOSP MANAGEMENT CO; 1998, WEISS RATINGS   0831; 1997, MODENR HEALTHCA 0104, P8; 1999, MODERN HEALTHCA 0111, P48	16	31	31	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1999	340	8					664	668		10.1056/NEJM199902253400822	http://dx.doi.org/10.1056/NEJM199902253400822			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	169NP	10029655				2022-12-28	WOS:000078755700036
J	Nutting, PA; Beasley, JW; Werner, JJ				Nutting, PA; Beasley, JW; Werner, JJ			Practice-based research networks answer primary care questions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ASPN; HEADACHE; TRIAL		Ambulatory Sentinel Practice Network, Denver, CO 80214 USA; Univ Wisconsin, Wisconsin Res Network, Madison, WI USA; Univ Wisconsin, Dept Family Med, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Nutting, PA (corresponding author), Ambulatory Sentinel Practice Network, 1650 Pierce St, Denver, CO 80214 USA.	paul.nutting@ASPN.amc.org						*AG HLTH CAR POL R, 1993, DHHS PUBL; *AM AC PED, PROS REF STUD; *AM AC PED, PROS CHILD BEH STUDY; BECKER L, 1988, J FAM PRACTICE, V27, P41; BECKER LA, 1993, J FAM PRACTICE, V37, P135; BECKER LA, 1993, J FAM PRACTICE, V37, P129; DIETRICH AJ, 1992, BRIT MED J, V304, P687, DOI 10.1136/bmj.304.6828.687; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; Flocke SA, 1997, J FAM PRACTICE, V45, P129; Freeman W L, 1988, Fam Med, V20, P192; Froom J, 1993, Arch Fam Med, V2, P841, DOI 10.1001/archfami.2.8.841; GREEN LA, 1994, J FAM PRACTICE, V38, P400; GREEN LA, 1988, J AM BOARD FAM PRACT, V1, P15; McBride PE, 1997, CIRCULATION, V96, P363; NUTTING PA, 1991, RES AGENDA PRIMARY C; ROST KM, 1998, 12 INT NIMH C MENT H; Stange KC, 1998, J FAM PRACTICE, V46, P377; STANGE KC, 1994, J GEN INTERN MED, V9, P278, DOI 10.1007/BF02599656; Stange KC, 1998, J FAM PRACTICE, V46, P363	19	121	121	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1999	281	8					686	688		10.1001/jama.281.8.686	http://dx.doi.org/10.1001/jama.281.8.686			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BD	10052423				2022-12-28	WOS:000078669900001
J	Fazel, S; Hope, T; Jacoby, R				Fazel, S; Hope, T; Jacoby, R			Assessment of competence to complete advance directives: validation of a patient centred approach	BRITISH MEDICAL JOURNAL			English	Article							CAPACITY; CONSENT	Objective To develop a patient centred approach for the assessment of competence to complete advance directives ("living wills") of elderly people with cognitive impairment Design Semistructured interviews. Setting Oxfordshire. Subjects 50 elderly volunteers living in the community, and 50 patients with dementia on first referral from primary care. Main outcome measures Psychometric properties of competence assessment. Results This patient centred approach for assessing competence to complete advance directives can discriminate between elderly persons living in the community and elderly patients with dementia, The procedure has good interrater (r = 0.95) and test-retest (r = 0.97) reliability Validity was examined by relating this approach with a global assessment of competence to complete an advance directive made by two of us (both specialising in old age psychiatry). The data were also used to determine the best threshold score for discriminating between those competent and those incompetent to complete an advance directive, Conclusion A patient centred approach to assess competence to complete advance directives can be reliably and validly used in routine clinical practice.	Univ Oxford, Warneford Hosp, Old Age Psychiat Sect, Oxford OX3 7JX, England	University of Oxford	Fazel, S (corresponding author), Univ Oxford, Warneford Hosp, Old Age Psychiat Sect, Oxford OX3 7JX, England.	seena.fazel@psychiatry.ox.ac.uk	Fazel, Seena/B-5307-2008	Fazel, Seena/0000-0002-5383-5365	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APPLEBAUM PS, 1995, LAW HUMAN BEHAV, V19, P149; APPLEBAUM PS, 1988, NEW ENGL J MED, V319, P1635; *BRIT MED ASS, 1994, STAT ADV DIR; Buchanan Allen E., 1989, DECIDING OTHERS ETHI; FITTEN LJ, 1990, J AM GERIATR SOC, V38, P1097, DOI 10.1111/j.1532-5415.1990.tb01372.x; GILLICK MR, 1995, ANN INTERN MED, V123, P621, DOI 10.7326/0003-4819-123-8-199510150-00009; HOPE T, 1992, BRIT MED J, V304, P398, DOI 10.1136/bmj.304.6824.398; JACOBY R, 1997, PSYCHIAT ELDERLY; JANOFSKY JS, 1992, HOSP COMMUNITY PSYCH, V43, P132; JOHNSTON SC, 1995, ARCH INTERN MED, V155, P1025, DOI 10.1001/archinte.155.10.1025; MARSON DC, 1994, ALZ DIS ASSOC DIS, V8, P5, DOI 10.1097/00002093-199400000-00002; MARSON DC, 1995, ARCH NEUROL-CHICAGO, V52, P949, DOI 10.1001/archneur.1995.00540340029010; SILBERFELD M, 1993, J AM GERIATR SOC, V41, P1141, DOI 10.1111/j.1532-5415.1993.tb06464.x	13	57	58	2	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1999	318	7182					493	+		10.1136/bmj.318.7182.493	http://dx.doi.org/10.1136/bmj.318.7182.493			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	170QT	10024254	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000078818100022
J	Woolf, SH; Grol, R; Hutchinson, A; Eccles, M; Grimshaw, J				Woolf, SH; Grol, R; Hutchinson, A; Eccles, M; Grimshaw, J			Clinical guidelines - Potential benefits, limitations, and harms of clinical guidelines	BRITISH MEDICAL JOURNAL			English	Article									Virginia Commonwealth Univ, Dept Family Practice, Fairfax, VA 22033 USA; Univ Nijmegen, Ctr Qual Care Res, NL-6500 HB Nijmegen, Netherlands; Univ Sheffield, Sch Hlth Related Res, Sheffield S1 4DA, S Yorkshire, England; Univ Newcastle Upon Tyne, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Univ Aberdeen, Hlth Serv Res Unit, Aberdeen AB9 2ZD, Scotland	Virginia Commonwealth University; Radboud University Nijmegen; University of Sheffield; Newcastle University - UK; University of Aberdeen	Woolf, SH (corresponding author), Virginia Commonwealth Univ, Dept Family Practice, Fairfax, VA 22033 USA.		Grol, Richard/C-8523-2013; Grimshaw, Jeremy/D-8726-2013; Eccles, Martin P/AAD-4029-2020	Grimshaw, Jeremy/0000-0001-8015-8243				*AG HLTH CAR POL R, 1995, AHCPR PUBL; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; ENTWISTLE VA, IN PRESS INT J TECH; FEDER G, 1994, BRIT MED J, V308, P470; FEDER G, IN PRESS BMJ; Field MJ., 1992, GUIDELINES CLIN PRAC; Field MJ, 1990, CLIN PRACTICE GUIDEL; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HEMMING M, 1993, BRIT MED J, V307, P678, DOI 10.1136/bmj.307.6905.678-a; HURWITZ B, IN PRESS BMJ; KANE RL, 1995, J LAW MED ETHICS, V23, P62, DOI 10.1111/j.1748-720X.1995.tb01332.x; SHAPIRO DW, 1993, ANNU REV PUBL HEALTH, V14, P219, DOI 10.1146/annurev.pu.14.050193.001251; SHEKELLE PG, IN PRESS BMJ; Woolf SH, 1997, J FAM PRACTICE, V45, P205; 1994, EFFECTIVE HLTH CARE	16	1494	1534	2	47	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1999	318	7182					527	+		10.1136/bmj.318.7182.527	http://dx.doi.org/10.1136/bmj.318.7182.527			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QT	10024268	Green Published			2022-12-28	WOS:000078818100036
J	Sandler, RS; Zorich, NL; Filloon, TG; Wiseman, HB; Lietz, DJ; Brock, MH; Royer, MG; Miday, RK				Sandler, RS; Zorich, NL; Filloon, TG; Wiseman, HB; Lietz, DJ; Brock, MH; Royer, MG; Miday, RK			Gastrointestinal symptoms in 3181 volunteers ingesting snack foods containing olestra or triglycerides - A 6-week randomized, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						fat substitutes; diarrhea; abdominal pain; activities of daily living; nausea	DOUBLE-BLIND	Background: Olestra is a nonabsorbable, energy-free fat substitute. Because it is not absorbed, it may cause digestive symptoms when consumed in large amounts. Objective: To compare the frequency and impact of gastrointestinal symptoms in adults and children who freely consume snacks containing olestra or regular snacks in the home. Design: 6-week, double-blind, randomized, parallel, placebo-controlled trial. Setting: General community. Participants: 3181 volunteers 2 to 89 years of age. Intervention: Households received identical packages labeled as containing olestra corn or potato chips. These packages contained either olestra or regular chips (control). Measurement: Gastrointestinal symptoms and their impact on daily activities were reported in a daily record. Results: At least one gastrointestinal symptom was reported by 619 of 1620 (38.2%) persons in the olestra group and 576 of 1561 (36.9%) controls (difference, 1.3 percentage points [95% CI, -3.6 to 6.2 percentage points]; P = 0.60). In general, the groups did not differ significantly in the proportion of participants who reported individual gastrointestinal symptoms; however, more controls reported nausea (8.4% compared with 5.7%; difference, -2.7 percentage points [Cl, -4.9 to -0.4 percentage points]; P = 0.02). The only difference between groups for the mean numbers of days on which symptoms were reported was that participants in the olestra group had 1 more symptom-day of more frequent bowel movements than did controls (3.7 symptom-days compared with 2.8 symptom days; difference, 0.9 symptom-days [Cl, 0.1 to 1.8 symptom-days]; P = 0.04). The groups did not differ in the impact of symptoms on daily activities. Conclusions: Clinically meaningful or bothersome gastrointestinal effects are not associated with unregulated consumption of olestra corn and potato chips in the home.	Univ N Carolina, Chapel Hill, NC 27599 USA; Procter & Gamble Co, Winton Hill Tech Ctr, Food & Beverage Div, Regulatory & Clin Dev, Cincinnati, OH 45224 USA	University of North Carolina; University of North Carolina Chapel Hill; Procter & Gamble	Sandler, RS (corresponding author), Univ N Carolina, CB 7080,326 Burnett Womack Bldg, Chapel Hill, NC 27599 USA.	rsandler@med.unc.edu						Cheskin LJ, 1998, JAMA-J AM MED ASSOC, V279, P150, DOI 10.1001/jama.279.2.150; Giannella R, 1998, GASTROENTEROLOGY, V114, pA372, DOI 10.1016/S0016-5085(98)81510-2; HENDERSON WG, 1988, CONTROL CLIN TRIALS, V9, P189, DOI 10.1016/0197-2456(88)90060-8; Koonsvitsky BP, 1997, J NUTR, V127, pS1636, DOI 10.1093/jn/127.8.1636S; Lee EW, 1996, STAT MED, V15, P1187, DOI 10.1002/(SICI)1097-0258(19960615)15:11<1187::AID-SIM223>3.0.CO;2-I; LEVINE A, 1997, US NEWS WORLD REP, V5, P53; MATTSON FH, 1972, J NUTR, V102, P1171, DOI 10.1093/jn/102.9.1171; MATTSON FH, 1972, J LIPID RES, V13, P325; Sandler RS, 1998, GASTROENTEROLOGY, V114, pA831, DOI 10.1016/S0016-5085(98)83383-0; Webb DR, 1997, J NUTR, V127, pS1547, DOI 10.1093/jn/127.8.1547S; WUERTHNER J, 1992, SNAKC WORLD      JAN, pSW1; Zorich NL, 1997, AM J MED, V103, P389, DOI 10.1016/S0002-9343(97)00164-2; Zorich NL, 1997, REGUL TOXICOL PHARM, V26, P200, DOI 10.1006/rtph.1997.1164; 1996, FED REG, V61, P3118	14	21	21	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	1				253	+		10.7326/0003-4819-130-4_Part_1-199902160-00002	http://dx.doi.org/10.7326/0003-4819-130-4_Part_1-199902160-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166PY	10068382				2022-12-28	WOS:000078587200001
J	Frankel, DH; Horton, R				Frankel, DH; Horton, R			Medicine and politics of medical journalism	LANCET			English	Editorial Material									Lancet, New York, NY 10010 USA; Lancet, London WC1B 3SL, England		Frankel, DH (corresponding author), Lancet, New York, NY 10010 USA.							Horton R, 1999, LANCET, V353, P252, DOI 10.1016/S0140-6736(99)00019-7	1	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 13	1999	353	9152					518	518		10.1016/S0140-6736(99)00043-4	http://dx.doi.org/10.1016/S0140-6736(99)00043-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028978				2022-12-28	WOS:000078670200007
J	Lorch, Y; Zhang, M; Kornberg, RD				Lorch, Y; Zhang, M; Kornberg, RD			Histone octamer transfer by a chromatin-remodeling complex	CELL			English	Article							NUCLEOSOMAL DNA; BINDING; PROTEIN	RSC, an abundant, essential chromatin-remodeling complex related to SWI/SNF complex, catalyzes the transfer of a histone octamer from a nucleosome core particle to naked DNA. The newly formed octamer-DNA complex is identical with a nucleosome in all respects. The reaction requires ATP and involves an activated RSC-nucleosome intermediate. The mechanism may entail formation of a duplex displacement loop on the nucleosome, facilitating the entry of exogeneous DNA and the release of the endogenous molecule.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.	kornberg@stanford.edu			NIGMS NIH HHS [GM36659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cairns BR, 1998, MOL CELL, V2, P639, DOI 10.1016/S1097-2765(00)80162-8; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KORNBERG RD, 1989, METHOD ENZYMOL, V170, P3; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3	13	227	244	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 5	1999	96	3					389	392		10.1016/S0092-8674(00)80551-6	http://dx.doi.org/10.1016/S0092-8674(00)80551-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025404	Bronze			2022-12-28	WOS:000078514600011
J	Daumit, GL; Hermann, JA; Coresh, J; Powe, NR				Daumit, GL; Hermann, JA; Coresh, J; Powe, NR			Use of cardiovascular procedures among black persons and white persons: A 7-year nationwide study in patients with renal disease	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CORONARY HEART-DISEASE; INVASIVE CARDIAC PROCEDURES; BYPASS GRAFT-SURGERY; NON-HISPANIC WHITES; UNITED-STATES; HEALTH-CARE; REVASCULARIZATION PROCEDURES; RACIAL-DIFFERENCES; ETHNIC-DIFFERENCES	Background: Black persons historically undergo fewer invasive cardiovascular procedures than white persons. Objective: To determine whether acquisition of Medicare health insurance and comprehensive care for severe illness reduce ethnic disparity in use of cardiovascular procedures. Design: 7-year longitudinal analyses in a cohort from the United States Renal Data System. Setting: Health care institutions in the United States. Patients: Nationwide random sample of 4987 adult black and white patients with incident end-stage renal disease (ESRD) from 303 dialysis facilities in 1986 to 1987. Measurements: Medical history and service use records, physical examination, and laboratory data. Main outcome measures were receipt of a coronary catheterization or revascularization procedure before (baseline) and after (follow-up) development of ESRD and acquisition of Medicare, adjusted for clinical and socioeconomic variables. Results: At baseline, 9.9% of white patients and 2.8% of black patients had had a cardiac procedure; the odds were almost three times greater in white than in black patients (adjusted odds ratio, 2.92 [95% CI, 2.04 to 4.18]). During follow-up, white patients were only 1.4 times more likely than black patients to have a procedure (adjusted relative risk, 1.41 [CI, 1.13 to 1.77]); rates were 7.8% for white persons and 8.5% for black persons. In patients with Medicare coverage before development of ESRD, the initial threefold difference in procedure use was eliminated over follow-up (odds ratio, 1.05 [CI, 0.56 to 1.60]). For procedures after hospital admission for myocardial infarction or coronary disease, no difference between ethnic groups was seen during follow-up (relative risk, 1.12 [CI, 0.68 to 1.85]). Conclusions: Differences between ethnic groups in use of cardiovascular procedures narrowed markedly once a serious illness (ESRD) developed and adequate insurance coverage was ensured; the disparity was eliminated in patients with previous Medicare insurance or a stronger indication for a procedure. These findings suggest that almost equal access to care is attainable by combining insurance with delivery of comprehensive, clinically appropriate rare.	Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University	Powe, NR (corresponding author), Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2-641, Baltimore, MD 21205 USA.	npowe@jhsmi.edu			NHLBI NIH HHS [5T32HLO7024] Funding Source: Medline; NIDDK NIH HHS [R01DK47797] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047797] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aday L A, 1974, Health Serv Res, V9, P208; ANDERSEN R, 1978, MED CARE, V16, P533, DOI 10.1097/00005650-197807000-00001; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; Bender FH, 1996, AM J KIDNEY DIS, V28, P67, DOI 10.1016/S0272-6386(96)90132-8; BLOEMBERGEN WE, 1994, J AM SOC NEPHROL, V5, P1231; BLOOM B, 1997, VITAL HLTH STAT, V10, P1; BLUSTEIN J, 1995, AM J PUBLIC HEALTH, V85, P345, DOI 10.2105/AJPH.85.3.345; CARLISLE DM, 1995, AM J PUBLIC HEALTH, V85, P352, DOI 10.2105/AJPH.85.3.352; Carlisle DM, 1997, AM J PUBLIC HEALTH, V87, P263, DOI 10.2105/AJPH.87.2.263; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DAVIS K, 1987, MILBANK Q, V65, P213, DOI 10.2307/3349956; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; DRACUP K, 1991, HEART LUNG, V20, P570; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; EVANS RW, 1981, JAMA-J AM MED ASSOC, V245, P487, DOI 10.1001/jama.245.5.487; FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; FORD ES, 1995, HEALTH SERV RES, V30, P237; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GILES WH, 1995, ARCH INTERN MED, V155, P318, DOI 10.1001/archinte.155.3.318; Gillum RF, 1997, ANN INTERN MED, V127, P111, DOI 10.7326/0003-4819-127-2-199707150-00003; GILLUM RF, 1994, J AM COLL CARDIOL, V23, P1273, DOI 10.1016/0735-1097(94)90367-0; Gillum RF, 1997, J AM COLL CARDIOL, V29, P1557, DOI 10.1016/S0735-1097(97)00089-2; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HAYWARD RA, 1991, AM J PUBLIC HEALTH, V81, P434, DOI 10.2105/AJPH.81.4.434; Held PJ, 1996, KIDNEY INT, V50, P550, DOI 10.1038/ki.1996.348; HUBBELL FA, 1989, AM J MED, V87, P127; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; *INT CLASS DIS, 1994, CLIN MOD; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; Lee H O, 1997, Am J Crit Care, V6, P7; LEVY P, 1998, ENCY BIOSTATISTICS, P2635; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MAYNARD C, 1986, AM J PUBLIC HEALTH, V76, P1446, DOI 10.2105/AJPH.76.12.1446; MCBEAN AM, 1994, AM HEART J, V127, P287, DOI 10.1016/0002-8703(94)90115-5; Mickelson JK, 1997, J AM COLL CARDIOL, V29, P915, DOI 10.1016/S0735-1097(97)00034-X; MORT EA, 1994, ARCH INTERN MED, V154, P761, DOI 10.1001/archinte.154.7.761; Neuhaus JM, 1998, BIOMETRICS, V54, P638, DOI 10.2307/3109770; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; PUGH JA, 1994, AM J KIDNEY DIS, V23, P803; Ramsey DJ, 1997, J CLIN EPIDEMIOL, V50, P603, DOI 10.1016/S0895-4356(97)80002-9; SEMPOS C, 1988, AM J PUBLIC HEALTH, V78, P1422, DOI 10.2105/AJPH.78.11.1422; STAFFORD RS, 1991, JAMA-J AM MED ASSOC, V265, P59, DOI 10.1001/jama.265.1.59; STAFFORD RS, 1990, AM J PUBLIC HEALTH, V80, P313, DOI 10.2105/AJPH.80.3.313; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; *US REN DAT SYST, 1994, USRDS ANN DAT REP; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WEISSMAN JS, 1993, ANNU REV PUBL HEALTH, V14, P243; Weissman JS., 1994, FALLING SAFETY NET I; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; Wild Sarah H., 1995, Annals of Epidemiology, V5, P432, DOI 10.1016/1047-2797(95)00058-5	59	81	82	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 2	1999	130	3					173	+		10.7326/0003-4819-130-3-199902020-00002	http://dx.doi.org/10.7326/0003-4819-130-3-199902020-00002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	162PD	10049195				2022-12-28	WOS:000078355000001
J	Singer, LT; Salvator, A; Guo, SY; Collin, M; Lilien, L; Baley, J				Singer, LT; Salvator, A; Guo, SY; Collin, M; Lilien, L; Baley, J			Maternal psychological distress and parenting stress after the birth of a very low-birth-weight infant	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BRONCHOPULMONARY DYSPLASIA; DEPRESSED MOTHERS; SOCIAL SUPPORT; SCHOOL-AGE; CHILDREN; IMPACT; FAMILY; HEALTH; ATTITUDES; HOME	Context Few studies document how parents adapt to the experience of a very low-birth-weight (VLBW; <1500 g) birth despite societal concerns about the ethics and justification of intensive care for these infants. Objective To determine the degree and type of stress experienced over time by mothers whose infants vary in degree of prematurity and medical and developmental risk. Design Longitudinal prospective follow-up study of-a cohort of mothers of high- and low-risk VLBW and term infants from birth to 3 years. Setting All level III neonatal intensive care units from a large midwestern metropolitan region, Participants Mothers and infants prospectively and consecutively enrolled in a longitudinal study between 1989 and 1991. High-risk VLBW infants were diagnosed as having bronchopulmonary dysplasia, and comparison groups were low-risk VLBW infants without bronchopulmonary dysplasia and term infants (>36 weeks, >2500 g). Main Outcome Measures Standardized, normative self-report measures of maternal psychological distress, parenting stress, family impact, and life stressors. Results Mothers of VLBW infants (high risk, n = 122; low risk, n = 84) had more psychological distress than mothers of term infants (n = 123) at 1 month (13% vs 1%; P = .003). At 2 years, mothers of low-risk VLBW infants did not differ from term mothers, while mothers of high-risk infants continued to report psychological distress. By 3 years, mothers of high-risk VLBW children did not differ from mothers of term children in distress symptoms, while parenting stress remained greater. Severity of maternal depression was related to lower child developmental outcomes in both VLBW groups. Conclusions The impact of VLBW birth varies with child medical risk status, age, and developmental outcome. Follow-up programs should incorporate psychological screening and support services for mothers of VLBW infants in the immediate postnatal period, with monitoring of mothers of high-risk VLBW infants.	Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Mandel Sch Appl Social Sci, Cleveland, OH 44106 USA; Univ Hosp, Cleveland, OH USA; Metrohlth Med Ctr, Cleveland, OH USA; Fairview Hosp, Cleveland, OH USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; MetroHealth System	Singer, LT (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pediat, Triangle Bldg,Suite 250A,11400 Euclid Ave, Cleveland, OH 44106 USA.	lxs5@po.cwru.edu	Singer, Lynn/Q-2045-2019	Singer, Lynn/0000-0003-2950-9460	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038193] Funding Source: NIH RePORTER; NHLBI NIH HHS [NIH-HL-38193] Funding Source: Medline; PHS HHS [MCJ-390592, MCJ-390715] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abidin R.R., 1986, PARENTING STRESS IND; BANCALARI E, 1986, PEDIATR CLIN N AM, V33, P1; Bayley N, 1993, BAYLEY SCALES DEV; Bayley N., 1969, BAYLEY SCALES INFANT; BLUMBERG NL, 1980, J ABNORM PSYCHOL, V89, P139, DOI 10.1037/0021-843X.89.2.139; BROOTEN D, 1986, NEW ENGL J MED, V315, P934, DOI 10.1056/NEJM198610093151505; BROOTEN D, 1988, NURS RES, V37, P213; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037//0033-2909.98.2.310; DEROGATIS LR, 1977, J CLIN PSYCHOL, V33, P981, DOI 10.1002/1097-4679(197710)33:4<981::AID-JCLP2270330412>3.0.CO;2-0; Derogatis LR., 1992, BRIEF SYMPTOM INVENT; DODGE KA, 1990, DEV PSYCHOL, V26, P3, DOI 10.1037/0012-1649.26.1.3; ECHERMAN CO, 1996, PSYCHOL DEV LOW BIRT, P91; ESCOBAR GJ, 1991, ARCH DIS CHILD, V66, P204, DOI 10.1136/adc.66.2.204; FIELD T, 1995, INFANT BEHAV DEV, V18, P1, DOI 10.1016/0163-6383(95)90003-9; GOLDBERG S, 1990, J PEDIATR PSYCHOL, V15, P347, DOI 10.1093/jpepsy/15.3.347; Hollingshead AA., 1957, 2 FACTOR INDEX SOCIA; KLEIN NK, 1989, J DEV BEHAV PEDIATR, V10, P32; LEE SK, 1991, PEDIATRICS, V88, P105; LEE SK, 1991, PEDIATRICS, V88, P110; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; LYTTON H, 1995, HDB PARENTING, P183; MCCORMICK MC, 1986, J DEV BEHAV PEDIATR, V7, P217, DOI 10.1097/00004703-198608000-00001; McCormick MC, 1996, PEDIATRICS, V97, P18; McCormick MC, 1997, PEDIATRICS, V99, P869, DOI 10.1542/peds.99.6.869; MCCORMICK MC, 1992, JAMA-J AM MED ASSOC, V267, P2204, DOI 10.1001/jama.267.16.2204; MCCUBBIN HI, 1985, FAMILY ASSESSMENT IN, P81; NORTHWAY WH, 1967, NEW ENGL J MED, V276, P357, DOI 10.1056/NEJM196702162760701; PANETH NS, 1995, FUTURE CHILD, V5, P19, DOI 10.2307/1602505; PEDERSON DR, 1987, AM J ORTHOPSYCHIAT, V57, P15, DOI 10.1111/j.1939-0025.1987.tb03504.x; RYAN RM, 1994, J PEDIATR-US, V125, P435, DOI 10.1016/S0022-3476(05)83291-3; SAIGAL S, 1991, J PEDIATR-US, V118, P751, DOI 10.1016/S0022-3476(05)80043-5; Saigal S, 1996, JAMA-J AM MED ASSOC, V276, P453, DOI 10.1001/jama.276.6.453; Singer L, 1997, DEV PSYCHOPATHOL, V9, P473, DOI 10.1017/S0954579497001259; SINGER L, 1989, FAM RELAT, V38, P444, DOI 10.2307/585751; Singer L, 1997, PEDIATRICS, V100, P987, DOI 10.1542/peds.100.6.987; SINGER L, 1990, J PEDIT PSYCHOL, V15, P6; Singer LT, 1996, FAM RELAT, V45, P343, DOI 10.2307/585507; Singer LT, 1996, J DEV BEHAV PEDIATR, V17, P69; STEIN REK, 1980, MED CARE, V18, P465, DOI 10.1097/00005650-198004000-00010; TRAUSE MA, 1983, DEV MED CHILD NEUROL, V25, P459; TYSON J, 1995, FUTURE CHILD, V5, P197, DOI 10.2307/1602515; Tyson JE, 1996, JAMA-J AM MED ASSOC, V276, P492, DOI 10.1001/jama.276.6.492; VENTURA SJ, 1997, REPORT FINAL NATALIT, P1	43	499	506	0	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					799	805		10.1001/jama.281.9.799	http://dx.doi.org/10.1001/jama.281.9.799			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	170KF	10071000	Bronze			2022-12-28	WOS:000078804300029
J	Unger, VM; Kumar, NM; Gilula, NB; Yeager, M				Unger, VM; Kumar, NM; Gilula, NB; Yeager, M			Three-dimensional structure of a recombinant gap junction membrane channel	SCIENCE			English	Article							MARIE-TOOTH-DISEASE; ELECTRON CRYOMICROSCOPY; 3-DIMENSIONAL STRUCTURE; WATER CHANNEL; RESOLUTION; CONNEXIN43; MUTATIONS; PROTEIN; HEART; COMMUNICATION	Gap junction membrane channels mediate electrical and metabolic coupling between adjacent cells. The structure of a recombinant cardiac gap junction channel was determined by electron crystallography at resolutions of 7.5 angstroms in the membrane plane and 21 angstroms in the vertical direction. The dodecameric channel was formed by the end-to-end docking of two hexamers, each of which displayed 24 rods of density in the membrane interior, which is consistent with an alpha-helical conformation for the four transmembrane domains of each connexin subunit. The transmembrane alpha-helical rods contrasted with the double-layered appearance of the extracellular domains. Although not indicative for a particular type of secondary structure, the protein density that formed the extracellular vestibule provided a tight seal to exclude the exchange of substances with the extracellular milieu.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Clin & Res Fdn, Div Cardiovasc Dis, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Yeager, M (corresponding author), Max Planck Inst Biophys, Abt Strukturbiol, Heinrich Hoffman Str 7, D-60528 Frankfurt, Germany.							AGARD DA, 1983, J MOL BIOL, V167, P849, DOI 10.1016/S0022-2836(83)80114-4; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BEYER EC, 1994, HDB MEMBRANE CHANNEL, P379; Bone LJ, 1997, NEUROBIOL DIS, V4, P221, DOI 10.1006/nbdi.1997.0152; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; CRAVATT BF, 1995, SCIENCE, V268, P1506, DOI 10.1126/science.7770779; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Ewart JL, 1997, DEVELOPMENT, V124, P1281; Foote CI, 1998, J CELL BIOL, V140, P1187, DOI 10.1083/jcb.140.5.1187; Guan XJ, 1997, J CELL BIOL, V139, P1785, DOI 10.1083/jcb.139.7.1785; Guerrero PA, 1997, J CLIN INVEST, V99, P1991, DOI 10.1172/JCI119367; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KUMAR NM, 1995, J CELL SCI, V108, P3725; Li HL, 1997, NAT STRUCT BIOL, V4, P263, DOI 10.1038/nsb0497-263; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; MAKOWSKI L, 1977, J CELL BIOL, V74, P629, DOI 10.1083/jcb.74.2.629; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; Perkins G, 1997, BIOPHYS J, V72, P533, DOI 10.1016/S0006-3495(97)78693-4; Perkins GA, 1998, J MOL BIOL, V277, P171, DOI 10.1006/jmbi.1997.1580; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; SPRAY DC, 1990, AM J PHYSIOL, V258, P195; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; Unger VM, 1997, NAT STRUCT BIOL, V4, P39, DOI 10.1038/nsb0197-39; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; White TW, 1998, NATURE, V394, P630, DOI 10.1038/29202; WHITE TW, 1995, MOL BIOL CELL, V6, P459, DOI 10.1091/mbc.6.4.459; YANCEY SB, 1989, J CELL BIOL, V108, P2241, DOI 10.1083/jcb.108.6.2241; YEAGER M, 1992, J MOL BIOL, V223, P929, DOI 10.1016/0022-2836(92)90253-G; Yeager M, 1999, Methods Enzymol, V294, P135; Yeager M, 1998, J STRUCT BIOL, V121, P231, DOI 10.1006/jsbi.1998.3972; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	41	410	420	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1176	1180		10.1126/science.283.5405.1176	http://dx.doi.org/10.1126/science.283.5405.1176			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024245				2022-12-28	WOS:000078738400054
J	Bodenheimer, T				Bodenheimer, T			The American health care system - Physicians and the changing medical marketplace	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		*AM MED ASS, 1996, MED GROUPS US; *AM MED ASS, 1999, MED GROUP PRACT US; *AM MED ASS, 1998, PHYS MARK STAT 1997; *AM MED ASS, 1998, SOC CHAR MED PRACT 1; *AM MED ASS, 1997, PHYS MARK STAT 1996; BENOFF M, 1998, HEALTHCARE FINAN AUG, P38; COFFMAN J, 1998, PEW HLTH PROFESSIONS; Cooper RA, 1998, JAMA-J AM MED ASSOC, V280, P788, DOI 10.1001/jama.280.9.788; *COUNC GRAD MED ED, 1998, 12 REP MIN MED; *COUNC GRAD MED ED, 1996, 8 REP PAT CAR PHYS S; Delbanco T, 1998, JAMA-J AM MED ASSOC, V280, P1560, DOI 10.1001/jama.280.18.1560; DiMatteo MR, 1998, WESTERN J MED, V168, P328; DIOGO S, 1998, AM MED NEWS     0907, P9; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Finger A L, 1998, Med Econ, V75, P170; FREUDENHEIM M, 1998, NY TIMES        0409, pC1; FREUDENHEIM M, 1998, NY TIMES        0110, P1; Ginzberg E, 1997, NEW ENGL J MED, V336, P1018, DOI 10.1056/NEJM199704033361411; GLABMAN M, 1998, PHYSICIANS FINA 1115, P36; GLABMAN M, 1998, PHYSICIANS FINA 1115, P1; Grumbach K, 1998, NEW ENGL J MED, V339, P1516, DOI 10.1056/NEJM199811193392106; HAGLAND M, 1997, CALIF MED, V8, P30; *HMO, 1998, 82 HMO; Kassirer JP, 1998, NEW ENGL J MED, V339, P1543, DOI 10.1056/NEJM199811193392109; Komaromy M, 1996, NEW ENGL J MED, V334, P1305, DOI 10.1056/NEJM199605163342006; LEIFER J, 1998, HOSP HLTH NETWO 0705, P82; Levit K, 1998, HEALTH AFFAIR, V17, P99, DOI 10.1377/hlthaff.17.6.99; *MED STAT GROUP, 1998, 1998 MED STAT QUAL C; Miller RS, 1998, JAMA-J AM MED ASSOC, V280, P777, DOI 10.1001/jama.280.9.777; *NAT CTR HLTH STAT, 1988, NAT AMB MED CAR SURV, V13; Relman A, 1998, HOSP HEALTH NETWORK, V72, P70; Rivo ML, 1996, NEW ENGL J MED, V334, P892, DOI 10.1056/NEJM199604043341405; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; Robinson JC, 1998, HEALTH AFFAIR, V17, P53, DOI 10.1377/hlthaff.17.4.53; Schroeder SA, 1996, JAMA-J AM MED ASSOC, V276, P1841, DOI 10.1001/jama.276.22.1841; TOKARSKI C, 1998, AM MEW NEWS     1207, P38; TOKARSKI C, 1998, AM MEW NEWS     1207, P1; Walker L, 1998, Bus Health, V16, P30; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; 1998, DIG MANAGED CARE, V2, P10	40	44	46	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1999	340	7					584	588		10.1056/NEJM199902183400725	http://dx.doi.org/10.1056/NEJM199902183400725			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168FD	10021483				2022-12-28	WOS:000078680100040
J	Hitchcock, P; Fransen, L				Hitchcock, P; Fransen, L			Preventing HIV infection: lessons from Mwanza and Rakai	LANCET			English	Editorial Material							TRANSMISSION		NIAID, Sexually Transmitted Dis Branch, Bethesda, MD 20892 USA; Commiss European Communities, Human Dev Unit DG VIII A2, B-1049 Brussels, Belgium	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Hitchcock, P (corresponding author), NIAID, Sexually Transmitted Dis Branch, 9000 Rockville Pike, Bethesda, MD 20892 USA.							Anderson R.M., 1991, RES ISSUES HUMAN BEH, P38; ANDERSON RM, 1988, NATURE, V333, P514, DOI 10.1038/333514a0; BLOWER SM, 1993, J ACQ IMMUN DEF SYND, V6, P1364; BOILY MC, 1997, HIDDEN EPIDEMIC CONF, P316; GARNETT GP, 1995, J ACQ IMMUN DEF SYND, V9, P500; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; MAY RM, 1989, CURRENT TOPICS AIDS, V2, P33; *WORLD BANK, 1998, CONFR AIDS PUBL PRIO, P103	8	55	55	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 13	1999	353	9152					513	515		10.1016/S0140-6736(99)00031-8	http://dx.doi.org/10.1016/S0140-6736(99)00031-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028974				2022-12-28	WOS:000078670200003
J	Rantanen, T; Guralnik, JM; Foley, D; Masaki, K; Leveille, S; Curb, JD; White, L				Rantanen, T; Guralnik, JM; Foley, D; Masaki, K; Leveille, S; Curb, JD; White, L			Midlife hand grip strength as a predictor of old age disability	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICAL-ACTIVITY; LATE-LIFE; WOMEN; MEN; PEOPLE; HEALTH	Context Poor muscle strength, functional limitations, and disability often coexist, but whether muscle strength during midlife predicts old age functional ability is not known. Objective To determine whether hand grip strength measured during midlife predicts old age functional limitations and disability in initially healthy men, Design and Setting A 25-year prospective cohort study, the Honolulu Heart Program, which began in 1965 among Japanese-American men living on Oahu, Hawaii. Participants A total of 6089 45- to 68-year-old men who were healthy at baseline and whose maximal hand grip strength was measured from 1965 through 1970, Altogether, 2259 men died over the follow-up period and 3218 survivors participated in the disability assessment in 1991 through 1993, Main Outcome Measures Functional limitations including slow customary walking speed (less than or equal to 0.4 m/s) and inability to rise from a seated position without using the arms, and multiple self-reported upper extremity, mobility, and self-care disability outcomes, Results After adjustment for multiple potential confounders, risk of functional limitations and disability 25 years later increased as baseline hand grip strength. divided into tertiles, declined. The odds ratio (OR) of walking speed of 0.4 m/s or slower was 2.87 (95% confidence interval [CI], 1.76-4.67) in those in the lowest third and 1.79 (95% CI, 1.14-2.81) in the middle third of grip strength vs those in the highest third, The risk of self-care disability was more than 2 times greater in the lowest vs the highest grip strength tertile. Adding chronic conditions identified at follow-up to the models predicting disability reduced the ORs related to grip strength only minimally, Conclusions Among healthy 45- to 68-year-old men, hand grip strength was highly predictive of functional limitations and disability 25 years later. Good muscle strength in midlife may protect people from old age disability by providing a greater safety margin above the threshold of disability.	NIA, Epidemiol Demog Biometry Program, NIH, Bethesda, MD 20892 USA; Kuakini Med Ctr, Asia Aging Study, Honolulu, HI USA; Honolulu Heart Program, Honolulu, HI USA; Univ Hawaii, Sch Med, Honolulu, HI 96822 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Hawaii System	Rantanen, T (corresponding author), Univ Jyvaskyla, Dept Hlth Sci, POB 35, SF-40351 Jyvaskyla, Finland.	Taina@maila.jyu.fi	Leveille, Suzanne G/ACS-6588-2022; Rantanen, Taina/O-6579-2016	Leveille, Suzanne G/0000-0003-0427-1580; Rantanen, Taina/0000-0002-1604-1945				Buchner DM, 1996, AGE AGEING, V25, P386, DOI 10.1093/ageing/25.5.386; ETTINGER WH, 1994, J AM GERIATR SOC, V42, P1035, DOI 10.1111/j.1532-5415.1994.tb06206.x; Ferrucci L, 1997, J GERONTOL A-BIOL, V52, pM275, DOI 10.1093/gerona/52A.5.M275; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FRONTERA WR, 1988, J APPL PHYSIOL, V64, P1038, DOI 10.1152/jappl.1988.64.3.1038; GURALNIK JM, 1989, AM J PUBLIC HEALTH, V79, P703, DOI 10.2105/AJPH.79.6.703; LACROIX AZ, 1993, AM J EPIDEMIOL, V137, P858, DOI 10.1093/oxfordjournals.aje.a116747; LaPlante MP, 1992, 7 US DEP ED NAT I DI; LAUNER LJ, 1995, JAMA-J AM MED ASSOC, V274, P1846, DOI 10.1001/jama.274.23.1846; Lissner L, 1996, AM J EPIDEMIOL, V143, P54; NAGI SZ, 1976, MILBANK FUND Q, V54, P439, DOI 10.2307/3349677; PINSKY JL, 1987, J CHRON DIS, V40, pS159, DOI 10.1016/S0021-9681(87)80045-0; Pinsky JL, 1987, J CHRONIC DIS S1, V40, p181S; Rantanen T, 1996, SCAND J REHABIL MED, V28, P89; Rantanen T, 1998, J APPL PHYSIOL, V85, P2047, DOI 10.1152/jappl.1998.85.6.2047; Rantanen T, 1998, AM J PHYS MED REHAB, V77, P299, DOI 10.1097/00002060-199807000-00008; Rantanen T., 2016, J AGING PHYS ACTIV, V2, P206, DOI 10.1123/japa.2.3.206; Rodriguez BL, 1996, DIABETES CARE, V19, P587, DOI 10.2337/diacare.19.6.587; Sakari-Rantala R, 1998, SCAND J REHABIL MED, V30, P121; Sipila S, 1996, ACTA PHYSIOL SCAND, V156, P457, DOI 10.1046/j.1365-201X.1996.461177000.x; TINETTI ME, 1995, JAMA-J AM MED ASSOC, V273, P1348, DOI 10.1001/jama.273.17.1348; VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1; White L, 1996, JAMA-J AM MED ASSOC, V276, P955, DOI 10.1001/jama.276.12.955	23	977	994	0	51	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1999	281	6					558	560		10.1001/jama.281.6.558	http://dx.doi.org/10.1001/jama.281.6.558			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	164FQ	10022113	Bronze			2022-12-28	WOS:000078452900035
J	Lipworth, BJ				Lipworth, BJ			Leukotriene-receptor antagonists	LANCET			English	Article							TO-MODERATE ASTHMA; AIRWAY-OBSTRUCTION; ALLERGIC RHINITIS; 5-LIPOXYGENASE; BRONCHOCONSTRICTION; ICI-204,219; ZAFIRLUKAST; ASPIRIN; POTENT	Leukotriene-receptor antagonists are the first novel class of antiasthma drugs to become available over the past three decades. They have an unique profile in that they are a hybrid of an anti-inflammatory and bronchodilator drug, and they can be taken as a tablet once or twice daily. The published data with leukotriene-receptor antagonists such as montelukast or zafirlukast show good antiasthmatic activity over a wide spectrum of asthma severity either as monotherapy or with inhaled steroids. Another potential spin-off of leukotriene-receptor antagonists is that they also seem to be effective in treating allergic rhinitis, which commonly coexists in patients with asthma. Here I overview the clinical pharmacology of leukotriene antagonists and appraise the published data from clinical trials, and look at the appropriate position of these agents in asthma management guidelines.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol, Dundee DD1 9SY, Scotland	University of Dundee	Lipworth, BJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol, Dundee DD1 9SY, Scotland.	b.j.lipworth@dundee.uk						Adkins JC, 1998, DRUGS, V55, P121, DOI 10.2165/00003495-199855010-00008; Altman LC, 1998, J ALLERGY CLIN IMMUN, V102, P50, DOI 10.1016/S0091-6749(98)70054-5; BARNES NC, 1996, AM J RESP CRIT CAR 2, V143, pA802; *BRIT MED ASS ROYA, 1998, BRIT NAT FORM; Calhoun WJ, 1998, AM J RESP CRIT CARE, V157, P1381, DOI 10.1164/ajrccm.157.5.9609014; Cheng HY, 1996, PHARM RES-DORDR, V13, P445, DOI 10.1023/A:1016056912698; Chiba M, 1997, DRUG METAB DISPOS, V25, P1022; CHRISTIE PE, 1991, AM REV RESPIR DIS, V144, P957, DOI 10.1164/ajrccm/144.4.957; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; DAHLEN B, 1993, EUR RESPIR J, V6, P1018; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DONNELLY AL, 1995, AM J RESP CRIT CARE, V151, P1734, DOI 10.1164/ajrccm.151.6.7767514; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953, DOI 10.1164/ajrccm.149.4.8143061; Fish JE, 1997, CLIN THER, V19, P675, DOI 10.1016/S0149-2918(97)80092-6; Grossman J., 1997, Journal of Allergy and Clinical Immunology, V99, pS443; Hamilton A, 1998, J ALLERGY CLIN IMMUN, V102, P177, DOI 10.1016/S0091-6749(98)70083-1; Hay DPH, 1997, CHEST, V111, pS35, DOI 10.1378/chest.111.2_Supplement.35S; Hofstra W. B., 1997, European Respiratory Journal Supplement, V10, p220S; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; Kemp JP, 1998, J PEDIATR-US, V133, P424, DOI 10.1016/S0022-3476(98)70281-1; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; Laitinen L. A., 1997, European Respiratory Journal Supplement, V10, p419S; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; LEFF JA, 1997, AM J RESP CRIT CARE, V155, pA977; LEFF JA, 1997, AM J RESP CRIT CARE, V155, pA976; Lipworth BJ, 1996, PULM PHARMACOL THER, V9, P19, DOI 10.1006/pulp.1996.0002; Malmstrom K., 1998, European Respiratory Journal, V12, p36S; Malmstrom K, 1998, J ALLERGY CLIN IMMUN, V101, pS97; NACLERIO RM, 1991, AM REV RESPIR DIS, V143, pS91, DOI 10.1164/ajrccm/143.5_Pt_2.S91; Nakamura Y, 1998, THORAX, V53, P835, DOI 10.1136/thx.53.10.835; National Institute of Occupational Safety and Health, 1997, NAT ASHM ED PREV PRO, P97; Nayak AS, 1998, J ALLERGY CLIN IMMUN, V101, pS233; Noonan MJ, 1998, EUR RESPIR J, V11, P1232, DOI 10.1183/09031936.98.11061232; OByrne PM, 1997, CHEST, V111, pS27, DOI 10.1378/chest.111.2_Supplement.27S; OSHAUGHNESSY KM, 1993, AM REV RESPIR DIS, V147, P142; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Riddick CA, 1997, EUR J BIOCHEM, V246, P112, DOI 10.1111/j.1432-1033.1997.00112.x; Ringdal N., 1997, European Respiratory Journal Supplement, V10, p437S; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856, DOI 10.1164/ajrccm.155.6.9196086; Rosenthal R, 1996, J ALLERGY CLIN IMMUN, V97, P270; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; Suissa S, 1997, ANN INTERN MED, V126, P177, DOI 10.7326/0003-4819-126-3-199702010-00001; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; TURPIN JA, 1998, AM J RESP CRIT CARE, V157, pA456; Wechsler ME, 1998, JAMA-J AM MED ASSOC, V279, P455, DOI 10.1001/jama.279.6.455; WESTBROEK J, 1997, EUR RESP J S25, V19, pS248; Zhao JJ, 1997, BIOPHARM DRUG DISPOS, V18, P769, DOI 10.1002/(SICI)1099-081X(199712)18:9<769::AID-BDD60>3.0.CO;2-K	49	156	165	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 2	1999	353	9146					57	62		10.1016/S0140-6736(98)09019-9	http://dx.doi.org/10.1016/S0140-6736(98)09019-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023966				2022-12-28	WOS:000077934800045
J	Kwiatkowska, J; Wigowska-Sowinska, J; Napierala, D; Slomski, R; Kwiatkowski, DJ				Kwiatkowska, J; Wigowska-Sowinska, J; Napierala, D; Slomski, R; Kwiatkowski, DJ			Mosaicism in tuberous sclerosis as a potential cause of the failure of molecular diagnosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOMATIC MOSAICISM; ASSOCIATION; TSC2; GENE; HETEROZYGOSITY; IDENTIFICATION; HAMARTOMAS; DISEASE; COMPLEX; AUTISM		Brigham & Womens Hosp, Div Expt Med & Med Oncol, Boston, MA 02115 USA; Polish Acad Sci, Inst Human Genet, PL-60479 Poznan, Poland; Univ Med Sci, Dept Dev Neurol, Poznan, Poland	Harvard University; Brigham & Women's Hospital; Polish Academy of Sciences; Institute of Human Genetics of the Polish Academy of Sciences	Kwiatkowski, DJ (corresponding author), Brigham & Womens Hosp, Div Expt Med & Med Oncol, 221 Longwood Ave, Boston, MA 02115 USA.	kwiatkowski@calvin.harvard.edu	Slomski, Ryszard/AGR-6196-2022; Jura, Jolanta/F-8889-2015	Slomski, Ryszard/0000-0001-5601-7002; Jura, Jolanta/0000-0002-0816-3475; Napierala, Dobrawa/0000-0002-7383-1011				Anliker MD, 1997, DERMATOLOGY, V195, P176, DOI 10.1159/000245727; Au KS, 1998, AM J HUM GENET, V62, P286, DOI 10.1086/301705; BERNARDS A, 1994, NEW ENGL J MED, V331, P1447, DOI 10.1056/NEJM199411243312110; Carbonara C, 1996, GENE CHROMOSOME CANC, V15, P18, DOI 10.1002/(SICI)1098-2264(199601)15:1<18::AID-GCC3>3.0.CO;2-7; Eng C, 1997, NAT BIOTECHNOL, V15, P422, DOI 10.1038/nbt0597-422; Gomez MR, 1988, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; HALL JG, 1988, AM J HUM GENET, V43, P355; Henske EP, 1996, AM J HUM GENET, V59, P400; Henske EP, 1997, AM J PATHOL, V151, P1639; HUNT A, 1993, J AUTISM DEV DISORD, V23, P323, DOI 10.1007/BF01046223; Jones AC, 1997, HUM MOL GENET, V6, P2155, DOI 10.1093/hmg/6.12.2155; KERR LA, 1993, UROLOGY, V41, P440, DOI 10.1016/0090-4295(93)90504-4; Kwiatkowska J, 1998, ANN HUM GENET, V62, P277, DOI 10.1046/j.1469-1809.1998.6240277.x; KWIATKOWSKI DJ, 1994, ARCH DERMATOL, V130, P348, DOI 10.1001/archderm.130.3.348; NELLIST M, 1993, CELL, V75, P1305; OSBORNE JP, 1991, ANN NY ACAD SCI, V615, P125; RAYMOND AA, 1994, NEUROLOGY, V44, P1841, DOI 10.1212/WNL.44.10.1841; ROACH ES, 1992, J CHILD NEUROL, V7, P221, DOI 10.1177/088307389200700219; SAMPSON JR, 1989, J MED GENET, V26, P28, DOI 10.1136/jmg.26.1.28; Sampson JR, 1997, AM J HUM GENET, V61, P843, DOI 10.1086/514888; SMALLEY SL, 1992, J AUTISM DEV DISORD, V22, P339, DOI 10.1007/BF01048239; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; VERHOEF S, 1995, LANCET, V345, P202, DOI 10.1016/S0140-6736(95)90213-9; Vrtel R, 1996, J MED GENET, V33, P47, DOI 10.1136/jmg.33.1.47; Yates JRW, 1997, HUM MOL GENET, V6, P2265, DOI 10.1093/hmg/6.13.2265	26	81	82	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1999	340	9					703	707		10.1056/NEJM199903043400905	http://dx.doi.org/10.1056/NEJM199903043400905			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172ZB	10053179				2022-12-28	WOS:000078955200005
J	Passner, JM; Ryoo, HD; Shen, LY; Mann, RS; Aggarwal, AK				Passner, JM; Ryoo, HD; Shen, LY; Mann, RS; Aggarwal, AK			Structure of a DNA-bound Ultrabithorax-Extradenticle homeodomain complex	NATURE			English	Article							CRYSTAL-STRUCTURE; HOMEOTIC GENE; SPECIFICITY; HOX; DROSOPHILA; PROTEINS; BINDING; MODEL; RECOGNITION; HETERODIMER	During the development of multicellular organisms, gene expression must be tightly regulated, both spatially and temporally, One set of transcription factors that are important in animal development is encoded by the homeotic (Hox) genes, which govern the choice between alternative developmental pathways along the anterior-posterior axis(1,2). Hox proteins, such as Drosophila Ultrabithorax, have low DNA-binding specificity by themselves but gain affinity and specificity when they bind together with the homeoprotein Extradenticle (or Pbx1 in mammals)(3,4). To understand the structural basis of Hox-Extradenticle pairing, we determine here the crystal structure of an Ultrabithorax-Extradenticle-DNA complex at 2.4 Angstrom resolution, using the minimal polypeptides that form a cooperative heterodimer. The Ultrabithorax and Extradenticle homeodomains bind opposite faces of the DNA, with their DNA-recognition helices almost touching each other. However, most of the cooperative interactions arise from the YPWM amino-acid motif of Ultrabithorax-located amino-terminally to its homeodomain-which forms a reverse turn and inserts into a hydrophobic pocket on the Extradenticle homeodomain surface. Together, these protein-DNA and protein-protein interactions define the general principles by which homeotic proteins interact with Extradenticle (or Pbx1) to affect development along the anterior-posterior axis of animals.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Columbia University	Aggarwal, AK (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, Box 1677,1425 Madison Ave, New York, NY 10029 USA.	aggarwal@inka.mssm.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054510] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM054510] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNNETT B, 1993, SURVEYS MATH IND, V3, P1; Chan SK, 1996, EMBO J, V15, P2476, DOI 10.1002/j.1460-2075.1996.tb00605.x; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; Chang CP, 1996, MOL CELL BIOL, V16, P1734; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fraenkel E, 1998, NAT STRUCT BIOL, V5, P692, DOI 10.1038/1382; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Hirsch JA, 1995, EMBO J, V14, P6280, DOI 10.1002/j.1460-2075.1995.tb00318.x; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klemm JD, 1996, GENE DEV, V10, P27, DOI 10.1101/gad.10.1.27; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; Lu Q, 1996, MOL CELL BIOL, V16, P1632; MANN RS, 1995, BIOESSAYS, V17, P855, DOI 10.1002/bies.950171007; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Phelan ML, 1997, J BIOL CHEM, V272, P8635, DOI 10.1074/jbc.272.13.8635; RAUSKOLB C, 1995, DEVELOPMENT, V121, P3663; Tan S, 1998, NATURE, V391, P660, DOI 10.1038/35563; Wolberger C, 1996, CURR OPIN STRUC BIOL, V6, P62, DOI 10.1016/S0959-440X(96)80096-0	30	256	262	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 25	1999	397	6721					714	719		10.1038/17833	http://dx.doi.org/10.1038/17833			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AP	10067897				2022-12-28	WOS:000078840100055
J	Schreiber, S; Nikolaus, S; Hampe, J; Hamling, J; Koop, I; Groessner, B; Lochs, H; Raedler, A				Schreiber, S; Nikolaus, S; Hampe, J; Hamling, J; Koop, I; Groessner, B; Lochs, H; Raedler, A			Tumour necrosis factor a and interleukin 1 beta in relapse of Crohn's disease	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; CHIMERIC MONOCLONAL-ANTIBODY; FACTOR-ALPHA; MAINTENANCE TREATMENT; RHEUMATOID-ARTHRITIS; ULCERATIVE-COLITIS; PLACEBO; INDEX; CA2	Background Concentrations of proinflammatory cytokines are increased in the intestinal mucosa of patients with active Crohn's disease. Experimental immunotherapeutic interventions with anticytokine agents in refractory Crohn's disease show that tumour necrosis factor cw (TNF alpha) may be an important mediator,of inflammation. We investigated the relation between production of TNF alpha and interleukin 1 beta by mononuclear cells of the colonic lamina propria in patients with remitting Crohn's disease and the risk of relapse. Methods We followed up 137 patients with Crohn's disease in steroid-induced remission for 1 year. Secretion of proinflammatory cytokines (tumour necrosis factor alpha [TNF alpha] and interleukin 1 beta) was assessed after short-term culture of human lamina propria mononuclear cells. Findings Increased secretion of TNF alpha and interleukin 1 beta were predictive for acute relapses within the next year. Site and extent of disease, baseline demographics, and serum acute-phase proteins had little predictive value. Interpretation TNF alpha is important as a target molecule for immune interventions in Crohn's disease. The capacity to produce TNFa or interleukin 1 beta may identify patients who would benefit from anti-inflammatory remission maintenance.	Univ Kiel, Dept Med 1, D-24105 Kiel, Germany; Univ Kiel, Dept Conservat Dent & Paradontol, D-24105 Kiel, Germany; Humboldt Univ, Charite Univ Hosp, 4th Med Dept, Berlin, Germany; Tabea Ctr Inflammatory Bowel Dis, Hamburg, Germany	University of Kiel; University of Kiel; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schreiber, S (corresponding author), Univ Kiel, Dept Med 1, D-24105 Kiel, Germany.	s.schreiber@mucosa.de	Hampe, Jochen/A-2555-2010	Hampe, Jochen/0000-0002-2421-6127				BELLUZI A, 1996, NEW ENGL J MED, V334, P1567; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; BRIGNOLA C, 1986, GASTROENTEROLOGY, V91, P1490, DOI 10.1016/0016-5085(86)90206-4; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; GENDRE JP, 1993, GASTROENTEROLOGY, V104, P435, DOI 10.1016/0016-5085(93)90411-5; Greenberg GR, 1996, GASTROENTEROLOGY, V110, P45, DOI 10.1053/gast.1996.v110.pm8536887; Hanauer SB, 1996, NEW ENGL J MED, V334, P841, DOI 10.1056/NEJM199603283341307; LIGUMSKY M, 1990, GUT, V31, P686, DOI 10.1136/gut.31.6.686; LILLIEFORS HW, 1967, J AM STAT ASSOC, V62, P399, DOI 10.2307/2283970; MACDONALD TT, 1990, CLIN EXP IMMUNOL, V81, P301; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; MUNKHOLM P, 1995, SCAND J GASTROENTERO, V30, P699, DOI 10.3109/00365529509096316; REINECKER HC, 1993, CLIN EXP IMMUNOL, V94, P174; RILEY SA, 1991, GUT, V32, P174, DOI 10.1136/gut.32.2.174; SCHREIBER S, 1995, GASTROENTEROLOGY, V108, P1434, DOI 10.1016/0016-5085(95)90692-4; Stack WA, 1997, LANCET, V349, P521, DOI 10.1016/S0140-6736(97)80083-9; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; WRIGHT JP, 1987, DIGEST DIS SCI, V32, P164, DOI 10.1007/BF01297104; WYATT J, 1993, LANCET, V341, P1437, DOI 10.1016/0140-6736(93)90882-H	19	239	246	1	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 6	1999	353	9151					459	461		10.1016/S0140-6736(98)03339-X	http://dx.doi.org/10.1016/S0140-6736(98)03339-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JQ	9989717				2022-12-28	WOS:000078572800013
J	Yusuf, S; Pogue, J; Anand, S; Flather, M; Fox, K; Tognoni, G; Diaz, R; Paolasso, E; Hunt, D; Varigos, J; Avezum, A; Piegas, L; Anand, S; Joyner, C; Theroux, P; Rupprecht, H; Wittlinger, T; Karatzas, N; Keltai, M; Sitkei, E; Halon, D; Lewis, BS; Franzosi, MG; Galli, M; Maggioni, A; Mauri, F; Ramos-Corrales, M; Budaj, A; Ceremuzynski, L; Commerford, P; Anderson, J				Yusuf, S; Pogue, J; Anand, S; Flather, M; Fox, K; Tognoni, G; Diaz, R; Paolasso, E; Hunt, D; Varigos, J; Avezum, A; Piegas, L; Anand, S; Joyner, C; Theroux, P; Rupprecht, H; Wittlinger, T; Karatzas, N; Keltai, M; Sitkei, E; Halon, D; Lewis, BS; Franzosi, MG; Galli, M; Maggioni, A; Mauri, F; Ramos-Corrales, M; Budaj, A; Ceremuzynski, L; Commerford, P; Anderson, J		Org Assess Strategies Ischemic Syndromes OASIS	Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial	LANCET			English	Article							MOLECULAR-WEIGHT HEPARIN; CORONARY-ARTERY DISEASE; UNFRACTIONATED HEPARIN; UNSTABLE ANGINA; ASPIRIN; THROMBIN; INHIBITION; PLACEBO	Background Despite the use of heparin and aspirin, 5-10% of patients with unstable angina develop myocardial infarction or refractory angina in hospital. We tested the hypothesis that recombinant hirudin (lepirudin), a direct thrombin inhibitor, would be superior to heparin, an indirect thrombin inhibitor, in patients with acute ischaemic syndromes who were receiving aspirin. Methods 10141 patients with unstable angina or suspected acute myocardial infarction without ST elevation were randomly assigned heparin (5000 units bolus then 15 units kg(-1) h(-1); n = 5058) or hirudin (0.4 mg/kg bolus then 0.15 mg kg(-1) h(-1) infusion; n = 5083) for 72 h in a double-blind trial. The primary outcome measure was cardiovascular death or new myocardial infarction at 7 days. Analysis was by intention to treat. Findings At 7 days, 213 (4.2%) patients in the heparin group and 182 (3.6%) in the hirudin group had experienced cardiovascular death or new myocardial infarction (relative risk 0.84 [95% CI 0.69-1.02]; p = 0.077). The numbers with cardiovascular death, new myocardial infarction, or refractory angina at 7 days were 340 (6.7%) with heparin and 284 (5.6%) with hirudin (0.82 [0.70-0.96]; p = 0.0125). These differences were primarily observed during the 72 h treatment period (cardiovascular death or myocardial infarction relative risk 0.76 [0.59-0.99], p = 0.039: cardiovascular death, myocardial infarction, or refractory angina 0.78 [0.63-0.96], p = 0.019). Although there was an excess of major bleeding requiring transfusion with hirudin (59 [1.2%] vs 34 [0.7%] with heparin; p = 0.01), there was no excess in life-threatening episodes (20 in each group) or strokes (14 in each group). Interpretation The data from OASIS-2 suggest that recombinant hirudin is superior to heparin in preventing cardiovascular death, myocardial infarction, and refractory angina with an acceptable safety profile in patients with unstable angina or acute myocardial infarction without ST elevation. Thus, a direct thrombin inhibitor is more effective than an indirect thrombin inhibitor.	McMaster Univ, Hamilton Gen Hosp, Div Cardiol, Hamilton, ON L8L 2X2, Canada	McMaster University	Yusuf, S (corresponding author), McMaster Univ, Hamilton Gen Hosp, Div Cardiol, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	yusufs@fhs.csu.mcmaster.ca	Avezum, Alvaro/AAP-7687-2020; Avezum, Alvaro AA/K-6137-2016; Manolis, Antonis/F-5003-2014	Avezum, Alvaro AA/0000-0002-3073-6890; Manolis, Antonis/0000-0002-0336-4745; Luz, Matthias/0000-0001-6646-3655				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Antman EM, 1996, CIRCULATION, V94, P911, DOI 10.1161/01.CIR.94.5.911; Bata I, 1997, CIRCULATION, V96, P769; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; Collins R, 1997, NEW ENGL J MED, V336, P847, DOI 10.1056/NEJM199703203361207; Eriksson BI, 1997, NEW ENGL J MED, V337, P1329, DOI 10.1056/NEJM199711063371901; FUSTER V, 1988, CIRCULATION, V77, P1213, DOI 10.1161/01.CIR.77.6.1213; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; HERAS M, 1990, CIRCULATION, V82, P1476, DOI 10.1161/01.CIR.82.4.1476; Klein W, 1997, CIRCULATION, V96, P61; MANTEL N, 1959, J NATL CANCER I, V22, P719; Oler A, 1996, JAMA-J AM MED ASSOC, V276, P811, DOI 10.1001/jama.276.10.811; SERRUYS PW, 1995, NEW ENGL J MED, V333, P757, DOI 10.1056/NEJM199509213331203; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol EJ, 1996, NEW ENGL J MED, V335, P775; Wallentin L, 1996, LANCET, V347, P561; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; White HD, 1997, CIRCULATION, V96, P2155; YUSUF S, 1988, JAMA-J AM MED ASSOC, V2601, P2259	22	292	296	2	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 6	1999	353	9151					429	438						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JQ	9989712				2022-12-28	WOS:000078572800008
J	Close, J; Ellis, M; Hooper, R; Glucksman, E; Jackson, S; Swift, C				Close, J; Ellis, M; Hooper, R; Glucksman, E; Jackson, S; Swift, C			Prevention of falls in the elderly trial (PROFET): a randomised controlled trial	LANCET			English	Article							NURSING-HOME RESIDENTS; HIP-FRACTURES; OLDER PERSONS; COMMUNITY; EMERGENCY; ACCIDENT; RISK; INJURY; DEPENDENCY; POPULATION	Background Falls in elderly people are a common presenting complaint to departments. Current practice commonly focuses on the injury, with little systematic assessment of the underlying cause, functional consequences, and possibilities for future prevention. We undertook a randomised controlled study to assess the benefit of a structured inderdisciplinary assessment of people who have fallen in terms of further falls. elderly people are a common to accident and emergency Methods Eligible patients were aged 65 years and older, lived in the community, and presented to an accident and emergency department with a fall. Patients assigned to the intervention group (n=184) underwent a detailed medical and occupational-therapy assessment with referral to relevant services if indicated; those assigned to the control group (n=213) received usual care only. The analyses were by intention to treat. Follow-up data were collected every 4 months for 1 year. Findings At 12-month follow-up, 77% of both groups remained in the study. The total reported number of falls during this period was 183 in the intervention group compared with 510 in the control group (p=0.0002). The risk of falling was significantly reduced in the intervention group (odds ratio 0.39 [95% CI 0.23-0.66]) as was the risk of recurrent falls (0.33 [0.16-0.68]). In addition, the odds of admission to hospital were lower in the intervention group (0.61 [0.35-1.05]) whereas the decline in Barthel score with time was greater in the control group (p<0.00001). Interpretation The study shows that an interdisciplinary approach to this high-risk population can significantly decrease the risk of further fails and limit functional impairment.	Univ London Kings Coll Hosp, Guys Kings & St Thomas Sch Med, Dept Hlth Care Elderly, Clin Age Res Unit, London, England; Univ London Kings Coll Hosp, Guys Kings & St Thomas Sch Med, Dept Publ Hlth Med, London, England; Univ London Kings Coll Hosp, Guys Kings & St Thomas Sch Med, Dept Accid & Emergency Med, London, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Close, J (corresponding author), Univ London Kings Coll, Sch Med & Dent, Dept Hlth Care Elderly, Clin Age Res Unit, London SE5 9PJ, England.		Close, Jacqueline CT/C-9803-2011	Close, Jacqueline CT/0000-0003-2908-9507; Hooper, Richard/0000-0002-1063-0917				CARPENTER GI, 1990, BMJ-BRIT MED J, V300, P1253, DOI 10.1136/bmj.300.6734.1253; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; Cryer PC, 1996, PUBLIC HEALTH, V110, P331, DOI 10.1016/S0033-3506(96)80004-7; CURRENS JH, 1948, AM HEART J, V35, P646, DOI 10.1016/0002-8703(48)90650-4; CURRIE CT, 1984, ARCH EMERG MED, V1, P205; Davies AJ, 1996, AGE AGEING, V25, P362, DOI 10.1093/ageing/25.5.362; FABACHER D, 1994, J AM GERIATR SOC, V42, P630, DOI 10.1111/j.1532-5415.1994.tb06862.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; HOLLINGWORTH W, 1995, J PUBLIC HEALTH MED, V17, P269; KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Khan SA, 1996, J ACCID EMERG MED, V13, P256; LAURITZEN JB, 1993, LANCET, V341, P11, DOI 10.1016/0140-6736(93)92480-H; LORD SR, 1995, J AM GERIATR SOC, V43, P1198, DOI 10.1111/j.1532-5415.1995.tb07394.x; MAHONEY F I, 1965, Md State Med J, V14, P61; MULROW CD, 1994, JAMA-J AM MED ASSOC, V271, P519, DOI 10.1001/jama.271.7.519; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; Prudham D, 1981, Age Ageing, V10, P141; RAI GS, 1995, J AM GERIATR SOC, V43, P723, DOI 10.1111/j.1532-5415.1995.tb07218.x; ROWLAND K, 1990, AGE AGEING, V19, P415, DOI 10.1093/ageing/19.6.415; RUBENSTEIN LZ, 1990, ANN INTERN MED, V113, P308, DOI 10.7326/0003-4819-113-4-308; SATTIN RW, 1990, AM J EPIDEMIOL, V131, P1028, DOI 10.1093/oxfordjournals.aje.a115594; SATTIN RW, 1992, ANNU REV PUBL HEALTH, V13, P489, DOI 10.1146/annurev.pu.13.050192.002421; *SECR STAT HLTH, 1998, OUR HLTH NAT CONTR H; Sheik JI, 1986, CLIN GERONTOLOGY GUI; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1987, J AM GERIATR SOC, V35, P644, DOI 10.1111/j.1532-5415.1987.tb04341.x; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TINETTI ME, 1994, J GERONTOL, V49, pM140, DOI 10.1093/geronj/49.3.M140; VETTER NJ, 1992, BMJ-BRIT MED J, V304, P888, DOI 10.1136/bmj.304.6831.888; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x; World Health Organization (WHO), 1981, GLOB STRAT HLTH ALL	33	637	650	0	60	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 9	1999	353	9147					93	97		10.1016/S0140-6736(98)06119-4	http://dx.doi.org/10.1016/S0140-6736(98)06119-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	157XP	10023893				2022-12-28	WOS:000078087200009
J	HSIEH, LC; YONKOVICH, S; KOCHERSPERGER, L; SCHULTZ, PG				HSIEH, LC; YONKOVICH, S; KOCHERSPERGER, L; SCHULTZ, PG			CONTROLLING CHEMICAL-REACTIVITY WITH ANTIBODIES	SCIENCE			English	Article							ENANTIOSELECTIVE REDUCTION; ORGANIC-SYNTHESIS; KETONES; MANDELATE	The remarkable specificity of an antibody molecule has been used to accomplish highly selective functional group transformations not attainable by current chemical methods. An antibody raised against an amine-oxide hapten catalyzes the reduction of a diketone to a hydroxyketone with greater than 75:1 regioselectivity for one of two nearly equivalent ketone moieties. The antibody-catalyzed reaction is highly stereoselective, affording the hydroxyketone in high enantiomeric excess. Similarly, the reduction of ketones containing branched and aryl substituents, including the highly symmetrical 1-nitrophenyl-3-phenyl-2-propanone, was enantioselective. The simple strategy presented herein may find general applicability to the regio- and stereoselective reduction of a broad range of compounds.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; AFFYMAX RES INST,DEPT BIOORGAN CHEM,PALO ALTO,CA 94304	University of California System; University of California Berkeley								COREY EJ, 1990, TETRAHEDRON LETT, V31, P611, DOI 10.1016/S0040-4039(00)94581-7; COREY EJ, 1987, J AM CHEM SOC, V109, P5551, DOI 10.1021/ja00252a056; DALE JA, 1973, J AM CHEM SOC, V95, P512, DOI 10.1021/ja00783a034; Finn MG, 1985, ASYMMETRIC SYNTHESIS, P247; GLADYSZ JA, 1992, ENANTIOSELECTIVE SYN, V92, P739; GONG B, 1992, J AM CHEM SOC, V114, P1486, DOI 10.1021/ja00030a056; GREENE TW, 1991, PROTECTIVE GROUPS OR; HUMMEL W, 1989, EUR J BIOCHEM, V184, P1, DOI 10.1111/j.1432-1033.1989.tb14983.x; JACOBS J, 1987, J AM CHEM SOC, V109, P2174, DOI 10.1021/ja00241a042; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KAGAN HB, 1982, COMPREHENSIVE ORGANO, V8, P463; KATSUKI T, 1980, J AM CHEM SOC, V102, P5974, DOI 10.1021/ja00538a077; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKAYAMA GR, 1992, J AM CHEM SOC, V114, P780, DOI 10.1021/ja00028a066; NOYORI R, 1989, MOD SYN MET, V5, P115; OJIMA I, 1985, ASYMMETRIC SYNTHESIS, V5, P104; SANTANIELLO E, 1992, CHEM REV, V92, P1071, DOI 10.1021/cr00013a016; SEEBACH D, 1990, ANGEW CHEM INT EDIT, V29, P1320, DOI 10.1002/anie.199013201; SIH CJ, 1984, ANGEW CHEM INT EDIT, V23, P570, DOI 10.1002/anie.198405701; SUH JH, 1991, B KOR CHEM SOC, V12, P352; TAIRA K, 1988, J MED CHEM, V31, P129, DOI 10.1021/jm00396a019; WAI JSM, 1989, J AM CHEM SOC, V111, P1123, DOI 10.1021/ja00185a050; WANG L, 1992, J AM CHEM SOC, V114, P7568, DOI 10.1021/ja00045a042; WONG CH, 1989, SCIENCE, V244, P1145, DOI 10.1126/science.2658059; XU DQ, 1992, J AM CHEM SOC, V114, P7570, DOI 10.1021/ja00045a043; ZASSINOVICH G, 1992, CHEM REV, V92, P1051, DOI 10.1021/cr00013a015	26	63	67	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 16	1993	260	5106					337	339		10.1126/science.10049109	http://dx.doi.org/10.1126/science.10049109			3	Multidisciplinary Sciences	Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX800	10049109				2022-12-28	WOS:A1993KX80000033
J	Saraste, M				Saraste, M			Oxidative phosphorylation at the fin de siecle	SCIENCE			English	Review							CYTOCHROME-C-OXIDASE; BOVINE HEART-MITOCHONDRIA; OXIDOREDUCTASE COMPLEX-I; PARACOCCUS-DENITRIFICANS; 2.8-ANGSTROM RESOLUTION; PROTON-TRANSLOCATION; CRYSTAL-STRUCTURE; BC(1) COMPLEX; ATP SYNTHASE; 2.8 ANGSTROM	Mitochondria produce most of the energy in animal cells by a process called oxidative phosphorylation. Electrons are passed along a series of respiratory enzyme complexes Located in the inner mitochondrial membrane, and the energy released by this electron transfer is used to pump protons across the membrane. The resultant electrochemical gradient enables another complex, adenosine 5'-triphosphate (ATP) synthase, to synthesize the energy carrier ATP. Important new mechanistic insights into oxidative phosphorylation have emerged from recent three-dimensional structural analyses of ATP synthase and two of the respiratory enzyme complexes, cytochrome be, and cytochrome c oxidase. This work, and new enzymological studies of ATP synthase's unusual catalytic mechanism, are reviewed here.	European Mol Biol Lab, D-69012 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Saraste, M (corresponding author), European Mol Biol Lab, Meyerhofstr 1,Postfach 102209, D-69012 Heidelberg, Germany.	Saraste@EMBL-Heidelberg.de						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; Behr J, 1998, BIOCHEMISTRY-US, V37, P7400, DOI 10.1021/bi9731697; Blanchet M. A., 1998, P NATL ACAD SCI USA, V95, P11065; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Brandt U, 1997, BBA-BIOENERGETICS, V1318, P79, DOI 10.1016/S0005-2728(96)00141-7; Brandt U, 1996, BBA-BIOENERGETICS, V1275, P41, DOI 10.1016/0005-2728(96)00048-5; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; Crofts AR, 1998, CURR OPIN STRUC BIOL, V8, P501, DOI 10.1016/S0959-440X(98)80129-2; Dutton PL, 1998, BBA-BIOENERGETICS, V1364, P245, DOI 10.1016/S0005-2728(98)00031-0; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; FRIEDRICH T, 1995, FEBS LETT, V367, P107, DOI 10.1016/0014-5793(95)00548-N; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hellwig P, 1998, BIOCHEMISTRY-US, V37, P7390, DOI 10.1021/bi9725576; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Jenkyns R, 1998, NEW YORK REV BOOKS, V45, P4; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; KNAFF DB, 1993, PHOTOSYNTH RES, V35, P117, DOI 10.1007/BF00014743; Konstantinov AA, 1997, P NATL ACAD SCI USA, V94, P9085, DOI 10.1073/pnas.94.17.9085; LAPPALAINEN P, 1993, J BIOL CHEM, V268, P26416; LUTTER R, 1993, BIOCHEM J, V295, P799, DOI 10.1042/bj2950799; MALMSTROM BG, 1993, FEBS LETT, V325, P49, DOI 10.1016/0014-5793(93)81411-R; Michel H, 1998, P NATL ACAD SCI USA, V95, P12819, DOI 10.1073/pnas.95.22.12819; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 1998, SCIENCE, V282, P1844, DOI 10.1126/science.282.5395.1844; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; RICH PR, 1995, AUST J PLANT PHYSIOL, V22, P479, DOI 10.1071/PP9950479; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sabbert D, 1997, P NATL ACAD SCI USA, V94, P4401, DOI 10.1073/pnas.94.9.4401; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Skehel JM, 1998, FEBS LETT, V438, P301, DOI 10.1016/S0014-5793(98)01317-9; Smith JL, 1998, SCIENCE, V281, P58, DOI 10.1126/science.281.5373.58; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VERHOVSKAYA ML, 1997, P NATL ACAD SCI USA, V94, P10128; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Wang HY, 1998, NATURE, V396, P279, DOI 10.1038/24409; Wikstrom M, 1998, CURR OPIN STRUC BIOL, V8, P480, DOI 10.1016/S0959-440X(98)80127-9; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WIKSTROM M, 1994, BBA-BIOENERGETICS, V1187, P106, DOI 10.1016/0005-2728(94)90093-0; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583	51	966	1000	3	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 5	1999	283	5407					1488	1493		10.1126/science.283.5407.1488	http://dx.doi.org/10.1126/science.283.5407.1488			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066163				2022-12-28	WOS:000078959200035
J	Berlin, JA; Colditz, GA				Berlin, JA; Colditz, GA			The role of meta-analysis in the regulatory process for foods, drugs, and devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; DOSE-RESPONSE DATA; PROSPECTIVE METAANALYSIS; RANDOMIZED TRIALS; LUNG-CANCER; CARDIOVASCULAR-DISEASE; INTRAVENOUS-MAGNESIUM; PUBLISHED LITERATURE; CLINICAL RESEARCH; BETA-CAROTENE	`Synthesis of research findings has a long-standing tradition in science. While synthesis is currently required in the US food and drug regulatory process, formal meta-analysis may substitute for a pivotal study or broaden the generalizability of drug efficacy through a preplanned meta-analysis, Preplanned meta-analysis of individual trials with deliberately introduced heterogeneity may maximize the generalizability of results from randomized trials. Combining observational data may help to support an alternative claim or to quantify adverse events. In this setting, methods to address potentially greater sources of bias are required. Overall, meta-analysis adds evidence through the synthesis study findings and permits examination of how treatment effects vary across of subgroups, such as age and sex, and across study settings.	Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Technol Assessment Grp, Boston, MA 02115 USA	University of Pennsylvania; Pennsylvania Medicine; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Berlin, JA (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 611 Blockley Hall, Philadelphia, PA 19104 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291				ANTMAN EM, 1995, AM J CARDIOL, V75, P391, DOI 10.1016/S0002-9149(99)80561-X; Antman EM, 1996, CARDIOVASC DRUG THER, V10, P297; Begg CB, 1996, STAT MED, V15, P1299, DOI 10.1002/(SICI)1097-0258(19960630)15:12<1299::AID-SIM311>3.0.CO;2-A; Berkey CS, 1996, CONTROL CLIN TRIALS, V17, P357, DOI 10.1016/S0197-2456(96)00014-1; BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406; BERLIN JA, 1993, EPIDEMIOLOGY, V4, P218, DOI 10.1097/00001648-199305000-00005; BERLIN JA, 1994, ONLINE J CURR CLIN T, V3; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; Cappelleri JC, 1996, JAMA-J AM MED ASSOC, V276, P1332, DOI 10.1001/jama.276.16.1332; Center for Drug Evaluation and Research, 1988, GUID FORM CONT CLIN; CHARLTON BG, 1994, BRIT J GEN PRACT, V44, P290; COLDITZ GA, 1995, PEDIATRICS, V96, P29; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; COLLINS R, 1995, LANCET, V345, P669; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; DICKMAN CA, 1994, SPINE, V19, P22665; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; Food and Drug Administration, 1998, FED REGISTER, V63, P8103; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P1089, DOI 10.1001/jama.279.14.1089; Kahlon T.S., 1997, FED REGISTER, V62, P3584; Langhorne P, 1998, BMJ-BRIT MED J, V316, P471; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; LINDSAY RM, 1993, AM STAT, V47, P217, DOI 10.2307/2684982; MARGITIC SE, 1995, J AM GERIATR SOC, V43, P435, DOI 10.1111/j.1532-5415.1995.tb05820.x; MOSTELLER F, 1992, STAT SCI, V7, P227; Olson BH, 1997, J NUTR, V127, P1973, DOI 10.1093/jn/127.10.1973; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; ONeill RT, 1996, CLIN RES REGUL AFF, V13, P23, DOI 10.3109/10601339609019626; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; PROBSTFIELD J, 1995, J AM GERIATR SOC, V43, P452, DOI 10.1111/j.1532-5415.1995.tb05823.x; RIPSIN CM, 1992, JAMA-J AM MED ASSOC, V267, P3317, DOI 10.1001/jama.267.24.3317; Shuster JJ, 1996, ANN ONCOL, V7, P1009; SIMES JR, 1995, AM J CARDIOL, V76, pC122; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; SMITH SJ, 1995, STAT MED, V14, P531, DOI 10.1002/sim.4780140513; TEMPLE R, 1992, DRUG INF J, V25, P485; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; TWEEDIE RL, 1995, STAT MED, V14, P545, DOI 10.1002/sim.4780140514; Valsecchi MG, 1996, ANN ONCOL, V7, P1005; Whitehead A, 1997, STAT MED, V16, P2901, DOI 10.1002/(SICI)1097-0258(19971230)16:24<2901::AID-SIM700>3.3.CO;2-X; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; YUSUF S, 1995, BRIT MED J, V310, P751, DOI 10.1136/bmj.310.6982.751; YUSUF S, 1988, LANCET, V1, P1088; Ziegler RG, 1996, CANCER CAUSE CONTROL, V7, P157, DOI 10.1007/BF00115646	47	68	69	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					830	834		10.1001/jama.281.9.830	http://dx.doi.org/10.1001/jama.281.9.830			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10071005				2022-12-28	WOS:000078804300034
J	Temple, R				Temple, R			Meta-analysis and epidemiologic studies in drug development and postmarketing surveillance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RANDOMIZED TRIALS; CLINICAL-TRIALS; METAANALYSIS; NEED		US FDA, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Temple, R (corresponding author), US FDA, Ctr Drug Evaluat & Res, 5600 Fishers Ln,HFD-101, Rockville, MD 20857 USA.							Alderman M, 1997, J HYPERTENS, V15, P105; ANGELL M, 1994, NEW ENGL J MED, V331, P189, DOI 10.1056/NEJM199407213310309; [Anonymous], FED REG; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Berlin JA, 1999, JAMA-J AM MED ASSOC, V281, P830, DOI 10.1001/jama.281.9.830; Brewer T, 1999, JAMA-J AM MED ASSOC, V281, P824, DOI 10.1001/jama.281.9.824; Cappelleri JC, 1996, JAMA-J AM MED ASSOC, V276, P1332, DOI 10.1001/jama.276.16.1332; Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research, 1998, GUID IND PROV CLIN E; *CTR DRUG EV RES, 1998, GUID FORM CONT CLIN; *CTR DRUG EV RES, 1989, GUID STUD DRUGS LIK; Food and Drug Administration, 1993, FED REG, V58, P39406; Fuchs CS, 1999, NEW ENGL J MED, V340, P169, DOI 10.1056/NEJM199901213400301; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; *INT SOC PHARM, 1996, PHARMACOEPIDEM DR S, V5, P333; LABARTHE DR, 1979, J CHRON DIS, V32, P95, DOI 10.1016/0021-9681(79)90021-3; LAU J, 1995, J CLIN EPIDEMIOL, V48, P45, DOI 10.1016/0895-4356(94)00106-Z; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; MacMahon S, 1997, J HYPERTENS, V15, P1201, DOI 10.1097/00004872-199715110-00002; MOHER D, 1995, JAMA-J AM MED ASSOC, V274, P1962, DOI 10.1001/jama.274.24.1962; ONEILL RT, 1966, CLIN RES REGUL AFF, V13, P23; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; ROSSI AC, 1983, JAMA-J AM MED ASSOC, V249, P2226, DOI 10.1001/jama.249.16.2226; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SCHOENBERGER JA, 1980, JAMA-J AM MED ASSOC, V243, P661; TAUBES G, 1995, SCIENCE, V269, P164, DOI 10.1126/science.7618077; Temple R, 1990, Int J Technol Assess Health Care, V6, P211; TEMPLE R, 1992, DRUG INF J, V25, P485; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; YUSUF S, 1986, CIRCULATION, V73, P14, DOI 10.1161/01.CIR.73.1.14	32	59	61	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					841	844		10.1001/jama.281.9.841	http://dx.doi.org/10.1001/jama.281.9.841			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10071007				2022-12-28	WOS:000078804300036
J	Potter, AR				Potter, AR			Conferences should be held where the problems are	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					613	613		10.1136/bmj.318.7183.613	http://dx.doi.org/10.1136/bmj.318.7183.613			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037670	Green Published			2022-12-28	WOS:000078966300088
J	Skelton, JR; Hobbs, FDR				Skelton, JR; Hobbs, FDR			Descriptive study of cooperative language in primary care consultations by male and female doctors	BRITISH MEDICAL JOURNAL			English	Article							PATIENT	Objective To compare the use of some of the characteristics of male and female language by male and female primary care practitioners during consultations. Design Doctors' use of the language of dominance and support was explored by using concordancing software. Three areas were examined: mean number of words per consultation; relative frequency of question tags; and use of migrated directives The analysis of language associated with cooperative talk examines relevant words or phrases and their immediate context Subjects 26 male and 14 female doctors in general practice, in a total of 373 consecutive consultations. Setting West Midlands. Results Doctors spoke significantly more words than patients, but the number of words spoken by male and female doctors did not differ significantly. Question tags were used far more frequently by doctors (P<0.001) than by patients or companions. Frequency of use was similar in male and female doctors, and the speech styles in consultation were similar. Conclusions These data show that male and female doctors use a speech style which is not gender specific, contrary to findings elsewhere; doctors consulted in an overtly non-directive, negotiated style, which is realised through suggestions and affective comments. This mode of communication is the core teaching of communication skills courses. These results suggest that men have more to learn to achieve competence as professional communicators.	Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Skelton, JR (corresponding author), Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.			hobbs, richard/0000-0001-7976-7172				ATKINSON JM, 1984, STRUCTURES SOCIAL A; CALDAS-COULTHARD C. R., 1996, TEXTS PRACTICE READI; Cameron D., 1992, FEMINISM LINGUISTIC, V2nd; Cameron Deborah, 1989, WOMEN THEIR SPEECH C, P74; Candlin C., 1976, P 4 INT C APPL LING, P297; Coates Jennifer, 1993, WOMEN MEN LANGUAGE, V2nd; COULTHARD M, 1975, J COMMUN, V25, P140, DOI 10.1111/j.1460-2466.1975.tb00616.x; COULTHARD M, 1993, DATA DESCRIPTION DIS, P86; Elyan O, 1978, SOCIOLINGUISTIC PATT, P122; FISHER S, 1983, SOCIAL ORG DOCTOR PA; Glaser BG, 1968, DISCOVERY GROUNDED T; GODWIN MJ, 1980, WOMEN LANGUAGE LIT S, P153; Hoey Michael., 1991, PATTERNS LEXIS TEXT; Holmes J., 1984, TE REO, V27, P47; Mishler EG, 1984, DISCOURSE MED DIALEC; Roter DL, 1989, COMMUNICATING MED PA; SIMPSON M, 1991, BRIT MED J, V303, P1385, DOI 10.1136/bmj.303.6814.1385; SINCLAIR J, 1989, LOOKING ACCOUNT COBU; Sinclair J. M., 1975, ANAL DISCOURSE; Sinclair John, 1987, COBUILD ENGLISH LANG; Stewart MA, 1995, CAN MED ASS, V152, P423; WEST C, 1984, SYMB INTERACT, V7, P87, DOI 10.1525/si.1984.7.1.87; West C., 1990, DISCOURSE SOC, V1, P85, DOI 10.1177/0957926590001001005; WEST C, 1983, ROUTINE COMPLICATION; WOODS N, 1989, WOMEN THEIR SPEECH C	25	32	32	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					576	579		10.1136/bmj.318.7183.576	http://dx.doi.org/10.1136/bmj.318.7183.576			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037635	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000078966300030
J	Gupta, K; Scholes, U; Stamm, WE				Gupta, K; Scholes, U; Stamm, WE			Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	38th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 24-28, 1998	SAN DIEGO, CALIFORNIA				URINARY-TRACT INFECTIONS	Context Guidelines for the management of acute uncomplicated cystitis in women that recommend empirical therapy in properly selected patients rely on the predictability of the agents causing cystitis and knowledge of their antimicrobial susceptibility patterns. Objective To assess the prevalence of and trends in antimicrobial resistance among uropathogens causing well-defined episodes of acute uncomplicated cystitis in a large population of women. Design Cross-sectional survey of antimicrobial susceptibilities of urine isolates collected during a 5-year period (January, May, and September 1992-1996). Setting Health maintenance organization. Patients Women aged 18 to 50 years with an outpatient diagnosis of acute cystitis. Main Outcome Measures Proportion of uropathogens demonstrating in vitro resistance to selected antimicrobials; trends in resistance over the 5-year study period. Results Escherichia coli and Staphylococcus saprophyticus were the most common uropathogens, accounting for 90% of the 4342 urine isolates studied. The prevalence of resistance among E coli and all isolates combined was more than 20% for ampicillin, cephalothin, and sulfamethoxazole in each year studied. The prevalence of resistance to trimethoprim and trimethoprim-sulfamethoxazole rose from more than 9% in 1992 to more than 18% in 1996 among E coli, and from 8% to 16% among all isolates combined. There was a statistically significant increasing linear trend in the prevalence of resistance from 1992 to 1996 among E coli and all isolates combined to ampicillin (P<.002), and to cephalothin, trimethoprim, and trimethoprim-sulfamethoxazole (P<.001). in contrast, the prevalence of resistance to nitrofurantoin, gentamicin, and ciprofloxacin hydrochloride was 0% to 2% among E coli and less than 10% among all isolates combined, and did not change significantly during the 5-year period. Conclusions While the prevalence of resistance to trimethoprim-sulfamethoxazole, ampicillin, and cephalothin increased significantly among uropathogens causing acute cystitis, resistance to nitrofurantoin and ciprofloxacin remained infrequent. These in vitro susceptibility patterns should be considered along with other factors, such as efficacy, cost, and cost-effectiveness in selecting empirical therapy for acute uncomplicated cystitis in women.	Univ Washington, Sch Med, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA	University of Washington; University of Washington Seattle; Group Health Cooperative	Stamm, WE (corresponding author), Univ Washington, Sch Med, Dept Med, Div Allergy & Infect Dis, 1959 NE Pacific St,BB1225,Box 356523, Seattle, WA 98195 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053369] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53369] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bacheller CD, 1997, MED CLIN N AM, V81, P719, DOI 10.1016/S0025-7125(05)70542-3; BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; GRUNEBERG RN, 1994, J ANTIMICROB CHEMO S, V33, pS1; HOOTON TM, 1995, JAMA-J AM MED ASSOC, V273, P41; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; Jinnah F, 1996, J INT MED RES, V24, P296, DOI 10.1177/030006059602400310; KONEMAN EW, 1992, COLOR ATLAS TXB DIAG, P77; KUNIN CM, 1994, CLIN INFECT DIS, V18, P1, DOI 10.1093/clinids/18.1.1; MAARTENS G, 1994, S AFR MED J, V84, P600; PATTON JP, 1991, MED CLIN N AM, V75, P495, DOI 10.1016/S0025-7125(16)30466-7; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P397; STAMM WE, 1993, NEW ENGL J MED, V329, P1328, DOI 10.1056/NEJM199310283291808; THOMSON KS, 1994, J ANTIMICROB CHEMOTH, V33, P9, DOI 10.1093/jac/33.suppl_A.9; Weber G, 1997, EUR J CLIN MICROBIOL, V16, P834, DOI 10.1007/BF01700414; Winstanley TG, 1997, J ANTIMICROB CHEMOTH, V40, P591, DOI 10.1093/jac/40.4.591	15	376	396	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1999	281	8					736	738		10.1001/jama.281.8.736	http://dx.doi.org/10.1001/jama.281.8.736			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BD	10052444				2022-12-28	WOS:000078669900033
J	Chui, SSY; Lo, SMF; Charmant, JPH; Orpen, AG; Williams, ID				Chui, SSY; Lo, SMF; Charmant, JPH; Orpen, AG; Williams, ID			A chemically functionalizable nanoporous material [Cu-3(TMA)(2)(H2O)(3)](n)	SCIENCE			English	Article							COORDINATION; ZEOLITE; FRAMEWORK; CHANNELS; NETWORK; TPT=2,4,6-TRI(4-PYRIDYL)-1,3,5-TRIAZINE; CATALYSIS; SOLIDS	Although zeolites and related materials combine nanoporosity with high thermal stability, they are difficult to modify or derivatize in a systematic way. A highly porous metal coordination polymer [Cu-3(TMA)(2)(H2O)(3)](n) (where TMA is benzene-1,3,5-tricarboxylate) was formed in 80 percent yield. It has interconnected [Cu-2(O2CR)(4)] units (where R is an aromatic ring), which create a three-dimensional system of channels with a pore size of 1 nanometer and an accessible porosity of about 40 percent in the solid. Unlike zeolites, the channel Linings can be chemically functionalized; for example, the aqua ligands can be replaced by pyridines. Thermal gravimetric analysis and high-temperature single-crystal diffractometry indicate that the framework is stable up to 240 degrees C.	Hong Kong Univ Sci & Technol, Dept Chem, Hong Kong, Peoples R China; Univ Bristol, Sch Chem, Bristol BS8 1TS, Avon, England	Hong Kong University of Science & Technology; University of Bristol	Williams, ID (corresponding author), Hong Kong Univ Sci & Technol, Dept Chem, Hong Kong, Peoples R China.	chwill@ust.hk	williams, ian d/B-2907-2009; Chui, Sin Yin/D-3067-2009	williams, ian d/0000-0001-8743-401X; 				Abrahams BF, 1996, CHEM COMMUN, P1313, DOI 10.1039/cc9960001313; ABRAHAMS BF, 1994, NATURE, V369, P727, DOI 10.1038/369727a0; Abrahams BF, 1996, ANGEW CHEM INT EDIT, V35, P1690, DOI 10.1002/anie.199616901; AKPORIAYE OE, 1994, J CHEM SOC CHEM COMM, P1711; ANDERSON MW, 1994, NATURE, V367, P347, DOI 10.1038/367347a0; BATTEN SR, 1995, J AM CHEM SOC, V117, P5385, DOI 10.1021/ja00124a032; Blake AJ, 1997, CHEM COMMUN, P1005, DOI 10.1039/a700866j; BLAKE AJ, 1996, CHEM COMMUN, P2027; BRECK DW, 1974, ZEOLITE MOL SIEVES, P48; Bu XH, 1997, SCIENCE, V278, P2080, DOI 10.1126/science.278.5346.2080; CARLUCCI L, 1995, J AM CHEM SOC, V117, P4562, DOI 10.1021/ja00121a014; CECCHERELLI P, 1991, TETRAHEDRON, V47, P7403, DOI 10.1016/S0040-4020(01)89741-6; Chui SSY, 1999, ACTA CRYSTALLOGR C, V55, P194, DOI 10.1107/S0108270198010944; Cotton F.A., 1972, INORG SYNTH, V13, P81; DAVIS ME, 1993, ACCOUNTS CHEM RES, V26, P111, DOI 10.1021/ar00027a006; FENG P, 1997, J AM CHEM SOC, V119, P24987; Feng PY, 1997, NATURE, V388, P735, DOI 10.1038/41937; Fujita M, 1996, B CHEM SOC JPN, V69, P1471, DOI 10.1246/bcsj.69.1471; FUJITA M, 1994, J AM CHEM SOC, V116, P1151, DOI 10.1021/ja00082a055; GABLE RW, 1990, J CHEM SOC CHEM COMM, P1677, DOI 10.1039/c39900001677; GARDNER GB, 1995, NATURE, V374, P792, DOI 10.1038/374792a0; Gutschke SOH, 1996, CHEM COMMUN, P823, DOI 10.1039/cc9960000823; Kawata S, 1996, INORG CHEM, V35, P4449, DOI 10.1021/ic9603520; KEPERT CJ, 1998, CHEM COMMUN, V31, P2027; KITAGAWA S, 1998, 1 INT C IN MAT VERS; Li H, 1998, J AM CHEM SOC, V120, P8571, DOI 10.1021/ja981669x; PECH R, 1988, ACTA CRYSTALLOGR C, V44, P992, DOI 10.1107/S0108270188002902; SOMA T, 1994, ANGEW CHEM INT EDIT, V33, P1665, DOI 10.1002/anie.199416651; SUBRAMANIAN S, 1995, ANGEW CHEM INT EDIT, V34, P2127, DOI 10.1002/anie.199521271; WILSON ST, 1982, J AM CHEM SOC, V104, P1146, DOI 10.1021/ja00368a062; YAGHI OM, 1995, NATURE, V378, P703, DOI 10.1038/378703a0	31	4872	5036	144	2491	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 19	1999	283	5405					1148	1150		10.1126/science.283.5405.1148	http://dx.doi.org/10.1126/science.283.5405.1148			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024237				2022-12-28	WOS:000078738400046
J	Voight, B; Sparks, RSJ; Miller, AD; Stewart, RC; Hoblitt, RP; Clarke, A; Ewart, J; Aspinall, WP; Baptie, B; Calder, ES; Cole, P; Druitt, TH; Hartford, C; Herd, RA; Jackson, P; Lejeune, AM; Lockhart, AB; Loughlin, SC; Luckett, R; Lynch, L; Norton, GE; Robertson, R; Watson, IM; Watts, R; Young, SR				Voight, B; Sparks, RSJ; Miller, AD; Stewart, RC; Hoblitt, RP; Clarke, A; Ewart, J; Aspinall, WP; Baptie, B; Calder, ES; Cole, P; Druitt, TH; Hartford, C; Herd, RA; Jackson, P; Lejeune, AM; Lockhart, AB; Loughlin, SC; Luckett, R; Lynch, L; Norton, GE; Robertson, R; Watson, IM; Watts, R; Young, SR			Magma flow instability and cyclic activity at Soufriere Hills Volcano, Montserrat, British West Indies	SCIENCE			English	Article							ERUPTIONS	Dome growth at the Soufriere Hills volcano (1996 to 1998) was frequently accompanied by repetitive cycles of earthquakes, ground deformation, degassing, and explosive eruptions. The cycles reflected unsteady conduit flow of volatile-charged magma resulting from gas exsolution, rheological stiffening, and pressurization. The cycles, over hours to days, initiated when degassed stiff magma retarded flow in the upper conduit. Conduit pressure built with gas exsolution, causing shallow seismicity and edifice inflation. Magma and gas were then expelled and the edifice deflated. The repeat time-scale is controlled by magma ascent rates, degassing, and microlite crystallization kinetics. Cyclic behavior allows short-term forecasting of timing, and of eruption style related to explosivity potential.	Montserrat Volcano Observ, Montserrat, W Ind Assoc St; US Geol Survey, Volcano Hazards program, Cascades Volcano Observ, Vancouver, WA USA	United States Department of the Interior; United States Geological Survey	Voight, B (corresponding author), Penn State Univ, Dept Geosci, University Pk, PA 16802 USA.	voight@ems.psu.edu	Cole, Paul D/A-8454-2011; Robertson, Richard/A-6949-2017; Aspinall, Willy/AAW-1022-2020; Watson, Matt/E-5236-2011; Jolly, Gill/G-9637-2014	Cole, Paul D/0000-0002-2964-311X; Robertson, Richard/0000-0001-5245-2787; Aspinall, Willy/0000-0001-6014-6042; Watson, Matt/0000-0001-9198-2203; Loughlin, Susan/0000-0001-7218-9664; Jolly, Gill/0000-0003-1413-2541; Clarke, Amanda/0000-0002-1637-0474; Druitt, Timothy/0000-0002-6594-1448				Aspinall WP, 1998, GEOPHYS RES LETT, V25, P3397, DOI 10.1029/98GL00858; Barclay J, 1998, GEOPHYS RES LETT, V25, P3437, DOI 10.1029/98GL00856; Devine JD, 1998, GEOPHYS RES LETT, V25, P3673, DOI 10.1029/98GL00912; Devine JD, 1998, GEOPHYS RES LETT, V25, P3669, DOI 10.1029/98GL01330; ENDO ET, 1991, B VOLCANOL, V53, P533, DOI 10.1007/BF00298154; GU JC, 1984, J MECH PHYS SOLIDS, V32, P167, DOI 10.1016/0022-5096(84)90007-3; Hess KU, 1996, AM MINERAL, V81, P1297; Jackson P, 1998, GEOPHYS RES LETT, V25, P3409, DOI 10.1029/98GL01656; Miller AD, 1998, GEOPHYS RES LETT, V25, P3401, DOI 10.1029/98GL01778; MILLER AD, 1996, NATURE, V380, P309; MINDLIN RD, 1950, J APPL PHYS, V21, P926, DOI 10.1063/1.1699785; Murphy MD, 1998, GEOPHYS RES LETT, V25, P3433, DOI 10.1029/98GL00713; Neuberg J, 1998, GEOPHYS RES LETT, V25, P3661, DOI 10.1029/98GL01441; OKUBO P, 1986, EARTHQUAKE SOURCE ME, P25; RABINOWICZ E, 1958, P PHYS SOC LOND, V71, P668, DOI 10.1088/0370-1328/71/4/316; RICE JR, 1983, J APPL MECH-T ASME, V50, P343, DOI 10.1115/1.3167042; Robertson R, 1998, GEOPHYS RES LETT, V25, P3429, DOI 10.1029/98GL01442; Scholz C. H., 1990, MECH EARTHQUAKES FAU; Shepherd JB, 1998, GEOPHYS RES LETT, V25, P3413, DOI 10.1029/98GL01655; Sparks RSJ, 1998, GEOPHYS RES LETT, V25, P3421, DOI 10.1029/98GL00639; Sparks RSJ, 1997, EARTH PLANET SC LETT, V150, P177, DOI 10.1016/S0012-821X(97)00109-X; STASIUK MV, 1993, EARTH PLANET SC LETT, V114, P505, DOI 10.1016/0012-821X(93)90079-O; Voight B, 1998, GEOPHYS RES LETT, V25, P3405, DOI 10.1029/98GL01160; WALSH JB, 1971, J GEOPHYS RES, V76, P3291, DOI 10.1029/JB076i014p03291; Young SR, 1998, GEOPHYS RES LETT, V25, P3681, DOI 10.1029/98GL01406; Young SR, 1998, GEOPHYS RES LETT, V25, P3389, DOI 10.1029/98GL01405	27	232	233	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1138	1142		10.1126/science.283.5405.1138	http://dx.doi.org/10.1126/science.283.5405.1138			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024234				2022-12-28	WOS:000078738400043
J	Goodnough, LT; Brecher, ME; Kanter, MH; AuBuchon, JP				Goodnough, LT; Brecher, ME; Kanter, MH; AuBuchon, JP			Medical progress - Transfusion medicine - Second of two parts - Blood conservation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE NORMOVOLEMIC HEMODILUTION; INTRAOPERATIVE AUTOLOGOUS TRANSFUSION; TOTAL-HIP-ARTHROPLASTY; RADICAL PROSTATECTOMY; COST-EFFECTIVENESS; ORTHOPEDIC-SURGERY; PERIOPERATIVE HEMODILUTION; VIRUS INACTIVATION; CARDIAC OPERATIONS; RANDOMIZED TRIAL		Washington Univ, Sch Med, Dept Med, Div Lab Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ N Carolina, Dept Pathol, Chapel Hill, NC USA; Univ N Carolina, Dept Lab Med, Chapel Hill, NC USA; So Calif Permanente Med Grp, Dept Pathol, Woodland Hills, CA USA; Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03766 USA	Washington University (WUSTL); Washington University (WUSTL); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; Dartmouth College	Goodnough, LT (corresponding author), Washington Univ, Sch Med, Dept Med, Div Lab Med, Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.		kanter, michael howard/W-2753-2019					AUBUCHON JP, 1994, JAMA-J AM MED ASSOC, V272, P1210, DOI 10.1001/jama.272.15.1210; AUBUCHON JP, 1994, VOX SANG, V66, P176, DOI 10.1111/j.1423-0410.1994.tb00306.x; AXELROD FB, 1989, TRANSFUSION, V29, P677, DOI 10.1046/j.1537-2995.1989.29890020438.x; BELL K, 1992, TRANSFUSION MED, V2, P295, DOI 10.1111/j.1365-3148.1992.tb00173.x; BIRKMEYER JD, 1993, TRANSFUSION, V33, P544, DOI 10.1046/j.1537-2995.1993.33793325048.x; BIRKMEYER JD, 1994, ANN THORAC SURG, V57, P161, DOI 10.1016/0003-4975(94)90386-7; Blum LN, 1998, TRANSFUSION, V38, P891, DOI 10.1046/j.1537-2995.1998.38998409012.x; BOVILL DF, 1986, ORTHOPEDICS, V9, P1403; BRECHER ME, 1994, TRANSFUSION, V34, P176, DOI 10.1046/j.1537-2995.1994.34294143950.x; Brecher ME, 1997, TRANSFUSION, V37, P1070, DOI 10.1046/j.1537-2995.1997.371098016448.x; BRECHER ME, IN PRESS TRANSFUSION; Charlton M, 1998, HEPATOLOGY, V28, P839, DOI 10.1002/hep.510280335; CLAGETT GP, IN PRESS J VASC SURG; CLEMENTS DH, 1992, J BONE JOINT SURG AM, V74A, P646, DOI 10.2106/00004623-199274050-00003; Cohen JA, 1996, TRANSFUSION, V36, P1036; COHEN JA, 1995, TRANSFUSION, V35, P640, DOI 10.1046/j.1537-2995.1995.35895357894.x; ENG J, 1990, EUR J CARDIO-THORAC, V4, P595, DOI 10.1016/1010-7940(90)90018-U; FARIS PM, 1991, J BONE JOINT SURG AM, V73A, P1169, DOI 10.2106/00004623-199173080-00005; Faris PM, 1991, J BONE JOINT SURG AM, V73, P15801; Goodnough L T, 1997, Hematology, V2, P413, DOI 10.1080/10245332.1997.11746363; Goodnough Lawrence T., 1996, American Journal of Medicine, V101, p33S, DOI 10.1016/S0002-9343(96)00167-2; GOODNOUGH LT, 1995, J LAB CLIN MED, V126, P57; Goodnough LT, 1996, J VASC SURG, V24, P213, DOI 10.1016/S0741-5214(96)70096-4; GOODNOUGH LT, 1994, UROLOGY, V44, P226; GOODNOUGH LT, 1992, VOX SANG, V63, P96, DOI 10.1111/j.1423-0410.1992.tb02493.x; GOODNOUGH LT, 1992, TRANSFUSION, V32, P441, DOI 10.1046/j.1537-2995.1992.32592327718.x; GOODNOUGH LT, 1994, AM J CLIN PATHOL, V101, P354; Goodnough LT, 1996, VOX SANG, V71, P133, DOI 10.1046/j.1423-0410.1996.7130133.x; GOODNOUGH LT, 1989, TRANSFUSION, V29, P821, DOI 10.1046/j.1537-2995.1989.29990070188.x; GOODNOUGH LT, 1990, VOX SANG, V59, P65, DOI 10.1111/j.1423-0410.1990.tb05010.x; GOODNOUGH LT, 1994, ANESTH ANALG, V78, P932; Goodnough LT, 1998, VOX SANG, V75, P128, DOI 10.1159/000030973; GOODNOUGH LT, IN PRESS VOX SANG; Grass JA, 1998, BLOOD, V91, P2180, DOI 10.1182/blood.V91.6.2180.2180_2180_2188; HEALY JC, 1994, ARCH PATHOL LAB MED, V118, P465; Kanter MH, 1996, JAMA-J AM MED ASSOC, V276, P798, DOI 10.1001/jama.276.10.798; Kasper SM, 1998, TRANSFUSION, V38, P669, DOI 10.1046/j.1537-2995.1998.38798346636.x; Kasper SM, 1998, ANESTH ANALG, V87, P284, DOI 10.1097/00000539-199808000-00009; Kasper SM, 1997, TRANSFUSION, V37, P1058, DOI 10.1046/j.1537-2995.1997.371098016445.x; Klein HG, 1998, TRANSFUSION, V38, P102, DOI 10.1046/j.1537-2995.1998.38198141508.x; Larocque BJ, 1997, TRANSFUSION, V37, P463, DOI 10.1046/j.1537-2995.1997.37597293874.x; Larocque BJ, 1998, TRANSFUSION, V38, P932, DOI 10.1046/j.1537-2995.1998.381098440857.x; Lin L, 1997, TRANSFUSION, V37, P423, DOI 10.1046/j.1537-2995.1997.37497265344.x; Linden JV, 1997, TRANSFUSION, V37, P455, DOI 10.1046/j.1537-2995.1997.37597293872.x; LORENTZ A, 1991, ANAESTHESIST, V40, P205; Loscalzo J, 1997, J LAB CLIN MED, V129, P580, DOI 10.1016/S0022-2143(97)90191-8; Ma ZM, 1997, CLIN CHEM, V43, P1732; MARGOLISNUNNO H, 1994, TRANSFUSION, V34, P802, DOI 10.1046/j.1537-2995.1994.34994378283.x; Mercuriali F, 1996, CURR MED RES OPIN, V13, P465, DOI 10.1185/03007999609115227; MERCURIALI F, 1993, TRANSFUSION, V33, P55, DOI 10.1046/j.1537-2995.1993.33193142311.x; MESSMER K, 1986, EUR SURG RES, V18, P254, DOI 10.1159/000128533; MONK TG, 1995, TRANSFUSION, V35, P559, DOI 10.1046/j.1537-2995.1995.35795357877.x; Monk TG, 1997, ANESTH ANALG, V85, P953, DOI 10.1097/00000539-199711000-00001; MONK TG, IN PRESS ANESTHESIOL; MOROFF G, 1992, BLOOD CELLS, V18, P43; Napier JAF, 1997, BRIT J ANAESTH, V78, P768, DOI 10.1093/bja/78.6.768; NESS PM, 1992, TRANSFUSION, V32, P226, DOI 10.1046/j.1537-2995.1992.32392213805.x; Nishizawa T, 1997, BIOCHEM BIOPH RES CO, V241, P92, DOI 10.1006/bbrc.1997.7765; POPOVSKY MA, 1995, TRANSFUSION, V35, P734, DOI 10.1046/j.1537-2995.1995.35996029156.x; RENNER SW, 1992, ARCH PATHOL LAB MED, V116, P613; RITTER MA, 1994, J BONE JOINT SURG AM, V76A, P35, DOI 10.2106/00004623-199401000-00005; ROBERTS SR, 1991, AM J SURG, V162, P477, DOI 10.1016/0002-9610(91)90265-F; SCHAFF HV, 1978, J THORAC CARDIOV SUR, V75, P632; Schmied H, 1998, ANESTH ANALG, V86, P387, DOI 10.1097/00000539-199802000-00032; Scott MG, 1997, CLIN CHEM, V43, P1724; Thomas MJG, 1996, TRANSFUSION, V36, P633, DOI 10.1046/j.1537-2995.1996.36796323063.x; THURER RL, 1979, ANN THORAC SURG, V27, P500, DOI 10.1016/S0003-4975(10)63358-9; TOY PTCY, 1993, TRANSFUSION, V33, P721, DOI 10.1046/j.1537-2995.1993.33994025020.x; TOY PTCY, 1987, NEW ENGL J MED, V316, P517, DOI 10.1056/NEJM198702263160906; TOY PTCY, 1992, TRANSFUSION, V32, P63, DOI 10.1046/j.1537-2995.1992.32192116435.x; UMLAS J, 1994, TRANSFUSION, V34, P402, DOI 10.1046/j.1537-2995.1994.34594249051.x; VOAK D, 1993, TRANSFUSION MED, V3, P307, DOI 10.1111/j.1365-3148.1993.tb00067.x; WAGNER SJ, 1993, PHOTOCHEM PHOTOBIOL, V57, P819, DOI 10.1111/j.1751-1097.1993.tb09217.x; WARD HB, 1993, ANN THORAC SURG, V56, P137, DOI 10.1016/0003-4975(93)90418-H; White KL, 1997, ANESTH ANALG, V84, pS58; WILLIAMSON KR, 1991, TRANSFUSION, V31, P662, DOI 10.1046/j.1537-2995.1991.31791368347.x; WINSLOW RM, 1995, NAT MED, V1, P1212, DOI 10.1038/nm1195-1212; WODA R, 1992, CAN J ANAESTH, V39, P290, DOI 10.1007/BF03008792; YAMADA AH, 1993, J UROLOGY, V149, P73, DOI 10.1016/S0022-5347(17)36002-0; YOMTOVIAN R, 1992, J BONE JOINT SURG AM, V74A, P1265, DOI 10.2106/00004623-199274080-00021; 1996, TRANSFUSION, V36, P667	81	220	230	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1999	340	7					525	533		10.1056/NEJM199902183400706	http://dx.doi.org/10.1056/NEJM199902183400706			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168FD	10021474				2022-12-28	WOS:000078680100006
J	Schofield, PM; Sharples, LD; Caine, N; Burns, S; Tait, S; Wistow, T; Buxton, M; Wallwork, J				Schofield, PM; Sharples, LD; Caine, N; Burns, S; Tait, S; Wistow, T; Buxton, M; Wallwork, J			Transmyocardial laser revascularisation in patients with refractory angina: a randomised controlled trial	LANCET			English	Article							MYOCARDIAL REVASCULARIZATION	Background Transmyocardial laser revascularisation (TMLR) is used to treat patients with refractory angina due to severe coronary artery disease, not suitable for conventional revascularisation. We aimed in a randomised controlled trial to assess the effectiveness of TMLR compared with medical management. Methods 188 patients with refractory angina were randomly assigned TMLR plus normal medication or medical management alone. At 3 months, 6 months, and 12 months after surgery (TMLR) or initial assessment (medical management) we assessed exercise capacity with the treadmill test and the 12 min walk. Findings Mean treadmill exercise time, adjusted for baseline values, was 40 s (95% CI -15 to 94) longer in the TMLR group than in the medical-management group at 12 months (p = 0.152). Mean 12 min walk distance was 33 m (-7 to 74) further in TMLR patients than medical-management patients (p = 0.108) at 12 months. The differences were not significant or clinically important. Perioperative mortality was 5%. Survival at 12 months was 89% (83-96) in the TMLR group and 96% (92-100) in the medical-management group (p = 0.14). Canadian Cardiovascular Society score for angina had decreased by at least two classes in 25% of TMLR and 4% of medical-management patients at 12 months (p < 0.001). Interpretation Our findings show that the adoption of TMLR cannot be advocated. Further research may be appropriate to assess any potential benefit for sicker patients.	Papworth Hosp, NHS Trust, Cambridge CB3 8RE, England; Univ Forvie Site, Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England; Norfolk & Norwich Hosp, Norwich NR1 3SR, Norfolk, England; Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England	Papworth Hospital; MRC Biostatistics Unit; University of Cambridge; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital; Brunel University	Wallwork, J (corresponding author), Papworth Hosp, NHS Trust, Papworth Everard, Cambridge CB3 8RE, England.			Sharples, Linda/0000-0003-0894-966X				BRESLOW NE, 1984, APPL STAT-J ROY ST C, V33, P38; Breslow NE., 1987, STAT METHODS CANC RE, P81; BRUCE RA, 1969, B NEW YORK ACAD MED, V45, P1288; Burns SM, 1998, J AM COLL CARDIOL, V31, p226A, DOI 10.1016/S0735-1097(97)84686-4; Burns SM, 1999, EUR HEART J, V20, P31, DOI 10.1053/euhj.1998.1202; Cooley DA, 1996, J THORAC CARDIOV SUR, V111, P791, DOI 10.1016/S0022-5223(96)70339-2; COOPER KH, 1968, J AMER MED ASSOC, V203, P201, DOI 10.1001/jama.203.3.201; *DEP HLTH, 1995, CLIN EFFECTIVENESS E, P105; *DEP HLTH, 1998, 1 CLASS SERV QUAL NE; DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378; FRAZIER OH, 1995, CIRCULATION, V92, P58, DOI 10.1161/01.CIR.92.9.58; HARDY RI, 1987, LASER SURG MED, V6, P563; HARDY RI, 1990, BASIC RES CARDIOL, V85, P179, DOI 10.1007/BF01906971; Horvath KA, 1997, J THORAC CARDIOV SUR, V113, P645, DOI 10.1016/S0022-5223(97)70221-6; HORVATH KA, 1995, J AM COLL CARDIOL, V25, P258, DOI 10.1016/0735-1097(94)00410-R; Josefson D, 1998, BRIT MED J, V316, P1409; MACHIN D, 1987, STAT TABLES DESIGN C, P136; MIRHOSEINI M, 1986, LASER SURG MED, V6, P459, DOI 10.1002/lsm.1900060507; MIRHOSEINI M, 1983, Lasers in Surgery and Medicine, V3, P241, DOI 10.1002/lsm.1900030307; MIRHOSEINI M, 1981, Journal of Microsurgery, V2, P253; Mirhoseini M, 1993, J Clin Laser Med Surg, V11, P15; MIRHOSEINI M, 1988, ANN THORAC SURG, V45, P415, DOI 10.1016/S0003-4975(98)90015-7; MIRHOSEINI M, 1982, Lasers in Surgery and Medicine, V2, P187, DOI 10.1002/lsm.1900020209; MIRHOSEINI M, 1990, J CLIN LASER MED SUR, V6, P73; VINEBERG A, 1954, J Int Coll Surg, V22, P503; Yamamoto N, 1998, J AM COLL CARDIOL, V31, P1426, DOI 10.1016/S0735-1097(98)00086-2	26	280	291	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 13	1999	353	9152					519	524		10.1016/S0140-6736(98)11478-2	http://dx.doi.org/10.1016/S0140-6736(98)11478-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028979				2022-12-28	WOS:000078670200008
J	Lensing, AWA; Prandoni, P; Prins, MH; Buller, HR				Lensing, AWA; Prandoni, P; Prins, MH; Buller, HR			Deep-vein thrombosis	LANCET			English	Article							MOLECULAR-WEIGHT HEPARIN; ORAL ANTICOAGULANT-THERAPY; SUSPECTED VENOUS-THROMBOSIS; COAGULATION-FACTOR-V; ACTIVATED PROTEIN-C; IMPEDANCE PLETHYSMOGRAPHY; PULMONARY-EMBOLISM; INITIAL TREATMENT; UNFRACTIONATED HEPARIN; COMPRESSION ULTRASONOGRAPHY	Deep-vein thrombosis is an important complication of several inherited and acquired disorders, but may also occur spontaneously, prevention of recurrent venous thrombosis and pulmonary embolism is the main reason for accurate diagnosis and adequate treatment. This seminar discusses only symptomatic deep-vein thrombosis. The diagnosis can be confirmed by objective tests in only about 30% of patients with symptoms. Venous thromboembolic complications happen in less than 1% of untreated patients in whom the presence of venous thrombosis is rejected on the basis of serial ultrasonography or ultrasonography plus either D-dimer or clinical score. Initial anticoagulant treatment (intravenous or subcutaneous heparin) should continue until oral anticoagulant treatment, started concurrently, increases the international normalised ratio above 2.0 for more than 24 h. The optimum duration of oral anticoagulant treatment is unresolved, but may be guided by the presence of temporary or persistent risk factors or presentation with recurrent venous thromboembolism.	Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands; Univ Hosp Padua, Inst Med Semeiot, Padua, Italy	University of Amsterdam; Academic Medical Center Amsterdam; University of Padua; Azienda Ospedaliera - Universita di Padova	Lensing, AWA (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, Meibergdreef 9,F-4, NL-1105 AZ Amsterdam, Netherlands.							AMIRAL J, 1995, THROMB HAEMOSTASIS, V73, P21; BASU D, 1972, NEW ENGL J MED, V287, P324, DOI 10.1056/NEJM197208172870703; Becker DM, 1996, ARCH INTERN MED, V156, P939, DOI 10.1001/archinte.156.9.939; BENARDI E, 1998, BMJ-BRIT MED J, V317, P1037; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BEYTH RJ, 1995, ARCH INTERN MED, V155, P1031, DOI 10.1001/archinte.155.10.1031; Birdwell BG, 1998, ANN INTERN MED, V128, P1, DOI 10.7326/0003-4819-128-1-199801010-00001; Brandjes DPM, 1997, LANCET, V349, P759, DOI 10.1016/S0140-6736(96)12215-7; BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; BULLER HR, 1991, THROMB HAEMOSTASIS, V66, P133; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; Cogo A, 1998, BRIT MED J, V316, P17, DOI 10.1136/bmj.316.7124.17; COGO A, 1993, ARCH INTERN MED, V153, P2777, DOI 10.1001/archinte.153.24.2777; Cohen AT, 1996, HAEMOSTASIS, V26, P65; Cornuz J, 1996, ANN INTERN MED, V125, P785, DOI 10.7326/0003-4819-125-10-199611150-00001; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; Davidson BL, 1998, BRIT MED J, V316, P2, DOI 10.1136/bmj.316.7124.2; Decousus H, 1998, NEW ENGL J MED, V338, P409, DOI 10.1056/NEJM199802123380701; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; denHeijer M, 1996, NEW ENGL J MED, V334, P759, DOI 10.1056/NEJM199603213341203; DeStefano V, 1996, BLOOD, V87, P3531, DOI 10.1182/blood.V87.9.3531.bloodjournal8793531; Fiessinger JN, 1996, THROMB HAEMOSTASIS, V76, P195; Franzeck UK, 1996, CIRCULATION, V93, P74, DOI 10.1161/01.CIR.93.1.74; Ginsberg JS, 1997, ARCH INTERN MED, V157, P1077, DOI 10.1001/archinte.157.10.1077; GREENFIELD LJ, 1988, SURGERY, V104, P706; Hansson PO, 1997, ARCH INTERN MED, V157, P1665, DOI 10.1001/archinte.157.15.1665; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HELDAL M, 1993, J INTERN MED, V234, P71, DOI 10.1111/j.1365-2796.1993.tb00707.x; HIRSH J, 1995, NEW ENGL J MED, V332, P1710, DOI 10.1056/NEJM199506223322510; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HIRSH J, 1995, CHEST, V108, pS231, DOI 10.1378/chest.108.4_Supplement.231S; HIRSH J, 1990, ACTA CHIR SCAND, P42; HIRSH J, 1993, HEMOSTASIS THROMBOSI, P1543; HIRSH J, 1993, HEMOSTASIS THROMBOSI, P1346; HOMMES DW, 1992, ANN INTERN MED, V116, P279, DOI 10.7326/0003-4819-116-4-279; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HUISMAN MV, 1989, CHEST, V95, P498, DOI 10.1378/chest.95.3.498; HUISMAN MV, 1988, ARCH INTERN MED, V148, P681, DOI 10.1001/archinte.148.3.681; HULL R, 1981, CIRCULATION, V64, P622, DOI 10.1161/01.CIR.64.3.622; HULL R, 1981, ANN INTERN MED, V94, P12, DOI 10.7326/0003-4819-94-1-12; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1983, CIRCULATION, V67, P901, DOI 10.1161/01.CIR.67.4.901; Karp R B, 1966, Surg Forum, V17, P147; Kearon C, 1998, ANN INTERN MED, V128, P663, DOI 10.7326/0003-4819-128-8-199804150-00011; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; KOSTER T, 1995, LANCET, V345, P152, DOI 10.1016/S0140-6736(95)90166-3; Kraaijenhagen R A, 1997, Curr Opin Pulm Med, V3, P268, DOI 10.1097/00063198-199707000-00006; Laffan M, 1998, BRIT MED J, V317, P520; Lee A Y, 1997, Curr Opin Pulm Med, V3, P275, DOI 10.1097/00063198-199707000-00007; LENSING AWA, 1990, RADIOLOGY, V177, P503, DOI 10.1148/radiology.177.2.2217792; LENSING AWA, 1992, THROMB HAEMOSTASIS, V67, P8; LENSING AWA, 1995, ARCH INTERN MED, V155, P601, DOI 10.1001/archinte.155.6.601; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LENSING AWA, 1993, HEMOSTASIS THROMBOSI, P1297; LENSING AWA, 1993, VASCULAR DIAGNOSIS, P875; LEVINE MN, 1995, THROMB HAEMOSTASIS, V74, P606; MAHORNER H, 1957, ANN SURG, V146, P510; MONREAL M, 1993, J INTERN MED, V233, P233, DOI 10.1111/j.1365-2796.1993.tb00981.x; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; POULTER NR, 1995, LANCET, V346, P1575; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; PRANDONI P, 1993, CIRCULATION, V88, P1730, DOI 10.1161/01.CIR.88.4.1730; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; Prins MH, 1997, THROMB HAEMOSTASIS, V78, P121; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; ROGERS LQ, 1990, AM J MED, V88, P389, DOI 10.1016/0002-9343(90)90494-X; ROSENDAAL FR, 1991, LANCET, V337, P260, DOI 10.1016/0140-6736(91)90867-O; Salzman E. X., 1993, HEMOSTASIS THROMBOSI, P1275; Schulman S, 1998, AM J MED, V104, P332, DOI 10.1016/S0002-9343(98)00060-6; Schulman S, 1997, NEW ENGL J MED, V336, P393, DOI 10.1056/NEJM199702063360601; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; Simioni P, 1997, NEW ENGL J MED, V336, P399, DOI 10.1056/NEJM199702063360602; Simonneau G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002; SUDLOW MF, 1992, LANCET, V340, P873; tenCate JW, 1997, NEW ENGL J MED, V337, P657; TRIPLETT DA, 1995, THROMB RES, V78, P1, DOI 10.1016/0049-3848(95)00001-1; van den Belt AGM, 1998, THROMB HAEMOSTASIS, V79, P259, DOI 10.1055/s-0037-1614975; VANDENBELT AGM, 1998, COCHRANE LIBRARY CDR; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007; Wells PS, 1995, THROMB HAEMOSTASIS, V74, P1423; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; Wells PS, 1997, LANCET, V350, P1795, DOI 10.1016/S0140-6736(97)08140-3; YOUNG E, 1992, THROMB HAEMOSTASIS, V67, P639	88	182	202	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 6	1999	353	9151					479	485		10.1016/S0140-6736(98)04298-6	http://dx.doi.org/10.1016/S0140-6736(98)04298-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JQ	9989735				2022-12-28	WOS:000078572800044
J	Munger, JS; Huang, XZ; Kawakatsu, H; Griffiths, MJD; Dalton, SL; Wu, JF; Pittet, JF; Kaminski, N; Garat, C; Matthay, MA; Rifkin, DB; Sheppard, D				Munger, JS; Huang, XZ; Kawakatsu, H; Griffiths, MJD; Dalton, SL; Wu, JF; Pittet, JF; Kaminski, N; Garat, C; Matthay, MA; Rifkin, DB; Sheppard, D			The integrin alpha v beta 6 binds and activates latent TGF beta 1: A mechanism for regulating pulmonary inflammation and fibrosis	CELL			English	Article							GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; TGF-BETA; EPITHELIAL INTEGRINS; FIBRONECTIN RECEPTOR; GENE-EXPRESSION; FACTOR-BETA-1; MICE	Transforming growth factor beta (TGF beta) family members are secreted in inactive complexes with a latency-associated peptide (LAP), a protein derived from the N-terminal region of the TGF beta gene product. Extracellular activation of these complexes is a critical but incompletely understood step in regulation of TGF beta function in vivo. We show that TGF beta 1 LAP is a ligand for the integrin alpha v beta 6 and that alpha v beta 6-expressing cells induce spatially restricted activation of TGF beta 1, This finding explains why mice lacking this integrin develop exaggerated inflammation and, as we show, are protected from pulmonary fibrosis. These data identify a novel mechanism for locally regulating TGF beta 1 function in vivo by regulating expression of the alpha v beta 6 integrin.	Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; New York University; New York University	Sheppard, D (corresponding author), Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA.			Kaminski, Naftali/0000-0001-5917-4601; Munger, John/0000-0002-9679-2983	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056385, R01HL047412, R01HL053949, P01HL056385] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47412, HL56385, HL53949] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; BARCELLOSHOFF MH, 1994, J CLIN INVEST, V93, P892, DOI 10.1172/JCI117045; BarcellosHoff MH, 1996, MOL ENDOCRINOL, V10, P1077, DOI 10.1210/me.10.9.1077; BARCELLOSHOFF MH, 1995, AM J PATHOL, V147, P1228; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BREUSS JM, 1995, J CELL SCI, V108, P2241; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; BUSK M, 1992, J BIOL CHEM, V267, P5790; CONE RI, 1994, CELL ADHES COMMUN, V2, P101, DOI 10.3109/15419069409004430; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; GIRI SN, 1993, THORAX, V48, P959, DOI 10.1136/thx.48.10.959; GRAINGER DJ, 1995, NAT MED, V1, P932, DOI 10.1038/nm0995-932; Huang XZ, 1998, J CELL SCI, V111, P2189; Huang XZ, 1996, J CELL BIOL, V133, P921, DOI 10.1083/jcb.133.4.921; Huang XZ, 1998, AM J RESP CELL MOL, V19, P636, DOI 10.1165/ajrcmb.19.4.3293; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; McMahon GA, 1996, BIOCHEM J, V313, P343, DOI 10.1042/bj3130343; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SCHULZ E, 1994, ACROS CHIMICA ACTA, V1, P1; SHEPPARD D, 1992, J BIOL CHEM, V267, P17409; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590; Taipale J, 1996, J HISTOCHEM CYTOCHEM, V44, P875, DOI 10.1177/44.8.8756760; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; Wang A, 1996, AM J RESP CELL MOL, V15, P664, DOI 10.1165/ajrcmb.15.5.8918373; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0	40	1528	1610	1	108	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 5	1999	96	3					319	328		10.1016/S0092-8674(00)80545-0	http://dx.doi.org/10.1016/S0092-8674(00)80545-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025398	Bronze			2022-12-28	WOS:000078514600005
J	Nguyen, MH; Kauffman, CA; Goodman, RP; Squier, C; Arbeit, RD; Singh, N; Wagener, MM; Yu, VL				Nguyen, MH; Kauffman, CA; Goodman, RP; Squier, C; Arbeit, RD; Singh, N; Wagener, MM; Yu, VL			Nasal carriage of and infection with Staphylococcus aureus in HIV-infected patients	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; AIDS-RELATED COMPLEX; BACTEREMIA; VIRUS; HEMODIALYSIS; COLONIZATION	Background: Staphylococcus aureus is a common cause of serious infection in patients infected with HIV. Objectives: To evaluate risk factors for and quantitative effect of S. aureus infection in HIV-infected patients, with special attention to nasal carriage. Design: Prospective, multihospital cohort study. Setting: Three tertiary care Veterans Affairs Medical Centers. Participants: 231 ambulatory HIV-infected patients. Results: Thirty-four percent of patients were nasal carriers of S. aureus. Of these patients, 38% were persistent carriers and 62% were intermittent carriers. Twenty-one episodes of infection occurred in 13 patients: Ten were bacteremias (including 2 cases of endocarditis), 1 was pneumonia, and 10 were cutaneous or subcutaneous infections. Seventeen (85%) of these episodes occurred in patients with CD4 counts less than 100 cells/mm(3). Recurrent infections occurred in 3 of 7 patients who survived an initial S. aureus infection. The mortality rate was higher among patients with S. aureus infection than among those without infection (P = 0.03). Factors significantly associated with S. aureus infection were nasal carriage, presence of a vascular catheter, low CD4 count, and neutropenia. Molecular strain typing indicated that for 6 of 7 infected patients, the strain of S. aureus isolated from the infected sites was the same as that previously cultured from the nares. Conclusion: Nasal carriage is an important risk factor for S. aureus infection in HIV-infected patients. Controlled studies are indicated to determine whether eradication of nasal carriage in a selected subset of patients (for example, those with a low CD4 cell count) might prevent invasive S. aureus infection in patients with HIV infection.	Vet Affairs Med Ctr, Infect Dis Sect 111, Pittsburgh, PA 15240 USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; Univ Michigan, Med Ctr, Ann Arbor, MI USA; Vet Affairs Med Ctr, Div Infect Dis, Ann Arbor, MI 48105 USA; Boston Univ, Med Ctr, Boston, MA USA; Vet Affairs Med Ctr, Boston, MA 02130 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Yu, VL (corresponding author), Vet Affairs Med Ctr, Infect Dis Sect 111, Univ Dr C, Pittsburgh, PA 15240 USA.	vly+@pitt.edu						BOELAERT JR, 1993, NEPHROL DIAL TRANSPL, V8, P235; ELLIS M, 1988, J INFECT DIS, V158, P1268, DOI 10.1093/infdis/158.6.1268; FICHTENBAUM CJ, 1995, J ACQ IMMUN DEF SYND, V8, P51; Fleiss JL, 1981, STATISTICAL METHODS, P75; GANESH R, 1989, LANCET, V2, P558; GOETZ AM, 1994, AM J INFECT CONTROL, V22, P334, DOI 10.1016/0196-6553(94)90031-0; JACOBSON MA, 1988, AM J MED, V85, P172, DOI 10.1016/S0002-9343(88)80337-1; Kluytmans JAJW, 1996, INFECT CONT HOSP EP, V17, P780; LUZAR MA, 1990, NEW ENGL J MED, V322, P505, DOI 10.1056/NEJM199002223220804; MASLOW JN, 1995, EUR J CLIN MICROBIOL, V14, P282, DOI 10.1007/BF02116520; MUDER RR, 1991, ANN INTERN MED, V114, P107, DOI 10.7326/0003-4819-114-2-1-107; MURPHY PM, 1988, J INFECT DIS, V158, P627, DOI 10.1093/infdis/158.3.627; POS O, 1992, CLIN EXP IMMUNOL, V88, P23; RAVIGLIONE MC, 1990, AM J INFECT CONTROL, V18, P64, DOI 10.1016/0196-6553(90)90083-5; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; TUMBARELLO M, 1995, J INFECTION, V31, P123, DOI 10.1016/S0163-4453(95)92110-9; WEINKE T, 1992, EUR J CLIN MICROBIOL, V11, P985, DOI 10.1007/BF01967787; WHIMBEY E, 1986, ANN INTERN MED, V104, P511, DOI 10.7326/0003-4819-104-4-511; YU VL, 1986, NEW ENGL J MED, V315, P91, DOI 10.1056/NEJM198607103150204	19	99	103	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 2	1999	130	3					221	225		10.7326/0003-4819-130-3-199902020-00026	http://dx.doi.org/10.7326/0003-4819-130-3-199902020-00026			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	162PD	10049200				2022-12-28	WOS:000078355000006
J	Burns, R				Burns, R			A simple procedure: A play in one act	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Tennessee, Memphis, TN 38104 USA	University of Tennessee System; University of Tennessee Health Science Center	Burns, R (corresponding author), 1726 Poplar Ave, Memphis, TN 38104 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	1999	130	2					158	160		10.7326/0003-4819-130-2-199901190-00013	http://dx.doi.org/10.7326/0003-4819-130-2-199901190-00013			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158KG	10068365				2022-12-28	WOS:000078114200012
J	Cohen, L; Angladette, L; Benoit, N; Pierrot-Deseilligny, C				Cohen, L; Angladette, L; Benoit, N; Pierrot-Deseilligny, C			A man who borrowed oars	LANCET			English	Article									Hop La Pitie Salpetriere, Serv Neurol, F-75651 Paris 13, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Cohen, L (corresponding author), Hop La Pitie Salpetriere, Serv Neurol, F-75651 Paris 13, France.			cohen, laurent/0000-0002-5010-9085				ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; MCGUIRE PK, 1994, BRIT J PSYCHIAT, V164, P459, DOI 10.1192/bjp.164.4.459; Sarazin M, 1998, NEUROLOGY, V51, P142, DOI 10.1212/WNL.51.1.142	3	28	30	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 2	1999	353	9146					34	34		10.1016/S0140-6736(98)09047-3	http://dx.doi.org/10.1016/S0140-6736(98)09047-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023949				2022-12-28	WOS:000077934800015
J	Stankovic, T; Weber, P; Stewart, G; Bedenham, T; Murray, J; Byrd, PJ; Moss, PAH; Taylor, AMR				Stankovic, T; Weber, P; Stewart, G; Bedenham, T; Murray, J; Byrd, PJ; Moss, PAH; Taylor, AMR			Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia	LANCET			English	Article							T-PROLYMPHOCYTIC LEUKEMIA; ATM GENE; MUTATIONS; DIFFERENTIATION; EXPRESSION; DELETIONS; DISEASE; REGION; BCL-2; CLL	Background Patients with the inherited disorder ataxia telangiectasia (A-T) have an increased susceptibility to lymphoid malignancies. in these patients mutations affect both alleles of the A-T gene (ATM). We have looked for mutations in the ATM gene in sporadic cases of B-cell chronic lymphocytic leukaemia (B-CLL). Methods 32 cases of B-CLL were analysed by restriction endonuclease fingerprinting to detect mutations within ATM. In six of the cases in which mutations were detected in tumour samples, germline DNA was screened to assess ATM carrier status. The samples in 20 cases were also studied by western blot for abnormal expression of ATM protein. Findings Expression of the ATM protein was impaired in eight (40%) of the 20 tumours analysed, being absent in three and decreased in five. Mutations within ATM were detected in six (18%) of the 32 patients. These point mutations, deletions, and one insertion were distributed across the coding sequence of ATM, Germline mutations, which indicate ATM carrier status, were found in two of these six patients compared with a frequency within the general population of below 1 in 200. Interpretation Abnormal expression of ATM protein is a frequent finding in B-CLL, Although the precise function of this protein is unknown, it is thought to have a role in programmed cell death, a deficiency of which would fit with the characteristic phenotype of prolonged cell survival seen in B-CLL tumour cells. Our results also suggest that carriers of ATM mutations may be at a particular risk for the development of B-CLL and this may partly explain the known genetic susceptibility to this disease.	Univ Birmingham, Sch Med, CRC, Inst Canc Studies, Edgbaston B15 2TA, England; Univ Birmingham, Sch Med, Dept Haematol, Edgbaston B15 2TA, England	University of Birmingham; University of Birmingham	Taylor, AMR (corresponding author), Univ Birmingham, Sch Med, CRC, Inst Canc Studies, Edgbaston B15 2TA, England.	a.m.r.taylor@bham.ac.uk	Moss, Paul/D-1728-2009	Moss, Paul/0000-0002-6895-1967; Stankovic, Tatjana/0000-0002-3780-274X; Stewart, Grant/0000-0002-0960-3241	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bullrich F, 1996, BLOOD, V88, P3109, DOI 10.1182/blood.V88.8.3109.bloodjournal8883109; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; Cordone I, 1998, BLOOD, V91, P4342, DOI 10.1182/blood.V91.11.4342.411k39_4342_4349; EASTON DF, 1994, INT J RADIAT BIOL, V66, pS177, DOI 10.1080/09553009414552011; Fegan C, 1995, LEUKEMIA, V9, P2003; FRAUMENI JF, 1969, ANN INTERN MED, V71, P279, DOI 10.7326/0003-4819-71-2-279; Lens D, 1997, BRIT J HAEMATOL, V99, P848, DOI 10.1046/j.1365-2141.1997.4723278.x; LIU Q, 1995, BIOTECHNIQUES, V18, P470; Luo LP, 1998, CANCER RES, V58, P2293; LUO LP, 1998, CANCER RES, V58, P4552; MARIANO MT, 1992, BLOOD, V80, P768; Neilson JR, 1997, LEUKEMIA, V11, P1929, DOI 10.1038/sj.leu.2400819; ROZMAN C, 1995, NEW ENGL J MED, V333, P1052, DOI 10.1056/NEJM199510193331606; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHENA M, 1992, BLOOD, V79, P2981; Spector BD, 1982, ATAXIA TELANGIECTASI, P103; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; STAROSTIK P, 1991, BLOOD, V78, P3269; Stilgenbauer S, 1996, P NATL ACAD SCI USA, V93, P11837, DOI 10.1073/pnas.93.21.11837; Stilgenbauer S, 1997, NAT MED, V3, P1155, DOI 10.1038/nm1097-1155; Stoppa-Lyonnet D, 1998, BLOOD, V91, P3920, DOI 10.1182/blood.V91.10.3920.3920_3920_3926; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Vorechovsky I, 1996, CANCER RES, V56, P2726; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397	26	266	276	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 2	1999	353	9146					26	29		10.1016/S0140-6736(98)10117-4	http://dx.doi.org/10.1016/S0140-6736(98)10117-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023947				2022-12-28	WOS:000077934800013
J	Elia, J; Ambrosini, PJ; Rapoport, JL				Elia, J; Ambrosini, PJ; Rapoport, JL			Treatment of attention-deficit-hyperactivity disorder	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SUSTAINED-RELEASE METHYLPHENIDATE; TERM STIMULANT TREATMENT; 4-YEAR FOLLOW-UP; PSYCHIATRIC STATUS; DOPAMINE TRANSPORTER; TOURETTES-SYNDROME; DOUBLE-BLIND; DIAGNOSTIC-CRITERIA; GENERAL-POPULATION; CLINICAL-RESPONSE		Childrens Hosp Philadelphia, Dept Child & Adolescent Psychiat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA; MCP Hahnemann Univ, Div Child & Adolescent Psychiat, Dept Psychiat, Philadelphia, PA 19103 USA; NIMH, Child Psychiat Branch, Bethesda, MD 20892 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Drexel University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Elia, J (corresponding author), Childrens Hosp Philadelphia, Dept Child & Adolescent Psychiat, Main Bldg,Rm 3636,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.		Ambrosini, Paul/AAY-4175-2020					ABIKOFF H, 1985, ARCH GEN PSYCHIAT, V42, P953; Aman MG, 1996, RES DEV DISABIL, V17, P417, DOI 10.1016/S0891-4222(96)00023-6; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDERSON JC, 1987, ARCH GEN PSYCHIAT, V44, P69; August GJ, 1996, J ABNORM CHILD PSYCH, V24, P571, DOI 10.1007/BF01670101; BARKLEY RA, 1990, J AM ACAD CHILD PSY, V29, P546, DOI 10.1097/00004583-199007000-00007; BARKLEY RA, 1989, J CHILD PSYCHOL PSYC, V30, P379, DOI 10.1111/j.1469-7610.1989.tb00253.x; BARKLEY RA, 1991, PEDIATRICS, V87, P519; BARKLEY RA, 1993, J CHILD PSYCHOL PSYC, V34, P437; BAUMGAERTEL A, 1995, J AM ACAD CHILD PSY, V34, P629, DOI 10.1097/00004583-199505000-00015; BIEDERMAN J, 1989, J AM ACAD CHILD PSY, V28, P903, DOI 10.1097/00004583-198911000-00015; BIEDERMAN J, 1994, PSYCHIAT RES, V53, P13, DOI 10.1016/0165-1781(94)90092-2; Biederman J, 1996, ARCH GEN PSYCHIAT, V53, P437; BIEDERMAN J, 1995, J CLIN PSYCHIAT, V56, P87; BIRD HR, 1993, J AM ACAD CHILD PSY, V32, P361, DOI 10.1097/00004583-199303000-00018; BIRMAHER B, 1989, J AM ACAD CHILD PSY, V28, P768, DOI 10.1097/00004583-198909000-00020; Bradley C, 1937, AM J PSYCHIAT, V94, P577, DOI 10.1176/ajp.94.3.577; BROWN GL, 1980, J AM ACAD CHILD PSY, V19, P225, DOI 10.1016/S0002-7138(09)60699-3; BROWN GL, 1979, PSYCHOPHARMACOLOGY, V62, P133, DOI 10.1007/BF00427126; Cantwell DP, 1997, J AM ACAD CHILD PSY, V36, P539, DOI 10.1097/00004583-199704000-00017; Castellanos FX, 1997, J AM ACAD CHILD PSY, V36, P589, DOI 10.1097/00004583-199705000-00008; Castellanos FX, 1996, ARCH GEN PSYCHIAT, V53, P607; Castellanos FX, 1998, MOL PSYCHIATR, V3, P431, DOI 10.1038/sj.mp.4000430; CLAUDE D, 1995, CAN J BEHAV SCI, V27, P226, DOI 10.1037/0008-400X.27.2.226; COHEN P, 1993, J CHILD PSYCHOL PSYC, V34, P851, DOI 10.1111/j.1469-7610.1993.tb01094.x; Conners CK, 1996, J AM ACAD CHILD PSY, V35, P1314, DOI 10.1097/00004583-199610000-00018; COOK EH, 1995, AM J HUM GENET, V56, P993; DENCKLA MB, 1976, JAMA-J AM MED ASSOC, V235, P1349, DOI 10.1001/jama.235.13.1349; ELIA J, 1990, CLIN PHARMACOL THER, V48, P57, DOI 10.1038/clpt.1990.118; ELIA J, 1991, PSYCHIAT RES, V36, P141, DOI 10.1016/0165-1781(91)90126-A; ELIA J, 1993, J CHILD PSYCHOL PSYC, V34, P785, DOI 10.1111/j.1469-7610.1993.tb01071.x; *FDA, 1997, FDA MED B, V27, P6; FENICHEL RR, 1995, J CHILD ADOL PSYCHOP, V5, P155, DOI 10.1089/cap.1995.5.155; FERGUSSON DM, 1993, J AM ACAD CHILD PSY, V32, P1127, DOI 10.1097/00004583-199311000-00004; FISCHER M, 1993, J AM ACAD CHILD PSY, V32, P324, DOI 10.1097/00004583-199303000-00013; GADOW KD, 1995, ARCH GEN PSYCHIAT, V52, P836; Gill M, 1997, MOL PSYCHIATR, V2, P311, DOI 10.1038/sj.mp.4000290; Gillberg C, 1997, ARCH GEN PSYCHIAT, V54, P857; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GITTELMAN R, 1985, ARCH GEN PSYCHIAT, V42, P937; GrossTsur V, 1997, J PEDIATR-US, V130, P670, DOI 10.1016/S0022-3476(97)70258-0; HART EL, 1995, J ABNORM CHILD PSYCH, V23, P729, DOI 10.1007/BF01447474; HECHTMAN L, 1984, J AM ACAD CHILD PSY, V23, P261, DOI 10.1016/S0002-7138(09)60501-X; Hunt R D, 1990, J Child Adolesc Psychopharmacol, V1, P87, DOI 10.1089/cap.1990.1.87; KLEIN RG, 1988, ARCH GEN PSYCHIAT, V45, P1127; KLEIN RG, 1988, ARCH GEN PSYCHIAT, V45, P1131; Klein RG, 1997, ARCH GEN PSYCHIAT, V54, P1073; Klein RG, 1992, ADVERSE EFFECTS PSYC, P470; KLORMAN R, 1990, J AM ACAD CHILD PSY, V29, P702, DOI 10.1097/00004583-199009000-00005; LaHoste GJ, 1996, MOL PSYCHIATR, V1, P121; Levy F, 1997, J AM ACAD CHILD PSY, V36, P737, DOI 10.1097/00004583-199706000-00009; Mannuzza S, 1998, AM J PSYCHIAT, V155, P493, DOI 10.1176/ajp.155.4.493; MANNUZZA S, 1993, ARCH GEN PSYCHIAT, V50, P565; MANNUZZA S, 1991, ARCH GEN PSYCHIAT, V48, P77; MANNUZZA S, 1988, ARCH GEN PSYCHIAT, V45, P13; MCCONAUGHY SH, 1994, J CHILD PSYCHOL PSYC, V35, P1141, DOI 10.1111/j.1469-7610.1994.tb01814.x; MILLICHAP JG, 1967, PEDIATR CLIN N AM, V14, P767; PELHAM WE, 1990, PEDIATRICS, V86, P226; Pelham WE, 1998, J CLIN CHILD PSYCHOL, V27, P190, DOI 10.1207/s15374424jccp2702_6; PELHAM WE, 1995, J AM ACAD CHILD PSY, V34, P1504, DOI 10.1097/00004583-199511000-00018; Pliszka SR, 1996, J AM ACAD CHILD PSY, V35, P264, DOI 10.1097/00004583-199603000-00006; PRICE RA, 1986, NEUROLOGY, V36, P232, DOI 10.1212/WNL.36.2.232; QUINN PO, 1975, AM J PSYCHIAT, V132, P241; RAPOPORT JL, 1980, ARCH GEN PSYCHIAT, V37, P933; RAPPORT MD, 1991, CLIN PSYCHOL REV, V11, P61, DOI 10.1016/0272-7358(91)90138-K; RAPPORT MD, 1994, J AM ACAD CHILD PSY, V33, P882, DOI 10.1097/00004583-199407000-00015; Rapport MD, 1997, J AM ACAD CHILD PSY, V36, P523, DOI 10.1097/00004583-199704000-00015; RICHTERS JE, 1995, J AM ACAD CHILD PSY, V34, P987, DOI 10.1097/00004583-199508000-00008; SALLEE FR, 1992, J AM ACAD CHILD PSY, V31, P244, DOI 10.1097/00004583-199203000-00010; SHAFFER D, 1994, AM J PSYCHIAT, V151, P633; Shaffer D, 1996, J AM ACAD CHILD PSY, V35, P865, DOI 10.1097/00004583-199607000-00012; SINGER HS, 1995, PEDIATRICS, V95, P74; Spencer T, 1996, J AM ACAD CHILD PSY, V35, P409, DOI 10.1097/00004583-199604000-00008; Spencer TJ, 1996, J AM ACAD CHILD PSY, V35, P1460, DOI 10.1097/00004583-199611000-00014; SWANSON JM, 1995, NEW ENGL J MED, V333, P944, DOI 10.1056/NEJM199510053331419; Swanson JM, 1998, MOL PSYCHIATR, V3, P38, DOI 10.1038/sj.mp.4000354; SZATMARI P, 1989, J AM ACAD CHILD PSY, V28, P865, DOI 10.1097/00004583-198911000-00010; TAYLOR E, 1991, MAUDSLEY MONOGRAPHS, V33, P93; Varley CK, 1997, J AM ACAD CHILD PSY, V36, P390, DOI 10.1097/00004583-199703000-00018; VOLKOW ND, 1995, ARCH GEN PSYCHIAT, V52, P456; WEISS G, 1985, J AM ACAD CHILD PSY, V24, P211, DOI 10.1016/S0002-7138(09)60450-7; WHALEN CK, 1991, J LEARN DISABIL, V24, P231, DOI 10.1177/002221949102400407; WINSBERG BG, 1974, PEDIATRICS, V53, P236; Wolraich ML, 1996, J AM ACAD CHILD PSY, V35, P319, DOI 10.1097/00004583-199603000-00013; Zametkin AJ, 1999, NEW ENGL J MED, V340, P40, DOI 10.1056/NEJM199901073400107	85	242	252	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 11	1999	340	10					780	788		10.1056/NEJM199903113401007	http://dx.doi.org/10.1056/NEJM199903113401007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	174KJ	10072414				2022-12-28	WOS:000079034100007
J	Friedman, J; Lannon, M; Comella, C; Factor, S; Kurlan, R; Richard, I; Parsa, M; Pfeiffer, R; Davies, R; Janko, K; Brown, D; Gardner, I; Pearson, N; Large, K; Rast, S; Oakes, D; Goetz, C; Paulson, G; Marshall, F; Kieburtz, K; Rudolph, A; Bourgeois, K; Casacelli, C; Freimuth, A; Guthrie, B; Pelusio, R; Watts, A; Tariot, P; Raubertas, R; Greenamyre, T				Friedman, J; Lannon, M; Comella, C; Factor, S; Kurlan, R; Richard, I; Parsa, M; Pfeiffer, R; Davies, R; Janko, K; Brown, D; Gardner, I; Pearson, N; Large, K; Rast, S; Oakes, D; Goetz, C; Paulson, G; Marshall, F; Kieburtz, K; Rudolph, A; Bourgeois, K; Casacelli, C; Freimuth, A; Guthrie, B; Pelusio, R; Watts, A; Tariot, P; Raubertas, R; Greenamyre, T		Parkinson Study Grp	Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEVODOPA-INDUCED PSYCHOSIS; LONG-TERM; DOPAMINOMIMETIC PSYCHOSIS; RISK-FACTORS; DOUBLE-BLIND; L-DOPA; TREMOR; RISPERIDONE; THERAPY; HOLIDAY	Background Drug-induced psychosis is a difficult problem to manage in patients with Parkinson's disease. Multiple open-label studies have reported that treatment with clozapine at low doses ameliorates psychosis without worsening parkinsonism. Methods We conducted a randomized, double-blind, placebo-controlled trial of low doses of clozapine (6.25 to 50 mg per day) in 60 patients at six sites over a period of 14 months. The patients (mean age, 72 years) had idiopathic Parkinson's disease and drug-induced psychosis of at least four weeks' duration. All the patients continued to receive fixed doses of antiparkinsonian drugs during the four weeks of the trial. Blood counts were monitored weekly in all the patients. Results The mean dose of clozapine was 24.7 mg per day. The patients in the clozapine group had significantly more improvement than those in the placebo group in all three of the measures used to determine the severity of psychosis. The mean (+/-SE) scores on the Clinical Global Impression Scale improved by 1.6+/-0.3 points for the patients receiving clozapine, as compared with 0.5+/-0.2 point for those receiving placebo (P<0.001). The score on the Brief Psychiatric Rating Scale improved by 9.3+/-1.5 points for the patients receiving clozapine, as compared with 2.6+/-1.3 points for those receiving placebo (P=0.002). The score on the Scale for the Assessment of Positive Symptoms improved by 11.8+/-2.0 points for the patients receiving clozapine, as compared with 3.8+/-1.9 points for those receiving placebo (P=0.01). Seven patients treated with clozapine had an improvement of at least three points on the seven-point Clinical Global Impression Scale, as compared with only one patient given placebo. Clozapine treatment improved tremor and had no deleterious effect on the severity of parkinsonism. In one patient, clozapine was discontinued because of leukopenia. Conclusions Clozapine, at daily doses of 50 mg or less, is safe and significantly improves drug-induced psychosis without worsening parkinsonism. (N Engl J Med 1999;340:757-63.) (C)1999, Massachusetts Medical Society.	Brown Univ, Mem Hosp Rhode Isl, Pawtucket, RI 02860 USA; Brown Univ, Sch Med, Providence, RI 02912 USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; Rush Sch Med, Chicago, IL USA; Albany Med Coll, Albany, NY 12208 USA; Univ Rochester, Rochester, NY USA; Case Western Reserve Univ, Sch Med, Cleveland, OH USA; Univ Tennessee, Med Ctr, Memphis, TN USA; Ohio State Univ, Columbus, OH 43210 USA; Emory Univ, Atlanta, GA 30322 USA	Brown University; Brown University; Rush University; Rush University; Albany Medical College; University of Rochester; Case Western Reserve University; University of Tennessee System; University of Tennessee Health Science Center; University System of Ohio; Ohio State University; Emory University	Friedman, J (corresponding author), Brown Univ, Mem Hosp Rhode Isl, 111 Brewster St, Pawtucket, RI 02860 USA.		Greenamyre, J. Timothy/B-4049-2011		FDA HHS [FD-R-001416-02] Funding Source: Medline	FDA HHS		ALVIR JMJ, 1993, NEW ENGL J MED, V329, P162, DOI 10.1056/NEJM199307153290303; Andreason NC, 1984, SCALE ASSESSMENT POS; BEAR D, 1989, BIOL PSYCHIAT, V25, pA163; Beasley CM, 1996, PSYCHOPHARMACOLOGY, V124, P159, DOI 10.1007/BF02245617; BERNARDI F, 1990, NEUROLOGY, V40, P1151, DOI 10.1212/WNL.40.7.1151; BOLDEN C, 1991, EUR J PHARMACOL, V192, P205, DOI 10.1016/0014-2999(91)90096-9; Carter JH, 1998, MOVEMENT DISORD, V13, P20, DOI 10.1002/mds.870130108; CASEY DE, 1992, NOVEL ANTIPSYCHOTIC DRUGS, P241; CELESIA GG, 1970, ARCH NEUROL-CHICAGO, V23, P193, DOI 10.1001/archneur.1970.00480270003001; CHACKO RC, 1995, J NEUROPSYCH CLIN N, V7, P471; Factor S A, 1995, Adv Neurol, V65, P115; FACTOR SA, 1994, NEUROLOGY, V44, P544, DOI 10.1212/WNL.44.3_Part_1.544; FACTOR SA, 1992, MOVEMENT DISORD, V7, P125, DOI 10.1002/mds.870070205; FELDMAN RG, 1986, J CLIN PHARMACOL, V26, P662, DOI 10.1002/j.1552-4604.1986.tb02969.x; FISCHER PA, 1990, J NEURAL TRANSM-PARK, V2, P233, DOI 10.1007/BF02257654; FLEISS JL, 1981, STATISTICAL METHODS, P260; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FORD B, 1994, LANCET, V344, P681, DOI 10.1016/S0140-6736(94)92114-8; FRIEDMAN A, 1991, ACTA NEUROL SCAND, V84, P111, DOI 10.1111/j.1600-0404.1991.tb04918.x; Friedman J, 1998, NEUROLOGY, V50, P1195, DOI 10.1212/WNL.50.4.1195-a; FRIEDMAN JH, 1991, CLIN NEUROPHARMACOL, V14, P283, DOI 10.1097/00002826-199108000-00001; FRIEDMAN JH, 1992, ANN NEUROL, V32, P277; FRIEDMAN JH, 1987, CLIN NEUROPHARMACOL, V10, P470, DOI 10.1097/00002826-198710000-00011; Friedman JH, 1997, NEUROLOGY, V48, P1077, DOI 10.1212/WNL.48.4.1077; FRIEDMAN JH, 1990, MOVEMENT DISORD, V5, P225, DOI 10.1002/mds.870050307; FRIEDMAN JH, 1995, THERAPY PARKINSONS D, P521; GOETZ CG, 1993, NEUROLOGY, V43, P2227, DOI 10.1212/WNL.43.11.2227; GOETZ CG, 1982, CLIN NEUROPHARMACOL, V5, P351, DOI 10.1097/00002826-198212000-00003; GOETZ CG, 1982, AM J PSYCHIAT, V139, P494; GOETZ CG, 1995, NEUROLOGY, V45, P669, DOI 10.1212/WNL.45.4.669; GONSKI PN, 1994, AUST NZ J MED, V24, P585, DOI 10.1111/j.1445-5994.1994.tb01772.x; GOODWIN FK, 1971, J AMER MED ASSOC, V218, P1915, DOI 10.1001/jama.218.13.1915; GREENE P, 1993, ADV NEUROL, V60, P703; Guy W, 1976, DHEW PUBLICATION, VADM 76-338, P217; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Honigfeld G, 1998, J CLIN PSYCHIAT, V59, P3; HURWITZ TA, 1988, CAN J NEUROL SCI, V15, P32, DOI 10.1017/S0317167100027141; JANSEN ENH, 1994, ACTA NEUROL SCAND, V89, P262; JENKINS RB, 1970, LANCET, V2, P177; Jimenez-Jimenez FJ, 1998, NEUROLOGY, V50, P1183, DOI 10.1212/WNL.50.4.1183-a; KAHN N, 1991, NEUROLOGY, V41, P1699, DOI 10.1212/WNL.41.10.1699; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; Kaplan HI., 1994, KAPLAN SADOCKS SYNOP; KOFMAN OS, 1984, CAN J NEUROL SCI, V11, P206, DOI 10.1017/S0317167100046424; KURLAN R, 1994, CLIN NEUROPHARMACOL, V17, P117, DOI 10.1097/00002826-199404000-00002; LANAZASORO G, 1992, MOV DISORD S1, V7, P100; Lang A. E. T., 1989, QUANTIFICATION NEURO, P285; LEW MF, 1993, J AM GERIATR SOC, V41, P669, DOI 10.1111/j.1532-5415.1993.tb06743.x; Meco G, 1997, MOVEMENT DISORD, V12, P610, DOI 10.1002/mds.870120423; MINDHAM RHS, 1970, J NEUROL NEUROSUR PS, V33, P188, DOI 10.1136/jnnp.33.2.188; OSTERGAARD K, 1988, ACTA NEUROL SCAND, V78, P349, DOI 10.1111/j.1600-0404.1988.tb03668.x; OVERALL JE, 1988, PSYCHOPHARMACOL BULL, V24, P97; PAKKENBERG H, 1986, ACTA NEUROL SCAND, V73, P295; PFEIFFER RF, 1990, MOVEMENT DISORD, V5, P239, DOI 10.1002/mds.870050310; PINTER MM, 1993, J NEURAL TRANSM-PARK, V5, P135, DOI 10.1007/BF02251204; RABEY JM, 1995, NEUROLOGY, V45, P432, DOI 10.1212/WNL.45.3.432; Rich SS, 1995, J CLIN PSYCHIAT, V56, P556; Roberts H E, 1989, J Neuropsychiatry Clin Neurosci, V1, P190; ROSENTHAL SH, 1992, GEN HOSP PSYCHIAT, V14, P285, DOI 10.1016/0163-8343(92)90100-O; Ruggieri S, 1997, CLIN NEUROPHARMACOL, V20, P204, DOI 10.1097/00002826-199706000-00003; SCHOLZ E, 1985, EUR ARCH PSY CLIN N, V235, P60, DOI 10.1007/BF00380972; Schwab J., 1968, 3 S PARK DIS, P152; SILVA MR, 1995, J NEUROL, V242, pS138; Trosch RM, 1998, MOVEMENT DISORD, V13, P377, DOI 10.1002/mds.870130302; Wagner ML, 1996, J NEUROPSYCH CLIN N, V8, P276; WOLK SI, 1992, J CLIN PSYCHIAT, V53, P373; Wolters EC, 1996, NEUROLOGY, V47, P1085, DOI 10.1212/WNL.47.4.1085; WOLTERS EC, 1990, NEUROLOGY, V40, P832, DOI 10.1212/WNL.40.5.832; Zimbroff DL, 1997, AM J PSYCHIAT, V154, P782	69	465	484	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 11	1999	340	10					757	763						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	174KJ	10072410				2022-12-28	WOS:000079034100003
J	Collier, J				Collier, J			Tackling institutional racism	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					679	679		10.1136/bmj.318.7184.679	http://dx.doi.org/10.1136/bmj.318.7184.679			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066235	Green Published			2022-12-28	WOS:000079089200079
J	Yaffe, MP				Yaffe, MP			The machinery of mitochondrial inheritance and behavior	SCIENCE			English	Review							OUTER-MEMBRANE; INTERMEDIATE FILAMENTS; ENDOPLASMIC-RETICULUM; YEAST MITOCHONDRIA; ACTIN CYTOSKELETON; FISSION YEAST; LIVING CELLS; MYOSIN-I; PROTEIN; MICROTUBULES	The distribution of mitochondria to daughter cells during cell division is an essential feature of cell proliferation. Until recently, it was commonly believed that inheritance of mitochondria and other organelles was a passive process, a consequence of their random diffusion throughout the cytoplasm. A growing recognition of the reticular morphology of mitochondria in many living cells, the association of mitochondria with the cytoskeleton, and the coordinated movements of mitochondria during cellular division and differentiation has illuminated the necessity for a cellular machinery that mediates mitochondrial behavior. Characterization of the underlying molecular components of this machinery is providing insight into mechanisms regulating mitochondrial morphology and distribution.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Yaffe, MP (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.	myaffe@ucsd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044614] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44614] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS RJ, 1986, NATURE, V322, P754, DOI 10.1038/322754a0; Altmann R, 1890, ELEMENTARORGANISMEN; Arbustini E, 1998, AM J PATHOL, V153, P1501, DOI 10.1016/S0002-9440(10)65738-0; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BALL EH, 1982, P NATL ACAD SCI-BIOL, V79, P123, DOI 10.1073/pnas.79.1.123; Barnett DK, 1996, DEV DYNAM, V205, P64, DOI 10.1002/(SICI)1097-0177(199601)205:1<64::AID-AJA6>3.0.CO;2-3; BAUMANN O, 1995, CELL MOTIL CYTOSKEL, V32, P305, DOI 10.1002/cm.970320407; Bereiter-Hahn J., 1990, International Review of Cytology, V122, P1, DOI 10.1016/S0074-7696(08)61205-X; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; Berger KH, 1997, J CELL BIOL, V136, P545, DOI 10.1083/jcb.136.3.545; Berger KH, 1996, EXPERIENTIA, V52, P1111, DOI 10.1007/BF01952109; Berger KH, 1998, MOL BIOL CELL, V9, p102A; BRADLEY TJ, 1979, J SUPRAMOL STR CELL, V12, P165, DOI 10.1002/jss.400120203; BURGESS SM, 1994, J CELL BIOL, V126, P1375, DOI 10.1083/jcb.126.6.1375; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; COUCHMAN JR, 1982, EUR J CELL BIOL, V27, P47; DAVIDFERREIRA KL, 1980, CELL BIOL INT REP, V4, P655, DOI 10.1016/0309-1651(80)90204-0; DJALDETTI M, 1982, ACTA HAEMATOL-BASEL, V68, P241, DOI 10.1159/000206987; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; Eapen CE, 1998, SCAND J GASTROENTERO, V33, P975; Fields SD, 1998, J CELL SCI, V111, P1717; Fisk HA, 1997, J CELL BIOL, V138, P485, DOI 10.1083/jcb.138.3.485; FISK HA, UNPUB; FISK HA, 1998, THESIS U CALIFORNIA; Fuller Margaret T., 1993, P71; GAMMIE AE, 1995, J CELL BIOL, V130, P553, DOI 10.1083/jcb.130.3.553; Goda Y, 1997, P NATL ACAD SCI USA, V94, P769, DOI 10.1073/pnas.94.3.769; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; HEGGENESS MH, 1978, P NATL ACAD SCI USA, V75, P3863, DOI 10.1073/pnas.75.8.3863; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; Hermann GJ, 1998, ANNU REV CELL DEV BI, V14, P265, DOI 10.1146/annurev.cellbio.14.1.265; HERMANN GJ, 1997, J CELL BIOL, V137, P141, DOI 10.1083/jcb.137.1.141; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HUFFAKER TC, 1988, J CELL BIOL, V106, P1997, DOI 10.1083/jcb.106.6.1997; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JametVierny C, 1997, MOL CELL BIOL, V17, P6359, DOI 10.1128/MCB.17.11.6359; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; KACHAR B, 1988, J CELL BIOL, V106, P1545, DOI 10.1083/jcb.106.5.1545; KENNEDY EP, 1949, J BIOL CHEM, V179, P957; LAZZARINO DA, 1994, MOL BIOL CELL, V5, P807, DOI 10.1091/mbc.5.7.807; Lewis MR, 1915, AM J ANAT, V17, P339, DOI 10.1002/aja.1000170304; LIU H, 1989, CELL, V57, P233, DOI 10.1016/0092-8674(89)90961-6; MARGULIS L, 1970, P349; MCCONNELL SJ, 1992, J CELL BIOL, V118, P385, DOI 10.1083/jcb.118.2.385; MCCONNELL SJ, 1990, J CELL BIOL, V111, P967, DOI 10.1083/jcb.111.3.967; MCCONNELL SJ, 1993, SCIENCE, V260, P687, DOI 10.1126/science.8480179; MIGNOTTE F, 1987, BIOL CELL, V60, P97, DOI 10.1111/j.1768-322X.1987.tb00549.x; MORRIS RL, 1995, J CELL BIOL, V131, P1315, DOI 10.1083/jcb.131.5.1315; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Nishino I, 1998, MUSCLE NERVE, V21, P40, DOI 10.1002/(SICI)1097-4598(199801)21:1<40::AID-MUS6>3.0.CO;2-G; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; Pelloquin L, 1998, BIOCHEM BIOPH RES CO, V251, P720, DOI 10.1006/bbrc.1998.9539; Pereira AJ, 1997, J CELL BIOL, V136, P1081, DOI 10.1083/jcb.136.5.1081; Porter K. R., 1973, FINE STRUCTURE CELLS; Rapaport D, 1998, J BIOL CHEM, V273, P20150, DOI 10.1074/jbc.273.32.20150; Roeder AD, 1998, MOL BIOL CELL, V9, P917, DOI 10.1091/mbc.9.4.917; Santel A, 1998, J CELL SCI, V111, P3299; Shepard K. A., 1997, Molecular Biology of the Cell, V8, p444A; SHEPARD KA, IN PRESS J CELL BIOL; SIMON VR, 1995, J CELL BIOL, V130, P345, DOI 10.1083/jcb.130.2.345; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; SOGO LF, 1994, J CELL BIOL, V126, P1361, DOI 10.1083/jcb.126.6.1361; STEINBERG G, 1993, J CELL SCI, V106, P555; Stevens B., 1981, MOL BIOL YEAST SACCH, V11, P471; STEVENS BJ, 1977, BIOL CELLULAIRE, V28, P37; STURMER K, 1995, J CELL SCI, V108, P2273; SUMMERHAYES IC, 1983, J CELL SCI, V61, P87; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; TANDLER B, 1986, ANN NY ACAD SCI, V488, P65; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; Tzagoloff A, 1982, MITOCHONDRIA; VALE RD, 1987, ANNU REV CELL BIOL, V3, P347, DOI 10.1146/annurev.cb.03.110187.002023; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Wallin IE, 1925, AM J ANAT, V36, P131, DOI 10.1002/aja.1000360106; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; Yaffe MP, 1996, P NATL ACAD SCI USA, V93, P11664, DOI 10.1073/pnas.93.21.11664; Zhu QL, 1997, P NATL ACAD SCI USA, V94, P7308, DOI 10.1073/pnas.94.14.7308	81	395	417	4	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 5	1999	283	5407					1493	1497		10.1126/science.283.5407.1493	http://dx.doi.org/10.1126/science.283.5407.1493			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066164				2022-12-28	WOS:000078959200036
J	Nightingale, SL				Nightingale, SL			Warning on abbokinase	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					786	786		10.1001/jama.281.9.786	http://dx.doi.org/10.1001/jama.281.9.786			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10070983				2022-12-28	WOS:000078804300005
J	Bremser, M; Nickel, W; Schweikert, M; Ravazzola, M; Amherdt, M; Hughes, CA; Sollner, TH; Rothman, JE; Wieland, FT				Bremser, M; Nickel, W; Schweikert, M; Ravazzola, M; Amherdt, M; Hughes, CA; Sollner, TH; Rothman, JE; Wieland, FT			Coupling of coat assembly and vesicle budding to packaging of putative cargo receptors	CELL			English	Article							ADP-RIBOSYLATION FACTOR; GOLGI MEMBRANES REQUIRES; ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; PROTEIN-TRANSPORT; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-EXCHANGE; BREFELDIN-A; ARF; BINDING	COPI-coated vesicle budding from lipid bilayers whose composition resembles mammalian Golgi membranes requires coatomer, ARF, GTP, and cytoplasmic tails of putative cargo receptors (p24 family proteins) or membrane cargo proteins (containing the KKXX retrieval signal) emanating from the bilayer surface. Liposome-derived COPI-coated vesicles are similar to their native counterparts with respect to diameter, buoyant density, morphology, and the requirement for an elevated temperature for budding. These results suggest that a bivalent interaction of coatomer with membrane-bound ARF[GTP] and with the cytoplasmic tails of cargo or putative cargo receptors is the molecular basis of COPI coat assembly and provide a simple mechanism to couple uptake of cargo to transport vesicle formation.	Heidelberg Univ, Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Geneva, Sch Med, Dept Morphol, CH-1211 Geneva 4, Switzerland	Ruprecht Karls University Heidelberg; Memorial Sloan Kettering Cancer Center; University of Geneva	Wieland, FT (corresponding author), Heidelberg Univ, Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany.	felix.wieland@urz.uni-heidelberg.de			NIGMS NIH HHS [GM19079-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; FLEISCHER B, 1974, Journal of Supramolecular Structure, V2, P737, DOI 10.1002/jss.400020517; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; Harter C, 1996, P NATL ACAD SCI USA, V93, P1902, DOI 10.1073/pnas.93.5.1902; Harter C, 1998, P NATL ACAD SCI USA, V95, P11649, DOI 10.1073/pnas.95.20.11649; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; KEENAN TW, 1970, BIOCHEMISTRY-US, V9, P19, DOI 10.1021/bi00803a003; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Matsuoka K, 1998, MOL CELL, V2, P703, DOI 10.1016/S1097-2765(00)80168-9; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; Nickel W, 1998, SEMIN CELL DEV BIOL, V9, P493, DOI 10.1006/scdb.1998.0256; Nickel W, 1997, FEBS LETT, V413, P395, DOI 10.1016/S0014-5793(97)00939-3; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Pavel J, 1998, P NATL ACAD SCI USA, V95, P2140, DOI 10.1073/pnas.95.5.2140; REINHARD C, 1999, IN PRESS P NATL ACAD; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; SPINGER S, 1998, SCIENCE, V281, P698; Stamnes M, 1998, P NATL ACAD SCI USA, V95, P13676, DOI 10.1073/pnas.95.23.13676; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TEAL SB, 1994, J BIOL CHEM, V269, P3135; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; van Meer G, 1998, TRENDS CELL BIOL, V8, P29, DOI 10.1016/S0962-8924(97)01196-3; WAGNER S, 1994, YEAST, V10, P1429, DOI 10.1002/yea.320101106; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	61	234	240	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 19	1999	96	4					495	506		10.1016/S0092-8674(00)80654-6	http://dx.doi.org/10.1016/S0092-8674(00)80654-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	168XN	10052452	Bronze			2022-12-28	WOS:000078718600001
J	Patapoutian, A; Backus, C; Kispert, A; Reichardt, LF				Patapoutian, A; Backus, C; Kispert, A; Reichardt, LF			Regulation of neurotrophin-3 expression by epithelial mesenchymal interactions: The role of Wnt factors	SCIENCE			English	Article							NEURONS; SURVIVAL; DEATH; MICE; NT-3	Neurotrophins regulate survival, axonal growth, and target innervation of sensory and other neurons. Neurotrophin-3 (NT-3) is expressed specifically in cells adjacent to extending axons of dorsal root ganglia neurons, and its absence results in loss of most of these neurons before their axons reach their targets. However, axons are not required for NT-3 expression in limbs; instead, Local signals from ectoderm induce NT-3 expression in adjacent mesenchyme. Wnt factors expressed in Limb ectoderm induce NT-3 in the underlying mesenchyme. Thus, epithelial-mesenchymal interactions mediated by Wnt factors control NT-3 expression and may regulate axonal growth and guidance.	Univ Calif San Francisco, Dept Psychol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Max Planck Inst Immunbiol, Dept Mol Embryol, D-79108 Freiburg, Germany	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Max Planck Society	Patapoutian, A (corresponding author), Univ Calif San Francisco, Dept Psychol, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016033] Funding Source: NIH RePORTER; NIMH NIH HHS [MH48200] Funding Source: Medline; NINDS NIH HHS [P01 NS016033-190014, P01 NS016033] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; ElShamy WM, 1996, NEURON, V16, P963, DOI 10.1016/S0896-6273(00)80119-1; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; Farinas I, 1998, NEURON, V21, P325, DOI 10.1016/S0896-6273(00)80542-5; FARINAS I, 1994, NATURE, V369, P658, DOI 10.1038/369658a0; Farinas I, 1996, NEURON, V17, P1065, DOI 10.1016/S0896-6273(00)80240-8; FRANZ T, 1993, ANAT EMBRYOL, V187, P371; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Kispert A, 1998, DEVELOPMENT, V125, P4225; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; PARR BA, 1993, DEVELOPMENT, V119, P247; PATAPOUTIAN A, UNPUB; Reichardt L. F., 1997, MOL CELLULAR APPROAC, P220; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Verdi JM, 1996, NEURON, V16, P515, DOI 10.1016/S0896-6273(00)80071-9; Wilkinson GA, 1996, J NEUROSCI, V16, P7661	19	57	57	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1180	1183		10.1126/science.283.5405.1180	http://dx.doi.org/10.1126/science.283.5405.1180			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024246	Green Accepted			2022-12-28	WOS:000078738400055
J	Richman, LK; Montali, RJ; Garber, RL; Kennedy, MA; Lehnhardt, J; Hildebrandt, T; Schmitt, D; Hardy, D; Alcendor, DJ; Hayward, GS				Richman, LK; Montali, RJ; Garber, RL; Kennedy, MA; Lehnhardt, J; Hildebrandt, T; Schmitt, D; Hardy, D; Alcendor, DJ; Hayward, GS			Novel endotheliotropic herpesviruses fatal for Asian and African elephants	SCIENCE			English	Article							INFECTION; MAXIMUS	A highly fatal hemorrhagic disease has been identified in 10 young Asian and African elephants at North American toes. In the affected animals there was ultrastructural evidence for herpesvirus-like particles in endothelial cells of the heart, liver, and tongue. Consensus primer polymerase chain reaction combined with sequencing yielded molecular evidence that confirmed the presence of two novel but rotated herpesviruses associated with the disease, one in Asian elephants and another in African elephants. Otherwise healthy African elephants with external herpetic Lesions yielded herpesvirus sequences identical to that found in Asian elephants with endothelial disease. This finding suggests that the Asian elephant deaths were caused by cross-species infection with a herpesvirus that is naturally latent in, but normally not lethal to, African elephants, A reciprocal relationship may exist for the African elephant disease.	Smithsonian Inst, Natl Zool Pk, Washington, DC 20008 USA; Johns Hopkins Sch Med, Baltimore, MD 21205 USA; PathoGenesis Corp, Seattle, WA 98119 USA; Univ Tennessee, Knoxville, TN 37901 USA; Inst Zoo Biol & Wildlife Res, D-10305 Berlin, Germany; SW Missouri State Univ, Springfield, MO 65804 USA; Dickerson Pk Zoo, Springfield, MO 65803 USA	Smithsonian Institution; Smithsonian National Zoological Park & Conservation Biology Institute; Johns Hopkins University; Johns Hopkins Medicine; University of Tennessee System; University of Tennessee Knoxville; Missouri State University	Richman, LK (corresponding author), Smithsonian Inst, Natl Zool Pk, Washington, DC 20008 USA.			Kennedy, Melissa/0000-0001-6237-1104; Alcendor, Donald/0000-0002-4568-8158	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001526] Funding Source: NIH RePORTER; NIAID NIH HHS [1 K08 AI01526-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		HARGIS AM, IN P0RESS VET DERM; JACOBSON ER, 1986, J AM VET MED ASSOC, V189, P1075; KARLIN S, 1994, J VIROL, V68, P1886, DOI 10.1128/JVI.68.3.1886-1902.1994; METZLER AE, 1990, J WILDLIFE DIS, V26, P41, DOI 10.7589/0090-3558-26.1.41; Munson L, 1995, J ZOO WILDLIFE MED, V26, P353; OSSENT P, 1990, VET PATHOL, V27, P131, DOI 10.1177/030098589002700212; Persoons MCJ, 1998, J PATHOL, V184, P103, DOI 10.1002/(SICI)1096-9896(199801)184:1<103::AID-PATH964>3.0.CO;2-C; RICHMAN L, UNPUB; SCHMITT DL, 1998, J ELEPHANT MANAGERS, V9, P103; VanDevanter DR, 1996, J CLIN MICROBIOL, V34, P1666, DOI 10.1128/JCM.34.7.1666-1671.1996	10	136	140	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1171	1176		10.1126/science.283.5405.1171	http://dx.doi.org/10.1126/science.283.5405.1171			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024244				2022-12-28	WOS:000078738400053
J	Kandela, P				Kandela, P			Sketches from the Lancet	LANCET			English	Editorial Material											Kandela, P (corresponding author), 29 Greenlands Rd, Staines TW18 4LR, Middx, England.								0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 13	1999	353	9152					601	601		10.1016/S0140-6736(05)75668-3	http://dx.doi.org/10.1016/S0140-6736(05)75668-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10029022				2022-12-28	WOS:000078670200069
J	Lee, P; Smith, I; Piesowicz, A; Brenton, D				Lee, P; Smith, I; Piesowicz, A; Brenton, D			Spastic paraparesis after anaesthesia	LANCET			English	Article							NITROUS-OXIDE		Middlesex Hosp, Metab Unit, London W1N 8AA, England; Queen Marys Hosp Children, Carshalton, Surrey, England	University of London; University College London	Lee, P (corresponding author), Middlesex Hosp, Metab Unit, Mortimer St, London W1N 8AA, England.							GUTTORMSEN AB, 1994, ACTA ANAESTH SCAND, V38, P753, DOI 10.1111/j.1399-6576.1994.tb03996.x; Hanley WB, 1996, EUR J PEDIATR, V155, pS145, DOI 10.1007/PL00014233; MCKEEVER M, 1995, CLIN SCI, V88, P471, DOI 10.1042/cs0880471; Rosener M, 1996, J NEUROL NEUROSUR PS, V60, P354, DOI 10.1136/jnnp.60.3.354; THOMPSON AJ, 1990, LANCET, V336, P602, DOI 10.1016/0140-6736(90)93401-A	5	31	31	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 13	1999	353	9152					554	554		10.1016/S0140-6736(98)10090-9	http://dx.doi.org/10.1016/S0140-6736(98)10090-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028985				2022-12-28	WOS:000078670200014
J	Bezard, B; Encrenaz, T; Lellouch, E; Feuchtgruber, H				Bezard, B; Encrenaz, T; Lellouch, E; Feuchtgruber, H			Planetary science - A new look at the Jovian planets	SCIENCE			English	Editorial Material									Observ Paris, Dept Rech Spatiale, F-92195 Meudon, France; Max Planck Inst Extraterr Phys, D-85748 Garching, Germany	UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Max Planck Society	Bezard, B (corresponding author), Observ Paris, Dept Rech Spatiale, F-92195 Meudon, France.	Bruno.Bezard@obspm.fr		Bezard, Bruno/0000-0002-5433-5661				*AM ASTR SOC DIV P, 1998, B AM ASTRON SOC, V30; Bezard B, 1998, ASTRON ASTROPHYS, V334, pL41; BEZARD B, 1999, ASTROPHYS J, V515; Bockelee-Morvan D, 1998, ICARUS, V133, P147, DOI 10.1006/icar.1998.5916; Crovisier J, 1997, SCIENCE, V275, P1904, DOI 10.1126/science.275.5308.1904; deGraauw T, 1996, ASTRON ASTROPHYS, V315, pL49; DEGRAAUW T, 1997, ASTRON ASTROPHYS, V321, P613; Feuchtgruber H, 1999, ASTRON ASTROPHYS, V341, pL17; Feuchtgruber H, 1997, NATURE, V389, P159, DOI 10.1038/38236; Griffin MJ, 1996, ASTRON ASTROPHYS, V315, pL389; Kessler MF, 1996, ASTRON ASTROPHYS, V315, pL27; KIM SJ, 1985, ICARUS, V64, P233, DOI 10.1016/0019-1035(85)90088-0; LELLOUCH E, 1996, B AM ASTRON SOC, V28, P1148; MOSES JI, 1996, COLLISION COMET SHOE, P243; *UNESCO, 1998, EUR SPAC AG SPEC PUB	16	8	8	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1999	283	5403					800	801		10.1126/science.283.5403.800	http://dx.doi.org/10.1126/science.283.5403.800			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	10049124				2022-12-28	WOS:000078496800028
J	Hentze, MW; Kulozik, AE				Hentze, MW; Kulozik, AE			A perfect message: RNA surveillance and nonsense-mediated decay	CELL			English	Review							TRANSLATION; CELLS; EXON; THALASSEMIA; MECHANISM; MUTATIONS; GENE		European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany; Charite Virchow Med Ctr, Dept Pediat, D-13353 Berlin, Germany	European Molecular Biology Laboratory (EMBL); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hentze, MW (corresponding author), European Mol Biol Lab, Gene Express Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Kulozik, Andreas/AAO-2432-2020; Hentze, Matthias W/V-3980-2017	Hentze, Matthias W/0000-0002-4023-7876				Beelman CA, 1996, NATURE, V382, P642, DOI 10.1038/382642a0; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Carter MS, 1996, EMBO J, V15, P5965, DOI 10.1002/j.1460-2075.1996.tb00983.x; CHANG JC, 1979, P NATL ACAD SCI USA, V76, P2886, DOI 10.1073/pnas.76.6.2886; Czaplinski K, 1998, GENE DEV, V12, P1665, DOI 10.1101/gad.12.11.1665; HALL GW, 1994, BLOOD, V83, P2031; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Li SL, 1998, IMMUNITY, V8, P135, DOI 10.1016/S1074-7613(00)80466-5; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; MAQUAT LE, 1995, RNA, V1, P453; Nagy E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; Ruiz-Echevarria MJ, 1998, EMBO J, V17, P575, DOI 10.1093/emboj/17.2.575; Shiga N, 1997, J CLIN INVEST, V100, P2204, DOI 10.1172/JCI119757; Sun XL, 1998, P NATL ACAD SCI USA, V95, P10009, DOI 10.1073/pnas.95.17.10009; Thermann R, 1998, EMBO J, V17, P3484, DOI 10.1093/emboj/17.12.3484; Zhang J, 1998, MOL CELL BIOL, V18, P5272, DOI 10.1128/MCB.18.9.5272; Zhang J, 1998, RNA, V4, P801, DOI 10.1017/S1355838298971849; Zhang J, 1997, EMBO J, V16, P826, DOI 10.1093/emboj/16.4.826	20	688	709	1	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 5	1999	96	3					307	310		10.1016/S0092-8674(00)80542-5	http://dx.doi.org/10.1016/S0092-8674(00)80542-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025395	Bronze			2022-12-28	WOS:000078514600002
J	Pittet, D; Mourouga, P; Perneger, TV				Pittet, D; Mourouga, P; Perneger, TV		Infection Control Program	Compliance with handwashing in a teaching hospital	ANNALS OF INTERNAL MEDICINE			English	Article							INTENSIVE-CARE UNITS; NOSOCOMIAL INFECTIONS; PREVENTION; GLOVE	Background: Transmission of microorganisms from the hands of health care workers is the main source of cross-infection in hospitals and can be prevented by handwashing. Objective: To identify predictors of noncompliance with handwashing during routine patient care. Design: Observational study. Setting: Teaching hospital in Geneva, Switzerland. Participants: Nurses (66%), physicians (10%), nursing assistants (13%), and other health care workers (11%). Measurements: Compliance with handwashing. Results: In 2834 observed opportunities for handwashing, average compliance was 48%. In multivariate analysis, noncompliance was higher among physicians (odds ratio [OR], 2.8 [95% CI, 1.9 to 4.1]), nursing assistants (OR, 1.3 [CI, 1.0 to 1.6]), and other health care workers (OR, 2.1 [CI, 1.4 to 3.2]) than among nurses and was lowest on weekends (OR, 0.6 [CI, 0.4 to 0.8]). Noncompliance was higher in intensive care than in internal medicine units (OR, 2.0 [CI, 1.3 to 3.1]), during procedures that carry a high risk for contamination (OR, 1.8 [CI, 1.4 to 2.4]), and when intensity of patient care was high (compared with less than or equal to 20 opportunities for handwashing per hour of care, 21 to 40 opportunities: OR, 1.3 [CI, 1.0 to 1.7]; 41 to 60 opportunities: OR, 2.7 [CI, 1.5 to 2.9]; and >60 opportunities: OR, 2.1 [CI, 1.3 to 3.5]). Conclusions: Compliance with handwashing was moderate. Variation across hospital ward and type of health care worker suggests that targeted educational programs may be useful. Even though observational data cannot prove causality, the association between noncompliance and intensity of care suggests that understaffing may decrease quality of patient ca re.	Univ Hosp Geneva, Dept Internal Med, Infect Control Program, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Inst Social & Prevent Med, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Med Directors Off, CH-1211 Geneva 14, Switzerland; Univ Geneva, Sch Med, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva; University of Geneva	Pittet, D (corresponding author), Univ Hosp Geneva, Dept Internal Med, Infect Control Program, CH-1211 Geneva 14, Switzerland.	didier.pittet@hcuge.ch		Pittet, Didier/0000-0002-3667-7131				ALBERT RK, 1981, NEW ENGL J MED, V304, P1465, DOI 10.1056/NEJM198106113042404; [Anonymous], 1991, Fed Regist, V56, P64004; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; DOEBBELING BN, 1988, ANN INTERN MED, V109, P394, DOI 10.7326/0003-4819-109-5-394; Fridkin SK, 1996, INFECT CONT HOSP EP, V17, P150; GOULD D, 1994, J HOSP INFECT, V28, P15, DOI 10.1016/0195-6701(94)90149-X; HALEY RW, 1982, J INFECT DIS, V145, P875, DOI 10.1093/infdis/145.6.875; HALEY RW, 1985, AM J EPIDEMIOL, V121, P182, DOI 10.1093/oxfordjournals.aje.a113990; JARVIS WR, 1994, LANCET, V344, P1311, DOI 10.1016/S0140-6736(94)90687-4; LARSON E, 1982, AM J INFECT CONTROL, V10, P93, DOI 10.1016/0196-6553(82)90019-0; LARSON EL, 1995, AM J INFECT CONTROL, V23, P251, DOI 10.1016/0196-6553(95)90070-5; LYNCH P, 1987, ANN INTERN MED, V107, P243, DOI 10.7326/0003-4819-107-2-243; PETTINGER A, 1991, INFECT CONT HOSP EP, V12, P303; Rotter LM, 1996, HOSP EPIDEMIOLOGY IN, P1052; SPROAT LJ, 1994, J HOSP INFECT, V26, P137, DOI 10.1016/0195-6701(94)90057-4; STEERE AC, 1975, ANN INTERN MED, V83, P683, DOI 10.7326/0003-4819-83-5-683; Thompson BL, 1997, INFECT CONT HOSP EP, V18, P97; Voss A, 1997, INFECT CONT HOSP EP, V18, P205; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	19	645	671	0	19	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	1999	130	2					126	130		10.7326/0003-4819-130-2-199901190-00006	http://dx.doi.org/10.7326/0003-4819-130-2-199901190-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158KG	10068358				2022-12-28	WOS:000078114200005
J	Cole, DEC; Peltekova, VD; Rubin, LA; Hawker, GA; Vieth, R; Liew, CC; Hwang, DM; Evrovski, J; Hendy, GN				Cole, DEC; Peltekova, VD; Rubin, LA; Hawker, GA; Vieth, R; Liew, CC; Hwang, DM; Evrovski, J; Hendy, GN			A986S polymorphism of the calcium-sensing receptor and circulating calcium concentrations	LANCET			English	Article							FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; NEONATAL SEVERE HYPERPARATHYROIDISM; PORTABLE CLINICAL ANALYZER; CA2+-SENSING RECEPTOR; SECONDARY HYPERPARATHYROIDISM; EXTRACELLULAR CALCIUM; GENE; MUTATIONS; CLONING; HEALTH	Background The regulation of extracellular calcium concentration by parathyroid hormone is mediated by a calcium-sensing, G-protein-coupled cell-surface receptor (CASR). Mutations of the CASR gene alter the set-point for extracellular ionised calcium [Ca2+](o) and cause familial hypercalcaemia or hypocalcaemia. The CASR missense polymorphism, A986S, is common in the general population and is, therefore, a prime candidate as a genetic determinant of extracellular calcium concentration. Methods We genotyped the CASR A986S variant (S allele frequency of 16.3%) in 163 healthy adult women and tested samples of their serum for total calcium, albumin, total protein, creatinine, phosphate, pH, and parathyroid hormone. A prospectively generated, random subset of 84 of these women provided a whole blood sample for assay of [Ca2+](o). Findings The A986S genotype showed no association with total serum concentration of calcium, until corrected for albumin. In a multivariate regression model, biochemical and genetic variables accounted for 74% of the total variation in calcium. The significant predictors of serum calcium were: albumin (p<0.001), phosphate (p=0.02), parathyroid hormone (p=0.007), pH (p=0.001), and A986S genotype (p=0.009). Fasting whole-blood [Ca2+](o) also showed an independent positive association with the 986S variant (p=0.013). Interpretation The CASR A986S variant has a significant effect on extracellular calcium. The CASR A986S polymorphism is a likely candidate locus for genetic predisposition to various bone and mineral disorders in which extracellular calcium concentrations have a prominent part.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Genet, Toronto, ON, Canada; McGill Univ, Dept Med Physiol & Human Genet, Montreal, PQ, Canada	University of Toronto; University of Toronto; University of Toronto; McGill University	Cole, DEC (corresponding author), Banting Inst, Room 402,100 Coll St, Toronto, ON M5G 1L5, Canada.	davidec.cole@utoronto.ca						Bai M, 1997, J CLIN INVEST, V99, P1917, DOI 10.1172/JCI119359; Bai M, 1997, J CLIN INVEST, V99, P88, DOI 10.1172/JCI119137; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; BROWN EM, 1995, NEW ENGL J MED, V333, P234, DOI 10.1056/NEJM199507273330407; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1997, BONE, V20, P303, DOI 10.1016/S8756-3282(97)00002-1; Butters RR, 1997, J BONE MINER RES, V12, P568, DOI 10.1359/jbmr.1997.12.4.568; Cole DEC, 1997, AM J MED GENET, V71, P202, DOI 10.1002/(SICI)1096-8628(19970808)71:2<202::AID-AJMG16>3.0.CO;2-I; Diaz R, 1997, AM J PHYSIOL-REG I, V273, pR1008, DOI 10.1152/ajpregu.1997.273.3.R1008; ERICKSON KA, 1993, CLIN CHEM, V39, P283; GARETT JE, 1995, J BIOL CHEM, V270, P12919; HAVLIK R, 1977, CLIN CHEM, V23, P659; Heath H, 1996, J CLIN ENDOCR METAB, V81, P1312, DOI 10.1210/jcem.81.4.8636323; JACOBS E, 1993, CLIN CHEM, V39, P1069; JANICIC N, 1995, AM J HUM GENET, V56, P880; KALOUSDIAN S, 1987, GENET EPIDEMIOL, V4, P1, DOI 10.1002/gepi.1370040102; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Michelangeli VP, 1997, ANN CLIN BIOCHEM, V34, P97, DOI 10.1177/000456329703400115; NORDIN BEC, 1989, CLIN CHEM, V35, P14; Pearce SHS, 1997, J ENDOCRINOL, V154, P371, DOI 10.1677/joe.0.1540371; Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; Rubin LA, 1997, SCAND J CLIN LAB INV, V57, P122; RUBIN LA, 1997, J BONE MINER RES  S1, V12, pS374; Sherwood Edith, 1994, Clinical Chemistry, V40, P1057; THODE J, 1989, SCAND J CLIN LAB INV, V49, P217, DOI 10.3109/00365518909089086; WHITE TF, 1986, CLIN CHIM ACTA, V157, P199, DOI 10.1016/0009-8981(86)90226-3; WHITFIELD JB, 1984, ANN CLIN BIOCHEM, V21, P176, DOI 10.1177/000456328402100303; WILLIAMS PD, 1992, CLIN SCI, V82, P493, DOI 10.1042/cs0820493	30	142	151	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 9	1999	353	9147					112	115		10.1016/S0140-6736(98)06434-4	http://dx.doi.org/10.1016/S0140-6736(98)06434-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023897				2022-12-28	WOS:000078087200013
J	Lloyd-Jones, DM; Larson, MG; Beiser, A; Levy, D				Lloyd-Jones, DM; Larson, MG; Beiser, A; Levy, D			Lifetime risk of developing coronary heart disease	LANCET			English	Article							GLOBAL BURDEN; POSTMENOPAUSAL WOMEN; MORTALITY; THERAPY; HEALTH; HYPERTENSION; DISABILITY; CANCER	Background The lifetime risk of developing coronary heart disease has not been estimated in a general population. We investigated the lifetime risks of initial coronary events at different ages. Methods We assessed data for 7733 participants in the Framingham Heart Study, who had been examined at least once at age 40-94 years between 1971 and 1975, found to be free of coronary heart disease, and then followed up. We estimated the lifetime risks of coronary heart disease (angina pectoris, coronary insufficiency, myocardia[ infarction, or death from coronary heart disease) by multiple-decrement life-table methods. Findings The 7733 patients were followed up for a total of 109 948 person-years. Overall, 1157 participants developed coronary heart disease. 1312 died from noncoronary heart disease causes. Lifetime risk of coronary heart disease at age 40 years was 48.6% (95% CI 45.8-51.3) for men and 31.7% (29.2-34.2) for women. At age 70 years, lifetime risk was 34.9% (31.2-38.7) for men and 24.2% (21.4-27.0) for women. After we excluded isolated angina pectoris as an initial event, the lifetime risk of coronary artery disease events at age 40 years was 42.4% for men and 24.9% for women. Interpretation Lifetime risk at age 40 years is one in two for men and one in three for women. Even at age 70 years it is one in three for men and one in four for women. This knowledge may promote efforts in education, screening, and treatment for prevention of coronary heart disease in younger and alder patients.	NHLBI, Framingham Heart Study, NIH, Framingham, MA 01702 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Unit, Boston, MA USA; Boston Univ, Sch Med, Div Cardiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Div Epidemiol & Prevent Med, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Boston, MA 02118 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Med, Sch Med, Boston, MA 02115 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Harvard Medical School; Massachusetts General Hospital; Boston University; Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Levy, D (corresponding author), NHLBI, Framingham Heart Study, NIH, 5 Thurber St, Framingham, MA 01702 USA.	dan@fram.nhlbi.nih.gov	Levy, Daniel/ABB-2752-2021; Lloyd-Jones, Donald M/C-5899-2009; Levy, Daniel/ABF-6873-2021	Levy, Daniel/0000-0003-1843-8724; Lloyd-Jones, Donald/0000-0003-0847-6110; Beiser, Alexa/0000-0001-8551-7778; Larson, Martin/0000-0002-9631-1254				Abbott RD, 1987, FRAMINGHAM STUDY EPI; *AM HEART ASS, 1998, 1998 HEART STROK STA; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445; Dawber, 1959, J CHRON DIS, V10, P186, DOI 10.1016/0021-9681(59)90002-5; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892; FRASER GE, 1995, AM J EPIDEMIOL, V142, P746, DOI 10.1093/oxfordjournals.aje.a117706; Garfinkel L, 1995, Stat Bull Metrop Insur Co, V76, P31; GAYNOR JJ, 1993, J AM STAT ASSOC, V88, P400, DOI 10.2307/2290318; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; *NAT CTR HLTH STAT, 1997, HLTH US 1996 97; *NAT HEART LUNG BL, 1996, MORB MORT 1996 CHART; National Center for Health Statistics, 1996, HLTH PEOPL 2000 REV; Pearson TA, 1998, J AM COLL CARDIOL, V31, p88A, DOI 10.1016/S0735-1097(97)84091-0; SCHOUTEN LJ, 1994, J EPIDEMIOL COMMUN H, V48, P596, DOI 10.1136/jech.48.6.596; Seshadri S, 1997, NEUROLOGY, V49, P1498, DOI 10.1212/WNL.49.6.1498; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P	28	606	633	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 9	1999	353	9147					89	92		10.1016/S0140-6736(98)10279-9	http://dx.doi.org/10.1016/S0140-6736(98)10279-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023892	hybrid			2022-12-28	WOS:000078087200008
J	Pearce, S				Pearce, S			Extracellular "calcistat" in health and disease	LANCET			English	Editorial Material							CALCIUM-SENSING RECEPTOR; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; CA2+-SENSING RECEPTOR; SPORADIC HYPOPARATHYROIDISM; PRIMARY HYPERPARATHYROIDISM; BENIGN HYPERCALCEMIA; MUTATIONS; GENE; KINDREDS		Univ Newcastle Upon Tyne, Sch Med, Dept Med, Endocrine Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Pearce, S (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Dept Med, Endocrine Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Pearce, Simon/AAB-3692-2019	Pearce, Simon/0000-0001-8384-8063				Baron J, 1996, HUM MOL GENET, V5, P601, DOI 10.1093/hmg/5.5.601; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; DeLuca F, 1997, J CLIN ENDOCR METAB, V82, P2710, DOI 10.1210/jc.82.8.2710; Heath David A., 1994, P699; HEATH H, 1989, ENDOCRIN METAB CLIN, V18, P723, DOI 10.1016/S0889-8529(18)30362-1; Heath H, 1996, J CLIN ENDOCR METAB, V81, P1312, DOI 10.1210/jcem.81.4.8636323; LAW WM, 1985, ANN INTERN MED, V102, P511, DOI 10.7326/0003-4819-102-4-511; MARX SJ, 1982, NEW ENGL J MED, V306, P257, DOI 10.1056/NEJM198202043060502; MARX SJ, 1981, MEDICINE, V60, P397, DOI 10.1097/00005792-198111000-00002; Pearce SHS, 1996, J CLIN ENDOCR METAB, V81, P2030, DOI 10.1210/jc.81.6.2030; Pearce SHS, 1996, J CLIN INVEST, V98, P1860, DOI 10.1172/JCI118987; Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y	15	14	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 9	1999	353	9147					83	84		10.1016/S0140-6736(05)76148-1	http://dx.doi.org/10.1016/S0140-6736(05)76148-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023887				2022-12-28	WOS:000078087200003
J	El-Serag, HB; Mason, AC				El-Serag, HB; Mason, AC			Rising incidence of hepatocellular carcinoma in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC HEPATITIS-B; VIRUS-INFECTION; ALPHA	Background and Methods Clinical observations have suggested that the number of cases of hepatocellular carcinoma has increased in the United States. We analyzed data from the Surveillance, Epidemiology, and End Results (SEER) data base to determine the age-adjusted incidence of hepatocellular carcinoma from 1976 to 1995, data from the U.S, vital-statistics data base to determine age-adjusted mortality rates from 1981 to 1995, and data from the Department of Veterans Affairs to determine age-adjusted rates of hospitalization for the disease from 1983 to 1997. Results The incidence of histologically proved hepatocellular carcinoma increased from 1.4 per 100,000 population (95 percent confidence interval, 1.3 to 1.4) for the period from 1976 to 1980 to 2.4 per 100,000 (95 percent confidence interval, 2.3 to 2.4) for the period from 1991 to 1995. Among black men, the incidence was 6.1 per 100,000 for the period from 1991 to 1995, and among white men, it was 2.8 per 100,000. There was a 41 percent increase in the mortality rate from primary liver cancer and a 46 percent increase in the proportion of hospitalizations attributable to this disease during the periods studied. The incidence increased significantly among younger persons (40 to 60 years old) during the period from 1991 to 1995 as compared with earlier periods. Conclusions An increase in the number of cases of hepatocellular carcinoma has occurred in the United States over the past two decades. The age-specific incidence of this cancer has progressively shifted toward younger people. (N Engl J Med 1999;340:745-50.) (C)1999, Massachusetts Medical Society.	Vet Affairs Med Ctr, Gastroenterol Sect, Albuquerque, NM 87108 USA; Univ New Mexico, Albuquerque, NM 87131 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of New Mexico	El-Serag, HB (corresponding author), Vet Affairs Med Ctr, Gastroenterol Sect, 111F,1501 San Pedro SE, Albuquerque, NM 87108 USA.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257				Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711; BISCEGLIE AM, 1991, HEPATOLOGY, V14, P969; Breslow NE, 1987, STAT METHODS CANC RE, P58; CASTELLS L, 1995, LIVER, V15, P159; Deuffic S, 1998, LANCET, V351, P214, DOI 10.1016/S0140-6736(05)78179-4; DIBISCEGLIE AM, 1988, ANN INTERN MED, V108, P390, DOI 10.7326/0003-4819-108-3-390; DiBisceglie AM, 1997, HEPATOLOGY, V26, pS34, DOI 10.1002/hep.510260706; DUFOUR MC, 1994, NIH PUBLICATION, P615; GODLEY PA, DIGESTIVE DIS US EPI; GRANT B, 1989, 11 NAT I ALC AB ALC; GRANT BFD, 1990, LIVER CIRRHOSIS MORT; KAHN HA, 1989, MONOGRAPHS EPIDEMIOL, V12, P87; KELEN GD, 1992, NEW ENGL J MED, V326, P1399, DOI 10.1056/NEJM199205213262105; Kew MC, 1998, SLEISENGER FORDTRANS, V1, P1364; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Landis SH, 1998, CA-CANCER J CLIN, V48, P192; MCQUILLAN GM, 1989, AM J MED, V87, pS5; MCQUILLAN GM, 1994, NIH PUBLICATION, P127; *NAT CANC I, 1998, SURV EP END RES PROG; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; OKUDA K, 1987, CANCER RES, V47, P4967; Percy C., 1990, INT CLASSIFICATION D; Serfaty L, 1998, HEPATOLOGY, V27, P1435, DOI 10.1002/hep.510270535; SHERLOCK S, 1994, GUT, V35, P828, DOI 10.1136/gut.35.6.828; TAKANO S, 1995, HEPATOLOGY, V21, P650; TaylorRobinson SD, 1997, LANCET, V350, P1142, DOI 10.1016/S0140-6736(05)63789-0; U.S. Department of Health and Human Services, 1989, DHHS PUBL; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; WONG JB, 1995, ANN INTERN MED, V122, P664, DOI 10.7326/0003-4819-122-9-199505010-00004; YARRISH RL, 1980, INT J CANCER, V26, P711, DOI 10.1002/ijc.2910260603	30	2379	2439	0	44	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 11	1999	340	10					745	750		10.1056/NEJM199903113401001	http://dx.doi.org/10.1056/NEJM199903113401001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	174KJ	10072408	Bronze			2022-12-28	WOS:000079034100001
J	Moran, JV; DeBerardinis, RJ; Kazazian, HH				Moran, JV; DeBerardinis, RJ; Kazazian, HH			Exon shuffling by L1 retrotransposition	SCIENCE			English	Article							HUMAN TRANSPOSABLE ELEMENT; HUMAN GENOME; SEQUENCE; LINE-1; GENE; INSERTION; EVOLUTION; ORIGIN	Long interspersed nuclear elements (LINE-1s or L1s) are the most abundant retrotransposons in the human genome, and they serve as major sources of reverse transcriptase activity. Engineered L1s retrotranspose at high frequency in cultured human cells. Here it is shown that L1s insert into transcribed genes and retrotranspose sequences derived from their 3' flanks to new genomic Locations. Thus, retrotransposition-competent L1s provide a vehicle to mobilize non-L1 sequences, such as exons or promoters, into existing genes and may represent a general mechanism for the evolution of new genes.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania	Moran, JV (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045398] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45398] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; Boeke JD, 1997, NAT GENET, V16, P6, DOI 10.1038/ng0597-6; CONWAY L, 1985, P NATL ACAD SCI USA, V82, P3949, DOI 10.1073/pnas.82.12.3949; DeBerardinis RJ, 1998, NAT GENET, V20, P288, DOI 10.1038/3104; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; FANNING T, 1987, NUCLEIC ACIDS RES, V15, P2251, DOI 10.1093/nar/15.5.2251; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Gilbert W, 1997, P NATL ACAD SCI USA, V94, P7698, DOI 10.1073/pnas.94.15.7698; Hohjoh H, 1997, EMBO J, V16, P6034, DOI 10.1093/emboj/16.19.6034; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; Leder P, 1982, Natl Cancer Inst Monogr, V60, P49; LONG MY, 1993, SCIENCE, V260, P91, DOI 10.1126/science.7682012; LUNQUE T, 1997, MOL BIOL EVOL, V14, P1316; Lupski JR, 1998, MOL MED, V4, P3, DOI 10.1007/BF03401724; MARTIN SL, 1995, GENE, V153, P261, DOI 10.1016/0378-1119(94)00785-Q; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; McNaughton JC, 1997, GENOMICS, V40, P294, DOI 10.1006/geno.1996.4543; MIKI Y, 1992, CANCER RES, V52, P643; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; MORAN JV, UNPUB; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; Rozmahel R, 1997, GENOMICS, V45, P554, DOI 10.1006/geno.1997.4968; Sassaman DM, 1997, NAT GENET, V16, P37, DOI 10.1038/ng0597-37; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253; YANDELL M, COMMUNICATION	30	460	467	4	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	1999	283	5407					1530	1534		10.1126/science.283.5407.1530	http://dx.doi.org/10.1126/science.283.5407.1530			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066175				2022-12-28	WOS:000078959200047
J	Staab, JF; Bradway, SD; Fidel, PL; Sundstrom, P				Staab, JF; Bradway, SD; Fidel, PL; Sundstrom, P			Adhesive and mammalian transglutaminase substrate properties of Candida albicans Hwp1	SCIENCE			English	Article							TRANSAMIDATING ENZYMES; EXPRESSION; MECHANISM; PROTEINS; PROLINE	The pathogenesis of candidiasis involves invasion of host tissues by filamentous forms of the opportunistic yeast Candida albicans. Morphology-specific gene products may confer proinvasive properties. A hypha-specific surface protein, Hwp1, with similarities to mammalian small proline-rich proteins was shown to serve as a substrate for mammalian transglutaminases. Candida albicans strains lacking Hwp1 were unable to form stable attachments to human buccal epithelial cells and had a reduced capacity to cause systemic candidiasis in mice. This represents a paradigm for microbial adhesion that implicates essential host enzymes.	Ohio State Univ, Coll Med & Publ Hlth, Dept Med Microbiol & Immunol, Columbus, OH 43210 USA; Ohio State Univ, Coll Dent, Dept Periodontol, Columbus, OH 43210 USA; Louisiana State Univ, Med Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70112 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Louisiana State University System	Sundstrom, P (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Dept Med Microbiol & Immunol, 333 W 10th Ave, Columbus, OH 43210 USA.	sundstrom.1@osu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032556, R01AI032556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011375] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32556] Funding Source: Medline; NIDCR NIH HHS [1 R01 DE11375-05A2] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Austin SJ, 1996, J BIOL CHEM, V271, P3737, DOI 10.1074/jbc.271.7.3737; BARSIGIAN C, 1991, J BIOL CHEM, V266, P22501; BRADWAY SD, 1993, CRIT REV ORAL BIOL M, V4, P293, DOI 10.1177/10454411930040030601; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHILDS WC, 1988, J DENT RES, V67, P826, DOI 10.1177/00220345880670050601; DESBUQUOIS B, 1975, EUR J BIOCHEM, V60, P335, DOI 10.1111/j.1432-1033.1975.tb21008.x; Fichtenbaum CJ, 1998, CLIN INFECT DIS, V26, P556, DOI 10.1086/514571; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; FONZI WA, 1993, GENETICS, V134, P717; Kaartinen MT, 1997, J BIOL CHEM, V272, P22736, DOI 10.1074/jbc.272.36.22736; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORAND L, 1968, BIOCHEMISTRY-US, V7, P1214, DOI 10.1021/bi00843a043; LORAND L, 1972, ANAL BIOCHEM, V50, P623, DOI 10.1016/0003-2697(72)90074-7; LORAND L, 1971, ANAL BIOCHEM, V44, P221, DOI 10.1016/0003-2697(71)90363-0; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; POSTLETHWAIT P, 1995, J BACTERIOL, V177, P1772, DOI 10.1128/jb.177.7.1772-1779.1995; Reichert Uwe, 1993, P107; Rex J H, 1998, Adv Intern Med, V43, P321; Sambrook J., 2002, MOL CLONING LAB MANU; Staab JF, 1998, YEAST, V14, P681, DOI 10.1002/(SICI)1097-0061(199805)14:7&lt;681::AID-YEA256&gt;3.0.CO;2-8; Staab JF, 1996, J BIOL CHEM, V271, P6298, DOI 10.1074/jbc.271.11.6298; STAAB JF, UNPUB; Tarcsa E, 1998, J BIOL CHEM, V273, P23297, DOI 10.1074/jbc.273.36.23297; VELASCO PT, 1988, BIOCHEM BIOPH RES CO, V152, P505, DOI 10.1016/S0006-291X(88)80066-4	25	451	470	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	1999	283	5407					1535	1538		10.1126/science.283.5407.1535	http://dx.doi.org/10.1126/science.283.5407.1535			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066176				2022-12-28	WOS:000078959200048
J	Jorenby, DE; Leischow, SJ; Nides, MA; Rennard, SI; Johnston, JA; Hughes, AR; Smith, SS; Muramoto, ML; Daughton, DM; Doan, K; Fiore, MC; Baker, TB				Jorenby, DE; Leischow, SJ; Nides, MA; Rennard, SI; Johnston, JA; Hughes, AR; Smith, SS; Muramoto, ML; Daughton, DM; Doan, K; Fiore, MC; Baker, TB			A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TOBACCO WITHDRAWAL; WEIGHT-GAIN; SYMPTOMS; SMOKERS; PLACEBO; GUM	Background and Methods Use of nicotine-replacement therapies and the antidepressant bupropion helps people stop smoking. We conducted a double-blind, placebo-controlled comparison of sustained-release bupropion (244 subjects), a nicotine patch (244 subjects), bupropion and a nicotine patch (245 subjects), and placebo (160 subjects) for smoking cessation. Smokers with clinical depression were excluded. Treatment consisted of nine weeks of bupropion (150 mg a day for the first three days, and then 150 mg twice daily) or placebo, as well as eight weeks of nicotine-patch therapy (21 mg per day during weeks 2 through 7,14 mg per day during week 8, and 7 mg per day during week 9) or placebo. The target day for quitting smoking was usually day 8. Results The abstinence rates at 12 months were 15.6 percent in the placebo group, as compared with 16.4 percent in the nicotine-patch group, 30.3 percent in the bupropion group (P<0.001), and 35.5 percent in the group given bupropion and the nicotine patch (P<0.001). By week 7, subjects in the placebo group had gained an average of 2.1 kg, as compared with a gain of 1.6 kg in the nicotine-patch group, a gain of 1.7 kg in the bupropion group, and a gain of 1.1 kg in the combined-treatment group (P<0.05). Weight gain at seven weeks was significantly less in the combined-treatment group than in the bupropion group and the placebo group (P<0.05 for both comparisons). A total of 311 subjects (34.8 percent) discontinued one or both medications. Seventy-nine subjects stopped treatment because of adverse events: 6 in the placebo group (3.8 percent), 16 in the nicotine-patch group (6.6 percent), 29 in the bupropion group (11.9 percent), and 28 in the combined-treatment group (11.4 percent). The most common adverse events were insomnia and headache. Conclusions Treatment with sustained-release bupropion alone or in combination with a nicotine patch resulted in significantly higher long-term rates of smoking cessation than use of either the nicotine patch alone or placebo. Abstinence rates were higher with combination therapy than with bupropion alone, but the difference was not statistically significant. (N Engl J Med 1999;340:685-91.) (C) 1999, Massachusetts Medical Society.	Univ Wisconsin, Sch Med, Ctr Tobacco Res & Intervent, Madison, WI USA; Univ Arizona, Arizona Program Nicotine & Tobacco Res, Tucson, AZ USA; Los Angeles Clin Trials, Los Angeles, CA USA; Univ Nebraska, Med Ctr, Pulm & Crit Care Med Sect, Omaha, NE USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	University of Wisconsin System; University of Wisconsin Madison; University of Arizona; University of Nebraska System; University of Nebraska Medical Center; GlaxoSmithKline	Jorenby, DE (corresponding author), 1300 Univ Ave,Rm 7278 MSC, Madison, WI 53706 USA.			Smith, Stevens/0000-0002-6824-2829				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDA RF, 1990, JAMA-J AM MED ASSOC, V264, P1541, DOI 10.1001/jama.264.12.1541; ASCHER JA, 1995, J CLIN PSYCHIAT, V56, P395; BAKER TB, 1987, NEBR S MOT, V34; Beck A.T, 1978, BECK DEPRESSION INVE; BRANDON TH, 1994, CURR DIR PSYCHOL SCI, V3, P33, DOI 10.1111/1467-8721.ep10769919; *DEP HLTH HUM SERV, 1989, COSTART COD SYMB THE; FAGERSTROM KO, 1978, ADDICT BEHAV, V3, P235, DOI 10.1016/0306-4603(78)90024-2; FAGERSTROM KO, 1994, HEALTH VALUES, V18, P15; FERRY LH, 1994, J ADDICT DIS, V13, P249; FIORE MC, 1996, CLIN PRACTICE GUIDEL, V18; Fowler JS, 1996, NATURE, V379, P733, DOI 10.1038/379733a0; Glassman AH, 1996, AM J HEALTH BEHAV, V20, P279; Hall SM, 1996, J CONSULT CLIN PSYCH, V64, P1003, DOI 10.1037/0022-006X.64.5.1003; HOSMER DW, 1989, APPL LOGISTIC REGRES; HUGHES JR, 1986, ARCH GEN PSYCHIAT, V43, P289; HUGHES JR, 1992, J CONSULT CLIN PSYCH, V60, P689, DOI 10.1037/0022-006X.60.5.689; Hurt RD, 1997, NEW ENGL J MED, V337, P1195, DOI 10.1056/NEJM199710233371703; Jorenby DE, 1996, PSYCHOPHARMACOLOGY, V128, P130, DOI 10.1007/s002130050118; KANDEL DB, 1986, ARCH GEN PSYCHIAT, V43, P255; Leischow S J, 1992, Arch Fam Med, V1, P233, DOI 10.1001/archfami.1.2.233; LIPKUS IM, 1994, HEALTH PSYCHOL, V13, P149, DOI 10.1037/0278-6133.13.2.149; NIDES M, 1994, HEALTH PSYCHOL, V13, P354, DOI 10.1037/0278-6133.13.4.354; SAS Institute, 1990, SAS STAT US GUID VER; 1993, MMWR MORB MORTAL WKL, V42, P504	25	1088	1131	1	76	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1999	340	9					685	691		10.1056/NEJM199903043400903	http://dx.doi.org/10.1056/NEJM199903043400903			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	172ZB	10053177				2022-12-28	WOS:000078955200003
J	Baker, R				Baker, R			American independence and the right to emergency care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Union Coll, Dept Philosophy, Schenectady, NY 12308 USA; Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA	Union College; University of Pennsylvania	Baker, R (corresponding author), Union Coll, Dept Philosophy, Schenectady, NY 12308 USA.							Baker R, 1997, JAMA-J AM MED ASSOC, V278, P163, DOI 10.1001/jama.278.2.163; BAKER R, 1995, CODIFICATION MED MOR, P75; DAVIS NS, 1903, HIST MED CODE MED ET; GOODPASTER KE, 1997, POLICIES PERSONS CAS; *NJ MED SOC, 1766, INSTR ASS NEW JERS M; Nozick Robert, 1974, ANARCHY STATE UTOPIA; Reich, 1996, ENCY BIOETHICS; WITHINGTON CF, 1886, RELATION HOSP MED ED; [No title captured]	9	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					859	860		10.1001/jama.281.9.859	http://dx.doi.org/10.1001/jama.281.9.859			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10071012	hybrid			2022-12-28	WOS:000078804300042
J	Khovidhunkit, W; Shoback, DM				Khovidhunkit, W; Shoback, DM			Clinical effects of raloxifene hydrochloride in women	ANNALS OF INTERNAL MEDICINE			English	Review							ESTROGEN-RECEPTOR MODULATORS; BREAST-CANCER-CELLS; RAT MAMMARY-CARCINOMA; BONE-MINERAL DENSITY; BETA-MESSENGER-RNA; OVARIECTOMIZED RATS; POSTMENOPAUSAL WOMEN; SERUM-CHOLESTEROL; LY139481 HCL; ANTIESTROGENIC PROPERTIES	Purpose: To review clinical data on raloxifene hydrochloride, a selective estrogen receptor modulator that was recently approved for the prevention of osteoporosis in postmenopausal women. Data Sources: English-language articles published from 1980 to May 1998 were identified through MEDLINE searches. Bibliographies, book chapters, and meeting abstracts were reviewed for additional relevant publications. Study Selection: Publications that contained information on the background of development, structure, mechanism of action, tissue-selective effects, and adverse effects of raloxifene hydrochloride were included. Data Extraction: data in selected articles were reviewed, and relevant clinical information was extracted. Data Synthesis: Raloxifene hydrochloride was developed in an effort to find a treatment for breast cancer and osteoporosis. It binds to the estrogen receptor and shows tissue-selective effects; thus, it belongs to a class of drugs recently described as selective estrogen receptor modulators. Tissue selectivity of raloxifene may be achieved through several mechanisms: the ligand structure, interaction of the ligand with different estrogen receptor subtypes in Various tissues, and intracellular events after ligand binding. Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. An increase in bone mineral density at the spine, total hip, and total body has been reported with raloxifene but seems to be less than that seen with estrogen or alendronate therapy. Raloxifene has been shown to produce a reduction in total and low-density lipoprotein cholesterol concentrations similar to that produced by estrogen therapy, but high-density lipoprotein cholesterol and triglyceride concentrations do not increase during raloxifene therapy. In the uterus, raloxifene does not stimulate the endometrium. Long-term data on the effects of raloxifene in reduction of risk for fracture; prevention of cardiovascular events; cognitive function; and the incidence of breast, ovarian, and uterine cancer are not available. The most common adverse effect of raloxifene is hot flashes. Conclusions: Raloxifene has been shown to have beneficial effects in selected organs in postmenopausal women. Although estrogen remains the drug of choice for hormonal therapy in most postmenopausal women, raloxifene may be an alternative in certain groups of women at risk for osteoporosis.	Vet Affairs Med Ctr, Metab Sect, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Vet Affairs Med Ctr, Endocrine Sect, San Francisco, CA 94121 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Khovidhunkit, W (corresponding author), Vet Affairs Med Ctr, Metab Sect, 4150 Clement St,111F, San Francisco, CA 94121 USA.				NIDDK NIH HHS [DK 43400] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043400] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE O, 1992, LANCET, V339, P71; Anzano MA, 1996, J NATL CANCER I, V88, P123, DOI 10.1093/jnci/88.2.123; Arts J, 1997, ENDOCRINOLOGY, V138, P5067, DOI 10.1210/en.138.11.5067; Baker V L, 1996, Obstet Gynecol Surv, V51, P45, DOI 10.1097/00006254-199601000-00021; Baker VL, 1998, J CLIN ENDOCR METAB, V83, P6, DOI 10.1210/jc.83.1.6; Bjarnason NH, 1997, CIRCULATION, V96, P1964, DOI 10.1161/01.CIR.96.6.1964; BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985; BLACK LJ, 1983, LIFE SCI, V32, P1031, DOI 10.1016/0024-3205(83)90935-9; BLACK LJ, 1982, BREAST CANC RES TREA, V2, P279; Boss SM, 1997, AM J OBSTET GYNECOL, V177, P1458, DOI 10.1016/S0002-9378(97)70091-7; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; BUZDAR AU, 1988, ONCOLOGY, V45, P344, DOI 10.1159/000226637; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Cheskis BJ, 1997, J BIOL CHEM, V272, P11384; Clarkson TB, 1998, J CLIN ENDOCR METAB, V83, P721, DOI 10.1210/jc.83.3.721; CLEMENS JA, 1983, LIFE SCI, V32, P2869, DOI 10.1016/0024-3205(83)90323-5; COLLETTA AA, 1994, BREAST CANCER RES TR, V31, P5, DOI 10.1007/BF00689672; CUMMINGS SR, 1998, P AM SOC CLIN ONC M, P3; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Delmas PD, 1998, NEW ENGL J MED, V338, P1313; Dodge JA, 1997, J STEROID BIOCHEM, V61, P97, DOI 10.1016/S0960-0760(97)00008-3; Dotzlaw H, 1997, J CLIN ENDOCR METAB, V82, P2371, DOI 10.1210/jc.82.7.2371; Draper MW, 1996, J BONE MINER RES, V11, P835; DRAPER MW, 1995, PHARMACOLOGY, V50, P209, DOI 10.1159/000139284; *E LILL CO, 1997, EV RAL TABL PROD MON; Elgort MG, 1996, MOL ENDOCRINOL, V10, P477, DOI 10.1210/me.10.5.477; ETTINGER B, 1998, OSTEOPOROSIS INT S3, V8, P11; EVANS G, 1994, ENDOCRINOLOGY, V134, P2283, DOI 10.1210/en.134.5.2283; Evans GL, 1996, ENDOCRINOLOGY, V137, P4139, DOI 10.1210/en.137.10.4139; Frolik CA, 1996, BONE, V18, P621, DOI 10.1016/8756-3282(96)00085-3; FROLIK CA, 1993, J BONE MINER RES, V8, pS282; FuchsYoung R, 1996, MOL CARCINOGEN, V17, P151, DOI 10.1002/(SICI)1098-2744(199611)17:3<151::AID-MC7>3.0.CO;2-I; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GLASEBROOK AL, 1995, BONE, V16, pS99; GOTTARDIS MM, 1990, CANCER RES, V50, P3189; GOTTARDIS MM, 1987, CANCER RES, V47, P4020; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grese TA, 1997, J MED CHEM, V40, P146, DOI 10.1021/jm9606352; Grese TA, 1997, P NATL ACAD SCI USA, V94, P14105, DOI 10.1073/pnas.94.25.14105; GREY AB, 1995, J CLIN ENDOCR METAB, V80, P3191, DOI 10.1210/jc.80.11.3191; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Heaney RP, 1997, J CLIN ENDOCR METAB, V82, P3425, DOI 10.1210/jc.82.10.3425; HOCK JM, 1993, J BONE MINER RES, V8, pS157; JONES CD, 1984, J MED CHEM, V27, P1057, DOI 10.1021/jm00374a021; JORDAN VC, 1987, BREAST CANCER RES TR, V10, P31, DOI 10.1007/BF01806132; JORDAN VC, 1995, J CELL BIOCHEM, P51; JORDAN VC, 1998, P AN M AM SOC CLIN, V17, P466; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kauffman RF, 1997, J PHARMACOL EXP THER, V280, P146; KESSEL B, 1987, LIFE SCI, V40, P1089, DOI 10.1016/0024-3205(87)90572-8; KHOVIDHUNKIT W, 1997, GROW FACT CYTOK  A&B, V3, P459; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; LERNER LJ, 1990, CANCER RES, V50, P4177; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; Lundeen SG, 1997, ENDOCRINOLOGY, V138, P1552, DOI 10.1210/en.138.4.1552; MA PTS, 1986, P NATL ACAD SCI USA, V83, P792, DOI 10.1073/pnas.83.3.792; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; Mitlak BH, 1997, HORM RES, V48, P155, DOI 10.1159/000185507; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; ORTMANN O, 1988, ENDOCRINOLOGY, V123, P962, DOI 10.1210/endo-123-2-962; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PETERSEN SL, 1989, BRAIN RES, V484, P279, DOI 10.1016/0006-8993(89)90371-5; POULIN R, 1989, BREAST CANCER RES TR, V14, P65, DOI 10.1007/BF01805977; Riggs BL, 1996, J CLIN ENDOCR METAB, V81, P2417, DOI 10.1210/jc.81.7.2417; SATO M, 1995, J PHARMACOL EXP THER, V272, P1252; Sato M, 1996, FASEB J, V10, P905, DOI 10.1096/fasebj.10.8.8666168; SATO M, 1994, J BONE MINER RES, V9, P715; Sato M, 1996, J PHARMACOL EXP THER, V279, P298; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; SIMARD J, 1985, MOL CELL ENDOCRINOL, V39, P141, DOI 10.1016/0303-7207(85)90131-5; Somjen D, 1996, J STEROID BIOCHEM, V59, P389, DOI 10.1016/S0960-0760(96)00135-5; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STEVENSON JC, 1994, DRUGS, V47, P35, DOI 10.2165/00003495-199400472-00007; THOMPSON EW, 1988, CANCER RES, V48, P6764; TURNER CH, 1994, ENDOCRINOLOGY, V135, P2001, DOI 10.1210/en.135.5.2001; VANLEEUWEN FE, 1994, LANCET, V343, P448, DOI 10.1016/S0140-6736(94)92692-1; WAKELING AE, 1984, J STEROID BIOCHEM, V20, P111, DOI 10.1016/0022-4731(84)90197-3; Walsh BW, 1998, JAMA-J AM MED ASSOC, V279, P1445, DOI 10.1001/jama.279.18.1445; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WEISS DJ, 1988, J STEROID BIOCHEM, V31, P671, DOI 10.1016/0022-4731(88)90017-9; Yang NN, 1996, ENDOCRINOLOGY, V137, P2075, DOI 10.1210/en.137.5.2075; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222; Ziegler J, 1996, J NATL CANCER I, V88, P1100, DOI 10.1093/jnci/88.16.1100; Zuckerman SH, 1996, ATHEROSCLEROSIS, V126, P65	86	110	121	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	1999	130	5					431	439		10.7326/0003-4819-130-5-199903020-00015	http://dx.doi.org/10.7326/0003-4819-130-5-199903020-00015			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172AA	10068418				2022-12-28	WOS:000078898100007
J	Karlseder, J; Broccoli, D; Dai, YM; Hardy, S; de Lange, T				Karlseder, J; Broccoli, D; Dai, YM; Hardy, S; de Lange, T			p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2	SCIENCE			English	Article							ATAXIA-TELANGIECTASIA; CELLS; DNA; PROTEIN; PATHWAY; ARREST; MICE	Although broken chromosomes can induce apoptosis, natural chromosome ends (telomeres) do not trigger this response. It is shown that this suppression of apoptosis involves the telomeric-repeat binding factor 2 (TRF2), Inhibition of TRF2 resulted in apoptosis in a subset of mammalian cell types, The response was mediated by p53 and the ATM (ataxia telangiectasia mutated) kinase, consistent with activation of a DNA damage checkpoint. Apoptosis was not due to rupture of dicentric chromosomes formed by end-to-end fusion, indicating that telomeres Lacking TRF2 directly signal apoptosis, possibly because they resemble damaged DNA. Thus, in some cells, telomere shortening may signal cell death rather than senescence.	Rockefeller Univ, Cell Biol & Genet Lab, New York, NY 10021 USA; Cell Genesys, Foster City, CA 94405 USA	Rockefeller University; Cell Genesys Inc	de Lange, T (corresponding author), Rockefeller Univ, Cell Biol & Genet Lab, 1230 York Ave, New York, NY 10021 USA.		de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM049046, R01GM049046] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49046] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; de Lange T, 1998, SCIENCE, V279, P334, DOI 10.1126/science.279.5349.334; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Greider CW, 1998, CURR BIOL, V8, pR178, DOI 10.1016/S0960-9822(98)70105-8; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shen MH, 1997, P NATL ACAD SCI USA, V94, P13618, DOI 10.1073/pnas.94.25.13618; SMOGORZEWSKA A, UNPUB; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; UNUTMAZ D, 1994, J EXP MED, V180, P1159, DOI 10.1084/jem.180.3.1159; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	29	869	911	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1321	1325		10.1126/science.283.5406.1321	http://dx.doi.org/10.1126/science.283.5406.1321			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037601				2022-12-28	WOS:000078839900040
J	Bo, K; Talseth, T; Holme, I				Bo, K; Talseth, T; Holme, I			Single blind, randomised controlled trial of pelvic floor exercises, electrical stimulation, vaginal cones, and no treatment in management of genuine stress incontinence in women	BMJ-BRITISH MEDICAL JOURNAL			English	Article							URINARY-INCONTINENCE; MUSCLE EXERCISE; PRESSURE MEASUREMENTS; STRENGTH	Objective To compare the effect of pelvic floor exercises, electrical stimulation, vaginal cones, and no treatment for genuine stress incontinence. Design Stratified, single blind, randomised controlled trial. Setting Multicentre. Participants 107 women with clinically and urodynamically proved genuine stress incontinence. Mean (range) age was 49.5 (24-70) years, and mean (range) duration of symptoms 10.8 (1-45) years. Interventions Pelvic floor exercise (n = 25) comprised 8-12 contractions 3 times a day and exercise in groups with skilled physical therapists once a week. The electrical stimulation group (n = 25) used vaginal intermittent stimulation with the MS 106 Twin at 50 Hz 30 minutes a day. The vaginal cones group (n = 27) used cones for 20 minutes a day. The untreated control group (n = 30) was offered the use of a continence guard. Muscle strength was measured by vaginal squeeze pressure once a month. Main outcome measures Pad test with standardised bladder volume, and self report of severity. Results Improvement in muscle strength was significantly greater (P = 0.03) after pelvic floor exercises (11.0 cm H2O (95% confidence interval 7.7 to 14.3) before v 19.2 cm H2O (15.3 to 23.1) after) than either electrical stimulation (14.8 cm H2O (10.9 to 18.7) v 18.6 cm H2O (13.3 to 23.9)) or vaginal cones (11.8 cm H2O (8.5 to 15.1)v 15.4 cm H2O (11.1 to 19.7)). Reduction in leakage on pad test was greater in the exercise group (- 30.2 g; - 43.3 to 16.9) than in the electrical stimulation group (- 7.4 g; - 20.9 to 6.1) and the vaginal cones group (- 14.7 g; - 27.6 to - 1.8). On completion of the trial one participant in the control group, 14 in the pelvic floor exercise group, three in the electrical stimulation group, and two in the vaginal cones group no longer considered themselves as having a problem. Conclusion Training of the pelvic floor muscles is superior to electrical stimulation and vaginal cones in the treatment of genuine stress incontinence.	Norwegian Ctr Physiotherapy Res, N-0806 Oslo, Norway; Norwegian Univ Sport & Phys Educ, N-0806 Oslo, Norway; Natl Hosp Norway, Oslo, Norway	Norwegian School of Sport Sciences; University of Oslo; National Hospital Norway	Bo, K (corresponding author), Norwegian Ctr Physiotherapy Res, POB 4014,Ulleval Stad, N-0806 Oslo, Norway.	karib@brage.idrettshs.no						ABRAMS P, 1988, SCAND J UROL NEPHROL, P5; [Anonymous], 1990, Med Sci Sports Exerc, V22, P265; Berghmans LCM, 1998, BRIT J UROL, V82, P181; BLAIVAS J, 1997, NEUROUROL URODYNAM, V16, P147; BO K, 1994, SCAND J UROL NEPHROL, V28, P97, DOI 10.3109/00365599409180479; BO K, 1989, Scandinavian Journal of Sports Sciences, V11, P117; Bo K, 1998, ACTA OBSTET GYN SCAN, V77, P3; BO K, 1990, NEUROUROL URODYNAM, V9, P489, DOI 10.1002/nau.1930090505; Bo K, 1996, OBSTET GYNECOL, V87, P261, DOI 10.1016/0029-7844(95)60375-1; BO K, 1990, NEUROUROL URODYNAM, V9, P479, DOI 10.1002/nau.1930090504; BO K, 1992, NEUROUROL URODYNAM, V11, P107, DOI 10.1002/nau.1930110205; BO K, 1995, ACTA OBSTET GYN SCAN, V74, P87, DOI 10.3109/00016349509008913; Bo K, 1997, Int Urogynecol J Pelvic Floor Dysfunct, V8, P3; Bo K., 1995, INT UROGYNECOL J, V6, P282, DOI [10.1007/BF01901527, DOI 10.1007/BF01901527]; BOUCHARD C, 1993, PHYSICAL ACTIVITY FI, P33; BOUCHARD C, 1994, PHYSICAL ACTIVITY FI; Brubaker L, 1997, AM J OBSTET GYNECOL, V177, P536, DOI 10.1016/S0002-9378(97)70142-X; DeLancey JOL, 1996, AM J OBSTET GYNECOL, V175, P311, DOI 10.1016/S0002-9378(96)70140-0; Dudley G. A., 1992, STRENGTH POWER SPORT, P329; Fantl J., 1996, URINARY INCONTINENCE; HENALLA SM, 1989, J OBSTET GYNAECOL, V9, P222, DOI 10.3109/01443618909151046; HUNSKAAR S, 1991, J AM GERIATR SOC, V39, P378, DOI 10.1111/j.1532-5415.1991.tb02903.x; KEGEL AH, 1948, AM J OBSTET GYNECOL, V56, P238, DOI 10.1016/0002-9378(48)90266-X; LAGROJANSSEN TLM, 1991, BRIT J GEN PRACT, V41, P445; LOSE G, 1988, UROLOGY, V32, P78, DOI 10.1016/0090-4295(88)90462-1; Luber KM, 1997, NEUROUROL URODYNAM, V16, P543, DOI 10.1002/(SICI)1520-6777(1997)16:6<543::AID-NAU4>3.0.CO;2-E; NORTON PA, 1988, BRIT MED J, V297, P1187, DOI 10.1136/bmj.297.6657.1187; NYGAARD I, 1990, OBSTET GYNECOL, V75, P848; SAND PK, 1995, AM J OBSTET GYNECOL, V173, P72, DOI 10.1016/0002-9378(95)90172-8; THYSSEN H, 1997, INT UROGYNECOL J, V81, P30	30	396	413	4	54	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 20	1999	318	7182					487	+		10.1136/bmj.318.7182.487	http://dx.doi.org/10.1136/bmj.318.7182.487			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QT	10024253	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000078818100021
J	Lowe, TM; Eddy, SR				Lowe, TM; Eddy, SR			A computational screen for methylation guide snoRNAs in yeast	SCIENCE			English	Article							SMALL NUCLEOLAR RNAS; HIDDEN MARKOV-MODELS; RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; GENES; ELEMENTS; SEQUENCE; INTRON	Small nucleolar RNAs (snoRNAs) are required for ribose 2'-O-methylation of eukaryotic ribosomal RNA. Many of the genes for this snoRNA family have remained unidentified in Saccharomyces cerevisiae, despite the availability of a complete genome sequence. Probabilistic modeling methods akin to those used in speech recognition and computational linguistics were used to computationally screen the yeast genome and identify 22 methylation guide snoRNAs, snR50 to snR71. Gene disruptions and other experimental characterization confirmed their methylation guide function. in total, 51 of the 55 ribose methylated sites in yeast ribosomal RNA were assigned to 41 different guide snoRNAs.	Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL)	Lowe, TM (corresponding author), Washington Univ, Sch Med, Dept Genet, 4566 Scott Ave, St Louis, MO 63110 USA.		Lowe, Todd Michael/ABJ-5261-2022	Eddy, Sean/0000-0001-6676-4706	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001363] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01-HG01363] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bachellerie JP, 1997, TRENDS BIOCHEM SCI, V22, P257, DOI 10.1016/S0968-0004(97)01057-8; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; Barrett C, 1997, COMPUT APPL BIOSCI, V13, P191; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Cavaille J, 1996, NATURE, V383, P732, DOI 10.1038/383732a0; Cavaille J, 1998, NUCLEIC ACIDS RES, V26, P1576, DOI 10.1093/nar/26.7.1576; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; Durbin R., 1998, BIOL SEQUENCE ANAL P; EDDY SR, 1994, NUCLEIC ACIDS RES, V22, P2079, DOI 10.1093/nar/22.11.2079; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; GANNOT P, 1997, CELL, V89, P799; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HADJICHRISTODOULOU A, 1985, Cyprus Agricultural Research Institute Technical Bulletin, P1; JARMOLOWSKI A, 1990, EMBO J, V9, P4503, DOI 10.1002/j.1460-2075.1990.tb07901.x; Kiss-Laszlo Z, 1998, EMBO J, V17, P797, DOI 10.1093/emboj/17.3.797; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; KLOOTWIJK J, 1973, EUR J BIOCHEM, V39, P325, DOI 10.1111/j.1432-1033.1973.tb03130.x; Lange TS, 1998, EMBO J, V17, P3176, DOI 10.1093/emboj/17.11.3176; Leader DJ, 1997, EMBO J, V16, P5742, DOI 10.1093/emboj/16.18.5742; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MADEN BEH, 1995, BIOCHIMIE, V77, P22, DOI 10.1016/0300-9084(96)88100-4; NI JS, COMMUNICATION; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; NICOLOSO M, 1994, MOL CELL BIOL, V14, P5766, DOI 10.1128/MCB.14.9.5766; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; Petfalski E, 1998, MOL CELL BIOL, V18, P1181, DOI 10.1128/MCB.18.3.1181; Qu LH, 1999, MOL CELL BIOL, V19, P1144; RAUE HA, 1988, PROG BIOPHYS MOL BIO, V51, P77, DOI 10.1016/0079-6107(88)90011-9; SAKAKIBARA Y, 1994, NUCLEIC ACIDS RES, V22, P5112, DOI 10.1093/nar/22.23.5112; Samarsky DA, 1998, EMBO J, V17, P3747, DOI 10.1093/emboj/17.13.3747; SINGH H, 1964, CAN J BIOCHEM PHYS, V42, P1011, DOI 10.1139/o64-112; Smith CM, 1997, CELL, V89, P669, DOI 10.1016/S0092-8674(00)80247-0; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; VELDMAN GM, 1981, NUCLEIC ACIDS RES, V9, P6935, DOI 10.1093/nar/9.24.6935; Watkins NJ, 1998, RNA, V4, P582, DOI 10.1017/S1355838298980128	37	374	408	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1168	1171		10.1126/science.283.5405.1168	http://dx.doi.org/10.1126/science.283.5405.1168			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024243				2022-12-28	WOS:000078738400052
J	Yamagishi, H; Garg, V; Matsuoka, R; Thomas, T; Srivastava, D				Yamagishi, H; Garg, V; Matsuoka, R; Thomas, T; Srivastava, D			A molecular pathway revealing a genetic basis for human cardiac and craniofacial defects	SCIENCE			English	Article							CONGENITAL HEART-DISEASE; NEURAL CREST; DIGEORGE-SYNDROME; VELOCARDIOFACIAL SYNDROMES; MICE DEFICIENT; UBIQUITIN; MICRODELETIONS; ENDOTHELIN-1; ETIOLOGY; REGION	Microdeletions of chromosome 22q11 are the most common genetic defects associated with cardiac and craniofacial anomalies in humans. A screen for mouse genes dependent on dHAND, a transcription factor implicated in neural crest development, identified Ufd1, which maps to human 22q11 and encodes a protein involved in degradation of ubiquitinated proteins. Mouse Ufd1 was specifically expressed in most tissues affected in patients with 22q11 deletion syndrome. The human UFD1L gene was deleted in all 182 patients studied with 22q11 deletion, and a smaller deletion of approximately 20 kilobases that removed exons 1 to 3 of UFD1L was found in one individual with features typical of 22q11 deletion syndrome. These data suggest that UFD1L haploinsufficiency contributes to the congenital heart and craniofacial defects seen in 22q11 deletion.	Univ Texas, SW Med Ctr, Dept Pediat, Div Cardiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75235 USA; Tokyo Womens Med Univ, Heart Inst Japan, Dept Pediat Cardiol, Tokyo, Japan	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tokyo Women's Medical University	Srivastava, D (corresponding author), Univ Texas, SW Med Ctr, Dept Pediat, Div Cardiol, 6000 Harry Hines Blvd,Room NA8-124, Dallas, TX 75235 USA.	dsriva@mednet.swmed.edu	Garg, Vidu/E-3101-2011; Yamagishi, Hiroyuki/A-6345-2017; Garg, Vidu/D-8240-2012	Garg, Vidu/0000-0002-3778-5927	NHLBI NIH HHS [R01HL57181-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057181] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Botta A, 1997, CYTOGENET CELL GENET, V77, P264, DOI 10.1159/000134592; BURN J, 1993, J MED GENET, V30, P822, DOI 10.1136/jmg.30.10.822; Clouthier DE, 1998, DEVELOPMENT, V125, P813; Dallapiccola B, 1996, AM J HUM GENET, V59, P7; Daw SCM, 1996, NAT GENET, V13, P458, DOI 10.1038/ng0896-458; DRISCOLL DA, 1992, AM J HUM GENET, V50, P924; DRISCOLL DA, 1993, J MED GENET, V30, P813, DOI 10.1136/jmg.30.10.813; EMANUEL BS, 1998, HEART DEV, P463; Fyler DC, 1992, NADAS PEDIAT CARDIOL, P273; Galili N, 1997, GENOME RES, V7, P17, DOI 10.1101/gr.7.1.17; Goldmuntz E, 1998, J AM COLL CARDIOL, V32, P492, DOI 10.1016/S0735-1097(98)00259-9; Gong WK, 1996, HUM MOL GENET, V5, P789, DOI 10.1093/hmg/5.6.789; HOFFMAN JIE, 1995, PEDIATR CARDIOL, V16, P103, DOI 10.1007/BF00801907; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; KIRBY ML, 1993, TRENDS CARDIOVAS MED, V3, P18, DOI 10.1016/1050-1738(93)90023-Y; KIRBY ML, 1990, CIRCULATION, V82, P332, DOI 10.1161/01.CIR.82.2.332; KIRBY ML, 1983, SCIENCE, V220, P1059, DOI 10.1126/science.6844926; KIRBY ML, 1995, CIRC RES, V77, P211, DOI 10.1161/01.RES.77.2.211; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; KURIHARA Y, 1995, J CLIN INVEST, V96, P293, DOI 10.1172/JCI118033; Lewin MB, 1997, AM J CARDIOL, V80, P493, DOI 10.1016/S0002-9149(97)00401-3; Li M., 1994, American Journal of Human Genetics, V55, pA10; Matsuoka R, 1998, HUM GENET, V103, P70, DOI 10.1007/s004390050786; McKie JM, 1998, GENOME RES, V8, P834, DOI 10.1101/gr.8.8.834; Monney L, 1998, J BIOL CHEM, V273, P6121, DOI 10.1074/jbc.273.11.6121; Novelli G, 1998, BBA-GENE STRUCT EXPR, V1396, P158, DOI 10.1016/S0167-4781(97)00211-X; OLSON EN, 1996, SCIENCE, V272, P1069; Pizzuti A, 1997, HUM MOL GENET, V6, P259, DOI 10.1093/hmg/6.2.259; Puech A, 1997, P NATL ACAD SCI USA, V94, P14608, DOI 10.1073/pnas.94.26.14608; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sears C, 1998, J BIOL CHEM, V273, P1409, DOI 10.1074/jbc.273.3.1409; SHAIKH TH, 1998, AM J HUM GENET, V63, pA193; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; SRIVASTAVA DK, UNPUB, P42502; Thomas T, 1998, DEVELOPMENT, V125, P3005; Thomas T, 1998, DEV BIOL, V196, P228, DOI 10.1006/dbio.1998.8849; VANMIEROP LHS, 1986, AM J CARDIOL, V58, P133, DOI 10.1016/0002-9149(86)90256-0; Wilming LG, 1997, HUM MOL GENET, V6, P247, DOI 10.1093/hmg/6.2.247; WILSON DI, 1993, J MED GENET, V30, P852, DOI 10.1136/jmg.30.10.852; YAMAGISHI H, UNPUB	41	215	223	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 19	1999	283	5405					1158	1161		10.1126/science.283.5405.1158	http://dx.doi.org/10.1126/science.283.5405.1158			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024240				2022-12-28	WOS:000078738400049
J	Chin, AE; Hedberg, K; Higginson, GK; Fleming, DW				Chin, AE; Hedberg, K; Higginson, GK; Fleming, DW			Legalized physician-assisted suicide in Oregon - The first year's experience	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EUTHANASIA; ATTITUDES	Background and Methods On October 27, 1997, Oregon legalized physician-assisted suicide. We collected data on all terminally ill Oregon residents who received prescriptions for lethal medications under the Oregon Death with Dignity Act and who died in 1998. The data were obtained from physicians' reports, death certificates, and interviews with physicians. We compared persons who took lethal medications prescribed under the act with those who died from similar illnesses but did not receive prescriptions for lethal medications. Results Information on 23 persons who received prescriptions for lethal medications was reported to the Oregon Health Division; 15 died after taking the lethal medications, 6 died from underlying illnesses, and 2 were alive as of January 1, 1999. The median age of the 15 patients who died after taking lethal medications was 69 years; 8 were male, and all 15 were white. Thirteen of the 15 patients had cancer. The case patients and controls were similar with regard to sex, race, urban or rural residence, level of education, health insurance coverage, and hospice enrollment. No case patients or control patients expressed concern about the financial impact of their illness. One case patient and 15 control patients expressed concern about inadequate control of pain (P=0.10). The case patients were more likely than the control patients to have never married (P=0.04) and were more likely to be concerned about loss of autonomy due to illness (P=0.01) and loss of control of bodily functions (P=0.02). At death, 21 percent of the case patients and 84 percent of the control patients were completely disabled (P<0.001). Conclusions During the first year of legalized physician-assisted suicide in Oregon, the decision to request and use a prescription for lethal medication was associated with concern about loss of autonomy or control of bodily functions, not with fear of intractable pain or concern about financial loss. In addition, we found that the choice of physician-assisted suicide was not associated with level of education or health insurance coverage. (N Engl J Med 1999;340:577-83.) (C)1999, Massachusetts Medical Society.	Oregon Hlth Div, Portland, OR 97232 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA USA	Oregon Health & Science University; Centers for Disease Control & Prevention - USA	Hedberg, K (corresponding author), Oregon Hlth Div, 800 NE Oregon St,Suite 772, Portland, OR 97232 USA.							ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; *CTR HLTH STAT OR, 1997, OR VIT STAT COUNTY D; DEAN A, 1995, EPI INFO VERSION 6 W; Drickamer MA, 1997, ANN INTERN MED, V126, P146, DOI 10.7326/0003-4819-126-2-199701150-00009; *DRUG ENF AG DRUG, 1998, 4 DEP JUST DRUG ENF, P43; Emanuel EJ, 1998, JAMA-J AM MED ASSOC, V280, P507, DOI 10.1001/jama.280.6.507; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; HALEY K, 1998, OREGON DEATH DIGNITY, P40; HEDBERG K, 1998, OREGON DEATH DIGNITY, P43; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; O'Keefe Mark, 1997, OREGONIAN       1019, pA1; OKEEFE M, 1994, OREGONIAN       1204, pA1; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PELLEGRINO ED, 1998, REGULATING WE DIE ET, P71; Preston T. A., 1996, J PHARM CARE PAIN SY, V4, P183; Slome LR, 1997, NEW ENGL J MED, V336, P417, DOI 10.1056/NEJM199702063360606; Tolle SW, 1998, ANN INTERN MED, V128, P567, DOI 10.7326/0003-4819-128-7-199804010-00009	20	211	211	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1999	340	7					577	583		10.1056/NEJM199902183400724	http://dx.doi.org/10.1056/NEJM199902183400724			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168FD	10021482				2022-12-28	WOS:000078680100039
J	Roberts, RR; Frutos, PW; Ciavarella, GG; Gussow, LM; Mensah, EK; Kampe, LM; Straus, HE; Joseph, G; Rydman, RJ				Roberts, RR; Frutos, PW; Ciavarella, GG; Gussow, LM; Mensah, EK; Kampe, LM; Straus, HE; Joseph, G; Rydman, RJ			Distribution of variable vs fixed costs of hospital care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	125th Annual Meeting of the American-Public-Health-Association	NOV 09-13, 1997	INDIANAPOLIS, INDIANA	Amer Public Hlth Assoc, Natl Assoc Publ Hlth Policy, APHA, Med Care Sect			UNITED-STATES; TECHNICAL EFFICIENCY; HEALTH; CONTAINMENT; EMERGENCY; INFLATION; RECOMMENDATIONS; PERFORMANCE; COMPETITION; EXPERIENCE	Context Most strategies proposed to control the rising cost of health care are aimed at reducing medical resource consumption rates. These approaches may be limited in effectiveness because of the relatively low variable cost of medical care. Variable costs (for medication and supplies) are saved if a facility does not provide a service while fixed costs (for salaried labor, buildings, and equipment) are not saved over the short term when a health care facility reduces service. Objective To determine the relative variable and fixed costs of inpatient and outpatient care for a large urban public teaching hospital. Design Cost analysis. Setting A large urban public teaching hospital. Main Outcome Measures All expenditures for the institution during 1993 and for each service were categorized as either variable or fixed. Fixed costs included capital expenditures, employee salaries and benefits, building maintenance, and utilities. Variable costs included health care worker supplies, patient care supplies, diagnostic and therapeutic supplies, and medications. Results In 1993, the hospital had nearly 114000 emergency department visits, 40000 hospital admissions, 240000 inpatient days, and more than 500000 outpatient clinic visits. The total budget for 1993 was $429.2 million, of which $360.3 million (84%) was fixed and $68.8 million (16%) was variable. Overall, 31.5% of total costs were for support expenses such as utilities, employee benefits, and housekeeping salaries, and 52.4% included direct costs of salary for service center personnel who provide services to individual patients. Conclusions The majority of cost in providing hospital service is related to buildings, equipment, salaried labor, and overhead, which are fixed over the short term. The high fixed costs emphasize the importance of adjusting fixed costs to patient consumption to maintain efficiency.	Rush Univ, Cook Cty Hosp, Dept Emergency Med, Chicago, IL 60612 USA; Midwestern Univ, Chicago Coll Osteopath Med, Downers Grove, IL 60515 USA; N Shore Univ Hosp, Dept Internal Med, Queens, NY USA; Univ Illinois, Sch Publ Hlth, Div Hlth Policy & Adm, Chicago, IL USA	John H Stroger Junior Hospital Cook County; Rush University; Midwestern University; Midwestern University - Chicago College of Osteopathic Medicine; Northwell Health; North Shore University Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Roberts, RR (corresponding author), Rush Univ, Cook Cty Hosp, Dept Emergency Med, 1900 W Polk St,10th Floor, Chicago, IL 60612 USA.				AHRQ HHS [R01-HS-07103] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM HOSP ASS, 1998, AM HOSP ASS PUBL; ANDERSON G, 1984, MED CARE, V22, P494, DOI 10.1097/00005650-198405000-00012; Anderson GF, 1996, INQUIRY-J HEALTH CAR, V33, P79; Anthony M., 1996, MATH EC FINANCE METH; ASHBY JL, 1992, HEALTH AFFAIR, V11, P134, DOI 10.1377/hlthaff.11.2.134; Berwick DM, 1996, NEW ENGL J MED, V335, P1227, DOI 10.1056/NEJM199610173351611; CARTER CL, 1993, J MED PRACT MANAGE, V9, P126; Catron B, 1996, MON LABOR REV, V119, P24; Conrad D, 1996, HEALTH SERV RES, V31, P235; EHRETH JL, 1994, MED CARE, V32, P568, DOI 10.1097/00005650-199406000-00003; EISENBERG JM, 1984, REV INFECT DIS, V6, pS909; EVANS DB, 1990, MED J AUSTRALIA, V153, pS10; Finkler SA., 1994, ESSENTIALS COST ACCO; FUCHS VR, 1990, SCIENCE, V247, P534, DOI 10.1126/science.2300814; FUCHS VR, 1993, JAMA-J AM MED ASSOC, V269, P631; Gaskin DJ, 1997, INQUIRY-J HEALTH CAR, V34, P205; HACKEY RB, 1993, J HEALTH POLIT POLIC, V18, P491, DOI 10.1215/03616878-18-2-491; Hadley J, 1996, MED CARE, V34, P205, DOI 10.1097/00005650-199603000-00002; HARTMAN SE, 1989, MED CARE, V27, P234, DOI 10.1097/00005650-198903000-00002; HEANEY DJ, 1992, FAM PRACT, V9, P177, DOI 10.1093/fampra/9.2.177; JAPSEN B, 1995, MODERN HEALTHCARE, V25, P34; LAVE JR, 1984, ANNU REV PUBL HEALTH, V5, P193; Levit KR, 1996, HEALTH CARE FINANC R, V18, P175; LEVIT KR, 1994, HEALTH AFFAIR, V13, P14, DOI 10.1377/hlthaff.13.5.14; Luce B R, 1990, Int J Technol Assess Health Care, V6, P57; LUDBROOK A, 1987, HLTH B EDINB, V44, P13; McDermott MF, 1997, ARCH INTERN MED, V157, P2055, DOI 10.1001/archinte.157.18.2055; MELNICK GA, 1988, JAMA-J AM MED ASSOC, V260, P2669, DOI 10.1001/jama.260.18.2669; NEWHOUSE JP, 1993, HEALTH AFFAIR, V12, P152, DOI 10.1377/hlthaff.12.suppl_1.152; NEWHOUSE JP, 1992, J ECON PERSPECT, V6, P3, DOI 10.1257/jep.6.3.3; NIGHTINGALE CH, 1987, ARCH SURG-CHICAGO, V122, P451; OZCAN YA, 1993, HEALTH SERV RES, V27, P719; OZCAN YA, 1992, MED CARE, V30, P781, DOI 10.1097/00005650-199209000-00003; PAULY MV, 1986, HEALTH SERV RES, V21, P403; PAULY MV, 1995, HEALTH AFFAIR, V14, P68, DOI 10.1377/hlthaff.14.2.68; Powe NR, 1995, CONTROL CLIN TRIALS, V16, P377, DOI 10.1016/S0197-2456(95)00075-5; Reinhardt UE, 1996, HEALTH AFFAIR, V15, P145, DOI 10.1377/hlthaff.15.2.145; REINHARDT UE, 1992, J HEALTH POLIT POLIC, V17, P637, DOI 10.1215/03616878-17-4-637; Roberts RR, 1997, JAMA-J AM MED ASSOC, V278, P1670, DOI 10.1001/jama.278.20.1670; Robinson JC, 1996, JAMA-J AM MED ASSOC, V276, P1060, DOI 10.1001/jama.276.13.1060; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; RUTIGLIANO MJ, 1995, NEUROSURGERY, V37, P436, DOI 10.1227/00006123-199509000-00011; Rydman RJ, 1998, MED CARE, V36, P599, DOI 10.1097/00005650-199804000-00015; Samuelson P.A., 1995, EKONOMIA, V1; SATHER MR, 1984, AM J HOSP PHARM, V41, P2624; SCHIFF G, 1996, AM COLL PHYSICIANS O, V16, P4; SCHWARTZ M, 1995, INQUIRY, V32, P476; SCHWARTZ WB, 1981, NEW ENGL J MED, V305, P1249, DOI 10.1056/NEJM198111193052104; SCHWARTZ WB, 1994, HEALTH AFFAIR, V13, P224, DOI 10.1377/hlthaff.13.1.224; Shi L, 1996, HEALTH CARE MANAGE R, V21, P46, DOI 10.1097/00004010-199605000-00007; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; Sochalski J, 1997, MED CARE, V35, pOS13, DOI 10.1097/00005650-199710001-00004; Steinbrook R, 1996, NEW ENGL J MED, V334, P657, DOI 10.1056/NEJM199603073341010; SUVER JD, 1992, MANAGE ACCOUNTING, P278; *US DEP COMM, 1997, STAT ABSTR US; *US DEP HHS, 1998, PHS US DEP HLTH HUM; VALDMANIS VG, 1990, MED CARE, V28, P552, DOI 10.1097/00005650-199006000-00007; Weil T P, 1996, J Health Care Finance, V22, P62; Weinstein M C, 1990, Int J Technol Assess Health Care, V6, P93; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; Williams RM, 1996, NEW ENGL J MED, V334, P642, DOI 10.1056/NEJM199603073341007; Woolhandler S, 1997, NEW ENGL J MED, V336, P769, DOI 10.1056/NEJM199703133361106; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805	63	188	189	2	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1999	281	7					644	649		10.1001/jama.281.7.644	http://dx.doi.org/10.1001/jama.281.7.644			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	165YA	10029127				2022-12-28	WOS:000078548400036
J	Wechsler, E; D'Aleo, C; Hill, VA; Hopper, J; Myers-Wiley, D; O'Keefe, E; Jacobs, J; Guido, F; Huang, A; Dodt, SN; Rowan, B; Sherman, M; Greenberg, A; Schneider, D; Noone, B; Fanella, L; Williamson, BR; Dinda, E; Mayer, M; Backer, M; Agasan, A; Kornstein, L; Stavinsky, F; Neal, B; Edwards, D; Haroon, M; Hurley, D; Colbert, L; Miller, J; Mojica, B; Carloni, E; Devine, B; Cambridge, M; Root, T; Schoonmaker, D; Shayegani, M; Hastback, W; Wallace, B; Kondracki, S; Smith, P; Matiuck, S; Pilot, K; Acharya, M; Wolf, G; Manley, W; Genese, C; Brooks, J; Dembek, Z; Hadler, J				Wechsler, E; D'Aleo, C; Hill, VA; Hopper, J; Myers-Wiley, D; O'Keefe, E; Jacobs, J; Guido, F; Huang, A; Dodt, SN; Rowan, B; Sherman, M; Greenberg, A; Schneider, D; Noone, B; Fanella, L; Williamson, BR; Dinda, E; Mayer, M; Backer, M; Agasan, A; Kornstein, L; Stavinsky, F; Neal, B; Edwards, D; Haroon, M; Hurley, D; Colbert, L; Miller, J; Mojica, B; Carloni, E; Devine, B; Cambridge, M; Root, T; Schoonmaker, D; Shayegani, M; Hastback, W; Wallace, B; Kondracki, S; Smith, P; Matiuck, S; Pilot, K; Acharya, M; Wolf, G; Manley, W; Genese, C; Brooks, J; Dembek, Z; Hadler, J			Outbreak of Vibrio parahaemolyticus infection associated with eating raw oysters and clams harvested from Long Island Sound - Connecticut, New Jersey, and New York, 1998 (Reprinted from MMWR, vol 48, pg 48, 1999)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint									Westchester Cty Hlth Dept, New Rochelle, NY USA; Nassau Cty Dept Hlth, Div Dis Control, Mineola, NY USA; Suffolk Cty Dept Hlth Serv, Hauppauge, NY USA; New York City Bur Labs, Enter Pathogens Lab, New York, NY USA; New York City Bur Labs, Environm Microbiol Lab, New York, NY USA; New York City Dept Hlth, New York, NY USA; Bur Community Sanitat & Food Protect, New York, NY USA; Wadsworth Ctr Labs & Res, Albany, NY USA; New York State Dept Hlth, Albany, NY 12237 USA; New York State Dept Environm Conservat, New York, NY USA; Bur Communicable Dis Control, New York, NY USA; Bur Labs, New York, NY USA; New Jersey State Dept Hlth, Trenton, NJ 08625 USA; Connecticut Dept Publ Hlth, US FDA, Hartford, CT USA; US Fish & Wildlife Serv, USDA, Washington, DC USA; CDC, Natl Ctr Infect Dis, Div Bacterial & Mycot Dis, Foodborne & Diarrheal Dis Branch, Atlanta, GA 30333 USA; CDC, Epidemiol Program Off, Div Appl Publ Hlth Training, State Branch, Atlanta, GA 30333 USA	New York City Department of Health & Mental Hygiene; Wadsworth Center; State University of New York (SUNY) System; New Jersey Department of Health & Senior Services; US Food & Drug Administration (FDA); United States Department of Agriculture (USDA); United States Department of the Interior; US Fish & Wildlife Service; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Wechsler, E (corresponding author), Westchester Cty Hlth Dept, New Rochelle, NY USA.							1999, MMWR, V48, P48	1	12	13	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1999	281	7					603	604						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	165YA	10029109				2022-12-28	WOS:000078548400010
J	Lau, JYW; Sung, JJY; Lam, YH; Chan, ACW; Ng, EKW; Lee, DWH; Chan, FKL; Suen, RCY; Chung, SCS				Lau, JYW; Sung, JJY; Lam, YH; Chan, ACW; Ng, EKW; Lee, DWH; Chan, FKL; Suen, RCY; Chung, SCS			Endoscopic retreatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UPPER GASTROINTESTINAL HEMORRHAGE; PEPTIC-ULCER; RANDOMIZED TRIAL; THERAPY; INJECTION; ERADICATION; POLIDOCANOL; HEMOSTASIS; PROBE; LASER	Background and Methods After endoscopic treatment to control bleeding of peptic ulcers, bleeding recurs in 15 to 20 percent of patients. In a prospective, randomized study, we compared endoscopic retreatment with surgery after initial endoscopy. Over a 40-month period, 1169 of 3473 adults who were admitted to our hospital with bleeding peptic ulcers underwent endoscopy to reestablish hemostasis. Of 100 patients with recurrent bleeding, 7 patients with cancer and 1 patient with cardiac arrest were excluded from the study; 48 patients were randomly assigned to undergo immediate endoscopic retreatment and 44 were assigned to undergo surgery. The type of operation used was left to the surgeon. Bleeding was considered to have recurred in the event of any one of the following: vomiting of fresh blood, hypotension and melena, or a requirement for more than four units of blood in the 72-hour period after endoscopic treatment. Results Of the 48 patients who were assigned to endoscopic retreatment, 35 had long-term control of bleeding. Thirteen underwent salvage surgery, 11 because retreatment failed and 2 because of perforations resulting from thermocoagulation. Five patients in the endoscopy group died within 30 days, as compared with eight patients in the surgery group (P = 0.37). Seven patients in the endoscopy group (including 6 who underwent salvage surgery) had complications, as compared with 16 in the surgery group (P = 0.03). The duration of hospitalization, the need for hospitalization in the intensive care unit and the resultant duration of that stay, and the number of blood transfusions were similar in the two groups. In multivariate analysis, hypotension at randomization (P = 0.01) and an ulcer size of at least 2 cm (P = 0.03) were independent factors predictive of the failure of endoscopic retreatment. Conclusions In patients with peptic ulcers and recurrent bleeding after initial endoscopic control of bleeding, endoscopic retreatment reduces the need for surgery without increasing the risk of death and is associated with fewer complications than surgery. (N Engl J Med 1999;340:751-6.) (C)1999, Massachusetts Medical Society.	Prince Wales Hosp, Dept Surg, Hong Kong, Peoples R China; Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong	Chung, SCS (corresponding author), Prince Wales Hosp, Dept Surg, Hong Kong, Peoples R China.	sydneychung@cuhk.edu.hk	Chan, Francis K. L./F-4851-2010; Lau, James Y. W./O-2612-2016; Sung, Joseph J. Y./R-3203-2018; Ng, Enders Kwok-wai/E-8276-2016	Chan, Francis K. L./0000-0001-7388-2436; Lau, James Y. W./0000-0003-0122-4068; Sung, Joseph J. Y./0000-0003-3125-5199; Ng, Enders Kwok-wai/0000-0001-7219-5810				Altman D.G., 1991, PRACTICAL STAT MED R; Chung SSC, 1997, BMJ-BRIT MED J, V314, P1307, DOI 10.1136/bmj.314.7090.1307; COOK DJ, 1992, GASTROENTEROLOGY, V102, P139, DOI 10.1016/0016-5085(92)91793-4; DELGUERCIO LRM, 1980, JAMA-J AM MED ASSOC, V243, P1350, DOI 10.1001/jama.243.13.1350; GILBERT DA, 1981, GASTROINTEST ENDOSC, V27, P94; HOSMER DW, 1989, APPL LOGISTIC REGRES; JASPERSEN D, 1995, GASTROINTEST ENDOSC, V41, P5, DOI 10.1016/S0016-5107(95)70267-9; JOHNSTON JH, 1987, GASTROENTEROLOGY, V92, P1101, DOI 10.1016/S0016-5085(87)91065-1; Khuroo MS, 1997, NEW ENGL J MED, V336, P1054, DOI 10.1056/NEJM199704103361503; Kubba AK, 1996, EUR J GASTROEN HEPAT, V8, P1175, DOI 10.1097/00042737-199612000-00008; Lau JYW, 1998, GASTROINTEST ENDOSC, V47, pAB87; Lin CK, 1996, GASTROENTEROLOGY, V110, pA177; Lin HJ, 1998, ARCH INTERN MED, V158, P54, DOI 10.1001/archinte.158.1.54; MESSMANN H, 1996, GASTROINTEST ENDOSC, V43, P354; QVIST P, 1994, SCAND J GASTROENTERO, V29, P569, DOI 10.3109/00365529409092474; ROCKALL TA, 1995, BRIT MED J, V311, P222, DOI 10.1136/bmj.311.6999.222; ROKKAS T, 1995, GASTROINTEST ENDOSC, V41, P1, DOI 10.1016/S0016-5107(95)70266-0; RUTGEERTS P, 1989, LANCET, V1, P1164; Rutgeerts P, 1997, LANCET, V350, P692, DOI 10.1016/S0140-6736(97)03233-9; SACKS HS, 1990, JAMA-J AM MED ASSOC, V264, P494, DOI 10.1001/jama.264.4.494; Saeed ZA, 1996, ENDOSCOPY, V28, P288, DOI 10.1055/s-2007-1005455; Sung JJY, 1997, DIGEST DIS SCI, V42, P2524, DOI 10.1023/A:1018816729449; SWAIN CP, 1986, GASTROENTEROLOGY, V90, P595, DOI 10.1016/0016-5085(86)91113-3; VILLANUEVA C, 1994, GASTROINTEST ENDOSC, V40, P34, DOI 10.1016/S0016-5107(94)70006-0	24	283	293	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 11	1999	340	10					751	756		10.1056/NEJM199903113401002	http://dx.doi.org/10.1056/NEJM199903113401002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	174KJ	10072409				2022-12-28	WOS:000079034100002
J	Hingorani, M; Wong, T; Vafidis, G				Hingorani, M; Wong, T; Vafidis, G			Patients' and doctors' attitudes to amount of information given after unintended injury during treatment: cross sectional questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									Cent Middlesex Hosp, Cent Eye Unit, London NW10 7NS, England	Imperial College London	Hingorani, M (corresponding author), Cent Middlesex Hosp, Cent Eye Unit, London NW10 7NS, England.							BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; *GEN MED COUNC, 1998, GOOD MED PRACT; LAURANCE J, 1998, INDEPENDENT     0520, P5; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; VINCENT C, 1994, LANCET, V343, P1609, DOI 10.1016/S0140-6736(94)93062-7	5	78	78	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					640	641		10.1136/bmj.318.7184.640	http://dx.doi.org/10.1136/bmj.318.7184.640			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066205	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000079089200028
J	Hurwitz, B				Hurwitz, B			Legal and political considerations of clinical practice guidelines	BRITISH MEDICAL JOURNAL			English	Article									Imperial Coll, Sch Med, Dept Primary Care & Gen Practice, London W2 1PG, England	Imperial College London	Hurwitz, B (corresponding author), Imperial Coll, Sch Med, Dept Primary Care & Gen Practice, St Marys Campus, London W2 1PG, England.	b.hurwitz@ic.ac.uk						Black D, 1998, J ROY COLL PHYS LOND, V32, P23; Bradley D J, 1997, Commun Dis Rep CDR Rev, V7, pR137; CANE P, 1992, INTRO ADM LAW, P137; DurandZaleski I, 1997, BRIT MED J, V315, P943; DWORKIN R, 1997, LIMITS ROLE LAW BIOE, P3; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; EVANS JG, 1995, AGE AGEING, V24, P461, DOI 10.1093/ageing/24.6.461; FIELD M, 1990, CLIN PRACTICE GUIDEL, P107; Grol R, 1998, BRIT MED J, V317, P858, DOI 10.1136/bmj.317.7162.858; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; HARPWOOD V, 1994, MED LAW INT, V1, P241; Hawkins, 1995, USES DISCRETION; Human Fertilisation and Embryology Authority, 1991, COD PRACT; Hurwitz B, 1998, CLIN GUIDELINES LAW; HYAMS AL, 1995, ANN INTERN MED, V122, P450, DOI 10.7326/0003-4819-122-6-199503150-00008; Maisonneuve H, 1997, J Eval Clin Pract, V3, P3, DOI 10.1111/j.1365-2753.1997.tb00065.x; MCPHERSON K, 1990, CHALLENGE MED PRACTI, P17; *NAT HLTH MED RES, 1995, GUID DEV IMPL CLIN G, P27; NEWDICK C, 1995, WHO SHOULD WE TREAT, P178; Newton J, 1996, BRIT J GEN PRACT, V46, P513; *NHS EX, 1996, CLIN GUID, P10; PLATO, 1995, STATESMAN, pR16; *SEC STAT HLTH, 1997, CM3807; Stern K., 1995, CLIN EFFECTIVENESS G, P127; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; WILLIAMS A, 1994, OUTCOMES CLIN PRACTI, P100; ZANCHETTI A, 1993, BMJ-BRIT MED J, V307, P1541, DOI 10.1136/bmj.307.6918.1541; 1986, CALIFORNIA REPORTER, V228, P661	28	106	109	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					661	664		10.1136/bmj.318.7184.661	http://dx.doi.org/10.1136/bmj.318.7184.661			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066215	Green Published			2022-12-28	WOS:000079089200035
J	Elchebly, M; Payette, P; Michaliszyn, E; Cromlish, W; Collins, S; Loy, AL; Normandin, D; Cheng, A; Himms-Hagen, J; Chan, CC; Ramachandran, C; Gresser, MJ; Tremblay, ML; Kennedy, BP				Elchebly, M; Payette, P; Michaliszyn, E; Cromlish, W; Collins, S; Loy, AL; Normandin, D; Cheng, A; Himms-Hagen, J; Chan, CC; Ramachandran, C; Gresser, MJ; Tremblay, ML; Kennedy, BP			Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene	SCIENCE			English	Article							IN-VIVO; RECEPTOR; 1B; VANADATE; PATHWAY; KINASE; ALPHA	Protein tyrosine phosphatase-1B (PTP-1B) has been implicated in the negative regulation of insulin signaling. Disruption of the mouse homolog of the gene encoding PTP-1B yielded healthy mice that, in the fed state, had blood glucose concentrations that were slightly lower and concentrations of circulating insulin that were one-half those of their PIP-1B(+/+) littermates. The enhanced insulin sensitivity of the PTP-1B(-/-) mice was also evident in glucose and insulin tolerance tests. The PTP-1B(-/-) mice showed increased phosphorylation of the insulin receptor in liver and muscle tissue after insulin injection in comparison to PTP-1B(+/+) mice. On a high-fat diet, the PTP-1B(-/-) and PTP-1B(+/-) mice were resistant to weight gain and remained insulin sensitive, whereas the PTP-1B(+/+) mice rapidly gained weight and became insulin resistant. These results demonstrate that PTP-1B has a major role in modulating both insulin sensitivity and fuel metabolism, thereby establishing it as a potential therapeutic target in the treatment of type 2 diabetes and obesity.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	Merck & Company; McGill University; University of Ottawa	Kennedy, BP (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R 4P8, Canada.		Cheng, Alan/M-9319-2013	Cheng, Alan/0000-0001-7897-4751				AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; Chen H, 1997, J BIOL CHEM, V272, P8026, DOI 10.1074/jbc.272.12.8026; Chiarugi P, 1997, BIOCHEM BIOPH RES CO, V238, P676, DOI 10.1006/bbrc.1997.7355; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Jacob KK, 1998, J BIOL CHEM, V273, P4800, DOI 10.1074/jbc.273.8.4800; Khandelwal RL, 1995, MOL CELL BIOCHEM, V153, P87, DOI 10.1007/BF01075922; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MAEGAWA H, 1995, J BIOL CHEM, V270, P7724, DOI 10.1074/jbc.270.13.7724; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; Norris K, 1997, FEBS LETT, V415, P243, DOI 10.1016/S0014-5793(97)01133-2; PAYETTE P, UNPUB; Ren JM, 1998, DIABETES, V47, P493, DOI 10.2337/diabetes.47.3.493; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; Schaapveld RQJ, 1997, DEV BIOL, V188, P134, DOI 10.1006/dbio.1997.8630; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; WHITE MF, 1994, J BIOL CHEM, V269, P1; YouTen KE, 1997, J EXP MED, V186, P683, DOI 10.1084/jem.186.5.683	23	1761	1901	2	132	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	1999	283	5407					1544	1548		10.1126/science.283.5407.1544	http://dx.doi.org/10.1126/science.283.5407.1544			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066179				2022-12-28	WOS:000078959200051
J	Foote, M; Hunter, JP; Janis, CM; Sepkoski, JJ				Foote, M; Hunter, JP; Janis, CM; Sepkoski, JJ			Evolutionary and preservational constraints on origins of biologic groups: Divergence times of eutherian mammals	SCIENCE			English	Article							STRATIGRAPHIC RANGES; MOLECULAR-CLOCK; FOSSIL PRESERVATION; ANGIOSPERM ORIGINS; ANIMAL PHYLA; PHYLOGENY; MONTANA; RECORD; RATES; DNA	Some molecular clack estimates of divergence times of taxonomic groups undergoing evolutionary radiation are much older than the groups' first observed fossil record. Mathematical models of branching evolution are used to estimate the maximal rate of fossil preservation consistent with a postulated missing history, given the sum of species durations implied by early origins under a range of species origination and extinction rates. The plausibility of postulated divergence times depends on origination, extinction, and preservation Fates estimated from the fossil record. For eutherian mammals, this approach suggests that it is unlikely that many modern orders arose much earlier than their oldest fossil records.	Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA; New York Inst Technol, New York Coll Osteopath Med, Old Westbury, NY 11568 USA; Brown Univ, Dept Ecol & Evolut Biol, Providence, RI 02912 USA	University of Chicago; New York Institute Technology; Brown University	Foote, M (corresponding author), Univ Chicago, Dept Geophys Sci, 5734 S Ellis Ave, Chicago, IL 60637 USA.	mfoote@midway.uchicago.edu	Janis, Christine/GPT-3398-2022; Hunter, John/A-2573-2013					Alroy J, 1998, SCIENCE, V280, P731, DOI 10.1126/science.280.5364.731; Archibald JD, 1996, SCIENCE, V272, P1150, DOI 10.1126/science.272.5265.1150; Ayala FJ, 1998, P NATL ACAD SCI USA, V95, P606, DOI 10.1073/pnas.95.2.606; BENTON MJ, 1990, J MOL EVOL, V30, P409, DOI 10.1007/BF02101113; Bleiweiss R, 1998, GEOLOGY, V26, P323, DOI 10.1130/0091-7613(1998)026<0323:FGASET>2.3.CO;2; BRITTEN RJ, 1986, SCIENCE, V231, P1393, DOI 10.1126/science.3082006; BUTLER PM, 1990, BIOL REV, V65, P529, DOI 10.1111/j.1469-185X.1990.tb01237.x; BUTLER PM, 1988, PHYLOGENY CLASSIFICA, V2, P117; Carroll RL, 1988, VERTEBRATE PALEONTOL; Cooper A, 1998, TRENDS ECOL EVOL, V13, P151, DOI 10.1016/S0169-5347(97)01277-9; CRANE PR, 1989, NATURE, V342, P131, DOI 10.1038/342131b0; de Jong WW, 1998, TRENDS ECOL EVOL, V13, P270, DOI 10.1016/S0169-5347(98)01335-4; Doyle James A., 1997, American Journal of Botany, V84, P132; Fitch W., 1976, MOL EVOLUTION, P160; Foote M, 1996, PALEOBIOLOGY, V22, P121, DOI 10.1017/S0094837300016134; Foote M, 1996, PALEOBIOLOGY, V22, P141, DOI 10.1017/S0094837300016146; Foote M, 1997, PALEOBIOLOGY, V23, P278, DOI 10.1017/S0094837300019692; FOX RC, 1994, J VERTEBR PALEONTOL, V14, P382, DOI 10.1080/02724634.1994.10011566; FOX RC, 1984, CARNEGIE MUS NAT HIS, V9, P9; Gheerbrant E, 1996, NATURE, V383, P68, DOI 10.1038/383068a0; GILLESPIE JH, 1984, P NATL ACAD SCI-BIOL, V81, P8009, DOI 10.1073/pnas.81.24.8009; GILLESPIE JH, 1986, MOL BIOL EVOL, V3, P138; GILLESPIE JH, 1986, GENETICS, V113, P1077; GINGERICH PD, 1986, MOL BIOL EVOL, V3, P205; GOODWIN MB, 1989, CAN J EARTH SCI, V26, P1384, DOI 10.1139/e89-118; GRADSTEIN FM, GEOCHRONOLOGY TIME S, P95; Harland W.B., 1990, GEOLOGIC TIME SCALE; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; Hitchin R, 1997, PALEOBIOLOGY, V23, P20, DOI 10.1017/S0094837300016626; HUELSENBECK JP, 1994, PALEOBIOLOGY, V20, P470, DOI 10.1017/S009483730001294X; Jacobs L.L., 1998, EVOLUTION TERTIARY M; KENDALL DG, 1948, ANN MATH STAT, V19, P1, DOI 10.1214/aoms/1177730285; KIMURA M, 1987, J MOL EVOL, V26, P24, DOI 10.1007/BF02111279; KRISHTALKA L, 1979, MILWAUKEE PUBL MUS C, V27, P1; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lillegraven J.A., 1972, Contributions Sci, VNo. 232, P1; Lillegraven J. A., 1990, GEOLOGICAL SOC AM SP, P1, DOI DOI 10.1130/SPE243-P1; MARSHALL CR, 1990, PALEOBIOLOGY, V16, P1, DOI 10.1017/S0094837300009672; Marshall CR, 1999, GEOLOGY, V27, P95, DOI 10.1130/0091-7613(1999)027<0095:FGASET>2.3.CO;2; MARTIN W, 1989, NATURE, V339, P46, DOI 10.1038/339046a0; MARTIN W, 1993, MOL BIOL EVOL, V10, P140; McKenna MC, 1997, CLASSIFICATION MAMMA; Messer Michael, 1998, Journal of Mammalian Evolution, V5, P95, DOI 10.1023/A:1020523120739; MIYAMOTO MM, 1995, MOL BIOL EVOL, V12, P503; Nessov Lev A., 1998, Bulletin of Carnegie Museum of Natural History, V34, P40; NORELL MA, 1992, SCIENCE, V255, P1690, DOI 10.1126/science.255.5052.1690; Normile D, 1998, SCIENCE, V281, P774, DOI 10.1126/science.281.5378.774; Novacek M.J., 1976, Contributions Sci Los Angeles, VNo. 283, P1; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; Patzkowsky ME, 1995, PALEOBIOLOGY, V21, P440, DOI 10.1017/S0094837300013476; RAUP DM, 1985, PALEOBIOLOGY, V11, P42, DOI 10.1017/S0094837300011386; RAUP DM, 1978, PALEOBIOLOGY, V4, P1; RAUP DM, 1983, P NATL ACAD SCI-BIOL, V80, P2981, DOI 10.1073/pnas.80.10.2981; RAUP DM, 1991, PALEOBIOLOGY, V17, P37, DOI 10.1017/S0094837300010332; RAUP DM, 1983, PALEOBIOLOGY, V9, P107, DOI 10.1017/S0094837300007491; RAUP DM, 1986, RATES EVOLUTION, P1; ROGERS RR, 1993, CAN J EARTH SCI, V30, P1066, DOI 10.1139/e93-090; RUNNEGAR B, 1982, LETHAIA, V15, P199, DOI 10.1111/j.1502-3931.1982.tb00645.x; Sanderson MJ, 1997, MOL BIOL EVOL, V14, P1218, DOI 10.1093/oxfordjournals.molbev.a025731; Seilacher A, 1998, SCIENCE, V282, P80, DOI 10.1126/science.282.5386.80; Shoshani J, 1998, MOL PHYLOGENET EVOL, V9, P572, DOI 10.1006/mpev.1998.0520; Solow AR, 1997, PALEOBIOLOGY, V23, P271, DOI 10.1017/S0094837300019680; Springer Mark S., 1997, Journal of Mammalian Evolution, V4, P285, DOI 10.1023/A:1027378615412; Springer MS, 1997, NATURE, V388, P61, DOI 10.1038/40386; Stanhope MJ, 1998, P NATL ACAD SCI USA, V95, P9967, DOI 10.1073/pnas.95.17.9967; Stanhope MJ, 1998, MOL PHYLOGENET EVOL, V9, P501, DOI 10.1006/mpev.1998.0517; Stanley S.M., 1990, P103; Stanley S. M., 1979, MACROEVOLUTION; STANLEY SM, 1985, PALEOBIOLOGY, V11, P13, DOI 10.1017/S0094837300011362; STRATHMANN RR, 1983, PALEOBIOLOGY, V9, P97, DOI 10.1017/S009483730000748X; STUCKY RK, 1993, FOSS REC, V2, P739; SWISHER CC, 1993, CAN J EARTH SCI, V30, P1981, DOI 10.1139/e93-174; SYSTMA KJ, 1996, FLOWERING PLANT ORIG, P314; Van Valen L., 1973, EVOL THEORY REV, V1, P1, DOI DOI 10.1038/344864A0; VANVALEN LM, 1985, EVOL THEOR, V7, P127; WAGNER PJ, 1995, PALEOBIOLOGY, V21, P153, DOI 10.1017/S009483730001318X; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201; Wray GA, 1996, SCIENCE, V274, P568, DOI 10.1126/science.274.5287.568; Yule G. V., 1924, Philosophical Transactions of the Royal Society London B, V213, P21; ZUCKERKANDL EMILE, 1965, P97; [No title captured]	81	202	208	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1310	1314		10.1126/science.283.5406.1310	http://dx.doi.org/10.1126/science.283.5406.1310			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037598				2022-12-28	WOS:000078839900037
J	Scholich, K; Mullenix, JB; Wittpoth, C; Poppleton, HM; Pierre, SC; Lindorfer, MA; Garrison, JC; Patel, TB				Scholich, K; Mullenix, JB; Wittpoth, C; Poppleton, HM; Pierre, SC; Lindorfer, MA; Garrison, JC; Patel, TB			Facilitation of signal onset and termination by adenylyl cyclase	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEINS; ALPHA-SUBUNITS; PURIFICATION; DOMAINS; ENZYME; FAMILY; SYSTEM; GAIP; RGS4; BETA	The alpha subunit (G(5 alpha)) of the stimulatory heterotrimeric guanosine triphosphate binding protein (G protein) G(s) activates all isoforms of mammalian adenylyl cyclase. Adenylyl cyclase (Type V) and its subdomains, which interact with G(5 alpha), promoted inactivation of the G protein by increasing its guanosine triphosphatase (GTPase) activity. Adenylyl cyclase and its subdomains also augmented the receptor-mediated activation of heterotrimeric G, and thereby facilitated the rapid onset of signaling. These findings demonstrate that adenylyl cyclase functions as a GTPase activating protein (GAP) for the monomeric G(5 alpha) and enhances the GTP/GDP exchange factor (EF) activity of receptors.	Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA; Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Virginia	Patel, TB (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.	tpatel@physio1.utmem.edu			NHLBI NIH HHS [HL48308, HL59679] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059679, R01HL048308] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BERNSTEIN G, 1992, CELL, V70, P411; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; GRABER SG, 1994, METHOD ENZYMOL, V237, P212; GRAZIANO MP, 1991, METHOD ENZYMOL, V195, P192; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; NEER EJ, 1984, J BIOL CHEM, V259, P4222; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; Scholich K, 1997, P NATL ACAD SCI USA, V94, P9602, DOI 10.1073/pnas.94.18.9602; SCHOLICH K, UNPUB; STERNWEIS PC, 1979, J BIOL CHEM, V254, P3333; SUN H, 1995, P NATL ACAD SCI USA, V92, P2229, DOI 10.1073/pnas.92.6.2229; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621	26	58	59	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 26	1999	283	5406					1328	1331		10.1126/science.283.5406.1328	http://dx.doi.org/10.1126/science.283.5406.1328			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037603				2022-12-28	WOS:000078839900042
J	Yanagisawa, J; Yanagi, Y; Masuhiro, Y; Suzawa, M; Watanabe, M; Kashiwagi, K; Toriyabe, T; Kawabata, M; Miyazono, K; Kato, S				Yanagisawa, J; Yanagi, Y; Masuhiro, Y; Suzawa, M; Watanabe, M; Kashiwagi, K; Toriyabe, T; Kawabata, M; Miyazono, K; Kato, S			Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators	SCIENCE			English	Article							D ENDOCRINE SYSTEM; NUCLEAR-RECEPTOR; MAD PROTEINS; HISTONE ACETYLTRANSFERASE; SUPERFAMILY; ACTIVATION; BINDING; PHOSPHORYLATION; METABOLISM; CBP/P300	Cell proliferation and differentiation are regulated by growth regulatory factors such as transforming growth factor-beta (TGF-beta) and the liphophilic hormone vitamin D. TGF-beta causes activation of SMAD proteins acting as coactivators or transcription factors in the nucleus. Vitamin D controls transcription of target genes through the vitamin D receptor (VDR). Smad3, one of the SMAD proteins downstream in the TGF-beta signaling pathway, was found in mammalian cells to act as a coactivator specific for Ligand-induced transactivation of VDR by forming a complex with a member of the steroid receptor coactivator-l protein family in the nucleus. Thus, Smad3 may mediate cross-talk between vitamin D and TGF-beta signaling pathways.	Japan Sci & Technol, CREST, Kawaguchi, Saitama 332, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Japan Soc Promot Sci, Res Future Program, Toshima Ku, Tokyo 1708455, Japan	Japan Science & Technology Agency (JST); University of Tokyo; Japanese Foundation for Cancer Research; Japan Society for the Promotion of Science	Kato, S (corresponding author), Japan Sci & Technol, CREST, 4-1-8 Honcho, Kawaguchi, Saitama 332, Japan.	uskato@hongo.ecc.u-tokyo.ac.jp	Yanagi, Yasuo/AAF-2670-2020					Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; DeLuca H F, 1986, Adv Exp Med Biol, V196, P361; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Ebihara K, 1996, MOL CELL BIOL, V16, P3393; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; KAMEL Y, 1997, CELL, V85, P403; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATO S, 1995, MOL CELL BIOL, V15, P5858; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NORMAN AW, 1982, ENDOCR REV, V3, P331, DOI 10.1210/edrv-3-4-331; ONATE SA, 1995, SCIENCE, V270, P1354; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STERN PH, 1997, VITAMIN D, P343; SUZUKI A, 1997, DEV BIOL, V184, P207; Takeshita A, 1998, J BIOL CHEM, V273, P14738, DOI 10.1074/jbc.273.24.14738; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YANAGISAWA J, UNPUB; YAO T, 1997, P NATL ACAD SCI USA, V93, P10626; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0	44	390	409	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1317	1321		10.1126/science.283.5406.1317	http://dx.doi.org/10.1126/science.283.5406.1317			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037600				2022-12-28	WOS:000078839900039
J	Zhu, BP; Rolfs, RT; Nangle, BE; Horan, JM				Zhu, BP; Rolfs, RT; Nangle, BE; Horan, JM			Effect of the interval between pregnancies on perinatal outcomes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	31st Annual Meeting of the Society-for-Epidemiological-Research	JUN 24-26, 1998	CHICAGO, IL	Soc Epidemiol Res			BIRTH-WEIGHT; INTERPREGNANCY INTERVAL; GESTATIONAL-AGE; MORTALITY; RISK	Background A short interval between pregnancies has been associated with adverse perinatal outcomes. Whether that association is due to confounding by other risk factors, such as maternal age, socioeconomic status, and reproductive history, is unknown. Methods We evaluated the interpregnancy interval in relation to low birth weight, preterm birth, and small size for gestational age by analyzing data from the birth certificates of 173,205 singleton infants born alive to multiparous mothers in Utah from 1989 to 1996. Results Infants conceived 18 to 23 months after a previous live birth had the lowest risks of adverse perinatal outcomes; shorter and longer interpregnancy intervals were associated with higher risks. These associations persisted when the data were stratified according to and controlled for 16 biologic, sociodemographic, and behavioral risk factors. As compared with infants conceived 18 to 23 months after a live birth, infants conceived less than 6 months after a live birth had odds ratios of 1.4 (95 percent confidence interval, 1.3 to 1.6) for low birth weight, 1.4 (95 percent confidence interval, 1.3 to 1.5) for preterm birth, and 1.3 (95 percent confidence interval, 1.2 to 1.4) for small size for gestational age; infants conceived 120 months or more after a live birth had odds ratios of 2.0 (95 percent confidence interval, 1.7 to 2.4), 1.5 (95 percent confidence interval, 1.3 to 1.7), and 1.8 (95 percent confidence interval, 1.6 to 2.0) for these three adverse outcomes, respectively, when we controlled for all 16 risk factors with logistic regression. Conclusions The optimal interpregnancy interval for preventing adverse perinatal outcomes is 18 to 23 months. (N Engl J Med 1999;340:589-94.) (C)1999, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Atlanta, GA USA; Utah Dept Hlth, Off Publ Hlth Data, Salt Lake City, UT 84116 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Zhu, BP (corresponding author), Michigan Dept Community Hlth, Div Epidemiol Serv, 3423 Martin Luther King Jr Blvd, Lansing, MI 48909 USA.	zhub@state.mi.us		Zhu, Baoping/0000-0003-0065-0153				Adams MM, 1997, PAEDIATR PERINAT EP, V11, P48, DOI 10.1046/j.1365-3016.11.s1.8.x; ALEXANDER GR, 1995, PUBLIC HEALTH REP, V110, P395; [Anonymous], 1985, PREV LOW BIRTHW; Bakketeig L. S., 1984, PERINATAL EPIDEMIOLO, P99; *BUR SURV AN, 1998, OV 1996 HLTH STAT SU, P64; COPPER RL, 1993, AM J OBSTET GYNECOL, V168, P78, DOI 10.1016/S0002-9378(12)90889-3; DOUGLAS JWB, 1950, J OBSTET GYN BRIT EM, V57, P143; Eastman NJ, 1944, AM J OBSTET GYNECOL, V47, P445, DOI 10.1016/S0002-9378(15)32197-9; ERICKSON JD, 1978, J EPIDEMIOL COMMUN H, V32, P124, DOI 10.1136/jech.32.2.124; FEDRICK J, 1973, BMJ-BRIT MED J, V4, P753, DOI 10.1136/bmj.4.5895.753; Fleiss J. L., 1981, STAT METHODS RATES P, V2; FREEMAN JM, 1985, NIH PUBLICATION; HACK M, 1994, NEW ENGL J MED, V331, P753, DOI 10.1056/NEJM199409223311201; HOSMER DW, 1989, APPL LOGISTIC REGRES; Illsley R, 1984, LOW BIRTH WEIGHT MED; Klerman LV, 1998, AM J PUBLIC HEALTH, V88, P1182, DOI 10.2105/AJPH.88.8.1182; LANG JM, 1990, AM J EPIDEMIOL, V132, P304, DOI 10.1093/oxfordjournals.aje.a115659; MACDORMAN MF, 1998, MON VITAL STAT REP S, V46; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; MILLER JE, 1991, FAM PLANN PERSPECT, V23, P62, DOI 10.2307/2135451; NELSON WE, 1996, NELSON TXB PEDIAT, P454; Resnik R., 1984, MATERNAL FETAL MED P, P141; VENTURA SJ, 1997, MON VITAL STAT REP S, V45; WINKVIST A, 1992, AM J PUBLIC HEALTH, V82, P691, DOI 10.2105/AJPH.82.5.691; WOODBURY RM, 1925, CHILDRENS BUREAU PUB, V142; Yerushalmy J., 1945, HUMAN BIOL, V17, P65	26	340	350	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1999	340	8					589	594		10.1056/NEJM199902253400801	http://dx.doi.org/10.1056/NEJM199902253400801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	169NP	10029642	Bronze			2022-12-28	WOS:000078755700001
J	Cutler, J				Cutler, J			Which drug for treatment of hypertension?	LANCET			English	Editorial Material							RATIONALE		NHLBI, Clin Applicat & Prevent Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Cutler, J (corresponding author), NHLBI, Clin Applicat & Prevent Program, Bldg 10, Bethesda, MD 20892 USA.							Black HR, 1997, ARCH INTERN MED, V157, P2413; BULPITT CJ, 1994, DRUG AGING, V5, P171, DOI 10.2165/00002512-199405030-00003; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Savage PJ, 1998, ARCH INTERN MED, V158, P741, DOI 10.1001/archinte.158.7.741; Stearne MR, 1998, BRIT MED J, V317, P713; WHO Int Soc Hyperten Blood Press Lower, 1998, J HYPERTENS, V16, P127	7	17	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 20	1999	353	9153					604	605		10.1016/S0140-6736(98)00361-4	http://dx.doi.org/10.1016/S0140-6736(98)00361-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QU	10030320				2022-12-28	WOS:000078818200002
J	Lupoli, G; Vitale, G; Caraglia, M; Fittipaldi, MR; Abbruzzese, A; Tagliaferri, P; Bianco, AR				Lupoli, G; Vitale, G; Caraglia, M; Fittipaldi, MR; Abbruzzese, A; Tagliaferri, P; Bianco, AR			Familial papillary thyroid microcarcinoma: a new clinical entity	LANCET			English	Article							WARRANTS AGGRESSIVE TREATMENT; EMERGING ENTITY; FOLLOW-UP; CARCINOMA; CANCER	Background Familial, non-medullary thyroid carcinoma is clinically more aggressive than the sporadic form. Mle wanted to find out whether papillary thyroid microcarcinoma also occurs in a familiar pattern, and, if so, to identify specific clinical and prognostic features. Methods We reviewed the clinical records of 119 patients with papillary thyroid microcarcinoma. Familial occurrence, together with clinical presentation, surgical treatment, pathological characteristics, and follow-up were recorded. Findings We identified a family history of thyroid carcinoma in seven patients. The tumour was multifocal in five patients, bilateral in three, and vascular invasion occurred in three of the seven patients. Lymph-node metastases were found in four patients. Three patients had a recurrence and one patient with pulmonary metastases died within 11 months. Interpretation We identified familial occurrence in 5.9% of cases of papillary thyroid microcarcinoma. The unfavourable behaviour in the familal form of papillary thyroid microcarcinoma suggests that radical treatment and careful follow-up are warranted.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Endocrinol & Oncol Mol & Clin, Naples, Italy; Univ Naples 2, Dipartimento Biochim & Biofis, Naples, Italy	University of Naples Federico II; Universita della Campania Vanvitelli	Lupoli, G (corresponding author), Via E Nicolardi 145,Pco Arcadia 8, I-80131 Naples, Italy.		Vitale, Giovanni/B-6548-2008; Tagliaferri, Pierosandro/K-9546-2016; Caraglia, Michele/AFY-9729-2022; Caraglia, Michele/AAK-4569-2020; Caraglia, Michele/N-5670-2015	Vitale, Giovanni/0000-0003-2478-683X; Caraglia, Michele/0000-0003-2408-6091; Caraglia, Michele/0000-0003-2408-6091; Caraglia, Michele/0000-0003-2408-6091; Lupoli, Giovanni/0000-0001-5278-380X				ALM T, 1973, CLIN GASTROENTEROL, V2, P577; Fagin JA, 1997, J CLIN ENDOCR METAB, V82, P342, DOI 10.1210/jc.82.2.342; FISHER DK, 1989, CANC INVEST, V7, P323; GROSSMAN RF, 1995, ARCH SURG-CHICAGO, V130, P892; HAY ID, 1992, SURGERY, V112, P1139; Hedinger C, 1988, INT HISTOLOGICAL CLA, P9; HRAFNKELSSON J, 1989, ACTA ONCOL, V28, P785, DOI 10.3109/02841868909092308; KOBAYASHI K, 1995, J SURG ONCOL, V58, P274, DOI 10.1002/jso.2930580415; Kupelian PA, 1997, J CLIN ONCOL, V15, P1478, DOI 10.1200/JCO.1997.15.4.1478; KWOK CG, 1995, THYROID, V5, P395, DOI 10.1089/thy.1995.5.395; Loh KC, 1997, THYROID, V7, P107, DOI 10.1089/thy.1997.7.107; LOTE K, 1980, CANCER, V46, P1291, DOI 10.1002/1097-0142(19800901)46:5<1291::AID-CNCR2820460534>3.0.CO;2-Q; MAZZAFERRI EL, 1981, AM J MED, V70, P511, DOI 10.1016/0002-9343(81)90573-8; Noguchi S, 1996, ARCH SURG-CHICAGO, V131, P187; OZAKI O, 1988, WORLD J SURG, V12, P565, DOI 10.1007/BF01655453; PLAIL RO, 1987, BRIT J SURG, V74, P377, DOI 10.1002/bjs.1800740517; RON E, 1991, ONCOLOGY, V48, P309; SCHNEIDER AB, 1996, THYROID, P902; STOFFER SS, 1986, AM J MED GENET, V25, P775, DOI 10.1002/ajmg.1320250415; Takami H, 1996, ARCH SURG-CHICAGO, V131, P676	20	141	146	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 20	1999	353	9153					637	639		10.1016/S0140-6736(98)08004-0	http://dx.doi.org/10.1016/S0140-6736(98)08004-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QU	10030330				2022-12-28	WOS:000078818200014
J	Bao, ZZ; Bruneau, BG; Seidman, JG; Seidman, CE; Cepko, CL				Bao, ZZ; Bruneau, BG; Seidman, JG; Seidman, CE; Cepko, CL			Regulation of chamber-specific gene expression in the developing heart by Irx4	SCIENCE			English	Article							MYOSIN HEAVY-CHAIN; CAUPOLICAN; LINEAGES; ARAUCAN; EYE	The vertebrate heart consists of two types of chambers, the atria and the ventricles, which differ in their contractile and electrophysiological properties. Little is known of the molecular mechanisms by which these chambers are specified during embryogenesis. Here a chicken iroquois-related homeobox gene, lrx4, was identified that has a ventricle-restricted expression pattern at all stages of heart development. lrx4 protein was shown to regulate the chamber-specific expression of myosin isoforms by activating the expression of the ventricle myosin heavy chain-1 (VMHC1) and suppressing the expression of the atrial myosin heavy chain-1 (AMHC1) in the ventricles. Thus, lrx4 may play a critical role in establishing chamber-specific gene expression in the developing heart.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital	Cepko, CL (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, 200 Longwood Ave, Boston, MA 02115 USA.			Bruneau, Benoit/0000-0002-0804-7597				BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BAO Z, UNPUB; Bao ZZ, 1997, J NEUROSCI, V17, P1425; Bellefroid EJ, 1998, EMBO J, V17, P191, DOI 10.1093/emboj/17.1.191; BELLEFROID EJ, 1998, EMBO J, P181; BISAHA JG, 1991, DEV BIOL, V148, P355, DOI 10.1016/0012-1606(91)90343-2; BRUNEAU BG, UNPUB; Chen J, 1998, J BIOL CHEM, V273, P1252, DOI 10.1074/jbc.273.2.1252; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; Conlon FL, 1996, DEVELOPMENT, V122, P2427; DEHAAN RL, 1965, ORGANOGENESIS, P377; Fishman MC, 1997, CELL, V91, P153, DOI 10.1016/S0092-8674(00)80397-9; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; GomezSkarmeta JL, 1996, GENE DEV, V10, P2935, DOI 10.1101/gad.10.22.2935; GomezSkarmeta JL, 1996, CELL, V85, P95, DOI 10.1016/S0092-8674(00)81085-5; Gruber PJ, 1998, DEVELOPMENT, V125, P4427; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; LYONS GE, 1994, TRENDS CARDIOVAS MED, V3, P184; McNeill H, 1997, GENE DEV, V11, P1073, DOI 10.1101/gad.11.8.1073; Mikawa T, 1996, ANNU REV PHYSIOL, V58, P509, DOI 10.1146/annurev.ph.58.030196.002453; Pawloski-Dahm CM, 1998, CIRCULATION, V97, P1508; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SATIN J, 1988, DEV BIOL, V129, P103, DOI 10.1016/0012-1606(88)90165-0; STAINIER DYR, 1993, DEVELOPMENT, V119, P31; Wang GF, 1998, MOL CELL BIOL, V18, P6023, DOI 10.1128/MCB.18.10.6023; Wang GF, 1996, J BIOL CHEM, V271, P19836, DOI 10.1074/jbc.271.33.19836; YELON D, UNPUB; YUTZEY KE, 1994, DEVELOPMENT, V120, P871; YUTZEY KE, 1995, DEV BIOL, V170, P531, DOI 10.1006/dbio.1995.1234; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693	31	183	205	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1161	1164		10.1126/science.283.5405.1161	http://dx.doi.org/10.1126/science.283.5405.1161			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024241				2022-12-28	WOS:000078738400050
J	Piper, DE; Batchelor, AH; Chang, CP; Cleary, ML; Wolberger, C				Piper, DE; Batchelor, AH; Chang, CP; Cleary, ML; Wolberger, C			Structure of a HoxB1-Pbx1 heterodimer bound to DNA: Role of the hexapeptide and a fourth homeodomain helix in complex formation	CELL			English	Article							CRYSTAL-STRUCTURE; BINDING SPECIFICITY; HOX PROTEINS; TRANSCRIPTIONAL ACTIVATOR; ENGRAILED HOMEODOMAIN; SECONDARY STRUCTURE; HOMEOBOX GENES; PBX PROTEINS; PRE-B; EXTRADENTICLE	Hox homeodomain proteins are developmental regulators that determine body plan in a variety of organisms. A majority of the vertebrate Hox proteins bind DNA as heterodimers with the Pbx1 homeodomain protein. We report here the 2.35 Angstrom structure of a ternary complex containing a human HoxB1-Pbx1 heterodimer bound to DNA. Heterodimer contacts are mediated by the hexapeptide of HoxB1, which binds in a pocket in the Pbx1 protein formed in part by a three-amino acid insertion in the Pbx1 homeodomain. The Pbx1 DNA-binding domain is larger than the canonical homeodomain, containing an additional alpha helix that appears to contribute to binding of the HoxB1 hexapeptide and to stable binding of Pbx1 to DNA. The structure suggests a model for modulation of Hox DNA binding activity by Pbx1 and related proteins.	Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Stanford University	Wolberger, C (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA.	cwolberg@jhmi.edu		Wolberger, Cynthia/0000-0001-8578-2969	NCI NIH HHS [CA42971] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042971, R37CA042971] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chang CP, 1996, MOL CELL BIOL, V16, P1734; CLARKE ND, 1994, PROTEIN SCI, V3, P1779, DOI 10.1002/pro.5560031018; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; COX M, 1995, J BIOMOL NMR, V6, P23, DOI 10.1007/BF00417488; DiRocco G, 1997, EMBO J, V16, P3644, DOI 10.1093/emboj/16.12.3644; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fraenkel E, 1998, J MOL BIOL, V284, P351, DOI 10.1006/jmbi.1998.2147; Fraenkel E, 1998, NAT STRUCT BIOL, V5, P692, DOI 10.1038/1382; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Green NC, 1998, J BIOL CHEM, V273, P13273, DOI 10.1074/jbc.273.21.13273; Grieder NC, 1997, EMBO J, V16, P7402, DOI 10.1093/emboj/16.24.7402; Hirsch JA, 1995, EMBO J, V14, P6280, DOI 10.1002/j.1460-2075.1995.tb00318.x; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Klemm JD, 1996, GENE DEV, V10, P27, DOI 10.1101/gad.10.1.27; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Lu Q, 1996, MOL CELL BIOL, V16, P1632; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; LU QA, 1995, MOL CELL BIOL, V15, P3786; MACONOCHIE MK, 1997, GENE DEV, V11, P1883; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Neuteboom STC, 1997, MOL CELL BIOL, V17, P4696, DOI 10.1128/MCB.17.8.4696; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OTINOWSKI Z, 1996, METHOD ENZYMOL, V276, P307; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; Phelan ML, 1997, J BIOL CHEM, V272, P8635, DOI 10.1074/jbc.272.13.8635; PHILLIPS CL, 1991, GENE DEV, V5, P764, DOI 10.1101/gad.5.5.764; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QIAN YQ, 1993, J MOL BIOL, V234, P1070, DOI 10.1006/jmbi.1993.1660; QIAN YQ, 1992, P NATL ACAD SCI USA, V89, P10738, DOI 10.1073/pnas.89.22.10738; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; Shen WF, 1996, NUCLEIC ACIDS RES, V24, P898, DOI 10.1093/nar/24.5.898; TSAO DHH, 1994, BIOCHEMISTRY-US, V33, P15053, DOI 10.1021/bi00254a014; TuckerKellogg L, 1997, STRUCTURE, V5, P1047, DOI 10.1016/S0969-2126(97)00256-6; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	62	269	276	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 19	1999	96	4					587	597		10.1016/S0092-8674(00)80662-5	http://dx.doi.org/10.1016/S0092-8674(00)80662-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	168XN	10052460	hybrid			2022-12-28	WOS:000078718600009
J	Gagel, RF; McCutcheon, IE				Gagel, RF; McCutcheon, IE			Pituitary gigantism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Gagel, RF (corresponding author), Univ Texas, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.		McCutcheon, Ian E./AGV-2293-2022						0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1999	340	7					524	524		10.1056/NEJM199902183400705	http://dx.doi.org/10.1056/NEJM199902183400705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168FD	10021473				2022-12-28	WOS:000078680100005
J	Reese, DM				Reese, DM			Restoring the literary to medical writing	LANCET			English	Article									Univ Calif San Francisco, Mt Zion Canc Ctr, Dept Med, Urol Oncol Program, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion	Reese, DM (corresponding author), Univ Calif San Francisco, Mt Zion Canc Ctr, Dept Med, Urol Oncol Program, 2356 Sutter St,5th Floor, San Francisco, CA 94115 USA.							[Anonymous], 2017, ARDEN SHAKESPEARE; Cushing Harvey, 1940, LIFE W OSLER; EBERLE J, 1849, TREATISE THEORY PRAC; LINCOLN A, 1991, DED CEM GETT NOV 19, P103; REHM S, 1997, TXB INTERNAL MED, P1867	5	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 13	1999	353	9152					585	586		10.1016/S0140-6736(98)12344-9	http://dx.doi.org/10.1016/S0140-6736(98)12344-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10029001				2022-12-28	WOS:000078670200045
J	Lechat, P; Brunhuber, KW; Hofmann, R; Kuhn, P; Nesser, HJ; Slany, J; Weihs, W; Wiedermann, C; Wimmer, H; van Mieghem, W; Boland, J; Chaudron, JM; Jordaens, L; Melchior, JP; Aschermann, M; Bruthansl, J; Hradec, M; Kolbel, F; Semrad, B; Haghfelt, T; Fischer-Hansen, J; Goetzsche, CO; Hildebrandt, P; Kassis, E; Rasmussen, V; Rokkedal, J; Thomassen, A; Groundstroem, K; Uusimaa, P; Le Heuzey, JY; Aumont, MC; Aupetit, JF; Baille, N; Baudouy, P; Belin, A; Bonneau, A; Bonneric, G; Bousser, JP; Citron, B; Dary, P; Decoulx, E; De Groote, P; Denolle, T; Dievart, F; Duriez, P; Eicher, JC; Enjuto, G; Ferriere, M; Fournier, E; Garandeau, M; Gauthier, J; Genest, M; Gerbe, A; Godenir, JP; Guillot, B; Guillot, JP; Guillot, P; Heno, P; d'Ivernois, C; Jean, M; Kacet, S; Kalle, R; Komajda, M; Lacroix, A; Lallemand, R; Lardoux, H; Marquet, M; Martin, M; Martin, O; Mery, D; Mossaz, R; Mothes, P; Olive, T; Ostorero, M; Paganelli, F; Page, E; Pauly-Laubry, C; Puel, J; Rousseau, JF; Roux, JJ; Schenowitz, A; Sourdais, K; Tremel, F; Verdun, A; Witchiz, S; Wolf, JE; Hombach, V; Assmann, I; Beyer, T; Bischoff, KO; Darius, H; Ertl, G; Fleck, E; Forster, K; Freytag, F; Gleichmann, U; Haasis, R; Henssge, R; Hey, D; Hesse, P; Hofs, T; Keck, M; Klein, H; Kromer, ET; Kruls-Munch, J; Luderitz, B; Maisch, B; Mitrovic, V; Neubauer, S; Osterziel, KJ; Simon, H; Spitzer, SG; Stohring, R; Taubert, G; Teichmann, W; Theisen, K; Wende, W; Wieser, H; Zotz, R; Preda, I; Csanady, M; Cserhalmi, L; Edes, I; Gesztesi, T; Karpati, P; Simon, K; Tarjan, J; Fogari, R; Tramarin, R; Galie, N; Giani, P; Milanese, U; Scalvini, S; Scrutinio, D; Sechi, LA; Tettamanti, F; De Vito, F; Crean, P; McCann, H; Mulcahy, D; Sugrue, D; van Hoogenhuyze, DCA; van der Burgh, PH; Ciampricotti, R; van Dantzig, JM; DenHartog, FR; Henneman, JA; van Kesteren, HAM; Kragten, JA; Liem, KL; Limburg, A; van der Linde, MR; Linssen, GCM; Pasteuning, H; Penn, HJAM; Van Rossum, P; Schaafsma, HJ; Schelling, A; Sloos, R; Wesdorp, JCL; Korewicki, J; Achremczyk, P; Czestockowska, E; Dowgird, M; Dyduszynski, A; Gorski, J; Ilmurzynska, K; Janicki, K; Kornacewicz-Jach, Z; Kraska, T; Krzeminska-Pakula, M; Kuch, J; Nartowicz, E; Petelenz, T; Piwowarska, W; Rawczynska-Englert, I; Ruzyllo, W; Swiatecka, G; Tendera, M; Wierzchowiecki, M; Wodniecki, J; Wojciechowoski, D; Wrabec, K; Wysocki, H; Gomes, RS; Ceia, MF; Lousada, N; Campos, JMM; Providencia, LA; de Moura, ALZC; Marejev, VJ; Aronov, DM; Arutjunov, GP; Bart, BJ; Basechikin, SS; Belenkov, JN; Beloussov, JB; Bokeria, OA; Charchogljan, RA; Doschytsin, V; Fedorova, TA; Glezer, MG; Gorbachenkov, A; Gorshkov, VA; Gospodarenko, AL; Ivashkin, VT; Ivleva, AJ; Kyrichenko, AA; Lavrov, AA; Lazebnik, LB; Marynov, A; Mazaev, VP; Polejev, NR; Shpektor, A; Sidorenko, BA; Sobolev, KE; Starodoubtsev, AK; Storozhakhov, GI; Syrkin, AL; Zodionchenko, VS; Zvereva, TV; Murin, J; Kaliska, G; Rybar, R; Valle, V; Artaza, M; Conthe, P; Cruz, JM; Garcia-Moll, M; Lopez-Sendon, JL; Martinez, A; Monzon, F; Ribas, M; Roig, E; Roldan, I; Hoglund, C; Ekdahl, S; Hjelmaeus, L; Lindberg, K; Lofdahl, P; Ulvenstam, G; Warselius, L; Follath, F; Anghern, W; Dubach, P; Erne, P; Gallino, A; Moccetti, T; Bridges, A; Adgey, J; Ambepitiya, G; Boon, N; Boyle, RM; Cowley, AJ; Cripps, T; Davies, MK; Dunn, F; Findlay, J; Forsey, P; Fyfe, T; Gould, B; Greenwood, TW; Hubner, P; Khan, S; Lewis, P; Mackay, A; Maltz, M; McArthur, J; McLeod, A; McLeod, D; Metcalfe, M; Millar-Craig, M; Mills, P; Nelson, JK; Nicholls, D; Oakley, GD; Patterson, DLH; Pohl, JEF; Ray, S; Silke, B; Wilkinson, PR; Jmouro, AV				Lechat, P; Brunhuber, KW; Hofmann, R; Kuhn, P; Nesser, HJ; Slany, J; Weihs, W; Wiedermann, C; Wimmer, H; van Mieghem, W; Boland, J; Chaudron, JM; Jordaens, L; Melchior, JP; Aschermann, M; Bruthansl, J; Hradec, M; Kolbel, F; Semrad, B; Haghfelt, T; Fischer-Hansen, J; Goetzsche, CO; Hildebrandt, P; Kassis, E; Rasmussen, V; Rokkedal, J; Thomassen, A; Groundstroem, K; Uusimaa, P; Le Heuzey, JY; Aumont, MC; Aupetit, JF; Baille, N; Baudouy, P; Belin, A; Bonneau, A; Bonneric, G; Bousser, JP; Citron, B; Dary, P; Decoulx, E; De Groote, P; Denolle, T; Dievart, F; Duriez, P; Eicher, JC; Enjuto, G; Ferriere, M; Fournier, E; Garandeau, M; Gauthier, J; Genest, M; Gerbe, A; Godenir, JP; Guillot, B; Guillot, JP; Guillot, P; Heno, P; d'Ivernois, C; Jean, M; Kacet, S; Kalle, R; Komajda, M; Lacroix, A; Lallemand, R; Lardoux, H; Marquet, M; Martin, M; Martin, O; Mery, D; Mossaz, R; Mothes, P; Olive, T; Ostorero, M; Paganelli, F; Page, E; Pauly-Laubry, C; Puel, J; Rousseau, JF; Roux, JJ; Schenowitz, A; Sourdais, K; Tremel, F; Verdun, A; Witchiz, S; Wolf, JE; Hombach, V; Assmann, I; Beyer, T; Bischoff, KO; Darius, H; Ertl, G; Fleck, E; Forster, K; Freytag, F; Gleichmann, U; Haasis, R; Henssge, R; Hey, D; Hesse, P; Hofs, T; Keck, M; Klein, H; Kromer, ET; Kruls-Munch, J; Luderitz, B; Maisch, B; Mitrovic, V; Neubauer, S; Osterziel, KJ; Simon, H; Spitzer, SG; Stohring, R; Taubert, G; Teichmann, W; Theisen, K; Wende, W; Wieser, H; Zotz, R; Preda, I; Csanady, M; Cserhalmi, L; Edes, I; Gesztesi, T; Karpati, P; Simon, K; Tarjan, J; Fogari, R; Tramarin, R; Galie, N; Giani, P; Milanese, U; Scalvini, S; Scrutinio, D; Sechi, LA; Tettamanti, F; De Vito, F; Crean, P; McCann, H; Mulcahy, D; Sugrue, D; van Hoogenhuyze, DCA; van der Burgh, PH; Ciampricotti, R; van Dantzig, JM; DenHartog, FR; Henneman, JA; van Kesteren, HAM; Kragten, JA; Liem, KL; Limburg, A; van der Linde, MR; Linssen, GCM; Pasteuning, H; Penn, HJAM; Van Rossum, P; Schaafsma, HJ; Schelling, A; Sloos, R; Wesdorp, JCL; Korewicki, J; Achremczyk, P; Czestockowska, E; Dowgird, M; Dyduszynski, A; Gorski, J; Ilmurzynska, K; Janicki, K; Kornacewicz-Jach, Z; Kraska, T; Krzeminska-Pakula, M; Kuch, J; Nartowicz, E; Petelenz, T; Piwowarska, W; Rawczynska-Englert, I; Ruzyllo, W; Swiatecka, G; Tendera, M; Wierzchowiecki, M; Wodniecki, J; Wojciechowoski, D; Wrabec, K; Wysocki, H; Gomes, RS; Ceia, MF; Lousada, N; Campos, JMM; Providencia, LA; de Moura, ALZC; Marejev, VJ; Aronov, DM; Arutjunov, GP; Bart, BJ; Basechikin, SS; Belenkov, JN; Beloussov, JB; Bokeria, OA; Charchogljan, RA; Doschytsin, V; Fedorova, TA; Glezer, MG; Gorbachenkov, A; Gorshkov, VA; Gospodarenko, AL; Ivashkin, VT; Ivleva, AJ; Kyrichenko, AA; Lavrov, AA; Lazebnik, LB; Marynov, A; Mazaev, VP; Polejev, NR; Shpektor, A; Sidorenko, BA; Sobolev, KE; Starodoubtsev, AK; Storozhakhov, GI; Syrkin, AL; Zodionchenko, VS; Zvereva, TV; Murin, J; Kaliska, G; Rybar, R; Valle, V; Artaza, M; Conthe, P; Cruz, JM; Garcia-Moll, M; Lopez-Sendon, JL; Martinez, A; Monzon, F; Ribas, M; Roig, E; Roldan, I; Hoglund, C; Ekdahl, S; Hjelmaeus, L; Lindberg, K; Lofdahl, P; Ulvenstam, G; Warselius, L; Follath, F; Anghern, W; Dubach, P; Erne, P; Gallino, A; Moccetti, T; Bridges, A; Adgey, J; Ambepitiya, G; Boon, N; Boyle, RM; Cowley, AJ; Cripps, T; Davies, MK; Dunn, F; Findlay, J; Forsey, P; Fyfe, T; Gould, B; Greenwood, TW; Hubner, P; Khan, S; Lewis, P; Mackay, A; Maltz, M; McArthur, J; McLeod, A; McLeod, D; Metcalfe, M; Millar-Craig, M; Mills, P; Nelson, JK; Nicholls, D; Oakley, GD; Patterson, DLH; Pohl, JEF; Ray, S; Silke, B; Wilkinson, PR; Jmouro, AV		CIBIS-II Investigators Comm	The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial	LANCET			English	Article							HEART-RATE-VARIABILITY; BETA-BLOCKADE; CLINICAL-TRIALS; FAILURE; MORTALITY; MORBIDITY	Background In patients with heart failure, beta-blochade has improved morbidity and left-ventricular function, but the impact on survival is uncertain. We investigated the efficacy of bisoprolol, a beta(1) selective adrenoceptor blocker in decreasing all-cause mortality in chronic heart failure. Methods In a multicentre double-blind randomised placebo-controlled trial in Europe, we enrolled 2647 symptomatic patients in New York Heart Association class III or IV, with left-ventricular ejection fraction of 35% or less receiving standard therapy with diuretics and inhibitors of angiotensin-converting enzyme. We randomly assigned patients bisoprolol 1.25 mg (n=1327) or placebo (n=1320) daily, the drug being progressively increased to a maximum of 10 mg per day. Patients were followed up for a mean of 1.3 years. Analysis was by intention to treat. Findings CIBIS-II was stopped early, after the second interim analysis, because bisoprolol showed a significant mortality benefit. All-cause mortality was significantly lower with bisoprolol than on placebo (156 [11.8%] vs 228 [17.3%] deaths with a hazard ratio of 0.66 (95% CI 0.54-0.81, p<0.0001). There were significantly fewer sudden deaths among patients on bisoprolol than in those on placebo (48 [3.6%] vs 83 [6.3%] deaths), with a hazard ratio of 0.56 (0.39-0.80, p=0.0011). Treatment effects were independent of the severity or cause of heart failure. Interpretation beta-blocker therapy had benefits for survival in stable heart-failure patients. Results should not, however, be extrapolated to patients with severe class IV symptoms and recent instability because safety and efficacy has not been established in these patients.	Hop La Pitie Salpetriere, AP HP, Dept Pharmacol, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Lechat, P (corresponding author), Hop La Pitie Salpetriere, AP HP, Dept Pharmacol, F-75013 Paris, France.	philippe.lechat@psl.ap-hop-paris.fr	Sechi, Leonardo Antonio/Y-3109-2018; Édes, István/B-8795-2011; Mazaev, Vladimir/M-8897-2013; Shpektor, Alexander V/B-1083-2016; Wiedermann, Christian J./ABG-9521-2020; Scalvini, Simonetta/AAB-8992-2020; scalvini, simonetta/ABG-9872-2020; David, Aronov M/P-4562-2016; Tramarin, Roberto/AAY-6223-2020; Scrutinio, Domenico/E-8074-2019; Maisch, Bernhard/AAH-9198-2020; Syrkin, Abram L/N-1789-2017; Fedorova, Tatiana/Q-7502-2018; Tendera, Michal/AAA-1875-2022; Jordaens, Luc/AAI-6541-2020	Mazaev, Vladimir/0000-0002-9782-0296; Scalvini, Simonetta/0000-0001-7387-505X; scalvini, simonetta/0000-0001-7387-505X; David, Aronov M/0000-0003-0484-9805; Tramarin, Roberto/0000-0001-5203-2969; Scrutinio, Domenico/0000-0002-8535-3264; Jordaens, Luc/0000-0002-1407-7186				ANDERSON JL, 1995, AM J CARDIOL, V75, P1220; BRISTOW M, 1996, CIRCULATION, V4, P2807; *CIBIS 2 SCI COMM, 1997, FUND CLIN PHARM, V11, P38; Copie X, 1996, AM HEART J, V132, P369, DOI 10.1016/S0002-8703(96)90435-4; Doughty RN, 1997, EUR HEART J, V18, P560; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Gottlieb SS, 1998, NEW ENGL J MED, V339, P489, DOI 10.1056/NEJM199808203390801; HAEUSLER G, 1986, J CARDIOVASC PHARM, V8, pS2; Heidenreich PA, 1997, J AM COLL CARDIOL, V30, P27, DOI 10.1016/S0735-1097(97)00104-6; Lauriola P, 1998, LANCET, V351, P1180, DOI 10.1016/S0140-6736(05)79124-8; Lechat P, 1997, CIRCULATION, V96, P2197; LECHAT P, 1994, CIRCULATION, V90, P1765, DOI 10.1161/01.CIR.90.4.1765; Lechat P, 1998, CIRCULATION, V98, P1184, DOI 10.1161/01.CIR.98.12.1184; LEIGER RE, 1987, AM J CARDIOL, V59, P256; MacMahon S, 1997, LANCET, V349, P375; Nolan J, 1998, CIRCULATION, V98, P1510, DOI 10.1161/01.CIR.98.15.1510; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Pousset F, 1996, AM J CARDIOL, V77, P612, DOI 10.1016/S0002-9149(97)89316-2; WAAGSTEIN F, 1975, BRIT HEART J, V37, P1022; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	21	3263	3388	3	105	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 2	1999	353	9146					9	13						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023943				2022-12-28	WOS:000077934800009
J	Walsh, TJ; Finberg, RW; Arndt, C; Hiemenz, J; Schwartz, C; Bodensteiner, D; Pappas, P; Seibel, N; Greenberg, RN; Dummer, S; Schuster, M; Holcenberg, JS				Walsh, TJ; Finberg, RW; Arndt, C; Hiemenz, J; Schwartz, C; Bodensteiner, D; Pappas, P; Seibel, N; Greenberg, RN; Dummer, S; Schuster, M; Holcenberg, JS		Natl Inst Allergy Infect Dis Mycoses Study Grp	Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INVASIVE FUNGAL-INFECTIONS; IMMUNOCOMPROMISED PATIENTS; RISK-FACTORS; TOXICITY; AMBISOME; MANAGEMENT; INFUSION; GRANULOCYTOPENIA; EXPERIENCE; EFFICACY	Background In patients with persistent fever and neutropenia, amphotericin B is administered empirically for the early treatment and prevention of clinically occult invasive fungal infections. However, breakthrough fungal infections can develop despite treatment, and amphotericin B has substantial toxicity. Methods We conducted a randomized, double-blind, multicenter trial comparing liposomal amphotericin B with conventional amphotericin B as empirical antifungal therapy. Results The mean duration of therapy was 10.8 days for liposomal amphotericin B (343 patients) and 10.3 days for conventional amphotericin B (344 patients). The composite rates of successful treatment were similar (50 percent for liposomal amphotericin B and 49 percent for conventional amphotericin B) and were independent of the use of antifungal prophylaxis or colony-stimulating factors. The outcomes were similar with liposomal amphotericin B and conventional amphotericin B with respect to survival (93 percent and 90 percent, respectively), resolution of fever (58 percent and 58 percent), and discontinuation of the study drug because of toxic effects or lack of efficacy (14 percent and 19 percent). There were fewer proved breakthrough fungal infections among patients treated with liposomal amphotericin B (11 patients [3.2 percent]) than among those treated with conventional amphotericin B (27 patients [7.8 percent], P = 0.009). With the liposomal preparation significantly fewer patients had infusion-related fever (17 percent vs. 44 percent), chills or rigors (18 percent vs. 54 percent), and other reactions, including hypotension, hypertension, and hypoxia. Nephrotoxic effects (defined by a serum creatinine level two times the upper limit of normal) were significantly less frequent among patients treated with liposomal amphotericin B (19 percent) than among those treated with conventional amphotericin B (34 percent, P<0.001). Conclusions Liposomal amphotericin B is as effective as conventional amphotericin B for empirical antifungal therapy in patients with fever and neutropenia, and it is associated with fewer breakthrough fungal infections, less infusion-related toxicity, and less nephrotoxicity. (N Engl J Med 1999;340:764-71.) (C)1999, Massachusetts Medical Society.	NCI, Div Clin Sci, Bethesda, MD 20892 USA; Dana Farber Canc Inst, Div Infect Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Mayo Clin & Mayo Fdn, Dept Pediat, Sect Pediat Hematol Oncol, Rochester, MN 55905 USA; H Lee Moffitt Canc Ctr & Res Inst, Div Bone Marrow Transplantat, Tampa, FL USA; Johns Hopkins Med Inst, Div Pediat Hematol Oncol, Baltimore, MD 21205 USA; Univ Kansas, Med Ctr, Kansas City, KS 66103 USA; Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA; Childrens Hosp, Natl Med Ctr, Div Hematol Oncol, Washington, DC 20010 USA; Vanderbilt Univ, Div Infect Dis, Nashville, TN USA; Hosp Univ Penn, Div Infect Dis, Philadelphia, PA 19104 USA; Childrens Hosp & Med Ctr, Seattle, WA 98105 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Mayo Clinic; H Lee Moffitt Cancer Center & Research Institute; Johns Hopkins University; Johns Hopkins Medicine; University of Kansas; University of Kansas Medical Center; University of Alabama System; University of Alabama Birmingham; Children's National Health System; Vanderbilt University; University of Pennsylvania; Pennsylvania Medicine; Seattle Children's Hospital	Walsh, TJ (corresponding author), NCI, Div Clin Sci, Bldg 10,Rm 13N-240, Bethesda, MD 20892 USA.		Finberg, Robert W/E-3323-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI065296] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-65296] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adler-moore J.P., 1993, J LIPOSOME RES, V3, P429, DOI DOI 10.3109/08982109309150729; ANDRIOLE VT, 1993, CLIN INFECT DIS, V17, pS481, DOI 10.1093/clinids/17.Supplement_2.S481; Arning M, 1995, MYCOSES, V38, P459, DOI 10.1111/j.1439-0507.1995.tb00020.x; ARNING M, 1995, EUR J CLIN MICROBIOL, V14, P41, DOI 10.1007/BF02112616; FRANCIS P, 1994, J INFECT DIS, V169, P356, DOI 10.1093/infdis/169.2.356; GALLIS HA, 1990, REV INFECT DIS, V12, P308; Hiemenz JW, 1996, CLIN INFECT DIS, V22, pS133, DOI 10.1093/clinids/22.Supplement_2.S133; Hughes WT, 1997, CLIN INFECT DIS, V25, P551, DOI 10.1086/513764; KARP JE, 1991, REV INFECT DIS, V13, P592; LEE JW, 1994, ANTIMICROB AGENTS CH, V38, P713, DOI 10.1128/AAC.38.4.713; LEVINE SJ, 1991, ANN INTERN MED, V114, P664, DOI 10.7326/0003-4819-114-8-664; LOUIE A, 1994, J ANTIMICROB CHEMOTH, V34, P975, DOI 10.1093/jac/34.6.975; MEHTA R, 1984, BIOCHIM BIOPHYS ACTA, V770, P230, DOI 10.1016/0005-2736(84)90135-4; MEUNIER F, 1991, J ANTIMICROB CHEMOTH, V28, P83, DOI 10.1093/jac/28.suppl_B.83; MEUNIER F, 1989, AM J MED, V86, P668; MILLS W, 1994, BRIT J HAEMATOL, V86, P754, DOI 10.1111/j.1365-2141.1994.tb04825.x; NG TTC, 1995, ARCH INTERN MED, V155, P1093, DOI 10.1001/archinte.155.10.1093; Nguyen MH, 1996, AM J MED, V100, P617, DOI 10.1016/S0002-9343(95)00010-0; Nguyen MH, 1998, J INFECT DIS, V177, P425, DOI 10.1086/514193; PANNUTI C, 1992, CANCER-AM CANCER SOC, V69, P2653, DOI 10.1002/1097-0142(19920601)69:11<2653::AID-CNCR2820691106>3.0.CO;2-8; PERKINS WR, 1992, BIOCHIM BIOPHYS ACTA, V1107, P271, DOI 10.1016/0005-2736(92)90414-H; PIZZO PA, 1990, J INFECT DIS, V161, P397, DOI 10.1093/infdis/161.3.397; PIZZO PA, 1993, NEW ENGL J MED, V328, P1323; PIZZO PA, 1982, AM J MED, V72, P101, DOI 10.1016/0002-9343(82)90594-0; PROFFITT RT, 1991, J ANTIMICROB CHEMOTH, V28, P49, DOI 10.1093/jac/28.suppl_B.49; PROFFITT RT, 1992, J ANTIMICROB CHEMOTH, V29, P355; RINGDEN O, 1991, J ANTIMICROB CHEMOTH, V28, P73, DOI 10.1093/jac/28.suppl_B.73; VARTIVARIAN SE, 1993, CLIN INFECT DIS, V17, pS487, DOI 10.1093/clinids/17.Supplement_2.S487; WALSH TJ, 1994, CLIN INFECT DIS, V18, P793, DOI 10.1093/clinids/18.5.793; Walsh TJ, 1998, ANTIMICROB AGENTS CH, V42, P2391, DOI 10.1128/AAC.42.9.2391; WASAN KM, 1994, ANTIMICROB AGENTS CH, V38, P223, DOI 10.1128/AAC.38.2.223; WASAN KM, 1994, ANTIMICROB AGENTS CH, V38, P2230	32	866	906	0	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 11	1999	340	10					764	771		10.1056/NEJM199903113401004	http://dx.doi.org/10.1056/NEJM199903113401004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	174KJ	10072411				2022-12-28	WOS:000079034100004
J	Shaw, JH; Shearer, PM				Shaw, JH; Shearer, PM			An elusive blind-thrust fault beneath metropolitan Los Angeles	SCIENCE			English	Article							WHITTIER-NARROWS EARTHQUAKE; SOUTHERN-CALIFORNIA; KINEMATICS; SEQUENCE; GEOMETRY; AREA	Seismic reflection profiles, petroleum wells, and relocated earthquakes reveal the presence of an active blind-thrust fault beneath metropolitan Los Angeles. A segment of this fault likely caused the 1987 Whittier Narrows (magnitude 6.0) earthquake. Mapped sizes of other fault segments suggest that the system is capable of much larger (magnitude 6.5 to 7) and more destructive earthquakes.	Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; Univ Calif San Diego, Scripps Inst Oceanog, Inst Geophys & Planetary Phys, La Jolla, CA 92093 USA	Harvard University; University of California System; University of California San Diego; Scripps Institution of Oceanography	Shaw, JH (corresponding author), Harvard Univ, Dept Earth & Planetary Sci, 20 Oxford St, Cambridge, MA 02138 USA.	shaw@eps.harvard.edu	Shearer, Peter/K-5247-2012	Shearer, Peter/0000-0002-2992-7630				Bock Y, 1997, J GEOPHYS RES-SOL EA, V102, P18013, DOI 10.1029/97JB01379; DAVIS TL, 1989, J GEOPHYS RES-SOLID, V94, P9644, DOI 10.1029/JB094iB07p09644; DOLAN JF, 1995, SCIENCE, V267, P199, DOI 10.1126/science.267.5195.199; HAUKSSON E, 1989, J GEOPHYS RES-SOLID, V94, P9569, DOI 10.1029/JB094iB07p09569; JONES L, 1994, SCIENCE, V266, P389, DOI 10.1126/science.266.5184.398; RICHARDSDINGER KB, 1997, EOS S, V78, pF445; Rubin CM, 1998, SCIENCE, V281, P398, DOI 10.1126/science.281.5375.398; Shaw JH, 1996, J GEOPHYS RES-SOL EA, V101, P8623, DOI 10.1029/95JB03453; Shearer PM, 1997, J GEOPHYS RES-SOL EA, V102, P8269, DOI 10.1029/96JB03228; STEIN RS, 1992, J GEOPHYS RES-SOL EA, V97, P4865, DOI 10.1029/91JB02847; SUPPE J, 1992, THRUST TECTONICS, P105; SUPPE J, 1990, ECLOGAE GEOL HELV, V83, P409; SUPPE J, 1983, AM J SCI, V283, P684, DOI 10.2475/ajs.283.7.684; Walls C, 1998, NATURE, V394, P356, DOI 10.1038/28590; WELLS DL, 1994, B SEISMOL SOC AM, V84, P974; Wright T.L., 1991, AAPG MEMOIR, V52, P35; YEATS RS, 1997, SO CALIFORNIA EARTHQ, V2, pC75; YERKES RF, 1972, 420C US GEOL SURV; [No title captured]	19	130	144	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	1999	283	5407					1516	1518		10.1126/science.283.5407.1516	http://dx.doi.org/10.1126/science.283.5407.1516			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066170				2022-12-28	WOS:000078959200042
J	Daina, E; Schieppati, A; Remuzzi, G				Daina, E; Schieppati, A; Remuzzi, G			Mycophenolate mofetil for the treatment of Takayasu arteritis: Report of three cases	ANNALS OF INTERNAL MEDICINE			English	Article							REJECTION	Background: Takayasu arteritis is a rare form of chronic inflammatory disease of the large arterial vessels. Some patients do not respond to steroids or immunosuppressant drugs. Objective: To evaluate the effect of mycophenolate mofetil in patients with severe Takayasu arteritis. Design: Case series. Setting: Clinical Research Center for Rare Diseases in Bergamo, Italy. Patients: Three patients with Takayasu arteritis. Intervention: Mycophenolate mofetil (2 g/d) given orally in two divided doses. Measurements: Clinical evaluation and assessment of leukocyte counts were done weekly. Vascular lesions were assessed by using Doppler ultrasonography. Results: All patients showed clinical benefit, and two resumed work after months of inactivity. Patients were also able to taper and discontinue steroid use. Mycophenolate mofetil was well tolerated, and no signs of toxicity were observed. Conclusions: Mycophenolate mofetil may be an alternative to steroids and cytotoxic agents in patients with Takayasu arteritis. Before results of controlled trials become available, mycophenolate mofetil should be considered only for patients who do not improve or stabilize with conventional therapy.	Osped Riuniti Bergamo, I-24100 Bergamo, Italy; Mario Negri Inst Pharmacol Res, I-24125 Bergamo, Italy	Ospedali Riuniti di Bergamo; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Schieppati, A (corresponding author), Mario Negri Inst Pharmacol Res, Via Gavazzeni 11, I-24125 Bergamo, Italy.		Daina, Erica/ABA-3117-2020; Daina, Erica/AAA-6433-2020; Remuzzi, Giuseppe/V-9766-2017	Daina, Erica/0000-0002-2419-5493; Remuzzi, Giuseppe/0000-0002-6194-3446				ALLISON AC, 1993, IMMUNOL REV, V136, P5, DOI 10.1111/j.1600-065X.1993.tb00652.x; Briggs WA, 1998, AM J KIDNEY DIS, V31, P213, DOI 10.1053/ajkd.1998.v31.pm9469489; FOEGH ML, 1990, TRANSPL P, V22, P119; GRINYO J, 1995, LANCET, V345, P1321; GutierrezUrena S, 1996, ARTHRITIS RHEUM, V39, P272, DOI 10.1002/art.1780390214; HOFFMAN GS, 1994, ARTHRITIS RHEUM, V37, P578, DOI 10.1002/art.1780370420; Hotchi M, 1992, Heart Vessels Suppl, V7, P11, DOI 10.1007/BF01744538; JUDGE RD, 1962, AM J MED, V32, P379, DOI 10.1016/0002-9343(62)90128-6; KERR GS, 1994, ANN INTERN MED, V120, P919, DOI 10.7326/0003-4819-120-11-199406010-00004; LUPIHERRERA E, 1977, AM HEART J, V93, P94, DOI 10.1016/S0002-8703(77)80178-6; Mathew TH, 1998, TRANSPLANTATION, V65, P1450, DOI 10.1097/00007890-199806150-00007; MCMANUS RP, 1992, TRANSPLANT P, V24, P619; SOLLINGER HW, 1995, TRANSPLANTATION, V60, P225, DOI 10.1097/00007890-199508000-00003; TalarWilliams C, 1996, ANN INTERN MED, V124, P477, DOI 10.7326/0003-4819-124-5-199603010-00003; 1992, HEART VESSELS S, V7, P1	15	95	100	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	1999	130	5					422	426		10.7326/0003-4819-130-5-199903020-00013	http://dx.doi.org/10.7326/0003-4819-130-5-199903020-00013			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172AA	10068416				2022-12-28	WOS:000078898100005
J	Grainger, R				Grainger, R			A happy coincidence	BRITISH MEDICAL JOURNAL			English	Article																		DELAL VD, 1966, BRIT MED J, V2, P1370	1	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					584	584		10.1136/bmj.318.7183.584	http://dx.doi.org/10.1136/bmj.318.7183.584			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037639	Green Published			2022-12-28	WOS:000078966300034
J	Hutin, YJF; Pool, V; Cramer, EH; Nainan, OV; Weth, J; Williams, IT; Goldstein, ST; Gensheimer, KF; Bell, BP; Shapiro, CN; Alter, MJ; Margolis, HS				Hutin, YJF; Pool, V; Cramer, EH; Nainan, OV; Weth, J; Williams, IT; Goldstein, ST; Gensheimer, KF; Bell, BP; Shapiro, CN; Alter, MJ; Margolis, HS		Natl Hepatitis A Invest Team	A multistate, foodborne outbreak of hepatitis A	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							A VIRUS; FROZEN RASPBERRIES; SEQUENCE-ANALYSIS; AMPLIFICATION; PROGRAMS; STRAINS	Background We investigated a large, foodborne outbreak of hepatitis A that occurred in February and March 1997 in Michigan and then extended the investigation to determine whether it was related to sporadic cases reported in other states among persons who had consumed frozen strawberries, the food suspected of causing the outbreak. Methods The cases of hepatitis A were serologically confirmed. Epidemiologic studies were conducted in the two states with sufficient numbers of cases, Michigan and Maine. Hepatitis A virus RNA detected in clinical specimens was sequenced to determine the relatedness of the virus from outbreak-related cases and other cases. Results A total of 213 cases of hepatitis A were reported from 23 schools in Michigan and 29 cases from 13 schools in Maine, with the median rate of attack ranging from 0.2 to 14 percent. Hepatitis A was associated with the consumption of frozen strawberries in a case-control study (odds ratio for the disease, 8.3; 95 percent confidence interval, 2.1 to 33) and a cohort study (relative risk of infection, 7.5; 95 percent confidence interval, 1.1 to 53) in Michigan and in a case-control study in Maine (odds ratio for infection, 3.4; 95 percent confidence interval, 1.0 to 14). The genetic sequences of viruses from 126 patients in Michigan and Maine were identical to one another and to those from 5 patients in Wisconsin and 7 patients in Arizona, all of whom attended schools where frozen strawberries from the same processor had been served, and to those in 2 patients from Louisiana, both of whom had consumed commercially prepared products containing frozen strawberries from the same processor. Conclusions We describe a large outbreak of hepatitis A in Michigan that was associated with the consumption of frozen strawberries. We found apparently sporadic cases in other states that could be linked to the same source by viral genetic analysis. (N Engl J Med 1999;340:595-602.) (C)1999, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Hepatitis Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Atlanta, GA 30333 USA; Calhoun Cty Dept Hlth, Battle Creek, MI USA; Maine State Bur Hlth, Augusta, ME USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Hutin, YJF (corresponding author), Ctr Dis Control & Prevent, Hepatitis Branch, Mailstop G37, Atlanta, GA 30333 USA.							Bell BP, 1998, J INFECT DIS, V178, P1579, DOI 10.1086/314518; Bender JB, 1997, NEW ENGL J MED, V337, P388, DOI 10.1056/NEJM199708073370604; BROWN VK, 1990, BIOTECHNIQUES, V8, P262; CARL M, 1983, J INFECT DIS, V148, P1133, DOI 10.1093/infdis/148.6.1133; *CDCP, 1996, 56 CDCP, P25; COHEN JI, 1987, J VIROL, V61, P50, DOI 10.1128/JVI.61.1.50-59.1987; Dean A.G., 1994, EPI INFO VERSION 6 W; DESENCLOS JCA, 1991, AM J PUBLIC HEALTH, V81, P1268, DOI 10.2105/AJPH.81.10.1268; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; *ENV PROT AG, 1997, FOOD SAF FARM TABL N; Killalea D, 1996, BMJ-BRIT MED J, V313, P1105, DOI 10.1136/bmj.313.7065.1105; MCCAUSTLAND KA, 1982, J CLIN MICROBIOL, V16, P957, DOI 10.1128/JCM.16.5.957-958.1982; Nainan OV, 1996, J VIROL METHODS, V61, P127, DOI 10.1016/0166-0934(96)02077-0; NAINAN OV, 1991, J GEN VIROL, V72, P1685, DOI 10.1099/0022-1317-72-7-1685; NIU MT, 1992, J INFECT DIS, V166, P518, DOI 10.1093/infdis/166.3.518; Noah N. D., 1981, MED LAB SCI, V38, P428; PORTNOY BL, 1975, JAMA-J AM MED ASSOC, V233, P1065, DOI 10.1001/jama.233.10.1065; RAMSAY CN, 1989, LANCET, V1, P43; REID TMS, 1987, EPIDEMIOL INFECT, V98, P109, DOI 10.1017/S095026880006177X; ROBERTSON BH, 1992, J GEN VIROL, V73, P1365, DOI 10.1099/0022-1317-73-6-1365; ROSENBLUM LS, 1990, AM J PUBLIC HEALTH, V80, P1075, DOI 10.2105/AJPH.80.9.1075; Rushing J. W., 1996, Dairy, Food and Environmental Sanitation, V16, P549; SCHUCHAT A, 1991, CLIN MICROBIOL REV, V4, P396, DOI 10.1128/CMR.4.3.396-.1991; SIEGL G, 1984, HEPATITIS A, P9; 1997, MMWR MORB MORTAL WKL, V46, P288	25	251	268	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1999	340	8					595	602		10.1056/NEJM199902253400802	http://dx.doi.org/10.1056/NEJM199902253400802			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	169NP	10029643				2022-12-28	WOS:000078755700002
J	Savonitto, S; Ardissino, D; Granger, CB; Morando, G; Prando, MD; Mafrici, A; Cavallini, C; Melandri, G; Thompson, TD; Vahanian, A; Ohman, EM; Califf, RM; Van de Werf, F; Topol, EJ				Savonitto, S; Ardissino, D; Granger, CB; Morando, G; Prando, MD; Mafrici, A; Cavallini, C; Melandri, G; Thompson, TD; Vahanian, A; Ohman, EM; Califf, RM; Van de Werf, F; Topol, EJ			Prognostic value of the admission electrocardiogram in acute coronary syndromes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WAVE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA-PECTORIS; ST SEGMENT DEPRESSION; ACUTE CHEST PAIN; RISK STRATIFICATION; TROPONIN-T; CLINICAL COURSE; EMERGENCY ROOM; REST; IDENTIFICATION	Context The presence of ischemic changes on electrocardiogram (ECC) correlates with poorer outcomes in patients with acute chest pain. Objective To determine the prognostic value of various ECC; presentations of acute myocardial ischemia. Design Retrospective analysis of the presenting ECGs of patients enrolled in Global Use of Strategies To Open Occluded Arteries in Acute Coronary Syndromes (GUSTO-IIb). Setting Three hundred seventy-three hospitals in 13 countries in North America, Europe, Australia, and New Zealand. Patients A total of 12 142 patients who reported symptoms of cardiac ischemia at rest within 12 hours of admission and had signs of myocardial ischemia confirmed by ECG. On presenting ECG, 22% of patients had T-wave inversion, 28% had ST-segment elevation, 35% had ST-segment depression, and 15% had a combination of ST-segment elevation and depression. Main Outcome Measure Ability of presenting ECG to predict death or myocardial reinfarction during the first 30 days of follow-up. Results The 30-day incidence of death or myocardial reinfarction was 5.5% in patients with T-wave inversion, 9.4% in those with ST-segment elevation, 10.5% in those with ST-segment depression, and 12.4% in those with ST-segment elevation and depression (P<.001). After adjusting for factors associated with an increased risk of 30-day death or reinfarction, compared with those who had T-wave inversion only, the odds of 30-day death or reinfarction were 1.68 (95% confidence interval [CI], 1.36-2.08) in those with ST-segment elevation, 1.62 (95% CI, 1.32-1.98) for those with ST-segment depression, and 2.27 (95% CI, 1.80-2.86) for those with combined elevation and depression. An elevated creatine kinase level at admission correlated with a higher risk of death (odds ratio [OR], 2.36; 95% CI, 1.92-2.91) and death or reinfarction (OR, 1.56; 95% CI, 1.32-1.85). The ECG category and creatine kinase level at admission remained highly predictive of death and myocardial infarction after multivariate adjustment for the significant baseline predictors of events. Conclusions The ECG at presentation allows immediate risk stratification across the spectrum of acute coronary syndromes. An elevated creatine kinase level at admission is associated with worse outcomes.	Osped Niguarda Ca Granda, Dept Cardiol A De Gasperis, Div Cardiol 2, I-20162 Milan, Italy; IRCCS, Policlin San Matteo, Div Cardiol, Pavia, Italy; Duke Clin Res Inst, Durham, NC USA; Univ Verona, Div Cardiol, I-37100 Verona, Italy; Osped Maggiore della Carita, Div Cardiol, Novara, Italy; Osped S Maria dei Battuti, Div Cardiol R Foligno, Treviso, Italy; Univ Bologna, Inst Cardiovasc Dis, Bologna, Italy; Hosp Tenon, Serv Cardiol & Cardiac Emergency, Paris, France; Univ Louvain, Ctr Thrombosis & Vasc Res, Louvain, Belgium; Cleveland Clin Fdn, Cleveland, OH 44195 USA	IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; IRCCS Fondazione San Matteo; University of Pavia; Duke University; University of Verona; University of Bologna; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Cleveland Clinic Foundation	Savonitto, S (corresponding author), Osped Niguarda Ca Granda, Dept Cardiol A De Gasperis, Div Cardiol 2, I-20162 Milan, Italy.	ssavoni@tin.it	Granger, Christopher B/D-3458-2014; Ardissino, Diego/AAC-4041-2022	Granger, Christopher B/0000-0002-0045-3291; Topol, Eric/0000-0002-1478-4729; solinas, emilia/0000-0003-3532-1317				Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Armstrong PW, 1998, CIRCULATION, V98, P1860, DOI 10.1161/01.CIR.98.18.1860; CALIFF RM, 1996, ATHEROSCLEROSIS CORO, P1299; Cannon CP, 1997, J AM COLL CARDIOL, V30, P133, DOI 10.1016/S0735-1097(97)00160-5; COHEN M, 1991, AM J CARDIOL, V67, P1368, DOI 10.1016/0002-9149(91)90467-Y; DESERVI S, 1986, AM HEART J, V111, P6, DOI 10.1016/0002-8703(86)90545-4; Goldman L, 1996, NEW ENGL J MED, V334, P1498, DOI 10.1056/NEJM199606063342303; GRANBORG J, 1986, AM J CARDIOL, V57, P203, DOI 10.1016/0002-9149(86)90891-X; HAINES DE, 1983, AM J CARDIOL, V52, P14, DOI 10.1016/0002-9149(83)90061-9; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; HUTTER AM, 1981, AM J CARDIOL, V48, P595, DOI 10.1016/0002-9149(81)90136-3; KATUS HA, 1988, J AM COLL CARDIOL, V11, P487, DOI 10.1016/0735-1097(88)91521-5; LEE TH, 1985, ARCH INTERN MED, V145, P65, DOI 10.1001/archinte.145.1.65; NICOD P, 1989, CIRCULATION, V79, P528, DOI 10.1161/01.CIR.79.3.528; NYMAN I, 1993, J INTERN MED, V234, P293, DOI 10.1111/j.1365-2796.1993.tb00746.x; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; Peterson ED, 1996, J AM COLL CARDIOL, V28, P305, DOI 10.1016/0735-1097(96)00133-7; ROUAN GW, 1989, AM J CARDIOL, V64, P1087, DOI 10.1016/0002-9149(89)90857-6; SCHECHTMAN KB, 1989, CIRCULATION, V80, P1148, DOI 10.1161/01.CIR.80.5.1148; SEVERI S, 1988, EUR HEART J, V9, P441, DOI 10.1093/oxfordjournals.eurheartj.a062522; SHIANG LH, 1993, LANCET, V345, P1204; SLATER DK, 1987, AM J CARDIOL, V60, P766, DOI 10.1016/0002-9149(87)91020-4; STARK ME, 1987, ARCH INTERN MED, V147, P843, DOI 10.1001/archinte.147.5.843; Stubbs P, 1996, CIRCULATION, V94, P1291, DOI 10.1161/01.CIR.94.6.1291; Topol E, 1997, NEW ENGL J MED, V337, P1118; Topol EJ, 1996, NEW ENGL J MED, V335, P775; WALLENTIN L, 1990, LANCET, V336, P827; WILCOX I, 1989, AM J CARDIOL, V64, P845, DOI 10.1016/0002-9149(89)90829-1	29	345	369	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1999	281	8					707	713		10.1001/jama.281.8.707	http://dx.doi.org/10.1001/jama.281.8.707			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BD	10052440				2022-12-28	WOS:000078669900029
J	Li, HL; Laine, A; O'Keeffe, M; Yaghi, OM				Li, HL; Laine, A; O'Keeffe, M; Yaghi, OM			Supertetrahedral sulfide crystals with giant cavities and channels	SCIENCE			English	Article							MOLECULAR-SIEVE; LARGE-PORE; FRAMEWORKS	Although aluminosilicates and metal phosphates can form porous open-framework materials such as zeolites, sulfide analogs usually form high-density phases because of the relatively small tetrahedral angle at sulfur atoms. One strategy to overcome this Limitation is to use tetrahedral clusters as the building blocks to achieve porous sulfide-based networks. The preparation and crystal structures of two indium sulfide open frameworks (ASU-31 and ASU-32) built of supertetrahedral clusters around organic template and water guests are described. ASU-31, based on the sodalite-tetrahedrite network, contains cavities 25.6 angstroms in diameter, and ASU-32, based on the tetragonal CrB4 network, contains channels with a minimum diameter of 14.7 angstroms, The organic cations can be completely exchanged with sodium ions in aqueous solution at room temperature without degradation of the crystals.	Arizona State Univ, Dept Chem & Biochem, Supremol Design & Discovery Grp, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Yaghi, OM (corresponding author), Arizona State Univ, Dept Chem & Biochem, Supremol Design & Discovery Grp, Tempe, AZ 85287 USA.		Yaghi, Omar M/C-6749-2013	Yaghi, Omar/0000-0002-5611-3325				BENNETT JM, 1968, MATER RES BULL, V3, P633, DOI 10.1016/0025-5408(68)90112-8; Bowes CL, 1996, ADV MATER, V8, P13, DOI 10.1002/adma.19960080103; Cahill CL, 1998, CHEM MATER, V10, P19, DOI 10.1021/cm9705707; Cahill CL, 1997, CHEM MATER, V9, P807, DOI 10.1021/cm960484r; DANCE IG, 1987, INORG CHEM, V26, P4057, DOI 10.1021/ic00271a019; Davis ME, 1997, CHEM-EUR J, V3, P1745, DOI 10.1002/chem.19970031104; ESTERMANN M, 1991, NATURE, V352, P320, DOI 10.1038/352320a0; HANSEN S, 1990, NATURE, V346, P799, DOI 10.1038/346799b0; Jiang T, 1998, J MATER CHEM, V8, P721, DOI 10.1039/a706279f; KREBS B, 1984, Z ANORG ALLG CHEM, V518, P101, DOI 10.1002/zaac.19845181110; MacGillivray LR, 1997, NATURE, V389, P469, DOI 10.1038/38985; MacLachlan MJ, 1998, ANGEW CHEM INT EDIT, V37, P2076; MCCUSKER LB, 1991, ZEOLITES, V11, P308, DOI 10.1016/0144-2449(91)80292-8; NYMAN H, 1981, ACTA CRYSTALLOGR A, V37, P11, DOI 10.1107/S056773948100003X; OKEEFFE M, 1976, ACTA CRYSTALLOGR B, V32, P2923, DOI 10.1107/S0567740876009308; PARISE JB, 1991, SCIENCE, V251, P293, DOI 10.1126/science.251.4991.293; PARISE JB, 1994, CHEM MATER, V6, P718, DOI 10.1021/cm00042a002; TAKEUCHI Y, 1973, Z KRISTALLOGR, V137, P380, DOI 10.1524/zkri.1973.137.5-6.380; Tan KM, 1996, CHEM MATER, V8, P448, DOI 10.1021/cm950375x; TAN KM, 1995, J AM CHEM SOC, V117, P7039, DOI 10.1021/ja00131a042; VOSSMEYER T, 1995, SCIENCE, V267, P1476, DOI 10.1126/science.267.5203.1476; YAGHI OM, 1994, J AM CHEM SOC, V116, P807, DOI 10.1021/ja00081a067; [No title captured]; [No title captured]; [No title captured]; [No title captured]	26	372	389	10	219	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1145	1147		10.1126/science.283.5405.1145	http://dx.doi.org/10.1126/science.283.5405.1145			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024236				2022-12-28	WOS:000078738400045
J	Shibahara, K; Stillman, B				Shibahara, K; Stillman, B			Replication-dependent marking of DNA by PCNA facilitates CAF-1-coupled inheritance of chromatin	CELL			English	Article							CELL NUCLEAR ANTIGEN; ASSEMBLY FACTOR-I; NUCLEOTIDE EXCISION-REPAIR; SIMIAN VIRUS-40 DNA; SACCHAROMYCES-CEREVISIAE; POLYMERASE-DELTA; FACTOR-C; AUXILIARY PROTEINS; ACCESSORY PROTEINS; INVITRO	Chromatin assembly factor 1 (CAF-1) is required for inheritance of epigenetically determined chromosomal states in vivo and promotes assembly of chromatin during DNA replication in vitro. Herein, we demonstrate that after DNA replication, replicated, but not unreplicated, DNA is also competent for CAF-1-dependent chromatin assembly. The proliferating cell nuclear antigen (PCNA), a DNA polymerase clamp, is a component of the replication-dependent marking of DNA for chromatin assembly. The clamp loader, replication factor C (RFC), can reverse this mark by unloading PCNA from the replicated DNA. PCNA binds directly to p150, the largest subunit of CAF-1, and the two proteins colocalize at sites of DNA replication in cells. We suggest that PCNA and CAF-1 connect DNA replication to chromatin assembly and the inheritance of epigenetic chromosome states.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Stillman, B (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	stillman@cshl.org		Stillman, Bruce/0000-0002-9453-4091	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; DEPAMPHILIS ML, 1980, ANNU REV BIOCHEM, V49, P627, DOI 10.1146/annurev.bi.49.070180.003211; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Ellison V, 1998, J BIOL CHEM, V273, P5979, DOI 10.1074/jbc.273.10.5979; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FOTEDAR R, 1989, P NATL ACAD SCI USA, V86, P6459, DOI 10.1073/pnas.86.17.6459; Gaillard PHL, 1997, EMBO J, V16, P6281, DOI 10.1093/emboj/16.20.6281; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grewal SIS, 1998, GENETICS, V150, P563; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HUBSCHER U, 1996, DNA REPLICATION EUKA, P525; Ivanova AV, 1998, NAT GENET, V19, P192, DOI 10.1038/566; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kamakaka RT, 1996, MOL CELL BIOL, V16, P810; Kaufman PD, 1998, MOL CELL BIOL, V18, P4793, DOI 10.1128/MCB.18.8.4793; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Klar AJS, 1998, CIBA F SYMP, V214, P87; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; LEE SH, 1991, J BIOL CHEM, V266, P594; Lewin B, 1998, CELL, V93, P301, DOI 10.1016/S0092-8674(00)81154-X; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; MILLER AM, 1984, COLD SPRING HARB SYM, V49, P105, DOI 10.1101/SQB.1984.049.01.014; Monson EK, 1997, P NATL ACAD SCI USA, V94, P13081, DOI 10.1073/pnas.94.24.13081; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; Qian ZJ, 1998, MOL CELL BIOL, V18, P4783, DOI 10.1128/MCB.18.8.4783; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SMITH S, 1991, J BIOL CHEM, V266, P12041; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WOLFFE AP, 1991, J CELL SCI, V99, P201; Yamamoto Y, 1997, DEVELOPMENT, V124, P3385	69	535	540	21	61	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 19	1999	96	4					575	585		10.1016/S0092-8674(00)80661-3	http://dx.doi.org/10.1016/S0092-8674(00)80661-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	168XN	10052459	Bronze			2022-12-28	WOS:000078718600008
J	Hintz, RL; Attie, KM; Baptista, J; Roche, A				Hintz, RL; Attie, KM; Baptista, J; Roche, A		Genentech Collaborative Grp	Effect of growth hormone treatment on adult height of children with idiopathic short stature	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the American-Pediatric-Society / Society-for-Pediatric-Research	MAY 07-11, 1995	SAN DIEGO, CA	Amer Pediat Soc, Soc Pediat Res			TURNER SYNDROME; CONSTITUTIONAL DELAY; FINAL HEIGHT; THERAPY; DEFICIENCY; TERM; DIAGNOSIS; TRIAL; BOYS	Background Short-term administration of growth hormone to children with idiopathic short: stature results in increases in growth rate and standard-deviation scores for height, However, the effect of longterm growth hormone therapy on adult height in these children is unknown. Methods We studied 121 children with idiopathic short stature, all of whom had an initial height below the third percentile, low growth rates, and maximal stimulated serum concentrations of growth hormone of at least 10 mu g per liter. The children were treated with growth hormone (0.3 mg per kilogram of body weight per week) for 2 to 10 years. Eighty of these children have reached adult height, with a bone age of at least 16 years in the boys and at least 14 years In the flirts, and pubertal stage 4 or 5. The difference between the predicted adult height before treatment and achieved adult height was compared with the corresponding difference in three untreated normal or short-statured control groups. Results In the 80 children who have reached adult height, growth hormone treatment increased the mean standard-deviation scare for height (number of standard deviations from the mean height for chronologic age) from -2.7 to -1.4, The mean (+/-SD) difference between predicted adult height before treatment and achieved adult height was +5.0+/-5.1 cm for boys and +5.9+/-5.2 cm for girls. The difference between predicted and achieved adult height among treated boys was 9.2 cm greater than the corresponding difference among untreated boys with initial standard-deviation scores of less than -2, and the difference among treated girls was 5.7 cm greater than the difference among untreated girls, Conclusions Long-term administration of growth hormone to children with idiopathic short stature can increase adult height to a level above the predicted adult height and above the adult height of untreated historical control children. (N Engl J Med 1999;340:502-7.) (C)1999, Massachusetts Medical Society.	Stanford Univ, Med Ctr, Dept Pediat, Stanford, CA 94305 USA; Genentech Inc, San Francisco, CA 94080 USA; Wright State Univ, Yellow Springs, OH USA	Stanford University; Roche Holding; Genentech; University System of Ohio; Wright State University Dayton	Hintz, RL (corresponding author), Stanford Univ, Med Ctr, Dept Pediat, Rm S-302, Stanford, CA 94305 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000865] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-0865-24, RR-06020] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALBERTSSONWIKLAND K, 1993, ACTA PAEDIATR, V82, P75, DOI 10.1111/j.1651-2227.1993.tb12934.x; ALLEN DB, 1990, J PEDIATR-US, V117, P16, DOI 10.1016/S0022-3476(05)82438-2; BAYLEY N, 1952, J PEDIATR-US, V40, P423, DOI 10.1016/S0022-3476(52)80205-7; BAYLEY N, 1952, J PEDIATR-US, V41, P371; BIERICH JR, 1992, ACTA ENDOCRINOL-COP, V127, P392, DOI 10.1530/acta.0.1270392; CELNIKER AC, 1989, J CLIN ENDOCR METAB, V68, P469, DOI 10.1210/jcem-68-2-469; GERTNER JM, 1984, J PEDIATR-US, V104, P172, DOI 10.1016/S0022-3476(84)80987-7; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HINDMARSH PC, 1990, ACTA PAEDIATR SCAND, P6; Hindmarsh PC, 1996, LANCET, V348, P13, DOI 10.1016/S0140-6736(96)01038-0; HOPWOOD NJ, 1993, J PEDIATR-US, V123, P215, DOI 10.1016/S0022-3476(05)81691-9; LAFRANCHI S, 1991, PEDIATRICS, V87, P82; LOCHE S, 1994, J PEDIATR-US, V125, P196, DOI 10.1016/S0022-3476(94)70192-X; MARIN G, 1994, J CLIN ENDOCR METAB, V79, P537, DOI 10.1210/jc.79.2.537; McCaughey ES, 1998, LANCET, V351, P940; NIENHUIS HE, 1993, HORM RES, V39, P31, DOI 10.1159/000182765; PLOTNICK LP, 1983, PEDIATRICS, V71, P324; RANKE MB, 1995, HORM RES, V44, P152, DOI 10.1159/000184616; Roche A, 1992, GROWTH MATURATION BO; Roche AF., 1988, ASSESSING SKELETAL M; ROSE SR, 1988, NEW ENGL J MED, V319, P201, DOI 10.1056/NEJM198807283190403; ROSENFELD RG, 1992, J PEDIATR-US, V121, P49, DOI 10.1016/S0022-3476(05)82540-5; ROSENFELD RG, 1995, J CLIN ENDOCR METAB, V80, P1532, DOI 10.1210/jc.80.5.1532; SHERMAN BM, 1989, J PEDIATR-US, V115, P713; STANHOPE R, 1992, BRIT MED J, V304, P777, DOI 10.1136/bmj.304.6829.777-c; TAKANO K, 1990, ACTA PAEDIATR SCAND, P14; TAKANO K, 1993, HORM RES, V39, P37, DOI 10.1159/000182766; VANVLIET G, 1983, NEW ENGL J MED, V309, P1016; VOSS LD, 1991, ARCH DIS CHILD, V66, P833, DOI 10.1136/adc.66.7.833; WIT JM, 1995, CLIN ENDOCRINOL, V42, P365, DOI 10.1111/j.1365-2265.1995.tb02644.x; ZADIK Z, 1994, J PEDIATR-US, V125, P189, DOI 10.1016/S0022-3476(18)31671-8	31	162	173	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1999	340	7					502	507		10.1056/NEJM199902183400702	http://dx.doi.org/10.1056/NEJM199902183400702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	168FD	10021470	Bronze			2022-12-28	WOS:000078680100002
J	Maron, BJ; Casey, SA; Poliac, LC; Gohman, TE; Almquist, AK; Aeppli, DM				Maron, BJ; Casey, SA; Poliac, LC; Gohman, TE; Almquist, AK; Aeppli, DM			Clinical course of hypertrophic cardiomyopathy in a regional United States cohort	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSTRUCTIVE CARDIOMYOPATHY; SUBAORTIC STENOSIS; PROGNOSIS; POPULATION; ECHOCARDIOGRAPHY; SPECTRUM; HISTORY	Context Hypertrophic cardiomyopathy (HCM) has been regarded as a disease that causes substantial disability, with annual mortality rates of up to 6%, based largely on reports from tertiary referral centers. Objective To assess the clinical course of HCM in a patient cohort more closely resembling the true disease state. Design Retrospective cohort study. Setting A regional cohort from Minnesota and adjoining regions, free of referral center bias, studied at Minneapolis Heart Institute. Patients Two hundred seventy-seven consecutively studied HCM patients, none referred for specialized HCM care, managed clinically in a standard fashion. Main Outcome Measures Mortality and clinical course of HCM. Results During a mean (SD) follow-up of 8.1 (6.6) years, 45 patients died and 29 of these deaths were directly related to HCM; however, 8 of the 29 HCM deaths were not premature (occurring >75 years of age). Annual HCM mortality rate was 1.3% (0.7% for sudden cardiac death). Patients identified in adulthood (n = 234) showed no statistically significant difference in mortality when compared with expected mortality, as calculated for the general US or Minnesota populations (P = .17). Patients identified as children (n = 43) showed decreased survival compared with the general population (P < .001). At most recent clinical evaluation, 192 patients (69%) had no or mild symptoms and 69 (25%) experienced incapacitating symptoms or HCM-related death; 53 (19%) of the patients had achieved estimated life expectancy of 75 years or older. More advanced symptoms at diagnosis-occurrence of atrial fibrillation (often associated with stroke), the presence of basal outflow obstruction of at least 30 mm Hg, and marked left ventricular wall thickness of more than 25 mm-were clinically important independent predictors of HCM mortality. Conclusions In a regionally selected patient population most closely resembling the true disease state, HCM did not significantly increase the risk of premature death or adversely affect overall life expectancy. Prevailing misconceptions of HCM as a generally unfavorable condition may largely be related to the skewed patient referral patterns characteristic of tertiary care centers. Hypertrophic cardiomyopathy is nevertheless a highly complex disease capable of serious clinical consequences and premature death in some patients.	Minneapolis Heart Inst Fdn, Cardiovasc Res Div, Minneapolis, MN 55407 USA; Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA	Minneapolis Heart Institute Foundation; University of Minnesota System; University of Minnesota Twin Cities	Maron, BJ (corresponding author), Minneapolis Heart Inst Fdn, Cardiovasc Res Div, 920 E 28th St,Suite 40, Minneapolis, MN 55407 USA.							ADELMAN AG, 1972, ANN INTERN MED, V77, P515, DOI 10.7326/0003-4819-77-4-515; CANNAN CR, 1995, CIRCULATION, V92, P2488, DOI 10.1161/01.CIR.92.9.2488; CECCHI F, 1995, J AM COLL CARDIOL, V26, P1529, DOI 10.1016/0735-1097(95)00353-3; *DEP HLTH HUM SERV, 1992, VIT STAT US A, V2; Eland-Johnson RC, 1980, SURVIVAL MODELS DATA; FAY WP, 1990, J AM COLL CARDIOL, V16, P321; FIDDLER GI, 1978, AM J CARDIOL, V42, P793, DOI 10.1016/0002-9149(78)90099-1; FRANK S, 1968, CIRCULATION, V37, P759, DOI 10.1161/01.CIR.37.5.759; HARDARSON T, 1973, LANCET, V2, P1462; Kappenberger L, 1997, EUR HEART J, V18, P1249; KLUES HG, 1995, J AM COLL CARDIOL, V26, P1699, DOI 10.1016/0735-1097(95)00390-8; Knight C, 1997, CIRCULATION, V95, P2075, DOI 10.1161/01.CIR.95.8.2075; KOFFLARD MJ, 1993, AM J CARDIOL, V72, P939, DOI 10.1016/0002-9149(93)91111-T; Maki S, 1998, AM J CARDIOL, V82, P774, DOI 10.1016/S0002-9149(98)00455-X; MARON BJ, 1976, CIRCULATION, V53, P9, DOI 10.1161/01.CIR.53.1.9; Maron BJ, 1998, CIRCULATION, V98, P1460, DOI 10.1161/01.CIR.98.14.1460; Maron BJ, 1997, LANCET, V350, P127, DOI 10.1016/S0140-6736(97)01282-8; MARON BJ, 1994, BR HEART J S, V72, P13; MCKENNA W, 1981, AM J CARDIOL, V47, P532, DOI 10.1016/0002-9149(81)90535-X; MCKENNA WJ, 1984, ARCH DIS CHILD, V59, P971, DOI 10.1136/adc.59.10.971; *MINN DEP HLTH, 1992, MENN HLTH STAT, P29; MORROW AG, 1975, CIRCULATION, V52, P88, DOI 10.1161/01.CIR.52.1.88; PANZA JA, 1992, J AM COLL CARDIOL, V19, P91, DOI 10.1016/0735-1097(92)90057-T; SHAH PM, 1974, CIRC RES, V35, P179; SHAPIRO LM, 1983, BRIT HEART J, V50, P530; Sherrid MV, 1998, CIRCULATION, V97, P41, DOI 10.1161/01.CIR.97.1.41; SPIRITO P, 1987, AM J CARDIOL, V60, P123, DOI 10.1016/0002-9149(87)90998-2; SPIRITO P, 1989, NEW ENGL J MED, V320, P749, DOI 10.1056/NEJM198903233201201; Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107; SWAN DA, 1971, BRIT HEART J, V33, P671; WIGLE ED, 1995, CIRCULATION, V92, P1680, DOI 10.1161/01.CIR.92.7.1680	31	370	389	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1999	281	7					650	655		10.1001/jama.281.7.650	http://dx.doi.org/10.1001/jama.281.7.650			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	165YA	10029128	Bronze			2022-12-28	WOS:000078548400037
J	Wawer, MJ; Sewankambo, NK; Serwadda, D; Quinn, TC; Paxton, LA; Kiwanuka, N; Wabwire-Mangen, F; Li, CJ; Lutalo, T; Nalugoda, F; Gaydos, CA; Moulton, LH; Meehan, MO; Ahmed, S; Gray, RH				Wawer, MJ; Sewankambo, NK; Serwadda, D; Quinn, TC; Paxton, LA; Kiwanuka, N; Wabwire-Mangen, F; Li, CJ; Lutalo, T; Nalugoda, F; Gaydos, CA; Moulton, LH; Meehan, MO; Ahmed, S; Gray, RH		Rakai Project Study Grp	Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial	LANCET			English	Article							BACTERIAL VAGINOSIS; RURAL TANZANIA; CHLAMYDIA-TRACHOMATIS; HIV-1 INFECTION; RISK-FACTORS; TRANSMISSION; IMPACT; WOMEN	Background The study tested the hypothesis that community-level control of sexually transmitted disease (STD) would result in lower incidence of HIV-1 infection in comparison with control communities. Methods This randomised, controlled, single-masked, community-based trial of intensive STD control, via home-based mass antibiotic treatment, took place in Rakai District, Uganda. Ten community clusters were randomly assigned to intervention or control groups. All consenting residents aged 15-59 years were enrolled; visited in the home every 10 months; interviewed; asked to provide biological samples for assessment of HIV-1 infection and STDs; and were provided with mass treatment (azithromycin, ciprofloxacin, metronidazole in the intervention group, vitamins/anthelmintic drug in the control). intention-to-treat analyses used multivariate, paired, cluster-adjusted rate ratios. Findings The baseline prevalence of HIV-1 infection was 15.9%. 6602 HIV-1-negative individuals were enrolled in the intervention group and 6124 in the control group. 75.0% of intervention-group and 72.6% of control-group participants provided at least one follow-up sample for HIV-1 testing. At enrolment, the two treatment groups were similar in STD prevalence rates. At 20-month follow-up, the prevalences of syphilis (352/6238 [5.6%) vs 359/5284 [6.8%]; rate ratio 0.80 [95% CI 0.71-0.89]) and trichomoniasis (182/1968 [9.3%] vs 261/1815 [14.4%]; rate ratio 0.59 [0.38-0.91]) were significantly lower in the intervention group than in the control group. The incidence of HIV-1 infection was 1.5 per 100 person-years in both groups (rate ratio 0.97 [0.81-1.16]). In pregnant women, the follow-up prevalences of trichomoniasis, bacterial vaginosis, gonorrhoea, and chlamydia infection were significantly lower in the intervention group than in the control group. No effect of the intervention on incidence of HIV-1 infection was observed in pregnant women or in stratified analyses. Interpretation We observed no effect of the STD intervention on the incidence of HIV-1 infection. In the Rakai population, a substantial proportion of HIV-1 acquisition appears to occur independently of treatable STD cofactors.	Columbia Univ, Sch Publ Hlth, Ctr Populat & Family Hlth, New York, NY 10032 USA; Makerere Univ, Dept Med, Kampala, Uganda; Makerere Univ, Clin Epidemiol Unit, Kampala, Uganda; Makerere Univ, Inst Publ Hlth, Dept Populat & Family Hlth Sci, Kampala, Uganda; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Int Hlth, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Uganda Virus Res Inst, Rakai Project, Entebbe, Uganda; NIAID, Bethesda, MD 20892 USA	Columbia University; Makerere University; Makerere University; Makerere University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Uganda Virus Research Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Wawer, MJ (corresponding author), Columbia Univ, Sch Publ Hlth, Ctr Populat & Family Hlth, Floor B-2,60 Haven Ave, New York, NY 10032 USA.		Quinn, Thomas/A-2494-2010; Gaydos, Charlotte A./E-9937-2010	Moulton, Lawrence/0000-0001-7041-7387; Sewankambo, Nelson/0000-0001-9362-053X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000358, Z01AI000361, R01AI034826] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI34826, R01 AI34826S] Funding Source: Medline; NICHD NIH HHS [5P30HD06826] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Brookmeyer R, 1998, STAT MED, V17, P2121, DOI 10.1002/(SICI)1097-0258(19980930)17:18<2121::AID-SIM907>3.0.CO;2-S; Buimer M, 1996, J CLIN MICROBIOL, V34, P2395, DOI 10.1128/JCM.34.10.2395-2400.1996; BURTIN P, 1995, AM J OBSTET GYNECOL, V172, P525, DOI 10.1016/0002-9378(95)90567-7; *CDCP, 1993, MMWR-MORBID MORTAL W, V43, P1; Cohen MS, 1998, LANCET, V351, P5, DOI 10.1016/S0140-6736(98)90002-2; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; Dallabetta GA, 1998, SEX TRANSM INFECT, V74, pS1; Ghys PD, 1997, AIDS, V11, pF85, DOI 10.1097/00002030-199712000-00001; GRAY RH, 1998, 12 WORLD AIDS C GEN; GRAY RH, 1998, 12 WORLD AIDS C GEN, P21; Grosskurth H, 1996, BRIT MED J, V312, P277, DOI 10.1136/bmj.312.7026.277; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HAYES R, 1995, AIDS, V9, P919, DOI 10.1097/00002030-199508000-00014; HAYES R, 1995, LANCET, V346, P1159; Hayes R, 1997, GENITOURIN MED, V73, P432; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; Mayaud P, 1997, AIDS, V11, P1873, DOI 10.1097/00002030-199715000-00013; MERTENS TE, 1990, AIDS, V4, P57, DOI 10.1097/00002030-199001000-00008; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; OKASI A, 1999, J INFECT DIS, V179, P16; Orle KA, 1996, J CLIN MICROBIOL, V34, P49, DOI 10.1128/JCM.34.1.49-54.1996; PAXTON L, 1996, 11 INT C AIDS VANC J; Robinson NJ, 1997, INT J EPIDEMIOL, V26, P180, DOI 10.1093/ije/26.1.180; Rockhill B, 1998, AM J PUBLIC HEALTH, V88, P15, DOI 10.2105/AJPH.88.1.15; SANCHEZMARTINEZ D, 1991, J INFECT DIS, V164, P1196, DOI 10.1093/infdis/164.6.1196; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SERWADDA D, 1995, AIDS, V9, P745, DOI 10.1097/00002030-199507000-00012; SERWADDA D, 1992, AIDS, V6, P983, DOI 10.1097/00002030-199209000-00012; Sewankambo N, 1997, LANCET, V350, P546, DOI 10.1016/S0140-6736(97)01063-5; SWEET RL, 1993, AM J OBSTET GYNECOL, V169, P479, DOI 10.1016/0002-9378(93)90346-K; Taha TE, 1998, AIDS, V12, P1699, DOI 10.1097/00002030-199813000-00019; Urnovitz HB, 1997, NAT MED, V3, P1258, DOI 10.1038/nm1197-1258; WASSERHEIT JN, 1992, SEX TRANSM DIS, V9, P2565; WAWER MJ, 1994, BRIT MED J, V308, P171, DOI 10.1136/bmj.308.6922.171; Wawer MJ, 1998, AIDS, V12, P1211, DOI 10.1097/00002030-199810000-00014; WAWER MJ, 1998, 12 WORLD AIDS C GEN	37	563	569	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 13	1999	353	9152					525	535		10.1016/S0140-6736(98)06439-3	http://dx.doi.org/10.1016/S0140-6736(98)06439-3			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028980	hybrid			2022-12-28	WOS:000078670200009
J	Daviglus, ML; Liao, YL; Greenland, P; Dyer, AR; Liu, K; Xie, XY; Huang, CF; Prineas, RJ; Stamler, J				Daviglus, ML; Liao, YL; Greenland, P; Dyer, AR; Liu, K; Xie, XY; Huang, CF; Prineas, RJ; Stamler, J			Association of nonspecific minor ST-T abnormalities with cardiovascular mortality - The Chicago Western Electric study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; MIDDLE-AGED MEN; ELECTROCARDIOGRAPHIC FINDINGS; DEATH; RISK	Context Minor electrocardiographic (ECG) ST-T abnormalities are common, but their prognostic importance has not been fully determined, Objective To examine associations of single (1 time only) and multiple (2 times only and greater than or equal to 3 times) nonspecific minor ST-T abnormalities in 5 years with long-term mortality due to myocardial infarction (MI), coronary heart disease (CHD), cardiovascular disease (CVD), and ail causes in middle-aged men. Design Prospective cohort study (29-year follow-up after 5 annual examinations). Setting and Participants A total of 1673 men employed at the Western Electric Company in Chicago, ill, aged 40 to 55 years at entry, with no evidence of CHD and no major ECC abnormalities throughout the first 5-year period. Main Outcome Measures Minor ST-T abnormalities identified from annual resting ECGs and mortality ascertained from death certificates. Results Of the 1673 men, 173 had evidence of isolated nonspecific minor ST-T segment abnormalities. During the follow-up period, there were 234 deaths due to MI, 352 deaths due to CHD, 463 deaths due to CVD, and 889 deaths due to all causes. For men with 3 or more annual recordings of minor ST-T abnormalities, risk of death due to Mi, CHD, CVD, and all causes was significantly greater than for those with normal ECG findings. For men with 3 or more ECGs with minor ST-T abnormalities, relative risks (and 95% confidence intervals) adjusted for cardiovascular and other risk factors were 2.28 (1.16-4.49), 2.39 (1.39-4.12), 2.30 (1.44-3.68), and 1.60 (1.06-2.42), respectively, with a graded relationship between frequency of occurrence of ST-T abnormalities and mortality risk (linear trend, P less than or equal to.007). Conclusions Persistent, minor, nonspecific ST-T abnormalities are associated with increased long-term risk of mortality due to MI, CHD, CVD, and all causes; the higher the frequency of occurrence of minor ST-T abnormalities, the greater the risk, These data underscore the potential value of including nonspecific ECC findings in the overall assessment of cardiovascular risk.	Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Loyola Univ, Stritch Sch Med, Dept Epidemiol & Prevent Med, Maywood, IL 60153 USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA	Northwestern University; Loyola University Chicago; University of Minnesota System; University of Minnesota Twin Cities	Daviglus, ML (corresponding author), Northwestern Univ, Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1102, Chicago, IL 60611 USA.		Greenland, Philip/ABD-5528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K14HL003387, R01HL021010] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 03387, HL 15174, HL 21010] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTERHOG JH, 1981, ACTA MED SCAND, V209, P75; BARTEL A, 1971, ARCH INTERN MED, V128, P929, DOI 10.1001/archinte.128.6.929; BLACKBURN H, 1970, Circulation Research Supplement, V41, P154; *COR DRUG PROJ RES, 1972, ANN INTERN MED, V77, P677; COX DR, 1972, J R STAT SOC B, V34, P187; CULLEN K, 1982, BRIT HEART J, V47, P209; DEBACQUER D, 1994, EUR HEART J, V15, P1604, DOI 10.1093/oxfordjournals.eurheartj.a060441; FURBERG C, 1967, ACTA MED SCAND, V181, P21; GARRISON RJ, 1993, INT J OBESITY, V17, P417; GOLDBARG AN, 1970, CIRCULATION, V41, P257, DOI 10.1161/01.CIR.41.2.257; GREIG M, 1980, J EPIDEMIOL COMMUN H, V34, P23, DOI 10.1136/jech.34.1.23; GUAZZI M, 1975, CARDIOVASC RES, V9, P342, DOI 10.1093/cvr/9.3.342; HARLAN WR, 1967, J CHRON DIS, V20, P853, DOI 10.1016/0021-9681(67)90023-9; HIGGINS ITT, 1965, BRIT J PREV SOC MED, V19, P53; *INT CLASS DIS, 1967, NATL CTR HLTH STAT, V49, P522; KANNEL WB, 1969, ANN INTERN MED, V71, P89, DOI 10.7326/0003-4819-71-1-89; KANNEL WB, 1987, AM HEART J, V113, P370, DOI 10.1016/0002-8703(87)90280-8; KEMP GL, 1968, ARCH INTERN MED, V121, P518, DOI 10.1001/archinte.121.6.518; KIESSLING CHARLES E., 1964, AMER J CARDIOL, V13, P598, DOI 10.1016/0002-9149(64)90193-6; KNUTSEN R, 1988, J CLIN EPIDEMIOL, V41, P293, DOI 10.1016/0895-4356(88)90134-5; LIAO YL, 1987, CIRCULATION, V75, P347, DOI 10.1161/01.CIR.75.2.347; MATHEWSON FAL, 1960, CIRCULATION, V21, P196, DOI 10.1161/01.CIR.21.2.196; OSTOR E, 1981, EUR HEART J, V2, P317; OSTRANDER LD, 1965, CIRCULATION, V31, P888, DOI 10.1161/01.CIR.31.6.888; OSTRANDER LD, 1966, CIRCULATION, V34, P1069, DOI 10.1161/01.CIR.34.6.1069; OSTRANDER LD, 1970, AM J CARDIOL, V25, P325, DOI 10.1016/S0002-9149(70)80010-8; PAUL O, 1963, CIRCULATION, V28, P20, DOI 10.1161/01.CIR.28.1.20; *POOL PROJ RES GRO, 1978, J CHRON DIS, V31, P201, DOI DOI 10.1016/0021-9681(78)90073-5; Prineas R., 1982, MINNESOTA CODE MANUA; RABKIN SW, 1982, BRIT HEART J, V47, P546; Reunanen A, 1978, Adv Cardiol, V21, P310; ROSE G, 1978, BRIT HEART J, V40, P636; SCHANG SJ, 1977, AM J CARDIOL, V39, P396, DOI 10.1016/S0002-9149(77)80095-7; Sigurdsson E, 1996, J AM COLL CARDIOL, V27, P1140, DOI 10.1016/0735-1097(95)00614-1; Singer R B, 1982, Trans Assoc Life Insur Med Dir Am, V65, P180; STAMLER J, 1991, HYPERTENSION S, V18, P195; SURAWICZ B, 1977, CARDIOVASC MED, V2, P629; TAGGART P, 1978, PROGR CARDIOLOGY, P103; UNGERLEIDER HE, 1960, AM J CARDIOL, V6, P35, DOI 10.1016/0002-9149(60)90033-3	39	129	132	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1999	281	6					530	536		10.1001/jama.281.6.530	http://dx.doi.org/10.1001/jama.281.6.530			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164FQ	10022109	Bronze			2022-12-28	WOS:000078452900031
J	Laumann, EO; Paik, A; Rosen, RC				Laumann, EO; Paik, A; Rosen, RC			Sexual dysfunction in the United States - Prevalence and predictors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LATENT CLASS ANALYSIS; ERECTILE DYSFUNCTION; SATISFACTION	Context While recent pharmacological advances have generated increased public interest and demand for clinical services regarding erectile dysfunction, epidemiologic data on sexual dysfunction are relatively scant for both women and men. Objective To assess the prevalence and risk of experiencing sexual dysfunction across various social groups and examine the determinants and health consequences of these disorders. Design Analysis of data from the National Health and Social Life Survey, a probability sample study of sexual behavior in a demographically representative, 1992 cohort of US adults. Participants A national probability sample of 1749 women and 1410 men aged 18 to 59 years at the time of the survey. Main Outcome Measures Risk of experiencing sexual dysfunction as well as negative concomitant outcomes. Results Sexual dysfunction is more prevalent for women (43%) than men (31%) and is associated with various demographic characteristics, including age and educational attainment. Women of different racial groups demonstrate different patterns of sexual dysfunction. Differences among men are not as marked but generally consistent with women. Experience of sexual dysfunction is more likely among women and men with poor physical and emotional health. Moreover, sexual dysfunction is highly associated with negative experiences in sexual relationships and overall wellbeing. Conclusions The results indicate that sexual dysfunction is an important public health concern, and emotional problems likely contribute to the experience of these problems.	Univ Chicago, Dept Sociol, Chicago, IL 60637 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA	University of Chicago; Rutgers State University New Brunswick; Rutgers State University Medical Center	Laumann, EO (corresponding author), Univ Chicago, Dept Sociol, 5848 S Univ Ave, Chicago, IL 60637 USA.	ob01@midway.uchicago.edu	Paik, Anthony/ABE-5953-2020		NICHD NIH HHS [R01-HD28356] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028356] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P493; Boolell M, 1996, BRIT J UROL, V78, P257, DOI 10.1046/j.1464-410X.1996.10220.x; Browning CR, 1997, AM SOCIOL REV, V62, P540, DOI 10.2307/2657425; BURNETT AL, 1995, BIOL REPROD, V52, P485, DOI 10.1095/biolreprod52.3.485; Clogg C. C., 1995, HDB STAT MODELING SO, P311, DOI DOI 10.1007/978-1-4899-1292-3_6; CLOGG CC, 1977, UNRESTRICTED RESTRIC; DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83; EATON WW, 1989, SOCIOL METHOD RES, V18, P104, DOI 10.1177/0049124189018001004; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; FRANK E, 1978, NEW ENGL J MED, V299, P111, DOI 10.1056/NEJM197807202990302; FuglMeyer AR, 1997, INT J IMPOT RES, V9, P141, DOI 10.1038/sj.ijir.3900269; HEATON JPW, 1995, UROLOGY, V45, P200, DOI 10.1016/0090-4295(95)80005-0; Kinsey A.C., 1998, SEXUAL BEHAV HUMAN F; Kinsey AC, 1948, SEXUAL BEHAV HUMAN F; Laumann E. O., 1994, SOCIAL ORG SEXUALITY; McCutheon A.L., 1987, LATENT CLASS ANAL; MORALES A, 1995, UROL CLIN N AM, V22, P879; MOROKOFF PJ, 1993, J SEX RES, V30, P43, DOI 10.1080/00224499309551677; Park K, 1997, INT J IMPOT RES, V9, P27, DOI 10.1038/sj.ijir.3900258; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; RINDSKOPF D, 1986, STAT MED, V5, P21, DOI 10.1002/sim.4780050105; ROSEN RC, 1993, ARCH SEX BEHAV, V22, P521, DOI 10.1007/BF01543299; ROSEN RC, 1993, J SEX MARITAL THER, V19, P171; SEGRAVES RT, 1993, J SEX MARITAL THER, V19, P198; SPECTOR IP, 1990, ARCH SEX BEHAV, V19, P389, DOI 10.1007/BF01541933; *STATA, 1997, STATA REL 5; UEBERSAX JS, 1990, STAT MED, V9, P559, DOI 10.1002/sim.4780090509; YOUNG MA, 1982, J NERV MENT DIS, V170, P443, DOI 10.1097/00005053-198208000-00001; YOUNG MA, 1983, J PSYCHIATR RES, V17, P285, DOI 10.1016/0022-3956(82)90007-3; [No title captured]	30	3429	3573	1	115	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1999	281	6					537	544		10.1001/jama.281.6.537	http://dx.doi.org/10.1001/jama.281.6.537			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	164FQ	10022110	Bronze			2022-12-28	WOS:000078452900032
J	Chard, J; Lilford, R; Gardiner, D				Chard, J; Lilford, R; Gardiner, D			Looking beyond the next patient: sociology and modern health care	LANCET			English	Review							CONSUMER CASE-MANAGEMENT; RANDOMIZED TRIAL; MENTAL-ILLNESS; OUTCOMES		Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England; Univ Bristol, Bristol BS8 1TH, Avon, England; Univ York, York YO1 5DD, N Yorkshire, England	University of Birmingham; University of Bristol; University of York - UK	Lilford, R (corresponding author), Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England.							*AG HLTH CAR POL R, 1996, CLIN PRACT GUID; ARMSTRONG D, 1995, SOCIOL HEALTH ILL, V17, P393, DOI 10.1111/1467-9566.ep10933329; Balint M., 1956, DOCTOR HIS PATIENT I; BECKER H, 1962, BOYS WHITE; Black D., 1982, INEQUALITIES HLTH BL; BOLAM AM, 1998, BRIT MED J, V316, P789; Brown George W., 1979, SOCIAL ORIGINS DEPRE; CALDWELL JC, 1993, SOC SCI MED, V36, P125, DOI 10.1016/0277-9536(93)90204-H; CHARD JA, 1997, J ROY SOC MED, V90, P97; Cornwell Jocelyn, 1984, HARD EARNED LIVES AC; Creatsas G C, 1995, Int J Fertil Menopausal Stud, V40 Suppl 2, P80; Dearden R, 1970, HOSP CHILDREN THEIR; DOHRENWEND BS, 1973, J HEALTH SOC BEHAV, V14, P167, DOI 10.2307/2137066; Draine J, 1997, RES SOCIAL WORK PRAC, V7, P32, DOI 10.1177/104973159700700102; Durkheim E, 1897, SUICIDE; Edwards AC, 1998, SOC SCI MED, V46, P1077, DOI 10.1016/S0277-9536(97)10039-9; Engels Friedrich, 1844, CONDITIONS WORKING C; FEACHEM RG, 1991, DIS MORALITY SUBSAHA; Freidson E., 1988, PROFESSION MED STUDY; GARDINER D, 1989, ANATOMY SUPERVISION; GARDINER DWG, 1998, ISSUE SOC WORK ED, V8, P3; Goffman E., 1963, STIGMA; GOFFMAN E, 1963, ASYLUMS ASSAYS SOCIA; GRAHAM H, 1995, J SOC POLICY, V24, P509, DOI 10.1017/S0047279400025411; Hannay DR., 1979, SYMPTOM ICEBERG STUD; Illich Ivan, 1975, MED NEMESIS; ILLSLEY R, 1980, PROFESSIONAL PUBLIC; JOHNSON Z, 1993, BRIT MED J, V306, P1449, DOI 10.1136/bmj.306.6890.1449; Jordan J, 1998, BRIT MED J, V316, P1668, DOI 10.1136/bmj.316.7145.1668; KESEY K, 1972, ONE FLEW CUCKOOS NES; KETTING E, 1994, PATIENT EDUC COUNS, V23, P161, DOI 10.1016/0738-3991(94)90032-9; Lawless S, 1996, SOC SCI MED, V43, P1371, DOI 10.1016/0277-9536(96)00017-2; LEGRAND J, 1992, EC SOCIAL PROBLEMS; MACINTYRE S, 1994, J PUBLIC HEALTH MED, V16, P53, DOI 10.1093/oxfordjournals.pubmed.a042936; MACINTYRE S, 1992, SOC SCI MED, V35, P453, DOI 10.1016/0277-9536(92)90338-Q; MAYER J, 1978, BASIC READINGS MED S; McKeown T., 1979, MED HIST, DOI DOI 10.1515/9781400854622; Mott J., 1993, MED CAPITALISM; *NHS CTR REV DISS, 1996, EFF HLTH CAR, V2; *NHS CTR REV DISS, 1997, EFF HLTH CAR, V3; Oakley Ann, 1980, WOMEN CONFINED; Oakley Ann, 1984, CAPTURED WOMB HIST M; Parsons T, 1964, SOCIAL SYSTEM; PRESTON B, 1994, J ADV TRANSPORT, V28, P129, DOI 10.1002/atr.5670280203; Ridgely MS, 1996, PSYCHIATR SERV, V47, P737; ROBSON B, 1994, ASSESSING IMPACT URB; ROSENHAN DL, 1973, SCIENCE, V179, P250, DOI 10.1126/science.179.4070.250; Rowntree B. S., 1901, POVERTY STUDY TOWN L; SEGALL A, 1976, SOC SCI MED, V10, P47, DOI 10.1016/0037-7856(76)90139-6; Smith A., 1804, WEALTH NATIONS; SOLOMON P, 1995, EVAL PROGRAM PLANN, V18, P117, DOI 10.1016/0149-7189(95)00003-T; SOLOMON P, 1995, J MENT HEALTH ADMIN, V22, P135, DOI 10.1007/BF02518754; SOLOMON P, 1994, J NERV MENT DIS, V182, P179, DOI 10.1097/00005053-199403000-00009; Starr P, 1982, SOCIAL TRANSFORMATIO; Tewksbury R, 1997, SOCIOL SPECTRUM, V17, P49, DOI 10.1080/02732173.1997.9982150; Thomas Keith, 1991, RELIG DECLINE MAGIC; VANLUNSEN RHW, 1994, PATIENT EDUC COUNS, V23, P197, DOI 10.1016/0738-3991(94)90035-3; von Hayek F., 1944, ROAD SERFDOM; Zborowski M, 1952, J SOC ISSUES, V8, P16; ZOLA IK, 1973, SOC SCI MED, V7, P677, DOI 10.1016/0037-7856(73)90002-4; ZORITCH B, 1998, HLTH WELFARE EFFECTS	61	14	15	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 6	1999	353	9151					486	489		10.1016/S0140-6736(98)07304-8	http://dx.doi.org/10.1016/S0140-6736(98)07304-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	166JQ	9989736				2022-12-28	WOS:000078572800045
J	Raju, TNK				Raju, TNK			The Nobel chronicles	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	2	2	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 6	1999	353	9151					508	508		10.1016/S0140-6736(05)75191-6	http://dx.doi.org/10.1016/S0140-6736(05)75191-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JQ	9989759				2022-12-28	WOS:000078572800071
J	Schattner, A; Gabovich, N; Lifschiz, A; Becker, S				Schattner, A; Gabovich, N; Lifschiz, A; Becker, S			Medline solution	LANCET			English	Article							INFECTION		Kaplan Med Ctr, Dept Med, Rehovot, Israel; Kaplan Med Ctr, Dept Surg, Rehovot, Israel; Kaplan Med Ctr, Gastroenterol Unit, Rehovot, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Kaplan Medical Center; Hebrew University of Jerusalem; Kaplan Medical Center; Hebrew University of Jerusalem; Kaplan Medical Center; Hebrew University of Jerusalem	Schattner, A (corresponding author), Kaplan Med Ctr, Dept Med, Rehovot, Israel.		Schattner, Ami/ABI-1894-2020	Schattner, Ami/0000-0002-1413-8858				Begos DG, 1996, YALE J BIOL MED, V69, P323; BERK T, 1985, AM J GASTROENTEROL, V80, P355; Eddleston M, 1997, CLIN INFECT DIS, V24, P52, DOI 10.1093/clinids/24.1.52; POWELL RD, 1961, AM J MED, V30, P334, DOI 10.1016/0002-9343(61)90105-X; Soderberg-Naucler C, 1997, J CLIN INVEST, V100, P3154, DOI 10.1172/JCI119871	5	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 6	1999	353	9151					462	462		10.1016/S0140-6736(98)10077-6	http://dx.doi.org/10.1016/S0140-6736(98)10077-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JQ	9989718				2022-12-28	WOS:000078572800014
J	Strauss, JH; Strauss, EG				Strauss, JH; Strauss, EG			Viral RNA replication - With a little help from the host	SCIENCE			English	Editorial Material							VIRUS-RNA; SACCHAROMYCES-CEREVISIAE; NONSTRUCTURAL PROTEINS; EXPRESSION; TRANSCRIPTION; POLYMERASE; REPLICONS; SEQUENCE		CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Strauss, JH (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.							AHLQUIST P, 1985, J VIROL, V53, P536, DOI 10.1128/JVI.53.2.536-542.1985; Ahlquist P, COMMUNICATION; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; Bullock PA, 1997, CRIT REV BIOCHEM MOL, V32, P503, DOI 10.3109/10409239709082001; Das T, 1998, P NATL ACAD SCI USA, V95, P1449, DOI 10.1073/pnas.95.4.1449; HASELOFF J, 1984, P NATL ACAD SCI-BIOL, V81, P4358, DOI 10.1073/pnas.81.14.4358; Ishikawa M, 1997, P NATL ACAD SCI USA, V94, P13810, DOI 10.1073/pnas.94.25.13810; Ishikawa M, 1997, J VIROL, V71, P7781, DOI 10.1128/JVI.71.10.7781-7790.1997; Janda M, 1998, P NATL ACAD SCI USA, V95, P2227, DOI 10.1073/pnas.95.5.2227; JANDA M, 1993, CELL, V72, P961, DOI 10.1016/0092-8674(93)90584-D; Lai MMC, 1998, VIROLOGY, V244, P1, DOI 10.1006/viro.1998.9098; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; Pardigon N, 1996, J VIROL, V70, P1173, DOI 10.1128/JVI.70.2.1173-1181.1996; Price BD, 1996, P NATL ACAD SCI USA, V93, P9465, DOI 10.1073/pnas.93.18.9465; QUADT R, 1995, P NATL ACAD SCI USA, V92, P4892, DOI 10.1073/pnas.92.11.4892; SVITKIN YV, 1994, J VIROL, V68, P7001, DOI 10.1128/JVI.68.11.7001-7007.1994	16	28	30	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					802	804		10.1126/science.283.5403.802	http://dx.doi.org/10.1126/science.283.5403.802			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	10049125				2022-12-28	WOS:000078496800030
J	Aldridge, J; Measham, F				Aldridge, J; Measham, F			Sildenafil (Viagra) is used as a recreational drug in England	BRITISH MEDICAL JOURNAL			English	Letter									Appl Res Ctr, Social Policy Social Problems SPARC, Manchester M13 9PL, Lancs, England	University of Manchester	Aldridge, J (corresponding author), Appl Res Ctr, Social Policy Social Problems SPARC, Manchester M13 9PL, Lancs, England.			Measham, Fiona/0000-0002-9322-1931				KIRBY R, 1999, STUDENT BMJ, V7, P11; Parker HowardJ., 1998, ILLEGAL LEISURE NORM	2	57	58	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					669	669		10.1136/bmj.318.7184.669	http://dx.doi.org/10.1136/bmj.318.7184.669			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066221	Green Published			2022-12-28	WOS:000079089200049
J	Saxena, S; Majeed, A; Jones, M				Saxena, S; Majeed, A; Jones, M			Socioeconomic differences in childhood consultation rates in general practice in England and Wales: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article								Objective To establish how consultation rates in children for episodes of illness, preventive activities, and home visits vary by social class. Design Analysis of prospectively collected data from the fourth national survey of morbidity in general practice, carried out between September 1991 and August 1992. Setting 60 general practices in England and Wales. Subjects 106 102 children aged 0 to 15 years registered with the participating practices. Main outcome measures Mean overall consultation rates for any reason, illness by severity of underlying disease, preventive episodes, home visits, and specific diagnostic category (infections, asthma, and injuries). Results Overall consultation rates increased from registrar general's social classes I-II to classes IV-V in a linear pattern (for IV-V v I-II rate ratio 1.18; 95% confidence interval 1.14 to 1.22). Children from social classes IV-V consulted more frequently than children from classes I-II for illnesses (I ate ratio 1.23; 1.15 to 1.30), including infections, asthma, and injuries and poisonings. They also had significantly higher consultation rates for minor; moderate, and serious illnesses and higher home visiting rates (rate ratio 2.00; 1.81 to 2.18). Consultations for preventive activities were lower in children from social classes TV-V than in children from social classes I-II (rate ratio 0.95; 0.86 to 1.05). Conclusions Childhood consultation rates for episodes of illness increase from social classes I-II through to classes IV-V. The findings on severity of underlying illness suggest the health of children from lower social classes is worse than that of children from higher social classes. These results reinforce the need to identify and target children for preventive health care in their socioeconomic context.	Off Natl Stat, London SW1V 2QQ, England; St Georges Hosp, Sch Med, Dept Gen Practice & Primary Care, London SW17 0RE, England; Univ London London Sch Hyg & Trop Med, Canc & Publ Hlth Unit, London WC1E 7HT, England	St Georges University London; University of London; London School of Hygiene & Tropical Medicine	Majeed, A (corresponding author), Off Natl Stat, London SW1V 2QQ, England.	azeem.majeed@ons.gov.uk	Saxena, Sonia K/G-4821-2013; Saxena, Sonia/ABD-7737-2021	Saxena, Sonia K/0000-0003-3787-2083; Saxena, Sonia/0000-0003-3787-2083; Majeed, Azeem/0000-0002-2357-9858; Jones, Michael/0000-0001-7479-3451	Department of Health [PDA/02/06/076] Funding Source: Medline	Department of Health		Acheson D., 1998, INDEPENDENT INQUIRY; Armitage P., 1987, STAT METHODS MED RES; Aylin P, 1996, BRIT MED J, V313, P207, DOI 10.1136/bmj.313.7051.207; Blaxter M., 1990, HLTH LIFESTYLES; CAMPION PD, 1985, SOC SCI MED, V20, P325, DOI 10.1016/0277-9536(85)90005-X; CarrHill RA, 1996, BRIT MED J, V312, P1008; Cooper H, 1998, BRIT MED J, V317, P1047; DAVIDSON N, 1980, INEQUALITIES HLTH BL; DONNER A, 1994, AM J EPIDEMIOL, V140, P279, DOI 10.1093/oxfordjournals.aje.a117247; DREVER F, 1997, HLTH INEQUALITIES S, V15; ERNST P, 1995, AM J RESP CRIT CARE, V152, P570, DOI 10.1164/ajrccm.152.2.7633709; Fleming DM, 1998, BRIT MED J, V316, P1572, DOI 10.1136/bmj.316.7144.1572; HEWISON J, 1990, BR J GEN PRACT, V40, P226; MAJEED FA, 1994, BMJ-BRIT MED J, V308, P1426, DOI 10.1136/bmj.308.6941.1426; MORRISON JM, 1991, BRIT MED J, V303, P1111, DOI 10.1136/bmj.303.6810.1111; *OFF POP CENS SURV, 1992, HLTH SURV ENGL; *OFF POP CENS SURV, 1982, LONG STUD SER LS, V1; Office of Population Censuses and Surveys, 1995, MORB STAT GEN PRACT; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; STRACHAN DP, 1994, ARCH DIS CHILD, V70, P174, DOI 10.1136/adc.70.3.174	20	79	79	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					642	646		10.1136/bmj.318.7184.642	http://dx.doi.org/10.1136/bmj.318.7184.642			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066207	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000079089200030
J	Nightingale, SL				Nightingale, SL			Cerebyx labels changed	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					786	786		10.1001/jama.281.9.786	http://dx.doi.org/10.1001/jama.281.9.786			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10070983				2022-12-28	WOS:000078804300007
J	Parker, RA; Hartman, EE				Parker, RA; Hartman, EE			A 75-year-old woman with an abdominal aortic aneurysm an emphysema, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Goldman L, 1998, JAMA-J AM MED ASSOC, V280, P366, DOI 10.1001/jama.280.4.366	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1999	281	8					744	744		10.1001/jama.281.8.744	http://dx.doi.org/10.1001/jama.281.8.744			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BD	10052446				2022-12-28	WOS:000078669900035
J	Smith, TL; Pearson, ML; Wilcox, KR; Cruz, C; Lancaster, MV; Robinson-Dunn, B; Tenover, FC; Zervos, MJ; Band, JD; White, E; Jarvis, WR				Smith, TL; Pearson, ML; Wilcox, KR; Cruz, C; Lancaster, MV; Robinson-Dunn, B; Tenover, FC; Zervos, MJ; Band, JD; White, E; Jarvis, WR		Glycopeptide Intermediate Staphylococ	Emergence of vancomycin resistance in Staphylococcus aureus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COAGULASE-NEGATIVE STAPHYLOCOCCI; UNITED-STATES HOSPITALS; DOUBLE-BLIND; AEROSOLIZED VANCOMYCIN; NEUTROPENIC CHILDREN; DIALYSIS PATIENTS; RANDOMIZED TRIAL; CANCER-PATIENTS; PROPHYLAXIS; PREVENTION	Background Since the emergence of methicillin-resistant Staphylococcus aureus, the glycopeptide vancomycin has been the only uniformly effective treatment for staphylococcal infections. In 1997, two infections due to S. aureus with reduced susceptibility to vancomycin were identified in the United States. Methods We investigated the two patients with infections due to S. aureus with intermediate resistance to glycopeptides, as defined by a minimal inhibitory concentration of vancomycin of 8 to 16 mu g per milliliter. To assess the carriage and transmission of these strains of S. aureus, we cultured samples from the patients and their contacts and evaluated the isolates. Results The first patient was a 59-year-old man in Michigan with diabetes mellitus and chronic renal failure. Peritonitis due to S. aureus with intermediate resistance to glycopeptides developed after 18 weeks of vancomycin treatment for recurrent methicillin-resistant S. aureus peritonitis associated with dialysis. The removal of the peritoneal catheter plus treatment with rifampin and trimethoprim-sulfamethoxazole eradicated the infection. The second patient was a 66-year-old man with diabetes in New Jersey. A bloodstream infection due to S. aureus with intermediate resistance to glycopeptides developed after 18 weeks of vancomycin treatment for recurrent methicillin-resistant S. aureus bacteremia. This infection was eradicated with vancomycin, gentamicin, and rifampin. Both patients died. The glycopeptide-intermediate S. aureus isolates differed by two bands on pulsed-field gel electrophoresis. On electron microscopy, the isolates from the infected patients had thicker extracellular matrixes than control methicillin-resistant S. aureus isolates. No carriage was documented among 177 contacts of the two patients. Conclusions The emergence of S. aureus with intermediate resistance to glycopeptides emphasizes the importance of the prudent use of antibiotics, the laboratory capacity to identify resistant strains, and the use of infection-control precautions to prevent transmission. (N Engl J Med 1999;340:493-501.) (C)1999, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Hosp Infect Program, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Michigan Dept Community Hlth, Lansing, MI USA; William Beaumont Hosp, Royal Oak, MI 48072 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; MDHHS - Michigan Department of Health & Human Services; Beaumont Health	Pearson, ML (corresponding author), Ctr Dis Control & Prevent, Hosp Infect Program, Natl Ctr Infect Dis, 1600 Clifton Rd NE,MS E-69, Atlanta, GA 30333 USA.							[Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P1; ATKINSON BA, 1984, J CLIN MICROBIOL, V20, P791, DOI 10.1128/JCM.20.4.791-796.1984; AUBERT G, 1990, J ANTIMICROB CHEMOTH, V25, P491, DOI 10.1093/jac/25.3.491; BAMBERGER DM, 1996, CLIN INFECT DIS, V23, P591; BANNERMAN TL, 1995, J CLIN MICROBIOL, V33, P551, DOI 10.1128/JCM.33.3.551-555.1995; BASTANI B, 1987, NEPHRON, V45, P283, DOI 10.1159/000184164; CALANDRA T, 1991, J INFECT DIS, V163, P951; CALANDRA T, 1991, J INFECT DIS, V164, P832; CANTU TG, 1994, CLIN INFECT DIS, V18, P533; CAPDEVILA JA, 1993, NEPHROL DIAL TRANSPL, V8, P231; CLARK NC, 1993, ANTIMICROB AGENTS CH, V37, P2311, DOI 10.1128/AAC.37.11.2311; CONTE JE, 1972, ANN INTERN MED, V76, P943, DOI 10.7326/0003-4819-76-6-943; COSTERTON JW, 1981, ANNU REV MICROBIOL, V35, P299, DOI 10.1146/annurev.mi.35.100181.001503; DAUM RS, 1992, J INFECT DIS, V166, P1066, DOI 10.1093/infdis/166.5.1066; EDELL LS, 1988, CLIN NEPHROL, V29, P86; Edmond MB, 1996, ANN INTERN MED, V124, P329, DOI 10.7326/0003-4819-124-3-199602010-00008; Favero MS, 1996, AM J INFECT CONTROL, V24, P380; Fowler VG, 1998, CLIN INFECT DIS, V27, P478, DOI 10.1086/514686; GAILLARD JL, 1990, JPEN-PARENTER ENTER, V14, P593, DOI 10.1177/0148607190014006593; Garner JS, 1996, INFECT CONT HOSP EP, V17, P214; GARRETT DO, 1997, INFECT CONT HOSP EP, V18, pP32; GRADON JD, 1992, ANN PHARMACOTHER, V26, P209, DOI 10.1177/106002809202600214; HENRICKSON KJ, 1992, J INFECT DIS, V166, P944, DOI 10.1093/infdis/166.4.944; HENRICKSON KJ, 1988, J INFECT DIS, V157, P600, DOI 10.1093/infdis/157.3.600; HERMANS PE, 1987, MAYO CLIN PROC, V62, P901, DOI 10.1016/S0025-6196(12)65046-0; Hiramatsu K, 1997, J ANTIMICROB CHEMOTH, V40, P135, DOI 10.1093/jac/40.1.135; Ingerman M J, 1989, Infect Dis Clin North Am, V3, P641; ISAACMAN DJ, 1990, PEDIATR INFECT DIS J, V9, P274, DOI 10.1097/00006454-199004000-00010; JOHNSON S, 1992, ANN INTERN MED, V117, P297, DOI 10.7326/0003-4819-117-4-297; Jorgensen JH, 1997, INFECT DIS CLIN N AM, V11, P785, DOI 10.1016/S0891-5520(05)70390-1; KACICA MA, 1994, J PEDIATR-US, V125, P253, DOI 10.1016/S0022-3476(94)70207-1; KAPLAN AH, 1988, J CLIN MICROBIOL, V26, P1216, DOI 10.1128/JCM.26.6.1216-1218.1988; KARP JE, 1986, AM J MED, V81, P237, DOI 10.1016/0002-9343(86)90257-3; Kloos Wesley E., 1995, P282; KRUMHOLZ HM, 1990, ANN INTERN MED, V113, P723, DOI 10.7326/0003-4819-113-9-723_3; KRUMHOLZ HM, 1990, ANN INTERN MED, V113, P290, DOI 10.7326/0003-4819-113-4-290; LAM TY, 1991, PERITON DIALYSIS INT, V11, P281; LAMYA T, 1993, ACTA HAEMATOL-BASEL, V90, P109, DOI 10.1159/000204389; MOLLITT DL, 1985, PEDIATR INFECT DIS J, V4, P326, DOI 10.1097/00006454-198505000-00049; *NAT COMM CLIN LAB, 1997, NCCLS PUBL, V17; Newman GR, 1984, IMMUNOLABELLING ELEC, P53; NEWMAN LN, 1993, ADV PERIT D, V9, P217; NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195; PANLILIO AL, 1992, INFECT CONT HOSP EP, V13, P582; PETERSEN NJ, 1973, HEALTH LAB SCI, V10, P18; PIZZO PA, 1986, NEW ENGL J MED, V315, P552, DOI 10.1056/NEJM198608283150905; RANSON MR, 1990, J HOSP INFECT, V15, P95, DOI 10.1016/0195-6701(90)90025-J; RIIKONEN P, 1991, PEDIATR INFECT DIS J, V10, P918, DOI 10.1097/00006454-199112000-00008; RUBIN M, 1988, ANN INTERN MED, V108, P30, DOI 10.7326/0003-4819-108-1-30; SANYAL D, 1991, LANCET, V337, P54, DOI 10.1016/0140-6736(91)93375-J; SCHWALBE RS, 1987, NEW ENGL J MED, V316, P927, DOI 10.1056/NEJM198704093161507; SCHWARTZ C, 1990, J CLIN ONCOL, V8, P1591, DOI 10.1200/JCO.1990.8.9.1591; SERRY C, 1980, J THORAC CARDIOV SUR, V80, P861; SHENEP JL, 1988, NEW ENGL J MED, V319, P1053, DOI 10.1056/NEJM198810203191604; SHLAES DM, 1993, ANTIMICROB AGENTS CH, V37, P2432, DOI 10.1128/AAC.37.11.2432; Sieradzki K, 1997, J BACTERIOL, V179, P2557, DOI 10.1128/jb.179.8.2557-2566.1997; SPAFFORD PS, 1994, J PEDIATR-US, V125, P259, DOI 10.1016/S0022-3476(94)70208-X; STRAND CL, 1993, JAMA-J AM MED ASSOC, V269, P1004, DOI 10.1001/jama.269.8.1004; Tenover FC, 1998, J CLIN MICROBIOL, V36, P1020, DOI 10.1128/JCM.36.4.1020-1027.1998; Tenover FC, 1998, J CLIN MICROBIOL, V36, P2167, DOI 10.1128/JCM.36.7.2167-2167.1998; VEACH LA, 1990, J CLIN MICROBIOL, V28, P2064, DOI 10.1128/JCM.28.9.2064-2068.1990; Waldvogel FA, 1995, MANDELL DOUGLAS BENN, P1754; WEATHERS L, 1990, PEDIATR INFECT DIS J, V9, P220, DOI 10.1097/00006454-199003000-00017; 1997, MMWR MORB MORTAL WKL, V46, P635; 1997, MMWR MORB MORTAL WKL, V46, P624; 1997, MMWR MORB MORTAL WKL, V46, P626	66	831	880	0	108	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1999	340	7					493	501		10.1056/NEJM199902183400701	http://dx.doi.org/10.1056/NEJM199902183400701			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168FD	10021469				2022-12-28	WOS:000078680100001
J	Goldman, L				Goldman, L			The impact of hospitalists on medical education and the academic health system	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	National Policy Conference on the Hospitalist Movement	DEC 05-06, 1997	SAN FRANCISCO, CA				CARE; EXPERIENCE; OUTCOMES; AIDS; CARDIOLOGISTS; PHYSICIANS; MORTALITY; SPECIALTY; PATTERNS	Hospitalism as a career option is likely to reinforce the emphasis of traditional medical residency programs on inpatient care; may become an alternative area of emphasis in many subspecialty fellowship programs; and may even generate its own specific types of advanced training and certification. In the academic setting, subspecialists and their trainees are concerned that hospitalists may request fewer consultations, which could adversely affect subspecialists and the education of both fellows and residents. However, the focus and expertise of hospitalists is likely to improve inpatient education for students and residents and is appealing because it has the potential to improve the quality of inpatient care. Perhaps the major effect of the hospitalist movement on academic centers will be the creation of a cadre of physicians committed to critical pathways; clinical guidelines; quality assurance; risk management; clinical re-engineering; and the use of the inpatient service as a laboratory for developing, evaluating, and implementing initiatives to improve patient care. Although any fundamental change in the organization of clinical services brings with it the risk that essential components of the current system will be jeopardized, the hospitalist movement may have great benefits if it can develop safeguards to ensure seamless patient care and the appropriate use of subspecialty expertise.	Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Goldman, L (corresponding author), Univ Calif San Francisco, Sch Med, Dept Med, 505 Parnassus Ave, San Francisco, CA 94143 USA.							Ayanian JZ, 1997, ARCH INTERN MED, V157, P2570, DOI 10.1001/archinte.157.22.2570; BENNETT CL, 1992, J ACQ IMMUN DEF SYND, V5, P856; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; MACPHERSON DS, 1994, J GEN INTERN MED, V9, P440, DOI 10.1007/BF02599059; Manian FA, 1996, JAMA-J AM MED ASSOC, V275, P145; *MED LEAD COUNC, 1998, HOSP PROGR NEW PRACT; Nash IS, 1997, J AM COLL CARDIOL, V29, P475, DOI 10.1016/S0735-1097(96)00528-1; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; Quirk DM, 1997, GASTROENTEROLOGY, V113, P1443, DOI 10.1053/gast.1997.v113.pm9352845; Reis SE, 1997, J AM COLL CARDIOL, V30, P733, DOI 10.1016/S0735-1097(97)00214-3; SCHREIBER TL, 1995, J AM COLL CARDIOL, V26, P577, DOI 10.1016/0735-1097(95)00214-O; STONE VE, 1992, JAMA-J AM MED ASSOC, V268, P2655, DOI 10.1001/jama.268.19.2655; TURNER BJ, 1994, MED CARE, V32, P902, DOI 10.1097/00005650-199409000-00002; Wachter RM, 1998, JAMA-J AM MED ASSOC, V279, P1560, DOI 10.1001/jama.279.19.1560; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713; WARD MM, 1993, ARCH INTERN MED, V153, P2229, DOI 10.1001/archinte.153.19.2229	17	40	40	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	2				364	367		10.7326/0003-4819-130-4-199902161-00007	http://dx.doi.org/10.7326/0003-4819-130-4-199902161-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	166QB	10068407				2022-12-28	WOS:000078587500007
J	Greendale, GA; Reboussin, BA; Sie, A; Singh, HR; Olson, LK; Gatewood, O; Bassett, LW; Wasilauskas, C; Bush, T; Barrett-Connor, E				Greendale, GA; Reboussin, BA; Sie, A; Singh, HR; Olson, LK; Gatewood, O; Bassett, LW; Wasilauskas, C; Bush, T; Barrett-Connor, E		PEPI Investigators	Effects of estrogen and estrogen-progestin on mammographic parenchymal density	ANNALS OF INTERNAL MEDICINE			English	Article						progestational hormones; estrogens; estrogen replacement therapy; mammography; breast density	BREAST-CANCER RISK; HORMONAL REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; PATTERNS; CLASSIFICATION; FEATURES; HUMANS	Background: In longitudinal studies, greater mammographic density is associated with an increased risk for breast cancer. Objective: To assess differences between placebo, estrogen, and three estrogen-progestin regimens on change in mammographic density. Design: Subset analysis of a 3-year, multicenter, double-blind, randomized, placebo-controlled trial. Setting: Seven ambulatory study centers. Participants: 307 of the 875 women in the Postmenopausal Estrogen/Progestin Interventions Trial. Participants had a baseline mammogram and at least one follow-up mammogram available, adhered to treatment, had not taken estrogen for at least 5 years before baseline, and did not have breast implants. Intervention: Treatments were placebo, conjugated equine estrogens (CEE), CEE plus cyclic medroxyprogesterone acetate (MPA), CEE plus daily MPA, and CEE plus cyclic micronized progesterone (MP). Measurements: Change in radiographic density (according to American College of Radiology Breast Imaging Reporting and Data System grades) on mammography. Results: Almost all increases in mammographic density occurred within the first year. At 12 months, the percentage of women with density grade increases was 0% (95% CI, 0.0% to 4.6%) in the placebo group, 3.5% (CI, 1.0% to 12.0%) in the CEE group, 23.5% (CI, 11.9% to 35.1%) in the CEE plus cyclic MPA group, 19.4% (CI, 9.9% to 28.9%) in the CEE plus daily MPA group, and 16.4% (CI, 6.6% to 26.2%) in the CEE plus cyclic MP group. At 12 months, the odds of an increase in mammographic density were 13.1 (95% CI, 2.4 to 73.3) with CEE plus cyclic MPA, 9.0 (CI, 1.6 to 50.1) with CEE plus daily MPA, and 7.2 (CI, 1.3 to 40.0) with CEE plus cyclic micronized progesterone compared with CEE alone. Conclusions: Further study of the magnitude and meaning of increased mammographic density due to use of estrogen and estrogen-progestins is warranted because mammographic density may be a marker for risk for breast cancer.	Univ Calif Los Angeles, Sch Med, Div Geriatr, Los Angeles, CA 90095 USA; Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21287 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Wake Forest University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; University of California System; University of California San Diego	Greendale, GA (corresponding author), Univ Calif Los Angeles, Sch Med, Div Geriatr, 10945 Le Conte Ave,Suite 2339, Los Angeles, CA 90095 USA.		Reboussin, Beth/AAY-9778-2020	Reboussin, Beth/0000-0002-7318-9081	NHLBI NIH HHS [UL-HL40195, U01-HL40154, U01-HL40185] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL040154, U01HL040195, U01HL040185] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM COLL RAD, 1995, BREAST IM REP DAT SY; BARTOW SA, 1990, CANCER, V66, P1721, DOI 10.1002/1097-0142(19901015)66:8<1721::AID-CNCR2820660812>3.0.CO;2-I; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P503, DOI 10.1093/oxfordjournals.aje.a115364; Bergkvist L, 1996, EUR J SURG ONCOL, V22, P250, DOI 10.1016/S0748-7983(96)80012-6; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BERKOWITZ JE, 1990, RADIOLOGY, V174, P199, DOI 10.1148/radiology.174.1.2152982; BLAND KI, 1980, CANCER, V45, P3027, DOI 10.1002/1097-0142(19800615)45:12<3027::AID-CNCR2820451225>3.0.CO;2-2; BOYD NF, 1992, JNCI-J NATL CANCER I, V84, P1170, DOI 10.1093/jnci/84.15.1170; BOYD NF, 1995, J NATL CANCER I, V87, P670, DOI 10.1093/jnci/87.9.670; BOYD NF, 1986, J CHRON DIS, V39, P465, DOI 10.1016/0021-9681(86)90113-X; BRIGHT RA, 1988, CANCER, V61, P266, DOI 10.1002/1097-0142(19880115)61:2<266::AID-CNCR2820610212>3.0.CO;2-N; BRISSON J, 1988, J NATL CANCER I, V80, P1534, DOI 10.1093/jnci/80.19.1534; BRISSON J, 1982, AM J EPIDEMIOL, V115, P438, DOI 10.1093/oxfordjournals.aje.a113321; Byng JW, 1996, EUR J CANCER PREV, V5, P319, DOI 10.1097/00008469-199610000-00003; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; EGAN RL, 1977, CANCER, V40, P2087, DOI 10.1002/1097-0142(197711)40:5<2087::AID-CNCR2820400516>3.0.CO;2-3; ELMORE JG, 1994, NEW ENGL J MED, V331, P1493, DOI 10.1056/NEJM199412013312206; ESPELAND MA, 1995, CONTROL CLIN TRIALS, V16, pS3, DOI 10.1016/0197-2456(94)00033-Y; Ginsburg ES, 1996, JAMA-J AM MED ASSOC, V276, P1747, DOI 10.1001/jama.276.21.1747; GREENDALE GA, 1995, MENOPAUSE, V2, P27; INGLEBY H, 1960, COMP ANATOMY PATHOLO; KAUFMAN Z, 1991, CLIN RADIOL, V43, P389, DOI 10.1016/S0009-9260(05)80566-5; Key TJA, 1995, MUTAT RES-FUND MOL M, V333, P59, DOI 10.1016/0027-5107(95)00132-8; LAYA MB, 1995, RADIOLOGY, V196, P433, DOI 10.1148/radiology.196.2.7617857; MCNICHOLAS MMJ, 1994, AM J ROENTGENOL, V163, P311, DOI 10.2214/ajr.163.2.8037021; MICHNOVICZ JJ, 1990, ANN NY ACAD SCI, V595, P291, DOI 10.1111/j.1749-6632.1990.tb34303.x; OZA AM, 1993, EPIDEMIOL REV, V15, P196, DOI 10.1093/oxfordjournals.epirev.a036105; SAFTLAS AF, 1987, EPIDEMIOL REV, V9, P146, DOI 10.1093/oxfordjournals.epirev.a036300; SAFTLAS AF, 1991, CANCER, V67, P2833, DOI 10.1002/1097-0142(19910601)67:11<2833::AID-CNCR2820671121>3.0.CO;2-U; SPITZER RL, 1967, ARCH GEN PSYCHIAT, V17, P83; STOMPER PC, 1990, RADIOLOGY, V174, P487, DOI 10.1148/radiology.174.2.2136958; URBANSKI S, 1988, BRIT J CANCER, V58, P474, DOI 10.1038/bjc.1988.244; WARNER E, 1992, CANCER DETECT PREV, V16, P67; WOLFE JN, 1987, AM J ROENTGENOL, V148, P1087, DOI 10.2214/ajr.148.6.1087; WOLFE JN, 1976, AM J ROENTGENOL, V126, P1130, DOI 10.2214/ajr.126.6.1130; ZELEN M, 1971, BIOMETRIKA, V58, P129, DOI 10.1093/biomet/58.1.129	36	326	336	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	1				262	+		10.7326/0003-4819-130-4_Part_1-199902160-00003	http://dx.doi.org/10.7326/0003-4819-130-4_Part_1-199902160-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166PY	10068383				2022-12-28	WOS:000078587200002
J	Wulffraat, N; van Royen, A; Bierings, M; Vossen, J; Kuis, W				Wulffraat, N; van Royen, A; Bierings, M; Vossen, J; Kuis, W			Autologous haemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis	LANCET			English	Article							BONE-MARROW TRANSPLANTATION; RHEUMATOID-ARTHRITIS; FOLLOW-UP; AUTOIMMUNE-DISEASES; APLASTIC-ANEMIA; REMISSION; IRRADIATION; SCLEROSIS; CHILDREN; BLOOD	Background Autologous haemopoietic stem-cell transplantation (AHSCT) had been described as a possible treatment for severe autoimmune disease refractory to conventional treatment. We report the first four children with severe forms of juvenile chronic arthritis (JCA) treated with AHSCT. Methods We studied three children with systemic JCA and one child with polyarticular JCA. Unprimed bane marrow was taken 1 month before AHSCT. T-cell depletion of the graft was done with CD2 and CD3 antibodies. We used a preparative regimen of antithymocyte globulin (20 mg/kg), cyclophosphamide (200 mg/kg) and low-dose total body irradiation (4 Gy). Methotrexate and cyclosporin were stopped before AHCST, prednisone was tapered after 2 months. Findings Our patients showed a drug-free follow-up of 6-18 months with a marked decrease in joint swelling, pain, and morning stiffness. Erythocyte sedimentation rate, C-reactive protein, and haemoglobin returned to almost normal values within 6 weeks. Despite T-cell depletion there was a rapid immune reconstitution in three out of four children. Two patients developed a limited varicella tester virus eruption, which was treated by aciclovir. Interpretation AHSCT for severe JCA was well tolerated and induced a remission of disease in four children with JCA that was resistant to conventional treatment. Prolonged prednisane-free growth catch-up and general well-being is a major therapeutic gain in such children. The actual follow-up is too short, however, for us to conclude that these children are completely cured of their disease.	Univ Hosp Children Het Wilhelmina Kinderziekenhui, Dept Pediat Immunol & Haematol, NL-3501 CA Utrecht, Netherlands; Leiden Univ, Med Ctr, Dept Pediat, Leiden, Netherlands	Wilhelmina Kinderziekenhuis; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Wulffraat, N (corresponding author), Univ Hosp Children Het Wilhelmina Kinderziekenhui, Dept Pediat Immunol & Haematol, POB 18009, NL-3501 CA Utrecht, Netherlands.		Wulffraat, Nico M/AAE-8929-2020	Wulffraat, Nico M/0000-0001-9548-5562				ADACHI JD, 1987, SEMIN ARTHRITIS RHEU, V16, P287, DOI 10.1016/0049-0172(87)90006-0; BALDWIN JL, 1977, ARTHRITIS RHEUM, V20, P1043, DOI 10.1002/art.1780200502; BROOKS PM, 1995, J RHEUMATOL, V22, P1809; ClementDeBoers A, 1996, J PEDIATR-US, V129, P544; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; Euler HH, 1996, BLOOD, V88, P3621, DOI 10.1182/blood.V88.9.3621.bloodjournal8893621; Fassas A, 1997, BONE MARROW TRANSPL, V20, P631, DOI 10.1038/sj.bmt.1700944; Giannini EH, 1997, ARTHRITIS RHEUM, V40, P1202; GROM AA, 1994, ARTHRITIS RHEUM, V37, P601, DOI 10.1002/art.1780370501; JACOBS P, 1986, BONE MARROW TRANSPL, V1, P237; Joske DJL, 1997, LANCET, V350, P337, DOI 10.1016/S0140-6736(05)63388-0; KNAANSHANZER S, 1991, BONE MARROW TRANSPL, V8, P333; LOWENTHAL RM, 1993, J RHEUMATOL, V20, P137; MARMONT A, 1997, BONE MARROW TRANS S1, V19, pS206; McKendry RJR, 1996, ARTHRITIS RHEUM, V39, P1246, DOI 10.1002/art.1780390727; RADIS CD, 1995, ARTHRITIS RHEUM, V38, P1120, DOI 10.1002/art.1780380815; ROUBENOFF R, 1987, ARTHRITIS RHEUM, V30, P1187, DOI 10.1002/art.1780301017; Sanders JE, 1997, J PEDIATR-US, V130, P174; SLAPERCORTENBACH ICM, 1990, EXP HEMATOL, V18, P49; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; STONE RM, 1994, BLOOD, V83, P3437; Tyndall A, 1997, BRIT J RHEUMATOL, V36, P1; Tyndall A, 1997, LANCET, V349, P254, DOI 10.1016/S0140-6736(05)64864-7; Tyndall A, 1997, BONE MARROW TRANSPL, V19, P643, DOI 10.1038/sj.bmt.1700727; VANBEKKUM DW, 1989, P NATL ACAD SCI USA, V86, P1090; VIDARSSON B, 1995, AM J MED, V98, P589, DOI 10.1016/S0002-9343(99)80019-9; Westhovens R, 1997, ARTHRITIS RHEUM, V40, P426, DOI 10.1002/art.1780400306	27	107	109	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 13	1999	353	9152					550	553		10.1016/S0140-6736(98)05399-9	http://dx.doi.org/10.1016/S0140-6736(98)05399-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028984				2022-12-28	WOS:000078670200013
J	Behr, MA; Warren, SA; Salamon, H; Hopewell, PC; de Leon, AP; Daley, CL; Small, PM				Behr, MA; Warren, SA; Salamon, H; Hopewell, PC; de Leon, AP; Daley, CL; Small, PM			Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli	LANCET			English	Article							EPIDEMIOLOGY; DIAGNOSIS; IMPACT; HIV	Background The microscopic examination of sputum for acid-fast bacilli, is a simple and rapid test that is used to provide a presumptive diagnosis of infectious tuberculosis. While patients with tuberculosis with sputum smears negative for acid-fast bacilli are less infectious than those with positive smears, both theoretical and empirical evidence suggest that they can still transmit Mycobacterium tuberculosis. We aimed to estimate the risk of transmission from smear-negative individuals. Methods As part of an ongoing study of the molecular epidemiology of tuberculosis in San Francisco, patients with tuberculosis with mycobacterial isolates with the same DNA fingerprint were assigned to clusters that were assumed to have involved recent transmission. Secondary cases with tuberculosis, whose mycobacterial isolates had the same DNA, were linked to their presumed source case to estimate transmission from smear-negative patients. Sensitivity analyses were done to assess potential bias due to misclassification of source cases, unidentified source cases, and HIV-1 co-infection. Findings 1574 patients with culture-positive tuberculosis were reported and DNA fingerprints were available for 1359 (86%) of these patients. Of the 71 clusters of patients infected with strains that had matching fingerprints, 28 (39% [95% CI 28-52]) had a smear-negative putative source. There were 183 secondary cases in these 71 clusters, of whom a minimum of 32 were attributed to infection by smear-negative patients (17% [12-24]), The relative transmission rate of smear-negative compared with smear-positive patients was calculated as 0.22 (95% CI 0.16-0.32). Sensitivity analyses and stratification for HIV-1 status had no impact on these estimates. Interpretation In San Francisco, the acid-fast-bacilli smear identifies the most infectious patients, but patients with smear-negative culture-positive tuberculosis appear responsible for about 17% of tuberculosis transmission.	McGill Univ, Ctr Hlth, Dept Med, Div Infect Dis, Montreal, PQ, Canada; Stanford Univ, Sch Med, Dept Med, Div Infect Dis & Geog Med, Stanford, CA USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; San Francisco Gen Hosp, Div Pulm & Crit Care Med, San Francisco, CA 94110 USA; Inst Nacl Nutr Salvador Zubiran, Div Infect Dis, Mexico City 14000, DF, Mexico	McGill University; Stanford University; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico	Behr, MA (corresponding author), Montreal Gen Hosp, Div Infect Dis, Room A5-156, Montreal, PQ H3G 1A4, Canada.	marcel@molepi.stanford.edu	Daley, Charles L./AAC-3231-2021	Ponce-de-Leon, Alfredo/0000-0003-2640-2916; Salamon, Hugh/0000-0003-1472-5785	PHS HHS [A134238, A101137] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Behr MA, 1998, AM J RESP CRIT CARE, V158, P465, DOI 10.1164/ajrccm.158.2.9801062; Braden CR, 1997, CLIN INFECT DIS, V24, P35, DOI 10.1093/clinids/24.1.35; Bradford WZ, 1998, J INFECT DIS, V177, P1104, DOI 10.1086/517405; Burman WJ, 1997, AM J RESP CRIT CARE, V155, P1140, DOI 10.1164/ajrccm.155.3.9117000; Casper C, 1996, AM J PUBLIC HEALTH, V86, P551, DOI 10.2105/AJPH.86.4.551; CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P15; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; Chin DP, 1998, AM J RESP CRIT CARE, V158, P1797, DOI 10.1164/ajrccm.158.6.9804029; DANIEL WW, 1991, BIOSTATISTICS FDN AN, P589; ELLIOTT AM, 1993, TUBERCLE LUNG DIS, V74, P191, DOI 10.1016/0962-8479(93)90010-U; ENARSON DA, 1996, TUBERCULOSIS GUIDE L, P5; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; HERTZBERG GERH, 1957, AN EPIDEMIOLOGICAL INVESTIGATION ACTA TUBERC SCAND SUPPL, V38, P1; HOBBY GL, 1973, ANTIMICROB AGENTS CH, V4, P954; HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540; JACOBSEN E, 1994, J HOSP INFECT, V30, P75; JOHNSTON RF, 1974, AM REV RESPIR DIS, V109, P636; LINCOLN EDITH M., 1965, ADVANCES TUBERC RES, V14, P157; LONG R, 1991, AM J PUBLIC HEALTH, V81, P1326, DOI 10.2105/AJPH.81.10.1326; LOUDON RG, 1958, AM REV TUBERC PULM, V77, P623; McPhedran FM, 1935, AM J HYG, V22, P565, DOI 10.1093/oxfordjournals.aje.a118191; MIETTINEN OS, 1985, THEORETICAL EPIDEMIO, P114; *NAT TUB I, 1974, B WORLD HEALTH ORGAN, V51, P473; RILEY RL, 1959, AM J HYG, V70, P185, DOI 10.1093/oxfordjournals.aje.a120069; ROUILLON A, 1976, TUBERCLE, V57, P275, DOI 10.1016/S0041-3879(76)80006-2; SHAW JB, 1954, AM REV TUBERC PULM, V69, P724; SKINNER C, 1990, BRIT MED J, V300, P995; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; STRUMPF IJ, 1979, AM REV RESPIR DIS, V119, P599; van Geuns H A, 1975, Bull Int Union Tuberc, V50, P107; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VANZWANENBERG D, 1960, AM REV RESPIR DIS, V82, P31; Vidal R, 1997, MED CLIN-BARCELONA, V108, P361; YEAGER H, 1967, AM REV RESPIR DIS, V95, P998	37	569	589	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 6	1999	353	9151					444	449		10.1016/S0140-6736(98)03406-0	http://dx.doi.org/10.1016/S0140-6736(98)03406-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JQ	9989714				2022-12-28	WOS:000078572800010
J	Cleare, AJ; Heap, E; Malhi, GS; Wessely, S; O'Keane, V; Miell, J				Cleare, AJ; Heap, E; Malhi, GS; Wessely, S; O'Keane, V; Miell, J			Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial	LANCET			English	Article							COGNITIVE-BEHAVIOR THERAPY; DYSFUNCTION	Background Reports of mild hypocortisolism in chronic fatigue syndrome led us to postulate that tow-dose hydrocortisone therapy may be an effective treatment. Methods In a randomised crossover trial, we screened 218 patients with chronic fatigue. 32 patients met our strict criteria for chronic fatigue syndrome without co-morbid psychiatric disorder. The eligible patients received consecutive treatment with low-dose hydrocortisone (5 mg or 10 mg daily) for 1 month and placebo for 1 month;the order of treatment was randomly assigned. Analysis was by intention to treat. Findings None of the patients dropped out. Compared with the baseline self-reported fatigue scores (mean 25.1 points), the score fell by 7.2 points for patients on hydrocortisone and by 3.3 points for those on placebo (paired difference in mean scores 4.5 points [95% CI 1.2-7.7], p = 0.009). In nine (28%) of the 32 patients on hydrocortisone, fatigue scores reached a predefined cut-off value similar to the normal population score, con;pared with three (9%) of the 32 on placebo (Fisher's exact test p = 0.05). The degree of disability was reduced with hydrocortisone treatment, but not with placebo. Insulin stress tests showed that endogenous adrenal function was not suppressed by hydrocortisone. Minor side-effects were reported by three patients after hydrocortisone treatment and by one patient after placebo. Interpretation In some patients with chronic fatigue syndrome, low-dose hydrocortisone reduces fatigue levels in the short term. Treatment for a longer time and follow-up studies are needed to find out whether this effect could be clinically useful.	Guys Kings & St Thomas Sch Med, Dept Psychol Med, London SE5 8AF, England; Guys Kings & St Thomas Sch Med, Dept Med, London SE5 8AF, England; Inst Psychiat, London SE5 8AF, England; Addenbrookes NHS Trust, Cambridge CB2 2QQ, England	University of London; King's College London; University of London; King's College London; University of London; King's College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital	Cleare, AJ (corresponding author), Guys Kings & St Thomas Sch Med, Dept Psychol Med, London SE5 8AF, England.		Malhi, Gin/Z-2418-2019; Wessely, Simon C/A-8713-2008; Cleare, Anthony J/B-4506-2008; Cleare, Anthony/AAN-5418-2021	o'keane, veronica/0000-0002-1519-099X; Wessely, Simon Charles/0000-0002-6743-9929				BARRON JL, 1985, J CLIN ENDOCR METAB, V60, P803, DOI 10.1210/jcem-60-4-803; BESSER M, 1995, BARTS ENDOCRINE PROT; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; CLEARE AJ, 1995, J AFFECT DISORDERS, V35, P283; DAVID AS, 1991, BRIT MED BULL, V47, P966, DOI 10.1093/oxfordjournals.bmb.a072524; Deale A, 1997, AM J PSYCHIAT, V154, P408; DEMITRACK MA, 1991, J CLIN ENDOCR METAB, V73, P1224, DOI 10.1210/jcem-73-6-1224; DINAN TG, 1994, BRIT J PSYCHIAT, V164, P365, DOI 10.1192/bjp.164.3.365; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Fulcher KY, 1997, BRIT MED J, V314, P1647, DOI 10.1136/bmj.314.7095.1647; Guy W., 1976, ECDEU ASSESSMENT MAN, VRev; Howlett TA, 1997, CLIN ENDOCRINOL, V46, P263, DOI 10.1046/j.1365-2265.1997.1340955.x; Leese G, 1996, J CLIN ENDOCR METAB, V81, P1867, DOI 10.1210/jc.81.5.1867; Lehmann M, 1992, Br J Sports Med, V26, P233; McKenzie R, 1998, JAMA-J AM MED ASSOC, V280, P1061, DOI 10.1001/jama.280.12.1061; Scott LV, 1998, J AFFECT DISORDERS, V47, P49, DOI 10.1016/S0165-0327(97)00101-8; Sharpe M, 1997, GEN HOSP PSYCHIAT, V19, P185, DOI 10.1016/S0163-8343(97)80315-5; Sharpe M, 1996, BRIT MED J, V312, P22, DOI 10.1136/bmj.312.7022.22; SHARPE M, 1997, PHYSICIANS HDB MIND, P169; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; Tanaka H, 1997, J CLIN ENDOCR METAB, V82, P1440, DOI 10.1210/jc.82.5.1440; Vercoulen JHMM, 1996, LANCET, V347, P858, DOI 10.1016/S0140-6736(96)91345-8; Vercoulen JHMM, 1996, J NEUROL NEUROSUR PS, V60, P489, DOI 10.1136/jnnp.60.5.489; Wearden AJ, 1998, BRIT J PSYCHIAT, V172, P485, DOI 10.1192/bjp.172.6.485; Wessely S, 1997, AM J PUBLIC HEALTH, V87, P1449, DOI 10.2105/AJPH.87.9.1449; WILSON A, 1994, BRIT MED J, V308, P756, DOI 10.1136/bmj.308.6931.756; WITTENBORN JR, 1979, ARCH GEN PSYCHIAT, V36, P465; [No title captured]	28	156	160	1	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 6	1999	353	9151					455	458		10.1016/S0140-6736(98)04074-4	http://dx.doi.org/10.1016/S0140-6736(98)04074-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	166JQ	9989716				2022-12-28	WOS:000078572800012
J	Dwyer, C				Dwyer, C			Ideas and trends: Medical informatics and health care computing	ANNALS OF INTERNAL MEDICINE			English	Article																			0	2	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	1999	130	2					170	172		10.7326/0003-4819-130-2-199901190-00102	http://dx.doi.org/10.7326/0003-4819-130-2-199901190-00102			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158KG	10068379				2022-12-28	WOS:000078114200029
J	Hasdai, D; Lerman, A; Grill, DE; Rihal, CS; Holmes, DR				Hasdai, D; Lerman, A; Grill, DE; Rihal, CS; Holmes, DR			Medical therapy after successful percutaneous coronary revascularization	ANNALS OF INTERNAL MEDICINE			English	Article						angioplasty, transluminal percutaneous coronary; angina pectoris; calcium channel blockers; adrenergic beta-antagonists; nitrates	TERM FOLLOW-UP; SINGLE-VESSEL; ARTERY DISEASE; RANDOMIZED TRIAL; ANGINA-PECTORIS; ANGIOPLASTY; WITHDRAWAL; SURVIVAL; ISCHEMIA; OUTCOMES	Background: Percutaneous coronary revascularization frequently relieves angina in patients with ischemic heart disease and may obviate the need for antianginal medications. Objective: To examine the use of antianginal medications after successful percutaneous coronary revascularization. Design: Retrospective cohort study of the Mayo Clinic PTCA [percutaneous transluminal coronary angioplasty] Registry. Setting: Tertiary care center. Patients: 3831 patients who underwent successful percutaneous coronary revascularization from September 1979 through August 1997 and had not had myocardial infarction within the year before the intervention. Measurements: Use of antianginal medications (beta-adrenergic blockers, nitrates, and calcium-channel blockers) before the intervention, at hospital discharge, and 6 months after the intervention. Results: 99% of patients reported improvement in their symptoms at hospital discharge. At 6 months, 87% of patients were free of myocardial infarction, coronary bypass surgery, or additional percutaneous intervention. Co mpa red with 66% of patients before the index intervention, only 12% of patients had severe angina at 6 months and 69% were completely free of angina. Nonetheless, at 6 months, 39% of patients were receiving beta-adrenergic blockers (preprocedure proportion, 43%; P < 0.001), 36% were receiving nitrates (preprocedure proportion, 41%; P < 0.001), and 57% were receiving calcium-channel blockers (preprocedure proportion, 50%; P < 0.001). These trends persisted for patients without hypertension and those who had complete revascularization. Conclusions: Successful percutaneous coronary revascularization did not substantially supplant the use of antianginal medications, which were commonly used despite the marked improvement in anginal status. This may reflect reluctance to alter therapy once symptoms of angina subside. Guidelines on continued medical therapy after percutaneous coronary revascularization are needed.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, Rochester, MN 55905 USA	Mayo Clinic	Holmes, DR (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, 200 1st St SW, Rochester, MN 55905 USA.	holmes.david@mayo.edu						BELL MR, 1990, J AM COLL CARDIOL, V16, P553, DOI 10.1016/0735-1097(90)90342-M; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; BOURASSA MG, 1989, EUR HEART J, V10, P36, DOI 10.1093/eurheartj/10.suppl_G.36; Braunwald E, 1994, AHCPR PUBLICATION, V94-0602, P1; BRITTEN N, 1995, J CLIN PHARM THER, V20, P199, DOI 10.1111/j.1365-2710.1995.tb00649.x; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; Chamberlain DA, 1997, LANCET, V350, P461; COHEN DJ, 1994, CIRCULATION, V89, P1859, DOI 10.1161/01.CIR.89.4.1859; Davies RF, 1997, CIRCULATION, V95, P2037, DOI 10.1161/01.CIR.95.8.2037; Folland ED, 1997, J AM COLL CARDIOL, V29, P1505, DOI 10.1016/S0735-1097(97)00097-1; GERSH BJ, 1997, HEART DIS TXB CARDIO, P1289; GRUNTZIG A, 1978, LANCET, V1, P263, DOI 10.1016/s0140-6736(78)90500-7; Hasdai D, 1997, NEW ENGL J MED, V336, P755, DOI 10.1056/NEJM199703133361103; Hasdai D, 1997, ARCH INTERN MED, V157, P677, DOI 10.1001/archinte.157.6.677; Hasdai D, 1997, AM J CARDIOL, V79, P1005, DOI 10.1016/S0002-9149(97)00038-6; HENDERSON RA, 1992, EUR HEART J, V13, P781, DOI 10.1093/oxfordjournals.eurheartj.a060256; HILLEMAN DE, 1994, CLIN THER, V16, P88; HOLMES DR, 1987, PERCUTANEOUS TRANSLU, P35; HUEB WA, 1995, J AM COLL CARDIOL, V26, P1600, DOI 10.1016/0735-1097(95)00384-3; JOHANSSON SR, 1990, AM J CARDIOL, V66, P915, DOI 10.1016/0002-9149(90)90925-Q; KADEL C, 1992, AM HEART J, V124, P1159, DOI 10.1016/0002-8703(92)90395-C; King SB, 1993, J AM COLL CARDIOL, V22, P353, DOI 10.1016/0735-1097(93)90037-2; MILLER RR, 1975, NEW ENGL J MED, V293, P416, DOI 10.1056/NEJM197508282930902; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PRZYBOJEWSKI JZ, 1983, S AFR MED J, V64, P101; RYAN TJ, 1993, CIRCULATION, V88, P2987, DOI 10.1161/01.CIR.88.6.2987; Vahanian A, 1996, DRUGS, V52, P9, DOI 10.2165/00003495-199600524-00005; vanHout BA, 1995, EUR HEART J, V16, P81, DOI 10.1093/eurheartj/16.suppl_L.81; WARNER MF, 1992, AM HEART J, V124, P1169, DOI 10.1016/0002-8703(92)90396-D; WEINTRAUB WS, 1995, J AM COLL CARDIOL, V26, P142, DOI 10.1016/0735-1097(95)00136-N; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	31	14	18	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	1999	130	2					108	+		10.7326/0003-4819-130-2-199901190-00004	http://dx.doi.org/10.7326/0003-4819-130-2-199901190-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158KG	10068356				2022-12-28	WOS:000078114200003
J	Harries, AD; Salaniponi, FM; Kwanjana, JH				Harries, AD; Salaniponi, FM; Kwanjana, JH			Directly observed treatment for tuberculosis	LANCET			English	Letter									Minist Hlth & Populat, Natl TB Control Programme, Lilongwe, Malawi		Harries, AD (corresponding author), Minist Hlth & Populat, Natl TB Control Programme, Lilongwe, Malawi.							Garner P, 1998, LANCET, V352, P1326, DOI 10.1016/S0140-6736(05)60739-8; Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7	2	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 9	1999	353	9147					146	147		10.1016/S0140-6736(05)76182-1	http://dx.doi.org/10.1016/S0140-6736(05)76182-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023921				2022-12-28	WOS:000078087200049
J	Nykjaer, A; Dragun, D; Walther, D; Vorum, H; Jacobsen, C; Herz, J; Melsen, F; Christensen, EI; Willnow, TE				Nykjaer, A; Dragun, D; Walther, D; Vorum, H; Jacobsen, C; Herz, J; Melsen, F; Christensen, EI; Willnow, TE			An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D-3	CELL			English	Article							D-BINDING-PROTEIN; MEDIATED ENDOCYTOSIS; RECEPTOR; GP330; SERUM; 1,25-DIHYDROXYVITAMIN-D; COMPLEXES; HORMONE; MEGALIN; CELLS	Steroid hormones may enter cells by diffusion through the plasma membrane. However, we demonstrate here that some steroid hormones are taken up by receptor-mediated endocytosis of steroid-carrier complexes. We show that 25-(OH) vitamin D-3 in complex with its plasma carrier, the vitamin D-binding protein, is filtered through the glomerulus and reabsorbed in the proximal tubules by the endocytic receptor megalin. Endocytosis is required to preserve 25-(OH) vitamin D-3 and to deliver to the cells the precursor for generation of 1,25-(OH)(2) Vitamin D-3, a regulator of the calcium metabolism. Megalin(-/-) mice are unable to retrieve the steroid from the glomerular filtrate and develop vitamin D deficiency and bone disease.	Max Delbrueck Ctr Mol Med, D-13125 Berlin, Germany; Franz Volhard Clin, D-13125 Berlin, Germany; Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus, Denmark; Aarhus Univ, Dept Cell Biol, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, Dept Pathol, DK-8000 Aarhus, Denmark; Univ Texas, SW Med Ctr, Dallas, TX 75235 USA	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Franz-Volhard Clinical Research Center; Aarhus University; Aarhus University; Aarhus University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Willnow, TE (corresponding author), Max Delbrueck Ctr Mol Med, D-13125 Berlin, Germany.			Dragun, Duska/0000-0002-0310-9269; Willnow, Thomas/0000-0001-9515-7921; Nykjaer, Anders/0000-0001-6422-6736	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R37HL063762] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL063762, HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIKLE DD, 1985, J CLIN ENDOCR METAB, V61, P969, DOI 10.1210/jcem-61-5-969; BIKLE DD, 1986, J CLIN ENDOCR METAB, V63, P954, DOI 10.1210/jcem-63-4-954; CHRISTENSEN EI, 1995, EUR J CELL BIOL, V66, P349; COOKE NE, 1997, VITAMIN D, P105; HADDAD JG, 1981, J CLIN INVEST, V67, P1550, DOI 10.1172/JCI110186; HADDAD JG, 1995, J STEROID BIOCHEM, V53, P1; Harrison HE, 1953, J CHRON DIS, V7, P346; KEENAN MJ, 1991, INT J BIOCHEM, V23, P1225, DOI 10.1016/0020-711X(91)90220-H; MENDEL CM, 1989, ENDOCR REV, V10, P232, DOI 10.1210/edrv-10-3-232; MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176; Moestrup SK, 1998, J CLIN INVEST, V102, P902, DOI 10.1172/JCI3772; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; OMDAHL JL, 1980, J BIOL CHEM, V255, P7460; PORTO CS, 1991, ENDOCRINOLOGY, V129, P436, DOI 10.1210/endo-129-1-436; PORTO CS, 1995, J STEROID BIOCH MOL, V53, P1; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SIITERI PK, 1986, CLIN ENDOCRINOL META, V15, P247, DOI 10.1016/S0300-595X(86)80023-8; SIITERI PK, 1982, RECENT PROG HORM RES, V38, P457; STEFANSSON S, 1995, J CELL SCI, V108, P2361; STJOHN A, 1992, NEPHRON, V61, P422; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; TERANISHI H, 1983, TOXICOL LETT, V15, P7; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YANG F, 1990, GENOMICS, V7, P509, DOI 10.1016/0888-7543(90)90193-X	25	754	785	0	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 19	1999	96	4					507	515		10.1016/S0092-8674(00)80655-8	http://dx.doi.org/10.1016/S0092-8674(00)80655-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	168XN	10052453	Bronze			2022-12-28	WOS:000078718600002
J	Malin, MC; Carr, MH				Malin, MC; Carr, MH			Groundwater formation of martian valleys	NATURE			English	Article							MARS; MORPHOLOGY; CHANNELS; ORIGIN	The martian surface shows large outflow channels, widely accepted as having been formed by gigantic floods that could have occurred under climatic conditions like those seen today(1-5). Also present are branching valley networks that commonly have tributaries(1-8). These valleys are much smaller than the outflow channels and their origins and ages have been controversial. For example, they might have formed through slow erosion by water running across the surface, either early or late in Mars' history(9-13), possibly protected from harsh conditions by ice cover(14-16). Alternatively, they might have formed through groundwater or ground-ice processes that undermine the surface and cause collapse, again either early or late in Mars' history(3,4). Long-duration surface runoff would imply climatic conditions quite different from the present environment. Here we present high-resolution images of martian valleys that support the view that ground water played an important role in their formation, although we are unable as yet to establish when this occurred.	Malin Space Sci Syst, San Diego, CA 92191 USA; US Geol Survey, Menlo Pk, CA 94025 USA	United States Department of the Interior; United States Geological Survey	Malin, MC (corresponding author), Malin Space Sci Syst, POB 910148, San Diego, CA 92191 USA.	malin@mss.com						[Anonymous], 1983, GEOL SOC AM BULL, V94, P1035; BAKER VR, 1974, ICARUS, V23, P27, DOI 10.1016/0019-1035(74)90101-8; BAKER VR, 1991, NATURE, V352, P589, DOI 10.1038/352589a0; BAKER VR, 1986, J GEOPHYS RES-SOLID, V91, P3561, DOI 10.1029/JB091iB03p03561; BAKER VR, 1982, CHANNELS VALLEYS MAR; BRAKENRIDGE GR, 1985, GEOLOGY, V13, P859, DOI 10.1130/0091-7613(1985)13<859:AHSOMO>2.0.CO;2; CARR MH, 1983, ICARUS, V56, P476, DOI 10.1016/0019-1035(83)90168-9; CARR MH, 1979, J GEOPHYS RES, V84, P2995, DOI 10.1029/JB084iB06p02995; CARR MH, 1995, J GEOPHYS RES-PLANET, V100, P7479, DOI 10.1029/95JE00260; CARR MH, 1992, WATER MARS; CRADDOCK RA, 1993, J GEOPHYS RES-PLANET, V98, P3453, DOI 10.1029/92JE02508; GOLDSPIEL JM, 1993, ICARUS, V105, P479, DOI 10.1006/icar.1993.1143; Gulick VC, 1997, ICARUS, V130, P68, DOI 10.1006/icar.1997.5802; GULICK VC, 1989, NATURE, V341, P514, DOI 10.1038/341514a0; Gulick VC, 1998, J GEOPHYS RES-PLANET, V103, P19365, DOI 10.1029/98JE01321; KRINSLEY D, 1979, ICARUS, V39, P364, DOI 10.1016/0019-1035(79)90147-7; Malin MC, 1998, SCIENCE, V279, P1681, DOI 10.1126/science.279.5357.1681; Masursky H., 1977, Journal of Geophysical Research, V82, P4016, DOI 10.1029/JS082i028p04016; NEWSOM HE, 1980, ICARUS, V44, P207, DOI 10.1016/0019-1035(80)90066-4; PIERI DC, 1980, SCIENCE, V210, P895, DOI 10.1126/science.210.4472.895; SHARP RP, 1975, GEOL SOC AM BULL, V86, P593, DOI 10.1130/0016-7606(1975)86<593:COM>2.0.CO;2; SODERBLOM LA, 1974, ICARUS, V22, P239, DOI 10.1016/0019-1035(74)90175-4; SQUYRES SW, 1994, SCIENCE, V265, P744, DOI 10.1126/science.265.5173.744; WALLACE D, 1979, ICARUS, V39, P385, DOI 10.1016/0019-1035(79)90148-9; [No title captured]	25	125	127	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 18	1999	397	6720					589	591		10.1038/17551	http://dx.doi.org/10.1038/17551			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GE	10050852				2022-12-28	WOS:000078738500041
J	Herxheimer, A				Herxheimer, A			Secret out-of-court settlements in drug-injury cases	LANCET			English	Editorial Material											Herxheimer, A (corresponding author), 9 Pk Crescent, London N3 2NL, England.							Herxheimer A, 1996, Int J Risk Saf Med, V9, P201, DOI 10.3233/JRS-1996-9311; 1998, GEN MED COUNCIL  WIN, P7	2	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 13	1999	353	9152					517	518		10.1016/S0140-6736(99)00042-2	http://dx.doi.org/10.1016/S0140-6736(99)00042-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028977				2022-12-28	WOS:000078670200006
J	Montgomery, H; Clarkson, P; Barnard, M; Bell, J; Brynes, A; Dollery, C; Hajnal, J; Hemingway, H; Mercer, D; Jarman, P; Marshall, R; Prasad, K; Rayson, M; Saeed, N; Talmud, P; Thomas, L; Jubb, M; World, M; Humphries, S				Montgomery, H; Clarkson, P; Barnard, M; Bell, J; Brynes, A; Dollery, C; Hajnal, J; Hemingway, H; Mercer, D; Jarman, P; Marshall, R; Prasad, K; Rayson, M; Saeed, N; Talmud, P; Thomas, L; Jubb, M; World, M; Humphries, S			Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training	LANCET			English	Article							CHRONIC HEART-FAILURE; INSULIN-RESISTANCE; BODY-COMPOSITION; MUSCLE; RAT; BRADYKININ; METABOLISM; INDIVIDUALS; KALLIKREIN; TRANSPORT	Background The function of local renin-angiotensin systems in skeletal muscle and adipose tissue remains largely unknown. A polymorphism of the human angiotensin converting enzyme (ACE) gene has been identified in which the insertion (I) rather than deletion (D) allele is associated with lower ACE activity in body tissues and increased response to some aspects of physical training. We studied the association between the ACE gene insertion or deletion polymorphism and changes in body composition related to an intensive exercise programme, to investigate the metabolic effects of local human renin-angiotensin systems. Methods We used three independent methods (bioimpedance, multiple skinfold-thickness assessment of whole-body composition, magnetic resonance imaging of the mid-thigh) to study changes in body composition in young male army recruits over 10 weeks of intensive physical training. Findings Participants with the II genotype had a greater anabolic response than those with one or more D alleles for fat mass (0.55 vs -0.20 kg, p=0.04 by bioimpedance) and non-fat mass (1.31 vs -0.15 kg, p=0.01 by bioimpedance). Changes in body morphology with training measured by the other methods were also dependent on genotype. Interpretation II genotype, as a marker of low ACE activity in body tissues, may conserve a positive energy balance during rigorous training, which suggests enhanced metabolic efficiency. This finding may explain some of the survival and functional benefits of therapy with ACE inhibitors.	UCL, UCH, Rayne Inst, Ctr Cardiovasc Genet, London WC1E 6JJ, England; UCL Hosp, London, England; Imperial Coll, Sch Med, MRI Unit, London, England; Imperial Coll, Sch Med, Nutr & Dietet Dept, London, England; UCL, Dept Epidemiol & Publ Hlth, London, England; DERA, Ctr Human Sci, Farnborough, Hants, England; UCL, Dept Pulm Biochem, London, England; St George Hosp, Dept Cardiol, London, England; Optimal Performance Ltd, Farnham, Surrey, England; Royal Def Med Coll, HMS Dolphin, Hants, England	University of London; King's College London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; Imperial College London; Imperial College London; University of London; University College London; University of London; University College London; St Georges University London	Montgomery, H (corresponding author), UCL, UCH, Rayne Inst, Ctr Cardiovasc Genet, Univ St, London WC1E 6JJ, England.	h.montgomery@ucl.ac.uk	Montgomery, Hugh/L-1229-2019; Thomas, Elizabeth Louise/AIF-0055-2022; Hemingway, Harry/C-1219-2009; Talmud, Philippa J/C-4402-2008; Montgomery, Hugh/C-2592-2008	Hemingway, Harry/0000-0003-2279-0624; Bell, Jimmy/0000-0003-3804-1281; Thomas, Elizabeth/0000-0003-4235-4694; Talmud, Philippa/0000-0002-5560-1933; Montgomery, Hugh/0000-0001-8797-5019; Jubb, Michael/0000-0001-5639-473X				Anker SD, 1997, LANCET, V349, P1050, DOI 10.1016/S0140-6736(96)07015-8; Anker SD, 1997, CIRCULATION, V96, P526; BALL SG, 1993, LANCET, V342, P821; BLOOM SR, 1976, J PHYSIOL-LONDON, V258, P1; BOLLA MK, 1995, CLIN CHEM, V41, P1599; Brink M, 1996, J CLIN INVEST, V97, P2509, DOI 10.1172/JCI118698; BUNNEMANN B, 1992, J CARDIOVASC PHARM, V19, pS51, DOI 10.1097/00005344-199219006-00010; CAMPBELL DJ, 1993, HYPERTENSION, V21, P155, DOI 10.1161/01.HYP.21.2.155; CARRETERO O, 1965, EXPERIENTIA, V21, P141, DOI 10.1007/BF02141980; DANSER AHJ, 1995, CIRCULATION, V92, P1387, DOI 10.1161/01.CIR.92.6.1387; DIETZE G, 1980, AGENTS ACTIONS, V10, P335, DOI 10.1007/BF01971435; Dragovic T, 1996, DIABETES, V45, pS34, DOI 10.2337/diab.45.1.S34; DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060; DZAU VJ, 1988, CIRCULATION, V77, P1; Ghosh S, 1997, EUR J GASTROEN HEPAT, V9, P783, DOI 10.1097/00042737-199708000-00009; GOLDMAN J, 1987, MOL CELL ENDOCRINOL, V50, P183, DOI 10.1016/0303-7207(87)90016-5; Gutin B, 1996, AM J CLIN NUTR, V63, P287, DOI 10.1093/ajcn/63.3.287; Hennes MMI, 1996, HYPERTENSION, V28, P120, DOI 10.1161/01.HYP.28.1.120; HENRIKSEN EJ, 1995, METABOLISM, V44, P267, DOI 10.1016/0026-0495(95)90276-7; Hespel P, 1996, DIABETES, V45, pS99, DOI 10.2337/diab.45.1.S99; JAUCH KW, 1988, METABOLISM, V37, P185, DOI 10.1016/S0026-0495(98)90016-6; Jones BH, 1997, AM J PHYSIOL-REG I, V273, pR236, DOI 10.1152/ajpregu.1997.273.1.R236; Jonsson J R, 1994, Blood Press, V3, P72; KATSUYA T, 1995, ARTERIOSCL THROM VAS, V15, P779, DOI 10.1161/01.ATV.15.6.779; KEM DC, 1990, NEW ENGL J MED, V323, P1136, DOI 10.1056/NEJM199010183231609; Laycock SK, 1998, CIRC RES, V82, P1263, DOI 10.1161/01.RES.82.12.1263; LEVENS NR, 1986, J CARDIOVASC PHARM, V8, pS17, DOI 10.1097/00005344-198600101-00005; Linz W, 1996, DIABETES, V45, pS51, DOI 10.2337/diab.45.1.S51; MCKENZIE CA, 1995, AM J HUM GENET, V57, P1426; MESSERLI FH, 1977, CIRC RES, V40, P204, DOI 10.1161/01.RES.40.2.204; Montgomery HE, 1997, CIRCULATION, V96, P741; Montgomery HE, 1998, NATURE, V393, P221, DOI 10.1038/30374; Rabito SF, 1996, DIABETES, V45, pS29, DOI 10.2337/diab.45.1.S29; Reisenleiter F, 1996, EUR J GASTROEN HEPAT, V8, P279, DOI 10.1097/00042737-199603000-00017; RENNIE MJ, 1976, BIOCHEM J, V156, P647, DOI 10.1042/bj1560647; Rossetti L, 1997, J CLIN INVEST, V100, P1831, DOI 10.1172/JCI119711; *SAS I, 1990, SAS US GUID; SCHIEFFER B, 1995, AM J PHYSIOL-HEART C, V269, pH1507, DOI 10.1152/ajpheart.1995.269.5.H1507; SENN S, 1991, STAT MED, V10, P1157; TOWNSEND RR, 1993, AM J PHYSIOL, V265, pE362, DOI 10.1152/ajpendo.1993.265.3.E362; WASSERMAN DH, 1986, BIOCH EXERCISE, V6, P167; WICKLMAYR M, 1980, AGENTS ACTIONS, V10, P339, DOI 10.1007/BF01971436; Wolin MS, 1997, BIOCHEM SOC T, V25, P934, DOI 10.1042/bst0250934; Zhang XP, 1997, CIRCULATION, V95, P176, DOI 10.1161/01.CIR.95.1.176	44	175	187	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 13	1999	353	9152					541	545		10.1016/S0140-6736(98)07131-1	http://dx.doi.org/10.1016/S0140-6736(98)07131-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028982				2022-12-28	WOS:000078670200011
J	Litwin, MS				Litwin, MS			Urology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Litwin, MS (corresponding author), Univ Calif Los Angeles, Dept Urol, Box 951738, Los Angeles, CA 90095 USA.	mlitwin@ucla.edu		Litwin, Mark/0000-0002-2318-344X				Albertsen PC, 1998, JAMA-J AM MED ASSOC, V280, P975, DOI 10.1001/jama.280.11.975; D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969; Eisenberger MA, 1998, NEW ENGL J MED, V339, P1036, DOI 10.1056/NEJM199810083391504; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Gueugniaud PY, 1998, NEW ENGL J MED, V339, P1595, DOI 10.1056/NEJM199811263392204; Jacobsen SJ, 1998, UROLOGY, V52, P173, DOI 10.1016/S0090-4295(98)00171-X; Lander J, 1997, JAMA-J AM MED ASSOC, V278, P2157, DOI 10.1001/jama.278.24.2157; Lepor H, 1996, NEW ENGL J MED, V335, P533, DOI 10.1056/NEJM199608223350801; McConnell JD, 1998, NEW ENGL J MED, V338, P557, DOI 10.1056/NEJM199802263380901; Mettlin CJ, 1998, CANCER, V82, P249, DOI 10.1002/(SICI)1097-0142(19980115)82:2<249::AID-CNCR1>3.0.CO;2-M; Mettlin CJ, 1998, CANCER, V82, P1802, DOI 10.1002/1097-0142(19980501)82:9<1802::AID-CNCR34>3.0.CO;2-H; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; *SURV EP END RES, 1997, J NATL CANCER I, V89, P12; Wasson JH, 1998, NEW ENGL J MED, V338, P612, DOI 10.1056/NEJM199802263380909; Wilt TJ, 1998, JAMA-J AM MED ASSOC, V280, P1604, DOI 10.1001/jama.280.18.1604	15	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1999	281	6					495	496		10.1001/jama.281.6.495	http://dx.doi.org/10.1001/jama.281.6.495			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164FQ	10022088				2022-12-28	WOS:000078452900002
J	Finlay, BB				Finlay, BB			Bacterial disease in diverse hosts	CELL			English	Review							VIRULENCE FACTORS; PATHOGENICITY; PLANT; MACROPHAGES; APOPTOSIS; SECRETION; CELLS		Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Microbiol & Immunol, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Finlay, BB (corresponding author), Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada.							Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Mahajan-Miklos S, 1999, CELL, V96, P47, DOI 10.1016/S0092-8674(00)80958-7; MALO D, 1994, TRENDS GENET, V10, P365, DOI 10.1016/0168-9525(94)90133-3; Mills SD, 1997, P NATL ACAD SCI USA, V94, P12638, DOI 10.1073/pnas.94.23.12638; Monack DM, 1997, P NATL ACAD SCI USA, V94, P10385, DOI 10.1073/pnas.94.19.10385; RAHME LG, 1995, SCIENCE, V268, P1899, DOI 10.1126/science.7604262; Rahme LG, 1997, P NATL ACAD SCI USA, V94, P13245, DOI 10.1073/pnas.94.24.13245; Skamene E, 1998, ANNU REV MED, V49, P275, DOI 10.1146/annurev.med.49.1.275; Strauss EJ, 1997, SCIENCE, V276, P707, DOI 10.1126/science.276.5313.707; TAN MW, 1999, IN PRESS P NATL ACAD, V96; Van Gijsegem F, 1993, Trends Microbiol, V1, P175, DOI 10.1016/0966-842X(93)90087-8	17	40	41	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 5	1999	96	3					315	318		10.1016/S0092-8674(00)80544-9	http://dx.doi.org/10.1016/S0092-8674(00)80544-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025397	Bronze			2022-12-28	WOS:000078514600004
J	Travers, A				Travers, A			An engine for nucleosome remodeling	CELL			English	Review							SW12/SNF2		MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Travers, A (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.							CORONA DFV, 1999, IN PRESS MOL CELL; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; Martinez-Balbas MA, 1998, P NATL ACAD SCI USA, V95, P132, DOI 10.1073/pnas.95.1.132; ORNAGHI P, 1999, IN PRESS J MOL BIOL; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PHELAN M, 1999, IN PRESS MOL CELL; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; ZHANG Y, 1998, CELL, V95, P625	17	62	62	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 5	1999	96	3					311	314		10.1016/S0092-8674(00)80543-7	http://dx.doi.org/10.1016/S0092-8674(00)80543-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025396	Bronze			2022-12-28	WOS:000078514600003
J	Kim, P; Eng, TR; Deering, MJ; Maxfield, A				Kim, P; Eng, TR; Deering, MJ; Maxfield, A			Published criteria for evaluating health related web sites: review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WORLD-WIDE-WEB; INTERNET; INFORMATION; QUALITY	Objective To review published criteria for specifically evaluating health related information on the world wide web, and to identify areas of consensus. Design Search of world wide web sites and peer reviewed medical journals for explicit criteria for evaluating health related information on the web, using Medline and Lexis-Nerds databases, and the following internet search engines: Yahoo!, Excite, Altavista, Webcrawler, HotBot, Infoseek, Magellan Internet Guide, and Lycos. Criteria were extracted and grouped into categories. Results 29 published rating tools and journal articles were identified that had explicit criteria for assessing health related web sites. Of the 165 criteria extracted fr om these tools and articles, 132 (80%) were grouped under one of 12 specific categories and 33 (20%,) were grouped as miscellaneous because they lacked specificity or were unique. The most frequently cited criteria were those dealing with content, design and aesthetics of site, disclosure of authors, sponsors, or developers, currency of information (includes frequency of update, freshness, maintenance of site), authority of source, ease of use, and accessibility and availability. Conclusions Results suggest that many authors agree on key criteria for evaluating health related web sites, and that efforts to develop consensus criteria may be helpful. The next step is to identify and assess a clear, simple set of consensus criteria that the general public can understand and use.	US Dept HHS, Off Dis Prevent & Hlth Promot, Washington, DC 20201 USA; Ctr Dis Control & Prevent, NIOSH, Washington, DC USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Eng, TR (corresponding author), US Dept HHS, Off Dis Prevent & Hlth Promot, Washington, DC 20201 USA.	teng@osophs.dhhs.gov						Bowen JW, 1997, J AM MED INFORM ASSN, P46; Bower H, 1996, BRIT MED J, V313, P497; *BRIT HEALTHC INT, 1998, QUAL STAND MED PUBL; Coiera E, 1996, BMJ-BRIT MED J, V312, P3, DOI 10.1136/bmj.312.7022.3; Eng TR, 1998, JAMA-J AM MED ASSOC, V280, P1371, DOI 10.1001/jama.280.15.1371; *GOV ACC OFF, 1996, CONS HLTH INF EM ISS; *HLTH INF TECHN I, 1998, CRIT ASS QUAL HLTH I; *HLTH NET FDN, 1998, HON COD COND MED HLT; Impicciatore P, 1997, BMJ-BRIT MED J, V314, P1875, DOI 10.1136/bmj.314.7098.1875; Jadad AR, 1998, JAMA-J AM MED ASSOC, V279, P611, DOI 10.1001/jama.279.8.611; KRIPPENDORF K, 1980, CONTENT ANAL INTRO I; Lawrence S, 1998, SCIENCE, V280, P98, DOI 10.1126/science.280.5360.98; Micke MM, 1996, J SCHOOL HEALTH, V66, P277, DOI 10.1111/j.1746-1561.1996.tb03397.x; MURRAY PJ, 1997, NURS STAND ONLINE, V30, P11; *NAT RES COUNC COM, 1997, REC PROT EL HLTH INF; Patrick K, 1999, AM J PREV MED, V16, P35, DOI 10.1016/S0749-3797(98)00103-2; Pealer LN, 1997, J SCHOOL HEALTH, V67, P232, DOI 10.1111/j.1746-1561.1997.tb06311.x; Robinson TN, 1998, JAMA-J AM MED ASSOC, V280, P1264, DOI 10.1001/jama.280.14.1264; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; Sonnenberg FA, 1997, ARCH INTERN MED, V157, P151, DOI 10.1001/archinte.157.2.151; *US FDA, 1997, T9726 FDA; Weisbord SD, 1997, NEW ENGL J MED, V337, P825, DOI 10.1056/NEJM199709183371205; Wyatt JC, 1997, BRIT MED J, V314, P1879, DOI 10.1136/bmj.314.7098.1879; 1997, LANCET, V349, P1781	24	333	342	1	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 6	1999	318	7184					647	649		10.1136/bmj.318.7184.647	http://dx.doi.org/10.1136/bmj.318.7184.647			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066209	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000079089200031
J	Gray, MW; Burger, G; Lang, BF				Gray, MW; Burger, G; Lang, BF			Mitochondrial evolution	SCIENCE			English	Review							RNA-MEDIATED TRANSFER; RIBOSOMAL-RNA; TRICHOMONAS-VAGINALIS; CHLAMYDOMONAS-REINHARDTII; ENDOSYMBIONT HYPOTHESIS; MARCHANTIA-POLYMORPHA; ARABIDOPSIS-THALIANA; GENOME; GENE; ORIGIN	The serial endosymbiosis theory is a favored model for explaining the origin of mitochondria, a defining event in the evolution of eukaryotic cells. As usually described, this theory posits that mitochondria are the direct descendants of a bacterial endosymbiont that became established at an early stage in a nucleus-containing (but amitochondriate) host cell. Gene sequence data strongly support a monophyletic origin of the mitochondrion from a eubacterial ancestor shared with a subgroup of the alpha-Proteobacteria. However, recent studies of unicellular eukaryotes (protists), some of them little known, have provided insights that challenge the traditional serial endosymbiosis-based view of how the eukaryotic cell and its mitochondrion came to be. These data indicate that the mitochondrion arose in a common ancestor of all extant eukaryotes an raise the possibility that this organelle originated at essentially the same time as the nuclear component of the eukaryotic cell rather than in a separate, subsequent event.	Dalhousie Univ, Dept Biochem, Halifax, NS B3H 4H7, Canada; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	Dalhousie University; Universite de Montreal	Gray, MW (corresponding author), Dalhousie Univ, Dept Biochem, Halifax, NS B3H 4H7, Canada.	M.W.Gray@Dal.Ca	Vasil, Indra K/F-6192-2011	Vasil, Indra K/0000-0002-8900-4897; Gray, Michael/0000-0001-7125-2625				Adachi J., 1996, COMPUTER SCI MONOGRA, V28; Altmann R, 1890, ELEMENTARORGANISMEN; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; BENDICH AJ, 1993, CURR GENET, V24, P279, DOI 10.1007/BF00336777; BOER PH, 1988, CELL, V55, P399, DOI 10.1016/0092-8674(88)90026-8; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; BONEN L, 1993, FASEB J, V7, P40, DOI 10.1096/fasebj.7.1.8422973; Budin K, 1998, MOL BIOL EVOL, V15, P943, DOI 10.1093/oxfordjournals.molbev.a026010; Bui ETN, 1996, P NATL ACAD SCI USA, V93, P9651, DOI 10.1073/pnas.93.18.9651; BURGER G, 1995, J MOL BIOL, V245, P522, DOI 10.1006/jmbi.1994.0043; BURGER G, UNPUB; Cavalier-Smith T, 1983, ENDOCYTOBIOLOGY, pl027; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; Cermakian N, 1997, J MOL EVOL, V45, P671, DOI 10.1007/PL00006271; CLARKWALKER GD, 1992, INT REV CYTOL, V141, P89, DOI 10.1016/S0074-7696(08)62064-1; COLEMAN AW, 1991, J PROTOZOOL, V38, P129, DOI 10.1111/j.1550-7408.1991.tb06032.x; CUMMINGS DJ, 1992, INT REV CYTOL, V141, P1, DOI 10.1016/S0074-7696(08)62062-8; DENOVANWRIGHT EM, 1994, J MOL BIOL, V241, P298, DOI 10.1006/jmbi.1994.1505; DIETRICH A, 1992, ANNU REV CELL BIOL, V8, P115, DOI 10.1146/annurev.cb.08.110192.000555; Edlind TD, 1996, MOL PHYLOGENET EVOL, V5, P359; Embley TM, 1998, CURR OPIN GENET DEV, V8, P624, DOI 10.1016/S0959-437X(98)80029-4; FEAGIN JE, 1994, ANNU REV MICROBIOL, V48, P81, DOI 10.1146/annurev.mi.48.100194.000501; Feagin JE, 1997, NUCLEIC ACIDS RES, V25, P438, DOI 10.1093/nar/25.2.438; Felsenstein J, PHYLIP PHYLOGENY INF; Feng DF, 1997, P NATL ACAD SCI USA, V94, P13028, DOI 10.1073/pnas.94.24.13028; FLAVIN M, 1993, J EUKARYOT MICROBIOL, V40, P172, DOI 10.1111/j.1550-7408.1993.tb04900.x; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Germot A, 1996, P NATL ACAD SCI USA, V93, P14614, DOI 10.1073/pnas.93.25.14614; Germot A, 1997, MOL BIOCHEM PARASIT, V87, P159, DOI 10.1016/S0166-6851(97)00064-9; Gillham N.W., 1994, ORGANELLE GENES GENO; GOLDING GB, 1995, MOL BIOL EVOL, V12, P1; Gott J. M., 1998, MODIFICATION EDITING, P395; Gray MW, 1998, NUCLEIC ACIDS RES, V26, P865, DOI 10.1093/nar/26.4.865; Gray MW, 1998, NATURE, V396, P109, DOI 10.1038/24030; GRAY MW, 1982, MICROBIOL REV, V46, P1; GRAY MW, 1989, P NATL ACAD SCI USA, V86, P2267, DOI 10.1073/pnas.86.7.2267; GRAY MW, 1993, CURR OPIN GENET DEV, V3, P884, DOI 10.1016/0959-437X(93)90009-E; Gray MW, 1998, TRENDS MICROBIOL, V6, P1, DOI 10.1016/S0966-842X(97)01182-7; GRAY MW, 1992, INT REV CYTOL, V141, P233, DOI 10.1016/S0074-7696(08)62068-9; GRAY MW, 1984, NUCLEIC ACIDS RES, V12, P5837, DOI 10.1093/nar/12.14.5837; Gray MW, 1998, PLANT MITOCHONDRIA: FROM GENE TO FUNCTION, P1; GRAY MW, 1996, EVOLUTION MICROBIAL, P107; GRAY MW, 1995, MOL BIOL PLANT MITOC, P635; GROHMANN L, 1992, NUCLEIC ACIDS RES, V20, P5641, DOI 10.1093/nar/20.21.5641; Gupta RS, 1996, TRENDS BIOCHEM SCI, V21, P166, DOI 10.1016/0968-0004(96)20013-1; HAJDUK SL, 1998, MODIFICATION EDITING, P377; HANSON MR, 1992, INT REV CYTOL, V141, P129, DOI 10.1016/S0074-7696(08)62065-3; Hashimoto T, 1998, P NATL ACAD SCI USA, V95, P6860, DOI 10.1073/pnas.95.12.6860; HENZE K, 1995, P NATL ACAD SCI USA, V92, P9122, DOI 10.1073/pnas.92.20.9122; HIMMELREICH R, 1996, NUCLEIC ACIDS RES, V3, P109; Hirt RP, 1999, P NATL ACAD SCI USA, V96, P580, DOI 10.1073/pnas.96.2.580; Hirt RP, 1997, CURR BIOL, V7, P995, DOI 10.1016/S0960-9822(06)00420-9; Horner DS, 1996, P ROY SOC B-BIOL SCI, V263, P1053, DOI 10.1098/rspb.1996.0155; Iwamoto M, 1998, CURR GENET, V33, P304, DOI 10.1007/s002940050341; Keeling PJ, 1996, MOL BIOL EVOL, V13, P1297, DOI 10.1093/oxfordjournals.molbev.a025576; Keeling PJ, 1998, TRENDS MICROBIOL, V6, P19, DOI 10.1016/S0966-842X(97)01185-2; Keeling PJ, 1997, P NATL ACAD SCI USA, V94, P1270, DOI 10.1073/pnas.94.4.1270; Kobayashi Y, 1997, MOL GEN GENET, V256, P589, DOI 10.1007/PL00008616; Korab-Laskowska M, 1998, NUCLEIC ACIDS RES, V26, P138, DOI 10.1093/nar/26.1.138; Kumar S, 1996, J MOL EVOL, V42, P183, DOI 10.1007/BF02198844; Lang BF, 1998, PROTIST, V149, P313, DOI 10.1016/S1434-4610(98)70038-0; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; LANG BF, UNPUB; LEIPE DD, 1993, MOL BIOCHEM PARASIT, V59, P41, DOI 10.1016/0166-6851(93)90005-I; LONERGAN KM, 1993, SCIENCE, V259, P812, DOI 10.1126/science.8430334; MARCHFELDER A, 1998, MODIFICATION EDITING, P307; Margulis L., 1993, SYMBIOSIS CELL EVOLU; Margulis L, 1970, ORIGIN EUKARYOTIC CE; MARKOS A, 1993, J MOL EVOL, V37, P631, DOI 10.1007/BF00182749; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; Moreira D, 1998, J MOL EVOL, V47, P517, DOI 10.1007/PL00006408; Muller M, 1997, PARASITOL TODAY, V13, P166, DOI 10.1016/S0169-4758(97)01036-3; NEDELCU AM, 1998, MOL BIOL CHLOROPLAST, P63; Nosek J, 1998, TRENDS GENET, V14, P184, DOI 10.1016/S0168-9525(98)01443-7; NUGENT JM, 1991, CELL, V66, P473, DOI 10.1016/0092-8674(81)90011-8; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; Oldenburg DJ, 1998, J MOL BIOL, V276, P745, DOI 10.1006/jmbi.1997.1581; OLSEN GJ, 1993, FASEB J, V7, P113, DOI 10.1096/fasebj.7.1.8422957; PACE NR, 1986, CELL, V45, P325, DOI 10.1016/0092-8674(86)90315-6; Paquin B, 1997, CURR GENET, V31, P380, DOI 10.1007/s002940050220; Patterson David J., 1992, P13; Philippe H, 1998, SYST ASSOC SPEC VOL, V56, P25; Philippe H, 1998, CURR OPIN GENET DEV, V8, P616, DOI 10.1016/S0959-437X(98)80028-2; Price DH, 1998, MODIFICATION EDITING, P289; Rivera MC, 1998, P NATL ACAD SCI USA, V95, P6239, DOI 10.1073/pnas.95.11.6239; Roger AJ, 1998, P NATL ACAD SCI USA, V95, P229, DOI 10.1073/pnas.95.1.229; Roger AJ, 1996, P NATL ACAD SCI USA, V93, P14618, DOI 10.1073/pnas.93.25.14618; Sanchez H, 1996, EMBO J, V15, P2138, DOI 10.1002/j.1460-2075.1996.tb00567.x; SANKOFF D, 1992, P NATL ACAD SCI USA, V89, P6575, DOI 10.1073/pnas.89.14.6575; Sapp Jan., 1994, EVOLUTION ASS HIST S; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Sogin ML, 1991, CURR OPIN GENET DEV, V1, P457, DOI 10.1016/S0959-437X(05)80192-3; Sogin ML, 1997, CURR OPIN GENET DEV, V7, P792, DOI 10.1016/S0959-437X(97)80042-1; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; Stiller JW, 1998, P NATL ACAD SCI USA, V95, P11769, DOI 10.1073/pnas.95.20.11769; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; STUART K, 1992, INT REV CYTOL, V141, P65, DOI 10.1016/S0074-7696(08)62063-X; TAYLOR FJR, 1987, ANN NY ACAD SCI, V503, P1; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; Unseld M, 1997, NAT GENET, V15, P57, DOI 10.1038/ng0197-57; VOSSBRINCK CR, 1989, NATURE, V362, P411; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; WISCHMANN C, 1995, FEBS LETT, V374, P152, DOI 10.1016/0014-5793(95)01100-S; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOLSTENHOLME DR, 1992, INT REV CYTOL, V141, P173, DOI 10.1016/S0074-7696(08)62066-5; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443; ZILLIG W, 1989, ENDOCYT CELL RES, V6, P1; ZILLIG W, 1992, ORIGIN EVOLUTION CEL, P47	111	1264	1350	13	443	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 5	1999	283	5407					1476	1481		10.1126/science.283.5407.1476	http://dx.doi.org/10.1126/science.283.5407.1476			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066161	Green Published			2022-12-28	WOS:000078959200033
J	Logan, DT; Andersson, J; Sjoberg, BM; Nordlund, P				Logan, DT; Andersson, J; Sjoberg, BM; Nordlund, P			A glycyl radical site in the crystal structure of a class III ribonucleotide reductase	SCIENCE			English	Article							PYRUVATE FORMATE-LYASE; IRON-SULFUR CENTER; ESCHERICHIA-COLI; CYSTEINE RESIDUES; ACTIVATING ENZYME; PROTEIN R1; MECHANISM; GLYCINE-734; REFINEMENT; MOLSCRIPT	Ribonucleotide reductases catalyze the reduction of ribonucleotides to deoxyribonucleotides. Three classes have been identified, all using free-radical chemistry but based on different cofactors. Classes I and II have been shown to be evolutionarily related, whereas the origin of anaerobic class III has remained elusive. The structure of a class III enzyme suggests a common origin,for the three classes but shows differences in the active site that can be understood on the basis of the radical-initiation system and source of reductive electrons, as well as a unique protein glycyl radical site. A possible evolutionary relationship between early deoxyribonucleotide metabolism and primary anaerobic metabolism is suggested.	Univ Stockholm, Dept Biochem, S-10691 Stockholm, Sweden; Univ Stockholm, Dept Mol Biol, S-10691 Stockholm, Sweden	Stockholm University; Stockholm University	Nordlund, P (corresponding author), Univ Stockholm, Dept Biochem, S-10691 Stockholm, Sweden.	derek@biokemi.su.se; par@milvus.biokemi.su.se	Logan, Derek/O-2497-2019; Logan, Derek T/A-1114-2011	Logan, Derek/0000-0002-0098-8560; Logan, Derek T/0000-0002-0098-8560; Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; ANDERSSON J, UNPUB; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOOKER S, 1994, BIOCHEMISTRY-US, V33, P12676, DOI 10.1021/bi00208a019; Broderick JB, 1997, J AM CHEM SOC, V119, P7396, DOI 10.1021/ja9711425; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; ELIASSON R, 1995, BIOCHEM BIOPH RES CO, V214, P28, DOI 10.1006/bbrc.1995.2252; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FREY M, 1994, J BIOL CHEM, V269, P12432; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; KING DS, 1995, BIOCHEM BIOPH RES CO, V206, P731, DOI 10.1006/bbrc.1995.1103; KNAPPE J, 1995, METHOD ENZYMOL, V258, P343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kulzer R, 1998, J BIOL CHEM, V273, P4897, DOI 10.1074/jbc.273.9.4897; Lenz R, 1997, J AM CHEM SOC, V119, P2784, DOI 10.1021/ja962974q; Licht S, 1996, SCIENCE, V271, P477, DOI 10.1126/science.271.5248.477; LOGAN DT, 1995, EMBO J, V14, P4156, DOI 10.1002/j.1460-2075.1995.tb00089.x; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; MULLIEZ E, 1995, P NATL ACAD SCI USA, V92, P8759, DOI 10.1073/pnas.92.19.8759; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; Olcott MC, 1998, J BIOL CHEM, V273, P24853, DOI 10.1074/jbc.273.38.24853; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PARAST CV, 1995, BIOCHEMISTRY-US, V34, P2393, DOI 10.1021/bi00008a001; Persson AL, 1998, J BIOL CHEM, V273, P31016, DOI 10.1074/jbc.273.47.31016; Persson AL, 1997, J BIOL CHEM, V272, P31533, DOI 10.1074/jbc.272.50.31533; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Riera J, 1997, P NATL ACAD SCI USA, V94, P475, DOI 10.1073/pnas.94.2.475; Sawers G, 1998, MOL MICROBIOL, V29, P945, DOI 10.1046/j.1365-2958.1998.00941.x; Siegbahn PEM, 1998, J AM CHEM SOC, V120, P8417, DOI 10.1021/ja9736065; Sjoberg BM, 1997, STRUCT BOND, V88, P139; STUART DI, UNPUB; STUBBE J, 1983, J BIOL CHEM, V258, P1625; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; SUN XY, 1995, J BIOL CHEM, V270, P2443, DOI 10.1074/jbc.270.6.2443; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; TRONRUD DE, 1987, ACTA CRYSTALLOGR D, V53, P240; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; Young P, 1996, J BIOL CHEM, V271, P20770, DOI 10.1074/jbc.271.34.20770	49	160	167	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 5	1999	283	5407					1499	1504		10.1126/science.283.5407.1499	http://dx.doi.org/10.1126/science.283.5407.1499			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066165				2022-12-28	WOS:000078959200037
J	Poncharal, P; Wang, ZL; Ugarte, D; de Heer, WA				Poncharal, P; Wang, ZL; Ugarte, D; de Heer, WA			Electrostatic deflections and electromechanical resonances of carbon nanotubes	SCIENCE			English	Article							INSTABILITIES; TUBULES	Static and dynamic mechanical deflections were electrically induced in canti-levered, multiwalled carbon nanotubes in a transmission electron microscope. The nanotubes were resonantly excited at the fundamental frequency and higher harmonics as revealed by their deflected contours, which correspond closely to those determined for cantilevered elastic beams. The elastic bending modulus as a function of diameter was found to decrease sharply (from about 1 to 0.1 terapascals) with increasing diameter (from 8 to 40 nanometers), which indicates a crossover from a uniform elastic mode to an elastic mode that involves wavelike distortions in the nanotube, The quality factors of the resonances are on the order of 500. The methods developed here have been applied to a nanobalance for nanoscopic particles and also to a Kelvin probe based on nanotubes.	Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA; Georgia Inst Technol, Sch Mat Sci & Engn, Atlanta, GA 30332 USA; Lab Natl Luz Sincrotron, BR-13083970 Campinas, SP, Brazil	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; Laboratorio Nacional de Luz Sincrotron (LNLS)	de Heer, WA (corresponding author), Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA.		Wang, Zhong Lin/E-2176-2011; wang, jie/GRS-0942-2022; Ugarte, Daniel/C-2326-2012	Wang, Zhong Lin/0000-0002-5530-0380; Ugarte, Daniel Mario/0000-0003-3332-9139				Carroll DL, 1997, PHYS REV LETT, V78, P2811, DOI 10.1103/PhysRevLett.78.2811; DEHEER WA, 1995, SCIENCE, V270, P1179, DOI 10.1126/science.270.5239.1179; DRESSELHAUS MS, 1995, CARBON, V33, P883, DOI 10.1016/0008-6223(95)00017-8; EBBESEN TW, 1992, NATURE, V358, P220, DOI 10.1038/358220a0; Ebbesen TW, 1996, PHYS TODAY, V49, P26, DOI 10.1063/1.881603; Falvo MR, 1997, NATURE, V389, P582, DOI 10.1038/39282; Frank S, 1998, SCIENCE, V280, P1744, DOI 10.1126/science.280.5370.1744; Gao GH, 1998, NANOTECHNOLOGY, V9, P184, DOI 10.1088/0957-4484/9/3/007; Griffiths DJ, 1996, AM J PHYS, V64, P706, DOI 10.1119/1.18236; Gurgoze M, 1996, J SOUND VIB, V190, P149, DOI 10.1006/jsvi.1996.0053; Iijima S, 1996, J CHEM PHYS, V104, P2089, DOI 10.1063/1.470966; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; KELLY BT, 1981, PHYSICS GRAPHITE; Kiang CH, 1998, PHYS REV LETT, V81, P1869, DOI 10.1103/PhysRevLett.81.1869; Knechtel WH, 1998, APPL PHYS LETT, V73, P1961, DOI 10.1063/1.122335; Kuzumaki T, 1998, PHILOS MAG A, V77, P1461, DOI 10.1080/01418619808214263; KYRIAKIDES S, 1992, INT J SOLIDS STRUCT, V29, P1117, DOI 10.1016/0020-7683(92)90139-K; Liu J, 1998, SCIENCE, V280, P1253, DOI 10.1126/science.280.5367.1253; Lu JP, 1997, PHYS REV LETT, V79, P1297, DOI 10.1103/PhysRevLett.79.1297; MEIROVICH L, 1986, ELEMENTS VIBRATION A; MINTMIRE JW, 1992, PHYS REV LETT, V68, P631, DOI 10.1103/PhysRevLett.68.631; Osakabe N, 1997, APPL PHYS LETT, V70, P940, DOI 10.1063/1.118447; ROBERTSON DH, 1992, PHYS REV B, V45, P12592, DOI 10.1103/PhysRevB.45.12592; RUOFF RS, 1995, CARBON, V33, P925, DOI 10.1016/0008-6223(95)00021-5; SALVETAT JP, IN PRESS ADV MAT; SULPICE NA, 1970, J PHYS E, V3, P477; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; Thomson William, 1898, PHILOS MAG, V46, P82, DOI DOI 10.1080/14786449808621172; TREACY MM, 1996, NATURE, V38, P678; UGARTE D, 1992, NATURE, V359, P707, DOI 10.1038/359707a0; Wong EW, 1997, SCIENCE, V277, P1971, DOI 10.1126/science.277.5334.1971; Yakobson BI, 1996, PHYS REV LETT, V76, P2511, DOI 10.1103/PhysRevLett.76.2511; Yao N, 1998, J APPL PHYS, V84, P1939, DOI 10.1063/1.368323	33	1709	1779	9	338	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	1999	283	5407					1513	1516		10.1126/science.283.5407.1513	http://dx.doi.org/10.1126/science.283.5407.1513			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066169				2022-12-28	WOS:000078959200041
J	[Anonymous]				[Anonymous]			Consultants object to government's action	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 27	1999	318	7183					609	609						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037662				2022-12-28	WOS:000078966300082
J	Yokota, Y; Mansouri, A; Mori, S; Sugawara, S; Adachi, S; Nishikawa, S; Gruss, P				Yokota, Y; Mansouri, A; Mori, S; Sugawara, S; Adachi, S; Nishikawa, S; Gruss, P			Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2	NATURE			English	Article							GERMINAL-CENTERS; MONOCLONAL-ANTIBODY; DNA-BINDING; T-CELL; B-CELL; MICE; LYMPHOTOXIN; RECEPTOR; SPLEEN; LYMPHOCYTES	Transcription factors with a basic helix-loop-helix (HLH) moth have been shown to be crucial for various cell differentiation processes during development of multicellular organisms(1), Id proteins inhibit the functions of these transcription factors in a dominant-negative manner by suppressing their heterodimerization partners through the HLH domains(2-4). Members of the Id family also promote cell proliferation(4,5), implying a role in the control of cell differentiation. Here we show that Id2 is indispensable for normal development of mice, Id2(-/-) mice lack lymph nodes and Peyer's patches. However, their splenic architecture is normal, exhibiting T-cell and B-cell compartments and distinct germinal centres, The cell population that produces lymphotoxins, essential factors for the development of secondary lymphoid organs(6-11), is barely detectable in the Id2(-/-) intestine, Furthermore, the null mutants show a greatly reduced population of natural killer (NK) cells, which is due to an intrinsic defect in NK-cell precursors, Our results indicate that Id2 has an essential role in the generation of peripheral lymphoid organs and NK cells.	Max Planck Inst Biophys Chem, Dept Mol Cell Biol, D-37077 Gottingen, Germany; Kyoto Univ, Grad Sch Med, Dept Mol Genet, Sakyo Ku, Kyoto 6068507, Japan	Max Planck Society; Kyoto University	Yokota, Y (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Cell Biol, Am Fassberg, D-37077 Gottingen, Germany.							Adachi S, 1997, INT IMMUNOL, V9, P507, DOI 10.1093/intimm/9.4.507; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; Chaplin DD, 1998, CURR OPIN IMMUNOL, V10, P289, DOI 10.1016/S0952-7915(98)80167-2; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Fu YX, 1997, P NATL ACAD SCI USA, V94, P5739, DOI 10.1073/pnas.94.11.5739; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Gonzalez M, 1998, J EXP MED, V187, P997, DOI 10.1084/jem.187.7.997; Heemskerk MHM, 1997, J EXP MED, V186, P1597, DOI 10.1084/jem.186.9.1597; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; KRAAL G, 1986, IMMUNOLOGY, V58, P665; KRAAL G, 1995, AM J PATHOL, V147, P763; Liu YJ, 1996, INT REV CYTOL, V166, P139, DOI 10.1016/S0074-7696(08)62508-5; Mebius RE, 1997, IMMUNITY, V7, P493, DOI 10.1016/S1074-7613(00)80371-4; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; PICARELLA DE, 1993, J IMMUNOL, V150, P4136; Rennert PD, 1996, J EXP MED, V184, P1999, DOI 10.1084/jem.184.5.1999; Rennert PD, 1998, IMMUNITY, V9, P71, DOI 10.1016/S1074-7613(00)80589-0; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; ROSE ML, 1980, NATURE, V284, P364, DOI 10.1038/284364a0; SMITH KGC, 1994, IMMUNITY, V1, P803, DOI 10.1016/S1074-7613(94)80022-7; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TANAKA T, 1993, J EXP MED, V178, P1103, DOI 10.1084/jem.178.3.1103; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YOSHIDA H, IN PRESS INT IMMUNOL	30	706	723	0	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 25	1999	397	6721					702	706		10.1038/17812	http://dx.doi.org/10.1038/17812			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AP	10067894				2022-12-28	WOS:000078840100052
J	Tucker, MAH; Wyatt, AFG				Tucker, MAH; Wyatt, AFG			Direct evidence for R- rotons having antiparallel momentum and velocity	SCIENCE			English	Article							QUANTUM EVAPORATION; SUPERFLUID HE-4; LIQUID-HE-4; SURFACE; HELIUM	Experimental evidence is presented that shows that the momentum of a R- roton (a particle-like excitation in Liquid heilum-4) is antiparallel to its velocity. Although this is anticipated from the negative slope of the dispersion curve for these excitations, it has only been possible to test since the development of a source of ballistic R- rotons. The backward refraction of the quantum evaporation process, which is the signature of antiparallel momentum and velocity, is observed.	Univ Exeter, Sch Phys, Exeter EX4 4QL, Devon, England	University of Exeter	Wyatt, AFG (corresponding author), Univ Exeter, Sch Phys, Stocker Rd, Exeter EX4 4QL, Devon, England.							ANDERSON PW, 1969, PHYS LETT A, VA 29, P563, DOI 10.1016/0375-9601(69)90441-1; BADDAR H, 1994, PHYSICA B, V194, P513, DOI 10.1016/0921-4526(94)90586-X; BAIRD MJ, 1983, NATURE, V304, P325, DOI 10.1038/304325a0; BROWN M, 1990, J PHYS-CONDENS MAT, V2, P5025, DOI 10.1088/0953-8984/2/22/022; Campbell CE, 1998, PHYS REV LETT, V80, P2169, DOI 10.1103/PhysRevLett.80.2169; COLE MW, 1972, PHYS REV LETT, V28, P1622, DOI 10.1103/PhysRevLett.28.1622; DALFOVO F, 1995, PHYS REV LETT, V75, P2510, DOI 10.1103/PhysRevLett.75.2510; Glyde HR, 1998, EUROPHYS LETT, V43, P422, DOI 10.1209/epl/i1998-00375-2; HOPE FR, 1984, PHYS REV LETT, V52, P1528, DOI 10.1103/PhysRevLett.52.1528; Landau L. D., 1947, J PHYS USSR, V11, P91; PALEVSKY H, 1958, PHYS REV, V112, P11, DOI 10.1103/PhysRev.112.11; Sobnack MB, 1997, PHYS REV B, V56, P14271, DOI 10.1103/PhysRevB.56.R14271; STIRLING WG, 1985, P 2 INT C PHON PHYS, P829; Tucker MAH, 1998, J LOW TEMP PHYS, V113, P615, DOI 10.1023/A:1022501623126; Tucker MAH, 1998, J LOW TEMP PHYS, V110, P455, DOI 10.1023/A:1022582010793; YARNELL JL, 1959, PHYS REV, V113, P1379, DOI 10.1103/PhysRev.113.1379	16	27	27	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1150	1152		10.1126/science.283.5405.1150	http://dx.doi.org/10.1126/science.283.5405.1150			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024238				2022-12-28	WOS:000078738400047
J	Galgiani, JN				Galgiani, JN			Coccidioidomycosis: A regional disease of national importance - Rethinking approaches for control	ANNALS OF INTERNAL MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; RECOMBINANT GAMMA-INTERFERON; TUMOR-NECROSIS-FACTOR; CRYPTOCOCCUS-NEOFORMANS; MURINE COCCIDIOIDOMYCOSIS; HISTOPLASMA-CAPSULATUM; AMPHOTERICIN-B; BLASTOMYCES-DERMATITIDIS; FLUCONAZOLE THERAPY; TELOMERIC SEQUENCES	Coccidioidomycosis is an increasingly important health problem because of the migration of large numbers of persons to portions of the southwestern United States in which the disease is endemic and because of the increasing numbers of immunosuppressed patients. Most infections due to Coccidioides immitis, although causing significant illness, are self-limited and resolve over a period of weeks to months without specific treatment. It is not known whether antifungal treatment of early infections hastens resolution of the primary illness or prevents complications. Even so, diagnosis of early infections is of Value for allaying patient anxiety, lessening the need for further diagnostic studies, decreasing empirical use of antibacterial agents, and facilitating early identification of patients with complications that are more serious. Patients who develop chronic coccidioidal pneumonia or extrapulmonary infection often have complicated courses that require the involvement of Various medical, surgical, and radiologic subspecialties for management, improvement of the ability to control the problem of coccidioidomycosis will require research into the molecular and cellular biology of C. immitis, vaccine development to prevent coccidioidal infection, a better understanding of the soil ecology that supports the fungus in its endemic regions, and discovery of new antifungal drugs. In addition, government agencies, colleges, the military, and employers could improve public health by initiating education programs about the most common manifestations of the disease among persons at risk for infection.	Vet Affairs Med Ctr, Tucson, AZ USA; Univ Arizona, Tucson, AZ USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System; University of Arizona	Galgiani, JN (corresponding author), Valley Fever Ctr Excellence, 3601 S 6th Ave, Tucson, AZ 85723 USA.		Galgiani, John/GLT-7012-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI065296] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-65296] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AlAbdely H, 1997, SEMIN RESP CRIT CARE, V18, P289, DOI 10.1055/s-2008-1070998; AMPEL NM, 1986, MEDICINE, V65, P312, DOI 10.1097/00005792-198609000-00004; AMPEL NM, 1993, AM J MED, V94, P235, DOI 10.1016/0002-9343(93)90054-S; BEAMAN L, 1981, INFECT IMMUN, V34, P347, DOI 10.1128/IAI.34.2.347-353.1981; BEAMAN L, 1987, INFECT IMMUN, V55, P2951, DOI 10.1128/IAI.55.12.2951-2955.1987; BEAMAN L, 1991, INFECT IMMUN, V59, P4227, DOI 10.1128/IAI.59.11.4227-4229.1991; BEAMAN L, 1983, INFECT IMMUN, V39, P1201, DOI 10.1128/IAI.39.3.1201-1207.1983; BEAMAN L, 1977, INFECT IMMUN, V17, P580, DOI 10.1128/IAI.17.3.580-585.1977; BEAMAN L, 1979, INFECT IMMUN, V23, P681, DOI 10.1128/IAI.23.3.681-685.1979; BODDICKER JH, 1980, AM REV RESPIR DIS, V122, P279; BOWMAN BH, 1992, MOL BIOL EVOL, V9, P893; BRONNIMANN DA, 1987, ANN INTERN MED, V106, P372, DOI 10.7326/0003-4819-106-3-372; BYRNE WR, 1989, ARCH INTERN MED, V149, P947, DOI 10.1001/archinte.149.4.947; CAIRNS L, 1997, 37 INT C ANT AG CHEM; CATANZARO A, 1995, AM J MED, V98, P249, DOI 10.1016/S0002-9343(99)80371-4; Centers for Disease Control and Prevention, 1994, ADDR EM INF DIS THRE, P1; Chang YC, 1996, INFECT IMMUN, V64, P1977, DOI 10.1128/IAI.64.6.1977-1983.1996; CHANG YC, 1994, MOL CELL BIOL, V14, P4912, DOI 10.1128/MCB.14.7.4912; Chang YC, 1997, INFECT IMMUN, V65, P1584, DOI 10.1128/IAI.65.5.1584-1592.1997; CLEMONS KV, 1991, ANTIMICROB AGENTS CH, V35, P1829, DOI 10.1128/AAC.35.9.1829; COHEN IM, 1982, ARCH INTERN MED, V142, P489, DOI 10.1001/archinte.142.3.489; Corry DB, 1996, J INFECT DIS, V174, P440, DOI 10.1093/infdis/174.2.440; COX RA, 1995, INFECT IMMUN, V63, P4178, DOI 10.1128/IAI.63.10.4178-4180.1995; DERESINSKI SC, 1975, MEDICINE, V54, P377, DOI 10.1097/00005792-197509000-00002; Dewsnup DH, 1996, ANN INTERN MED, V124, P305, DOI 10.7326/0003-4819-124-3-199602010-00004; DIAZ M, 1991, CHEST, V100, P682, DOI 10.1378/chest.100.3.682; DITOMASSO JP, 1994, DIAGN MICR INFEC DIS, V18, P83, DOI 10.1016/0732-8893(94)90070-1; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; DRUTZ DJ, 1983, DRUGS, V26, P337, DOI 10.2165/00003495-198326040-00003; DRUTZ DJ, 1978, AM REV RESPIR DIS, V117, P727; EDWARDS PQ, 1957, DIS CHEST, V31, P35, DOI 10.1378/chest.31.1.35; EGEBERG RO, 1956, AM J MED SCI, V231, P151, DOI 10.1097/00000441-195623120-00005; EINSTEIN HE, 1993, CLIN INFECT DIS, V16, P349, DOI 10.1093/clind/16.3.349; ELCONIN AF, 1964, J BACTERIOL, V87, P500, DOI 10.1128/JB.87.3.500-503.1964; ELCONIN AF, 1957, P S COCC PHOEN AZ WA, P168; Erly WK, 1997, INT J NEURORADIOL, V3, P385; FISH DG, 1990, MEDICINE, V69, P384, DOI 10.1097/00005792-199011000-00006; Galgiani J N, 1997, Curr Clin Top Infect Dis, V17, P188; GALGIANI JN, 1990, J INFECT DIS, V162, P944, DOI 10.1093/infdis/162.4.944; GALGIANI JN, 1988, AM J MED, V84, P603, DOI 10.1016/0002-9343(88)90143-X; GALGIANI JN, 1993, ANN INTERN MED, V119, P28, DOI 10.7326/0003-4819-119-1-199307010-00005; GIFFORD MA, 1936, DATA COCCIDIOIDES FU, P39; GRAYBILL JR, 1990, AM J MED, V89, P282, DOI 10.1016/0002-9343(90)90339-F; HALL KA, 1993, TRANSPLANTATION, V55, P1422, DOI 10.1097/00007890-199306000-00039; HALL KA, 1993, J HEART LUNG TRANSPL, V12, P525; HARDENBROOK MH, 1982, MYCOPATHOLOGIA, V78, P65, DOI 10.1007/BF00442628; HECTOR RF, 1990, ANTIMICROB AGENTS CH, V34, P587, DOI 10.1128/AAC.34.4.587; Hernandez JL, 1997, EUR J CLIN MICROBIOL, V16, P592, DOI 10.1007/BF02447922; Hogan LH, 1997, GENE, V186, P219, DOI 10.1016/S0378-1119(96)00713-5; Holt CD, 1997, CLIN INFECT DIS, V24, P216, DOI 10.1093/clinids/24.2.216; HUPPERT M, 1978, J CLIN MICROBIOL, V8, P346; HUPPERT M, 1967, J BACTERIOL, V94, P924, DOI 10.1128/JB.94.4.924-927.1967; HUPPERT M, 1965, COCCIDIOIDOMYCOSIS, P323; HUTH RG, 1994, CLIN INFECT DIS, V18, P262, DOI 10.1093/clinids/18.2.262; JONES JL, 1995, J INFECT DIS, V171, P961, DOI 10.1093/infdis/171.4.961; KERRICK SS, 1985, AM REV RESPIR DIS, V131, P100; Kirkland TN, 1998, INFECT IMMUN, V66, P3519, DOI 10.1128/IAI.66.8.3519-3522.1998; Kirkland TN, 1998, INFECT IMMUN, V66, P424, DOI 10.1128/IAI.66.2.424-431.1998; Kirkland TN, 1996, EMERG INFECT DIS, V2, P192, DOI 10.3201/eid0203.960305; KONG YCM, 1964, J IMMUNOL, V92, P779; Koufopanou V, 1997, P NATL ACAD SCI USA, V94, P5478, DOI 10.1073/pnas.94.10.5478; Kushwaha VP, 1996, CLIN ORTHOP RELAT R, P190, DOI 10.1097/00003086-199611000-00026; KWONCHUNG KJ, 1992, INFECT IMMUN, V60, P602, DOI 10.1128/IAI.60.2.602-605.1992; Levan N. E., 1977, Coccidioidomycosis. Current clinical and diagnostic status., P11; LEVINE HB, 1961, J IMMUNOL, V87, P218; LEVINE HB, 1965, J IMMUNOL, V94, P132; LODGE JK, 1994, P NATL ACAD SCI USA, V91, P12008, DOI 10.1073/pnas.91.25.12008; Lund PJ, 1996, SKELETAL RADIOL, V25, P661, DOI 10.1007/s002560050154; Lutz JE, 1997, ANTIMICROB AGENTS CH, V41, P1558, DOI 10.1128/AAC.41.7.1558; MADDY K T, 1961, Ariz Med, V18, P184; MADDY K T, 1965, Ariz Med, V22, P281; MADDY K T, 1958, Ariz Med, V15, P178; MADDY KEITH T., 1957, JOUR AMER VET MED ASSOC, V130, P475; Magee DM, 1996, INFECT IMMUN, V64, P3609, DOI 10.1128/IAI.64.9.3609-3613.1996; MAGEE DM, 1995, INFECT IMMUN, V63, P3514, DOI 10.1128/IAI.63.9.3514-3519.1995; MARTINS TB, 1995, J CLIN MICROBIOL, V33, P940, DOI 10.1128/JCM.33.4.940-943.1995; MONHEIT JE, 1984, ARCH PATHOL LAB MED, V108, P616; Ophuls W, 1900, PHILA MED J, V5, P1471; PADHYE AA, 1994, J CLIN MICROBIOL, V32, P867, DOI 10.1128/JCM.32.4.867-870.1994; PALMER CE, 1957, PHS PUBLICATION, V575; Pappagianis D., 1988, Laboratory diagnosis of infectious diseases. Volume 1. Bacterial, mycotic and parasitic diseases., P600; Pappagianis D, 1988, Curr Top Med Mycol, V2, P199; PAPPAGIANIS D, 1994, CLIN INFECT DIS, V19, pS14, DOI 10.1093/clinids/19.Supplement_1.14; PAPPAGIANIS D, 1978, WESTERN J MED, V129, P527; PAPPAGIANIS D, 1990, CLIN MICROBIOL REV, V3, P247, DOI 10.1128/CMR.3.3.247-268.1990; PAPPAGIANIS D, 1979, AM REV RESPIR DIS, V120, P959; PAPPAGIANIS D, 1993, AM REV RESPIR DIS, V148, P656, DOI 10.1164/ajrccm/148.3.656; PAPPAGIANIS D, 1967, J INVEST DERMATOL, V49, P71, DOI 10.1038/jid.1967.105; PAPPAGIANIS D, 1983, OCCUPATIONAL MYCOSES, P13; PEREZ JA, 1995, ARCH INTERN MED, V155, P1665, DOI 10.1001/archinte.155.15.1665; Peterson C M, 1993, Obstet Gynecol Surv, V48, P149, DOI 10.1097/00006254-199303000-00002; RILEY DK, 1993, TRANSPLANTATION, V56, P1531; Rixford E, 1894, OCCIDENTAL MED TIMES, V8, P704; RIXFORD E, 1894, OCCIDENTAL MED TIMES, V8, P326; RUTALA PJ, 1978, AM J MED SCI, V275, P283, DOI 10.1097/00000441-197805000-00006; Salas SD, 1996, J EXP MED, V184, P377, DOI 10.1084/jem.184.2.377; SANDHU GS, 1995, J CLIN MICROBIOL, V33, P2913, DOI 10.1128/JCM.33.11.2913-2919.1995; Schneider E, 1997, JAMA-J AM MED ASSOC, V277, P904, DOI 10.1001/jama.277.11.904; Schwartz S, 1997, BRIT J HAEMATOL, V97, P663, DOI 10.1046/j.1365-2141.1997.972911.x; Singh VR, 1996, CLIN INFECT DIS, V23, P563, DOI 10.1093/clinids/23.3.563; SMITH C. E., 1943, Medical Clinics of North America, V27, P790; SMITH CE, 1948, ANN INTERN MED, V29, P623, DOI 10.7326/0003-4819-29-4-623; SMITH CE, 1946, JAMA-J AM MED ASSOC, V132, P833, DOI 10.1001/jama.1946.02870490011003; SMITH CE, 1956, JAMA-J AM MED ASSOC, V160, P546, DOI 10.1001/jama.1956.02960420026008; SMITH CHARLES E., 1951, CALIFORNIA MED, V75, P385; SMITH GR, 1988, MICROBIOL REV, V52, P1; SOBONYA RE, 1990, CHEST, V97, P1349, DOI 10.1378/chest.97.6.1349; STADALNIK RC, 1980, AM REV RESPIR DIS, V121, P673; STANDAERT SM, 1995, J INFECT DIS, V171, P1672, DOI 10.1093/infdis/171.6.1672; STEVENS DA, 1995, NEW ENGL J MED, V332, P1077, DOI 10.1056/NEJM199504203321607; Stevens DA, 1997, CLIN INFECT DIS, V25, P1211, DOI 10.1086/516118; STEVENS DA, 1994, CLIN INFECT DIS, V18, P470, DOI 10.1093/clinids/18.3.470; STOCKMAN L, 1993, J CLIN MICROBIOL, V31, P845, DOI 10.1128/JCM.31.4.845-850.1993; SUN SH, 1976, J CLIN MICROBIOL, V3, P186; TORRESGUERERRO H, 1994, J MED VET MYCOL, V32, P303; TUCKER RM, 1990, ANN INTERN MED, V112, P108, DOI 10.7326/0003-4819-112-2-108; VARTIVARIAN SE, 1987, AM J MED, V83, P949, DOI 10.1016/0002-9343(87)90657-7; WALKER MPR, 1992, OBSTET GYNECOL, V79, P815; WELCH G, 1992, 120 ANN M AM PUBL HL; Wieden MA, 1996, J INFECT DIS, V173, P1273, DOI 10.1093/infdis/173.5.1273; WOODS JP, 1992, MOL MICROBIOL, V6, P3603, DOI 10.1111/j.1365-2958.1992.tb01796.x; WOODS JP, 1993, J BACTERIOL, V175, P636, DOI 10.1128/JB.175.3.636-641.1993; WORSHAM PL, 1990, MOL GEN GENET, V221, P358, DOI 10.1007/BF00259400; YOZWIAK ML, 1988, WESTERN J MED, V149, P419; Zartarian M, 1997, AM J CLIN PATHOL, V107, P148, DOI 10.1093/ajcp/107.2.148; Zimmermann CR, 1998, INFECT IMMUN, V66, P2342, DOI 10.1128/IAI.66.5.2342-2345.1998; 1993, MMWR MORB MORTAL WKL, V42, P21; 1996, MED ADVERTISING  MAY, P35	128	117	122	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	1				293	300		10.7326/0003-4819-130-4-199902160-00015	http://dx.doi.org/10.7326/0003-4819-130-4-199902160-00015			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166PY	10068388				2022-12-28	WOS:000078587200007
J	Kelley, MA				Kelley, MA			The hospitalist: A new medical specialty?	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	National Policy Conference on the Hospitalist Movement	DEC 05-06, 1997	SAN FRANCISCO, CA					Economic forces have stimulated a growing role for physician "hospitalists" in caring for patients hospitalized by other physicians, and the question of whether hospital care constitutes a new medical specialty has been raised. Three recently recognized specialties-emergency medicine, family practice, and critical care-originated from trends in medical practice. All three fulfill the major criteria for a medical specialty: scientific legitimacy, the development of new training pathways, and the existence of academic departments. The hospitalist movement is currently underdeveloped in each of these areas. By training, most hospitalists are internists who are well prepared to care for inpatients. Internal medicine must determine how this new movement fits into the traditional framework of general internal medicine and medical subspecialties. Until it does, the future of inpatient medicine as a recognized specialty will remain uncertain.	Univ Penn, Med Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania	Kelley, MA (corresponding author), Univ Penn, Med Ctr, 34th St & Civ Ctr Blvd,21 Penn Tower Hotel, Philadelphia, PA 19104 USA.							*AM BOARD INT MED, 1993, FIN REP ADV COMM REC; *AM BOARD MED SPEC, 1997, ANN REP REF HDB; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; ENDE J, 1997, GRADUATE ED INTERNAL; Lindenauer PK, 1999, ANN INTERN MED, V130, P343, DOI 10.7326/0003-4819-130-4-199902161-00003; *MED GROUP MAN ASS, 1996, PHYS COMP PROD SURV; Wachter RM, 1998, JAMA-J AM MED ASSOC, V279, P1560, DOI 10.1001/jama.279.19.1560	7	25	25	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	2				373	375		10.7326/0003-4819-130-4-199902161-00009	http://dx.doi.org/10.7326/0003-4819-130-4-199902161-00009			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	166QB	10068409				2022-12-28	WOS:000078587500009
J	Cody, SH; Glynn, MK; Farrar, JA; Cairns, KL; Griffin, PM; Kobayashi, J; Fyfe, M; Hoffman, R; King, AS; Lewis, JH; Swaminathan, B; Bryant, RG; Vugia, DJ				Cody, SH; Glynn, MK; Farrar, JA; Cairns, KL; Griffin, PM; Kobayashi, J; Fyfe, M; Hoffman, R; King, AS; Lewis, JH; Swaminathan, B; Bryant, RG; Vugia, DJ			An outbreak of Escherichia coli O157 : H7 infection from unpasteurized commercial apple juice	ANNALS OF INTERNAL MEDICINE			English	Article							HEMOLYTIC-UREMIC-SYNDROME; MULTISTATE OUTBREAK; CIDER; CYCLOSPORIASIS; RASPBERRIES; DIARRHEA; SURVIVAL; MODEL; SHEEP; FATE	Background: Escherichia coli O157:H7 infections have traditionally been associated with animal products, but outbreaks associated with produce have been reported with increasing frequency. In fall 1996, a small cluster of E. coli O157:H7 infections was epidemiologically linked to a particular brand (brand A) of unpasteurized apple juice. Objective: To define the extent of the outbreak, confirm the source, and determine how the apple juice became contaminated. Design: Descriptive epidemiologic study and traceback investigation. Setting: Western United States and British Columbia, Canada. Patients: Patients with E. coli O157:H7 infection who were exposed to brand A apple juice. Measurements: Clinical outcome and juice exposure histories of case-patients, pulsed-field gel electrophoresis of case and juice isolates, and juice production practices. Results: Seventy persons with E. coli O157:H7 infection and exposure to brand A unpasteurized apple juice were identified. Of these persons, 25 (36%) were hospitalized, 14 (20%) developed the hemolytic uremic syndrome, and 1 (1%) died. Recalled apple juice that was produced on 7 October 1996 grew E, coli O157:H7 with a pulsed-field gel electrophoresis pattern indistinguishable from that of case isolates. Apple juice produced on 7 October 1996 accounted for almost all of the cases, and the source of contamination was suspected to be incoming apples. Three lots of apples could explain contamination of the juice: Two lots originated from an orchard frequented by deer that were subsequently shown to carry E. coli O157:H7, and one lot contained decayed apples that had been waxed. Conclusions: Standard procedures at a state-of-the-art plant that produced unpasteurized juices were inadequate to eliminate contamination with E. coli O157:H7. This outbreak demonstrated that unpasteurized juices must be considered a potentially hazardous food and led to widespread changes in the fresh juice industry.	Calif Dept Hlth Serv, Food & Drug Branch, Sacramento, CA 94234 USA; Ctr Dis Control & Prevent, Div Publ Hlth Surveillance & Informat, Epidemiol Program Off, Atlanta, GA 30333 USA; Washington State Dept Hlth, Shoreline, WA 98155 USA; British Columbia Ctr Dis Control, Vancouver, BC V52Z 4R4, Canada; Hlth Canada, Lab Ctr Dis Control, Ottawa, ON, Canada; Colorado Dept Publ Hlth & Environm, Denver, CO 80246 USA; Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Div Bacterial & Mycot Dis, Atlanta, GA 30333 USA; Calif Dept Hlth Serv, Microbial Dis Lab, Berkeley, CA 94704 USA; Calif Dept Hlth Serv, Div Communicable Dis Control, Berkeley, CA 94704 USA	California Department of Health Care Services; Centers for Disease Control & Prevention - USA; Health Canada; Colorado Department of Public Health & Environment; Centers for Disease Control & Prevention - USA; California Department of Health Care Services; California Department of Health Care Services	Cody, SH (corresponding author), Santa Clara Cty Dept Publ Hlth, 2220 Moorpark Ave 115, San Jose, CA 95128 USA.							Armstrong GL, 1996, EPIDEMIOL REV, V18, P29, DOI 10.1093/oxfordjournals.epirev.a017914; BARRETT TJ, 1991, CURR MICROBIOL, V23, P189, DOI 10.1007/BF02092278; BARRETT TJ, 1994, J CLIN MICROBIOL, V32, P3013, DOI 10.1128/JCM.32.12.3013-3017.1994; BELL BP, 1994, JAMA-J AM MED ASSOC, V272, P1349, DOI 10.1001/jama.272.17.1349; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; Besser TE, 1997, J INFECT DIS, V175, P726, DOI 10.1093/infdis/175.3.726; BOYCE TG, 1995, NEW ENGL J MED, V333, P364, DOI 10.1056/NEJM199508103330608; CEBULA TA, 1995, J CLIN MICROBIOL, V33, P248, DOI 10.1128/JCM.33.1.248-250.1995; CONNER DE, 1995, APPL ENVIRON MICROB, V61, P382, DOI 10.1128/AEM.61.1.382-385.1995; Cook KA, 1998, JAMA-J AM MED ASSOC, V280, P1504, DOI 10.1001/jama.280.17.1504; DEAN A, 1995, EPI INFO VERSION 6 W; DOYLE MP, 1987, APPL ENVIRON MICROB, V53, P2394, DOI 10.1128/AEM.53.10.2394-2396.1987; *FDA, 1998, FED REGISTER, V63, P20486; *FDA, 1998, FED REGISTER, V63, P20449; GLASS KA, 1992, APPL ENVIRON MICROB, V58, P2513, DOI 10.1128/AEM.58.8.2513-2516.1992; HEDBERG CW, 1992, JAMA-J AM MED ASSOC, V268, P3203, DOI 10.1001/jama.268.22.3203; Herwaldt BL, 1997, NEW ENGL J MED, V336, P1548, DOI 10.1056/NEJM199705293362202; Keene WE, 1997, JAMA-J AM MED ASSOC, V277, P1229, DOI 10.1001/jama.277.15.1229; Kudva IT, 1996, J CLIN MICROBIOL, V34, P431, DOI 10.1128/JCM.34.2.431-433.1996; KUDVA IT, 1995, APPL ENVIRON MICROB, V61, P1363, DOI 10.1128/AEM.61.4.1363-1370.1995; MILLARD PS, 1994, JAMA-J AM MED ASSOC, V272, P1592, DOI 10.1001/jama.272.20.1592; MILLER LG, 1994, J FOOD PROTECT, V57, P460, DOI 10.4315/0362-028X-57.6.460; Olsvik Orjan, 1993, P271; Osterholm MT, 1997, NEW ENGL J MED, V336, P1597, DOI 10.1056/NEJM199705293362210; Shukla R, 1995, Commun Dis Rep CDR Rev, V5, pR86; STEELE BT, 1982, J PEDIATR-US, V101, P963, DOI 10.1016/S0022-3476(82)80021-8; TABERSHAW IR, 1967, ARCH ENVIRON HEALTH, V15, P72, DOI 10.1080/00039896.1967.10664878; ZADIK PM, 1993, J MED MICROBIOL, V39, P155, DOI 10.1099/00222615-39-2-155; ZHAO T, 1993, APPL ENVIRON MICROB, V59, P2526, DOI 10.1128/AEM.59.8.2526-2530.1993; 1975, MMWR MORB MORTAL WKL, V24, P87; 1996, MMWR MORB MORTAL WKL, V45, P975; 1997, MMWR MORB MORTAL WKL, V46, P4; 1997, MMWR MORB MORTAL WKL, V46, P288; 1997, MMWR MORB MORTAL WKL, V46, P295	34	296	305	1	38	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 2	1999	130	3					202	+		10.7326/0003-4819-130-3-199902020-00005	http://dx.doi.org/10.7326/0003-4819-130-3-199902020-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	162PD	10049198				2022-12-28	WOS:000078355000004
J	Smith, R; Hiatt, H; Berwick, D; Benatar, SR; Berwick, DM; Bisognano, M; Dalton, J; Davidoff, F; Frenk, J; Hiatt, H; Hurwitz, B; Janeway, P; Marshall, MH; Norling, R; Rocklage, MR; Scott, H; Sen, A; Smith, R; Sommerville, A				Smith, R; Hiatt, H; Berwick, D; Benatar, SR; Berwick, DM; Bisognano, M; Dalton, J; Davidoff, F; Frenk, J; Hiatt, H; Hurwitz, B; Janeway, P; Marshall, MH; Norling, R; Rocklage, MR; Scott, H; Sen, A; Smith, R; Sommerville, A		Tavistock Grp	A shared statement of ethical principles for those who shape and give health care: A working draft from the Tavistock group	ANNALS OF INTERNAL MEDICINE			English	Article								Health care delivery in many countries has expanded over the past 150 years from a largely social service delivered by individual practitioners to an intricate network of services provided by teams of professionals. The problems of in creasing resource consumption, financial constraints, complexity, and poor system design that have emerged as consequences of these changes have exacerbated many of the ethical tensions inherent in health care and have created new ones. Many groups of professionals that give and affect health care have established separate codes of ethics for their own disciplines, but no shared code exists that might bring all stakeholders in health care into a more consistent moral framework. A multidisciplinary group therefore recently met at Tavistock Square in London in an effort to prepare such a shared code. The result was not a code but a more basic and generic statement of ethical principles. The intent and hope is that it will offer clear guidance for tough calls in real world settings. it is presented here not as a finished work, but as a draft to elicit comment, critique, suggestions for revision, and, especially, ideas for implementation.	Inst Healthcare Improvement, Boston, MA 02215 USA; BMJ, London WC1H 9JR, England; Brigham & Womens Hosp, Boston, MA 02115 USA	Institute for Healthcare Improvement; Harvard University; Brigham & Women's Hospital	Berwick, DM (corresponding author), Inst Healthcare Improvement, 135 Francis St, Boston, MA 02215 USA.		Bisognano, Maureen/AAR-9724-2020					Berwick D, 1997, BRIT MED J, V315, P1633, DOI 10.1136/bmj.315.7123.1633	1	13	13	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	1999	130	2					143	147		10.7326/0003-4819-130-2-199901190-00009	http://dx.doi.org/10.7326/0003-4819-130-2-199901190-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158KG	10068361				2022-12-28	WOS:000078114200008
J	Lawrie, SM; Whalley, H; Kestelman, JN; Abukmeil, SS; Byrne, M; Hodges, A; Rimmington, JE; Best, JJK; Owens, DGC; Johnstone, EC				Lawrie, SM; Whalley, H; Kestelman, JN; Abukmeil, SS; Byrne, M; Hodges, A; Rimmington, JE; Best, JJK; Owens, DGC; Johnstone, EC			Magnetic resonance imaging of brain in people at high risk of developing schizophrenia	LANCET			English	Article							FIRST-EPISODE SCHIZOPHRENIA; ABNORMALITIES; TOMOGRAPHY; ILLNESS	Background Schizophrenia is a multifactorial disorder that is associated with disturbed cerebral development, Structural brain-imaging studies have consistently shown that the volumes of some parts of the brain, particularly the mesial temporal lobes, are! smaller in patients with schizophrenia than in healthy people. Whether these abnormalities of brain structure predate the onset of symptoms is not known. Methods 100 people at high risk of developing schizophrenia (two or more first-degree or second-degree relatives affected), 20 patients in their first episode of schizophrenia, and 30 healthy controls underwent magnetic resonance imaging of the brain. The volumes of regions of interest were measured by standard techniques. Findings Mean whole-brain volume was 1356 cm(3) (SD 178) in the first-episode group, 1347 cm(3) (122) in the high-risk group, and 1334 cm(3). (149) in the controls (p=0.8). The mean volume of the left amygdala-hippocampal complex (AHC) was lower in the first-episode group (4.3 cm(3) [0.6]) than in the high-risk group (4.6 cm(3) [0.6]), and in turn than in the controls (4.8 cm(3) [0.7]); these differences were significant (p<0.05) both for absolute volumes and values adjusted for brain volume and other confounders. The right AHC showed a similar pattern (absolute volumes 4.5 cm(3) [0.7], 4.8 cm(3) [0.6], 4.9 cm(3) [0.9]; respectively). Both thalamic nuclei were significantly smaller in the high-risk group than in the control group. Interpretation People at high risk of developing schizophrenia for genetic reasons have several structural brain abnormalities that are similar to those in patients with the disorder. lit-risk individuals with particularly small AHC or thalami are most likely to develop schizophrenia, this feature might assist in early detection and treatment.	Univ Edinburgh, Royal Edinburgh Hosp, Dept Psychiat, Edinburgh EH10 5HF, Midlothian, Scotland; City Hosp Edinburgh, Magnet Resonance Imaging Unit, Edinburgh EH10 5SB, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh	Lawrie, SM (corresponding author), Univ Edinburgh, Royal Edinburgh Hosp, Dept Psychiat, Edinburgh EH10 5HF, Midlothian, Scotland.	s.lawrie@ed.ac.uk	Whalley, Heather C/N-1886-2019; Lawrie, Stephen MacGregor/AAD-1607-2021	Whalley, Heather C/0000-0002-4505-8869; Lawrie, Stephen MacGregor/0000-0002-2444-5675				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ANDREASEN NC, 1994, SCIENCE, V266, P294, DOI 10.1126/science.7939669; BILDER RM, 1994, AM J PSYCHIAT, V151, P1437; BOGERTS B, 1990, PSYCHIAT RES-NEUROIM, V35, P1; CANNON M, 1996, J NEUROL NEUROSUR PS, V61, P604; CANNON TD, 1993, ARCH GEN PSYCHIAT, V50, P551; DONE DJ, 1994, BRIT MED J, V309, P699, DOI 10.1136/bmj.309.6956.699; FRITH C, 1995, LANCET, V346, P615, DOI 10.1016/S0140-6736(95)91441-2; JOHNSTONE EC, 1976, LANCET, V2, P924; JOHNSTONE EC, 1994, SEARCH CAUSE SCHIZOP; Jones EG, 1997, SCHIZOPHRENIA BULL, V23, P483, DOI 10.1093/schbul/23.3.483; JONES P, 1994, LANCET, V344, P1398, DOI 10.1016/S0140-6736(94)90569-X; Knapp M, 1997, BRIT J PSYCHIAT, V171, P509, DOI 10.1192/bjp.171.6.509; LAWRIE SM, 1995, BRIT J PSYCHIAT, V167, P202, DOI 10.1192/bjp.167.2.202; Lawrie SM, 1998, BRIT J PSYCHIAT, V172, P110, DOI 10.1192/bjp.172.2.110; LEWIS SW, 1990, BRIT J PSYCHIAT, V157, P16, DOI 10.1192/S0007125000291824; Lim KO, 1996, AM J PSYCHIAT, V153, P1548; MCGUFFIN P, 1991, ARCH GEN PSYCHIAT, V48, P764; MCGUFFIN P, 1995, LANCET, V346, P678, DOI 10.1016/S0140-6736(95)92285-7; Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0; NOPOULOS P, 1995, AM J PSYCHIAT, V152, P1721; Seidman LJ, 1997, AM J MED GENET, V74, P507, DOI 10.1002/(SICI)1096-8628(19970919)74:5<507::AID-AJMG11>3.0.CO;2-G; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; Spitzer R.L., 1978, SCHEDULE AFFECTIVE D; Squire LR, 1996, P NATL ACAD SCI USA, V93, P13515, DOI 10.1073/pnas.93.24.13515; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; VITA A, 1994, PSYCHIAT RES, V53, P41, DOI 10.1016/0165-1781(94)90094-9; WEINBERGER DR, 1995, LANCET, V346, P552, DOI 10.1016/S0140-6736(95)91386-6; WEINBERGER DR, 1981, PSYCHIAT RES, V4, P65, DOI 10.1016/0165-1781(81)90009-3; Wing JK, 1974, DESCRIPTION CLASSIFI	30	273	278	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 2	1999	353	9146					30	33		10.1016/S0140-6736(98)06244-8	http://dx.doi.org/10.1016/S0140-6736(98)06244-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023948				2022-12-28	WOS:000077934800014
J	Iota, V; Yoo, CS; Cynn, H				Iota, V; Yoo, CS; Cynn, H			Quartzlike carbon dioxide: An optically nonlinear extended solid at high pressures and temperatures	SCIENCE			English	Article							CO2; PHASE; ICE; COMPRESSION; GENERATION; SILICA; RAMAN	An extended-solid phase, carbon dioxide phase V (CO2-V), was synthesized in a diamond anvil cell by Laser heating the molecular orthorhombic phase, carbon dioxide phase III, above 40 gigapascals and 1800 kelvin. This new material can be quenched to ambient temperature above 1 gigapascal. The vibration spectrum of CO2-V is similar to that of the quartz polymorph of silicon dioxide, indicating that it is an extended covalent solid with carbon-oxygen single bonds. This material is also optically nonlinear, generating the second harmonic of a neodymium-yttrium-lithium-fluoride Laser at a wavelength of 527 nanometers with a conversion efficiency that is near 0.1 percent.	Univ Calif Lawrence Livermore Natl Lab, Livermore, CA 94551 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Yoo, CS (corresponding author), Univ Calif Lawrence Livermore Natl Lab, Livermore, CA 94551 USA.	yoo1@llnl.gov	cynn, hyunchae/AAX-7543-2020	cynn, hyunchae/0000-0003-4658-5764				AOKI K, 1994, SCIENCE, V263, P356, DOI 10.1126/science.263.5145.356; Bernard S, 1998, PHYS REV LETT, V81, P2092, DOI 10.1103/PhysRevLett.81.2092; BUNDY FP, 1967, J CHEM PHYS, V46, P3437, DOI 10.1063/1.1841236; DRISCOLL TJ, 1994, J OPT SOC AM B, V11, P355, DOI 10.1364/JOSAB.11.000355; Goncharov AF, 1996, SCIENCE, V273, P218, DOI 10.1126/science.273.5272.218; HANSON RC, 1981, J CHEM PHYS, V75, P1102, DOI 10.1063/1.442183; HANSON RC, 1985, J PHYS CHEM-US, V89, P4499, DOI 10.1021/j100267a019; HERNLEY RJ, 1987, HIGH PRESSURE RES MI, P347; JORGENSEN JD, 1978, J APPL PHYS, V49, P5473, DOI 10.1063/1.324517; LIU AY, 1989, SCIENCE, V245, P841, DOI 10.1126/science.245.4920.841; LIU LG, 1983, NATURE, V303, P508, DOI 10.1038/303508a0; MAILHIOT C, 1992, PHYS REV B, V46, P14419, DOI 10.1063/1.46314; MILLER SL, 1970, SCIENCE, V170, P531, DOI 10.1126/science.170.3957.531; Olijnyk H, 1998, PHYS REV B, V57, P879, DOI 10.1103/PhysRevB.57.879; OLINGER B, 1982, J CHEM PHYS, V77, P6255, DOI 10.1063/1.443828; SASAKI Y, 1981, APPL PHYS LETT, V39, P466, DOI 10.1063/1.92775; SHARMA SK, 1981, NATURE, V292, P140, DOI 10.1038/292140a0; Span R, 1996, J PHYS CHEM REF DATA, V25, P1509, DOI 10.1063/1.555991; Stishov S., 1961, GEOCHEMISTRY-USSR, P837; Wyckoff R.W.G, 1963, CRYST STRUCT; YOO CS, 1997, PHYS REV B, V56, P149	21	239	250	3	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	1999	283	5407					1510	1513		10.1126/science.283.5407.1510	http://dx.doi.org/10.1126/science.283.5407.1510			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066168				2022-12-28	WOS:000078959200040
J	Tsao, HS; Tahan, SR				Tsao, HS; Tahan, SR			Keratoacanthoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Massachusetts Gen Hosp, Boston, MA 02114 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center	Tsao, HS (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.		Soyer, H. Peter/E-6000-2010; Tahan, Steven/V-6968-2019	Soyer, H. Peter/0000-0002-4770-561X; Tahan, Steven/0000-0003-4712-7001					0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1999	340	9					708	708		10.1056/NEJM199903043400906	http://dx.doi.org/10.1056/NEJM199903043400906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172ZB	10053180				2022-12-28	WOS:000078955200006
J	Steffen, R; Collard, F; Tornieporth, N; Campbell-Forrester, S; Ashley, D; Thompson, S; Mathewson, JJ; Maes, E; Stephenson, B; DuPont, HL; von Sonnenburg, F				Steffen, R; Collard, F; Tornieporth, N; Campbell-Forrester, S; Ashley, D; Thompson, S; Mathewson, JJ; Maes, E; Stephenson, B; DuPont, HL; von Sonnenburg, F			Epidemiology, etiology, and impact of traveler's diarrhea in Jamaica	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFLAMMATORY BOWEL-DISEASE; ESCHERICHIA-COLI; CLINICAL-TRIALS; PREVENTION; QUALITY; LIFE	Context Traveler's diarrhea (TD) can incapacitate travelers. Characteristics of TD could be helpful in identifying individuals who might benefit from a vaccine against TD, Objective To determine epidemiology, etiology, and impact of TD in Jamaica. Design Two-armed, cross-sectional survey conducted between March 1996 and May 1997, Setting Sangster International Airport and 10 hotels in Montego Bay area, Jamaica. Subjects To investigate epidemiology and impact, 30369 short-term visitors completed a questionnaire just before boarding their homebound aircrafts, To investigate etiology, 322 patients (hotel guests) with TD provided stool samples. Main Outcome Measures Attack and incidence rates of reported diarrhea and of classically defined TD (greater than or equal to 3 unformed stool samples in 24 hours and greater than or equal to 1 accompanying symptom), incapacity, risk factors, and etiology. Results The attack rate for diarrhea was 23.6% overall, with 11.7% having classically defined TD, For a mean duration of stay of 4 to 7 days, the incidence rate was 20.9% (all TD) and 10.0% (classic TD), Among airport respondents, the incapacity lasted a mean of 11.6 hours. Less than 3% of all travelers avoided potentially highrisk food and beverages. The most frequently detected pathogens were enterotoxigenic Escherichia coli, Rotavirus, and Salmonella species. Conclusions A realistic plan for reducing TD is needed. Preventive measures such as the improvement of hygienic conditions at the destination, and/or the development of vaccines against the most frequent pathogens associated with TD may contribute toward achieving this goal.	Univ Zurich, Inst Social & Prevent Med, Div Epidemiol & Prevent Communicable Dis, CH-8006 Zurich, Switzerland; SmithKline Beecham Biol, Rixensart, Belgium; Univ Munich, Div Int Med & Publ Hlth, Munich, Germany; Minist Hlth Jamaica, Western Area Hlth Adm, Kingston, Jamaica; Cornwall Reg Hosp, Dept Microbiol, Montego Bay, Jamaica; Univ Texas, Ctr Infect Dis, Houston, TX USA; Lewin Grp, Mechelen, Belgium; McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; St Lukes Episcopal Hosp, Houston, TX 77030 USA	University of Zurich; GlaxoSmithKline; University of Munich; University of Texas System; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; Saint Lukes Episcopal Hospital	Steffen, R (corresponding author), Univ Zurich, Inst Social & Prevent Med, Div Epidemiol & Prevent Communicable Dis, Sumatrastr 30, CH-8006 Zurich, Switzerland.	travclin@ifspm.unizh.ch	DuPont, Herbert/AAH-6776-2021					Beecham HJ, 1997, AM J TROP MED HYG, V57, P699, DOI 10.4269/ajtmh.1997.57.699; BERLIN OGW, 1994, CLIN INFECT DIS, V18, P606, DOI 10.1093/clinids/18.4.606; BLACK RE, 1990, REV INFECT DIS, V12, P573; *CAN COORD OFF HLT, 1994, GUID EC EV PHARM; CARTWRIGHT R, 1992, PHLS MICROBIOLOGY DI, V9, P121; Cartwright R. Y., 1997, World Health Statistics Quarterly, V50, P102; DUPONT HL, 1993, NEW ENGL J MED, V328, P1821, DOI 10.1056/NEJM199306243282507; DUPONT HL, 1980, MICROBIOLOGY PATHOPH, P219; FARTHING MJG, 1992, GASTROENTEROLOGY INT, V5, P162; GUYATT G, 1989, GASTROENTEROLOGY, V96, P804, DOI 10.1016/0016-5085(89)90905-0; GUYATT GH, 1989, CAN MED ASSOC J, V140, P1441; HOLMGREN J, 1990, SCAND J INFECT DIS S, V70, P149; KOZICKI M, 1985, INT J EPIDEMIOL, V14, P169, DOI 10.1093/ije/14.1.169; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; MATHEWSON JJ, 1987, J CLIN MICROBIOL, V25, P1917, DOI 10.1128/JCM.25.10.1917-1919.1987; Mattila, 1995, J Travel Med, V2, P77, DOI 10.1111/j.1708-8305.1995.tb00631.x; MITCHELL A, 1988, J CLIN GASTROENTEROL, V10, P306, DOI 10.1097/00004836-198806000-00014; MURRAY BE, 1987, J INFECT DIS, V155, P809, DOI 10.1093/infdis/155.4.809; PELTOLA H, 1991, LANCET, V338, P1285, DOI 10.1016/0140-6736(91)92590-X; PEREDES P, IN PRESS J TRAVEL ME; PICKERING LK, 1977, J INFECT DIS, V135, P1003, DOI 10.1093/infdis/135.6.1003; RYAN NJ, 1993, J CLIN MICROBIOL, V31, P3264, DOI 10.1128/JCM.31.12.3264-3269.1993; STEFFEN R, 1994, JAMA-J AM MED ASSOC, V272, P885, DOI 10.1001/jama.272.11.885; STEFFEN R, 1983, JAMA-J AM MED ASSOC, V249, P1176; STUCKI A, 1997, THESIS U ZURICH ZURI; SVENNERHOLM AM, 1995, ADV EXP MED BIOL, V371, P1623; VIBOUD GI, 1993, J CLIN MICROBIOL, V31, P558, DOI 10.1128/JCM.31.3.558-564.1993; WHO, 1996, WHOPSA962, P5	28	114	118	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					811	817		10.1001/jama.281.9.811	http://dx.doi.org/10.1001/jama.281.9.811			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10071002	Bronze			2022-12-28	WOS:000078804300031
J	Kirby, M; Denihan, A; Bruce, I; Radic, A; Coakley, D; Lawlor, BA				Kirby, M; Denihan, A; Bruce, I; Radic, A; Coakley, D; Lawlor, BA			Influence of symptoms of anxiety on treatment of depression in later life in primary care: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							DISORDERS		St James Hosp, Mercers Inst Res Ageing, Dublin 8, Ireland; Hlth Res Board, Dept Med Elderly, Dublin 2, Ireland; Hlth Res Board, Dept Psychiat Elderly, Dublin 2, Ireland	Trinity College Dublin; Health Research Board - Ireland; Health Research Board - Ireland	Kirby, M (corresponding author), St James Hosp, Mercers Inst Res Ageing, Dublin 8, Ireland.							BLANCHARD MR, 1994, BRIT J PSYCHIAT, V164, P396, DOI 10.1192/bjp.164.3.396; COPELAND JRM, 1990, INT J GERIATR PSYCH, V5, P47, DOI 10.1002/gps.930050108; Kirby M, 1997, BRIT J PSYCHIAT, V171, P369, DOI 10.1192/bjp.171.4.369; KUA EH, 1996, INT J GERIATR PSYCH, V11, P699; Sartorius N, 1996, BRIT J PSYCHIAT, V168, P38, DOI 10.1192/S0007125000298395	5	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					579	580		10.1136/bmj.318.7183.579	http://dx.doi.org/10.1136/bmj.318.7183.579			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037636	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000078966300031
J	Piccolo, S; Agius, E; Leyns, L; Bhattacharyya, S; Grunz, H; Bouwmeester, T; De Robertis, EM				Piccolo, S; Agius, E; Leyns, L; Bhattacharyya, S; Grunz, H; Bouwmeester, T; De Robertis, EM			The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals	NATURE			English	Article							ANTERIOR PRIMITIVE ENDODERM; SPEMANN ORGANIZER; INDUCTION; MOUSE; GASTRULATION; REQUIREMENT; MESODERM	Embryological and genetic evidence indicates that the vertebrate head is induced by a different set of signals from those that organize trunk-tail development(1-6). The gene cerberus encodes a secreted protein that is expressed in anterior endoderm and has the unique property of inducing ectopic heads in the absence of trunk structures(1). Here we show that the cerberus protein functions as a multivalent growth-factor antagonist in the extracellular space: it binds to Nodal, BMP and Wnt proteins via independent sites. The expression of cerberus during gastrulation is activated by earlier nodal-related signals in endoderm and by Spemann-organizer factors that repress signalling by BMP and Wnt. In order for the head territory to form, we propose that signals involved in trunk development, such as those involving BMP, Wnt and Nodal proteins, must be inhibited in rostral regions.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; European Molecular Biology Laboratory (EMBL)	De Robertis, EM (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.		agius, Eric/AHC-9705-2022	Agius, Eric/0000-0003-2123-9283; PICCOLO, STEFANO/0000-0002-2037-0004; Leyns, Luc/0000-0001-7124-3155	NICHD NIH HHS [R37 HD021502, R37 HD021502-13] Funding Source: Medline; Telethon [E.0815] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Telethon(Fondazione Telethon); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Bouwmeester T, 1997, BIOESSAYS, V19, P855, DOI 10.1002/bies.950191005; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Chang CB, 1997, DEVELOPMENT, V124, P827; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Feldman B, 1998, NATURE, V395, P181, DOI 10.1038/26013; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Glinka A, 1997, NATURE, V389, P517, DOI 10.1038/39092; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Henry GL, 1998, SCIENCE, V281, P91, DOI 10.1126/science.281.5373.91; Hoppler S, 1998, MECH DEVELOP, V71, P119, DOI 10.1016/S0925-4773(98)00004-5; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; JONES CM, 1995, DEVELOPMENT, V121, P3651; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; Rhinn M, 1998, DEVELOPMENT, V125, P845; Sampath K, 1998, NATURE, V395, P185, DOI 10.1038/26020; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; Varlet I, 1997, DEVELOPMENT, V124, P1033; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5	24	655	701	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 25	1999	397	6721					707	710		10.1038/17820	http://dx.doi.org/10.1038/17820			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AP	10067895	Green Accepted			2022-12-28	WOS:000078840100053
J	Kenagy, JW; Berwick, DM; Shore, MF				Kenagy, JW; Berwick, DM; Shore, MF			Service quality in health care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SELF-MANAGEMENT; OUTCOMES; PHYSICIAN; MEDICINE; SATISFACTION; INVOLVEMENT	Although US health care is described as "the world's largest service industry," the quality of service-that is, the characteristics that shape the experience of care beyond technical competence-is rarely discussed in the medical literature, This article illustrates service quality principles by analyzing a routine encounter in health care from a service quality point of view, This illustration and a review of related literature from both inside and outside health care has led to the following 2 premises: First, if high-quality service had a greater presence in our practices and institutions, it would improve clinical outcomes and patient and physician satisfaction while reducing cost, and it would create competitive advantage for those who are expert in its application. Second, many other industries in the service sector have taken service quality to a high level, their techniques are readily transferable to health care, and physicians caring for patients can learn from them.	Harvard Univ, Sch Business, Boston, MA 02163 USA; Univ Washington, Sch Med, Seattle, WA USA; Harvard Univ, Sch Med, Inst Healthcare Improvement, Cambridge, MA 02138 USA; Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA	Harvard University; University of Washington; University of Washington Seattle; Harvard University; Institute for Healthcare Improvement; Harvard University	Kenagy, JW (corresponding author), MPA, 11 Brattle Cir, Cambridge, MA 02138 USA.							ANTHONY R, 1992, NOTE SERVICE MAPPING; Bennis W, 1970, AM BUREAUCRACY, P3; Blau P.M., 1974, NATURE ORG, P80; BLENDON RJ, 1988, JAMA-J AM MED ASSOC, V259, P3587, DOI 10.1001/jama.259.24.3587; BRODY DS, 1989, J GEN INTERN MED, V4, P506, DOI 10.1007/BF02599549; Cleary PD, 1997, JAMA-J AM MED ASSOC, V278, P1608, DOI 10.1001/jama.278.19.1608; DEVINE EC, 1992, PATIENT EDUC COUNS, V19, P129, DOI 10.1016/0738-3991(92)90193-M; EDGMANLEVITAN S, 1997, HLTH AFF, V15, P46; Gerteis M., 1993, PATIENTS EYES; Gray BH, 1997, HEALTH AFFAIR, V16, P34, DOI 10.1377/hlthaff.16.1.34; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; HART CWL, 1990, HARVARD BUSINESS JUL, P148; Heifetz Ronald A., 1994, LEADERSHIP EASY ANSW, P69; HERZLINGER R, 1997, MARKET DRIVEN HLTH C; HESKETT JL, 1997, SERVICE PROFIT CHAIN, P16; HESKETT JL, 1997, HARVARD BUSINESS MAR, P118; JONES TO, 1995, HARVARD BUSINESS NOV, P88; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; KELLEHER H, 1993, PEOPLE SERVICE SUCCE; KLEIN N, 1994, BRIT AIRWAYS USING I; Klein N., 1995, RITZ CARLTON USING I; Lahdensuo A, 1996, BRIT MED J, V312, P748; Larson CO, 1996, INT J QUAL HEALTH C, V8, P447, DOI 10.1093/intqhc/8.5.447; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEWIS CE, 1991, ANN INTERN MED, V114, P1, DOI 10.7326/0003-4819-114-1-1; LORIG KR, 1993, ARTHRITIS RHEUM, V36, P439, DOI 10.1002/art.1780360403; MAISTER PH, 1984, PSYCHOL WAITING TIME; MCSKIMMING SA, 1997, EXECUTIVE SUMMARY LI; Nolan T.W., 1996, REDUCING DELAYS WAIT; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; PARKINGTON JJ, 1979, ACAD MANAGE J, V22, P270, DOI 10.2307/255589; Porras JI., 1994, BUILT LAST SUCCESSFU; *ROP CTR PUBL OP R, 1994, PRINC SURV RES ASS N; *ROP CTR PUBL OP R, 1994, GALL CNN US TOD POLL; ROSENBLUTH HF, 1992, CUSTOMER COMES 2, P59; SCHLESINGER LA, 1991, HARVARD BUSINESS NOV, P148; SCHLESINGER LA, 1991, HUMAN RESOURCE PLANN, V14, P141; SOBEL DS, 1995, PSYCHOSOM MED, V57, P234, DOI 10.1097/00006842-199505000-00005; SPEAR S, IN PRESS TOYOTA PROD; SUCHMAN AL, 1993, MED CARE, V31, P1083, DOI 10.1097/00005650-199312000-00002; 1995, CONSUMER REPORTS FEB, P81	41	144	148	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1999	281	7					661	665		10.1001/jama.281.7.661	http://dx.doi.org/10.1001/jama.281.7.661			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	165YA	10029131				2022-12-28	WOS:000078548400040
J	Lip, GYH				Lip, GYH			Thromboprophylaxis for atrial fibrillation	LANCET			English	Editorial Material							LOW-DOSE WARFARIN; SECONDARY PREVENTION; TRIAL		Univ Birmingham, City Hosp, Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England	University of Birmingham	Lip, GYH (corresponding author), Univ Birmingham, City Hosp, Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England.							[Anonymous], 1997, ARCH INTERN MED, V157, P1237; BERN MM, 1990, ANN INTERN MED, V112, P423, DOI 10.7326/0003-4819-76-3-112-6-423; Blackshear JL, 1996, LANCET, V348, P633; Chan Kwan-Leung, 1998, Annals of Internal Medicine, V128, P639; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; Ezekowitz M, 1998, ARCH INTERN MED, V158, P1316; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Gullov AL, 1998, ARCH INTERN MED, V158, P1513, DOI 10.1001/archinte.158.14.1513; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LEVINE M, 1994, LANCET, V343, P886, DOI 10.1016/S0140-6736(94)90008-6; Lip GYH, 1996, CIRCULATION, V94, P425, DOI 10.1161/01.CIR.94.3.425; Meade TW, 1998, LANCET, V351, P233; Morocutti C, 1997, STROKE, V28, P1015, DOI 10.1161/01.STR.28.5.1015; Pengo V, 1998, AM J CARDIOL, V82, P433, DOI 10.1016/S0002-9149(98)00357-9; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Vermeer F., 1998, European Heart Journal, V19, P154	17	53	55	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 2	1999	353	9146					4	6		10.1016/S0140-6736(05)74877-7	http://dx.doi.org/10.1016/S0140-6736(05)74877-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023940				2022-12-28	WOS:000077934800005
J	Buchel, C; Coull, JT; Friston, KJ				Buchel, C; Coull, JT; Friston, KJ			The predictive value of changes in effective connectivity for human learning	SCIENCE			English	Article							SPATIAL LOCATION; OBJECT-LOCATION; EPISODIC MEMORY; REGIONS; HIPPOCAMPUS; MECHANISMS; RETRIEVAL; ATTENTION; NETWORKS; TERM	During learning, neural responses decrease over repeated exposure to identical stimuli. This repetition suppression is thought to reflect a progressive optimization of neuronal responses elicited by the task. Functional magnetic resonance imaging was used to study the neural basis of associative learning of visual objects and their locations. As expected, activation in specialized cortical areas decreased with time. However, with path analysis it was shown that, in parallel to this adaptation, increases in effective connectivity occurred between distinct cortical systems specialized for spatial and object processing. The time course of these plastic changes was highly correlated with individual learning performance, suggesting that interactions between brain areas underlie associative learning.	Inst Neurol, Wellcome Dept Cognit Neurol, 12 Queen Sq, London WC1N 3BG, England	University of London; University College London	Buchel, C (corresponding author), Inst Neurol, Wellcome Dept Cognit Neurol, 12 Queen Sq, London WC1N 3BG, England.	c.buechel@fil.ion.ucl.ac.uk	Friston, Karl/D-9230-2011; Coull, Jennifer T/M-4243-2015	Friston, Karl/0000-0001-7984-8909; Coull, Jennifer T/0000-0002-8790-5835				Aertsen A., 1991, DYNAMICS ACTIVITY CO; BAYLIS GC, 1987, EXP BRAIN RES, V65, P614; Buchel C, 1998, NEURON, V20, P947, DOI 10.1016/S0896-6273(00)80476-6; Buchel C, 1997, CEREB CORTEX, V7, P768, DOI 10.1093/cercor/7.8.768; BUCKNER RL, 1995, J NEUROSCI, V15, P12; Damasio A., 1994, LARGE SCALE NEURONAL, P61; Desimone R, 1996, P NATL ACAD SCI USA, V93, P13494, DOI 10.1073/pnas.93.24.13494; DISTLER C, 1993, J COMP NEUROL, V334, P125, DOI 10.1002/cne.903340111; EVANS AC, 1993, NUCLEAR SCIENCE SYMPOSIUM & MEDICAL IMAGING CONFERENCE, VOLS 1-3, P1813, DOI 10.1109/NSSMIC.1993.373602; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Friston K, 1995, HUM BRAIN MAPP, V2, P1; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Friston KJ, 1995, HUM BRAIN MAPP, V3, P302, DOI 10.1002/hbm.460030405; GERSTEIN GL, 1969, SCIENCE, V164, P828, DOI 10.1126/science.164.3881.828; Holmes AP, 1997, NEUROIMAGE, V5, pS480; HORWITZ B, 1992, J COGNITIVE NEUROSCI, V4, P311, DOI 10.1162/jocn.1992.4.4.311; Jouve B, 1998, CEREB CORTEX, V8, P28, DOI 10.1093/cercor/8.1.28; Kohler S, 1998, NEUROPSYCHOLOGIA, V36, P129, DOI 10.1016/S0028-3932(97)00098-5; Kohler S, 1998, CEREB CORTEX, V8, P451, DOI 10.1093/cercor/8.5.451; Luna B, 1998, CEREB CORTEX, V8, P40, DOI 10.1093/cercor/8.1.40; McIntosh A. R., 1994, Human Brain Mapping, V2, P2; McIntosh AR, 1998, J NEUROPHYSIOL, V80, P2790, DOI 10.1152/jn.1998.80.5.2790; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; Milner B, 1997, PHILOS T R SOC B, V352, P1469, DOI 10.1098/rstb.1997.0133; MOSCOVITCH M, 1995, P NATL ACAD SCI USA, V92, P3721, DOI 10.1073/pnas.92.9.3721; Owen AM, 1996, J COGNITIVE NEUROSCI, V8, P588, DOI 10.1162/jocn.1996.8.6.588; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SINGER W, 1995, SCIENCE, V270, P758, DOI 10.1126/science.270.5237.758; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; Ungerleider Leslie G., 1994, Current Opinion in Neurobiology, V4, P157, DOI 10.1016/0959-4388(94)90066-3; Wiggs CL, 1998, CURR OPIN NEUROBIOL, V8, P227, DOI 10.1016/S0959-4388(98)80144-X; WORSLEY KJ, 1995, NEUROIMAGE, V2, P173, DOI 10.1006/nimg.1995.1023	34	340	347	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 5	1999	283	5407					1538	1541		10.1126/science.283.5407.1538	http://dx.doi.org/10.1126/science.283.5407.1538			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066177				2022-12-28	WOS:000078959200049
J	Haywood, JM; Ramaswamy, V; Soden, BJ				Haywood, JM; Ramaswamy, V; Soden, BJ			Tropospheric aerosol climate forcing in clear-sky satellite observations over the oceans	SCIENCE			English	Article							SEA-SALT AEROSOLS; ANTHROPOGENIC SULFATE; ATMOSPHERIC AEROSOLS; RADIATION BUDGET; GREENHOUSE GASES; MODEL; SULFUR	Tropospheric aerosols affect the radiative forcing of Earth's climate, but their variable concentrations complicate an understanding of their global influence. Model-based estimates of aerosol distributions helped reveal spatial patterns indicative of the presence of tropospheric aerosols in the satellite-observed clear-sky solar radiation budget over the world's oceans. The results show that, although geographical signatures due to both natural and anthropogenic aerosols are manifest in the satellite observations, the naturally occurring sea-salt is the leading aerosol contributor to the global-mean dear-sky radiation balance over oceans.	Princeton Univ, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA; United Kingdom Meteorol Off, Meteorol Res Flight, Farnborough GU14 0LX, Hants, England	National Oceanic Atmospheric Admin (NOAA) - USA; Princeton University; Met Office - UK	Ramaswamy, V (corresponding author), Princeton Univ, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA.	vr@gfdl.gov	Ramaswamy, Venkatachalam/AAJ-6265-2021; Haywood, Jim/GQA-6691-2022; Soden, Brian/ABC-3659-2021	Ramaswamy, Venkatachalam/0000-0002-1984-6423; Haywood, Jim/0000-0002-2143-6634; Soden, Brian/0000-0001-9693-8236				Boucher O, 1995, J GEOPHYS RES-ATMOS, V100, P26117, DOI 10.1029/95JD02531; CHARLSON RJ, 1991, TELLUS A, V43, P152, DOI 10.1034/j.1600-0889.1991.t01-1-00013.x; Clegg NA, 1998, J GEOPHYS RES-ATMOS, V103, P31095, DOI 10.1029/98JD02595; COAKLEY JA, 1983, J ATMOS SCI, V40, P116, DOI 10.1175/1520-0469(1983)040<0116:TEOTAO>2.0.CO;2; Cooke WF, 1996, J GEOPHYS RES-ATMOS, V101, P19395, DOI 10.1029/96JD00671; CUSACK S, 1998, Q J R METEOROL SOC, V124, P2181; EXTON HJ, 1986, OCEANIC WHITECAPS TH, P195; FREIDENREICH SM, UNPUB; FREIDENREICH SM, 1997, 9 C ATM RAD FEBR 2 7, P129; GLEW MD, IN PRESS J GEOPHYS R; Gong SL, 1997, J GEOPHYS RES-ATMOS, V102, P3819, DOI 10.1029/96JD03401; HANSEN JE, 1983, MON WEATHER REV, V4, P609; HARRISON EF, 1990, J GEOPHYS RES-ATMOS, V95, P18687, DOI 10.1029/JD095iD11p18687; Haywood JM, 1998, J GEOPHYS RES-ATMOS, V103, P6043, DOI 10.1029/97JD03426; Haywood JM, 1997, J CLIMATE, V10, P1562, DOI 10.1175/1520-0442(1997)010<1562:GCMCOT>2.0.CO;2; Kasibhatla P, 1997, J GEOPHYS RES-ATMOS, V102, P3737, DOI 10.1029/96JD03084; Kiehl JT, 1998, J CLIMATE, V11, P1151, DOI 10.1175/1520-0442(1998)011<1151:TEBOTN>2.0.CO;2; KIEHL JT, 1993, SCIENCE, V260, P311, DOI 10.1126/science.260.5106.311; LANGNER J, 1991, J ATMOS CHEM, V13, P225, DOI 10.1007/BF00058134; LATHAM J, 1990, NATURE, V347, P372, DOI 10.1038/347372a0; Liousse C, 1996, J GEOPHYS RES-ATMOS, V101, P19411, DOI 10.1029/95JD03426; LOVETT RF, 1978, TELLUS, V30, P358, DOI 10.1111/j.2153-3490.1978.tb00851.x; Monahan E C, 1971, J PHYS OCEANOGR, V1, P139, DOI [10.1175/1520-0485(1971)0012.0.CO;2, DOI 10.1175/1520-0485(1971)0012.0.CO;2]; Murphy DM, 1998, NATURE, V392, P62, DOI 10.1038/32138; Quinn PK, 1998, J GEOPHYS RES-ATMOS, V103, P16547, DOI 10.1029/97JD02345; QUINN PK, IN PRESS J GEOPHYS R; RAMASWAMY, 1998, J GEOPHYS RES, V103, P23255; Schimel D, 1996, CLIMATE CHANGE 1995; Shettle E.P., 1979, MODELS AEROSOLS LOWE, P94; SIEVERING H, 1992, NATURE, V360, P571, DOI 10.1038/360571a0; Soden BJ, 1998, GEOPHYS RES LETT, V25, P2149, DOI 10.1029/98GL01509; TAYLOR KE, 1994, NATURE, V369, P734, DOI 10.1038/369734a0; Tegen I, 1996, NATURE, V380, P419, DOI 10.1038/380419a0; Tegen I, 1997, J GEOPHYS RES-ATMOS, V102, P23895, DOI 10.1029/97JD01864; TEGEN I, 1995, J GEOPHYS RES-ATMOS, V100, P18707, DOI 10.1029/95JD02051; TOON OB, 1976, J GEOPHYS RES-OC ATM, V81, P5733, DOI 10.1029/JC081i033p05733; TOON OB, 1976, J APPL METEOROL, V15, P225, DOI 10.1175/1520-0450(1976)015<0225:AGAMOA>2.0.CO;2; *WCP, 1986, PREL CLOUDL STAND AT; WENTZ FJ, 1992, IEEE T GEOSCI REMOTE, V30, P960, DOI 10.1109/36.175331	39	253	263	3	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 26	1999	283	5406					1299	1303		10.1126/science.283.5406.1299	http://dx.doi.org/10.1126/science.283.5406.1299			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037595				2022-12-28	WOS:000078839900034
J	Ochs, FA; Lange, RA				Ochs, FA; Lange, RA			The density of hydrous magmatic liquids	SCIENCE			English	Article							SILICATE MELTS; OXYGEN FUGACITY; CHAMBERS; GLASSES; COMPRESSIBILITY; WATER; TEMPERATURE; CONSTRAINTS; CONVECTION; H2O	Density measurements on several hydrous (less than or equal to 19 mole percent of H2O) silicate melts demonstrate that dissolved water has a partial molar volume ((V) over bar(H2O),) that is independent of the silicate melt composition, the total water concentration, and the speciation of water. The derived value for (V) over bar(H2O) is 22.9 +/- 0.6 cubic centimeters per mole at 1000 degrees C and 1 bar of pressure, whereas the partial molar thermal expansivity (partial derivative (V) over bar(H2O)/partial derivative T) and compressibility (partial derivative (V) over bar(H2O)/partial derivative P) are 9.5 +/- 0.8 x 10(-3) cubic centimeters per mole per kelvin and -3.2 +/- 0.6 x 10(-4) cubic centimeters per mole per bar, respectively. The effect of 1 weight percent dissolved H2O on the density of a basaltic melt is equivalent to increasing the temperature of the melt by similar to 400 degrees C or decreasing the pressure of the melt by similar to 500 megapascals. These measurements are used to illustrate the viability of plagioclase sinking in iron-rich basaltic Liquids and the dominance of compositional convection in hydrous magma chambers.	Univ Michigan, Dept Geol Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Ochs, FA (corresponding author), Univ Michigan, Dept Geol Sci, 1006 CC Little Bldg, Ann Arbor, MI 48109 USA.							BOCKRIS JO, 1956, T FARADAY SOC, V52, P299, DOI 10.1039/tf9565200299; BOTTINGA Y, 1970, AM J SCI, V269, P169, DOI 10.2475/ajs.269.2.169; Boudreau AE, 1997, J PETROL, V38, P1003, DOI 10.1093/petrology/38.8.1003; Brandeis G., 1987, ORIGINS IGNEOUS LAYE, P613; BURNHAM CW, 1971, AM J SCI, V270, P54, DOI 10.2475/ajs.270.1.54; CAMPBELL IH, 1978, LITHOS, V11, P311, DOI 10.1016/0024-4937(78)90038-5; CAMPBELL IH, 1978, CONTRIB MINERAL PETR, V67, P369, DOI 10.1007/BF00383297; FORNARI DJ, 1983, J GEOPHYS RES, V88, P519, DOI 10.1029/JB088iB12p10519; Irvine TN, 1998, GEOL SOC AM BULL, V110, P1398, DOI 10.1130/0016-7606(1998)110<1398:IBABWB>2.3.CO;2; JOHNSON MC, 1994, REV MINERAL, V30, P281; KRESS VC, 1991, CONTRIB MINERAL PETR, V108, P82, DOI 10.1007/BF00307328; KRESS VC, 1988, GEOCHIM COSMOCHIM AC, V52, P288; Lange RA, 1996, GEOCHIM COSMOCHIM AC, V60, P4989, DOI 10.1016/S0016-7037(96)00301-8; Lange RA, 1996, CONTRIB MINERAL PETR, V125, P167, DOI 10.1007/s004100050214; LANGE RA, 1987, GEOCHIM COSMOCHIM AC, V51, P2931, DOI 10.1016/0016-7037(87)90368-1; LANGE RL, 1990, REV MINERAL, V24, P25; MARTIN D, 1987, CONTRIB MINERAL PETR, V96, P465, DOI 10.1007/BF01166691; MCBIRNEY AR, 1985, J VOLCANOL GEOTH RES, V24, P1, DOI 10.1016/0377-0273(85)90026-5; Moore G, 1998, AM MINERAL, V83, P36; Moynihan CT, 1995, REV MINERAL, V32, P1; MUENOW DW, 1990, NATURE, V343, P159, DOI 10.1038/343159a0; MYSEN BO, 1982, REV GEOPHYS, V20, P353, DOI 10.1029/RG020i003p00353; Ochs FA, 1997, CONTRIB MINERAL PETR, V129, P155, DOI 10.1007/s004100050329; Richet P, 1998, SCIENCE, V281, P396, DOI 10.1126/science.281.5375.396; RIVERS ML, 1987, J GEOPHYS RES-SOLID, V92, P9247, DOI 10.1029/JB092iB09p09247; Shaw H.R., 1974, CARNEGIE I WASH YR B, V634, P139; SILVER LA, 1990, CONTRIB MINERAL PETR, V104, P142, DOI 10.1007/BF00306439; SNYDER D, 1993, CONTRIB MINERAL PETR, V113, P73, DOI 10.1007/BF00320832; SPARKS RSJ, 1984, PHILOS T R SOC A, V310, P511, DOI 10.1098/rsta.1984.0006; SPERA FJ, 1984, NATURE, V310, P764, DOI 10.1038/310764a0; STEIN DJ, 1986, J AM CERAM SOC, V69, P396, DOI 10.1111/j.1151-2916.1986.tb04767.x; TANGEMAN JA, 1998, THESIS U MICHIGAN AN; TRIAL AF, 1990, GEOL SOC AM BULL, V102, P353, DOI 10.1130/0016-7606(1990)102<0353:MFTGOC>2.3.CO;2; TURNER JS, 1986, EARTH-SCI REV, V23, P255, DOI 10.1016/0012-8252(86)90015-2; VENNEMANN TW, 1993, CHEM GEOL, V103, P227, DOI 10.1016/0009-2541(93)90303-Z; Wager L. R., 1968, LAYERED IGNEOUS ROCK; Wallace PJ, 1998, B VOLCANOL, V59, P327, DOI 10.1007/s004450050195; Zhang YX, 1997, GEOCHIM COSMOCHIM AC, V61, P3089, DOI 10.1016/S0016-7037(97)00151-8	38	277	281	3	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 26	1999	283	5406					1314	1317		10.1126/science.283.5406.1314	http://dx.doi.org/10.1126/science.283.5406.1314			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037599				2022-12-28	WOS:000078839900038
J	Black, ME				Black, ME			Personal view - Breast feeding and my brain	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Queensland, N Queensland Clin Sch, St Lucia, Qld 4067, Australia	University of Queensland	Black, ME (corresponding author), Univ Queensland, N Queensland Clin Sch, St Lucia, Qld 4067, Australia.								0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1999	318	7182					545	545		10.1136/bmj.318.7182.545	http://dx.doi.org/10.1136/bmj.318.7182.545			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QT	10024289	Green Published			2022-12-28	WOS:000078818100072
J	Beecham, L				Beecham, L			Defence medical services have been cut too steeply	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					675	675						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066228				2022-12-28	WOS:000079089200075
J	Shalala, DE				Shalala, DE			A patients' Bill of Rights: The medical student's role	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Knowles E., 1997, OXFORD DICT PHRASE S; President's Advisory Commission on Consumer Protection and Quality in the Health Care Industry, 1998, QUAL 1 BETT HLTH CAR	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					857	857		10.1001/jama.281.9.857	http://dx.doi.org/10.1001/jama.281.9.857			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10071010	hybrid			2022-12-28	WOS:000078804300040
J	Schroeder, SA; Schapiro, R				Schroeder, SA; Schapiro, R			The hospitalist: New boon for internal medicine or retreat from primary care?	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	National Policy Conference on the Hospitalist Movement	DEC 05-06, 1997	SAN FRANCISCO, CA				PHYSICIANS	The growing reliance on hospitalists in the United States has implications for several areas of internal medicine, including patient care, administration, clinical practice, and medical education. This paper discusses some of the potential advantages and disadvantages of the use of hospitalists in each of these areas. The new hospitalist practice mode highlights long-standing tensions about the role and direction of internal medicine, tensions that affect generalist and specialty care in both outpatient and hospital settings. The career trajectory of hospitalists will depend on whether burnout is a problem and on whether hospitalists will be able to compete effectively with subspecialists, such as cardiologists and physicians specializing in AIDS. Clearly, hospitalism meets a clinical need and expands opportunities for internists, but it is important that it not overreach, forfeiting primary care turf and distorting medical education. This new field warrants close monitoring because of its potential effects and because-unlike related fields, such as emergency medicine and intensive care-its birth was strongly influenced by system-wide financial considerations.	Robert Wood Johnson Fdn, Princeton, NJ 08543 USA	Robert Wood Johnson Foundation (RWJF)	Schroeder, SA (corresponding author), Robert Wood Johnson Fdn, POB 2316, Princeton, NJ 08543 USA.							*AM AC FAM PHYS DI, 1998, 1997 NAT RES MATCH P; *COUNC GRAD MED ED, 1995, PHYS WORKF FUND REC; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; Diamond HS, 1998, ANN INTERN MED, V129, P197, DOI 10.7326/0003-4819-129-3-199808010-00006; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; GESENSWAY D, 1997, ACP OBSERVER, V5, P1; KAPOOR WN, 1983, NEW ENGL J MED, V309, P197, DOI 10.1056/NEJM198307283090401; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LARSON EB, 1985, J GERONTOL, V40, P536, DOI 10.1093/geronj/40.5.536; LUFT HS, 1987, HEALTH SERV RES, V22, P157; Miller RS, 1997, JAMA-J AM MED ASSOC, V277, P1699, DOI 10.1001/jama.277.21.1699; SCHROEDER SA, 1986, ANN INTERN MED, V104, P554, DOI 10.7326/0003-4819-104-4-554; STEVENS R, 1986, ANN INTERN MED, V105, P592, DOI 10.7326/0003-4819-105-4-592; Wachter RM, 1999, ANN INTERN MED, V130, P338, DOI 10.7326/0003-4819-130-4-199902161-00002; Wachter RM, 1998, JAMA-J AM MED ASSOC, V279, P1560, DOI 10.1001/jama.279.19.1560; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713; WIEBE C, 1997, AM MED NEWS     0901, P1	19	41	41	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	2				382	387		10.7326/0003-4819-130-4-199902161-00011	http://dx.doi.org/10.7326/0003-4819-130-4-199902161-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	166QB	10068411				2022-12-28	WOS:000078587500011
J	Sox, HC				Sox, HC			The hospitalist model: Perspectives of the patient, the internist, and internal medicine	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	National Policy Conference on the Hospitalist Movement	DEC 05-06, 1997	SAN FRANCISCO, CA					The use of hospitalists has implications for patients, for internists, and for the specialty of internal medicine. For patients, the greatest concern is interrupting the continuity of a supportive relationship with their regular physican. For many internists, the hospitalist model is attractive, but they are concerned that health plans will compel physicians to transfer their patients to a hospitalist at the time of admission to the hospital (mandatory hand-off). Thus, the hospitalist could become the means to exclude internists from hospital care and deprive them of an important source of professional satisfaction. The specialty of internal medicine is very concerned about the mandatory hand-off because it threatens the internist's identity as the physician who can care for the sickest patients in any venue, making it harder for patients and health plans to distinguish the internist from family physicians and nurse practitioners. The hospitalist movement has much to offer internal medicine. To enjoy the benefits and avoid the harms associated with the hospitalist model, internal medicine must resist the imposition of the mandatory hand-off and use the hospitalist's focus on excellent inpatient care to improve the practice of medicine by all internists.	Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA	Dartmouth College	Sox, HC (corresponding author), 9 Faraway Lane, Hanover, NH 03755 USA.	harold.c.sox@dartmouth.edu						BABBOTT D, 1991, ANN INTERN MED, V114, P16, DOI 10.7326/0003-4819-114-1-16; ENDE J, 1997, GRADUATE ED INTERNAL; LURIE JD, IN PRESS AM J MED; *RW JOHNS FDN, 1981, MED PRACT US; SCHWARTZ MD, 1991, ANN INTERN MED, V114, P6, DOI 10.7326/0003-4819-114-1-6; SOX HC, 1994, ANN INTERN MED, V121, P616, DOI 10.7326/0003-4819-121-8-199410150-00011; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713	7	46	46	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	2				368	372		10.7326/0003-4819-130-4-199902161-00008	http://dx.doi.org/10.7326/0003-4819-130-4-199902161-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	166QB	10068408				2022-12-28	WOS:000078587500008
J	Mortimer, PP				Mortimer, PP			The bacteria craze of the 1880s	LANCET			English	Article									Cent Publ Hlth Lab, Div Virus Reference, Hepatitis & Retrovirus Lab, London NW9 5HT, England	Public Health England	Mortimer, PP (corresponding author), Cent Publ Hlth Lab, Div Virus Reference, Hepatitis & Retrovirus Lab, London NW9 5HT, England.							ANDREWES FW, 1925, EE KLEIN OBITUARY NO, pR25; Bulloch W., 1938, HIST BACTERIOLOGY; Bulloch William, 1925, J PATHOL BACTERIOL, V28, p[684, 696]; CLARK PF, 1961, PIONEER MICROBIOLOGI, P51; CROOKSHANK EM, 1887, PHOTOGRAPHY BACTERIA; CROOKSHANK EM, 1886, INTRO PRACTICAL BACT; CROOKSHANK EM, 1882, LANCET, V1, P615; Crookshank EM, 1889, HIST PATHOLOGY VACCI; FLUGGE C, 1890, MICROORGANISMS SPECI; HART E, 1882, BRIT MED J, V2, P807; HOWARDJONES N, 1975, SCI BACKGROUND INT S, P53; Isaacs JD, 1998, MED HIST, V42, P279, DOI 10.1017/S0025727300063997; KOCH R, 1998, LIFE MED BACTERIOLOG; MOONEY G, 1997, MED HIST, V41, P278; Sternberg G.M., 1896, TXB BACTERIOLOGY, V2nd rev; STERNBERG GM, 1893, MANUAL BACTERIOLOGY; 1928, LANCET, V1, P41; 1915, JAMA, P1745; 1928, VET REC, V8, P550	19	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 13	1999	353	9152					581	584		10.1016/S0140-6736(98)08519-5	http://dx.doi.org/10.1016/S0140-6736(98)08519-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10029000				2022-12-28	WOS:000078670200044
J	Hojo, M; Morimoto, T; Maluccio, M; Asano, T; Morimoto, K; Lagman, M; Shimbo, T; Suthanthiran, M				Hojo, M; Morimoto, T; Maluccio, M; Asano, T; Morimoto, K; Lagman, M; Shimbo, T; Suthanthiran, M			Cyclosporine induces cancer progression by a cell-autonomous mechanism	NATURE			English	Article							GROWTH-FACTOR-BETA; MONOCLONAL-ANTIBODIES; CARCINOMA; TUMOR; EXPRESSION; THERAPY; MICE; TRANSPLANTATION; FACTOR-BETA-1; INTERLEUKIN-2	Malignancy is a common and dreaded complication following, organ transplantation(1-4). The high incidence of neoplasm and its aggressive progression, which are associated with immunosuppressive therapy, are thought to be due to the resulting impairment of the organ recipient's immune-surveillance system(5-9). Here we report a mechanism for the heightened malignancy that is independent of host immunity. We show that cyclosporine (cyclosporin A), an immunosuppressant that has had a major impact on improving patient outcome following organ transplantation(4,5), induces phenotypic changes, including invasiveness of non-transformed cells, by a cell-autonomous mechanism. Our studies show that cyclosporine treatment of adenocarcinoma cells results in striking morphological alterations, including membrane ruffling and numerous pseudopodial protrusions, increased cell motility, and anchorage-independent (invasive) growth. These changes are prevented by treatment with monoclonal antibodies directed at transforming growth factor-beta (TGF-beta). In vivo, cyclosporine enhances tumour growth in immunodeficient SCID-beige Mice; anti-TGF-beta monoclonal antibodies but not control antibodies prevent the cyclosporine-induced increase in the number of metastases. Our findings suggest that immunosuppressants like cyclosporine can promote cancer progression by a direct cellular effect that is independent of its effect on the host's immune cells, and that cyclosporine-induced TGF-beta production is involved in this.	Cornell Univ, Weill Med Coll, Dept Transplantat Med & Extracorporeal Therapy, Div Nephrol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Surg, New York, NY 10021 USA; Teikyo Univ, Sch Med, Mizonokuchi Hosp, Dept Pediat,Takatsu Ku, Kawasaki, Kanagawa 213, Japan; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; Natl Def Med Coll, Dept Urol, Tokorozawa, Saitama 359, Japan	Cornell University; Cornell University; Cornell University; Teikyo University; New York University; National Defense Medical College - Japan	Hojo, M (corresponding author), Cornell Univ, Weill Med Coll, Dept Transplantat Med & Extracorporeal Therapy, Div Nephrol, 525 E 68th St, New York, NY 10021 USA.		Suthanthiran, Manikkam/AAL-9104-2020					ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; Asano T, 1997, J UROLOGY, V157, P2396, DOI 10.1016/S0022-5347(01)64787-6; ATREGA CI, 1993, J CLIN INVEST, V92, P2569; BERTRAM JS, 1980, CANCER LETT, V11, P63, DOI 10.1016/0304-3835(80)90130-5; BUBENIK J, 1973, INT J CANCER, V11, P765, DOI 10.1002/ijc.2910110327; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; COHENGOULD L, 1987, AM J PATHOL, V127, P327; COUCHMAN JR, 1985, EUR J CELL BIOL, V36, P182; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DASCH JR, 1989, J IMMUNOL, V142, P1536; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GUIRGUIS R, 1987, NATURE, V329, P261, DOI 10.1038/329261a0; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KHANNA A, 1994, TRANSPLANTATION, V57, P577; LI B, 1991, J EXP MED, V174, P1259, DOI 10.1084/jem.174.5.1259; LONDON NJ, 1995, LANCET, V346, P403, DOI 10.1016/S0140-6736(95)92780-8; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASUHARA M, 1993, CARCINOGENESIS, V14, P1579, DOI 10.1093/carcin/14.8.1579; MOORADIAN DL, 1992, J NATL CANCER I, V84, P523, DOI 10.1093/jnci/84.7.523; MOSIER DE, 1993, J EXP MED, V177, P191, DOI 10.1084/jem.177.1.191; MURPHY GP, 1973, JNCI-J NATL CANCER I, V50, P1013, DOI 10.1093/jnci/50.4.1013; PENN I, 1987, TRANSPLANTATION, V43, P32, DOI 10.1097/00007890-198701000-00008; SHIMIZU T, 1989, IMMUNOBIOLOGY, V178, P401, DOI 10.1016/S0171-2985(89)80062-2; SUTHANTHIRAN M, 1994, NEW ENGL J MED, V331, P365, DOI 10.1056/NEJM199408113310606; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; VANDERELST J, 1986, J NATL CANCER I, V77, P227; VandeVrie W, 1997, J CANCER RES CLIN, V123, P21, DOI 10.1007/BF01212610; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; WOLF G, 1995, TRANSPLANTATION, V60, P237, DOI 10.1097/00007890-199508000-00005; YOKOYAMA I, 1991, CANCER, V68, P2095, DOI 10.1002/1097-0142(19911115)68:10<2095::AID-CNCR2820681002>3.0.CO;2-Y	30	874	920	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 11	1999	397	6719					530	534		10.1038/17401	http://dx.doi.org/10.1038/17401			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KN	10028970				2022-12-28	WOS:000078574900052
J	Grant, SR				Grant, SR			Dissecting the mechanisms of posttranscriptional gene silencing: Divide and conquer	CELL			English	Review							DE-NOVO METHYLATION; TRANSGENIC PLANTS; RNA; SUPPRESSION; VIRUS; EXPRESSION; RESISTANCE; SEQUENCES; DNA		Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Mol Biol & Genet, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Grant, SR (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.							Anandalakshmi R, 1998, P NATL ACAD SCI USA, V95, P13079, DOI 10.1073/pnas.95.22.13079; Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; Baulcombe DC, 1996, CURR OPIN BIOTECH, V7, P173, DOI 10.1016/S0958-1669(96)80009-7; Brigneti G, 1998, EMBO J, V17, P6739, DOI 10.1093/emboj/17.22.6739; Bruening G, 1998, P NATL ACAD SCI USA, V95, P13349, DOI 10.1073/pnas.95.23.13349; Carrington JC, 1998, CURR OPIN PLANT BIOL, V1, P336, DOI 10.1016/1369-5266(88)80056-6; English JJ, 1996, PLANT CELL, V8, P179, DOI 10.1105/tpc.8.2.179; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Hamilton AJ, 1998, PLANT J, V15, P737, DOI 10.1046/j.1365-313X.1998.00251.x; Jones AL, 1998, EMBO J, V17, P6385, DOI 10.1093/emboj/17.21.6385; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; Mette MF, 1999, EMBO J, V18, P241, DOI 10.1093/emboj/18.1.241; Palauqui JC, 1999, CURR BIOL, V9, P59, DOI 10.1016/S0960-9822(99)80016-5; Pang SZ, 1996, PLANT J, V9, P899, DOI 10.1046/j.1365-313X.1996.9060899.x; ROMANO N, 1992, MOL MICROBIOL, V6, P3343, DOI 10.1111/j.1365-2958.1992.tb02202.x; Ruiz F, 1998, MOL BIOL CELL, V9, P931, DOI 10.1091/mbc.9.4.931; Schiebel W, 1998, PLANT CELL, V10, P2087, DOI 10.1105/tpc.10.12.2087; Vaucheret H, 1998, PLANT J, V16, P651, DOI 10.1046/j.1365-313x.1998.00337.x; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959	24	75	104	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 5	1999	96	3					303	306		10.1016/S0092-8674(00)80541-3	http://dx.doi.org/10.1016/S0092-8674(00)80541-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025394	Bronze			2022-12-28	WOS:000078514600001
J	Lynn, LA; Bellini, LM				Lynn, LA; Bellini, LM			Portable knowledge: A look inside white coat pockets	ANNALS OF INTERNAL MEDICINE			English	Article									Univ Penn, Med Ctr, Div Gen Internal Med, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Lynn, LA (corresponding author), Univ Penn, Med Ctr, Div Gen Internal Med, 3400 Spruce St, Philadelphia, PA 19104 USA.							CAREY CF, 1998, WASHINGTON MANUAL ME; FARRAJ R, 1991, J ROY SOC MED, V84, P43, DOI 10.1177/014107689108400116; GILBERT D, 1998, SANFORD GUIDE ANTIMI; GREEN S, 1998, POCKET PHARMACOPOEIA; ROLLINGS RC, 1998, FACTS FORMULAS	5	12	14	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 2	1999	130	3					247	250		10.7326/0003-4819-130-3-199902020-00039	http://dx.doi.org/10.7326/0003-4819-130-3-199902020-00039			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	162PD	10049219				2022-12-28	WOS:000078355000037
J	Widell, A; Christensson, B; Wiebe, T; Schalen, C; Hansson, HB; Allander, T; Persson, MAA				Widell, A; Christensson, B; Wiebe, T; Schalen, C; Hansson, HB; Allander, T; Persson, MAA			Epidemiologic and molecular investigation of outbreaks of hepatitis C virus infection on a pediatric oncology service	ANNALS OF INTERNAL MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; NOSOCOMIAL TRANSMISSION; HEMODIALYSIS UNIT; RISK-FACTORS; B VIRUS; WORKERS; ASSAYS	Background: Despite screening of blood donors, hepatitis C virus (HCV) infection can occur in patients who receive multiple transfusions. Objective: To clarify mechanisms of nosocomial transmission of HCV. Design: Epidemiologic and molecular analyses of hepatitis C outbreaks. Setting: Pediatric oncology ward. Patients: Children with cancer. Measurements: Epidemiologic analysis, HCV RNA detection, genotyping, and hypervariable region 1 (HVR1) sequencing. Results: Ten cases of infection with acute HCV genotype 3a occurred between 1990 and 1993. Sequencing of HVR1 revealed three related strains. Despite an overhaul of hygiene procedures, a patient infected with genotype 1b generated nine subsequent infected patients in 1994. Several patients had high virus titers and strongly delayed anti-HCV antibody responses. All had permanent intravenous catheters. Multidose Vials used for flushing or treatment had probably been contaminated during periods of overlapping treatment Conclusions: Contamination of multidose vials was the most likely mode of HCV transmission; therefore, use of such Vials should be restricted. Rigorous adherence to hygiene routines remains essential to preventing transmission of bloodborne infections.	Malmo Univ Hosp, Dept Med Microbiol, S-20502 Malmo, Sweden; Univ Lund Hosp, Dept Infect Dis, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Pediat, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Hosp Infect Control, S-22185 Lund, Sweden; Malmo Univ Hosp, Reg Ctr Communicable Dis, S-20502 Malmo, Sweden; Univ Uppsala Hosp, Dept Clin Microbiol, S-75185 Uppsala, Sweden; Karolinska Hosp, Dept Med, S-17176 Stockholm, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Uppsala University; Uppsala University Hospital; Karolinska Institutet; Karolinska University Hospital	Widell, A (corresponding author), Malmo Univ Hosp, Dept Med Microbiol, S-20502 Malmo, Sweden.			Persson, Mats/0000-0002-5118-6584; Wiebe, Thomas/0000-0002-7567-9076				Abulrahi HA, 1997, LANCET, V349, P23, DOI 10.1016/S0140-6736(96)03508-8; ALLANDER T, 1995, LANCET, V345, P603, DOI 10.1016/S0140-6736(95)90518-9; ALLANDER T, 1994, J MED VIROL, V43, P415, DOI 10.1002/jmv.1890430417; CHEN TZ, 1995, J MED VIROL, V46, P247, DOI 10.1002/jmv.1890460314; ElSayed NM, 1996, AM J TROP MED HYG, V55, P179, DOI 10.4269/ajtmh.1996.55.179; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; FARCI P, 1992, J INFECT DIS, V165, P1006, DOI 10.1093/infdis/165.6.1006; Flaum A., 1926, ACTA MED SCAND, V16, P544; Guadagnino V, 1997, HEPATOLOGY, V26, P1006, DOI 10.1053/jhep.1997.v26.pm0009328327; HAYASHI J, 1995, AM J GASTROENTEROL, V90, P794; POLISH LB, 1992, NEW ENGL J MED, V326, P721, DOI 10.1056/NEJM199203123261101; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHVARCZ R, 1995, LANCET, V346, P190, DOI 10.1016/S0140-6736(95)91252-5; Stuyver L, 1996, KIDNEY INT, V49, P889, DOI 10.1038/ki.1996.122; TEDDER RS, 1995, LANCET, V346, P137, DOI 10.1016/S0140-6736(95)91207-X; WIDELL A, 1994, J MED VIROL, V44, P272, DOI 10.1002/jmv.1890440311; WIDELL A, 1991, J MED VIROL, V35, P253, DOI 10.1002/jmv.1890350409; Widell A, 1997, TRANSFUSION, V37, P313, DOI 10.1046/j.1537-2995.1997.37397240215.x; Zeuzem S, 1996, J HEPATOL, V24, P3	19	89	92	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	1999	130	2					130	134		10.7326/0003-4819-130-2-199901190-00007	http://dx.doi.org/10.7326/0003-4819-130-2-199901190-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158KG	10068359				2022-12-28	WOS:000078114200006
J	Isles, C; Norrie, J; Paterson, J; Ritchie, L				Isles, C; Norrie, J; Paterson, J; Ritchie, L			Risk of major gastrointestinal bleeding with aspirin	LANCET			English	Letter									Dumfries Infirm, Dept Med, Dumfries DG1 4AP, Scotland; Univ Glasgow, Glasgow, Lanark, Scotland; Univ Aberdeen, Aberdeen, Scotland	University of Glasgow; University of Aberdeen	Isles, C (corresponding author), Dumfries Infirm, Dept Med, Dumfries DG1 4AP, Scotland.			zanchetti, alberto/0000-0003-4796-7959				Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Meade TW, 1998, LANCET, V351, P233; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; Suissa S, 1998, AM J MED, V105, P230, DOI 10.1016/S0002-9343(98)00239-3; 1997, DRUG THER B, V35, P7	5	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 9	1999	353	9147					148	149		10.1016/S0140-6736(05)76185-7	http://dx.doi.org/10.1016/S0140-6736(05)76185-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023923				2022-12-28	WOS:000078087200052
J	Muennig, P; Pallin, D; Sell, RL; Chan, MS				Muennig, P; Pallin, D; Sell, RL; Chan, MS			The cost effectiveness of strategies for the treatment of intestinal parasites in immigrants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOUTHEAST-ASIAN REFUGEES; STRONGYLOIDES-STERCORALIS; STOOL EXAMINATIONS; CONTROLLED TRIAL; ALBENDAZOLE; PREVALENCE; INFECTION; MORBIDITY; DISEASE; COMMUNITY	Background Currently, more than 600,000 immigrants enter the United States each year from countries where intestinal parasites are endemic. At entry persons with parasitic infections may be asymptomatic, and stool examinations are not a sensitive method of screening for parasitosis. Albendazole is a new, broad-spectrum antiparasitic drug, which was approved recently by the Food and Drug Administration. International trials have shown albendazole to be safe and effective in eradicating many parasites. In the United States there is now disagreement about whether to screen all immigrants for parasites, treat all immigrants presumptively, or do nothing unless they have symptoms. Methods We compared the costs and benefits of no preventive intervention (watchful waiting) with those of universal screening or presumptive treatment with 400 mg of albendazole per day for five days. Those at risk were defined as immigrants to the United States from Asia, the Middle East, sub-Saharan Africa, Eastern Europe, and Latin America and the Caribbean. Cost effectiveness was expressed both in terms of the cost of treatment per disability-adjusted life-year (DALY) averted (one DALY is defined as the loss of one year of healthy life to disease) and in terms of the cost per hospitalization averted. Results As compared with watchful waiting, presumptive treatment of all immigrants at risk for parasitosis would avert at least 870 DALYs, prevent at least 33 deaths and 374 hospitalizations, and save at least $4.2 million per year. As compared with watchful waiting, screening would cost $159,236 per DALY averted. Conclusions Presumptive administration of albendazole to all immigrants at risk for parasitosis would save lives and money. Universal screening, with treatment of persons with positive stool examinations, would save lives but is less cost effective than presumptive treatment. (N Engl J Med 1999;340:773-9.) (C)1999, Massachusetts Medical Society.	New York City Dept Hlth, Refugee Hlth Program, New York, NY 10013 USA; New York City Dept Hlth, Prevent Med Residency Program, New York, NY 10013 USA; Columbia Univ, Sch Publ Hlth, Div Sociomed Sci, New York, NY USA; Univ Oxford, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford, England	New York City Department of Health & Mental Hygiene; New York City Department of Health & Mental Hygiene; Columbia University; University of Oxford	Muennig, P (corresponding author), New York City Dept Hlth, Refugee Hlth Program, 125 Worth St,Box 21-A, New York, NY 10013 USA.		Pallin, Daniel J/H-6382-2013	Pallin, Daniel J/0000-0002-8517-9702; Muennig, Peter/0000-0002-4234-0498				*AG HLTH CAR POL R, 1994, HCUP3 AG HLTH CAR PO; ALBONICO M, 1994, T ROY SOC TROP MED H, V88, P585, DOI 10.1016/0035-9203(94)90174-0; Allan JC, 1997, T ROY SOC TROP MED H, V91, P595, DOI 10.1016/S0035-9203(97)90042-0; ANDERSON JP, 1985, JAMA-J AM MED ASSOC, V15, P2229; ARCHIBALD LK, 1993, Q J MED, V86, P191; ARFAA F, 1981, J FAM PRACTICE, V12, P223; BARRETTCONNOR E, 1982, AM J TROP MED HYG, V31, P466, DOI 10.4269/ajtmh.1982.31.466; BUCHWALD D, 1995, J CLIN PHARM THER, V20, P271, DOI 10.1111/j.1365-2710.1995.tb00662.x; CATANZARO A, 1982, JAMA-J AM MED ASSOC, V247, P1303, DOI 10.1001/jama.247.9.1303; Cromwell J, 1997, JAMA-J AM MED ASSOC, V278, P1759, DOI 10.1001/jama.278.21.1759; deSilva NR, 1997, TROP MED INT HEALTH, V2, P519; FERNANDEZ EW, 1994, 8 BUR CENS; Freedberg KA, 1998, JAMA-J AM MED ASSOC, V279, P130, DOI 10.1001/jama.279.2.130; GENTA RM, 1989, REV INFECT DIS, V11, P755; GILL GV, 1979, BRIT MED J, V2, P572, DOI 10.1136/bmj.2.6190.572; GILLES HM, 1991, HUMAN PARASITIC DIS, V4, P170; Gold MR, 1996, COST EFFECTIVENESS H; GROVE DI, 1989, STRONGYLOIDIASIS MAJ, P218; GROVE DI, 1989, STRONGYLOIDIASIS MAJ, P210; GUYATT HL, 1991, T ROY SOC TROP MED H, V85, P778, DOI 10.1016/0035-9203(91)90453-6; GYORKOS TW, 1989, AM J EPIDEMIOL, V129, P753, DOI 10.1093/oxfordjournals.aje.a115190; HALL A, 1993, T ROY SOC TROP MED H, V87, P84, DOI 10.1016/0035-9203(93)90435-S; *IMM NAT SERV, 1997, STAT YB IMM NAT SERV; *MA DEP HLTH REF I, 1997, REF HLTH PROGR DAT J; Marti H, 1996, AM J TROP MED HYG, V55, P477, DOI 10.4269/ajtmh.1996.55.477; MARTI H, 1993, J CLIN MICROBIOL, V31, P3044, DOI 10.1128/JCM.31.11.3044-3045.1993; MCCAW BR, 1985, WESTERN J MED, V143, P271; *MN DEP HLTH REF H, 1997, REF HLTH PROGR DAT; MURRAY CLJ, 1996, GLOBAL BURDEN DIS CO, V1, P64; MURRAY CLJ, 1996, GLOBAL BURDEN DIS CO, V1, P413; *NY CIT DEP CIT PL, 1996, PUBL DCP, V9619, P7; *NY STAT DEP HLTH, 1996, CLAIM DET SPEC REP C; *NY STAT DEP HLTH, 1996, STAT PLANN RES COOP; *NY STAT DEP SOC S, 1997, MMIS PROV MAN MED MA; PERSSON A, 1994, SCAND J INFECT DIS, V26, P199, DOI 10.3109/00365549409011784; Pungpak S, 1997, AM J TROP MED HYG, V56, P311, DOI 10.4269/ajtmh.1997.56.311; PUNGPARK S, 1984, Southeast Asian Journal of Tropical Medicine and Public Health, V15, P44; Romero-Cabello Raul, 1995, Revista Latinoamericana de Microbiologia, V37, P315; ROSSIGNOL JF, 1983, T ROY SOC TROP MED H, V77, P707, DOI 10.1016/0035-9203(83)90211-0; SALAS SD, 1990, ARCH INTERN MED, V150, P1514, DOI 10.1001/archinte.150.7.1514; SATO Y, 1995, AM J TROP MED HYG, V53, P248, DOI 10.4269/ajtmh.1995.53.248; SCHANTZ PM, 1992, NEW ENGL J MED, V327, P692, DOI 10.1056/NEJM199209033271004; Sisk JE, 1997, JAMA-J AM MED ASSOC, V278, P1333, DOI 10.1001/jama.278.16.1333; SKEELS MR, 1982, AM J PUBLIC HEALTH, V72, P57, DOI 10.2105/AJPH.72.1.57; Smith S, 1997, INFECT CONT HOSP EP, V18, P688; Trussell J, 1997, FAM PLANN PERSPECT, V29, P248, DOI 10.2307/2953412; *US BUR CENS, 1993, CENS POP SOC EC CHAR, V1; *US BUR CENS, 1996, CURR POP SURV	48	97	101	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 11	1999	340	10					773	779		10.1056/NEJM199903113401006	http://dx.doi.org/10.1056/NEJM199903113401006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	174KJ	10072413	Bronze, Green Published			2022-12-28	WOS:000079034100006
J	Maudsley, G				Maudsley, G			Roles and responsibilities of the problem based learning tutor in the undergraduate medical curriculum	BMJ-BRITISH MEDICAL JOURNAL			English	Article							STUDENT; EXPERTISE; FACULTY; ISSUES		Univ Liverpool, Dept Publ Hlth, Liverpool L69 3GB, Merseyside, England	University of Liverpool	Maudsley, G (corresponding author), Univ Liverpool, Dept Publ Hlth, Liverpool L69 3GB, Merseyside, England.							ALBANESE MA, 1993, ACAD MED, V68, P52, DOI 10.1097/00001888-199301000-00012; ANDRESEN L, 1993, USING EXPERIENCE LEA, P59; Barrows H. S., 1980, PROBLEM BASED LEARNI, V1; BERKSON L, 1993, ACAD MED, V68, pS79, DOI 10.1097/00001888-199310000-00053; Brookfield S., 1993, USING EXPERIENCE LEA, P21; Brookfield SD, 1987, DEV CRITICAL THINKER; DAVIS WK, 1992, ACAD MED, V67, P470, DOI 10.1097/00001888-199207000-00013; DEVOLDER ML, 1982, HIGH EDUC, V11, P269, DOI 10.1007/BF00155618; DOLMANS DHJM, 1994, MED EDUC, V28, P372, DOI 10.1111/j.1365-2923.1994.tb02547.x; EAGLE CJ, 1992, ACAD MED, V67, P465, DOI 10.1097/00001888-199207000-00012; Evans PA, 1996, MED EDUC, V30, P365, DOI 10.1111/j.1365-2923.1996.tb00848.x; General Medical Council, 1993, TOM DOCT REC UND MED; GRANDMAISON P, 1991, CAN MED ASSOC J, V144, P557; HOLT J, 1982, CHILDREN FAIL; Kalaian HA, 1996, ACAD MED, V71, P390, DOI 10.1097/00001888-199604000-00019; Kaufman DM, 1998, MED EDUC, V32, P255, DOI 10.1046/j.1365-2923.1998.00158.x; Kaufman DM, 1997, ACAD MED, V72, pS16, DOI 10.1097/00001888-199710001-00006; MARGETSON D, 1994, STUD HIGH EDUC, V19, P5, DOI 10.1080/03075079412331382103; Maudsley G, 1999, ACAD MED, V74, P178, DOI 10.1097/00001888-199902000-00016; MAYO WP, 1995, EVAL HEALTH PROF, V18, P124, DOI 10.1177/016327879501800202; NEAME RLB, 1984, TUTORIALS PROBLEM BA, P33; NEUFELD VR, 1974, J MED EDUC, V49, P1040; Perry W.G., 1970, FORMS INTELLECTUAL E; Ross B., 1991, CHALLENGE PROBLEM BA, P34; ROSTAS J, 1997, IMPERATIVES MED ED N, P84; SCHMIDT HG, 1993, ACAD MED, V68, P784, DOI 10.1097/00001888-199310000-00018; SCHMIDT HG, 1995, ACAD MED, V70, P708, DOI 10.1097/00001888-199508000-00015; SCHMIDT HG, 1983, MED EDUC, V17, P11, DOI 10.1111/j.1365-2923.1983.tb01086.x; SCHMIDT HG, 1994, ACAD MED, V69, P656, DOI 10.1097/00001888-199408000-00015; SCHWARTZ P, 1994, ART POSSIBLE IDEAS T; SILVER M, 1991, ACAD MED, V66, P298, DOI 10.1097/00001888-199105000-00017; THOMPSON DG, 1985, STUD HIGH EDUC, V10, P199, DOI 10.1080/03075078512331378609; TIPPING J, 1995, ACAD MED, V70, P1050, DOI 10.1097/00001888-199511000-00028; VERNON DTA, 1995, ACAD MED, V70, P216, DOI 10.1097/00001888-199503000-00013; VERNON DTA, 1993, ACAD MED, V68, P550, DOI 10.1097/00001888-199307000-00015; WALTON HJ, 1994, MED EDUC, V28, P1; WALTON HJ, 1989, MED EDUC, V23, P542, DOI 10.1111/j.1365-2923.1989.tb01581.x; Wetzel MS, 1996, POSTGRAD MED J, V72, P474, DOI 10.1136/pgmj.72.850.474; WILKERSON L, 1991, ACAD MED, V66, pS79, DOI 10.1097/00001888-199109000-00048; Woods D. R., 1994, PROBLEM BASED LEARNI	40	123	128	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 6	1999	318	7184					657	661		10.1136/bmj.318.7184.657	http://dx.doi.org/10.1136/bmj.318.7184.657			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066213	Green Published			2022-12-28	WOS:000079089200034
J	Riou-Khamlichi, C; Huntley, R; Jacqmard, A; Murray, JAH				Riou-Khamlichi, C; Huntley, R; Jacqmard, A; Murray, JAH			Cytokinin activation of Arabidopsis cell division through a D-type cyclin	SCIENCE			English	Article							PLANT-CELLS; KINASE; THALIANA; TOBACCO; CULTURE; ALFALFA; FAMILY; PHASE; ACID	Cytokinins are plant hormones that regulate plant cell division. The D-type cyclin CycD3 was found to be elevated in a mutant of Arabidopsis-with a high level of cytokinin and to be rapidly induced by cytokinin application in both cell cultures and whole plants. Constitutive expression of CycD3 in transgenic plants allowed induction and maintenance of cell division in the absence of exogenous cytokinin. Results suggest that cytokinin activates Arabidopsis cell division through induction of CycD3 at the G(1)-S cell cycle phase transition.	Univ Cambridge, Inst Biotechnol, Cambridge CB2 1QT, England; Univ Liege, Dept Biol Vegetale, Serv Physiol, B-4000 Liege, Belgium	University of Cambridge; University of Liege	Murray, JAH (corresponding author), Univ Cambridge, Inst Biotechnol, Tennis Court Rd, Cambridge CB2 1QT, England.		Huntley, Rachael/R-1036-2016; Huntley, Rachael/J-4951-2019; Murray, James AH/D-3399-2009	Huntley, Rachael/0000-0001-6718-3559; Huntley, Rachael/0000-0001-6718-3559; Murray, James AH/0000-0002-2282-3839; Riou, Catherine/0000-0001-6437-785X				ABEL S, 1995, J MOL BIOL, V251, P533, DOI 10.1006/jmbi.1995.0454; Bryant ja, 1985, CELL DIVISION CYCLE, P157; ChinAtkins AN, 1996, PLANTA, V198, P549, DOI 10.1007/BF00262641; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; COOKE R, 1981, PLANTA, V152, P1, DOI 10.1007/BF00384976; DAHL M, 1995, PLANT CELL, V7, P1847; Fuerst RAUA, 1996, PLANT PHYSIOL, V112, P1023, DOI 10.1104/pp.112.3.1023; Jacobs T, 1997, PLANT CELL, V9, P1021, DOI 10.1105/tpc.9.7.1021; JACQMARD A, 1994, CYTOKININS CHEM ACTI, P197; Kakimoto T, 1996, SCIENCE, V274, P982, DOI 10.1126/science.274.5289.982; KAPROS T, 1992, PLANT PHYSIOL, V98, P621, DOI 10.1104/pp.98.2.621; KILBY NJ, 1995, PLANT J, V8, P637, DOI 10.1046/j.1365-313X.1995.08050637.x; KRAIGHER H, 1991, PHYTOCHEMISTRY, V30, P2249, DOI 10.1016/0031-9422(91)83623-S; LETHAM DS, 1978, PHYTOHORMONES RELATE, V2; Mader JC, 1996, J PLANT GROWTH REGUL, V15, P95, DOI 10.1007/BF00192938; MAY MJ, 1993, PLANT PHYSIOL, V103, P621, DOI 10.1104/pp.103.2.621; MILLER CO, 1955, J AM CHEM SOC, V77, P1392, DOI 10.1021/ja01610a105; NAGATA T, 1994, INT J DEV BIOL, V38, P321; Redig P, 1996, FEBS LETT, V391, P175, DOI 10.1016/0014-5793(96)00728-4; RIOUKHAMLICHI C, UNPUB; Segers G, 1996, PLANT J, V10, P601, DOI 10.1046/j.1365-313X.1996.10040601.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SONI R, 1995, PLANT CELL, V7, P85, DOI 10.1105/tpc.7.1.85; Sorrell DA, 1999, PLANT PHYSIOL, V119, P343, DOI 10.1104/pp.119.1.343; Zhang K, 1996, PLANTA, V200, P2	25	586	648	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	1999	283	5407					1541	1544		10.1126/science.283.5407.1541	http://dx.doi.org/10.1126/science.283.5407.1541			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066178				2022-12-28	WOS:000078959200050
J	Kosarev, G; Kind, R; Sobolev, SV; Yuan, X; Hanka, W; Oreshin, S				Kosarev, G; Kind, R; Sobolev, SV; Yuan, X; Hanka, W; Oreshin, S			Seismic evidence for a detached Indian lithospheric mantle beneath Tibet	SCIENCE			English	Article							SOUTHERN TIBET; RECEIVER FUNCTIONS; CRUSTAL STRUCTURE; PLATEAU; PROPAGATION; CONSTRAINTS; VELOCITIES; TOMOGRAPHY; XENOLITHS; EVOLUTION	P-to-S converted teleseismic waves recorded by temporary broadband networks across Tibet show a north-dipping interface that begins 50 kilometers north of the Zangbo suture at the depth of the Moho (80 kilometers) and extends to a depth of 200 kilometers beneath the Bangong suture. Under northern Tibet a segmented south-dipping structure was imaged. These observations suggest a different form of detachment of the Indian and Asian Lithospheric mantles caused by differences in their composition and buoyancy.	Free Univ Berlin, D-12249 Berlin, Germany; Russian Acad Sci, Inst Phys Earth, Moscow 128810, Russia; Geoforschungszentrum Potsdam, D-14473 Potsdam, Germany	Free University of Berlin; Russian Academy of Sciences; Schmidt Institute of Physics of the Earth of the Russian Academy of Sciences; Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences	Kind, R (corresponding author), Free Univ Berlin, Malteser Str 74-100, D-12249 Berlin, Germany.		Yuan, Xiaohui/G-5149-2010; Sobolev, Stephan V/G-3813-2011	Yuan, Xiaohui/0000-0002-2891-1354; Sobolev, Stephan V/0000-0002-3382-4028				Bernstein S, 1998, EARTH PLANET SC LETT, V154, P221, DOI 10.1016/S0012-821X(97)00175-1; Bostock MG, 1997, NATURE, V390, P392, DOI 10.1038/37102; Boyd FR, 1997, CONTRIB MINERAL PETR, V128, P228, DOI 10.1007/s004100050305; Brown LD, 1996, SCIENCE, V274, P1688, DOI 10.1126/science.274.5293.1688; Downes H., 1987, MANTLE XENOLITHS, P125; HIRN A, 1984, NATURE, V307, P25, DOI 10.1038/307025a0; HIRN A, 1995, NATURE, V375, P571, DOI 10.1038/375571a0; Jin Y, 1996, J GEOPHYS RES-SOL EA, V101, P11275, DOI 10.1029/96JB00531; Jones CH, 1998, J GEOPHYS RES-SOL EA, V103, P10065, DOI 10.1029/97JB03540; JORDAN TH, 1978, NATURE, V274, P544, DOI 10.1038/274544a0; KENNETT BLN, 1991, GEOPHYS J INT, V105, P429, DOI 10.1111/j.1365-246X.1991.tb06724.x; Kind R, 1996, SCIENCE, V274, P1692, DOI 10.1126/science.274.5293.1692; KIND R, 1995, GEOPHYS J INT, V121, P191, DOI 10.1111/j.1365-246X.1995.tb03520.x; KIND R, 1985, J GEOPHYS-Z GEOPHYS, V58, P146; MCNAMARA DE, 1994, J GEOPHYS RES-SOL EA, V99, P13655, DOI 10.1029/93JB03406; MCNAMARA DE, 1995, J GEOPHYS RES-SOL EA, V100, P22215, DOI 10.1029/95JB01863; McNamara DE, 1997, J GEOPHYS RES-SOL EA, V102, P493, DOI 10.1029/96JB02112; MOLNAR P, 1983, J GEOPHYS RES, V88, P1180, DOI 10.1029/JB088iB02p01180; MOLNAR P, 1988, PHILOS T R SOC A, V326, P33, DOI 10.1098/rsta.1988.0080; MOLNAR P, 1993, REV GEOPHYS, V31, P357, DOI 10.1029/93RG02030; Nelson KD, 1996, SCIENCE, V274, P1684, DOI 10.1126/science.274.5293.1684; NI J, 1983, GEOPHYS J ROY ASTR S, V72, P665, DOI 10.1111/j.1365-246X.1983.tb02826.x; OWENS TJ, 1993, B SEISMOL SOC AM, V83, P1959; OWENS TJ, 1984, J GEOPHYS RES, V89, P7783, DOI 10.1029/JB089iB09p07783; Owens TJ, 1997, NATURE, V387, P37, DOI 10.1038/387037a0; SOBALEV NV, 1977, DEEP SEATED INCLUSIO; SOBOLEV SV, 1994, SURV GEOPHYS, V15, P515, DOI 10.1007/BF00690173; Sobolev SV, 1996, EARTH PLANET SC LETT, V139, P147, DOI 10.1016/0012-821X(95)00238-8; TURNER S, 1993, NATURE, V364, P50, DOI 10.1038/364050a0; Werling F, 1997, TECTONOPHYSICS, V275, P119, DOI 10.1016/S0040-1951(97)00018-8; WILLETT SD, 1994, NATURE, V369, P642, DOI 10.1038/369642a0; Wittlinger G, 1996, EARTH PLANET SC LETT, V139, P263, DOI 10.1016/0012-821X(95)00235-5; Yuan XH, 1997, J GEOPHYS RES-SOL EA, V102, P27491, DOI 10.1029/97JB02379; Zeng RS, 1995, PURE APPL GEOPHYS, V145, P425, DOI 10.1007/BF00879582; Zhao LS, 1996, GEOPHYS J INT, V125, P355, DOI 10.1111/j.1365-246X.1996.tb00004.x; ZHAO WJ, 1993, NATURE, V366, P557, DOI 10.1038/366557a0; Zhu LP, 1995, B SEISMOL SOC AM, V85, P1531	37	339	415	3	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1306	1309		10.1126/science.283.5406.1306	http://dx.doi.org/10.1126/science.283.5406.1306			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037597				2022-12-28	WOS:000078839900036
J	Winckler, B; Forscher, P; Mellman, I				Winckler, B; Forscher, P; Mellman, I			A diffusion barrier maintains distribution of membrane proteins in polarized neurons	NATURE			English	Article							GROWTH CONE; HIPPOCAMPAL-NEURONS; LATERAL MOBILITY; CELLS; MOLECULES; RANVIER; FAMILY	The asymmetric distribution of proteins to distinct domains in the plasma membrane is crucial to the function of many polarized cells. In epithelia, distinct apical and basolateral surfaces are maintained by tight junctions that prevent diffusion of proteins and lipids between the two domains(1). Polarized neurons maintain axonal and somatodendritic plasma membrane domains without an obvious physical barrier. Indeed, the artificial lipid DiI encounters no diffusion barrier at the presumptive domain boundary, the axon hillock(2). By measuring the lateral mobility of membrane proteins using optical tweezers, we show here that some membrane proteins exhibit markedly reduced mobility in the initial segment of the axon. Disruption of F-actin and low levels of dimethyl sulphoxide (DMSO) abolish this diffusion barrier and lead to redistribution of membrane markers that had previously been polarized. Immobilization in the initial segment may reflect, at least in part, differential tethering to cytoskeletal components. Therefore, the ability to maintain a polarized distribution of membrane proteins depends on a specialized domain at the initial segment of the axon, which restricts lateral mobility and serves as a new type of diffusion barrier that acts in the absence of cell-cell contact.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, MCDB, New Haven, CT 06520 USA	Yale University; Yale University	Mellman, I (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St,POB 208002, New Haven, CT 06520 USA.	ira.mellman@yale.edu	Mellman, Ira/ABG-5896-2020	Forscher, Paul/0000-0003-1988-5155				ANGELIDES KJ, 1988, J CELL BIOL, V106, P1911, DOI 10.1083/jcb.106.6.1911; Banker G., 1997, CULTURING NERVE CELL; BARTLES JR, 1995, TRENDS CELL BIOL, V5, P400, DOI 10.1016/S0962-8924(00)89089-3; BARTLETT WP, 1984, J NEUROSCI, V4, P1944; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; DAI JW, 1995, BIOPHYS J, V68, P988, DOI 10.1016/S0006-3495(95)80274-2; Dargent B., 1998, Society for Neuroscience Abstracts, V24, P1078; DAVIS JQ, 1997, J CELL BIOL, V137, P703; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; Garver TD, 1997, J CELL BIOL, V137, P703, DOI 10.1083/jcb.137.3.703; Jareb M, 1998, NEURON, V20, P855, DOI 10.1016/S0896-6273(00)80468-7; KOBAYASHI T, 1992, NATURE, V359, P647, DOI 10.1038/359647a0; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; KUSUMI A, 1993, BIOPHYS J, V65, P2021, DOI 10.1016/S0006-3495(93)81253-0; Kusumi A, 1998, METHOD CELL BIOL, V55, P173; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; MELLMAN I, 1996, COLD SPRING HARB SYM, V60, P745; PETERS A, 1968, J CELL BIOL, V39, P604, DOI 10.1083/jcb.39.3.604; SHEETZ MP, 1993, ANNU REV BIOPH BIOM, V22, P417, DOI 10.1146/annurev.bb.22.060193.002221; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Thompson C, 1996, J CELL SCI, V109, P2843; Vogt L, 1996, CURR BIOL, V6, P1153, DOI 10.1016/S0960-9822(02)70682-9; Winckler B, 1996, NATURE, V379, P213, DOI 10.1038/379213a0; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	26	320	325	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 25	1999	397	6721					698	701		10.1038/17806	http://dx.doi.org/10.1038/17806			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AP	10067893				2022-12-28	WOS:000078840100051
J	Buckley, G; Setchfield, N; Frampton, R				Buckley, G; Setchfield, N; Frampton, R			Two case reports of possible noise trauma after inflation of air bags in low speed car crashes	BRITISH MEDICAL JOURNAL			English	Article									St James Univ Hosp, Dept Otolaryngol Head & Neck Surg, Leeds LS9 7TF, W Yorkshire, England; St Jamess Univ Hosp, Dept Audiol, Leeds, W Yorkshire, England; Vehicle Safety Res Ctr, Loughborough LE11 3UZ, Leics, England	Saint James's University Hospital; Saint James's University Hospital; University of Leeds; Loughborough University	Buckley, G (corresponding author), St James Univ Hosp, Dept Otolaryngol Head & Neck Surg, Leeds LS9 7TF, W Yorkshire, England.			Frampton, Richard/0000-0003-1899-2565				ANTOSIA RE, 1995, ANN EMERG MED, V25, P794, DOI 10.1016/S0196-0644(95)70210-5; RICHTER HJ, 1974, 741185 SOC AUT ENG; Rouhana SW, 1994, 942218 SOC AUT ENG; Saunders JE, 1998, OTOLARYNG HEAD NECK, V118, P228, DOI 10.1016/S0194-5998(98)80021-1	4	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1999	318	7182					499	500		10.1136/bmj.318.7182.499	http://dx.doi.org/10.1136/bmj.318.7182.499			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QT	10024256	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000078818100025
J	Holmes, GL				Holmes, GL			Buccal route for benzodiazepines in treatment of seizures?	LANCET			English	Editorial Material							STATUS EPILEPTICUS		Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Holmes, GL (corresponding author), Childrens Hosp, Dept Neurol, Boston, MA 02115 USA.							DEIFUSS FE, 1998, NEW ENGL J MED, V338, P1869; DODSON WE, 1993, JAMA-J AM MED ASSOC, V270, P854; GRAVES NM, 1987, CLIN NEUROPHARMACOL, V10, P555, DOI 10.1097/00002826-198712000-00007; Lowenstein DH, 1998, NEW ENGL J MED, V338, P970, DOI 10.1056/NEJM199804023381407; LOWENSTEIN DH, 1993, NEUROLOGY, V43, P483, DOI 10.1212/WNL.43.3_Part_1.483; MILLIGAN NM, 1984, J NEUROL NEUROSUR PS, V47, P235, DOI 10.1136/jnnp.47.3.235; REVES JG, 1985, ANESTHESIOLOGY, V62, P310, DOI 10.1097/00000542-198503000-00017; WALTON NY, 1988, EXP NEUROL, V101, P267, DOI 10.1016/0014-4886(88)90010-6; YAGER JY, 1988, AM J DIS CHILD, V142, P931, DOI 10.1001/archpedi.1988.02150090029016	9	15	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 20	1999	353	9153					608	609		10.1016/S0140-6736(98)00357-2	http://dx.doi.org/10.1016/S0140-6736(98)00357-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QU	10030323				2022-12-28	WOS:000078818200005
J	Horton, R				Horton, R			Evidence and primary care	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Horton, R (corresponding author), Lancet, London WC1B 3SL, England.							Chisholm J, 1999, BMJ-BRIT MED J, V318, P273, DOI 10.1136/bmj.318.7179.273; Rosenblatt RA, 1998, JAMA-J AM MED ASSOC, V279, P1364, DOI 10.1001/jama.279.17.1364; Skelton JR, 1999, LANCET, V353, P108, DOI 10.1016/S0140-6736(98)02469-6; Starfield B, 1998, PRIMARY CARE BALANCI; Thomas T, 1998, BRIT J GEN PRACT, V48, P1229	5	22	22	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 20	1999	353	9153					609	610		10.1016/S0140-6736(99)00056-2	http://dx.doi.org/10.1016/S0140-6736(99)00056-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QU	10030324				2022-12-28	WOS:000078818200006
J	Irish, C; Herbert, J; Bennett, D; Gilham, G; Drobniewski, F; Williams, R; Smith, EG; Magee, JG; Watt, B; Chadwick, M; Watson, JM				Irish, C; Herbert, J; Bennett, D; Gilham, G; Drobniewski, F; Williams, R; Smith, EG; Magee, JG; Watt, B; Chadwick, M; Watson, JM			Database study of antibiotic resistant tuberculosis in the United Kingdom, 1994-6	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Brent & Harrow Hlth Author, Harrow HA1 3EX, Middx, England; Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England; Publ Hlth Lab Serv, Stat Unit, London NW9 5EQ, England; Univ London Kings Coll Hosp, Publ Hlth Lab Serv, Mycobacterium Reference Unit, London SE22 8QF, England; Univ Wales Hosp, Cardiff Publ Hlth Lab, Reg Ctr Mycobacteriol, Cardiff CF4 4XW, S Glam, Wales; Birmingham Heartlands Hosp, Birmingham Publ Hlth Lab, Reg Ctr Mycobacteriol, Birmingham B9 5ST, W Midlands, England; Newcastle Gen Hosp, Newcastle Publ Hlth Lab, Reg Ctr Mycobacteriol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; City Hosp Edinburgh, Scottish Mycobacteria Reference Lab, Edinburgh EH10 5SB, Midlothian, Scotland; Royal Brompton Hosp, Dept Microbiol, London SW3 6NP, England	Public Health England; Public Health England; King's College Hospital NHS Foundation Trust; King's College Hospital; Public Health England; University of London; King's College London; Cardiff University; Heart of England NHS Foundation Trust; University of Birmingham; Newcastle General Hospital; Royal Brompton Hospital	Irish, C (corresponding author), Brent & Harrow Hlth Author, Grace House, Harrow HA1 3EX, Middx, England.	charles@bhha.dcmon.co.uk						Drobniewski F A, 1997, Commun Dis Rep CDR Rev, V7, pR106; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; Hayward A C, 1995, Commun Dis Rep CDR Rev, V5, pR29; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; Warburton A R, 1993, Commun Dis Rep CDR Rev, V3, pR175	5	35	35	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 20	1999	318	7182					497	498		10.1136/bmj.318.7182.497	http://dx.doi.org/10.1136/bmj.318.7182.497			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QT	10024255	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000078818100023
J	Rosser, WW				Rosser, WW			Application of evidence from randomised controlled trials to general practice	LANCET			English	Article							PRIMARY-CARE; DIAGNOSIS		Univ Toronto, Fac Med, Dept Family & Community Med, Toronto, ON M5G 2C1, Canada	University of Toronto	Rosser, WW (corresponding author), Univ Toronto, Fac Med, Dept Family & Community Med, Toronto, ON M5G 2C1, Canada.							[Anonymous], 1991, Arch Intern Med, V151, P1413; *CAN TASK FORC PER, 1994, CLIN PREV HLTH CAR, P680; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; DAYTON S, 1969, CIRCULATION       S2, V40, P1; EWIGMAN BG, 1993, NEW ENGL J MED, V329, P821, DOI 10.1056/NEJM199309163291201; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; LAMBERTS H, 1987, INT CLASSIFICATION P, P16; Leopold N, 1996, J FAM PRACTICE, V42, P129; MASON J, 1993, BRIT MED J, V306, P570, DOI 10.1136/bmj.306.6877.570; MCWHINNEY IR, 1997, TXB FAMILY MED, P104; Rosser WW, 1996, J FAM PRACTICE, V42, P139; ROSSER WW, 1993, CAN FAM PHYSICIAN, V39, P75; ROSSER WW, 1998, EVIDENCE BASED FAMIL, P81; ROSSER WW, 1998, EVIDENCE BASED FAMIL, P139; ROSSER WW, 1998, EVIDENCE BASED FAMIL, P53; ROSSER WW, 1998, EVIDENCE BASED FAMIL, P19; SHAPIRO S, 1985, NCI MONOGRAPH, V67; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STARFIELD B, 1994, LANCET, V344, P1129, DOI 10.1016/S0140-6736(94)90634-3; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; *US DEP HHS, 1990, DHHS PUBL CDC; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, pR39; vanWeel C, 1996, LANCET, V348, P1431, DOI 10.1016/S0140-6736(96)08116-0; VANWEEL C, 1996, EUR J GEN PRACT, V2, P17; Waddell G, 1997, BRIT J GEN PRACT, V47, P647; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WHITE KL, 1961, NEW ENGL J MED, V265, P885, DOI 10.1056/NEJM196111022651805	29	69	71	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 20	1999	353	9153					661	664		10.1016/S0140-6736(98)09103-X	http://dx.doi.org/10.1016/S0140-6736(98)09103-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QU	10030347				2022-12-28	WOS:000078818200046
J	Hoon, MA; Adler, E; Lindemeier, J; Battey, JF; Ryba, NJP; Zuker, CS				Hoon, MA; Adler, E; Lindemeier, J; Battey, JF; Ryba, NJP; Zuker, CS			Putative mammalian taste receptors: A class of taste-specific GPCRs with distinct topographic selectivity	CELL			English	Article							PHEROMONE RECEPTORS; SWEET TASTE; CHORDA-TYMPANI; NECTURUS-MACULOSUS; MULTIGENE FAMILY; NERVE-FIBERS; RAT TONGUE; C-ELEGANS; TRANSDUCTION; CELLS	Taste represents a major form of sensory input in the animal kingdom. In mammals, taste perception begins with the recognition of tastant molecules by unknown membrane receptors localized on the apical surface of receptor cells of the tongue and palate epithelium. We report the cloning and characterization of two novel seven-transmembrane domain proteins expressed in topographically distinct subpopulations of taste receptor cells and taste buds. These proteins are specifically localized to the taste pore and are members of a new group of G protein-coupled receptors distantly related to putative mammalian pheromone receptors. We propose that these genes encode taste receptors.	Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD 20892 USA; Natl Inst Deafness & Other Commun Disorders, NIH, Bethesda, MD 20892 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Zuker, CS (corresponding author), Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD 20892 USA.	ryba@yoda.nidr.nih.gov; czuker4@flyeye.ucsd.edu		Ryba, Nicholas/0000-0002-2060-8393	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000561] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKABAS MH, 1988, SCIENCE, V242, P1047, DOI 10.1126/science.3194756; AVENET P, 1988, NATURE, V331, P351, DOI 10.1038/331351a0; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BARTOSHUK LM, 1994, PHYSIOL BEHAV, V56, P1165, DOI 10.1016/0031-9384(94)90361-1; BEHE P, 1990, J GEN PHYSIOL, V96, P1061, DOI 10.1085/jgp.96.5.1061; Bernhardt SJ, 1996, J PHYSIOL-LONDON, V490, P325, DOI 10.1113/jphysiol.1996.sp021147; BRADLEY RM, 1985, ANAT REC, V212, P246, DOI 10.1002/ar.1092120305; BRAND JG, 1985, BRAIN RES, V334, P207, DOI 10.1016/0006-8993(85)90212-4; BrillatSavarin J. A., 1826, PHYSL GOUT MEDITATIO; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CAO Y, 1989, P NATL ACAD SCI USA, V95, P11987; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; Chaudhari N, 1996, J NEUROSCI, V16, P3817; Corey DP, 1996, CURR OPIN NEUROBIOL, V6, P437, DOI 10.1016/S0959-4388(96)80046-8; CUMMINGS TA, 1987, J COMP NEUROL, V261, P604, DOI 10.1002/cne.902610411; Cummings TA, 1996, J NEUROPHYSIOL, V75, P1256, DOI 10.1152/jn.1996.75.3.1256; Doolin RE, 1996, J GEN PHYSIOL, V107, P545, DOI 10.1085/jgp.107.4.545; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; FRANK ME, 1991, J NEUROPHYSIOL, V65, P1452, DOI 10.1152/jn.1991.65.6.1452; FRANK ME, 1983, J NEUROPHYSIOL, V50, P941, DOI 10.1152/jn.1983.50.4.941; Furue H, 1997, BRAIN RES, V776, P133, DOI 10.1016/S0006-8993(97)00974-8; Furue H, 1998, J NEUROSCI METH, V84, P109, DOI 10.1016/S0165-0270(98)00104-6; GILBERTSON TA, 1992, J GEN PHYSIOL, V100, P803, DOI 10.1085/jgp.100.5.803; HECK GL, 1984, SCIENCE, V223, P403, DOI 10.1126/science.6691151; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Hoffmann A, 1875, ARCH PATHOL ANAT PHY, V62, P516; Hoon MA, 1997, J DENT RES, V76, P831, DOI 10.1177/00220345970760040301; KAWAMURA Y, 1987, INTRO UMAMI BASIC TA; KINNAMON JC, 1988, J COMP NEUROL, V270, P1, DOI 10.1002/cne.902700102; KINNAMON JC, 1985, J COMP NEUROL, V235, P48, DOI 10.1002/cne.902350105; KINNAMON SC, 1988, P NATL ACAD SCI USA, V85, P7023, DOI 10.1073/pnas.85.18.7023; KINNAMON SC, 1992, ANNU REV PHYSIOL, V54, P715, DOI 10.1146/annurev.physiol.54.1.715; Kinnamon SC, 1996, CURR OPIN NEUROBIOL, V6, P506, DOI 10.1016/S0959-4388(96)80057-2; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; KRIMM RF, 1987, PHYSIOL BEHAV, V41, P495, DOI 10.1016/0031-9384(87)90086-2; Lindemann B, 1996, PHYSIOL REV, V76, P719, DOI 10.1152/physrev.1996.76.3.719; LUSH IE, 1984, GENET RES, V44, P151, DOI 10.1017/S0016672300026355; LUSH IE, 1989, GENET RES, V53, P95, DOI 10.1017/S0016672300027968; LUSH IE, 1981, GENET RES, V38, P93, DOI 10.1017/S0016672300020425; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; MILLER IJ, 1990, PHYSIOL BEHAV, V47, P1213, DOI 10.1016/0031-9384(90)90374-D; Mombaerts P, 1996, COLD SPRING HARB SYM, V61, P135; Naito T, 1998, P NATL ACAD SCI USA, V95, P5178, DOI 10.1073/pnas.95.9.5178; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NEJAD MS, 1986, CHEM SENSES, V11, P283, DOI 10.1093/chemse/11.3.283; NOLTE C, 1992, J NEUROCYTOL, V21, P19, DOI 10.1007/BF01206895; Ogura T, 1997, J NEUROSCI, V17, P3580; ROYER SM, 1988, J COMP NEUROL, V270, P11, DOI 10.1002/cne.902700103; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; SPIELMAN AI, 1992, SOC GEN PHY, V47, P307; Stewart RE, 1997, AM J PHYSIOL-CELL PH, V272, pC1, DOI 10.1152/ajpcell.1997.272.1.C1; STRIEM BJ, 1989, BIOCHEM J, V260, P121, DOI 10.1042/bj2600121; Troemel ER, 1997, CELL, V91, P161, DOI 10.1016/S0092-8674(00)80399-2; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Wong GT, 1996, NATURE, V381, P796, DOI 10.1038/381796a0	56	529	602	2	80	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 19	1999	96	4					541	551		10.1016/S0092-8674(00)80658-3	http://dx.doi.org/10.1016/S0092-8674(00)80658-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	168XN	10052456	Bronze			2022-12-28	WOS:000078718600005
J	Meda, HA; Diallo, B; Buchet, JP; Lison, D; Barennes, H; Ouangre, A; Sanou, M; Cousens, S; Tall, F; Van de Perre, P				Meda, HA; Diallo, B; Buchet, JP; Lison, D; Barennes, H; Ouangre, A; Sanou, M; Cousens, S; Tall, F; Van de Perre, P			Epidemic of fatal encephalopathy in preschool children in Burkina Faso and consumption of unripe ackee (Blighia sapida) fruit	LANCET			English	Article							JAMAICAN VOMITING SICKNESS	Background On March 21, 1998, the Regional Health Authority of Bobo-Dioulasso, Burkina Faso, asked the Centre Muraz to investigate an unexplained outbreak of epidemic fatal encephalopathy (EFE). We aimed to identify the cause of this epidemic. Methods We identified cases retrospectively through review of hearth-service records and interviews of family members, village chiefs, and local heaters. Active surveillance was started in administrative divisions within the study area in April, 1998, to identify further EFE-cases. We did a case-control study of households to investigate the risk from various environmental and health factors. Blood and urine samples were collected if possible and urine dicarboxylic acid concentrations measured by gas chromatography. Findings 29 cases of EFE were identified from January to May, 1998. Estimated age-specific attack rates (2-6 years) ranged from 31 to 847 per 100000 population (p < 0.001). The most common symptoms were hypotonia, vomiting, convulsions, and coma. Ali children died in 2-48 h. The only factor associated with EFE was the presence of ackee trees (Blighia sapida) within 100 m of households (odds ratio 5.1 [95% CI 1.8-14.7] p = 0.001). Poisoning with unripe ackee fruits was suggested by urine concentrations of dicarboxylic acids four to 200 times higher in cases (n = 2) than in controls (n = 3). Conclusion Consumption of unripe ackee fruit probably caused this epidemic and may lead to a substantial number of unexplained deaths in preschool children in west Africa every year. Educational campaigns have the potential to prevent these deaths.	Ctr Muraz, Bobo Dioulasso, Burkina Faso; Dist Sanitaire Secteur 22, Bobo Dioulasso, Burkina Faso; Univ Catholique Louvain, Unite Toxicol Ind & Med Travail, B-1200 Brussels, Belgium; Hop Natl Sanou Souro, Serv Pediat, Bobo Dioulasso, Burkina Faso; London Sch Hyg & Trop Med, London WC1, England	Centre Muraz; Universite Catholique Louvain; University of London; London School of Hygiene & Tropical Medicine	Meda, HA (corresponding author), Ctr Muraz, OCCGE 01 BP 153, Bobo Dioulasso, Burkina Faso.		Barennes, hubert/E-9728-2011; Van de Perre, Philippe/B-9692-2008; Lison, Dominique/A-8985-2010	Van de Perre, Philippe/0000-0002-3912-0427; Lison, Dominique/0000-0001-6557-2518				BARETZ BH, 1976, CLIN CHIM ACTA, V73, P199, DOI 10.1016/0009-8981(76)90325-9; BRUN T, 1988, LANCET, V1, P934; CHASE GW, 1990, J ASSOC OFF ANA CHEM, V73, P318; HADIDANE R, 1985, HUM TOXICOL, V4, P491, DOI 10.1177/096032718500400505; HAUTEKEETE ML, 1990, ACTA CLIN BELG, V45, P311, DOI 10.1080/17843286.1990.11718105; ISHIKAWA T, 1993, BRAIN DEV-JPN, V15, P192, DOI 10.1016/0387-7604(93)90064-F; LARSON J, 1994, AM J GASTROENTEROL, V89, P1577; MCTAGUE JA, 1994, ANN EMERG MED, V23, P1116, DOI 10.1016/S0196-0644(94)70112-1; MILLS J, 1987, BIOCHEM PHARMACOL, V36, P495, DOI 10.1016/0006-2952(87)90357-1; MOWAT AP, 1987, ANN NESTLE, V45, P24; SCOTT H. Harold, 1916, Annals of Tropical Medicine and Parasitology, V10, P1; SHIH VE, 1978, CLIN CHIM ACTA, V88, P539, DOI 10.1016/0009-8981(78)90289-9; Shimizu Nobuo, 1994, Acta Paediatrica Japonica, V36, P139; TANAKA K, 1976, CLIN CHIM ACTA, V69, P105, DOI 10.1016/0009-8981(76)90478-2; TANAKA K, 1976, NEW ENGL J MED, V295, P461, DOI 10.1056/NEJM197608262950901; TANAKA K, 1990, PROG CLIN BIOL RES, V321, P167; VONHOLT C, 1966, BIOCHIM BIOPHYS ACTA, V125, P11, DOI 10.1016/0005-2760(66)90139-1; WAINWRIGHT J, 1977, S AFR MED J, V52, P313; 1992, MORB MORT WKLY REP M, V41, P53	19	41	41	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 13	1999	353	9152					536	540		10.1016/S0140-6736(99)01088-0	http://dx.doi.org/10.1016/S0140-6736(99)01088-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028981				2022-12-28	WOS:000078670200010
J	Kubisch, C; Schroeder, BC; Friedrich, T; Lutjohann, B; El-Amraoui, A; Marlin, S; Petit, C; Jentsch, TJ				Kubisch, C; Schroeder, BC; Friedrich, T; Lutjohann, B; El-Amraoui, A; Marlin, S; Petit, C; Jentsch, TJ			KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness	CELL			English	Article							INHERITED CARDIAC-ARRHYTHMIAS; MYOSIN-VIIA GENE; LONG QT SYNDROME; KVLQT1 MUTATIONS; HEARING-LOSS; FAMILIES; JERVELL; K(V)LQT1; PROTEINS; LINKAGE	Potassium channels regulate electrical signaling and the ionic composition of biological fluids. Mutations in the three known genes of the KCNQ branch of the K+ channel gene family underlie inherited cardiac arrhythmias (in some cases associated with deafness) and neonatal epilepsy. We have now cloned KCNQ4, a novel member of this branch. It maps to the DFNA2 locus for a form of nonsyndromic dominant deafness. In the cochlea, it is expressed in sensory outer hair cells, A mutation in this gene in a DFNA2 pedigree changes a residue in the KCNQ4 pore region. It abolishes the potassium currents of wild-type KCNQ4 on which it exerts a strong dominant-negative effect. Whereas mutations in KCNQ1 cause deafness by affecting endolymph secretion, the mechanism leading to KCNQ4-related hearing loss is intrinsic to outer hair cells.	Univ Hamburg, Zentrum Mol Neurobiol Hamburg, D-20246 Hamburg, Germany; Inst Pasteur, Unite Genet Deficits Sensoriels, CNRS, URA 1968, F-75724 Paris 15, France	University of Hamburg; University Medical Center Hamburg-Eppendorf; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Jentsch, TJ (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol Hamburg, Martinistr 85, D-20246 Hamburg, Germany.	jentsch@plexus.uke.uni-hamburg.de	Friedrich, Thomas/AAA-3418-2022; Kubisch, Christian/F-1893-2011	Kubisch, Christian/0000-0003-4220-0978; EL-AMRAOUI, Aziz/0000-0003-2692-4984; Petit, Christine/0000-0002-9069-002X; marlin, sandrine/0000-0002-4115-9806; Jentsch, Thomas/0000-0002-3509-2553				Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; COUCKE P, 1994, NEW ENGL J MED, V331, P425, DOI 10.1056/NEJM199408183310702; Denoyelle F, 1998, NATURE, V393, P319, DOI 10.1038/30639; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Friedmann I, 1966, J Laryngol Otol, V80, P451, DOI 10.1017/S002221510006552X; GORLIN RJ, 1995, J PHYSL, V448, P73; Kakehata S, 1996, J NEUROSCI, V16, P4881; Kalatzis V, 1998, HUM MOL GENET, V7, P1589, DOI 10.1093/hmg/7.10.1589; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KIKUCHI T, 1995, ANAT EMBRYOL, V191, P101, DOI 10.1007/BF00186783; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Mammano F, 1996, J PHYSIOL-LONDON, V496, P639, DOI 10.1113/jphysiol.1996.sp021715; Marrion NV, 1997, ANNU REV PHYSIOL, V59, P483, DOI 10.1146/annurev.physiol.59.1.483; MUSTAPHA M, 1999, IN PRESS HUM MOL GEN; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Nobili R, 1998, TRENDS NEUROSCI, V21, P159, DOI 10.1016/S0166-2236(97)01192-2; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; Russell MW, 1996, HUM MOL GENET, V5, P1319, DOI 10.1093/hmg/5.9.1319; SAKAGAMI M, 1991, HEARING RES, V56, P168, DOI 10.1016/0378-5955(91)90166-7; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schroeder BC, 1998, NATURE, V396, P687, DOI 10.1038/25367; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Spicer SS, 1996, HEARING RES, V100, P80, DOI 10.1016/0378-5955(96)00106-2; Spicer SS, 1998, HEARING RES, V118, P1, DOI 10.1016/S0378-5955(98)00006-9; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; VanCamp G, 1997, GENOMICS, V41, P70, DOI 10.1006/geno.1997.4624; Verhoeven K, 1998, NAT GENET, V19, P60, DOI 10.1038/ng0598-60; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; Wang HS, 1998, SCIENCE, V282, P1890, DOI 10.1126/science.282.5395.1890; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; WILSON J, 1985, ARCH OTOLARYNGOL, V111, P2; Wollnik B, 1997, HUM MOL GENET, V6, P1943, DOI 10.1093/hmg/6.11.1943; Yang WP, 1998, J BIOL CHEM, V273, P19419, DOI 10.1074/jbc.273.31.19419	41	636	687	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 5	1999	96	3					437	446		10.1016/S0092-8674(00)80556-5	http://dx.doi.org/10.1016/S0092-8674(00)80556-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025409	hybrid			2022-12-28	WOS:000078514600016
J	Sagar, M; Bowerfind, WM; Wigley, FM				Sagar, M; Bowerfind, WM; Wigley, FM			A man with diabetes and a swollen leg	LANCET			English	Article							MUSCLE INFARCTION		Johns Hopkins Hosp, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Hosp, Div Rheumatol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Sagar, M (corresponding author), Johns Hopkins Hosp, Dept Med, Room 9030,1830 E Monument St, Baltimore, MD 21205 USA.		Sagar, Manish/ABB-3816-2020					BANKER BQ, 1973, NEUROLOGY, V23, P667, DOI 10.1212/WNL.23.7.667; Chason DP, 1996, SKELETAL RADIOL, V25, P127, DOI 10.1007/s002560050048; ROCCA PV, 1993, SEMIN ARTHRITIS RHEU, V22, P280, DOI 10.1016/0049-0172(93)80076-R; Umpierrez GE, 1996, AM J MED, V101, P245, DOI 10.1016/S0002-9343(96)00156-8; VANSLYKE MA, 1995, MAGN RESON IMAGING, V13, P325, DOI 10.1016/0730-725X(94)00102-9	5	11	12	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 9	1999	353	9147					116	116		10.1016/S0140-6736(98)07243-2	http://dx.doi.org/10.1016/S0140-6736(98)07243-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023898	hybrid			2022-12-28	WOS:000078087200014
J	de Silva, WP				de Silva, WP			ABC of sexual health - Sexual variations	BRITISH MEDICAL JOURNAL			English	Review									Univ London, Inst Psychiat, London, England; Bethlem Royal & Maudsley Hosp, London, England	University of London; King's College London; South London & Maudsley NHS Trust	de Silva, WP (corresponding author), Univ London, Inst Psychiat, London, England.							Masters W., 1995, HUMAN SEXUALITY	1	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					654	656		10.1136/bmj.318.7184.654	http://dx.doi.org/10.1136/bmj.318.7184.654			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066212	Green Published			2022-12-28	WOS:000079089200033
J	Beringer, J				Beringer, J			Keeping watch over genetically modified crops and foods	LANCET			English	Editorial Material									Univ Bristol, Sch Biol Sci, Bristol BS8 1UG, Avon, England	University of Bristol	Beringer, J (corresponding author), Univ Bristol, Sch Biol Sci, Woodland Rd, Bristol BS8 1UG, Avon, England.							DURANT J, 1998, BIOTECHNOLOGY PUBLIC; GILLARD M, 1999, GUARDIAN        0212; HORNSBY M, 1999, TIMES           0211; *HOUS LORDS SEL CO, 1992, REG UK BIOT IND GLOB; Nielsen KM, 1998, FEMS MICROBIOL REV, V22, P79, DOI 10.1111/j.1574-6976.1998.tb00362.x; *PARL OFF SCI TECH, 1998, GEN MOD FOODS BEN RI; *SEL COMM EUR COMM, 1998, EC REG GEN MOD AGR	7	4	5	3	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 20	1999	353	9153					605	606		10.1016/S0140-6736(99)00041-0	http://dx.doi.org/10.1016/S0140-6736(99)00041-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QU	10030321				2022-12-28	WOS:000078818200003
J	Rissoan, MC; Soumelis, V; Kadowaki, N; Grouard, G; Briere, F; Malefyt, RD; Liu, YJ				Rissoan, MC; Soumelis, V; Kadowaki, N; Grouard, G; Briere, F; Malefyt, RD; Liu, YJ			Reciprocal control of T helper cell and dendritic cell differentiation	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; PRECURSOR POPULATION; HUMAN BLOOD; IN-VIVO; RESPONSES; PHENOTYPE; ANTIGEN; SUBSETS; LINEAGE; CD40	It is not known whether subsets of dendritic cells provide different cytokine microenvironments that determine the differentiation of either type-1 T helper (T(H)1) or T(H)2 cells. Human monocyte (pDC1)-derived dendritic cells (DC1) were found to induce T(H)1 differentiation, whereas dendritic cells (DC2) derived from CD4(+)CD3(-)CD11c(-) plasmacytoid cells (pDC2) induced T(H)2 differentiation by use of a mechanism unaffected by interleukin-4 (IL-4) or IL-12. The T(H)2 cytokine IL-4 enhanced DC1 maturation and killed pDC2, an effect potentiated by IL-10 but blocked by CD40 Ligand and interferon-gamma, Thus, a negative feedback Loop from the mature T helper cells may selectively inhibit prolonged T(H)1 or T(H)2 responses by regulating survival of the appropriate dendritic cell subset.	Schering Plough Corp, Lab Immunol Res, F-69571 Dardilly, France; DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA	Merck & Company; Schering Plough Corporation; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Liu, YJ (corresponding author), Schering Plough Corp, Lab Immunol Res, 27 Chemin Peupliers,Boite Postale 11, F-69571 Dardilly, France.	yliu@dnax.org		de Waal Malefyt, Rene/0000-0002-2663-383X				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ARDAVIN C, 1993, NATURE, V362, P761, DOI 10.1038/362761a0; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bruno L, 1997, J EXP MED, V185, P875, DOI 10.1084/jem.185.5.875; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; DeSmedt T, 1996, J EXP MED, V184, P1413, DOI 10.1084/jem.184.4.1413; Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Inaba K, 1997, J EXP MED, V186, P665, DOI 10.1084/jem.186.5.665; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; ODOHERTY U, 1994, IMMUNOLOGY, V82, P487; Olweus J, 1997, P NATL ACAD SCI USA, V94, P12551, DOI 10.1073/pnas.94.23.12551; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Pulendran B, 1997, J IMMUNOL, V159, P2222; Randolph GJ, 1998, SCIENCE, V282, P480, DOI 10.1126/science.282.5388.480; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Saunders D, 1996, J EXP MED, V184, P2185, DOI 10.1084/jem.184.6.2185; Seder RA, 1998, J IMMUNOL, V160, P5719; Sousa CRE, 1997, J EXP MED, V186, P1819, DOI 10.1084/jem.186.11.1819; Suss G, 1996, J EXP MED, V183, P1789, DOI 10.1084/jem.183.4.1789; Wu L, 1996, J EXP MED, V184, P903, DOI 10.1084/jem.184.3.903	29	1558	1663	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 19	1999	283	5405					1183	1186		10.1126/science.283.5405.1183	http://dx.doi.org/10.1126/science.283.5405.1183			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024247				2022-12-28	WOS:000078738400056
J	Schuchat, A				Schuchat, A			Group B streptococcus	LANCET			English	Article							SELECTIVE INTRAPARTUM CHEMOPROPHYLAXIS; VAGINAL CHLORHEXIDINE DISINFECTION; MULTISTATE SURVEILLANCE ANALYSIS; TOXOID CONJUGATE VACCINE; SINGLE-DOSE PENICILLIN; EARLY-ONSET DISEASE; PRETERM DELIVERY; PREGNANT-WOMEN; RISK-FACTORS; VERTICAL TRANSMISSION	During the 1990s the focus of group B streptococcus (GBS) disease research has shifted to prevention. increased use of intrapartum antimicrobial prophylaxis in North America and Australia has led to substantial declines in perinatal disease. Vaccine development (initiated two decades earlier) has yielded results-for example, polysaccharide-protein conjugate vaccines given to women of reproductive age proved to be highly immunogenic and well tolerated. Also economic evaluations have assessed the cost-effectiveness of prevention strategies in different populations. Although GBS has traditionally been considered a perinatal pathogen, the burden of invasive GBS disease among nonpregnant adults has been measured. Adverse outcomes of pregnancy attributable to GBS were addressed through a multicentre study which confirmed the important role of heavy colonisation with GBS in preterm low-birthweight deliveries. Finally, the pathogen itself has continued to evolve: new capsular serotypes described in the past decade are now causing an important proportion of clinical infections.	Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Schuchat, A (corresponding author), Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Mailstop C-23, Atlanta, GA 30333 USA.	acs1@cdc.gov						ADRIAANSE AH, 1995, EUR J OBSTET GYN R B, V61, P135, DOI 10.1016/0301-2115(95)02134-S; *AM COLL OBST GYN, 1996, PREV EARL ONS GROUP; ANTHONY BF, 1978, J INFECT DIS, V137, P524, DOI 10.1093/infdis/137.5.524; Baker C., 1995, INFECT DIS FETUS NEW, V4th ed., P980; BAKER CJ, 1988, NEW ENGL J MED, V319, P1180, DOI 10.1056/NEJM198811033191802; BAKER CJ, 1976, NEW ENGL J MED, V294, P753, DOI 10.1056/NEJM197604012941404; BAKER CJ, 1985, REV INFECT DIS, V7, P458; Baker CJ, 1996, OBSTET GYNECOL, V88, P51, DOI 10.1016/0029-7844(96)00111-1; Blumberg HM, 1996, J INFECT DIS, V173, P365, DOI 10.1093/infdis/173.2.365; BOYER KM, 1986, NEW ENGL J MED, V314, P1665, DOI 10.1056/NEJM198606263142603; BOYER KM, 1983, J INFECT DIS, V148, P802, DOI 10.1093/infdis/148.5.802; BOYER KM, 1983, J INFECT DIS, V148, P795, DOI 10.1093/infdis/148.5.795; BURMAN LG, 1992, LANCET, V340, P65, DOI 10.1016/0140-6736(92)90393-H; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P473; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P65; CHRISTENSEN KK, 1981, EUR J OBSTET GYN R B, V12, P143, DOI 10.1016/0028-2243(81)90069-1; DAUGAARD HO, 1988, AM J OBSTET GYNECOL, V158, P28, DOI 10.1016/0002-9378(88)90769-7; De Cueto M, 1998, OBSTET GYNECOL, V91, P112, DOI 10.1016/S0029-7844(97)00587-5; DILLON HC, 1987, J PEDIATR-US, V110, P31, DOI 10.1016/S0022-3476(87)80283-4; EASMON CSF, 1983, BRIT J OBSTET GYNAEC, V90, P633, DOI 10.1111/j.1471-0528.1983.tb09280.x; FACTOR SH, IN PRESS AM J OBSTET; Fargason CA, 1997, OBSTET GYNECOL, V90, P347, DOI 10.1016/S0029-7844(97)00278-0; FARLEY MM, 1993, NEW ENGL J MED, V328, P1807, DOI 10.1056/NEJM199306243282503; FAXELIUS G, 1988, J PERINAT MED, V16, P423, DOI 10.1515/jpme.1988.16.5-6.423; Fernandez M, 1998, ANTIMICROB AGENTS CH, V42, P1517, DOI 10.1128/AAC.42.6.1517; GARLAND SM, 1991, AUST NZ J OBSTET GYN, V31, P119, DOI 10.1111/j.1479-828X.1991.tb01797.x; GIBBS RS, 1994, OBSTET GYNECOL, V84, P496; GILBERT GL, 1995, AUST NZ J OBSTET GYN, V35, P120, DOI 10.1111/j.1479-828X.1995.tb01853.x; Goldenberg RL, 1997, CLIN PERINATOL, V24, P23, DOI 10.1016/S0095-5108(18)30182-9; Goldenberg RL, 1998, AM J PUBLIC HEALTH, V88, P233, DOI 10.2105/AJPH.88.2.233; Gotoff SP, 1997, PEDIATRICS, V99, P866, DOI 10.1542/peds.99.6.866; GRAY BM, 1989, J INFECT DIS, V159, P1139, DOI 10.1093/infdis/159.6.1139; Halsey NA, 1997, PEDIATRICS, V99, P489, DOI 10.1542/peds.99.3.489; Harrison LH, 1998, J INFECT DIS, V177, P998, DOI 10.1086/515260; HASTINGS MJG, 1986, J INFECTION, V12, P23, DOI 10.1016/S0163-4453(86)94775-4; Hillier Sharon L., 1997, Clinical Microbiology Newsletter, V19, P113, DOI 10.1016/S0196-4399(97)80992-0; Hillier SL, 1995, NEW ENGL J MED, V333, P1737, DOI 10.1056/NEJM199512283332604; JACKSON LA, 1995, ANN INTERN MED, V123, P415, DOI 10.7326/0003-4819-123-6-199509150-00003; Jeffery HE, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.1.e2; Joseph TA, 1998, ARCH PEDIAT ADOL MED, V152, P35; Kann Laura, 1996, Morbidity and Mortality Weekly Report, V45, P1; Kaspar DL, 1996, J CLIN INVEST, V98, P2308, DOI 10.1172/JCI119042; KASPER DL, 1979, J INFECT DIS, V139, P147, DOI 10.1093/infdis/139.2.147; KLEBANOFF MA, 1995, AM J OBSTET GYNECOL, V172, P1540, DOI 10.1016/0002-9378(95)90493-X; KROHN MA, 1995, J INFECT DIS, V171, P1475, DOI 10.1093/infdis/171.6.1475; LAGERGARD T, 1990, INFECT IMMUN, V58, P687, DOI 10.1128/IAI.58.3.687-694.1990; LANCEFIELD RC, 1975, J EXP MED, V142, P165, DOI 10.1084/jem.142.1.165; Lieu TA, 1998, OBSTET GYNECOL, V92, P21, DOI 10.1016/S0029-7844(98)00147-1; LIM DV, 1986, J CLIN MICROBIOL, V23, P489, DOI 10.1128/JCM.23.3.489-492.1986; MATORRAS R, 1989, GYNECOL OBSTET INVES, V27, P14, DOI 10.1159/000293607; MATORRAS R, 1991, EUR J OBSTET GYN R B, V40, P57, DOI 10.1016/0028-2243(91)90045-M; Mayon-White R T, 1985, Antibiot Chemother (1971), V35, P17; MCKENZIE H, 1994, BRIT J OBSTET GYNAEC, V101, P107, DOI 10.1111/j.1471-0528.1994.tb13074.x; MERCER BM, 1995, AM J OBSTET GYNECOL, V173, P1325, DOI 10.1016/0002-9378(95)91380-7; MERCER BM, 1995, AM J OBSTET GYNECOL, V173, P842, DOI 10.1016/0002-9378(95)90352-6; MOLLER M, 1984, LANCET, V2, P69; NEWTON ER, 1988, OBSTET GYNECOL, V71, P198; Newton ER, 1996, OBSTET GYNECOL, V88, P577, DOI 10.1016/0029-7844(96)00264-5; Parry S, 1998, NEW ENGL J MED, V338, P663, DOI 10.1056/NEJM199803053381006; Pearlman MD, 1998, OBSTET GYNECOL, V92, P258, DOI 10.1016/S0029-7844(98)00155-0; Poulain P, 1997, EUR J OBSTET GYN R B, V72, P137, DOI 10.1016/S0301-2115(96)02677-2; Regan JA, 1996, AM J OBSTET GYNECOL, V174, P1354, DOI 10.1016/S0002-9378(96)70684-1; REGAN JA, 1981, AM J OBSTET GYNECOL, V141, P184, DOI 10.1016/S0002-9378(16)32589-3; Rosenstein NE, 1997, OBSTET GYNECOL, V90, P901, DOI 10.1016/S0029-7844(97)00486-9; ROUSE DJ, 1994, OBSTET GYNECOL, V83, P483, DOI 10.1097/00006250-199404000-00001; Schuchat A, 1998, CLIN MICROBIOL REV, V11, P497, DOI 10.1128/CMR.11.3.497; SCHUCHAT A, 1990, J INFECT DIS, V162, P672, DOI 10.1093/infdis/162.3.672; SCHUCHAT A, 1994, EPIDEMIOL REV, V16, P374, DOI 10.1093/oxfordjournals.epirev.a036159; Siegel JD, 1996, OBSTET GYNECOL, V87, P692, DOI 10.1016/0029-7844(96)00004-X; SIEGEL JD, 1982, LANCET, V1, P1426; *SOC OBST GYN CAN, 1994, J SOC OBSTET GYNAECO, V16, P2271; Stoll BJ, 1998, PEDIATR INFECT DIS J, V17, P499, DOI 10.1097/00006454-199806000-00013; SWEET RL, 1987, AM J OBSTET GYNECOL, V156, P824, DOI 10.1016/0002-9378(87)90338-3; Taha TE, 1997, BRIT MED J, V315, P216, DOI 10.1136/bmj.315.7102.216; TEMMERMAN M, 1992, INT J STD AIDS, V3, P418, DOI 10.1177/095646249200300603; THOMSEN AC, 1987, LANCET, V1, P591; Towers CV, 1998, AM J OBSTET GYNECOL, V179, P879, DOI 10.1016/S0002-9378(98)70182-6; WALSH JA, 1989, PEDIATR INFECT DIS J, V8, P271; Wessels MR, 1998, J INFECT DIS, V178, P569, DOI 10.1086/517476; WESSELS MR, 1995, J INFECT DIS, V171, P879, DOI 10.1093/infdis/171.4.879; Whitney CG, 1997, OBSTET GYNECOL, V89, P28, DOI 10.1016/S0029-7844(96)00372-9; WOOD EG, 1981, AM J OBSTET GYNECOL, V140, P515, DOI 10.1016/0002-9378(81)90226-X; Yancey MK, 1996, OBSTET GYNECOL, V88, P811, DOI 10.1016/0029-7844(96)00320-1; YANCEY MK, 1994, OBSTET GYNECOL, V84, P816; YOW MD, 1979, JAMA-J AM MED ASSOC, V241, P1245, DOI 10.1001/jama.241.12.1245; ZANGWILL KM, 1992, MMWR SURVEILL SUMM, V6, P25	86	273	319	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 2	1999	353	9146					51	56		10.1016/S0140-6736(98)07128-1	http://dx.doi.org/10.1016/S0140-6736(98)07128-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023965				2022-12-28	WOS:000077934800044
J	Shlipak, MG; Lyons, WL; Go, AS; Chou, TM; Evans, GT; Browner, WS				Shlipak, MG; Lyons, WL; Go, AS; Chou, TM; Evans, GT; Browner, WS			Should the electrocardiogram be used to guide therapy for patients with left bundle-branch block and suspected myocardial infarction?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONVALVULAR ATRIAL-FIBRILLATION; CARDIAC TROPONIN-T; THROMBOLYTIC THERAPY; COST-EFFECTIVENESS; DECISION-ANALYSIS; ELDERLY PATIENTS; Q-WAVE; DIAGNOSIS; ISOENZYME; ASSAY	Context Recently, an algorithm based on the electrocardiogram (ECG) was reported to predict myocardial infarction (MI) in patients with left bundle-branch block (LBBB), but the clinical impact of this testing strategy is unknown. Objective To determine the diagnostic test characteristics and clinical utility of this ECC algorithm for patients with suspected MI. Design Retrospective cohort study to which an algorithm was applied, followed by decision analysis regarding thrombolysis made with or without the algorithm. Setting University emergency department, 1994 through 1997. Patients Eighty-three patients with LBBB who presented 103 times with symptoms suggestive of MI. Main Outcome Measures Myocardial infarction determined by serial cardiac enzyme analyses and stroke-free survival. Results Of 9 ECG findings assessed, none effectively distinguished the 30% of patients with MI from those with other diagnoses. The ECG algorithm indicated positive findings in only 3% of presentations and had a sensitivity of 10% (95% confidence interval, 2%-26%). The decision analysis showed that among 1000 patients with LBBB and chest pain, 929 would survive without major stroke if all received thrombolysis compared with 918 if the ECC algorithm was used as a screening test. Conclusions The ECG is a poor predictor of MI in a community-based cohort of patients with LBBB and acute cardiopulmonary symptoms. Acute thrombolytic therapy should be considered for all patients with LBBB who have symptoms consistent with MI.	Univ Calif San Francisco, Vet Affairs Med Ctr, Gen Internal Med Sect 111A1, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA; Kaiser Permanente Med Care Program No Calif, Div Res, Oakland, CA USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kaiser Permanente	Shlipak, MG (corresponding author), Univ Calif San Francisco, Vet Affairs Med Ctr, Gen Internal Med Sect 111A1, 4150 Clement St, San Francisco, CA 94121 USA.		Go, Alan S./AAE-7745-2019					ADAMS JE, 1994, CLIN CHEM, V40, P1291; ALEXANDER RW, 1998, HURSTS HEART; ANTMAN EM, 1995, JAMA-J AM MED ASSOC, V273, P1279, DOI 10.1001/jama.273.16.1279; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Barron HV, 1998, CIRCULATION, V97, P1150, DOI 10.1161/01.CIR.97.12.1150; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Braunwald E., 1997, HEART DIS TXB CARDIO, V5th; BYRNE J, 1996, NEW ENGL J MED, V334, P528; CABRERA E, 1953, Arch Inst Cardiol Mex, V23, P441; Cannon CP, 1997, J AM COLL CARDIOL, V30, P133, DOI 10.1016/S0735-1097(97)00160-5; CHAPMAN MG, 1957, CIRCULATION, V16, P558, DOI 10.1161/01.CIR.16.4.558; CHOU TC, 1991, ELECTROCARDIOGRAPHY; CLYNE CA, 1989, AM HEART J, V118, P901, DOI 10.1016/0002-8703(89)90221-4; DOUCET P, 1966, AM J CARDIOL, V17, P171, DOI 10.1016/0002-9149(66)90349-3; DRESSLER W, 1950, AM HEART J, V39, P217, DOI 10.1016/0002-8703(50)90218-3; EHSANI A, 1976, AM J CARDIOL, V37, P12, DOI 10.1016/0002-9149(76)90492-6; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; FENDRICK AM, 1994, ARCH INTERN MED, V154, P1605, DOI 10.1001/archinte.154.14.1605; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; GLASZIOU PP, 1994, MED J AUSTRALIA, V161, P532, DOI 10.5694/j.1326-5377.1994.tb127596.x; HAMBY RI, 1983, AM HEART J, V106, P471, DOI 10.1016/0002-8703(83)90688-9; Hamm CW, 1997, NEW ENGL J MED, V337, P1648, DOI 10.1056/NEJM199712043372302; HANDS ME, 1988, AM HEART J, V116, P23, DOI 10.1016/0002-8703(88)90245-1; HELLER GV, 1983, AM J CARDIOL, V51, P24, DOI 10.1016/S0002-9149(83)80006-X; HINDMAN MC, 1978, CIRCULATION, V58, P679, DOI 10.1161/01.CIR.58.4.679; HORAN LG, 1971, CIRCULATION, V43, P428, DOI 10.1161/01.CIR.43.3.428; KALISH SC, 1995, J GEN INTERN MED, V10, P321, DOI 10.1007/BF02599951; Krumholz HM, 1997, JAMA-J AM MED ASSOC, V277, P1683, DOI 10.1001/jama.277.21.1683; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; LAJI K, 1995, AM HEART J, V130, P705, DOI 10.1016/0002-8703(95)90067-5; LEE TH, 1986, ANN INTERN MED, V105, P221, DOI 10.7326/0003-4819-105-2-221; LEVENSON J, 1996, NEW ENGL J MED, V334, P528; LUY G, 1973, AM HEART J, V85, P332, DOI 10.1016/0002-8703(73)90367-0; MACLURE M, 1987, AM J EPIDEMIOL, V126, P161, DOI 10.1093/aje/126.2.161; MATCHAR DB, 1987, JAMA-J AM MED ASSOC, V258, P793, DOI 10.1001/jama.258.6.793; Mendelson T., 1998, EVIDENCE BASED MED F; NAGLIE IG, 1992, MED DECIS MAKING, V12, P239, DOI 10.1177/0272989X9201200401; Newby KH, 1996, CIRCULATION, V94, P2424, DOI 10.1161/01.CIR.94.10.2424; Ryan TJ, 1996, CIRCULATION, V94, P2341, DOI 10.1161/01.CIR.94.9.2341; Sgarbossa EB, 1996, NEW ENGL J MED, V334, P481, DOI 10.1056/NEJM199602223340801; Sgarbossa EB, 1998, J AM COLL CARDIOL, V31, P105, DOI 10.1016/S0735-1097(97)00446-4; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; Sodeman WA, 1944, AM HEART J, V28, P271, DOI 10.1016/S0002-8703(44)90087-6; Spaulding CM, 1997, NEW ENGL J MED, V336, P1629, DOI 10.1056/NEJM199706053362302; *STAT CORP, 1997, STAT COMP PROGR VERS; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; Tiefenbrunn AJ, 1998, J AM COLL CARDIOL, V31, P1240, DOI 10.1016/S0735-1097(98)00094-1; *TREEAG SOFTW INC, 1997, DATA DEC AN TREEA CO; TURI ZG, 1985, AM J CARDIOL, V55, P1463, DOI 10.1016/0002-9149(85)90954-3; Wackers F J, 1987, Cardiol Clin, V5, P393; WACKERS FJ, 1983, INT J CARDIOL, V2, P521, DOI 10.1016/0167-5273(83)90157-2; Wellens HJJ, 1996, NEW ENGL J MED, V334, P528, DOI 10.1056/NEJM199602223340809; Wilson F. N., 1945, ARCH INST CARDIOL [MEXICO], V14, P201; YUSUF S, 1987, AM J CARDIOL, V59, P245, DOI 10.1016/0002-9149(87)90793-4	55	70	71	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1999	281	8					714	719		10.1001/jama.281.8.714	http://dx.doi.org/10.1001/jama.281.8.714			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BD	10052441	Bronze			2022-12-28	WOS:000078669900030
J	Sloan, RP; Bagiella, E; Powell, T				Sloan, RP; Bagiella, E; Powell, T			Religion, spirituality, and medicine	LANCET			English	Editorial Material							UNITED-STATES; MORTALITY; HEALTH; ATTENDANCE; PRAYER; SERVICES; ASSOCIATION; POPULATION; PREDICTORS; DISABILITY		Columbia Univ, Columbia Presbyterian Med Ctr, Behav Med Program, New York, NY 10032 USA; Columbia Univ, Dept Psychiat, New York, NY 10032 USA; Columbia Univ, Sch Publ Hlth, Div Biostat, New York, NY 10027 USA; Columbia Univ, New York State Psychiat Inst, New York, NY 10027 USA; Columbia Univ, Ctr Study Soc & Med, New York, NY 10032 USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; Columbia University; Columbia University; New York State Psychiatry Institute; Columbia University	Sloan, RP (corresponding author), Columbia Univ, Columbia Presbyterian Med Ctr, Behav Med Program, Box 427,622 W 168th St, New York, NY 10032 USA.	rps7@columbia.edu						Benson H, 1996, TIMELESS HEALING; BYRD RC, 1988, SOUTHERN MED J, V81, P826, DOI 10.1097/00007611-198807000-00005; COLANTONIO A, 1992, AM J EPIDEMIOL, V136, P884, DOI 10.1093/aje/136.7.884; COMSTOCK GW, 1972, J CHRON DIS, V25, P665, DOI 10.1016/0021-9681(72)90002-1; COMSTOCK GW, 1977, J HEALTH SOC BEHAV, V18, P54, DOI 10.2307/2955396; DEGOUW HWF, 1996, AM J EPIDEMIOL, V141, P771; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FRIEDLANDER Y, 1986, INT J CARDIOL, V10, P33, DOI 10.1016/0167-5273(86)90163-4; GARDNER JW, 1982, AM J EPIDEMIOL, V116, P243, DOI 10.1093/oxfordjournals.aje.a113409; GOLDBOURT U, 1993, CARDIOLOGY, V82, P100, DOI 10.1159/000175862; GOULD SJ, 1981, MISMEASURE MAN; HOUSE JS, 1982, AM J EPIDEMIOL, V116, P123, DOI 10.1093/oxfordjournals.aje.a113387; Idler EL, 1997, J GERONTOL B-PSYCHOL, V52, pS306, DOI 10.1093/geronb/52B.6.S306; IDLER EL, 1992, AM J SOCIOL, V97, P1052, DOI 10.1086/229861; Kark JD, 1996, AM J PUBLIC HEALTH, V86, P341, DOI 10.2105/AJPH.86.3.341; KING DE, 1994, J FAM PRACTICE, V39, P349; Koenig HG, 1997, INT J PSYCHIAT MED, V27, P233, DOI 10.2190/40NF-Q9Y2-0GG7-4WH6; KOENIG HG, 1997, IS RELIGION GOOD YOU; Levin J S, 1997, JAMA, V278, P792, DOI 10.1001/jama.278.9.792; LEVIN JS, 1994, SOC SCI MED, V38, P1475, DOI 10.1016/0277-9536(94)90109-0; LEVIN JS, 1993, SOUTHERN MED J, V86, P1022, DOI 10.1097/00007611-199309000-00010; LEVIN JS, 1987, SOC SCI MED, V24, P589, DOI 10.1016/0277-9536(87)90063-3; LYON JL, 1994, CANCER CAUSE CONTROL, V5, P149, DOI 10.1007/BF01830261; MARWICK C, 1995, JAMA-J AM MED ASSOC, V273, P1561, DOI 10.1001/jama.273.20.1561; Matthews DA, 1998, ARCH FAM MED, V7, P118, DOI 10.1001/archfami.7.2.118; Matthews DA, 1997, MIND BODY MED, V2, P3; McNicol T., 1996, US WEEKEND      0405, P4; MICHALEK AM, 1981, J SURG ONCOL, V17, P129, DOI 10.1002/jso.2930170205; OXMAN TE, 1995, PSYCHOSOM MED, V57, P5, DOI 10.1097/00006842-199501000-00002; POWELL T, 1995, J CLIN ETHIC, V6, P73; Prager KM, 1997, JAMA-J AM MED ASSOC, V277, P1589, DOI 10.1001/jama.277.20.1589; PRESSMAN P, 1990, AM J PSYCHIAT, V147, P758; Rasanen J, 1996, INT J EPIDEMIOL, V25, P1244, DOI 10.1093/ije/25.6.1244; Sides H, 1997, NY TIMES MAGAZINE, P92; SORLIE PD, 1995, AM J PUBLIC HEALTH, V85, P949, DOI 10.2105/AJPH.85.7.949; Strawbridge WJ, 1997, AM J PUBLIC HEALTH, V87, P957, DOI 10.2105/AJPH.87.6.957; Timio Mario, 1997, Blood Pressure, V6, P81, DOI 10.3109/08037059709061804; WALDEN RT, 1964, AM J MED, V36, P269, DOI 10.1016/0002-9343(64)90089-0; ZUCKERMAN DM, 1984, AM J EPIDEMIOL, V119, P410, DOI 10.1093/oxfordjournals.aje.a113759	39	458	458	0	52	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 20	1999	353	9153					664	667		10.1016/S0140-6736(98)07376-0	http://dx.doi.org/10.1016/S0140-6736(98)07376-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	170QU	10030348	hybrid			2022-12-28	WOS:000078818200047
J	Baxter, PJ; Bonadonna, C; Dupree, R; Hards, VL; Kohn, SC; Murphy, MD; Nichols, A; Nicholson, RA; Norton, G; Searl, A; Sparks, RSJ; Vickers, BP				Baxter, PJ; Bonadonna, C; Dupree, R; Hards, VL; Kohn, SC; Murphy, MD; Nichols, A; Nicholson, RA; Norton, G; Searl, A; Sparks, RSJ; Vickers, BP			Cristobalite in volcanic ash of the Soufriere Hills Volcano, Montserrat, British West Indies	SCIENCE			English	Article							HAZARDS; SILICA	Crystalline silica (mostly cristobalite) was produced by vapor-phase crystallization and devitrification in the andesite Lava dome of the Soufriere Hills volcano, Montserrat. The sub-10-micrometer fraction of ash generated by pyroclastic flows formed by Lava dome collapse contains 10 to 24 weight percent crystalline silica, an enrichment of 2 to 5 relative to the magma caused by selective crushing of the groundmass. The sub-10-micrometer fraction of ash generated by explosive eruptions has much lower contents (3 to 6 percent) of crystalline silica. High Levels of cristobalite in respirable ash raise concerns about adverse health effects of Long-term human exposure to ash from lava dome eruptions.	Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England; Univ Cambridge, Dept Community Med, Cambridge CB12 ES, England; Univ Warwick, Dept Phys, Coventry CV4 7AL, W Midlands, England; British Geol Survey, Nottingham NG12 5GG, England; Inst Occupat Med Ltd, Edinburgh EH8 9SU, Midlothian, Scotland	University of Bristol; University of Cambridge; University of Warwick; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Geological Survey	Sparks, RSJ (corresponding author), Univ Bristol, Dept Earth Sci, Queens Rd, Bristol BS8 1RJ, Avon, England.	steve.parks@bristol.ac.uk	dupree, ray/F-6997-2012; Jolly, Gill E/G-9637-2014; Kohn, simon c/C-5150-2012	dupree, ray/0000-0002-3334-0429; Jolly, Gill E/0000-0003-1413-2541; Kohn, Simon/0000-0001-6415-8518; Bonadonna, Costanza/0000-0002-2368-2193				BUIST AS, 1986, AM J PUBLIC HEALTH, V76, P66, DOI 10.2105/AJPH.76.Suppl.66; DOLLBERG DD, 1986, AM J PUBLIC HEALTH, V76, P53, DOI 10.2105/AJPH.76.Suppl.53; *EXP PAN AIR QUAL, 1995, PART; HAY RL, 1959, J GEOL, V67, P540, DOI 10.1086/626606; HEANEY PJ, 1993, REV MINERAL, V28, P185; *HLTH SAF EX, 1997, AM C GOV HYG THRESH; *HLTH SAF EX, 1997, EH4097 HLTH SAF EX; *HLTH SAF EX UK, 1997, METH DET HAZ SUBS, V14; *HLTH SAF EX UK, 1994, METH DET HAZ SUBST, V76; Murphy MD, 1998, GEOPHYS RES LETT, V25, P3433, DOI 10.1029/98GL00713; SOREM RK, 1982, J VOLCANOL GEOTH RES, V13, P63, DOI 10.1016/0377-0273(82)90019-1; SPARKS RSJ, 1997, J VOLCANOL GEOTHERM, V2, P329; TALVITIE N A, 1964, Am Ind Hyg Assoc J, V25, P169, DOI 10.1080/00028896409342573; WALKER GPL, 1972, CONTRIB MINERAL PETR, V36, P135, DOI 10.1007/BF00371184; *WHO, 1997, MON EV CARC RISK HUM, V68; Young SR, 1998, GEOPHYS RES LETT, V25, P3389, DOI 10.1029/98GL01405	16	147	150	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 19	1999	283	5405					1142	1145		10.1126/science.283.5405.1142	http://dx.doi.org/10.1126/science.283.5405.1142			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024235				2022-12-28	WOS:000078738400044
J	Morady, F				Morady, F			Drug therapy - Radio-frequency ablation as treatment for cardiac arrhythmias	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RADIOFREQUENCY CATHETER ABLATION; NODAL REENTRANT TACHYCARDIA; PARKINSON-WHITE SYNDROME; ACCESSORY ATRIOVENTRICULAR CONNECTIONS; CORONARY-ARTERY-DISEASE; TERM FOLLOW-UP; IDIOPATHIC DILATED CARDIOMYOPATHY; INAPPROPRIATE SINUS TACHYCARDIA; ENDOCARDIAL MAPPING TECHNIQUES; LEFT-VENTRICULAR TACHYCARDIA		Univ Michigan, Med Ctr, Dept Internal Med, Div Cardiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Morady, F (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Cardiol, 1500 E Med Ctr Dr,Box 0022, Ann Arbor, MI 48109 USA.							Baker BM, 1996, J AM COLL CARDIOL, V28, P411, DOI 10.1016/0735-1097(96)00154-4; Bogun F, 1997, CIRCULATION, V95, P183, DOI 10.1161/01.CIR.95.1.183; BORGGREFE M, 1990, CLIN CARDIOL, V13, P127, DOI 10.1002/clc.4960130212; Brignole M, 1996, PACE, V19, P348, DOI 10.1111/j.1540-8159.1996.tb03337.x; Bubien RS, 1996, CIRCULATION, V94, P1585, DOI 10.1161/01.CIR.94.7.1585; CACERES J, 1989, CIRCULATION, V79, P256, DOI 10.1161/01.CIR.79.2.256; CALKINS H, 1993, AM J CARDIOL, V71, P1104, DOI 10.1016/0002-9149(93)90581-V; CALKINS H, 1991, CIRCULATION, V84, P2376, DOI 10.1161/01.CIR.84.6.2376; CALKINS H, 1994, CIRCULATION, V90, P1279, DOI 10.1161/01.CIR.90.3.1279; CALKINS H, 1992, CIRCULATION, V85, P1337, DOI 10.1161/01.CIR.85.4.1337; CALKINS H, 1991, NEW ENGL J MED, V324, P1612, DOI 10.1056/NEJM199106063242302; Cauchemez B, 1996, CIRCULATION, V93, P284, DOI 10.1161/01.CIR.93.2.284; CHEN SA, 1994, CIRCULATION, V90, P1262, DOI 10.1161/01.CIR.90.3.1262; CHEN SA, 1993, CIRCULATION, V88, P578, DOI 10.1161/01.CIR.88.2.578; COGGINS DL, 1994, J AM COLL CARDIOL, V23, P1333, DOI 10.1016/0735-1097(94)90375-1; COHEN TJ, 1991, J AM COLL CARDIOL, V18, P1767, DOI 10.1016/0735-1097(91)90519-F; COSIO FG, 1993, AM J CARDIOL, V71, P705, DOI 10.1016/0002-9149(93)91014-9; COX JL, 1993, ANN THORAC SURG, V56, P814, DOI 10.1016/0003-4975(93)90338-I; DESHPANDE SS, 1994, J CARDIOVASC ELECTR, V5, P219, DOI 10.1111/j.1540-8167.1994.tb01159.x; ENGELSTEIN ED, 1994, CIRCULATION, V89, P2645, DOI 10.1161/01.CIR.89.6.2645; FELD GK, 1992, CIRCULATION, V86, P1233, DOI 10.1161/01.CIR.86.4.1233; Fitzpatrick AP, 1996, AM HEART J, V131, P499, DOI 10.1016/S0002-8703(96)90528-1; GALLAGHER JJ, 1982, NEW ENGL J MED, V306, P194, DOI 10.1056/NEJM198201283060402; GOLDBERGER J, 1993, AM J CARDIOL, V72, P787, DOI 10.1016/0002-9149(93)91063-N; GONSKA BD, 1994, J AM COLL CARDIOL, V24, P1506, DOI 10.1016/0735-1097(94)90147-3; GROGAN M, 1992, AM J CARDIOL, V69, P1570, DOI 10.1016/0002-9149(92)90705-4; HAINES DE, 1990, CIRC RES, V67, P124, DOI 10.1161/01.RES.67.1.124; HAINES DE, 1990, CIRCULATION, V82, P1034, DOI 10.1161/01.CIR.82.3.1034; HAINES DE, 1989, PACE, V12, P962, DOI 10.1111/j.1540-8159.1989.tb05034.x; Haissaguerre M, 1996, J CARDIOVASC ELECTR, V7, P1132, DOI 10.1111/j.1540-8167.1996.tb00492.x; HAISSAGUERRE M, 1992, CIRCULATION, V85, P2162, DOI 10.1161/01.CIR.85.6.2162; Hamdan M, 1996, AM J CARDIOL, V78, P1292, DOI 10.1016/S0002-9149(96)00616-9; HOGENHUIS W, 1993, CIRCULATION, V88, P437; HUANG SKS, 1988, PACE, V11, P449, DOI 10.1111/j.1540-8159.1988.tb06006.x; JACKMAN WM, 1991, NEW ENGL J MED, V324, P1605, DOI 10.1056/NEJM199106063242301; JACKMAN WM, 1992, NEW ENGL J MED, V327, P313, DOI 10.1056/NEJM199207303270504; Jais P, 1997, CIRCULATION, V95, P572, DOI 10.1161/01.CIR.95.3.572; JAZAYERI MR, 1992, CIRCULATION, V85, P1318, DOI 10.1161/01.CIR.85.4.1318; JENTZER JH, 1994, CIRCULATION, V90, P2820, DOI 10.1161/01.CIR.90.6.2820; KALBFLEISCH SJ, 1991, J AM COLL CARDIOL, V18, P1761, DOI 10.1016/0735-1097(91)90518-E; KALBFLEISCH SJ, 1994, J AM COLL CARDIOL, V23, P716, DOI 10.1016/0735-1097(94)90759-5; KALBFLEISCH SJ, 1993, J AM COLL CARDIOL, V21, P567, DOI 10.1016/0735-1097(93)90086-G; KALBFLEISCH SJ, 1993, AM J CARDIOL, V72, P1406, DOI 10.1016/0002-9149(93)90188-I; KALBFLEISCH SJ, 1993, J AM COLL CARDIOL, V21, P85, DOI 10.1016/0735-1097(93)90720-L; KALBFLEISCH SJ, 1992, J AM COLL CARDIOL, V19, P1583, DOI 10.1016/0735-1097(92)90621-S; Kalman JM, 1997, J CARDIOVASC ELECTR, V8, P121, DOI 10.1111/j.1540-8167.1997.tb00775.x; Kalman JM, 1996, CIRCULATION, V93, P502, DOI 10.1161/01.CIR.93.3.502; KAY GN, 1993, J CARDIOVASC ELECTR, V4, P371, DOI 10.1111/j.1540-8167.1993.tb01277.x; KAY GN, 1993, J AM COLL CARDIOL, V21, P901, DOI 10.1016/0735-1097(93)90345-2; KAY GN, 1992, CIRCULATION, V85, P1675, DOI 10.1161/01.CIR.85.5.1675; KEIM S, 1992, CIRCULATION, V86, P919, DOI 10.1161/01.CIR.86.3.919; KIM YH, 1994, CIRCULATION, V89, P1094, DOI 10.1161/01.CIR.89.3.1094; KLEIN GJ, 1979, NEW ENGL J MED, V301, P1080, DOI 10.1056/NEJM197911153012003; KLEIN LS, 1992, CIRCULATION, V85, P1666, DOI 10.1161/01.CIR.85.5.1666; KOSINSKI DJ, 1993, EUR J CARDIAC PACING, V1, P63; KOTTKAMP H, 1995, CIRCULATION, V92, P1159, DOI 10.1161/01.CIR.92.5.1159; Krahn AD, 1995, J CARDIOVASC ELECTR, V6, P1124, DOI 10.1111/j.1540-8167.1995.tb00391.x; KUCK KH, 1991, LANCET, V337, P1557, DOI 10.1016/0140-6736(91)93258-B; LANGBERG JJ, 1992, J AM COLL CARDIOL, V19, P1588, DOI 10.1016/0735-1097(92)90622-T; LANGBERG JJ, 1993, PACE, V16, P465, DOI 10.1111/j.1540-8159.1993.tb01609.x; LANGBERG JJ, 1992, CIRCULATION, V86, P1469, DOI 10.1161/01.CIR.86.5.1469; LANGBERG JJ, 1993, PACE, V16, P1001, DOI 10.1111/j.1540-8159.1993.tb04574.x; LEE MA, 1991, CIRCULATION, V83, P827, DOI 10.1161/01.CIR.83.3.827; LEE RJ, 1995, CIRCULATION, V92, P2919, DOI 10.1161/01.CIR.92.10.2919; LESH MD, 1994, CIRCULATION, V89, P1074, DOI 10.1161/01.CIR.89.3.1074; LESH MD, 1992, J AM COLL CARDIOL, V19, P1303, DOI 10.1016/0735-1097(92)90338-N; LINDSAY BD, 1993, J AM COLL CARDIOL, V22, P733, DOI 10.1016/0735-1097(93)90184-3; MAN KC, 1993, AM J CARDIOL, V72, P1323, DOI 10.1016/0002-9149(93)90308-Y; MCCLELLAND JH, 1994, CIRCULATION, V89, P2655, DOI 10.1161/01.CIR.89.6.2655; MCGUIRE MA, 1993, CIRCULATION, V88, P2315, DOI 10.1161/01.CIR.88.5.2315; Morady F, 1996, J AM COLL CARDIOL, V27, P683, DOI 10.1016/0735-1097(95)00493-9; Morady F, 1997, J AM COLL CARDIOL, V29, P113, DOI 10.1016/S0735-1097(96)00445-7; MORADY F, 1993, CIRCULATION, V87, P363, DOI 10.1161/01.CIR.87.2.363; MORADY F, 1986, CARDIAC PREEXCITATIO, P119; NAKAGAWA H, 1993, CIRCULATION, V88, P2607, DOI 10.1161/01.CIR.88.6.2607; NAKAGAWA H, 1995, CIRCULATION, V91, P2264, DOI 10.1161/01.CIR.91.8.2264; NATH S, 1994, CIRCULATION, V89, P2667, DOI 10.1161/01.CIR.89.6.2667; NATH S, 1993, CIRCULATION, V88, P1826, DOI 10.1161/01.CIR.88.4.1826; Pappone C, 1996, J AM COLL CARDIOL, V27, P1090, DOI 10.1016/0735-1097(95)00597-8; Park TH, 1996, PACE, V19, P1363, DOI 10.1111/j.1540-8159.1996.tb04216.x; PHILIPPON F, 1995, CIRCULATION, V92, P430, DOI 10.1161/01.CIR.92.3.430; Poty H, 1996, CIRCULATION, V94, P3204, DOI 10.1161/01.CIR.94.12.3204; SANDERS WE, 1994, J AM COLL CARDIOL, V23, P926, DOI 10.1016/0735-1097(94)90639-4; SCHEINMAN MM, 1982, JAMA-J AM MED ASSOC, V248, P851, DOI 10.1001/jama.248.7.851; Simmers TA, 1996, J CARDIOVASC ELECTR, V7, P243, DOI 10.1111/j.1540-8167.1996.tb00521.x; SIMMERS TA, 1994, PACE, V17, P523, DOI 10.1111/j.1540-8159.1994.tb01421.x; STEVENSON WG, 1993, CIRCULATION, V88, P1647, DOI 10.1161/01.CIR.88.4.1647; Strickberger SA, 1997, CIRCULATION, V96, P1525, DOI 10.1161/01.CIR.96.5.1525; SWARTZ JF, 1993, CIRCULATION, V87, P487, DOI 10.1161/01.CIR.87.2.487; TANG CW, 1995, J AM COLL CARDIOL, V26, P1315, DOI 10.1016/0735-1097(95)00307-X; TRACY CM, 1993, J AM COLL CARDIOL, V21, P910, DOI 10.1016/0735-1097(93)90346-3; TROHMAN RG, 1992, AM J CARDIOL, V70, P1438, DOI 10.1016/0002-9149(92)90296-B; VanHare GF, 1997, J CARDIOVASC ELECTR, V8, P952; WALSH EP, 1992, CIRCULATION, V86, P1138, DOI 10.1161/01.CIR.86.4.1138; WEN MS, 1994, CIRCULATION, V89, P1690, DOI 10.1161/01.CIR.89.4.1690; WILLIAMSON BD, 1995, NEW ENGL J MED, V332, P479; WILLIAMSON BD, 1994, NEW ENGL J MED, V331, P910, DOI 10.1056/NEJM199410063311404; WU DL, 1992, J AM COLL CARDIOL, V20, P884, DOI 10.1016/0735-1097(92)90189-T; ZARDINI M, 1994, PACE, V17, P966, DOI 10.1111/j.1540-8159.1994.tb01440.x; ZHU DWX, 1995, J AM COLL CARDIOL, V26, P843, DOI 10.1016/0735-1097(95)00287-7; [No title captured]	101	190	200	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1999	340	7					534	544		10.1056/NEJM199902183400707	http://dx.doi.org/10.1056/NEJM199902183400707			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168FD	10021475				2022-12-28	WOS:000078680100007
J	Cauley, JA; Lucas, FL; Kuller, LH; Stone, K; Browner, W; Cummings, SR				Cauley, JA; Lucas, FL; Kuller, LH; Stone, K; Browner, W; Cummings, SR		Study of Osteoporotic Fractures Res Grp	Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer	ANNALS OF INTERNAL MEDICINE			English	Article						breast neoplasms; estradiol; testosterone; estrogen antagonists; risk factors	SEX-HORMONE LEVELS; POSTMENOPAUSAL WOMEN; ALCOHOL-CONSUMPTION; AROMATASE-ACTIVITY; STEROID-HORMONES; ADIPOSE-TISSUE; ESTROGEN; FAT; PREMENOPAUSAL; EPIDEMIOLOGY	Background: The relation between endogenous steroid hormones and risk for breast cancer is uncertain. Measurement of sex hormone levels may identify women at high risk for breast cancer who should consider preventive therapies. Objective: To test the hypothesis that serum concentrations of estradiol and testosterone predict risk for breast cancer. Design: Prospective case-cohort study. Setting: Four clinical centers in the United States. Participants: 97 women with confirmed incident breast cancer and 244 randomly selected controls; all women were white, 65 years of age or older, and were not receiving estrogen. Measurements: Sex-steroid hormone concentrations were assayed by using serum that was collected at baseline and stored at -190 degrees C. Risk factors for breast cancer were ascertained by questionnaire. Incident cases of breast cancer were confirmed by review of medical records during an average period of 3.2 years. Results: The relative risk for breast cancer in women with the highest concentration of bioavailable estradiol (greater than or equal to 6.83 pmol/L or 1.9 pg/mL) was 3.6 (95% CI, 1.3 to 10.0) compared with women with the lowest concentration. The risk for breast cancer in women with the highest concentration of free testosterone compared with those with the lowest concentration was 3.3 (CI, 1.1 to 10.3). The estimated incidence of breast cancer per 1000 person-years was 0.4 (CI, 0.0 to 1.3) in women with the lowest levels of bioavailable estradiol and free testosterone compared with 6.5 (CI 2.7 to 10.3) in women with the highest concentrations of these hormones. Traditional risk factors for breast cancer were similar in case-patients and controls. Adjustments for these risk factors had little effect on the results. Conclusions: Estradiol and testosterone levels may play important roles in the development of breast cancer in older women. A single measurement of bioavailable estradiol and free testosterone may be used to estimate a woman's risk for breast cancer. Women identified as being at high risk for breast cancer as determined by these hormone levels may benefit from antiestrogen treatment for primary prevention.	Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA; Maine Med Ctr, Portland, ME 04102 USA; Univ Calif San Francisco, Dept Biostat & Epidemiol, San Francisco, CA 94105 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Maine Medical Center; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Cauley, JA (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, 130 DeSoto St,Crabtree Hall A524, Pittsburgh, PA 15261 USA.		Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408	NIADDK NIH HHS [AM35584] Funding Source: Medline; NIAMS NIH HHS [AR35582] Funding Source: Medline; NIA NIH HHS [AG05407] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; ARMSTRONG BK, 1981, J NATL CANCER I, V67, P761; Berrino F, 1996, JNCI-J NATL CANCER I, V88, P291, DOI 10.1093/jnci/88.5.291; BLANKENSTEIN MA, 1992, J STEROID BIOCHEM, V41, P891, DOI 10.1016/0960-0760(92)90443-M; BULBROOK RD, 1986, ANN NY ACAD SCI, V464, P378, DOI 10.1111/j.1749-6632.1986.tb16017.x; Cauley JA, 1996, JAMA-J AM MED ASSOC, V276, P1404, DOI 10.1001/jama.276.17.1404; CAULEY JA, 1989, AM J EPIDEMIOL, V129, P1120, DOI 10.1093/oxfordjournals.aje.a115234; Colditz GA, 1998, JNCI-J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1998, P AM SOC CLIN ONC PR; DEWAARD F, 1982, MATURITAS, V4, P155, DOI 10.1016/0378-5122(82)90042-1; Dorgan JF, 1997, CANCER EPIDEM BIOMAR, V6, P177; Dorgan JF, 1996, CANCER EPIDEM BIOMAR, V5, P533; Dorgan JF, 1996, AM J CLIN NUTR, V64, P25, DOI 10.1093/ajcn/64.1.25; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; GARLAND CF, 1992, AM J EPIDEMIOL, V135, P1220, DOI 10.1093/oxfordjournals.aje.a116228; Hankinson SE, 1998, JNCI-J NATL CANCER I, V90, P1292, DOI 10.1093/jnci/90.17.1292; HANKINSON SE, 1995, CANCER EPIDEM BIOMAR, V4, P649; HELZLSOUER KJ, 1994, CANCER DETECT PREV, V18, P79; Jaffe RB, 1986, REPRODUCTIVE ENDOCRI, P406; Kelsey JL, 1996, ANNU REV PUBL HEALTH, V17, P47, DOI 10.1146/annurev.pu.17.050196.000403; KILLINGER D W, 1987, Steroids, V50, P523, DOI 10.1016/0039-128X(87)90036-5; KULLER LH, 1990, ARTERIOSCLEROSIS, V10, P1058, DOI 10.1161/01.ATV.10.6.1058; MACINDOE JH, 1981, J CLIN ENDOCR METAB, V53, P836, DOI 10.1210/jcem-53-4-836; Mannisto S, 1996, INT J CANCER, V68, P8, DOI 10.1002/(SICI)1097-0215(19960927)68:1<8::AID-IJC2>3.0.CO;2-V; MEEMA S, 1966, CANCER, V19, P433, DOI 10.1002/1097-0142(196603)19:3<433::AID-CNCR2820190318>3.0.CO;2-I; MILLER BA, 1994, SIGNIFICANCE RISING, P193; MOORE JW, 1986, INT J CANCER, V38, P625, DOI 10.1002/ijc.2910380502; Muti P, 1996, CANCER EPIDEM BIOMAR, V5, P917; ONEILL JS, 1987, BRIT J CANCER, V56, P601, DOI 10.1038/bjc.1987.248; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PEREL E, 1980, J STEROID BIOCHEM, V13, P89, DOI 10.1016/0022-4731(80)90117-X; PRENTICE R, 1990, J NATL CANCER I, V82, P129, DOI 10.1093/jnci/82.2.129; PRENTICE RL, 1986, BIOMETRIKA, V73, P1; Rink JD, 1996, J CLIN ENDOCR METAB, V81, P2443, DOI 10.1210/jc.81.7.2443; Rockhill B, 1998, AM J EPIDEMIOL, V147, P826, DOI 10.1093/oxfordjournals.aje.a009535; ROSE DP, 1993, BREAST CANCER RES TR, V27, P253, DOI 10.1007/BF00665695; SANTEN RJ, 1986, ANN NY ACAD SCI, V464, P126, DOI 10.1111/j.1749-6632.1986.tb16000.x; SCHATZKIN A, 1987, NEW ENGL J MED, V316, P1169, DOI 10.1056/NEJM198705073161901; SELLERS TA, 1993, AM J EPIDEMIOL, V138, P799, DOI 10.1093/oxfordjournals.aje.a116783; Spratt JS, 1996, J SURG ONCOL, V61, P68, DOI 10.1002/1096-9098(199601)61:1<68::AID-JSO2930610102>3.0.CO;2-E; THIJSSEN JHH, 1991, J STEROID BIOCHEM, V39, P799, DOI 10.1016/0960-0760(91)90028-4; Thomas HV, 1997, CANCER CAUSE CONTROL, V8, P922, DOI 10.1023/A:1018476631561; Thomas HV, 1997, BRIT J CANCER, V76, P401, DOI 10.1038/bjc.1997.398; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; *US DEP HHS, 1993, NIH PUBL; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; WYSOWSKI DK, 1987, AM J EPIDEMIOL, V125, P791, DOI 10.1093/oxfordjournals.aje.a114596; ZeleniuchJacquotte A, 1997, AM J EPIDEMIOL, V145, P1030, DOI 10.1093/oxfordjournals.aje.a009059; Zhang YQ, 1997, NEW ENGL J MED, V336, P611, DOI 10.1056/NEJM199702273360903; 1998, EVISTA PACKAGE INSER	51	328	333	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	1				270	+		10.7326/0003-4819-130-4_Part_1-199902160-00004	http://dx.doi.org/10.7326/0003-4819-130-4_Part_1-199902160-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166PY	10068384				2022-12-28	WOS:000078587200003
J	Greendale, GA; Lee, NP; Arriola, ER				Greendale, GA; Lee, NP; Arriola, ER			The menopause	LANCET			English	Review							HORMONE-REPLACEMENT THERAPY; LOW-DOSE ESTRADIOL; POSTMENOPAUSAL UROGENITAL ATROPHY; CARDIOVASCULAR RISK-FACTORS; CORONARY HEART-DISEASE; BONE-MINERAL DENSITY; ESTROGEN REPLACEMENT; URINARY-INCONTINENCE; SURGICAL MENOPAUSE; VAGINAL RING	Menopause is diagnosed after 12 months of amenorrhoea resulting from the permanent cessation of ovarian function. The mean age at menopause is 51 years. The perimenopause, a time of changing ovarian function, precedes the final menses by several years. The physiology and clinical manifestations of this transition to menopause are not well understood; however, some symptoms, such as hot flashes, certainty begin in the perimenopause. Causal associations between menopause and several symptoms and diseases are proposed. The evidence for these associations varies and is reviewed. Hormone replacement therapy can be directed-at symptom relief or at prevention or treatment of chronic diseases. Doses and routes of hormone replacement therapy vary by indication. Complications of hormone replacment therapy depend on the regimen used. Knowing the expected vaginal bleeding pattern for each hormone replacement therapy regimen is important, since unexpected bleeding may signal endometrial hyperplasia. Postmenopausal hormone therapy is a complex intervention that produces positive and negative specific health effects. Overall, based on observational studies, postmenopausal women who use hormones have a 30-50% lower all-cause mortality rate than those who do not use hormones. It is important to recognise that the value that individual women place on various health outcomes associated with hormone replacement therapy may differ. Thus, the decision to use hormone replacement therapy should be made jointly by each woman and her health-care provider, after careful consideration of possible benefits, risks, and her personal preferences.	Univ Calif Los Angeles, Sch Med, Div Geriatr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Ctr Hlth Sci, Dept Pharmaceut Serv, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Greendale, GA (corresponding author), Univ Calif Los Angeles, Sch Med, Div Geriatr, 2339 PVUB,Box 951687, Los Angeles, CA 90095 USA.		Hilton, Paul/D-9300-2011; Hunter, Myra S/F-2133-2010	Hilton, Paul/0000-0002-2541-5195; 				*ACOG COMM OP, 1993, J GYNECOL OBSTET, V43, P89; *AM COLL OBST GYN, 1992, ACOG TECHN B, V166, P166; AMY JJ, 1993, INT J FERTIL, V38, P5; ARCHER DF, 1994, OBSTET GYNECOL, V83, P686; Avis Nancy E., 1994, Annals of Epidemiology, V4, P214; Ayton RA, 1996, BRIT J OBSTET GYNAEC, V103, P351, DOI 10.1111/j.1471-0528.1996.tb09741.x; BEYENE Y, 1986, CULT MED PSYCHIAT, V10, P47, DOI 10.1007/BF00053262; BOLAJI II, 1993, EUR J OBSTET GYN R B, V48, P61, DOI 10.1016/0028-2243(93)90054-G; Bourne T, 1997, INT J GYNECOL OBSTET, V56, P115, DOI 10.1016/S0020-7292(96)02813-5; Brinton LA, 1997, ENDOCRIN METAB CLIN, V26, P361, DOI 10.1016/S0889-8529(05)70252-8; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; Casson PR, 1996, INT J FERTIL MENOP S, V41, P412; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Cauley JA, 1997, ARCH INTERN MED, V157, P2181, DOI 10.1001/archinte.157.19.2181; Cerin A, 1996, NEW ENGL J MED, V334, P668, DOI 10.1056/NEJM199603073341018; CHAI CU, 1997, THROMB HAEMOSTASIS, V78, P70; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; CIGNARELLI M, 1989, GYNECOL OBSTET INVES, V27, P34, DOI 10.1159/000293612; COBLEIGH MA, 1995, JAMA-J AM MED ASSOC, V273, P378; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; Creasy G W, 1992, Obstet Gynecol Surv, V47, P654, DOI 10.1097/00006254-199209000-00026; CROOK D, 1997, BRIT J OBSTET GYNAEC, V104, pS4; Cumming RG, 1997, AM J EPIDEMIOL, V145, P242; Cushing KL, 1998, OBSTET GYNECOL, V91, P35, DOI 10.1016/S0029-7844(97)00577-2; DIOKNO AC, 1990, ARCH INTERN MED, V150, P197, DOI 10.1001/archinte.150.1.197; Dunn LB, 1997, ARCH DERMATOL, V133, P339, DOI 10.1001/archderm.133.3.339; ETTINGER B, 1994, OBSTET GYNECOL, V83, P693; ETTINGER B, 1992, AM J OBSTET GYNECOL, V166, P479, DOI 10.1016/0002-9378(92)91653-R; Fantl JA, 1996, OBSTET GYNECOL, V88, P745; FANTL JA, 1994, OBSTET GYNECOL, V83, P12; Ferenczy A, 1997, MATURITAS, V26, P219, DOI 10.1016/S0378-5122(97)01104-3; FIELD CS, 1993, AM J OBSTET GYNECOL, V168, P114, DOI 10.1016/S0002-9378(12)90897-2; Foster RH, 1997, DRUG AGING, V11, P309, DOI 10.2165/00002512-199711040-00006; FRANCESCHI S, 1990, TUMORI, V76, P439, DOI 10.1177/030089169007600505; Gelfand MM, 1997, CLIN THER, V19, P383, DOI 10.1016/S0149-2918(97)80125-7; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; GILLET JY, 1994, MATURITAS, V19, P103, DOI 10.1016/0378-5122(94)90060-4; GINSBURG ES, 1994, OBSTET GYN CLIN N AM, V21, P381; GOLDBERG RM, 1994, J CLIN ONCOL, V12, P155, DOI 10.1200/JCO.1994.12.1.155; Grady D, 1997, J NATL CANCER I, V89, P1088, DOI 10.1093/jnci/89.15.1088; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Greendale GA, 1997, ENDOCRIN METAB CLIN, V26, P261, DOI 10.1016/S0889-8529(05)70246-2; GREENDALE GA, 1996, J WOMENS HEALTH, V5, P445; Griebling TL, 1997, ENDOCRIN METAB CLIN, V26, P347, DOI 10.1016/S0889-8529(05)70251-6; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Grodstein F, 1996, J AM DENT ASSOC, V127, P370, DOI 10.14219/jada.archive.1996.0208; HANSEN MA, 1991, BMJ-BRIT MED J, V303, P961, DOI 10.1136/bmj.303.6808.961; HAPELS AA, 1981, MATURITAS, V3, P321; HARRIS ST, 1991, ARCH INTERN MED, V151, P1980, DOI 10.1001/archinte.151.10.1980; HAY AG, 1994, BRIT J PSYCHIAT, V164, P513, DOI 10.1192/bjp.164.4.513; HICKOK LR, 1993, OBSTET GYNECOL, V82, P919; HINTON P, 1990, INT UROGYNECOL J, V1, P800; Hirvonen E, 1997, BRIT J OBSTET GYNAEC, V104, P19, DOI 10.1111/j.1471-0528.1997.tb11563.x; HIRVONEN E, 1995, MATURITAS, V21, P39, DOI 10.1016/0378-5122(94)00862-2; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; HUNTER MS, 1990, PSYCHOSOM MED, V52, P357, DOI 10.1097/00006842-199005000-00009; JENSEN J, 1991, BAILLIERE CLIN OB GY, V5, P867, DOI 10.1016/S0950-3552(05)80294-9; Judd HL, 1996, JAMA-J AM MED ASSOC, V275, P370, DOI 10.1001/jama.1996.03530290040035; KAUFERT PA, 1992, MATURITAS, V14, P143, DOI 10.1016/0378-5122(92)90006-P; KICOVIC PM, 1980, MATURITAS, V2, P275, DOI 10.1016/0378-5122(80)90029-8; Kornhauser C, 1997, J HUM HYPERTENS, V11, P405, DOI 10.1038/sj.jhh.1000420; Krall EA, 1997, AM J MED, V102, P536; KRONENBERG F, 1994, EXP GERONTOL, V29, P319, DOI 10.1016/0531-5565(94)90012-4; Langer RD, 1997, NEW ENGL J MED, V337, P1792, DOI 10.1056/NEJM199712183372502; LAVECCHIA C, 1992, J EPIDEMIOL COMMUN H, V46, P234, DOI 10.1136/jech.46.3.234; LINDGREN R, 1993, ACTA OBSTET GYN SCAN, V72, P292, DOI 10.3109/00016349309068040; LINDSAY R, 1980, LANCET, V2, P1151; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; MAGOS AL, 1985, OBSTET GYNECOL, V65, P496; MANSON JE, 1994, AM HEART J, V128, P1337, DOI 10.1016/0002-8703(94)90257-7; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; MCKINLAY SM, 1992, MATURITAS, V14, P103, DOI 10.1016/0378-5122(92)90003-M; METCALF MG, 1979, NEW ZEAL MED J, V89, P45; METTLER L, 1991, MATURITAS, V14, P23, DOI 10.1016/0378-5122(91)90144-F; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; MILSOM I, 1993, J UROLOGY, V149, P1459, DOI 10.1016/S0022-5347(17)36415-7; MYERS LS, 1990, J CLIN ENDOCR METAB, V70, P1124, DOI 10.1210/jcem-70-4-1124; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; NACHTIGALL LE, 1979, OBSTET GYNECOL, V53, P277; NACHTIGALL LE, 1994, FERTIL STERIL, V61, P178; Nachtigall LE, 1995, MATURITAS, V22, pS43, DOI 10.1016/0378-5122(95)00963-9; Naessen T, 1997, AM J OBSTET GYNECOL, V177, P115, DOI 10.1016/S0002-9378(97)70448-4; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; NILSSON K, 1992, MATURITAS, V15, P121, DOI 10.1016/0378-5122(92)90246-Z; Notelovitz M, 1997, MENOPAUSE, V4, P80; OSBORN M, 1988, BMJ-BRIT MED J, V296, P259; Pearlstein T, 1997, ENDOCRIN METAB CLIN, V26, P279, DOI 10.1016/S0889-8529(05)70247-4; Portaluppi F, 1997, HYPERTENSION, V29, P976, DOI 10.1161/01.HYP.29.4.976; POTTER JD, 1995, JNCI-J NATL CANCER I, V87, P1039, DOI 10.1093/jnci/87.14.1039; RAUDASKOSKI TH, 1995, AM J OBSTET GYNECOL, V172, P114, DOI 10.1016/0002-9378(95)90095-0; RAZ R, 1993, NEW ENGL J MED, V329, P753, DOI 10.1056/NEJM199309093291102; REKERS H, 1992, MATURITAS, V15, P101, DOI 10.1016/0378-5122(92)90244-X; Ross D, 1997, AM J OBSTET GYNECOL, V177, P937, DOI 10.1016/S0002-9378(97)70297-7; SANCHEZGUERRERO J, 1995, ANN INTERN MED, V122, P430, DOI 10.7326/0003-4819-122-6-199503150-00005; SCHMIDT G, 1994, GYNECOL OBSTET INVES, V38, P253, DOI 10.1159/000292492; Schneider DL, 1997, JAMA-J AM MED ASSOC, V277, P543, DOI 10.1001/jama.277.7.543; Schneider LS, 1997, AM J GERIAT PSYCHIAT, V5, P97; SEELEY DG, 1995, ARCH INTERN MED, V155, P293, DOI 10.1001/archinte.155.3.293; Sener AB, 1996, FERTIL STERIL, V65, P354; SHERWIN BB, 1985, PSYCHOSOM MED, V47, P339, DOI 10.1097/00006842-198507000-00004; SHERWIN BB, 1985, PSYCHONEUROENDOCRINO, V10, P325, DOI 10.1016/0306-4530(85)90009-5; SMITH P, 1993, MATURITAS, V16, P145, DOI 10.1016/0378-5122(93)90059-Q; SOBEL NB, 1994, OBSTET GYN CLIN N AM, V21, P299; Sowers MR, 1995, EPIDEMIOL REV, V17, P287, DOI 10.1093/oxfordjournals.epirev.a036194; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STONE SC, 1975, OBSTET GYNECOL, V45, P625, DOI 10.1097/00006250-197506000-00005; STUDD JWW, 1994, BRIT J OBSTET GYNAEC, V101, P787, DOI 10.1111/j.1471-0528.1994.tb11947.x; Sturdee DW, 1997, BRIT J OBSTET GYNAEC, V104, P1109, DOI 10.1111/j.1471-0528.1997.tb10932.x; Suhonen S, 1997, ACTA OBSTET GYN SCAN, V76, P145, DOI 10.3109/00016349709050071; TAITEL HF, 1995, INT J FERTIL MENOP S, V40, P207; THOMPSON B, 1973, J BIOSOC SCI, V5, P71, DOI 10.1017/S0021932000008956; VANDERMOOREN MJ, 1994, MATURITAS, V20, P175, DOI 10.1016/0378-5122(94)90014-0; Varas-Lorenzo C, 1998, AM J EPIDEMIOL, V147, P387; VOOIJS GP, 1995, EUR J OBSTET GYN R B, V62, P101, DOI 10.1016/0301-2115(95)02170-C; WALTER S, 1978, UROL INT, V33, P135, DOI 10.1159/000280190; WATTS NB, 1995, OBSTET GYNECOL, V85, P529, DOI 10.1016/0029-7844(94)00448-M; WHITEHEAD MI, 1990, OBSTET GYNECOL, V75, pS59; WOODRUFF JD, 1994, AM J OBSTET GYNECOL, V170, P1213; WREN BG, 1997, INT J GYNECOL CANCER, V4, P217; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688	122	338	349	1	33	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 13	1999	353	9152					571	580		10.1016/S0140-6736(98)05352-5	http://dx.doi.org/10.1016/S0140-6736(98)05352-5			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028999				2022-12-28	WOS:000078670200043
J	Lauer, MS; Francis, GS; Okin, PM; Pashkow, FJ; Snader, CE; Marwick, TH				Lauer, MS; Francis, GS; Okin, PM; Pashkow, FJ; Snader, CE; Marwick, TH			Impaired chronotropic response to exercise stress testing as a predictor of mortality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; CONGESTIVE HEART-FAILURE; ST-SEGMENT DEPRESSION; PROGNOSTIC IMPLICATIONS; RATE-VARIABILITY; INCOMPETENCE; PERFORMANCE; ADJUSTMENT; EXTENT	Context Chronotropic incompetence, an attenuated heart rate response to exercise, is a predictor of all-cause mortality in healthy populations. This association may be independent of exercise-induced myocardial perfusion defects, Objective To examine the prognostic significance of chronotropic incompetence in a low-risk cohort of patients referred for treadmill stress testing with thallium imaging. Design Prospective cohort study conducted between September 1990 and December 1993, Setting Tertiary care academic medical center, Patients Consecutive patients (1877 men and 1076 women; mean age, 58 years) who were not taking beta-blockers and who were referred for symptom-limited treadmill thallium testing. Main Outcome Measures Association of chronotropic incompetence, defined as either failure to achieve 85% of the age-predicted maximum heart rate or a low chronotropic index, a heart rate response measure that accounts for effects of age, resting heart rate, and physical fitness, with all-cause mortality during 2 years of follow-up. Results Three hundred sixteen patients (11%) failed to reach 85% of the age-adjusted maximum heart rate, 762 (26%) had a low chronotropic index, and 672 (21%) had thallium perfusion defects. Ninety-one patients died during the follow-up period, After adjustment for age, sex, thallium perfusion defects, and other confounders, failure to reach 85% of the age-predicted maximum heart rate was associated with increased risk of death (adjusted relative risk [RR], 1.84; 95% confidence interval [CI], 1.13-3.00; P=.01), as was a low chronotropic index (adjusted RR, 2.19; 95% CI, 1.43-3.44; P<.001). Conclusion Among patients with known or suspected coronary disease, chronotropic incompetence is independently predictive of all-cause mortality, even after considering thallium perfusion defects, Incorporation of chronotropic response into the routine interpretation of stress thallium studies may improve the prognostic power of this test.	Cleveland Clin Fdn, Dept Cardiol, Ctr Heart Failure, Cleveland, OH 44195 USA; Cornell Univ, Med Ctr, New York Hosp, Dept Cardiol, New York, NY 10021 USA	Cleveland Clinic Foundation; Cornell University; NewYork-Presbyterian Hospital	Lauer, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiol, Ctr Heart Failure, Desk F-25,9500 Euclid Ave, Cleveland, OH 44195 USA.	lauerm@cesmtp.ccf.org	Marwick, Thomas H/C-7261-2013; Lauer, Michael S/L-9656-2013	Marwick, Thomas H/0000-0001-9065-0899; Lauer, Michael S/0000-0002-9217-8177				Barron HV, 1996, J AM COLL CARDIOL, V27, P1053, DOI 10.1016/0735-1097(95)00615-X; BOYLE CA, 1990, AM J EPIDEMIOL, V131, P160, DOI 10.1093/oxfordjournals.aje.a115470; COLUCCI WS, 1989, CIRCULATION, V80, P314, DOI 10.1161/01.CIR.80.2.314; COX DR, 1972, J R STAT SOC B, V34, P187; Ellestad MH, 1996, CIRCULATION, V93, P1485, DOI 10.1161/01.CIR.93.8.1485; Fauchier L, 1997, J AM COLL CARDIOL, V30, P1009, DOI 10.1016/S0735-1097(97)00265-9; FLETCHER GF, 1995, CIRCULATION, V91, P580, DOI 10.1161/01.CIR.91.2.580; FRANCIS GS, 1985, J AM COLL CARDIOL, V5, P832, DOI 10.1016/S0735-1097(85)80420-4; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GO RT, 1990, J NUCL MED, V31, P1899; HELLER GV, 1992, AM HEART J, V123, P909, DOI 10.1016/0002-8703(92)90695-R; Huang Por-Jau, 1992, Journal of the Formosan Medical Association, V91, P1096; LADENHEIM ML, 1986, J AM COLL CARDIOL, V7, P464, DOI 10.1016/S0735-1097(86)80454-5; Lauer MS, 1996, CIRCULATION, V93, P1520, DOI 10.1161/01.CIR.93.8.1520; LAUER MS, 1995, J AM COLL CARDIOL, V26, P1630, DOI 10.1016/0735-1097(95)00388-6; Lauer MS, 1996, AM J CARDIOL, V78, P278, DOI 10.1016/S0002-9149(96)00277-9; Marwick TH, 1997, J AM COLL CARDIOL, V30, P83, DOI 10.1016/S0735-1097(97)00148-4; MYERS J, 1991, J AM COLL CARDIOL, V17, P1334, DOI 10.1016/S0735-1097(10)80144-5; Okin PM, 1996, CIRCULATION, V94, P3226, DOI 10.1161/01.CIR.94.12.3226; OKIN PM, 1995, J AM COLL CARDIOL, V25, P1726, DOI 10.1016/0735-1097(95)00085-I; Perkiomaki JS, 1997, J AM COLL CARDIOL, V30, P1331, DOI 10.1016/S0735-1097(97)00301-X; SCHWARTZ PJ, 1992, CIRCULATION S1, V85, P177; Snader CE, 1997, J AM COLL CARDIOL, V30, P641, DOI 10.1016/S0735-1097(97)00217-9; Wilkoff Bruce L., 1992, Cardiology Clinics, V10, P705	24	406	432	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1999	281	6					524	529		10.1001/jama.281.6.524	http://dx.doi.org/10.1001/jama.281.6.524			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164FQ	10022108				2022-12-28	WOS:000078452900030
J	Wiener, J; Quinn, JP; Bradford, PA; Goering, RV; Nathan, C; Bush, K; Weinstein, RA				Wiener, J; Quinn, JP; Bradford, PA; Goering, RV; Nathan, C; Bush, K; Weinstein, RA			Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPECTRUM BETA-LACTAMASES; MOLECULAR EPIDEMIOLOGY; 3RD-GENERATION CEPHALOSPORINS; TRANSFERABLE RESISTANCE; CEFTAZIDIME RESISTANCE; NOSOCOMIAL OUTBREAK; MEDICAL-CENTER; PLASMID DNA; PNEUMONIAE; ENTEROBACTERIACEAE	Context infections caused by ceftazidime sodium-resistant gram-negative bacteria that harbor extended-spectrum beta-lactamases (ESBLs) are increasing in frequency in hospitals in the United States. Objectives To report a citywide nursing home-centered outbreak of infections caused by ESBL-producing gram-negative bacilli and to describe the clinical and molecular epidemiology of the outbreak. Design Hospital-based case-control study and a nursing home point-prevalence survey. Molecular epidemiological techniques were applied to resistant strains. Settings A 400-bed tertiary care hospital and a community nursing home. Patients Patients who were infected and/or colonized with ceftazidime-resistant Escherichia coli, Klebsiella pneumoniae, or both and controls who were admitted from nursing homes between November 1990 and July 1992, Main Outcome Measures Clinical and epidemiological factors associated with colonization or infection by ceftazidime-resistant E coli or K pneumoniae; molecular genetic characteristics of plasmid-mediated ceftazidime resistance. Results Between November 1990 and October 1992, 55 hospital patients infected or colonized with ceftazidime-resistant E coli, K pneumoniae, or both were identified. Of the 35 admitted from 8 nursing homes, 31 harbored the resistant strain on admission. All strains were resistant to ceftazidime, gentamicin, and tobramycin; 96% were resistant to trimethoprim-sulfamethoxazole and 41% to ciprofloxacin hydrochloride, In a case-control study, 24 nursing home patients colonized with resistant strains on hospital admission were compared with 16 nursing home patients who were not colonized on hospital admission; independent risk factors for colonization included poor functional level, presence of a gastrostomy tube or decubitus ulcers, and prior receipt of ciprofloxacin and/or trimethoprim-sulfamethoxazole. In a nursing home point-prevalence survey, 18 of 39 patients were colonized with ceftazidime-resistant E coli; prior receipt of ciprofloxacin or trimethoprim-sulfamethoxazole and presence of a gastrostomy tube were independent predictors of resistance. Plasmid studies on isolates from 20 hospital and nursing home patients revealed that 17 had a common 54-kilobase plasmid, which conferred ceftazidime resistance via the ESBL TEM-10, and mediated resistance to trimethoprim-sulfamethoxazole, gentamicin, and tobramycin; all 20 isolates harbored this ESBL. Molecular fingerprinting showed 7 different strain types of resistant K pneumoniae and E coli distributed among the nursing homes. Conclusions Nursing home patients may be an important reservoir of ESBL-containing multiple antibiotic-resistant E coli and K pneumoniae. Widespread dissemination of a predominant antibiotic resistance plasmid has occurred. Use of broad-spectrum oral antibiotics and probably poor infection control practices may facilitate spread of this plasmid-mediated resistance. Nursing homes should monitor and control antibiotic use and regularly survey antibiotic resistance patterns among pathogens.	Michael Reese Hosp & Med Ctr, Chicago, IL 60616 USA; Wyeth Ayerst Res, Pearl River, NY USA; Creighton Univ, Omaha, NE 68178 USA; RW Johnson Pharmaceut Res Inst, Raritan, NJ 08869 USA	Michael Reese Hospital & Medical Center; Pfizer; Creighton University; Johnson & Johnson; Johnson & Johnson USA	Weinstein, RA (corresponding author), Cook Cty Hosp, Div Infect Dis, 1835 W Harrison St, Chicago, IL 60612 USA.	rweinste@rush.edu	Bush, Karen/O-2820-2017	Goering, Richard/0000-0001-7502-7185; Bradford, Patricia/0000-0002-1285-2978				ARLET G, 1994, J CLIN MICROBIOL, V32, P2553, DOI 10.1128/JCM.32.10.2553-2558.1994; BINGEN EH, 1993, J CLIN MICROBIOL, V31, P179, DOI 10.1128/JCM.31.2.179-184.1993; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRADFORD PA, 1994, ANTIMICROB AGENTS CH, V38, P760; BRUNBUISSON C, 1987, LANCET, V2, P302; Coudron PE, 1997, J CLIN MICROBIOL, V35, P2593, DOI 10.1128/JCM.35.10.2593-2597.1997; Denman S., 1993, Morbidity and Mortality Weekly Report, V42, P672; DiMartino P, 1997, J CLIN MICROBIOL, V35, P1499, DOI 10.1128/JCM.35.6.1499-1503.1997; ELSOLH N, 1986, ANTIMICROB AGENTS CH, V30, P161, DOI 10.1128/AAC.30.1.161; Emery CL, 1997, J CLIN MICROBIOL, V35, P2061, DOI 10.1128/JCM.35.8.2061-2067.1997; GOERING RV, 1995, EUR J CLIN MICROBIOL, V14, pS3; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; Goldmann DA, 1996, JAMA-J AM MED ASSOC, V275, P234, DOI 10.1001/jama.275.3.234; GOUBY A, 1994, J CLIN MICROBIOL, V32, P301, DOI 10.1128/JCM.32.2.301-305.1994; JARLIER V, 1988, REV INFECT DIS, V10, P867; JETT BD, 1995, ANTIMICROB AGENTS CH, V39, P1187, DOI 10.1128/AAC.39.5.1187; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; KITZIS MD, 1988, ANTIMICROB AGENTS CH, V32, P9, DOI 10.1128/AAC.32.1.9; KNOTHE H, 1983, INFECTION, V11, P315, DOI 10.1007/BF01641355; LEVY SB, 1982, ANTIBIOTIC PARADOX; M'Zali FH, 1997, J ANTIMICROB CHEMOTH, V40, P823, DOI 10.1093/jac/40.6.823; Martinez-Martinez L, 1998, LANCET, V351, P797, DOI 10.1016/S0140-6736(97)07322-4; Medeiros AA, 1997, CLIN INFECT DIS, V24, pS19, DOI 10.1093/clinids/24.Supplement_1.S19; MEYER KS, 1993, ANN INTERN MED, V119, P353, DOI 10.7326/0003-4819-119-5-199309010-00001; MURRAY BE, 1990, J CLIN MICROBIOL, V28, P2059, DOI 10.1128/JCM.28.9.2059-2063.1990; National Committee for Clinical Laboratory Standards, 1998, M100S8 NAT COMM CLIN; NAUMOVSKI L, 1992, ANTIMICROB AGENTS CH, V36, P1991, DOI 10.1128/AAC.36.9.1991; PAPANICOLAOU GA, 1990, ANTIMICROB AGENTS CH, V34, P2200, DOI 10.1128/AAC.34.11.2200; PETIT A, 1990, ANTIMICROB AGENTS CH, V34, P219, DOI 10.1128/AAC.34.2.219; Prodinger WM, 1996, J CLIN MICROBIOL, V34, P564, DOI 10.1128/JCM.34.3.564-568.1996; QUINN JP, 1989, ANTIMICROB AGENTS CH, V33, P1451, DOI 10.1128/AAC.33.9.1451; QUINN JP, 1996, 34 ANN INFECT DIS SO; RASMUSSEN BA, 1993, ANTIMICROB AGENTS CH, V37, P1989, DOI 10.1128/AAC.37.9.1989; RICE LB, 1990, ANTIMICROB AGENTS CH, V34, P2193, DOI 10.1128/AAC.34.11.2193; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SCHABERG DR, 1977, ANTIMICROB AGENTS CH, V11, P449, DOI 10.1128/AAC.11.3.449; Schiappa DA, 1996, J INFECT DIS, V174, P529, DOI 10.1093/infdis/174.3.529; SIROT J, 1988, REV INFECT DIS, V10, P850; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; URBAN C, 1994, ANTIMICROB AGENTS CH, V38, P392, DOI 10.1128/AAC.38.2.392; WEINSTEIN RA, 1981, AM J MED, V70, P449; White AC, 1997, CLIN INFECT DIS, V25, P230	42	355	374	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1999	281	6					517	523		10.1001/jama.281.6.517	http://dx.doi.org/10.1001/jama.281.6.517			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164FQ	10022107				2022-12-28	WOS:000078452900029
J	Goldie, SJ; Weinstein, MC; Kuntz, KM; Freedberg, KA				Goldie, SJ; Weinstein, MC; Kuntz, KM; Freedberg, KA			The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	20th Annual Meeting of the Society-of-General-Internal-Medicine	MAY 01-03, 1997	WASHINGTON, D.C.	Soc Gen Internal Med		cost-benefit analysis; cervix neoplasms; human immunodeficiency virus infections; vaginal smears; colposcopy	HUMAN-IMMUNODEFICIENCY-VIRUS; SQUAMOUS INTRAEPITHELIAL LESIONS; HUMAN-PAPILLOMAVIRUS INFECTION; LOOP ELECTROSURGICAL EXCISION; TERM FOLLOW-UP; SEROPOSITIVE WOMEN; PAPANICOLAOU SMEARS; POSITIVE WOMEN; RISK-FACTORS; NEOPLASIA	Background: Women with HIV infection have a higher risk for cervical squamous intraepithelial lesions than do women without HIV infection, and the optimal regimen for cervical cancer screening in these women is uncertain. Objective: To assess the net health consequences, costs, and cost-effectiveness of Various screening strategies for cervical neoplasia and cancer in HIV-infected women. Design: A cost-effectiveness analysis from a societal perspective done by using a state-transition Markov model. Values for incidence, progression, and regression of cervical neoplasia; efficacy of screening and treatment; progression of HIV disease; mortality from HIV infection and cancer; quality of life; and costs were obtained from the literature. Setting: Simulated clinical practice in the United States. Patients: HIV-infected women representative of the U.S. population. Intervention: Six main screening strategies-no screening, annual Papanicolaou smears, annual Papanicolaou smears after two negative smears obtained 6 months apart (recommended by the Centers for Disease Control and Prevention), semiannual Papanicolaou smears, annual colposcopy, and semiannual colposcopy-were considered. Measurements: Quality-adjusted life-years (QALYs), lifetime costs, and incremental cost-effectiveness. Results: Annual Papanicolaou smear screening resulted in a 2.1-month gain in quality-adjusted life expectancy for an incremental cost of $12 800 per QALY saved. Annual Papanicolaou smear screening after two negative smears obtained 6 months apart provided an additional 0.04 QALYs at a cost of $14 800 per QALY saved. Semiannual Papanicolaou smear screening provided a further 0.17 QALYs at a cost of $27 600 per QALY saved. Annual colposcopy cost more but provided no additional benefit compared with that given by semiannual Papanicolaou smear screening, and semiannual colposcopy exceeded $375 000 per QALY saved. Results were most sensitive to the rate of progression of neoplasia to invasive cancer. Conclusions: in HIV-infected women, cervical cancer screening with annual Papanicolaou smears after two negative smears obtained 6 months apart offers quality-adjusted life expectancy benefits at a cost comparable to that of other clinical preventive interventions.	Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Dept Hlth Policy & Management, Boston, MA 02115 USA; Boston Univ, Sch Publ Hlth, Boston, MA USA; Boston Med Ctr, Evans Med Fdn, Boston, MA 02118 USA	Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Boston Medical Center	Goldie, SJ (corresponding author), Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Dept Hlth Policy & Management, 718 Huntington Ave,2nd Floor, Boston, MA 02115 USA.	sgoldie@hsph.harvard.edu			AHRQ HHS [R01-HS07317-01A1] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADACHI A, 1993, OBSTET GYNECOL, V81, P372; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BARRON BA, 1978, GYNECOL ONCOL, V6, P196, DOI 10.1016/0090-8258(78)90022-7; BARRON BA, 1970, J NATL CANCER I, V45, P1025; Belafsky P, 1996, J ACQ IMMUN DEF SYND, V11, P511, DOI 10.1097/00042560-199604150-00013; BELAFSKY P, 1996, GYNECOL ONCOL, V60, P118; BERK M, 1993, AHCPR PUBLICATION; BIBBO M, 1971, J REPROD MED, V6, P184; BIGGERS SD, 1996, 11 INT C AIDS 7 12 J; BOARDMAN LA, 1994, OBSTET GYNECOL, V84, P1016; Bongain A, 1996, EUR J OBSTET GYN R B, V65, P195, DOI 10.1016/0301-2115(95)02357-7; Branca M., 1995, European Journal of Gynaecological Oncology, V16, P410; BROSGART C, 1995, 2 NAT C HUM RETR REL, P90; CAMPION MJ, 1986, LANCET, V2, P237; CAMPION MJ, 1990, OBSTET GYN CLIN N AM, V17, P695; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; *CDCP, 1996, HIV AIDS SURV REP AT; *CDCP, 1997, HIV AIDS SURV REP, P5; CELENTANO D P, 1989, Public Health Reviews, V17, P173; CHAISSON RE, 1995, NEW ENGL J MED, V333, P751, DOI 10.1056/NEJM199509213331202; Chertow GM, 1996, ARCH INTERN MED, V156, P1345, DOI 10.1001/archinte.156.12.1345; Chiasson MA, 1997, OBSTET GYNECOL, V89, P690, DOI 10.1016/S0029-7844(97)00069-0; CLARK RA, 1993, CLIN INFECT DIS, V17, P165, DOI 10.1093/clinids/17.2.165; Condra JH, 1998, ANN INTERN MED, V128, P951, DOI 10.7326/0003-4819-128-11-199806010-00017; CONTI M, 1993, GYNECOL ONCOL, V49, P344, DOI 10.1006/gyno.1993.1137; CONTI M, 1992, 7 INT C AIDS 3 STD W, V8, pB95; COPPLESON LW, 1974, AM J OBSTET GYNECOL, V119, P953, DOI 10.1016/0002-9378(74)90013-1; Cornelius L, 1991, AHCPR PUBLICATION; DELMAS MC, 1998, 12 WORLD AIDS C 28 J; DelPriore G, 1996, J REPROD MED, V41, P653; DELPRIORE G, 1995, GYNECOL ONCOL, V56, P395, DOI 10.1006/gyno.1995.1069; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; EHMANN WC, 1994, J ACQ IMMUN DEF SYND, V7, P1095; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; FAHS MC, 1992, ANN INTERN MED, V117, P520, DOI 10.7326/0003-4819-117-6-520; FINK MJ, 1994, GYNECOL ONCOL, V55, P133, DOI 10.1006/gyno.1994.1262; FLANIGAN TP, 1992, J WOMENS HEALTH, V1, P231, DOI DOI 10.1089/JWH.1992.1.231; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Freedberg KA, 1998, JAMA-J AM MED ASSOC, V279, P130, DOI 10.1001/jama.279.2.130; FRUCHTER RG, 1994, AM J OBSTET GYNECOL, V171, P531, DOI 10.1016/0002-9378(94)90294-1; Fruchter RG, 1996, OBSTET GYNECOL, V87, P338, DOI 10.1016/0029-7844(95)00408-4; FRUCHTER RG, 1997, 1 NAT MAL AIDS C 28; GILES JA, 1988, BRIT MED J, V296, P1099, DOI 10.1136/bmj.296.6629.1099; Gold MR, 1996, COST EFFECTIVENESS H; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gulick RM, 1998, JAMA-J AM MED ASSOC, V280, P35, DOI 10.1001/jama.280.1.35; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HANKINS CA, 1994, CAN MED ASSOC J, V150, P681; HAYWARD RA, 1988, ARCH INTERN MED, V148, P1177, DOI 10.1001/archinte.148.5.1177; Heard I, 1997, INT J STD AIDS, V8, P388, DOI 10.1258/0956462971920316; HEARD I, 1995, OBSTET GYNECOL, V86, P749, DOI 10.1016/0029-7844(95)00282-V; HEARD I, 1998, 12 WORLD AIDS C 28 J, P325; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; Hillemanns P, 1996, AIDS, V10, P1641, DOI 10.1097/00002030-199612000-00008; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Hockstad R L, 1992, Fam Pract Res J, V12, P53; HOCUTT JE, 1992, J FAM PRACTICE, V34, P38; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; HSIAO WC, 1988, JAMA-J AM MED ASSOC, V260, P2347, DOI 10.1001/jama.260.16.2347; JONES MH, 1992, LANCET, V339, P1440, DOI 10.1016/0140-6736(92)92031-A; KASHGARI.M, 1970, AM J EPIDEMIOL, V92, P211, DOI 10.1093/oxfordjournals.aje.a121201; KLEIN RS, 1994, J INFECT DIS, V170, P1404, DOI 10.1093/infdis/170.6.1404; KLEIN RS, 1997, 4 C RETR OPP INF 22, V126, P339; KORN AP, 1994, OBSTET GYNECOL, V83, P401; KORN AP, 1995, J ACQ IMMUN DEF SYND, V9, P361; LONGINI IM, 1991, J ACQ IMMUN DEF SYND, V4, P1141; LONGINI IM, 1989, STAT MED, V8, P831, DOI 10.1002/sim.4780080708; MAIMAN M, 1991, OBSTET GYNECOL, V78, P84; MAIMAN M, 1993, OBSTET GYNECOL, V82, P170; Mandelblatt JS, 1997, J GEN INTERN MED, V12, P551, DOI 10.1046/j.1525-1497.1997.07107.x; MANDELBLATT JS, 1992, AIDS, V6, P173, DOI 10.1097/00002030-199202000-00005; *MED EC, 1996, DRUG TOP RED BOOK; MULLER C, 1990, COSTS EFFECTIVENESS; NASIELL K, 1983, OBSTET GYNECOL, V61, P609; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; *NAT TECHN INF SER, 1994, AIDS COST SERV UT SU; *NAT TECHN INF SER, 1995, MULT AIDS COH STUD M; NIGHTINGALE SD, 1993, ARCH INTERN MED, V153, P1313, DOI 10.1001/archinte.153.11.1313; Northfelt D W, 1994, Oncology (Williston Park), V8, P33; Olaitan A, 1997, OBSTET GYNECOL, V89, P71, DOI 10.1016/S0029-7844(96)00377-8; PALEFSKY J, 1997, 1 NAT MAL AIDS C 28; Palefsky Joel, 1995, Current Opinion in Oncology, V7, P437, DOI 10.1097/00001622-199509000-00009; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PETRY KU, 1994, INT J CANCER, V57, P836, DOI 10.1002/ijc.2910570612; Petry KU, 1996, GYNECOL ONCOL, V60, P30, DOI 10.1006/gyno.1996.0007; Phillips P, 1997, JAMA-J AM MED ASSOC, V277, P1747, DOI 10.1001/jama.277.22.1747; RICHART RM, 1969, AM J OBSTET GYNECOL, V105, P386, DOI 10.1016/0002-9378(69)90268-3; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; RYLANDER E, 1977, ACTA OBSTET GYN SCAN, V56, P115, DOI 10.3109/00016347709158352; Schechter CB, 1996, ACTA CYTOL, V40, P1272; SEDLIS A, 1997, 1 NAT MAL AIDS C 28, P131; SEGAL MJ, 1997, MEDICARE RBRVS PHYSI; SHA BE, 1995, J ACQ IMMUN DEF SYND, V8, P486, DOI 10.1097/00042560-199504120-00009; Six C, 1998, AIDS, V12, P1047, DOI 10.1097/00002030-199809000-00012; STERN E, 1964, CANCER, V17, P508, DOI 10.1002/1097-0142(196404)17:4<508::AID-CNCR2820170412>3.0.CO;2-S; Sun XW, 1997, NEW ENGL J MED, V337, P1343, DOI 10.1056/NEJM199711063371903; SUN XW, 1995, OBSTET GYNECOL, V85, P680, DOI 10.1016/0029-7844(95)00025-M; U. S. Bureau of the Census, 1996, STAT ABSTR US; *US BUR LAB STAT, 1996, 98186 USDL US BUR LA; *US DEP HHS PHS NI, 1997, SURV EP END RES SEER; VERMUND SH, 1997, MED MANAGEMENT AIDS, P125; Vermund Sten H., 1995, P189; WATTS DH, 1996, 11 INT C AIDS 7 12 J; Wortley PM, 1997, JAMA-J AM MED ASSOC, V278, P911, DOI 10.1001/jama.278.11.911; WRIGHT TC, 1994, OBSTET GYNECOL, V84, P591; Wright TC, 1996, OBSTET GYN CLIN N AM, V23, P861, DOI 10.1016/S0889-8545(05)70280-1; Wright TC, 1996, OBSTET GYNECOL, V87, P515, DOI 10.1016/0029-7844(95)00472-6; WRIGHT TC, 1994, GYNECOL ONCOL, V55, P253, DOI 10.1006/gyno.1994.1286; WRIGHT TC, 1995, 2 NAT C HUM RETR REL	110	87	90	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	1999	130	2					97	+		10.7326/0003-4819-130-2-199901190-00003	http://dx.doi.org/10.7326/0003-4819-130-2-199901190-00003			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	158KG	10068381				2022-12-28	WOS:000078114200002
J	Krumholz, HM				Krumholz, HM			beta-blockers for mild to moderate heart failure	LANCET			English	Editorial Material									Yale Univ, Sch Med, New Haven, CT 06520 USA; Yale New Haven Hosp, New Haven, CT 06520 USA	Yale University; Yale University	Krumholz, HM (corresponding author), Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06520 USA.		, Harlan/AAI-2875-2020					Eichhorn EJ, 1996, CIRCULATION, V94, P2285, DOI 10.1161/01.CIR.94.9.2285; FOREMAN J, 1988, BOSTON GLOBE    1018, P1; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; Lechat P, 1998, CIRCULATION, V98, P1184, DOI 10.1161/01.CIR.98.12.1184; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115	5	13	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 2	1999	353	9146					2	3		10.1016/S0140-6736(98)00413-9	http://dx.doi.org/10.1016/S0140-6736(98)00413-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023937	hybrid			2022-12-28	WOS:000077934800002
J	Brewer, T; Colditz, GA				Brewer, T; Colditz, GA			Postmarketing surveillance and adverse drug reactions - Current perspectives and future needs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-DISEASE; FENFLURAMINE-PHENTERMINE; MYOCARDIAL-INFARCTION; ACTIVE SURVEILLANCE; BREAST-CANCER; EVENTS; THERAPY; SAFETY; RISK; MORTALITY	Spontaneous reporting systems like MEDWATCH can be effective in revealing unusual or rare adverse events that occur with the use of medications, and such reports may often be sufficient to assign causality. However, spontaneous reports do not reliably detect adverse drug reactions (ADRs) that occur widely separated in time from the original use of the drug or that represent an increased risk of an adverse event that occurs commonly in populations not exposed to the drug. In these situations, spontaneous reports alone do not provide sufficient evidence to conclude that the adverse event was an ADR, identification of ADRs associated with long-term administration of drugs for chronic diseases also remains problematic. Methods to evaluate ADRs using data from clinical trials, medical records, and computerized databases of medication users and nonusers must be developed to complement spontaneous reporting systems. Without these methods, potentially important ADRs will remain undetected, and spurious associations between adverse outcomes and medications or devices will remain unchallenged.	Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Technol Assessment Grp, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Brewer, T (corresponding author), Brigham & Womens Hosp, Channing Lab, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NIAID NIH HHS [1 KO8 AI01444-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001444] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anello C, 1996, CLIN RES REGUL AFF, V13, P13, DOI 10.3109/10601339609019625; [Anonymous], 1995, J Clin Epidemiol, V48, P1441; AURICHE M, 1993, DRUG SAFETY, V9, P230, DOI 10.2165/00002018-199309030-00008; BLUM MD, 1994, CLIN INFECT DIS, V18, P946, DOI 10.1093/clinids/18.6.946; BROWN RB, 1986, ARCH INTERN MED, V146, P2159, DOI 10.1001/archinte.146.11.2159; Capella D, 1998, EUR J CLIN PHARMACOL, V53, P299, DOI 10.1007/s002280050382; CASE B, 1991, AM J HOSP PHARM, V48, P121, DOI 10.1093/ajhp/48.1.121; CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8; CHEN RT, 1995, LANCET, V345, P1369, DOI 10.1016/S0140-6736(95)92568-6; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; EIRIS JM, 1995, NEUROLOGY, V45, P1155, DOI 10.1212/WNL.45.6.1155; Ellenberg SS, 1997, PUBLIC HEALTH REP, V112, P10; ENAS GG, 1995, STAT MED, V14, P1099, DOI 10.1002/sim.4780140930; FARRINGTON P, 1995, LANCET, V345, P567, DOI 10.1016/S0140-6736(95)90471-9; FEELY J, 1990, BRIT MED J, V300, P22, DOI 10.1136/bmj.300.6716.22; FRAZIER HS, 1995, MED WORTH PAYING FOR, P212; Graham DJ, 1997, NEW ENGL J MED, V337, P635, DOI 10.1056/NEJM199708283370911; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; HALVORSEN KT, 1992, MED USES STAT, P413; HANKINSON SE, 1992, OBSTET GYNECOL, V80, P708; HELDENBERG D, 1983, NEUROLOGY, V33, P510, DOI 10.1212/WNL.33.4.510; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; HINE LK, 1989, ARCH INTERN MED, V149, P2694, DOI 10.1001/archinte.149.12.2694; HORWITZ RI, 1985, ARCH INTERN MED, V145, P1873, DOI 10.1001/archinte.145.10.1873; INMAN W, 1993, LANCET, V342, P658, DOI 10.1016/0140-6736(93)91763-C; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V269, P2765, DOI 10.1001/jama.269.21.2765; KOCH KE, 1990, AM J HOSP PHARM, V47, P1314, DOI 10.1093/ajhp/47.6.1314; LABARTHE DR, 1979, J CHRON DIS, V32, P95, DOI 10.1016/0021-9681(79)90021-3; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LORTIE FM, 1986, CAN MED ASSOC J, V135, P27; MIREMONT G, 1994, EUR J CLIN PHARMACOL, V46, P285; MITCHELL AS, 1988, BRIT MED J, V297, P891, DOI 10.1136/bmj.297.6653.891; MUURONEN A, 1985, BRIT MED J, V291, P1481, DOI 10.1136/bmj.291.6507.1481; NASH JQ, 1995, EPIDEMIOL INFECT, V114, P475, DOI 10.1017/S0950268800052183; PIAZZAHEPP TD, 1995, AM J HEALTH-SYST PH, V52, P1436, DOI 10.1093/ajhp/52.13.1436; PINI L-G, 1990, Acta Physiologica Hungarica, V75, P237; ROSSI AC, 1983, JAMA-J AM MED ASSOC, V249, P2226, DOI 10.1001/jama.249.16.2226; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; SCOTT HD, 1990, JAMA-J AM MED ASSOC, V263, P1785, DOI 10.1001/jama.263.13.1785; SENEKJIAN EK, 1988, AM J OBSTET GYNECOL, V158, P493, DOI 10.1016/0002-9378(88)90012-9; SILLS JM, 1986, AM J HOSP PHARM, V43, P2764, DOI 10.1093/ajhp/43.11.2764; STOLLEY PD, 1982, J CLIN PHARMACOL, V22, P499, DOI 10.1002/j.1552-4604.1982.tb02642.x; Strom B L, 1991, Ann Ist Super Sanita, V27, P235; TUBERT P, 1992, J CLIN EPIDEMIOL, V45, P283, DOI 10.1016/0895-4356(92)90088-5; VENNING GR, 1983, BRIT MED J, V286, P544, DOI 10.1136/bmj.286.6364.544; VENULET J, 1992, INT J CLIN PHARM RES, V12, P61; White GG, 1998, J TOXICOL-CLIN TOXIC, V36, P145, DOI 10.3109/15563659809162609; Wise RP, 1997, JAMA-J AM MED ASSOC, V278, P1176, DOI 10.1001/jama.278.14.1176	50	233	238	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					824	829		10.1001/jama.281.9.824	http://dx.doi.org/10.1001/jama.281.9.824			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10071004				2022-12-28	WOS:000078804300033
J	Nichol, KL; Baken, L; Nelson, A				Nichol, KL; Baken, L; Nelson, A			Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE RESPIRATORY-DISEASE; PREVENTING HOSPITALIZATION; COST-EFFECTIVENESS; EPIDEMIC; EFFICACY; PNEUMONIA; COMMUNITY; IMPACT; RISK	Background: Influenza Vaccine is underused in groups targeted for vaccination. Objective: To define the effects of influenza and the benefits of influenza Vaccination in elderly persons with chronic lung disease. Design: Retrospective, multiseason cohort study. Setting: Large managed care organization. Patients: All elderly members of a managed care organization who had a previous diagnosis of chronic lung disease. Measurements: Outcomes in vaccinated and unvaccinated persons for the 1993-1994, 1994-1995, and 1995-1996 influenza seasons were compared after adjustment for baseline demographic and health characteristics. All data were obtained from administrative databases. Results: Vaccination rates were greater than 70% for each season. Among unvaccinated persons, hospitalization rates for pneumonia and influenza were twice as high in the influenza seasons as they were in the interim (non-influenza) periods. Influenza vaccination was associated with fewer hospitalizations for pneumonia and influenza (adjusted risk ratio, 0.48 [95% CI, 0.28 to 0.82]) and with lower risk for death (adjusted odds ratio, 0.30 [Cl, 0.21 to 0.43]) during the influenza seasons. It was also associated with fewer outpatient visits for pneumonia and influenza and for all respiratory conditions. Conclusions: For elderly persons with chronic lung disease, influenza is associated with significant adverse health effects and influenza vaccination is associated with substantial health benefits, including fewer outpatient visits, fewer hospitalizations, and fewer deaths. Health care providers should take advantage of all opportunities to immunize these high-risk patients.	Vet Affairs Med Ctr 111, Minneapolis, MN 55417 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; Hlth Partners & Grp Hlth Fdn, Bloomington, MN USA	University of Minnesota System; University of Minnesota Twin Cities	Nichol, KL (corresponding author), Vet Affairs Med Ctr 111, 1 Vet Dr, Minneapolis, MN 55417 USA.							Ahmed AH, 1997, EPIDEMIOL INFECT, V118, P27, DOI 10.1017/S0950268896007121; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; BARKER WH, 1986, AM J PUBLIC HEALTH, V76, P761, DOI 10.2105/AJPH.76.7.761; BEYER WEP, 1989, VACCINE, V7, P385, DOI 10.1016/0264-410X(89)90150-3; COUCH RB, 1993, ANN NY ACAD SCI, V685, P803, DOI 10.1111/j.1749-6632.1993.tb35946.x; FEDSON DS, 1993, JAMA-J AM MED ASSOC, V270, P1956, DOI 10.1001/jama.270.16.1956; Fleming DM, 1995, EPIDEMIOL INFECT, V115, P581, DOI 10.1017/S095026880005874X; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; FOX R, 1995, RESP MED, V89, P559, DOI 10.1016/0954-6111(95)90158-2; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GROSS PA, 1989, VACCINE, V7, P303, DOI 10.1016/0264-410X(89)90190-4; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; IEZZONI LI, 1994, RISK ADJUSTMENT MEAS, P1; Kelsey JL., 1996, METHODS OBSERVATIONA; LUI KJ, 1987, AM J PUBLIC HEALTH, V77, P712, DOI 10.2105/AJPH.77.6.712; MACDONALD R, IN PRESS AM J PREV M; MARGOLIS KL, 1992, J AM GERIATR SOC, V40, P1021, DOI 10.1111/j.1532-5415.1992.tb04480.x; MCBEAN AM, 1993, ARCH INTERN MED, V153, P2105, DOI 10.1001/archinte.153.18.2105; MULLOOLY JP, 1994, ANN INTERN MED, V121, P947, DOI 10.7326/0003-4819-121-12-199412150-00008; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; Ohmit SE, 1995, INT J EPIDEMIOL, V24, P1240, DOI 10.1093/ije/24.6.1240; PAUL WS, 1988, J INFECT DIS, V157, P633, DOI 10.1093/infdis/157.4.633; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468, DOI 10.1093/oxfordjournals.aje.a114128; Rothenberg RB, 1996, PREVENTION EFFECTIVE, P193; SACKETT DL, 1985, CLIN EPIDEMIOLOGY BA, P285; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; 1995, MMWR MORB MORTAL WKL, V44, P561; 1998, MMWR MORB MORTAL WKL, V47, P797	31	253	262	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	1999	130	5					397	+		10.7326/0003-4819-130-5-199903020-00003	http://dx.doi.org/10.7326/0003-4819-130-5-199903020-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172AA	10068413	Green Submitted			2022-12-28	WOS:000078898100002
J	Morrison, A; Stone, DH; Redpath, A; Campbell, H; Norrie, J				Morrison, A; Stone, DH; Redpath, A; Campbell, H; Norrie, J			Trend analysis of socioeconomic differentials in deaths from injury in childhood in Scotland, 1981-95	BRITISH MEDICAL JOURNAL			English	Article									Univ Glasgow, Dept Child Hlth, Paediat Epidemiol & Community Hlth Unit, Glasgow G3 8SJ, Lanark, Scotland; Scottish Hlth Serv, Informat & Stat Div, Edinburgh EH5 3SQ, Midlothian, Scotland; Univ Edinburgh, Sch Med, Dept Publ Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow; University of Edinburgh; University of Glasgow	Morrison, A (corresponding author), Univ Glasgow, Dept Child Hlth, Paediat Epidemiol & Community Hlth Unit, Glasgow G3 8SJ, Lanark, Scotland.		Campbell, Harry/E-2959-2010	Campbell, Harry/0000-0002-6169-6262				Carstairs V., 1991, DEPRIVATION HLTH SCO; JARVIS S, 1995, HLTH OUR CHILDREN S; LINDSEY J. K., 1995, MODELLING FREQUENCY; Roberts I, 1996, BRIT MED J, V313, P784; SMITH GD, 1997, PROGR PUBLIC HLTH	5	22	22	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					567	568		10.1136/bmj.318.7183.567	http://dx.doi.org/10.1136/bmj.318.7183.567			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037632	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000078966300027
J	Rodriguez, LAG; Ruigomez, A				Rodriguez, LAG; Ruigomez, A			Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study	BRITISH MEDICAL JOURNAL			English	Article									Ctr Espanol Invest Farmacoepidemiol, E-28004 Madrid, Spain		Rodriguez, LAG (corresponding author), Ctr Espanol Invest Farmacoepidemiol, E-28004 Madrid, Spain.		rodriguez, luis a garcia/B-1980-2010; Ruigomez, Ana/HDN-8290-2022					Barber R, 1997, BRIT MED J, V314, P1903; MCKENDRICK MW, 1994, J INFECTION, V29, P1, DOI 10.1016/S0163-4453(94)94871-2; Neal KR, 1997, BRIT MED J, V314, P779, DOI 10.1136/bmj.314.7083.779; Rodriguez LAG, 1997, EPIDEMIOLOGY, V8, P571; Rodriguez LAG, 1998, BRIT J CLIN PHARMACO, V45, P419	5	259	278	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					565	566		10.1136/bmj.318.7183.565	http://dx.doi.org/10.1136/bmj.318.7183.565			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037630	Green Published			2022-12-28	WOS:000078966300025
J	Green, DJ; Tandon, R; Sglavo, VM				Green, DJ; Tandon, R; Sglavo, VM			Crack arrest and multiple cracking in class through the use of designed residual stress profiles	SCIENCE			English	Article							STRENGTH VARIABILITY; STABILITY	A processing approach has been identified and reduced to practice in which a residual stress profile can be designed such that cracks in a brittle material are arrested or grow in a stable manner. In the approach, cracks in the body encounter an increase in the magnitude of residual compression as the crack propagates. If correctly designed, the process increases strength and significantly decreases strength variability. This approach was demonstrated for a silicate grass, and multiple cracking was observed as a forewarning of the final failure. Normally, such glasses would fail catastrophically with the propagation of a dominant crack.	Penn State Univ, Dept Mat Sci & Engn, University Pk, PA 16802 USA; Caterpillar Inc, Ctr Tech, Peoria, IL 61656 USA; Univ Trento, Dipartimento Ingn Mat, I-38050 Trento, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Caterpillar Inc; University of Trento	Green, DJ (corresponding author), Penn State Univ, Dept Mat Sci & Engn, University Pk, PA 16802 USA.		sglavo, vincenzo m./M-7981-2015	sglavo, vincenzo m./0000-0001-9133-7204				BEAUCHAMP EK, COMMUNICATION; Green DJ, 1998, INTRO MECH PROPERTIE, P218; Hui CY, 1996, J MECH PHYS SOLIDS, V44, P1715, DOI 10.1016/0022-5096(96)00045-2; Lawn P.R, 1993, CAMBRIDGE SOLID STAT, Vsecond; MATSUNO K, 1987, GLASS DIV AM CER SOC; TANDON R, 1990, J AM CERAM SOC, V73, P2628, DOI 10.1111/j.1151-2916.1990.tb06738.x; TANDON R, 1993, ACTA METALL MATER, V41, P399, DOI 10.1016/0956-7151(93)90070-9; TANDON R, 1992, J MATER RES, V7, P765, DOI 10.1557/JMR.1992.0765; TANDON R, 1991, J AM CERAM SOC, V74, P1981, DOI 10.1111/j.1151-2916.1991.tb07818.x; TANDON R, 1992, CRACK STABILITY RESI, P659; VIRKAR AV, 1990, J AM CERAM SOC, V73, P2100, DOI 10.1111/j.1151-2916.1990.tb05276.x	11	146	182	3	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1295	1297		10.1126/science.283.5406.1295	http://dx.doi.org/10.1126/science.283.5406.1295			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037593				2022-12-28	WOS:000078839900032
J	Hoeyberghs, JL				Hoeyberghs, JL			Fortnightly review - Cosmetic surgery	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SOFT-TISSUE AUGMENTATION; DYE-LASER; TRANSPLANTATION; INJECTION; ARTECOLL; IMPLANT; FACE		Wellness Klin, B-3600 Genk, Belgium		Hoeyberghs, JL (corresponding author), Wellness Klin, Grotestr 42,POB 103, B-3600 Genk, Belgium.	wellness.kliniek@village.uunet.be						ACHAUER BM, 1993, PLAST RECONSTR SURG, V92, P1233; ASTON SJ, 1997, GRABB SMITHS PLASTIC, P713; ASTON SJ, 1997, GRABB SMITHS PLASTIC, P101; BAKER TJ, 1996, SURG REJUVENATION FA, P11; BENEDETTO AV, 1992, J AM ACAD DERMATOL, V27, P439, DOI 10.1016/0190-9622(92)70214-Z; Bostwick III J, 1995, ENDOSCOPIC PLASTIC S; CHANG KN, 1994, PLAST RECONSTR SURG, V94, P126, DOI 10.1097/00006534-199407000-00013; COLEMAN WP, 1991, PLAST RECONSTR SURG, V88, P736, DOI 10.1097/00006534-199110000-00038; Cooper C, 1998, BMJ-BRIT MED J, V316, P403, DOI 10.1136/bmj.316.7129.403; DILLERUD E, 1991, PLAST RECONSTR SURG, V88, P239, DOI 10.1097/00006534-199108000-00011; FITZPATRICK RE, 1994, AESTHET PLAST SURG, V18, P91, DOI 10.1007/BF00444255; GLOGAN RG, 1995, DERMATOL CLIN, V13, P25; GREKIN RC, 1993, J DERMATOL SURG ONC, V19, P380, DOI 10.1111/j.1524-4725.1993.tb00361.x; GROSSMAN MC, 1995, LASERS SURG MED S, V7, P47; GUYURON B, 1994, PLAST RECONSTR SURG, V93, P913, DOI 10.1097/00006534-199404001-00003; *HAIRT HOLL, 1998, MAT SAF DAT SHEET; HAVAS DR, 1991, J DERMATOLOG SURG ON, V17, P382; ISSE NG, 1994, AESTHET PLAST SURG, V18, P21, DOI 10.1007/BF00444243; JOHNSON GW, 1993, PLAST RECONSTR SURG, V92, P801, DOI 10.1097/00006534-199392050-00004; KANVAR ANB, 1995, LASER SURG MED, V16, P50; KLEIN JA, 1993, PLAST RECONSTR SURG, V92, P1085, DOI 10.1097/00006534-199311000-00014; LEMPERLE G, 1995, PLAST RECONSTR SURG, V96, P627, DOI 10.1097/00006534-199509000-00015; MALE B, 1992, PLAST RECONSTR SURG, V90, P200; MAXWELL GP, 1996, OPERATIVE TECHNIQUES; McClelland M, 1997, PLAST RECONSTR SURG, V100, P1466, DOI 10.1097/00006534-199711000-00014; ORGENTAS HF, 1994, ANN PLAST SURG, V33, P171; PFENNINGER JL, 1994, PROCEDURES PRIMARY C, P91; Piacquadio D, 1997, J AM ACAD DERMATOL, V36, P544, DOI 10.1016/S0190-9622(97)70241-X; RAMIREZ OM, 1996, ENDOSCOPIC PLASTIC S; RAUS P, 1997, INT J AEST RESTOR SU, V2, P96; REID WH, 1983, BRIT J PLAST SURG, V36, P4559; RODDI R, 1994, EUR J PLAST SURG, V17, P79, DOI 10.1007/BF00176920; ROHRICH RJ, 1997, PLAST RECONSTR SURG, V99, P1; SPIZA M, 1993, CLIN PLAST SURG, V20, P181; UEBEL CO, 1995, PLAST SURG TECHNIQUE, V1, P95; Uebel CO, 1994, AM J COSMET SURG, V11, P293; UNGER WP, 1994, J DERMATOL SURG ONC, V20, P515, DOI 10.1111/j.1524-4725.1994.tb00136.x; ZOCCHI M, 1995, ADV PLAST RECONSTR S, V11, P197	38	9	9	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 20	1999	318	7182					512	516		10.1136/bmj.318.7182.512	http://dx.doi.org/10.1136/bmj.318.7182.512			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QT	10024262	Green Published			2022-12-28	WOS:000078818100030
J	Jacobson, RR; Krahenbuhl, JL				Jacobson, RR; Krahenbuhl, JL			Leprosy	LANCET			English	Article							MYCOBACTERIUM-LEPRAE; RELAPSE; PROGRAM; LESSONS; RATES; SKIN	Leprosy is an ancient disease which is still poorly understood and often feared by the general public and even by some healthcare professionals. Fortunately, improvements in the management of leprosy over the past three decades have diminished the stigma and greatly altered the outlook for patients. Public understanding of the disease has benefited from WHO's goal of eliminating leprosy as a public health problem by the year 2000. Unfortunately that goal has also led many to believe that leprosy has been or will soon be eradicated. This will not happen in the near future because, despite a fall in registered cases, the incidence of the disease has changed very little, and eradication of a bacterial infectious disease such as this is unlikely with chemotherapy alone. Nevertheless, as a result of the WHO's efforts, patients nearly everywhere should have! access to care, and the incidence may begin to diminish if adequate control efforts are maintained beyond the year 2000. Given the mobility of patients today a physician anywhere may occasionally see a case or be asked about the disease so a basic understanding of leprosy and its management should prove useful.	Gillis W Long Hansens Dis Ctr, Div Natl Hansens Dis Programs, Carville, LA 70721 USA; Gillis W Long Hansens Dis Ctr, Lab Res Branch, Carville, LA 70721 USA		Jacobson, RR (corresponding author), Gillis W Long Hansens Dis Ctr, Div Natl Hansens Dis Programs, 5445 Point Clair Rd, Carville, LA 70721 USA.	jkrahe1@lsu.edu						Abel L, 1998, J INFECT DIS, V177, P133, DOI 10.1086/513830; Abraham S, 1998, INT J LEPROSY, V66, P131; [Anonymous], 1998, Wkly Epidemiol Rec, V73, P153; [Anonymous], 1997, Indian J Lepr, V69, P121; Bertolli J, 1997, INT J EPIDEMIOL, V26, P888, DOI 10.1093/ije/26.4.888; BINFORD CH, 1976, PATHOLOGY TROPICAL E, P205; Brennan PJ, 1996, INT J LEPROSY, V64, pS58; Buhrer SS, 1998, AM J TROP MED HYG, V58, P133; Butlin CR, 1997, INT J LEPROSY, V65, P465; Corral LG, 1996, MOL MED, V2, P506, DOI 10.1007/BF03401909; Cree IA, 1998, LEPROSY REV, V69, P112; Croft RP, 1997, LEPROSY REV, V68, P316; DEVRIES RRP, 1994, LEPROSY, P113; Dockrell HM, 1996, INFECT IMMUN, V64, P4385, DOI 10.1128/IAI.64.10.4385-4389.1996; Fine PEM, 1996, LANCET, V348, P17, DOI 10.1016/S0140-6736(96)02166-6; Fine PEM, 1996, INT J LEPROSY, V64, pS44; FRANZBLAU SG, 1992, LEPROSY REV, V63, P125; Gillis TP, 1998, REV MED MICROBIOL, V9, P39; Green AT, 1998, LEPROSY REV, V69, P134; Gupte MD, 1996, INT J LEPROSY, V64, pS29; HASTINGS RC, 1977, INT J LEPROSY, V45, P281; HASTINGS RC, 1994, LEPROSY; Jacobson RR, 1996, INT J LEPROSY, V64, pS16; JACOBSON RR, 1998, BACTERIAL INFECT HUM, P377; JAMET P, 1995, INT J LEPROSY, V63, P195; Ji B, 1998, LEPROSY REV, V69, P106; JI B, 1988, LEPROSY REV, V69, P106; Ji BH, 1997, ANTIMICROB AGENTS CH, V41, P1953, DOI 10.1128/AAC.41.9.1953; Ji BH, 1996, ANTIMICROB AGENTS CH, V40, P393, DOI 10.1128/AAC.40.2.393; Job CK, 1997, INT J LEPROSY, V65, P461; Kampirapap K, 1998, INT J LEPROSY, V66, P16; KHANOLKARYOUNG S, 1995, CLIN EXP IMMUNOL, V99, P196, DOI 10.1111/j.1365-2249.1995.tb05532.x; Lockwood DNJ, 1996, LEPROSY REV, V67, P253; Lockwood DNJ, 1997, LEPROSY REV, V68, P299; LOCKWOOD DNJ, 1995, BRIT MED J, V311, P862, DOI 10.1136/bmj.311.7009.862; Meima A, 1997, INT J LEPROSY, V65, P305; Meyers WM, 1998, INT J LEPROSY, V66, P43; MODLIN RL, 1994, J INVEST DERMATOL, V102, P828, DOI 10.1111/1523-1747.ep12381958; MODLIN RL, 1994, LEPROSY, P225; Moreira AL, 1998, INT J LEPROSY, V66, P61; Noussitou F. M., 1976, LEPROSY CHILDREN; OTTENHOFF THM, 1994, INT J LEPROSY, V62, P108; PONNIGHAUS JM, 1994, INT J LEPROSY, V62, P10; Roche P, 1998, LEPROSY REV, V69, P151; Sarno EN, 1996, INT J LEPROSY, V64, pS69; Saunderson Paul, 1998, Leprosy Review, V69, P160; Schreuder PAM, 1998, INT J LEPROSY, V66, P149; Smith WCS, 1997, LEPROSY REV, V68, P195; Valverde CR, 1998, INT J LEPROSY, V66, P140; vanBeers SM, 1996, FEMS MICROBIOL LETT, V136, P221, DOI 10.1016/0378-1097(95)00505-6; Waters MFR, 1998, LEPROSY REV, V69, P110; *WHO, 1998, WKLY EPID REC, V73, P150; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P205; *WHO ACT PROG EL L, 1998, ACT PROGR EL LEPR ST; *WHO EXP COMM LEPR, 1998, WHO TECH REP SER, V874; *WHO EXP COMM LEPR, 1998, WHO TECH REP SERV, V874; *WHO STUD GROUP, 1994, WHO TECH REP SER, V847; WILLIAMS DL, 1990, MOL MICROBIOL, V4, P1653, DOI 10.1111/j.1365-2958.1990.tb00542.x; WILLIAMS DL, 1994, ANTIMICROB AGENTS CH, V38, P2380, DOI 10.1128/AAC.38.10.2380; World Health Organization, 1998, GUID LEPR CONTR; Young D, 1996, INT J LEPROSY, V64, pS68; Young D, 1996, INT J LEPROSY, V64, pS75	62	106	114	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 20	1999	353	9153					655	660		10.1016/S0140-6736(98)06322-3	http://dx.doi.org/10.1016/S0140-6736(98)06322-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QU	10030346				2022-12-28	WOS:000078818200045
J	Buckley, RH; Schiff, SE; Schiff, RI; Markert, ML; Williams, LW; Roberts, JL; Myers, LA; Ward, FE				Buckley, RH; Schiff, SE; Schiff, RI; Markert, ML; Williams, LW; Roberts, JL; Myers, LA; Ward, FE			Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; IN-UTERO TRANSPLANTATION; SOYBEAN LECTIN; BLOOD; RECONSTITUTION; DISORDERS; DISEASES; CHILDREN; MUTATION; INFANTS	Background Since 1968 it has been known that bone marrow transplantation can ameliorate severe combined immunodeficiency, bur data on the longterm efficacy of this treatment are limited. We prospectively studied immunologic function in 89 consecutive infants with severe combined immunodeficiency who received hematopoietic stem-cell transplants at Duke University Medical Center between May 1982 and September 1998. Methods Serum immunoglobulin levels and lymphocyte phenotypes and function were assessed and genetic analyses performed according to standard methods. Bone marrow was depleted of T cells by agglutination with soybean lectin and by sheep-erythrocyte resetting before transplantation. Results Seventy-seven of the infants received T-cell-depleted, HLA-haploidentical parental marrow, and 12 received HLA-identical marrow from a related donor; 3 of the recipients of haploidentical marrow also received placental-blood transplants from unrelated donors. Except for two patients who received placental blood, none of the recipients received chemotherapy before transplantation or prophylaxis against graft-versus-host: disease. Of the 89 infants, 72 (81 percent) were still alive 3 months to 16.5 years after transplantation, including all of the 12 who received HLA-identical marrow, 60 of the 77 (78 percent) who were given haploidentical marrow, and 2 of the 3 (67 percent) who received both haploidentical marrow and placental blood. T-cell function became normal within two weeks after transplantation in the patients who received unfractionated HLA-identical marrow but usually not until three to four months after transplantation in those who received T-cell-depleted marrow. At the time of the most recent evaluation, all but 4 of the 72 survivors had normal T-cell function, and all the T cells in their blood were of donor origin. B-cell function remained abnormal in many of the recipients of haploidentical marrow. In 26 children (5 recipients of HLA-identical marrow and 21 recipients of haploidentical marrow) between 2 percent and 100 percent of B cells were of donor origin. Forty-five of the 72 children were receiving intravenous immune globulin. Conclusions Transplantation of marrow from a related donor is a life-saving and life-sustaining treatment for patients with any type of severe combined immunodeficiency, even when there is no HLA-identical donor. (N Engl J Med 1999;340:508-16.) (C)1999. Massachusetts Medical Society.	Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University; Duke University	Buckley, RH (corresponding author), Duke Univ, Med Ctr, Dept Pediat, Box 2898, Durham, NC 27710 USA.		Buckley, Rebecca/AAB-1578-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI038550, R37AI018613] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR-30] Funding Source: Medline; NIAID NIH HHS [5R37AI18613, U19 AI38550] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman PL, 1961, BLOOD OTHER BODY FLU, P125; AMOS DB, 1968, J EXP MED, V128, P623, DOI 10.1084/jem.128.4.623; BORTIN MM, 1977, JAMA-J AM MED ASSOC, V238, P591, DOI 10.1001/jama.238.7.591; BUCKLEY RH, 1975, J CLIN INVEST, V55, P157, DOI 10.1172/JCI107906; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; BUCKLEY RH, 1986, J IMMUNOL, V136, P2398; BUCKLEY RH, 1968, PEDIATRICS, V41, P600; BUCKLEY RH, 1967, J ALLERGY, V40, P294, DOI 10.1016/0021-8707(67)90077-9; BUCKLEY RH, 1996, CLIN IMMUNOLOGY, P1813; ClementDeBoers A, 1996, J PEDIATR-US, V129, P544; DAUSSET J., 1958, ACTA HAEMATOL, V20, P156; DROR Y, 1993, BLOOD, V81, P2021; FISCHER A, 1992, Immunodeficiency Reviews, V3, P83; FISCHER A, 1990, LANCET, V336, P850, DOI 10.1016/0140-6736(90)92348-L; Flake AW, 1996, NEW ENGL J MED, V335, P1806, DOI 10.1056/NEJM199612123352404; FRIEDRICH W, 1985, EUR J PEDIATR, V144, P125, DOI 10.1007/BF00451897; GATTI RA, 1968, LANCET, V2, P1366; GERRITSEN EJA, 1993, BLOOD, V82, P3493; GHORY P, 1986, J CLIN IMMUNOL, V6, P161, DOI 10.1007/BF00918749; GIRI N, 1994, AUST NZ J MED, V24, P26, DOI 10.1111/j.1445-5994.1994.tb04421.x; Gluckman E, 1997, NEW ENGL J MED, V337, P373, DOI 10.1056/NEJM199708073370602; Haddad E, 1998, BLOOD, V91, P3646; HIRSCHHORN R, 1993, PEDIATR RES, V33, pS35; KENT EF, 1990, J CLIN IMMUNOL, V10, P106, DOI 10.1007/BF00918192; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MOEN RC, 1987, BLOOD, V70, P664; MULLERRUCHHOLTZ W, 1976, TRANSPLANT P, V8, P537; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; O'Reilly R J, 1989, Immunodefic Rev, V1, P273; OREILLY RJ, 1986, VOX SANG, V51, P81, DOI 10.1111/j.1423-0410.1986.tb02013.x; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; PUCK JM, 1994, J CLIN IMMUNOL, V14, P81, DOI 10.1007/BF01541340; PUCK JM, 1993, HUM MOL GENET, V2, P1099, DOI 10.1093/hmg/2.8.1099; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; REISNER Y, 1983, BLOOD, V61, P341; REISNER Y, 1978, P NATL ACAD SCI USA, V75, P2933, DOI 10.1073/pnas.75.6.2933; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; SCHIFF SE, 1987, CLIN EXP IMMUNOL, V68, P685; STEPHAN JL, 1993, J PEDIATR-US, V123, P564, DOI 10.1016/S0022-3476(05)80951-5; VANDENBERG H, 1991, LAB INVEST, V64, P623; Wengler GS, 1996, LANCET, V348, P1484, DOI 10.1016/S0140-6736(96)09392-0; WIJNAENDTS L, 1989, BLOOD, V74, P2212; 1997, CLIN EXP IMMUNOL S, V109, P1	44	514	528	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1999	340	7					508	516		10.1056/NEJM199902183400703	http://dx.doi.org/10.1056/NEJM199902183400703			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168FD	10021471				2022-12-28	WOS:000078680100003
J	Holmes, AM; Haber, JE				Holmes, AM; Haber, JE			Double-strand break repair in yeast requires both leading and lagging strand DNA polymerases	CELL			English	Article							CELL NUCLEAR ANTIGEN; ALPHA-PRIMASE COMPLEX; REPLICATION FACTOR-C; SACCHAROMYCES-CEREVISIAE; MATING-TYPE; HOMOLOGOUS RECOMBINATION; CHROMOSOMAL REPLICATION; ESCHERICHIA-COLI; GENE CONVERSION; MISMATCH REPAIR	Mitotic double-strand break (DSB)-induced gene conversion at MAT in Saccharomyces cerevisiae was analyzed molecularly in mutant strains thermosensitive for essential replication factors. The processivity cofactors PCNA and RFC are essential even to synthesize as little as 30 nucleotides following strand invasion. Both PCNA-associated DNA polymerases delta and epsilon are important for gene conversion, though a temperature-sensitive Pol epsilon mutant is more severe than one in Pol delta. Surprisingly, mutants of lagging strand replication, DNA polymerase alpha (pol1-17), DNA primase (pri2-1), and Rad27p (rad27 Delta) also greatly inhibit completion of DSB repair, even in G1-arrested cells. We propose a novel model for DSB-induced gene conversion in which a strand invasion creates a modified replication fork, involving leading and lagging strand synthesis from the donor template. Replication is terminated by capture of the second end of the DSB.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA	Brandeis University; Brandeis University	Holmes, AM (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA.			Haber, James/0000-0002-1878-0610	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020056, R37GM020056] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM01722, GM20056] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ASAI T, 1993, EMBO J, V12, P3287, DOI 10.1002/j.1460-2075.1993.tb05998.x; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Bosco G, 1998, GENETICS, V150, P1037; BROOKS M, 1989, J BIOL CHEM, V264, P3602; BUDD ME, 1995, MOL CELL BIOL, V15, P2173; BUDD ME, 1989, MOL CELL BIOL, V9, P365, DOI 10.1128/MCB.9.2.365; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; COLAIACOVO M, 1999, IN PRESS GENETICS; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Dillin A, 1998, SCIENCE, V279, P1733, DOI 10.1126/science.279.5357.1733; DUNN B, 1984, CELL, V39, P191, DOI 10.1016/0092-8674(84)90205-8; FABRE F, 1991, MOL GEN GENET, V229, P353, DOI 10.1007/BF00267455; Ferguson DO, 1996, P NATL ACAD SCI USA, V93, P5419, DOI 10.1073/pnas.93.11.5419; FISHMANLOBELL J, 1992, SCIENCE, V258, P480, DOI 10.1126/science.1411547; FOIANI M, 1994, MOL CELL BIOL, V14, P923, DOI 10.1128/MCB.14.2.923; FOLANI M, 1995, MOL CELL BIOL, V15, P883; FRANCESCONI S, 1991, P NATL ACAD SCI USA, V88, P3877, DOI 10.1073/pnas.88.9.3877; George JW, 1996, GENETICS, V143, P1507; GIOT L, 1995, MOL GEN GENET, V246, P212, DOI 10.1007/BF00294684; GORDON JE, 1992, GEOMORPHOLOGY, V6, P89, DOI 10.1016/0169-555X(92)90051-O; HABER JE, 1993, P NATL ACAD SCI USA, V90, P3363, DOI 10.1073/pnas.90.8.3363; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; HASTINGS PJ, 1988, BIOESSAYS, V9, P61, DOI 10.1002/bies.950090206; IVANOV EL, 1995, MOL CELL BIOL, V15, P2245; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KLAR AJS, 1984, COLD SPRING HARB SYM, V49, P77, DOI 10.1101/SQB.1984.049.01.011; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; Kokoska RJ, 1998, MOL CELL BIOL, V18, P2779, DOI 10.1128/MCB.18.5.2779; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LONGHESE MP, 1993, GENETICS, V133, P183; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; MCGILL C, 1989, CELL, V57, P459, DOI 10.1016/0092-8674(89)90921-5; Morrow DM, 1997, GENETICS, V147, P371; Mueller JE, 1996, GENE DEV, V10, P351, DOI 10.1101/gad.10.3.351; NASMYTH KA, 1982, ANNU REV GENET, V16, P439, DOI 10.1146/annurev.ge.16.120182.002255; NASSIF N, 1994, MOL CELL BIOL, V14, P1613, DOI 10.1128/MCB.14.3.1613; Paques F, 1998, MOL CELL BIOL, V18, P2045, DOI 10.1128/MCB.18.4.2045; PAQUES F, 1995, J MOL EVOL, V41, P615; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; PLEVANI P, 1985, J BIOL CHEM, V260, P7102; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; RAVEH D, 1989, MOL GEN GENET, V220, P33; RAY BL, 1991, MOL CELL BIOL, V11, P5372, DOI 10.1128/MCB.11.10.5372; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; Shcherbakova PV, 1996, GENETICS, V142, P717; Sherman DA, 1998, MOL BIOL CELL, V9, P1833, DOI 10.1091/mbc.9.7.1833; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; STRATHERN JN, 1995, GENETICS, V140, P965; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TorresRamos CA, 1996, P NATL ACAD SCI USA, V93, P9676, DOI 10.1073/pnas.93.18.9676; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; VOELKELMEIMAN K, 1990, GENETICS, V124, P561; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WU XH, 1995, GENE DEV, V9, P1922, DOI 10.1101/gad.9.15.1922; ZEHFUS BR, 1990, GENETICS, V126, P41	72	218	222	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 5	1999	96	3					415	424		10.1016/S0092-8674(00)80554-1	http://dx.doi.org/10.1016/S0092-8674(00)80554-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025407	Bronze			2022-12-28	WOS:000078514600014
J	Benigni, A; Remuzzi, G				Benigni, A; Remuzzi, G			Endothelin antagonists	LANCET			English	Article							ACUTE-RENAL-FAILURE; CONGESTIVE-HEART-FAILURE; ET(A) RECEPTOR ANTAGONIST; INDUCED PULMONARY-HYPERTENSION; ETA-RECEPTOR; A-RECEPTOR; BLOOD-PRESSURE; ENDOGENOUS ENDOTHELIN-1; PLASMA-CONCENTRATIONS; CEREBRAL VASOSPASM	The very potent endogenous vasoconstrictor endothelin was discovered in 1988. We know now that there are three isoforms (1, 2, and 3) and two receptor subtypes (A and B). A whole range of peptide and non-peptide antagonists has been developed, some selective for A or B receptors and others with non-selective A/B antagonistic activity. So far the main application of these agents has been experimental-ie, endothelin blockers are used to throw light on disease mechanisms, most notably cardiovascular and renal. However, the non-selective antagonist bosentan and a few other agents have been studied clinically. Evidence so far from preclinical studies and healthy volunteers and from the limited number of investigations in patients permits a listing of the potential areas of clinical interest. These are mainly cardiovascular leg, hypertension, cerebrovascular damage, and possibly heart failure) and renal. Clouds on the horizon are the need to show that these new agents are better than existing drugs; the possibility of conflicting actions if mixed A/B antagonists are used; and animal evidence hinting that endothelin blockade during development could be dangerous.	Mario Negri Inst Pharmacol Res, I-24100 Bergamo, Italy; Osped Riuniti Bergamo, Unit Nephrol & Dialysis, Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ospedali Riuniti di Bergamo	Remuzzi, G (corresponding author), Mario Negri Inst Pharmacol Res, Via Gavazzeni 11, I-24100 Bergamo, Italy.	gremuzzi@cyberg.it	Ariela, Benigni/ABH-3492-2020; Remuzzi, Giuseppe/V-9766-2017	Ariela, Benigni/0000-0002-4721-5485; Remuzzi, Giuseppe/0000-0002-6194-3446				Barton M, 1998, HYPERTENSION, V31, P499, DOI 10.1161/01.HYP.31.1.499; Benigni A, 1996, AM J KIDNEY DIS, V27, P416, DOI 10.1016/S0272-6386(96)90366-2; BENIGNI A, 1993, KIDNEY INT, V44, P440, DOI 10.1038/ki.1993.263; Benigni A, 1998, DIABETES, V47, P450, DOI 10.2337/diabetes.47.3.450; Benigni A, 1995, Curr Opin Nephrol Hypertens, V4, P349, DOI 10.1097/00041552-199507000-00011; Benigni A, 1997, EXPERT OPIN THER PAT, V7, P139, DOI 10.1517/13543776.7.2.139; Benigni A, 1998, NEPHROL DIAL TRANSPL, V13, P5, DOI 10.1093/ndt/13.1.5; BENIGNI A, 1991, TRANSPLANTATION, V52, P175; BINET I, IN PRESS NEPHROL DIA; BIRD E, 1995, J AM SOC NEPHROL, V6, P994; Brooks DP, 1995, EUR J PHARMACOL, V294, P571, DOI 10.1016/0014-2999(95)00591-9; Brooks DP, 1994, J PHARMACOL EXP THER, V271, P1; Buyukgebiz O, 1996, TRANSPL INT, V9, P201; Chen SJ, 1997, J CARDIOVASC PHARM, V29, P713, DOI 10.1097/00005344-199706000-00003; Clouthier DE, 1998, DEVELOPMENT, V125, P813; CLOZEL M, 1994, J PHARMACOL EXP THER, V270, P228; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; CODY WL, 1993, MED CHEM RES, V3, P154; DICARLO VS, 1995, AM J PHYSIOL-LUNG C, V269, pL690, DOI 10.1152/ajplung.1995.269.5.L690; DOUGLAS SA, 1994, CIRC RES, V75, P190, DOI 10.1161/01.RES.75.1.190; DOUGLAS SA, 1995, HYPERTENSION, V25, P818, DOI 10.1161/01.HYP.25.4.818; Ferro CJ, 1996, DRUGS, V51, P12, DOI 10.2165/00003495-199651010-00003; Fraccarollo D, 1997, CIRCULATION, V96, P3963; GELLAI M, 1994, J CLIN INVEST, V93, P900, DOI 10.1172/JCI117046; GELLAI M, 1994, FASEB J, V8, pA260; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; Haynes WG, 1998, NEW ENGL J MED, V339, P346; Haynes WG, 1996, CIRCULATION, V93, P1860, DOI 10.1161/01.CIR.93.10.1860; HAYNES WG, 1994, LANCET, V344, P852, DOI 10.1016/S0140-6736(94)92827-4; HERRERO I, 1997, J AM SOC NEPHROL, V8, pA657; Hocher B, 1997, J CLIN INVEST, V99, P1380, DOI 10.1172/JCI119297; Hofstra RMW, 1996, NAT GENET, V12, P445, DOI 10.1038/ng0496-445; HOSADA K, 1994, CELL, V79, P1267; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIKAWA K, 1994, P NATL ACAD SCI USA, V91, P4892, DOI 10.1073/pnas.91.11.4892; ITOH S, 1993, BIOCHEM BIOPH RES CO, V195, P969, DOI 10.1006/bbrc.1993.2139; IWASAKI S, 1995, J BIOL CHEM, V270, P6997, DOI 10.1074/jbc.270.12.6997; KARAM H, 1995, J PHARMACOL EXP THER, V274, P481; KIOWSKI W, 1995, LANCET, V346, P732, DOI 10.1016/S0140-6736(95)91504-4; KON V, 1995, TRANSPLANTATION, V60, P89, DOI 10.1097/00007890-199507150-00017; Krum H, 1998, NEW ENGL J MED, V338, P784, DOI 10.1056/NEJM199803193381202; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; KURIHARA Y, 1995, J CLIN INVEST, V96, P293, DOI 10.1172/JCI118033; KUSUMOTO K, 1994, LIFE SCI, V55, P301, DOI 10.1016/0024-3205(94)00732-2; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; LIEFELDT L, 1995, J CARDIOVASC PHARM, V26, pS32; LOPEZFARRE A, 1991, J PHYSIOL-LONDON, V444, P513, DOI 10.1113/jphysiol.1991.sp018891; Love MP, 1996, CIRCULATION, V94, P2131, DOI 10.1161/01.CIR.94.9.2131; MCMURRAY JJ, 1992, CIRCULATION, V85, P1374, DOI 10.1161/01.CIR.85.4.1374; MINO N, 1992, EUR J PHARMACOL, V221, P77; MIYAUCHI T, 1989, LANCET, V2, P53, DOI 10.1016/S0140-6736(89)90303-6; MORELAND S, 1992, BIOCHEM BIOPH RES CO, V184, P100, DOI 10.1016/0006-291X(92)91163-K; Mulder P, 1997, CIRCULATION, V96, P1976, DOI 10.1161/01.CIR.96.6.1976; Nabokov A, 1996, NEPHROL DIAL TRANSPL, V11, P514; NAKAMURA T, 1995, KIDNEY INT, V47, P481, DOI 10.1038/ki.1995.61; Niranjan V, 1996, J CLIN INVEST, V98, P2364, DOI 10.1172/JCI119049; NISHIKIBE M, 1993, LIFE SCI, V52, P717, DOI 10.1016/0024-3205(93)90233-S; OHLSTEIN EH, 1992, EUR J PHARM-MOLEC PH, V225, P347, DOI 10.1016/0922-4106(92)90109-9; Okada K, 1998, CIRCULATION, V97, P2346, DOI 10.1161/01.CIR.97.23.2346; OLDROYD SD, 1995, RADIOLOGY, V196, P661, DOI 10.1148/radiology.196.3.7644626; Pacher R, 1996, J AM COLL CARDIOL, V27, P633, DOI 10.1016/0735-1097(95)00520-X; Patel TR, 1996, CNS DRUGS, V5, P293, DOI 10.2165/00023210-199605040-00007; PERICO N, 1990, J AM SOC NEPHROL, V1, P76; POLLOCK DM, 1993, AM J PHYSIOL, V264, pR222, DOI 10.1152/ajpregu.1993.264.1.R222; POLLOCK DM, 1995, J AM SOC NEPHROL, V6, P667; Prie S, 1997, J PHARMACOL EXP THER, V282, P1312; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; REMUZZI G, 1993, LANCET, V342, P589, DOI 10.1016/0140-6736(93)91414-H; RODEHEFFER RJ, 1992, MAYO CLIN PROC, V67, P719, DOI 10.1016/S0025-6196(12)60795-2; SAITO Y, 1990, NEW ENGL J MED, V322, P205; Sakai S, 1996, NATURE, V384, P353, DOI 10.1038/384353a0; Sakai S, 1996, CIRCULATION, V93, P1214, DOI 10.1161/01.CIR.93.6.1214; Schiffrin EL, 1997, BRIT J PHARMACOL, V121, P935, DOI 10.1038/sj.bjp.0701224; Sharifi AM, 1997, J HYPERTENS, V15, P1441, DOI 10.1097/00004872-199715120-00011; SORENSEN SS, 1994, AM J PHYSIOL, V266, pF411, DOI 10.1152/ajprenal.1994.266.3.F411; Spinale FG, 1997, CIRCULATION, V95, P1918; STEWART DJ, 1991, ANN INTERN MED, V114, P464, DOI 10.7326/0003-4819-114-6-464; STINGO AJ, 1993, HYPERTENSION, V22, P62, DOI 10.1161/01.HYP.22.1.62; TEERLINK JR, 1994, CIRCULATION, V90, P2510, DOI 10.1161/01.CIR.90.5.2510; Wang A., 1998, Journal of the American Society of Nephrology, V9, p137A; WEI CM, 1994, CIRCULATION, V89, P1580, DOI 10.1161/01.CIR.89.4.1580; WILLETTE RN, 1994, STROKE, V25, P2450, DOI 10.1161/01.STR.25.12.2450; Willette RN, 1997, J PHARMACOL EXP THER, V280, P695; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOKOKAWA K, 1991, ANN INTERN MED, V114, P213, DOI 10.7326/0003-4819-114-3-213; Yu M, 1998, J CARDIOVASC PHARM, V31, pS262, DOI 10.1097/00005344-199800001-00074	87	206	216	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 9	1999	353	9147					133	138		10.1016/S0140-6736(98)09423-9	http://dx.doi.org/10.1016/S0140-6736(98)09423-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023915				2022-12-28	WOS:000078087200043
J	Goulis, J; Patch, D; Burroughs, AK				Goulis, J; Patch, D; Burroughs, AK			Bacterial infection in the pathogenesis of variceal bleeding	LANCET			English	Article							NITRIC-OXIDE PATHWAY; ENDOTHELIN RECEPTORS; PORTAL-HYPERTENSION; CIRRHOTIC-PATIENTS; HYPERDYNAMIC CIRCULATION; PLATELET-AGGREGATION; ESOPHAGEAL-VARICES; STELLATE CELLS; RAT-LIVER; PRESSURE	Variceal bleeding is a life-threatening complication of cirrhosis. Potential risk factors include clinical, endoscopic, and haemodynamic factors, but why bleeding occurs unpredictably in individual patients is not known. We postulate that bacterial infections in patients with variceal haemorrhage may be the critical factor that triggers bleeding. In patients with large varices and a high wall tension, the release of endotoxin into the systemic circulation during episodes of bacterial infection results in a further increase in portal pressure through the induction endothelin and possibly vasoconstrictive cyclo-oxygenase products. The Subsequent. contraction of hepatic stellate cells causes a rise in intrahepatic vascular resistance., furthermore, endotoxin-induced nitric oxide and postacyclin, and prostacyclin induced by endothelin could inhibit platelet aggregation, which may result in a further deterioration of primary haemostasis at the level of varix. We propose that the combination of these two effects leads to the onset of variceal haemorrhage.	Royal Free Hosp, London NW3 2QG, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Burroughs, AK (corresponding author), Royal Free Hosp, Pond St, London NW3 2QG, England.		Burroughs, Andrew K/C-5645-2009	Burroughs, Andrew K/0000-0001-6527-457X				Armonis A, 1997, HEPATOLOGY, V25, P245, DOI 10.1053/jhep.1997.v25.ajhep0250245; BENARI Z, 1996, J HEPATOL, V20, P92; BERNARD B, 1995, GASTROENTEROLOGY, V108, P1828, DOI 10.1016/0016-5085(95)90146-9; BERNARD B, 1996, GUT S3, V39, pA186; BLEICHNER G, 1986, BRIT J SURG, V73, P724, DOI 10.1002/bjs.1800730916; BURROUGHS AK, 1989, HEPATOLOGY, V9, P801, DOI 10.1002/hep.1840090602; DAMICO G, 1995, HEPATOLOGY, V22, P332, DOI 10.1002/hep.1840220145; DESAI K, 1989, LANCET, V1, P693; Eakes AT, 1997, AM J PHYSIOL-GASTR L, V272, pG605, DOI 10.1152/ajpgi.1997.272.3.G605; Gandhi CR, 1998, LIVER, V18, P39; GERBES AL, 1995, HEPATOLOGY, V21, P735, DOI 10.1002/hep.1840210321; Gines P, 1998, J HEPATOL, V29, P490, DOI 10.1016/S0168-8278(98)80072-X; Goulis J, 1998, HEPATOLOGY, V27, P1207, DOI 10.1002/hep.510270504; GRATTON JP, 1995, J CARDIOVASC PHARM, V26, pS88; GUARNER C, 1993, HEPATOLOGY, V18, P1139; HOUSSET C, 1993, P NATL ACAD SCI USA, V90, P9266, DOI 10.1073/pnas.90.20.9266; HUGHES AK, 1995, KIDNEY INT, V47, P53, DOI 10.1038/ki.1995.6; Laffi G, 1995, HEPATOLOGY, V22, P1666, DOI 10.1016/0270-9139(95)90189-2; MCCORMICK PA, 1995, GUT, V36, P100, DOI 10.1136/gut.36.1.100; MOLLER S, 1995, J HEPATOL, V23, P135, DOI 10.1016/0168-8278(95)80327-0; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; OKUDA K, 1984, GASTROENTEROLOGY, V86, P600; Pannen BHJ, 1996, AM J PHYSIOL-HEART C, V271, pH1953, DOI 10.1152/ajpheart.1996.271.5.H1953; Pinzani M, 1996, GASTROENTEROLOGY, V110, P534, DOI 10.1053/gast.1996.v110.pm8566602; POLIO J, 1986, SEMIN LIVER DIS, V6, P318, DOI 10.1055/s-2008-1040614; Preneta E, 1998, HEPATOLOGY, V28, p453A; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; READY JB, 1991, GASTROENTEROLOGY, V100, P1403; Riddell DR, 1997, J BIOL CHEM, V272, P89; Rockey DC, 1998, HEPATOLOGY, V27, P472, DOI 10.1002/hep.510270222; Rockey DC, 1996, HEPATOLOGY, V24, P233; Rocky D, 1997, HEPATOLOGY, V25, P2, DOI 10.1002/hep.510250102; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; Sogni P, 1998, HEPATOLOGY, V28, P655, DOI 10.1002/hep.510280308; SPENCE RAJ, 1984, SURG GYNECOL OBSTET, V159, P253; SUTTORP N, 1987, AM J PHYSIOL, V253, pC384, DOI 10.1152/ajpcell.1987.253.3.C384; VALLANCE P, 1991, LANCET, V337, P776, DOI 10.1016/0140-6736(91)91384-7; VANE JR, 1995, AM J CARDIOL, V75, pA3, DOI 10.1016/S0002-9149(99)80377-4; YAMAMOTO S, 1997, AM J PHYSIOL, V272, pH1; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001	41	196	202	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 9	1999	353	9147					139	142		10.1016/S0140-6736(98)06020-6	http://dx.doi.org/10.1016/S0140-6736(98)06020-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023916				2022-12-28	WOS:000078087200044
J	Kendall, MJ; Henry, RY				Kendall, MJ; Henry, RY			Clinical trials in stroke	LANCET			English	Letter									Queen Elizabeth Hosp, Dept Med, Clin Pharmacol Sect, Birmingham B15 2TH, W Midlands, England	University of Birmingham	Kendall, MJ (corresponding author), Queen Elizabeth Hosp, Dept Med, Clin Pharmacol Sect, Birmingham B15 2TH, W Midlands, England.							Blauw GJ, 1997, STROKE, V28, P946, DOI 10.1161/01.STR.28.5.946; Bucher HC, 1998, ANN INTERN MED, V128, P89, DOI 10.7326/0003-4819-128-2-199801150-00002; HERBERT PR, 1997, JAMA-J AM MED ASSOC, V278, P313; LEES KR, 1998, LANCET S3, V352, P28; Tonkin A, 1998, NEW ENGL J MED, V339, P1349	5	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 9	1999	353	9147					151	151		10.1016/S0140-6736(05)76190-0	http://dx.doi.org/10.1016/S0140-6736(05)76190-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023926	Bronze			2022-12-28	WOS:000078087200057
J	Stevenson, KP; Kimmel, GA; Dohnalek, Z; Smith, RS; Kay, BD				Stevenson, KP; Kimmel, GA; Dohnalek, Z; Smith, RS; Kay, BD			Controlling the morphology of amorphous solid water	SCIENCE			English	Article							ASTROPHYSICAL IMPLICATIONS; ICE; ADSORPTION; GROWTH; ENERGY; GASES	The morphology of amorphous solid water grown by vapor deposition was found to depend strongly on the angular distribution of the water molecules incident from the gas phase. Systematic variation of the incident angle during deposition using a collimated beam of water led to the growth of nonporous to highly porous amorphous solid water. The physical and chemical properties of amorphous solid water are of interest because of its presence in astrophysical environments. The ability to control its properties in the laboratory may shed light on some of the outstanding conflicts related to this important material.	Pacific NW Natl Lab, Environm Mol Sci Lab, Richland, WA 99352 USA	United States Department of Energy (DOE); Pacific Northwest National Laboratory	Kay, BD (corresponding author), Pacific NW Natl Lab, Environm Mol Sci Lab, POB 999,Mail Stop K8-88, Richland, WA 99352 USA.		Smith, Scott/G-2310-2015; Kimmel, Greg/H-5355-2018	Smith, Scott/0000-0002-7145-1963; Kimmel, Greg/0000-0003-4447-2440; Dohnalek, Zdenek/0000-0002-5999-7867				ADAMSON AW, 1967, J COLLOID INTERF SCI, V25, P206, DOI 10.1016/0021-9797(67)90023-9; Barabasi A.-L., 1995, FRACTAL CONCEPTS SUR; BARNUN A, 1985, ICARUS, V63, P317, DOI 10.1016/0019-1035(85)90048-X; BARNUN A, 1987, PHYS REV B, V35, P2427, DOI 10.1103/PhysRevB.35.2427; BARNUN A, 1988, PHYS REV B, V38, P7749, DOI 10.1103/PhysRevB.38.7749; Brown DE, 1996, J PHYS CHEM-US, V100, P4988, DOI 10.1021/jp952547j; Debenedetti P.G., 1996, METASTABLE LIQUIDS C; DELSEMME AH, 1970, SCIENCE, V167, P44, DOI 10.1126/science.167.3914.44; GHORMLEY JA, 1971, SCIENCE, V171, P62, DOI 10.1126/science.171.3966.62; GHORMLEY JA, 1967, J CHEM PHYS, V46, P1321, DOI 10.1063/1.1840851; GREGG SJ, 1982, ADSORPTION SURFACE; HALLBRUCKER A, 1990, J CHEM SOC FARADAY T, V86, P3785, DOI 10.1039/ft9908603785; JENNISKENS P, 1994, SCIENCE, V265, P753, DOI 10.1126/science.11539186; KLINGER J, 1980, SCIENCE, V209, P271, DOI 10.1126/science.209.4453.271; Leu MT, 1997, J PHYS CHEM B, V101, P6259, DOI 10.1021/jp963251w; MAYER E, 1986, NATURE, V319, P298, DOI 10.1038/319298a0; MAYER E, 1984, J CHEM PHYS, V80, P2938; MEAKIN P, 1993, PHYS REP, V235, P189, DOI 10.1016/0370-1573(93)90047-H; NARTEN AH, 1976, J CHEM PHYS, V64, P1106, DOI 10.1063/1.432298; OCAMPO J, 1982, J COLLOID INTERF SCI, V86, P377, DOI 10.1016/0021-9797(82)90083-2; PATASHNICK H, 1974, NATURE, V250, P313, DOI 10.1038/250313a0; PLETZER R, 1989, J CHEM PHYS, V90, P5207, DOI 10.1063/1.456540; Robbie K, 1998, J VAC SCI TECHNOL B, V16, P1115, DOI 10.1116/1.590019; SEIBER BA, 1970, SCIENCE, V170, P652, DOI 10.1126/science.170.3958.652; Smith RS, 1997, PHYS REV LETT, V79, P909, DOI 10.1103/PhysRevLett.79.909; SMOLUCHOWSKI R, 1978, SCIENCE, V201, P809, DOI 10.1126/science.201.4358.809; Speedy RJ, 1996, J CHEM PHYS, V105, P240, DOI 10.1063/1.471869; STEVENSON K, UNPUB; TIELENS AGG, 1986, COMPOSITION STRUCTUR, P397; VANKRANENBURG H, 1994, MAT SCI ENG R, V11, P295, DOI 10.1016/0927-796X(94)90021-3; Westley MS, 1998, J CHEM PHYS, V108, P3321, DOI 10.1063/1.475730; ZHANG Q, 1990, J CHEM PHYS, V92, P5004, DOI 10.1063/1.458536	32	354	355	4	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	1999	283	5407					1505	1507		10.1126/science.283.5407.1505	http://dx.doi.org/10.1126/science.283.5407.1505			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066166				2022-12-28	WOS:000078959200038
J	Soumerai, SB; Ross-Degnan, D				Soumerai, SB; Ross-Degnan, D			Inadequate prescription-drug coverage for Medicare enrollees - A call to action	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MYOCARDIAL-INFARCTION; THERAPY; HEALTH; HOSPITALIZATION; SCHIZOPHRENIA; ASTHMA; IMPACT; COST		Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Pilgrim Hlth Care, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care	Soumerai, SB (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.				NIA NIH HHS [AG14474] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014474] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAUGHER E, 1996, CURRENT POPUL P60194, P15; Davis M, 1999, HEALTH AFFAIR, V18, P231, DOI 10.1377/hlthaff.18.1.231; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; FINEBERG HV, 1981, LANCET, V1, P1305; *GEN ACC OFF, 1994, GAOHEHS94194FS; *GEN ACC OFF, 1997, GAOHEHS9760; Gerdtham UG, 1996, MED CARE, V34, P1188, DOI 10.1097/00005650-199612000-00004; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; GROSS D, 1998, ESTIMATES FINANCIAL; GROSS DJ, IN PRESS HLTH SERV R; *HLTH CAR FIN ADM, 1998, PROF MED CHART BOOK; *HLTH CAR FIN ADM, 1998, PROF MED CHART BOOK, P10; LASCHOBER M, 1996, HLTH HLTH CARE MEDIC; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; Levit K, 1998, HEALTH AFFAIR, V17, P99, DOI 10.1377/hlthaff.17.6.99; *LEW GROUP, 1998, CURR KNOWL 3 PART OU; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; Martin BC, 1996, MED CARE, V34, P686, DOI 10.1097/00005650-199607000-00003; *NAT PHARM COUNC, 1997, PHARM BEN STAT MED A; Pedersen TR, 1996, CIRCULATION, V93, P1796, DOI 10.1161/01.CIR.93.10.1796; PEDERSEN TR, 1996, CIRCULATION, V94, P849; REINHARDT UE, 1995, HEALTH AFFAIR, V14, P33, DOI 10.1377/hlthaff.14.1.33; RICE T, 1990, HEALTH AFFAIR, V9, P75, DOI 10.1377/hlthaff.9.3.75; Rosenheck R, 1997, NEW ENGL J MED, V337, P809, DOI 10.1056/NEJM199709183371202; SHEILS J, 1998, COMPREHENSIVE MEDICA; *SOC SEC ADM, 1998, FACT SHEET 1999 SOC; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1993, MILBANK Q, V71, P217, DOI 10.2307/3350399; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; *U WA DEP PHARM, 1998, PHARM OUTCOMES RES P, V4, P1; YANKELOVICH D, 1995, HEALTH AFFAIR, V14, P7, DOI 10.1377/hlthaff.14.1.7; 1998, WALL STREET J   1116, pA1; 1996, HLTH CARE FINANC REV, V19, P171; 1998, BOSTON GLOBE    1110, pD1; 1998, WALL STREET J   1117, P1; 1998, BOSTON GLOBE    1117, pA1; 1998, WALL STREET J   1218, pB1	39	101	102	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1999	340	9					722	728		10.1056/NEJM199903043400909	http://dx.doi.org/10.1056/NEJM199903043400909			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172ZB	10053183	Green Published			2022-12-28	WOS:000078955200009
J	Rao, VK; Iademarco, EP; Fraser, VJ; Kollef, MH				Rao, VK; Iademarco, EP; Fraser, VJ; Kollef, MH			Delays in the suspicion and treatment of tuberculosis among hospitalized patients	ANNALS OF INTERNAL MEDICINE			English	Article							RESISTANT MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; DIAGNOSIS; OUTBREAK; INFECTION; CARE; TRANSMISSION; MORTALITY; FAILURE; RISK	Background: Despite increased awareness of tuberculosis, delays in management are common. Objective: To investigate management delays among hospitalized patients with tuberculosis. Design: Retrospective cohort study. Setting: The Barnes-Jewish-Christian Health System, a network of eight community and tertiary-care facilities serving the St. Louis, Missouri, metropolitan area. Patients: All 203 patients with tuberculosis hospitalized in the Barnes-Jewish-Christian Health System from 1988 to 1996. Measurements: Time from admission to first consideration of the diagnosis (suspicion interval), first consideration and treatment initiation (treatment interval), and admission and treatment initiation (overall management interval) were determined. Delays were defined as intervals longer than 24 hours. Results: The overall management interval (median, 6 days [5th and 95th percentiles, 1 and 52 days]) exceeded 24 hours in 152 patients (74.9% [95% CI, 68.9% to 80.9%]). The suspicion interval (median, 1 day [5th and 95th percentiles, 0 and 16 days]) exceeded 24 hours in 54 patients (26.6% [CI, 20.5% to 32.7%]), and the treatment interval (median, 3 days [5th and 95th percentiles, 0 and 51 days]) was prolonged in 130 patients (64.0% [CI, 57.4% to 70.6%]). Overall management delays of more than 10 and 25 days occurred in 33.5% (CI, 27.0% to 40.0%) and 18.7% (CI, 13.3% to 24.1%) of patients, respectively. The 55 patients with smears that were positive for acid-fast bacilli had a median treatment interval of 3 days (5th and 95th percentiles, 0 and 33 days); in 58.2% of patients (CI, 45.2% to 71.2%), this interval exceeded 24 hours. Conclusions: Delays in initiation of treatment were more common than delays in the initial suspicion of tuberculosis. Both types of delays were common even in patients with disease that was confirmed by a positive smear. These data illustrate a need for improved education of physicians about the benefits of early initiation of therapy for tuberculosis.	Washington Univ, Sch Med, Div Pulm & Crit Care, St Louis, MO 63110 USA	Washington University (WUSTL)	Kollef, MH (corresponding author), Washington Univ, Sch Med, Div Pulm & Crit Care, Campus Box 8052,660 S Euclid Ave, St Louis, MO 63110 USA.	mkollef@pulmonary.wustl.edu		Fraser, Victoria/0000-0001-6251-0733	PHS HHS [U50-CCU-710076-04] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; Arno P S, 1993, J Law Med Ethics, V21, P317, DOI 10.1111/j.1748-720X.1993.tb01256.x; BASS J, 1992, AM REV RESPIR DIS, V146, P1623; BASS JB, 1990, AM REV RESPIR DIS, V142, P725; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; Bock NN, 1996, AM J RESP CRIT CARE, V154, P1468, DOI 10.1164/ajrccm.154.5.8912766; BROWN RE, 1995, ARCH INTERN MED, V155, P1595, DOI 10.1001/archinte.155.15.1595; BYRD RB, 1977, ANN INTERN MED, V86, P799, DOI 10.7326/0003-4819-86-6-799; CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; COUNSELL SR, 1989, ARCH INTERN MED, V149, P1274, DOI 10.1001/archinte.149.6.1274; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; ENARSON DA, 1978, CAN MED ASSOC J, V118, P1520; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; GORDIN FM, 1989, AM REV RESPIR DIS, V139, P1090, DOI 10.1164/ajrccm/139.5.1090; HEFFNER JE, 1988, ARCH INTERN MED, V148, P1103, DOI 10.1001/archinte.148.5.1103; Kellerman S, 1997, INFECT CONT HOSP EP, V18, P542; LEVY H, 1989, CHEST, V95, P1193, DOI 10.1378/chest.95.6.1193; Liam CK, 1997, INT J TUBERC LUNG D, V1, P326; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; MATHUR P, 1994, ARCH INTERN MED, V154, P306, DOI 10.1001/archinte.154.3.306; MOHLEBOETANI JC, 1995, JAMA-J AM MED ASSOC, V274, P613, DOI 10.1001/jama.274.8.613; MORAN GJ, 1995, ANN EMERG MED, V26, P290, DOI 10.1016/S0196-0644(95)70074-9; Murray P.R., 1995, MANUAL CLIN MICROBIO; PablosMendez A, 1996, JAMA-J AM MED ASSOC, V276, P1223, DOI 10.1001/jama.276.15.1223; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P153; *SAS I, 1990, SAS STAT US GUID, V2, P1071; Sumartojo EM, 1997, AM J PUBLIC HEALTH, V87, P2008, DOI 10.2105/AJPH.87.12.2008; Tacconelli E, 1997, INT J TUBERC LUNG D, V1, P582; VALWAY SE, 1994, AM J EPIDEMIOL, V140, P113, DOI 10.1093/oxfordjournals.aje.a117222; *WHO, 1994, WHO PUBL, P170; 1996, AM J RESP CRIT CARE, V154, P251	36	65	68	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	1999	130	5					404	+		10.7326/0003-4819-130-5-199903020-00004	http://dx.doi.org/10.7326/0003-4819-130-5-199903020-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172AA	10068414				2022-12-28	WOS:000078898100003
J	Josefson, D				Josefson, D			New malaria vaccine shows promise	BRITISH MEDICAL JOURNAL			English	News Item																		1999, PROCEEDINGS NATL ACA, V96, P1615	1	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					557	557		10.1136/bmj.318.7183.557	http://dx.doi.org/10.1136/bmj.318.7183.557			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037624	Green Published			2022-12-28	WOS:000078966300016
J	Riley, GF; Potosky, AL; Klabunde, CN; Warren, JL; Ballard-Barbash, R				Riley, GF; Potosky, AL; Klabunde, CN; Warren, JL; Ballard-Barbash, R			Stage at diagnosis and treatment patterns among older women with breast cancer - An HMO and fee-for-service comparison	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH MAINTENANCE ORGANIZATION; ACUTE MYOCARDIAL-INFARCTION; MEDICAL OUTCOMES; RESOURCE UTILIZATION; MANAGED CARE; MASTECTOMY; SYSTEMS; PREPAID; RADIOTHERAPY; RADIATION	Context Few studies have compared patterns of care in health maintenance organization (HMO) and fee-for-service (FFS) settings. Objective To examine breast cancer stage at diagnosis and, for those at an early stage, treatment patterns for elderly women in HMO and FFS settings. Design Cancer registry data from the Surveillance, Epidemiology, and End Results (SEER) program linked to Medicare enrollment records. Settings and Participants Women aged 65 years or older residing in 11 geographic areas who were newly diagnosed as having breast cancer between 1988 and 1993. Main Outcome Measures Standardized percentage of cases diagnosed at late stages for HMO vs FFS; standardized percentage of early-stage cases undergoing initial treatment with breast-conserving surgery (BCS); and, among BCS cases, standardized percentage receiving adjuvant radiation therapy. Standardization was achieved through logistic regression, controlling for patient demographics, cancer history, county of residence, year of diagnosis, and educational attainment at the census tract level. Analyses of treatment patterns were controlled for stage at diagnosis and tumor size. Results The HMO enrollees were less likely to have breast cancer diagnosed at late stages than FFS patients (HMO, 7.6%; FFS, 10.8%; difference, -3.2% [95% confidence interval (CI), -4.2% to -2.2%]). Among early-stage cases, the percentages undergoing BCS were similar in HMO and FFS settings overall (HMO, 38.4%; FFS, 36.8%; difference, 1.6% [95% CI, 0.0%-3.2%]); percentages, varied markedly at the individual plan level. Among women undergoing BCS, HMO enrollees were significantly more likely to receive radiation therapy but, again, results varied by plan (HMO, 69.0%; FFS, 63.7%; difference, 5.3% [95% CI, 2.9%-7.7%]). In general, use of BCS and radiation therapy was substantially higher than that found in an earlier study examining cases diagnosed between 1985 and 1989. Conclusions Treatment of early-stage breast cancer in HMOs often differs from local FFS patterns, but not in a consistent way. During the period of our study, elderly HMO enrollees did not appear to have systematic access problems with adjuvant radiation therapy following BCS compared with women in an FFS setting.	US Hlth Care Financing Adm, Baltimore, MD 21244 USA; NCI, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Riley, GF (corresponding author), US Hlth Care Financing Adm, 7500 Secur Blvd,Room C3-20-17, Baltimore, MD 21244 USA.	griley@hcfa.gov						American Joint Committee on Cancer, 1992, MAN STAG CANC; [Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P1; BallardBarbash R, 1996, JNCI-J NATL CANCER I, V88, P716, DOI 10.1093/jnci/88.11.716; BARLOW W, 1997, COST COMP TREATMENT; BERNSTEIN AB, 1991, MED CARE, V29, P196; BROWN RS, 1993, MEDICARE RISK PROGRA; CARLISLE DM, 1992, AM J PUBLIC HEALTH, V82, P1626, DOI 10.2105/AJPH.82.12.1626; CLANCY CM, 1995, JAMA-J AM MED ASSOC, V273, P338, DOI 10.1001/jama.273.4.338; CLEMENT DG, 1994, JAMA-J AM MED ASSOC, V271, P1487, DOI 10.1001/jama.271.19.1487; EVERY NR, 1995, J AM COLL CARDIOL, V26, P401, DOI 10.1016/0735-1097(95)80013-7; FARROW DC, 1992, NEW ENGL J MED, V326, P1097, DOI 10.1056/NEJM199204233261701; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GREENWALD HP, 1992, AM J PUBLIC HEALTH, V82, P1099, DOI 10.2105/AJPH.82.8.1099; Guadagnoli E, 1998, J CLIN ONCOL, V16, P101, DOI 10.1200/JCO.1998.16.1.101; Hadley J, 1997, INQUIRY-J HEALTH CAR, V34, P288; HALL WH, 1991, JAMA-J AM MED ASSOC, V265, P391; JACOBSON JA, 1995, NEW ENGL J MED, V332, P907, DOI 10.1056/NEJM199504063321402; LANGA KM, 1993, NEW ENGL J MED, V329, P1784, DOI 10.1056/NEJM199312093292407; LEEFELDSTEIN A, 1994, JAMA-J AM MED ASSOC, V271, P1163, DOI 10.1001/jama.271.15.1163; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; Miller RH, 1997, HEALTH AFFAIR, V16, P7, DOI 10.1377/hlthaff.16.5.7; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; MUNOZ E, 1986, ARCH SURG-CHICAGO, V121, P1297, DOI 10.1001/archsurg.121.11.1297; Nattinger AB, 1996, MED CARE, V34, P479, DOI 10.1097/00005650-199605000-00009; NELSON L, 1996, ACCESS CARE MEDICARE; Potosky AL, 1998, MED CARE, V36, P257, DOI 10.1097/00005650-199803000-00004; Potosky AL, 1997, JNCI-J NATL CANCER I, V89, P1683, DOI 10.1093/jnci/89.22.1683; POTOSKY AL, 1993, MED CARE, V31, P732; RETCHIN SM, 1992, HEALTH SERV RES, V27, P651; RIES LAG, 1997, NIH PUBL; Riley G, 1996, HEALTH CARE FINANC R, V17, P65; RILEY GF, 1994, AM J PUBLIC HEALTH, V84, P1598, DOI 10.2105/AJPH.84.10.1598; SAFRAN DG, 1994, JAMA-J AM MED ASSOC, V271, P1579, DOI 10.1001/jama.271.20.1579; SILLIMAN RA, 1993, JNCI-J NATL CANCER I, V85, P190, DOI 10.1093/jnci/85.3.190; STURM R, 1995, HEALTH SERV RES, V30, P319; TROCK B, 1993, CANCER EPIDEM BIOMAR, V2, P151; VERONESI U, 1993, NEW ENGL J MED, V328, P1587, DOI 10.1056/NEJM199306033282202; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027; YOUNG GJ, 1991, INQUIRY-J HEALTH CAR, V28, P255	42	167	168	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1999	281	8					720	726		10.1001/jama.281.8.720	http://dx.doi.org/10.1001/jama.281.8.720			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	168BD	10052442	Bronze			2022-12-28	WOS:000078669900031
J	Epstein, DS; Lange, JR; Gruber, SB; Mofid, M; Koch, SE				Epstein, DS; Lange, JR; Gruber, SB; Mofid, M; Koch, SE			Is physician detection associated with thinner melanomas?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MALIGNANT-MELANOMA; PREVENTION; CANCER; SKIN	Context In cutaneous melanoma, tumor depth remains the best biologic predictor of patient survival. Detection of prognostically favorable lesions may be associated with improved survival in patients with melanoma. Objective To determine melanoma detection patterns and relate them to tumor thickness. Design interview survey, Setting and Patients All patients with newly detected primary cutaneous melanoma at the Melanoma Center, Johns Hopkins Medical Institutions, between June 1995 and June 1997. Main Outcome Measure Tumor thickness grouped according to detection source. Results Of the 102 patients (47 men, 55 women) in the study, the majority of melanomas were self-detected (55%), followed by detection by physician (24%), spouse (12%), and others (10%), Physicians were more likely to detect thinner lesions than were patients who detected their own melanomas (median thickness, 0.23 mm vs 0.9 mm; P < .001), When grouped according to thickness, 11 (46%) of 24 physician-detected melanomas were in situ, vs only 8 (14%) of 56 patient-detected melanomas. Physician detection was associated with an increase in the probability of detecting thinner (less than or equal to 0.75 mm) melanomas (relative risk, 4.2; 95% confidence interval, 1,4-11.1; P = .01), Conclusions Thinner melanomas are more likely to have been detected by physicians. Increased awareness by all physicians may result in greater detection of early melanomas.	Oregon Hlth Sci Univ, Dept Dermatol, Portland, OR 97201 USA; Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; Univ Michigan, Dept Med & Mol Genet, Ann Arbor, MI USA	Oregon Health & Science University; Johns Hopkins University; Johns Hopkins University; University of Michigan System; University of Michigan	Koch, SE (corresponding author), Oregon Hlth Sci Univ, Dept Dermatol, Ll468,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.							AUSTOKER J, 1994, BRIT MED J, V308, P1682, DOI 10.1136/bmj.308.6945.1682; BALCH CM, 1992, CUTANEOUS MELANOMA, P165; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; FRIEDMAN RJ, 1985, CA-CANCER J CLIN, V35, P130, DOI 10.3322/canjclin.35.3.130; HERSEY P, 1991, MED J AUSTRALIA, V154, P583, DOI 10.5694/j.1326-5377.1991.tb121217.x; KOH HK, 1992, J AM ACAD DERMATOL, V26, P914, DOI 10.1016/0190-9622(92)70132-Y; Koh HK, 1996, ARCH DERMATOL, V132, P436, DOI 10.1001/archderm.132.4.436; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Liu TP, 1996, SURG CLIN N AM, V76, P1205, DOI 10.1016/S0039-6109(05)70511-9; Marks R, 1996, CA-CANCER J CLIN, V46, P199, DOI 10.3322/canjclin.46.4.199; Rigel DS, 1996, J AM ACAD DERMATOL, V34, P839, DOI 10.1016/S0190-9622(96)90041-9; Schuchter L, 1996, ANN INTERN MED, V125, P369, DOI 10.7326/0003-4819-125-5-199609010-00003	12	132	133	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1999	281	7					640	643		10.1001/jama.281.7.640	http://dx.doi.org/10.1001/jama.281.7.640			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	165YA	10029126	Bronze			2022-12-28	WOS:000078548400035
J	Wachter, RM				Wachter, RM			An introduction to the hospitalist model	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	National Policy Conference on the Hospitalist Movement	DEC 05-06, 1997	SAN FRANCISCO, CA				INTENSIVE-CARE UNIT; PHYSICIAN	Motivated by a search for improved quality and efficiency, increasing numbers of hospitals and physicians are moving from systems in which all primary care providers manage their own hospitalized patients or rotate this responsibility among themselves at infrequent intervals to voluntary or mandatory systems in which patients are "handed off" to the care of an inpatient physician, the "hospitalist." All hospitalists manage medical patients in the hospital. Other potential roles for these physicians include triage in the emergency department, transfer of "out-of-network" patients, management of patients in the intensive care unit, preoperative and postoperative management of surgical patients, and leadership in hospital quality improvement and regulatory work. Hospitalists may add value by being more available to inpatients, having more hospital experience and expertise, and having an increased commitment to hospital quality improvement compared with primary care providers. Potential disadvantages of the hospitalist model include loss of information as a result of discontinuity of care, patient dissatisfaction, loss of acute care skills by primary care physicians, and burnout among hospitalists. A variety of models of care are needed to meet the clinical, organizational, financial, and political demands of diverse health care systems. The favored model should be that which produces the best clinical outcomes and the highest patient satisfaction at the lowest cost.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Moffitt Long Hosp, San Francisco, CA USA	University of California System; University of California San Francisco	Wachter, RM (corresponding author), Univ Calif San Francisco, Dept Med, Box 0120, San Francisco, CA 94143 USA.				AHRQ HHS [1 R13 HS09544-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BOSCHERT S, 1997, INTERNAL MED NEWS, V30, P5; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; Chalfin D B, 1997, Cost Qual Q J, V3, P43; Chesanow N, 1997, Med Econ, V74, P116; CHESANOW N, 1997, MED ECON, V74, P125; CHESANOW N, 1997, MED ECON, V74, P130; Craig DE, 1999, ANN INTERN MED, V130, P355, DOI 10.7326/0003-4819-130-4-199902161-00005; Freese RB, 1999, ANN INTERN MED, V130, P350, DOI 10.7326/0003-4819-130-4-199902161-00004; GAPE B, 1997, MODERN HEALTHCA 0428, P25; GESENSWAY D, 1997, ACP OBSERVER    0501, P16; GESENSWAY D, 1997, ACP OBSERVER    0501, P17; HENRY LA, 1997, FAMILY PRACTICE  JUL, P54; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; KUBLERROSS E, 1997, DEATH DYING DYING HA; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; LINDENAUER PK, IN PRESS ANN INTERN; Manthous CA, 1997, MAYO CLIN PROC, V72, P391, DOI 10.4065/72.5.391; Moore J D Jr, 1997, Mod Healthc, V27, P54; *PICK I, 1997, EYE PAT; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; SHEPHERD G, 1997, TAMPA BAY BUSIN 1013, P1; Shook TL, 1996, AM J CARDIOL, V77, P331, DOI 10.1016/S0002-9149(97)89359-9; SLATAPER R, 1997, NEWSLETTER NATL ASS, V1, P5; Sox HC, 1999, ANN INTERN MED, V130, P368, DOI 10.7326/0003-4819-130-4-199902161-00008; STARFIELD B, 1993, JAMA-J AM MED ASSOC, V269, P3136, DOI 10.1001/jama.269.24.3136; Starfield B., 1992, PRIMARY CARE CONCEPT; *US I MED DIV HLTH, 1994, DEF PRIM CAR INT REP; WACHTER R, 1997, MED PRACT MANAGE NOV, P123; Wachter RM, 1998, JAMA-J AM MED ASSOC, V279, P1560, DOI 10.1001/jama.279.19.1560; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713; WACHTER RM, 1999, IN PRESS HEALTHCARE; ZUGER A, 1998, NY TIMES        0324, pB19	33	132	134	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	2				338	342		10.7326/0003-4819-130-4-199902161-00002	http://dx.doi.org/10.7326/0003-4819-130-4-199902161-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	166QB	10068402				2022-12-28	WOS:000078587500002
J	Plotkin, SA; Katz, M; Cordero, JF				Plotkin, SA; Katz, M; Cordero, JF			The eradication of rubella	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							VACCINATION STRATEGY; SAO-PAULO; MEASLES; MUMPS; INFECTION; BRAZIL; RISK		Pasteur Merieux Connaught, Swiftwater, PA USA; Pasteur Merieux Connaught, Lyon, France; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; March Dimes Birth Defect Fdn, White Plains, NY USA; Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA 30333 USA	University of Pennsylvania; Centers for Disease Control & Prevention - USA	Plotkin, SA (corresponding author), 4650 Wismer Rd, Doylestown, PA 18901 USA.	splotkin@us.pmc-vacc.com						ANDERSON RM, 1983, J HYG-CAMBRIDGE, V90, P259, DOI 10.1017/S002217240002893X; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Cooper L.Z., 1995, INFECT DIS FETUS NEW, P268; Cutts FT, 1997, B WORLD HEALTH ORGAN, V75, P55; GALAZKA A, 1991, EPIDEMIOL INFECT, V107, P43, DOI 10.1017/S0950268800048664; HINMAN A, 1998, PAN AM J PUBLIC HLTH, V4, P156; JUDELSOHN RG, 1973, JAMA-J AM MED ASSOC, V223, P401, DOI 10.1001/jama.223.4.401; KHOURY MJ, 1989, PEDIATRICS, V84, P658; MASSAD E, 1994, EPIDEMIOL INFECT, V112, P579, DOI 10.1017/S0950268800051281; MASSAD E, 1995, INT J EPIDEMIOL, V24, P842, DOI 10.1093/ije/24.4.842; MillardStafford M, 1997, INT J SPORT NUTR, V7, P26, DOI 10.1123/ijsn.7.1.26; PELTOLA H, 1994, NEW ENGL J MED, V331, P1397, DOI 10.1056/NEJM199411243312101; PERRY KR, 1993, J MED VIROL, V40, P235, DOI 10.1002/jmv.1890400312; PLOTKIN SA, 1969, AM J DIS CHILD, V118, P178, DOI 10.1001/archpedi.1969.02100040180004; PLOTKIN SA, 1999, RUBELLA VACCINES, P409; Ray P, 1997, JAMA-J AM MED ASSOC, V278, P551, DOI 10.1001/jama.278.7.551; SCHEIE HG, 1967, ARCH OPHTHALMOL-CHIC, V77, P440, DOI 10.1001/archopht.1967.00980020442005; Schluter WW, 1998, J INFECT DIS, V178, P636, DOI 10.1086/515384; SCHOUB BD, 1990, PEDIATR INFECT DIS J, V9, P263, DOI 10.1097/00006454-199004000-00008; *WHO, IN PRESS B WORLD HLT; WILLIAMS NM, 1983, MMWR-MORBID MORTAL W, V33, pS1; Yamamoto L, 1995, TROP GEOGR MED, V47, P235; ZgorniakNowosielska I, 1996, EUR J EPIDEMIOL, V12, P303, DOI 10.1007/BF00145421	23	17	20	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1999	281	6					561	562		10.1001/jama.281.6.561	http://dx.doi.org/10.1001/jama.281.6.561			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164FQ	10022114				2022-12-28	WOS:000078452900036
J	Kramer, U; Heinrich, J; Wjst, M; Wichmann, HE				Kramer, U; Heinrich, J; Wjst, M; Wichmann, HE			Age of entry to day nursery and allergy in later childhood	LANCET			English	Article							DAY-CARE ATTENDANCE; RESPIRATORY ILLNESS; INFECTIONS; ATOPY; CHILDREN; SENSITIZATION; PREVALENCE; INFANCY; DISEASE	Background Infections in early childhood may prevent allergies in later life. If this hypothesis is true, early exposure to childcare, outside the home would protect against atopy by promotion of cross infections. We investigated whether children who attend a nursery at a young age have a lower rate of atopy and fewer allergies than children who attend from an older age. Methods In a cross-sectional study carried out in 1992-93, we examined 2471 children in three age-groups (5-7, 8-10, and 11-14 years) from the towns of Bitterfeld, Hettstedt, and Zerbst in eastern Germany. The children's parents answered a questionnaire about allergies and symptoms, attendance at day care, and related factors. Sensitisation was assessed by shin-prick tests and measurement of allergen-specific IgE antibodies in serum. Findings In 669 children from small families (up to three people), the prevalance of atopy was higher among children who started to attend day nursery at an older age than in those who started to attend at a younger age (p < 0.05). Compared with children who first attended at age 6-11 months, the adjusted odds ratios for a positive skin-prick test were 1.99 (95% CI 1.08-3.66) for children who attended at age 12-23 months and 2.72 (1.37-5.40) for those who attended at age 24 months and older. In 1761 children from large families (more than three people), age of entry to day nursery had no effect on atopy. Interpretation Our findings accord with the hypothesis that early infection may protect against allergies in later life.	GSF, Res Ctr Environm & Hlth, Inst Epidemiol Neuherberg, D-85764 Oberschleissheim, Germany; Univ Dusseldorf, Med Inst Environm Hyg, D-4000 Dusseldorf, Germany; Univ Munich, Dept Epidemiol, Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Heinrich Heine University Dusseldorf; University of Munich	Heinrich, J (corresponding author), GSF, Res Ctr Environm & Hlth, Inst Epidemiol Neuherberg, D-85764 Oberschleissheim, Germany.		Heinrich, Joachim/N-1720-2013; Annesi-Maesano, Isabella/D-9173-2016; Wichmann, Heinz Erich/AAA-5695-2022	Heinrich, Joachim/0000-0002-9620-1629; Annesi-Maesano, Isabella/0000-0002-6340-9300; 				Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; BACKMAN A, 1984, ALLERGY, V39, P309, DOI 10.1111/j.1398-9995.1984.tb00867.x; CAUGHY MO, 1994, CHILD DEV, V65, P457, DOI 10.1111/j.1467-8624.1994.tb00763.x; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Heinrich J, 1998, AM J PUBLIC HEALTH, V88, P1319, DOI 10.2105/AJPH.88.9.1319; HOLBERG CJ, 1993, PEDIATRICS, V91, P885; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P59, DOI 10.1111/j.1399-3038.1995.tb00261.x; HURWITZ ES, 1991, PEDIATRICS, V87, P62; Kopjar B, 1996, PEDIATRICS, V97, P43; Marbury MC, 1997, AM J RESP CRIT CARE, V155, P156, DOI 10.1164/ajrccm.155.1.9001305; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; NIEBSCH G, 1989, HEILBERUFE, V41, P383; OSTERHOLM MT, 1994, PEDIATRICS, V94, P987; Passauer I, 1991, Padiatr Grenzgeb, V30, P311; PICKERING LK, 1992, SOZIALPADIATRIE, V14, P235; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279, DOI 10.1159/000236199; SCHWARTZ B, 1994, PEDIATRICS, V94, P1018; Shaheen S, 1997, BRIT MED J, V314, P987, DOI 10.1136/bmj.314.7086.987; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P296, DOI 10.1111/j.1365-2222.1995.tb01046.x; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WALD ER, 1988, J PEDIATR-US, V112, P540, DOI 10.1016/S0022-3476(88)80164-1; Woolcock AJ, 1995, PROG ALLER CLIN IMM, V3, P167	26	333	341	0	15	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 6	1999	353	9151					450	454		10.1016/S0140-6736(98)06329-6	http://dx.doi.org/10.1016/S0140-6736(98)06329-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JQ	9989715				2022-12-28	WOS:000078572800011
J	Jakob, U; Muse, W; Eser, M; Bardwell, JCA				Jakob, U; Muse, W; Eser, M; Bardwell, JCA			Chaperone activity with a redox switch	CELL			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; IN-VIVO; MOLECULAR CHAPERONES; DENATURED PROTEINS; OXIDATIVE STRESS; DISULFIDE BONDS; INDUCTION; DEGRADATION; CYTOPLASM	Hsp33, a member of a newly discovered heal shock protein family, was found to be a very potent molecular chaperone. Hsp33 is distinguished from all other known molecular chaperones by its mode of functional regulation. Its activity is redox regulated, Hsp33 is a cytoplasmically localized protein with highly reactive cysteines that respond quickly to changes in the redox environment. Oxidizing conditions like H2O2 cause disulfide bonds to form in Hsp33, a process that leads to the activation of its chaperone function. In vitro and in vivo experiments suggest that Hsp33 protects cells from oxidants, leading us to conclude that we have found a protein family that plays an important role in the bacterial defense system toward oxidative stress.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Jakob, U (corresponding author), Univ Michigan, Dept Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.	ujakob@biology.lsa.umich.edu						BARDWELL JCA, 1988, J BACTERIOL, V170, P2977, DOI 10.1128/jb.170.7.2977-2983.1988; BENOV L, 1995, J BACTERIOL, V177, P3344, DOI 10.1128/jb.177.11.3344-3346.1995; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; CHUANG SE, 1993, J BACTERIOL, V175, P5242, DOI 10.1128/JB.175.16.5242-5252.1993; Creighton T. E., 1989, PROTEIN STRUCTURE PR, P155; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; DAVIES KJA, 1988, FREE RADICAL BIO MED, V5, P215, DOI 10.1016/0891-5849(88)90015-9; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; Ding HG, 1997, P NATL ACAD SCI USA, V94, P8445, DOI 10.1073/pnas.94.16.8445; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Gross CA, 1996, ESCHERICHIA COLI SAL, P1382; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HUNT JB, 1984, J BIOL CHEM, V259, P4793; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Korber P, 1999, J BIOL CHEM, V274, P249, DOI 10.1074/jbc.274.1.249; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; McDuffee AT, 1997, J CELL PHYSIOL, V171, P143, DOI 10.1002/(SICI)1097-4652(199705)171:2<143::AID-JCP4>3.0.CO;2-O; Miller RA, 1997, CLIN MICROBIOL REV, V10, P1; Oh HJ, 1997, J BIOL CHEM, V272, P31636, DOI 10.1074/jbc.272.50.31636; PARSELL DA, 1989, GENE DEV, V3, P1226, DOI 10.1101/gad.3.8.1226; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; Sherman M Y, 1996, EXS, V77, P57; Takemoto T, 1998, FREE RADICAL BIO MED, V24, P556, DOI 10.1016/S0891-5849(97)00287-6; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; Thorstenson YR, 1997, J BACTERIOL, V179, P5333, DOI 10.1128/jb.179.17.5333-5339.1997; VANBOGELEN RA, 1987, J BACTERIOL, V169, P26, DOI 10.1128/jb.169.1.26-32.1987; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	39	422	431	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 5	1999	96	3					341	352		10.1016/S0092-8674(00)80547-4	http://dx.doi.org/10.1016/S0092-8674(00)80547-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025400	Bronze			2022-12-28	WOS:000078514600007
J	Zheleznova, EE; Markham, PN; Neyfakh, AA; Brennan, RG				Zheleznova, EE; Markham, PN; Neyfakh, AA; Brennan, RG			Structural basis of multidrug recognition by BmrR, a transcription activator of a multidrug transporter	CELL			English	Article							DNA-BINDING; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; ALPHA-HELIX; PROTEIN; EFFLUX; DOMAIN; RESISTANCE; REPRESSOR; REGULATOR	Multidrug-efflux transporters demonstrate an unusual ability to recognize multiple structurally dissimilar toxins. A comparable ability to bind diverse hydrophobic cationic drugs is characteristic of the Bacillus subtilis transcription regulator BmrR, which upon drug binding activates expression of the multidrug transporter Bmr. Crystal structures of the multidrug-binding domain of BmrR (2.7 Angstrom resolution) and of its complex with the drug tetraphenylphosphonium (2.8 Angstrom resolution) revealed a drug-induced unfolding and relocation of an alpha helix, which exposes an internal drug-binding pocket. Tetraphenylphosphonium binding is mediated by stacking and van der Waals contacts with multiple hydrophobic residues of the pocket and by an electrostatic interaction between the positively charged drug and a buried glutamate residue, which is the key to cation selectivity. Similar binding principles may be used by other multidrug-binding proteins.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Illinois, Ctr Pharmaceut Biotechnol, Chicago, IL 60607 USA	Oregon Health & Science University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Brennan, RG (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.	brennanr@ohsu.edu		Brennan, Richard/0000-0001-7647-485X; Heldwein, Ekaterina/0000-0003-3113-6958	NIGMS NIH HHS [GM49819, GM49244] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049244] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED M, 1994, J BIOL CHEM, V269, P28506; ANSARI AZ, 1995, NATURE, V374, P371; Blundell T.L., 1976, PROTEIN CRYSTALLOGRA; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; Chen X, 1998, J MOL BIOL, V278, P641, DOI 10.1006/jmbi.1998.1734; Constantine KL, 1998, BIOCHEMISTRY-US, V37, P7965, DOI 10.1021/bi980203o; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; Flomer WA, 1996, ACTA CRYSTALLOGR C, V52, P2445, DOI 10.1107/S0108270196005847; Flower DR, 1996, BIOCHEM J, V318, P1; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Gaudu P, 1996, P NATL ACAD SCI USA, V93, P10094, DOI 10.1073/pnas.93.19.10094; Goffeau A, 1997, YEAST, V13, P43, DOI 10.1002/(SICI)1097-0061(199701)13:1<43::AID-YEA56>3.0.CO;2-J; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; Hidalgo E, 1997, TRENDS BIOCHEM SCI, V22, P207, DOI 10.1016/S0968-0004(97)01068-2; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLMES DJ, 1993, EMBO J, V12, P3183, DOI 10.1002/j.1460-2075.1993.tb05987.x; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LALONDE JM, 1994, FASEB J, V8, P1240, DOI 10.1096/fasebj.8.15.8001736; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEMASTER DM, 1985, BIOCHEMISTRY-US, V24, P7263, DOI 10.1021/bi00346a036; LOMOVSKAYA O, 1995, J BACTERIOL, V177, P2328, DOI 10.1128/jb.177.9.2328-2334.1995; Ma D, 1996, MOL MICROBIOL, V19, P101, DOI 10.1046/j.1365-2958.1996.357881.x; Markham PN, 1997, BIOCHEM BIOPH RES CO, V239, P269, DOI 10.1006/bbrc.1997.7467; MARKHAM PN, 1996, J BACTERIOL, V178, P473; NAGADOI A, 1995, STRUCTURE, V3, P1217, DOI 10.1016/S0969-2126(01)00257-X; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SADOWSKY MJ, 1991, P NATL ACAD SCI USA, V88, P637, DOI 10.1073/pnas.88.2.637; SCHUMACHER MA, 1995, CELL, V83, P147, DOI 10.1016/0092-8674(95)90243-0; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; UTSCHIG LM, 1995, SCIENCE, V268, P380, DOI 10.1126/science.7716541; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; Zheleznova EE, 1997, PROTEIN SCI, V6, P2465	48	162	169	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 5	1999	96	3					353	362		10.1016/S0092-8674(00)80548-6	http://dx.doi.org/10.1016/S0092-8674(00)80548-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025401	Bronze			2022-12-28	WOS:000078514600008
J	Mariner, WK				Mariner, WK			Going Hollywood with patient rights in managed care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA; Boston Univ, Sch Med, Boston, MA 02215 USA	Boston University; Boston University	Mariner, WK (corresponding author), Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA.			Mariner, Wendy/0000-0001-5176-5917				Annas GJ, 1998, NEW ENGL J MED, V338, P695, DOI 10.1056/NEJM199803053381020; Kuttner R, 1998, NEW ENGL J MED, V338, P1635, DOI 10.1056/NEJM199805283382221; Mariner W K, 1998, J Contemp Health Law Policy, V15, P1; Mariner WK, 1996, NEW ENGL J MED, V335, P1986, DOI 10.1056/NEJM199612263352610; RODWIN MA, 1996, HOUSTON LAW REV, V32, P1319	5	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					861	861		10.1001/jama.281.9.861	http://dx.doi.org/10.1001/jama.281.9.861			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10071013	hybrid			2022-12-28	WOS:000078804300043
J	Black, DA				Black, DA			Unerring trust	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					592	592		10.1136/bmj.318.7183.592	http://dx.doi.org/10.1136/bmj.318.7183.592			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037644	Green Published			2022-12-28	WOS:000078966300038
J	Dewar, HA				Dewar, HA			Charles Nathaniel ("Natty") Armstrong - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					607	607		10.1136/bmj.318.7183.607	http://dx.doi.org/10.1136/bmj.318.7183.607			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037661	Green Published			2022-12-28	WOS:000078966300070
J	McClure, EA				McClure, EA			Patients not protocols	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					596	596		10.1136/bmj.318.7183.596	http://dx.doi.org/10.1136/bmj.318.7183.596			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037646	Green Published			2022-12-28	WOS:000078966300040
J	Taylor, KL; Cheng, NQ; Williams, RW; Steven, AC; Wickner, RB				Taylor, KL; Cheng, NQ; Williams, RW; Steven, AC; Wickner, RB			Prion domain initiation of amyloid formation in vitro from native Ure2p	SCIENCE			English	Article							YEAST SUP35 PROTEIN; SACCHAROMYCES-CEREVISIAE; IN-VITRO; PROPAGATION; DETERMINANT; TRANSLATION; TERMINATION; PSI(+); GENES; ERF1	The [URE3] non-Mendelian genetic element of Saccharomyces cerevisiae is an infectious protein (prion) form of Ure2p, a regulator of nitrogen catabolism. Here, synthetic Ure2p(1-65) were shown to polymerize to form filaments 40 to 45 angstroms in diameter with more than 60 percent beta sheet. Ure2p(1-65) specifically induced full-length native Ure2p to copolymerize under conditions where native Ure2p alone did not polymerize. Like Ure2p in extracts of [URE3] strains, these 180- to 220-angstrom-diameter filaments were protease resistant, The Ure2p(1-65)-Ure2p cofilaments could seed polymerization of native Ure2p to form thicker, Less regular filaments. All filaments stained with Congo Red to produce the green birefringence typical of amyloid. This self-propagating amyloid formation can explain the properties of [URE3].	NIDDKD, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA; NIAMSD, Struct Biol Lab, NIH, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Uniformed Services University of the Health Sciences - USA	Wickner, RB (corresponding author), NIDDKD, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA.	wickner@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK024943] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Cooper T. G., 1982, MOL BIOL YEAST SACCH, V2, P39; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; COURCHESNE WE, 1988, J BACTERIOL, V170, P708, DOI 10.1128/jb.170.2.708-713.1988; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; DRILLIEN R, 1972, J BACTERIOL, V109, P203, DOI 10.1128/JB.109.1.203-208.1972; EDSKES HK, IN PRESS P NATL ACAD; GLENNER GG, 1980, NEW ENGL J MED, V302, P1333, DOI 10.1056/NEJM198006123022403; GLENNER GG, 1981, PROG HISTOCHEM CYTOC, V13, P1; GLENNER GG, 1971, SCIENCE, V174, P712, DOI 10.1126/science.174.4010.712; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; HIRS CHW, 1986, ENZYME STRUCTURE, V130, P311; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; Kisilevsky R, 1997, CRIT REV BIOCHEM MOL, V32, P361, DOI 10.3109/10409239709082674; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1293, DOI 10.1177/37.8.2666512; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; Masison DC, 1997, P NATL ACAD SCI USA, V94, P12503, DOI 10.1073/pnas.94.23.12503; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; PRUSINER SB, 1996, FIELDS VIROLOGY, V2, P2901; SCHOUN J, 1969, CR ACAD SCI D NAT, V269, P1412; Seilheimer B, 1997, J STRUCT BIOL, V119, P59, DOI 10.1006/jsbi.1997.3859; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; TAYLOR KJ, UNPUB; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; WILLIAMS RW, 1983, J MOL BIOL, V166, P581, DOI 10.1016/S0022-2836(83)80285-X; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	34	257	258	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 26	1999	283	5406					1339	1343		10.1126/science.283.5406.1339	http://dx.doi.org/10.1126/science.283.5406.1339			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037606				2022-12-28	WOS:000078839900045
J	Cox, J				Cox, J			A memorable patient - Say what you mean	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1999	318	7182					521	521		10.1136/bmj.318.7182.521	http://dx.doi.org/10.1136/bmj.318.7182.521			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QT	10024265	Green Published			2022-12-28	WOS:000078818100033
J	Hansson, L; Lindholm, LH; Niskanen, L; Lanke, J; Hedner, T; Niklason, A; Luomanmaki, K; Dahlof, B; de Faire, U; Morlin, C; Karlberg, BE; Wester, PO; Bjorck, JE				Hansson, L; Lindholm, LH; Niskanen, L; Lanke, J; Hedner, T; Niklason, A; Luomanmaki, K; Dahlof, B; de Faire, U; Morlin, C; Karlberg, BE; Wester, PO; Bjorck, JE		CAPPP study grp	Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial	LANCET			English	Article							LEFT-VENTRICULAR HYPERTROPHY; ANTIHYPERTENSIVE THERAPY; INSULIN SENSITIVITY; BLOOD-PRESSURE; METAANALYSIS; REDUCTIONS; POPULATION; REVERSAL; GLUCOSE	Background Angiotensin-converting-enzyme (ACE) inhibitors have been used for more than a decade to treat high blood pressure, despite the lack of data from randomised intervention trials to show that such treatment affects cardiovascular morbidity and mortality. The Captopril Prevention Project (CAPPP) is a randomised intervention trial to compare the effects of ACE inhibition and conventional therapy on cardiovascular morbidity mortality in patients with hypertension. Methods CAPPP was a prospective, randomised, open trial with blinded endpoint evaluation. 10 985 patients were enrolled at 536 health centres in Sweden and Finland. Patients aged 25-66 years with a measured diastolic blood pressure of 100 mm Hg or more on two occasions were randomly assigned captopril or conventional antihypertensive treatment (diuretics, beta-blockers). Analysis was by intention-to-treat. The primary endpoint was a composite of fatal and non-fatal myocardial infarction, stroke, and other cardiovascular deaths. Findings Of 5492 patients assigned captopril and 5493 assigned conventional therapy, 14 and 13, respectively, were lost to follow-up. Primary endpoint events occurred in 363 patients in the captopril group (11.1 per 1000 patient-years) and 335 in the conventional-treatment group (10.2 per 1000 patient-years; relative risk 1.05 [95% CI 0.90-1.22], p = 0.52). Cardiovascular mortality was lower with captopril than with conventional treatment (76 vs 95 events; relative risk 0.77 [0.57-1.04], p = 0.092), the rate of fatal and non-fatal myocardial infarction was similar (162 vs 161), but fatal and non-fatal stroke was more common with captopril (189 vs 148; 1.25 [1.01-1.55]. p = 0.044). Interpretation Captopril and conventional treatment did not differ in efficacy in preventing cardiovascular morbidity and mortality. The difference in stroke risk is probably due to the lower levels of blood pressure obtained initially in previously treated patients randomised to conventional therapy.	Uppsala Univ, Dept Publ Hlth & Social Sci, Div Clin Hypertens Res, S-75125 Uppsala, Sweden; Univ Umea Hosp, Dept Med, S-90185 Umea, Sweden; Univ Umea Hosp, Dept Publ Hlth & Clin Med, S-90185 Umea, Sweden; Kuopio Univ Hosp, Dept Med, SF-70210 Kuopio, Finland; Univ Lund, Dept Stat, Lund, Sweden; Sahlgrens Univ Hosp, Dept Clin Pharmacol, S-41345 Gothenburg, Sweden; Bristol Myers Squibb, Stockholm, Sweden; Univ Helsinki, Cent Hosp, Dept Med, Helsinki, Finland; GU Clin Res Inst, Gothenburg, Sweden; Karolinska Hosp, Dept Cardiovasc Res, S-10401 Stockholm, Sweden; Linkoping Univ Hosp, Dept Med, Linkoping, Sweden	Uppsala University; Umea University; Umea University; Kuopio University Hospital; University of Eastern Finland; Lund University; Sahlgrenska University Hospital; Bristol-Myers Squibb; University of Helsinki; Helsinki University Central Hospital; Karolinska Institutet; Karolinska University Hospital; Linkoping University	Hansson, L (corresponding author), Uppsala Univ, Dept Publ Hlth & Social Sci, Div Clin Hypertens Res, Box 609, S-75125 Uppsala, Sweden.							*1988 JOINT NAT CO, 1988, ARCH INTERN MED, V148, P1023; ALLEMANN Y, 1992, EUR J CLIN PHARMACOL, V42, P275; Black HR, 1997, ARCH INTERN MED, V157, P2413; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOK NR, 1995, ARCH INTERN MED, V155, P701, DOI 10.1001/archinte.155.7.701; CROOGH, 1984, N ENGL J MED, V314, P1657; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; ELLIOTT WJ, 1995, AM J HYPERTENS, V8, pA80; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HAENNI A, 1993, 6 EUR SOC HYP M; Hansson L, 1992, Blood Press, V1, P113, DOI 10.3109/08037059209077502; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; HANSSON L, 1990, J HYPERTENS, V8, P985; Hansson Lennart, 1997, Blood Pressure, V6, P365, DOI 10.3109/08037059709062096; HILLEMAN DE, 1994, CLIN THER, V16, P88; Himmelmann A, 1996, AM J HYPERTENS, V9, P850, DOI 10.1016/S0895-7061(96)00176-8; Himmelmann Anders, 1995, Blood Pressure, V4, P85, DOI 10.3109/08037059509077575; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1988, DRUGS, V35, P1, DOI 10.2165/00003495-198800355-00002; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Lindholm Lars H., 1996, Blood Pressure, V5, P300, DOI 10.3109/08037059609078063; MCCOMBS JS, 1994, MED CARE, V32, P214, DOI 10.1097/00005650-199403000-00003; MCINNES GT, 1998, DO ACE INHIBITORS RE; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; Mogensen CE, 1998, BRIT MED J, V317, P693, DOI 10.1136/bmj.317.7160.693; Monane M, 1997, AM J HYPERTENS, V10, P697, DOI 10.1016/S0895-7061(97)00056-3; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; SANTORO D, 1992, HYPERTENSION, V20, P181, DOI 10.1161/01.HYP.20.2.181; Schmieder RE, 1996, JAMA-J AM MED ASSOC, V275, P1507, DOI 10.1001/jama.275.19.1507; Sharpe N., 1988, LANCET, V1, P225; Stearne MR, 1998, BRIT MED J, V317, P713; Zanchetti A, 1993, Blood Press, V2, P86, DOI 10.3109/08037059309077535	35	1481	1553	0	55	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 20	1999	353	9153					611	616		10.1016/S0140-6736(98)05012-0	http://dx.doi.org/10.1016/S0140-6736(98)05012-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QU	10030325				2022-12-28	WOS:000078818200009
J	Scott, RC; Besag, FMC; Neville, BGR				Scott, RC; Besag, FMC; Neville, BGR			Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial	LANCET			English	Article							STATUS EPILEPTICUS; NASAL RATHER; BENZODIAZEPINES; MANAGEMENT; MORTALITY; CHILDREN	Background Convulsive status epilepticus is the most common neurological medical emergency and has high morbidity and mortality. Early treatment before admission to hospital is best with an effective medication that can be administered safely. We aimed to find out whether there are differences in efficacy and adverse events between buccal administration of liquid midazolam and rectal administration of liquid diazepam in the acute treatment of seizures. Methods At a residential school with on-site medical facilities 42 young people with severe epilepsy were enrolled. Continuous seizures of more than 5 min duration were randomly treated with buccal midazolam or rectal diazepam. If the seizure did not stop within 10 min additional medication chosen by the attending physician was administered. We monitored oxygen saturation and blood pressure for 30 min after treatment. The main outcome measures were efficacy, time from arrival of the nurse to drug administration, time from drug administration to end of seizure, and incidence of adverse cardiorespiratory events. Findings Buccal midazolam was used to treat 40 seizures in 14 students, and rectal diazepam 39 seizures in 14 students. Midazolam stopped 30 (75%) of 40 seizures and diazepam 23 (59%) of 39 (p = 0.16). The median time from arrival of the nurse to administration of medication was 2 min. Time from administration to end of seizure did not differ significantly between the two treatments. No clinically important adverse cardiorespiratory events were identified in the two groups. Buccal midazolam was universally acceptable to the nursing and care staff. Interpretation Buccal midazolam is at least as effective as rectal diazepam in the acute treatment of seizures. Administration via the mouth is more socially acceptable and convenient and may become the preferred treatment for long seizures that occur outside hospital.	Great Ormond St Hosp Sick Children, Inst Child Hlth, Wolfson Ctr, London WC1N 2AP, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Scott, RC (corresponding author), Great Ormond St Hosp Sick Children, Inst Child Hlth, Wolfson Ctr, Mecklenburgh Sq, London WC1N 2AP, England.	r.scott@ich.ucl.ac.uk	Scott, Rod/C-5363-2008; Besag, FM/H-7031-2019	Scott, Rod/0000-0002-8944-928X				ALLDREDGE BK, 1995, PEDIATR NEUROL, V12, P213, DOI 10.1016/0887-8994(95)00044-G; DEBOER AG, 1984, BRIT J ANAESTH, V56, P69, DOI 10.1093/bja/56.1.69; DELORENZO RJ, 1995, J CLIN NEUROPHYSIOL, V12, P316; HAUSER WA, 1990, NEUROLOGY, V40, P9; Lahat E, 1998, LANCET, V352, P620, DOI 10.1016/S0140-6736(05)79574-X; LOMBROSO CT, 1989, EPILEPSIA, V30, pS11, DOI 10.1111/j.1528-1157.1989.tb05819.x; MAYTAL J, 1989, PEDIATRICS, V83, P323; ORegan ME, 1996, DEV MED CHILD NEUROL, V38, P1037; Scott RC, 1997, DEV MED CHILD NEUROL, V39, P137; Scott RC, 1998, EPILEPSIA, V39, P290, DOI 10.1111/j.1528-1157.1998.tb01375.x; SHORVON S, 1993, J NEUROL NEUROSUR PS, V56, P125, DOI 10.1136/jnnp.56.2.125; Shorvon S., 1994, STATUS EPILEPTICUS I, P218; TOWNE AR, 1994, EPILEPSIA, V35, P27, DOI 10.1111/j.1528-1157.1994.tb02908.x; Wallace SJ, 1997, LANCET, V349, P222, DOI 10.1016/S0140-6736(05)64856-8	14	259	267	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 20	1999	353	9153					623	626		10.1016/S0140-6736(98)06425-3	http://dx.doi.org/10.1016/S0140-6736(98)06425-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QU	10030327				2022-12-28	WOS:000078818200011
J	Vierhapper, H; Nowotny, P				Vierhapper, H; Nowotny, P			Gynaecomastia and raised oestradiol concentrations	LANCET			English	Article							MEN				Vierhapper, H (corresponding author), Univ Vienna, Clin Internal Med 3, Clin Div Endocrinol & Metab, Waehringer Guertel 18, A-1090 Vienna, Austria.							FRANTZ AG, 1998, WILLIAMS TXB ENDOCRI, P877; MILLS MH, 1991, MED HYPOTHESES, V36, P195, DOI 10.1016/0306-9877(91)90129-M; PHILLIPS GB, 1976, LANCET, V2, P14; Vierhapper H, 1997, J CLIN ENDOCR METAB, V82, P1492, DOI 10.1210/jc.82.5.1492; VIERHAPPER H, 1986, J CLIN INVEST, V77, P1063, DOI 10.1172/JCI112405	5	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 20	1999	353	9153					640	640		10.1016/S0140-6736(98)11227-8	http://dx.doi.org/10.1016/S0140-6736(98)11227-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QU	10030331				2022-12-28	WOS:000078818200015
J	Naylor, MD; Brooten, D; Campbell, R; Jacobsen, BS; Mezey, MD; Pauly, MV; Schwartz, JS				Naylor, MD; Brooten, D; Campbell, R; Jacobsen, BS; Mezey, MD; Pauly, MV; Schwartz, JS			Comprehensive discharge planning and home follow-up of hospitalized elders - A randomized clinical trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONGESTIVE-HEART-FAILURE; MEDICARE PATIENTS; CARE; READMISSION; COMMUNITY; OUTCOMES; IMPACT; BIRTH	Context Comprehensive discharge planning by advanced practice nurses has demonstrated short-term reductions in readmissions of elderly patients, but the benefits of more intensive follow-up of hospitalized elders at risk for poor outcomes after discharge has not been studied. Objective To examine the effectiveness of an advanced practice nurse-centered discharge planning and home follow-up intervention for elders at risk for hospital readmissions. Design Randomized clinical trial with follow-up at 2, 6, 12, and 24 weeks after index hospital discharge. Setting Two urban, academically affiliated hospitals in Philadelphia, Pa. Participants Eligible patients were 65 years or older, hospitalized between August 1992 and March 1996, and had 1 of several medical and surgical reasons for admission. Intervention Intervention group patients received a comprehensive discharge planning and home follow-up protocol designed specifically for elders at risk for poor outcomes after discharge and implemented by advanced practice nurses. Main Outcome Measures Readmissions, time to first readmission, acute care visits after discharge, costs, functional status, depression, and patient satisfaction. Results A total of 363 patients (186 in the control group and 177 in the intervention group) were enrolled in the study; 70% of intervention and 74% of control subjects completed the trial. Mean age of sample was 75 years; 50% were men and 45% were black. By week 24 after the index hospital discharge, control group patients were more likely than intervention group patients to be readmitted at least once (37.1% vs 20.3%; P < .001). Fewer intervention group patients had multiple readmissions (6.2% vs 14.5%; P = .01) and the intervention group had fewer hospital days per patient (1.53 vs 4.09 days; P < .001). Time to first readmission was increased in the intervention group (P < .001). At 24 weeks after discharge, total Medicare reimbursements for health services were about $1.2 million in the control group vs about $0.6 million in the intervention group (P < .001). There were no significant group differences in postdischarge acute care visits, functional status, depression, or patient satisfaction. Conclusions An advanced practice nurse-centered discharge planning and home care intervention for at-risk hospitalized elders reduced readmissions, lengthened the time between discharge and readmission, and decreased the costs of providing health care. Thus, the intervention demonstrated great potential in promoting positive outcomes for hospitalized elders at high risk for rehospitalization while reducing costs.	Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Case Western Reserve Univ, Sch Nursing, Cleveland, OH 44106 USA; NYU, Div Nursing, New York, NY USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Case Western Reserve University; New York University	Naylor, MD (corresponding author), Univ Penn, Sch Nursing, 420 Guardian Dr, Philadelphia, PA 19104 USA.	naylor@pobox.upenn.edu			NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR002095] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		ASHTON CM, 1995, ANN INTERN MED, V122, P415, DOI 10.7326/0003-4819-122-6-199503150-00003; BROOTEN D, 1986, NEW ENGL J MED, V315, P934, DOI 10.1056/NEJM198610093151505; BROOTEN D, 1994, OBSTET GYNECOL, V84, P832; BROOTEN D, 1995, AM J MANAGE CARE, V1, P35; COX DR, 1972, J R STAT SOC, V66, P188; CUMMINGS JE, 1990, ARCH INTERN MED, V150, P1274, DOI 10.1001/archinte.150.6.1274; DEY AN, 1993, IN PRESS VITAL HLTH, V272; ELASHOFF JD, 1997, NQUERY ADVISOR VERSI; Experton B, 1997, AM J PUBLIC HEALTH, V87, P210, DOI 10.2105/AJPH.87.2.210; FEASLEY J, 1996, HLTH OUTC OLD PEOP; Fonarow GC, 1997, J AM COLL CARDIOL, V30, P725, DOI 10.1016/S0735-1097(97)00208-8; FRANKL SE, 1991, AM J MED, V90, P667; Graves E.J., 1995, VITAL HLTH STAT, V13, P1; *HLTH CAR FIN ADM, 1997, DAT DIV BUDG; *HLTH CAR INV AUTH, 1996, DRG HDB COMP CLIN FI; Kane RL, 1996, J AM GERIATR SOC, V44, P242, DOI 10.1111/j.1532-5415.1996.tb00909.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KORNOWSKI R, 1995, AM HEART J, V129, P762, DOI 10.1016/0002-8703(95)90327-5; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; Lee E, 2013, STAT METHODS SURVIVA; MADDOX GL, 1964, J CHRON DIS, V17, P449, DOI 10.1016/0021-9681(64)90105-5; MAMON J, 1992, HEALTH SERV RES, V27, P155; MOINPOUR C, 1992, INSTRUMENTS CLIN NUR, P385; MORROWHOWELL N, 1994, MED CARE, V32, P486, DOI 10.1097/00005650-199405000-00007; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; Oddone EZ, 1996, J GEN INTERN MED, V11, P597, DOI 10.1007/BF02599027; PEARLIN LI, 1990, GERONTOLOGIST, V30, P583, DOI 10.1093/geront/30.5.583; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; Smith LE, 1997, CLIN CARDIOL, V20, P949, DOI 10.1002/clc.4960201109; STUCK AE, 1995, NEW ENGL J MED, V333, P1184, DOI 10.1056/NEJM199511023331805; Titler M G, 1995, J Cardiovasc Nurs, V9, P64; TOWNSEND J, 1988, BMJ-BRIT MED J, V297, P544, DOI 10.1136/bmj.297.6647.544; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; West JA, 1997, AM J CARDIOL, V79, P58, DOI 10.1016/S0002-9149(96)00676-5	37	1197	1213	6	101	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1999	281	7					613	620		10.1001/jama.281.7.613	http://dx.doi.org/10.1001/jama.281.7.613			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	165YA	10029122	Bronze			2022-12-28	WOS:000078548400031
J	Showstack, J; Katz, PP; Weber, E				Showstack, J; Katz, PP; Weber, E			Evaluating the impact of hospitalists	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	National Policy Conference on the Hospitalist Movement	DEC 05-06, 1997	SAN FRANCISCO, CA					The hospital-based generalist physician is a recent organizational innovation in health care in the United States. Does the hospitalist model provide improved health care? The answer to this question lies in a rigorous evaluation of the hospitalist system in the clinical setting. This paper describes key outcomes that need to be assessed and methodologic issues that need to be addressed when conducting and interpreting the results of evaluations of the hospitalist model. To provide evidence about the value of the hospitalist model, quality of care should be evaluated through the measurement of both processes and outcomes. The clinical processes assessed may include diagnostic tests and treatments that are causally linked with outcomes. A variety of outcomes can be measured, such as death, clinical or physiologic status, physical function, and psychological well-being. The analysis of resource use data can aid in an assessment of the relative costs and effectiveness of clinical services. An evaluation of the hospitalist model requires an adequate research design, which should include a precise definition of the model being studied, the selection of an appropriate comparison group, the collection of clinical and demographic information on patients, the specification of both process and outcome measures, and the use of statistical techniques that are appropriate to the questions being asked and the data being collected. The design must distinguish between outcomes attributable to the introduction of hospitalists and those attributable to other changes in medical treatments and the organization of care.	Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Emergency Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Showstack, J (corresponding author), Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA.	jas1@itsa.ucsf.edu	Weber, Ellen/GRR-9967-2022; Showstack, Jonathan/L-6556-2013	Weber, Ellen/0000-0002-0094-1973; Showstack, Jonathan/0000-0002-1367-419X				[Anonymous], 1980, EXPLORATIONS QUALITY; Browner WS, 1988, DESIGNING CLIN RES E; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; Fleiss J. L., 1981, STAT METHODS RATES P, V2; HOSMER DW, 1989, APPL LOGISTIC REGRES; Iezzoni LI, 1997, RISK ADJUSTMENT MEAS; Katz PP, 1997, ARTHRIT CARE RES, V10, P370, DOI 10.1002/art.1790100605; KATZ PP, IN PRESS INT J TECHN; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; LOHR KN, 1988, INQUIRY-J HEALTH CAR, V25, P37; Milstein A, 1999, ANN INTERN MED, V130, P360, DOI 10.7326/0003-4819-130-4-199902161-00006; *NAT ASTHM ED PREV, 1997, GUID DIAGN MAN ASTHM; Pett M.A., 1997, NONPARAMETRIC STAT H; *US I MED, 1994, AM HLTH TRANS PROT I; Wachter RM, 1999, ANN INTERN MED, V130, P338, DOI 10.7326/0003-4819-130-4-199902161-00002; Wachter RM, 1998, JAMA-J AM MED ASSOC, V279, P1560, DOI 10.1001/jama.279.19.1560; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713; Ware J. E., 1993, SF36 HLTH SURVEY MAN	18	21	21	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	2				376	381		10.7326/0003-4819-130-4-199902161-00010	http://dx.doi.org/10.7326/0003-4819-130-4-199902161-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	166QB	10068410				2022-12-28	WOS:000078587500010
J	Huse, M; Chen, YG; Massague, J; Kuriyan, J				Huse, M; Chen, YG; Massague, J; Kuriyan, J			Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12	CELL			English	Article							GROWTH-FACTOR-BETA; DEPENDENT PROTEIN-KINASE; TYROSINE KINASE; CATALYTIC SUBUNIT; INSULIN-RECEPTOR; BINDING-PROTEIN; FAMILY; SUBSTRATE; MECHANISM; ACTIVATION	Activation of the type I TGF beta receptor (T beta R-I) requires phosphorylation of a regulatory segment known as the GS region, located upstream of the serine/threonine kinase domain in the cytoplasmic portion of the receptor, The crystal structure of a fragment of unphosphorylated T beta R-I, containing both the GS region and the catalytic domain, has been determined in complex with the FK506-binding protein FKBP12. T beta R-I adopts an inactive conformation that is maintained by the unphosphorylated GS region, FKBP12 binds to the GS region of the receptor, capping the T beta R-II phosphorylation sites and further stabilizing the inactive conformation of T beta R-I. Certain structural features at the catalytic center of T beta R-I are characteristic of tyrosine kinases rather than Ser/Thr kinases.	Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Kuriyan, J (corresponding author), Rockefeller Univ, Labs Mol Biophys, 1230 York Ave, New York, NY 10021 USA.	kuriyan@rocky2.rockefeller.edu		Massague, Joan/0000-0001-9324-8408	NCI NIH HHS [CA34610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034610, R37CA034610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG RN, 1979, BIOCHEMISTRY-US, V18, P1230, DOI 10.1021/bi00574a018; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Charng MJ, 1996, J BIOL CHEM, V271, P22941, DOI 10.1074/jbc.271.38.22941; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1994, J BIOL CHEM, V269, P22868; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kleywegt GJ, 1997, STRUCTURE, V5, P1557, DOI 10.1016/S0969-2126(97)00305-5; KLEYWEGT GJ, 1993, ESF CCP4 NEWSLETTER, V28, P56; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lawler S, 1997, J BIOL CHEM, V272, P14850, DOI 10.1074/jbc.272.23.14850; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LU G, 1999, IN PRESS FIND NCS PR; Luo KX, 1996, EMBO J, V15, P4485, DOI 10.1002/j.1460-2075.1996.tb00826.x; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okadome T, 1996, J BIOL CHEM, V271, P21687, DOI 10.1074/jbc.271.36.21687; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; ROBERTS JR, 1990, PHYS SCRIPTA, V41, P9, DOI 10.1088/0031-8949/41/1/003; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; Stockwell BR, 1998, CHEM BIOL, V5, P385, DOI 10.1016/S1074-5521(98)90072-2; Stockwell BR, 1998, CURR BIOL, V8, P761, DOI 10.1016/S0960-9822(98)70299-4; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WILSON KP, 1995, ACTA CRYSTALLOGR D, V51, P511, DOI 10.1107/S0907444994014514; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	59	349	379	1	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 5	1999	96	3					425	436		10.1016/S0092-8674(00)80555-3	http://dx.doi.org/10.1016/S0092-8674(00)80555-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025408	Bronze			2022-12-28	WOS:000078514600015
J	Strandberg, TE; Vanhanen, H; Tikkanen, MJ				Strandberg, TE; Vanhanen, H; Tikkanen, MJ			Effect of statins on C-reactive protein in patients with coronary artery disease	LANCET			English	Article									Univ Helsinki, Dept Med, FIN-00029 Helsinki, Finland	University of Helsinki	Strandberg, TE (corresponding author), Univ Helsinki, Dept Med, HYK5, FIN-00029 Helsinki, Finland.			strandberg, timo/0000-0001-6299-925X				Ridker PM, 1998, CIRCULATION, V97, P2007, DOI 10.1161/01.CIR.97.20.2007; Ridker PM, 1998, CIRCULATION, V98, P839, DOI 10.1161/01.CIR.98.9.839; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643	3	174	191	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 9	1999	353	9147					118	119		10.1016/S0140-6736(05)76154-7	http://dx.doi.org/10.1016/S0140-6736(05)76154-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023901				2022-12-28	WOS:000078087200017
J	Dixon, PA; Milicich, MJ; Sugihara, G				Dixon, PA; Milicich, MJ; Sugihara, G			Episodic fluctuations in larval supply	SCIENCE			English	Article							REEF FISH POPULATIONS; GREAT-BARRIER-REEF; LIZARD ISLAND; TIME-SERIES; CORAL; REPLENISHMENT; PATTERNS	The lack of a clear relationship between spawning output and recruitment success continues to confound attempts to understand and manage temporally variable fish populations. This relationship for a common reef fish is shown to be obscured by nonlinear processes in operation during the larval phase. Non-linear responses of larval fish to their noisy physical environment may offer a general explanation for the erratic, often episodic, replenishment of open marine populations.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Griffith Univ, Brisbane, Qld 4111, Australia	University of California System; University of California San Diego; Scripps Institution of Oceanography; Griffith University	Dixon, PA (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.	paul@complex.ucsd.edu						CAPUTI N, 1988, CAN J FISH AQUAT SCI, V45, P178, DOI 10.1139/f88-019; Cushing D.H., 1982, CLIMATE FISHERIES; DOHERTY PJ, 1988, OCEANOGR MAR BIOL, V26, P487; HILBORN R, 1992; LEGGETT WC, 1994, NETH J SEA RES, V32, P119, DOI 10.1016/0077-7579(94)90036-1; LEIS JM, 1986, MAR BIOL, V90, P505, DOI 10.1007/BF00409271; LOASKER R, 1981, MARINE FISH LARVAE; MEEKAN MG, 1993, MAR ECOL PROG SER, V93, P217, DOI 10.3354/meps093217; MILICICH MJ, 1994, MAR ECOL PROG SER, V110, P135, DOI 10.3354/meps110135; MILICICH MJ, 1994, MAR ECOL PROG SER, V110, P121, DOI 10.3354/meps110121; Rothschild B.J., 1986, DYNAMICS MARINE FISH; SHENKER JM, 1993, MAR ECOL PROG SER, V98, P31, DOI 10.3354/meps098031; Sponaugle S, 1996, MAR ECOL PROG SER, V133, P13, DOI 10.3354/meps133013; STOBUTZKI IC, 1994, J EXP MAR BIOL ECOL, V175, P275, DOI 10.1016/0022-0981(94)90031-0; SUGIHARA G, 1990, NATURE, V344, P734, DOI 10.1038/344734a0; SUGIHARA G, 1994, PHILOS T R SOC A, V348, P477, DOI 10.1098/rsta.1994.0106; Takens F., 1981, DYNAMICAL SYSTEMS TU, V898, P366, DOI [10.1007/bfb0091924, DOI 10.1007/BFB0091924, 10.1007/BFb0091924]; Wand M.P., 1994, KERNEL SMOOTHING; YAO QW, 1994, STAT SINICA, V4, P51	19	144	146	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 5	1999	283	5407					1528	1530		10.1126/science.283.5407.1528	http://dx.doi.org/10.1126/science.283.5407.1528			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066174				2022-12-28	WOS:000078959200046
J	Krabill, W; Frederick, E; Manizade, S; Martin, C; Sonntag, J; Swift, R; Thomas, R; Wright, W; Yungel, J				Krabill, W; Frederick, E; Manizade, S; Martin, C; Sonntag, J; Swift, R; Thomas, R; Wright, W; Yungel, J			Rapid thinning of parts of the southern Greenland ice sheet	SCIENCE			English	Article								Aircraft laser-altimeter surveys over southern Greenland in 1993 and 1998 show three areas of thickening by more than 10 centimeters per year in the southern part of the region and large areas of thinning, particularly in the east. Above 2000 meters elevation the ice sheet is in balance but thinning predominates at lower elevations, with rates exceeding 1 meter per year on east coast outlet glaciers. These high thinning rates occur at different latitudes and at elevations up to 1500 meters, which suggests that they are caused by increased rates of creep thinning rather than by excessive melting. Taken as a whole, the surveyed region is in negative balance.	NASA, Lab Hydrospher Proc, Goddard Space Flight Ctr, Wallops Flight Facil, Wallops Island, VA 23337 USA; EG&G Serv, Wallops Flight Facil, Wallops Island, VA 23337 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Krabill, W (corresponding author), NASA, Lab Hydrospher Proc, Goddard Space Flight Ctr, Wallops Flight Facil, Bldg N-159, Wallops Island, VA 23337 USA.							ABDALATI W, 1998, COMMUNICATION    OCT; BRAITHWAITE RJ, 1994, GLOBAL PLANET CHANGE, V9, P251, DOI 10.1016/0921-8181(94)90019-1; Bromwich DH, 1998, J GEOPHYS RES-ATMOS, V103, P26007, DOI 10.1029/98JD02278; Davis CH, 1998, SCIENCE, V279, P2086, DOI 10.1126/science.279.5359.2086; KRABILL WB, 1995, INT J REMOTE SENS, V16, P1211, DOI 10.1080/01431169508954472; SCHUTZ B, 1998, P WEG 98 KROKKL NORW; THOMAS RH, IN PRESS J GLACIOL; Weidick A, 1991, RAPP GRONLANDS GEOL, V152, P73; WRIGHT CW, 1992, P SPIE C ORLANDO, P2; ZWALLY HJ, 1998, SCIENCE, V281, P1251	10	127	130	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	1999	283	5407					1522	1524		10.1126/science.283.5407.1522	http://dx.doi.org/10.1126/science.283.5407.1522			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066172				2022-12-28	WOS:000078959200044
J	Bachmaier, K; Neu, N; de la Maza, LM; Pal, S; Hessel, A; Penninger, JM				Bachmaier, K; Neu, N; de la Maza, LM; Pal, S; Hessel, A; Penninger, JM			Chlamydia infections and heart disease linked through antigenic mimicry	SCIENCE			English	Article							DEPENDENT DIABETES-MELLITUS; OUTER-MEMBRANE PROTEIN; TRACHOMATIS INFECTION; PNEUMONIAE INFECTION; AUTOIMMUNE-DISEASE; CORONARY-ARTERIES; MYOCARDIAL-INFARCTION; NUCLEOTIDE-SEQUENCE; MOLECULAR MIMICRY; TWAR	Chlamydia infections are epidemiologically Linked to human heart disease. A peptide from the murine heart muscle-specific a myosin heavy chain that has sequence homology to the 60-kilodalton cysteine-rich outer membrane proteins of Chlamydia pneumoniae, C. psittaci, and C. trachomatis was shown to induce autoimmune inflammatory heart disease in mice. Injection of the homologous Chlamydia peptides into mice also induced perivascular inflammation, fibrotic changes, and blood vessel occlusion in the heart, as well as triggering T and B cell reactivity to the homologous endogenous heart muscle-specific peptide. Chlamydia DNA functioned as an adjuvant in the triggering of peptide-induced inflammatory heart disease. Infection with C, trachomatis Led to the production of autoantibodies to heart muscle-specific epitopes, Thus, Chlamydia-mediated heart disease is induced by antigenic mimicry of a heart muscle-specific protein.	Univ Toronto, Dept Med Biophys & Immunol, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Innsbruck, Sch Med, Dept Pediat, A-6020 Innsbruck, Austria; Univ Calif Irvine, Dept Pathol, Irvine, CA 92697 USA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Innsbruck; University of California System; University of California Irvine	Penninger, JM (corresponding author), Univ Toronto, Dept Med Biophys & Immunol, Toronto, ON M5G 2C1, Canada.	jpenning@amgen.com	Neu, Nikolaus/AAC-4056-2021; Penninger, Josef M/I-6860-2013; Bachmaier, Kurt/AHC-5491-2022; Bachmaier, Kurt/B-6331-2014	Penninger, Josef M/0000-0002-8194-3777; Bachmaier, Kurt/0000-0002-0299-2707; Bachmaier, Kurt/0000-0002-0299-2707				BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; Bachmaier K, 1997, CIRCULATION, V96, P585; Bachmaier K, 1996, J IMMUNOL, V157, P1752; BACHMAIER K, UNPUB; CAMPBELL LA, 1995, J INFECT DIS, V172, P585, DOI 10.1093/infdis/172.2.585; COLES AM, 1990, NUCLEIC ACIDS RES, V18, P6713, DOI 10.1093/nar/18.22.6713; COMANDUCCI M, 1990, PLASMID, V23, P149, DOI 10.1016/0147-619X(90)90034-A; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Darville T, 1998, Pediatr Rev, V19, P85, DOI 10.1542/pir.19-3-85; DELAMAZA LM, 1991, INFECT IMMUN, V59, P1196, DOI 10.1128/IAI.59.3.1196-1201.1991; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; Diaz F, 1997, SCAND J INFECT DIS, V29, P93, DOI 10.3109/00365549709008673; DONERMEYER DL, 1995, J EXP MED, V182, P1291, DOI 10.1084/jem.182.5.1291; Fong IW, 1997, J CLIN MICROBIOL, V35, P48, DOI 10.1128/JCM.35.1.48-52.1997; Gaydos CA, 1996, INFECT IMMUN, V64, P1614, DOI 10.1128/IAI.64.5.1614-1620.1996; GRAYSTON JT, 1993, EUR HEART J, V14, P66; GRAYSTON JT, 1981, JAMA-J AM MED ASSOC, V246, P2823, DOI 10.1001/jama.246.24.2823; Gupta S, 1997, CIRCULATION, V96, P404; Halme S, 1997, EUR HEART J, V18, P1095; Horwitz MS, 1998, NAT MED, V4, P781, DOI 10.1038/nm0798-781; Jackson LA, 1997, AM J PATHOL, V150, P1785; Janeway CA, 1998, IMMUNITY, V8, P391, DOI 10.1016/S1074-7613(00)80544-0; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; KUO CC, 1995, P NATL ACAD SCI USA, V92, P6911, DOI 10.1073/pnas.92.15.6911; Libby P, 1997, CIRCULATION, V96, P4095; Maass M, 1997, ANGIOLOGY, V48, P699, DOI 10.1177/000331979704800805; Maass M, 1998, J AM COLL CARDIOL, V31, P827, DOI 10.1016/S0735-1097(98)00016-3; Maclaren NK, 1997, MOL MED TODAY, V3, P76, DOI 10.1016/S1357-4310(96)10056-3; Matsusaka T, 1996, J CLIN INVEST, V98, P1867, DOI 10.1172/JCI118988; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; Miettinen H, 1996, EUR HEART J, V17, P682; Moazed TC, 1996, AM J PATHOL, V148, P667; Moazed TC, 1997, J INFECT DIS, V175, P883, DOI 10.1086/513986; Muhlestein JB, 1998, CIRCULATION, V97, P633, DOI 10.1161/01.CIR.97.7.633; Muhlestein JB, 1996, J AM COLL CARDIOL, V27, P1555, DOI 10.1016/0735-1097(96)00055-1; Munoz B, 1997, EPIDEMIOL REV, V19, P205, DOI 10.1093/oxfordjournals.epirev.a017953; NEU N, 1987, J IMMUNOL, V139, P3630; ODEH M, 1991, J INTERN MED, V229, P289, DOI 10.1111/j.1365-2796.1991.tb00347.x; Ohashi PS, 1996, CURR OPIN IMMUNOL, V8, P808, DOI 10.1016/S0952-7915(96)80009-4; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; Ossewaarde JM, 1998, EPIDEMIOL INFECT, V120, P93, DOI 10.1017/S0950268897008303; Pal S, 1997, INFECT IMMUN, V65, P3361, DOI 10.1128/IAI.65.8.3361-3369.1997; Pummerer CL, 1996, LAB INVEST, V74, P845; Pummerer CL, 1996, J CLIN INVEST, V97, P2057, DOI 10.1172/JCI118642; Quinn TC, 1996, JAMA-J AM MED ASSOC, V276, P1737, DOI 10.1001/jama.276.21.1737; Ramirez JA, 1996, ANN INTERN MED, V125, P979, DOI 10.7326/0003-4819-125-12-199612150-00008; Ridker PM, 1998, CIRCULATION, V97, P1671, DOI 10.1161/01.CIR.97.17.1671; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SMITH SC, 1992, P NATL ACAD SCI USA, V89, P9131, DOI 10.1073/pnas.89.19.9131; Stiegler H, 1998, LANCET, V351, P143, DOI 10.1016/S0140-6736(05)78113-7; Stokes T, 1997, J PUBLIC HEALTH MED, V19, P222, DOI 10.1093/oxfordjournals.pubmed.a024614; TONG CYW, 1995, LANCET, V346, P710, DOI 10.1016/S0140-6736(95)92327-6; vonHerrath MG, 1996, CURR OPIN IMMUNOL, V8, P878, DOI 10.1016/S0952-7915(96)80019-7; WATSON MW, 1994, MICROBIOL-SGM, V140, P2003, DOI 10.1099/13500872-140-8-2003; WATSON MW, 1990, NUCLEIC ACIDS RES, V18, P5299, DOI 10.1093/nar/18.17.5299; WATSON MW, 1990, NUCLEIC ACIDS RES, V18, P5300, DOI 10.1093/nar/18.17.5300; WESSLEN L, 1992, LANCET, V340, P427, DOI 10.1016/0140-6736(92)91509-7; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; ZABRISKIE JB, 1983, ADV EXP MED BIOL, V161, P457; Zhao ZS, 1998, SCIENCE, V279, P1344, DOI 10.1126/science.279.5355.1344	61	322	353	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 26	1999	283	5406					1335	1339		10.1126/science.283.5406.1335	http://dx.doi.org/10.1126/science.283.5406.1335			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037605				2022-12-28	WOS:000078839900044
J	Kollef, MH				Kollef, MH			Current concepts - The prevention of ventilator-associated pneumonia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HOSPITAL-ACQUIRED PNEUMONIA; CRITICALLY ILL PATIENTS; INTENSIVE-CARE UNITS; NOSOCOMIAL PNEUMONIA; MECHANICAL VENTILATION; ATTRIBUTABLE MORTALITY; FEBRILE NEUTROPENIA; CONTROLLED TRIAL; RISK-FACTORS; COLONIZATION		Washington Univ, Sch Med, Dept Internal Med, Div Pulm & Crit Care, St Louis, MO 63110 USA; Barnes Jewish Hosp, Med Intens Care Unit, St Louis, MO 63110 USA; Barnes Jewish Hosp, Dept Resp Care Serv, St Louis, MO 63110 USA	Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	Kollef, MH (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Pulm & Crit Care, Box 8052,660 S Euclid Ave, St Louis, MO 63110 USA.	mkollef@pulmonary.wustl.edu			PHS HHS [UR8/CCU715087] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOYCE JM, 1985, AM J INFECT CONTROL, V13, P228, DOI 10.1016/0196-6553(85)90063-X; Brewer C, 1996, CHEST, V109, P1019; COMETTA A, 1992, NEW ENGL J MED, V327, P234; Cook D, 1998, NEW ENGL J MED, V338, P791, DOI 10.1056/NEJM199803193381203; COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P308, DOI 10.1001/jama.275.4.308; CRAVEN DE, 1995, CHEST, V108, pS1, DOI 10.1378/chest.108.2_Supplement.1S; CRAVEN DE, 1984, AM REV RESPIR DIS, V129, P625; DELFAVERO A, 1991, ANN INTERN MED, V115, P7, DOI 10.7326/0003-4819-115-1-7; DeRiso A, 1996, CHEST, V109, P1556, DOI 10.1378/chest.109.6.1556; DJEDAINI K, 1995, AM J RESP CRIT CARE, V152, P1562, DOI 10.1164/ajrccm.152.5.7582295; DOEBBELING BN, 1992, NEW ENGL J MED, V327, P88, DOI 10.1056/NEJM199207093270205; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; GarrousteOrgeas M, 1997, AM J RESP CRIT CARE, V156, P1647, DOI 10.1164/ajrccm.156.5.96-04076; GASTINNE H, 1992, NEW ENGL J MED, V326, P594, DOI 10.1056/NEJM199202273260903; Gaynes RP, 1996, JOINT COMM J QUAL IM, V22, P457, DOI 10.1016/S1070-3241(16)30248-6; Goldmann DA, 1996, JAMA-J AM MED ASSOC, V275, P234, DOI 10.1001/jama.275.3.234; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; Hall JC, 1996, BRIT MED J, V312, P148; Herceg A, 1997, Commun Dis Intell, V21, P173; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; Joiner G A, 1996, Am J Med Qual, V11, P100, DOI 10.1177/0885713X9601100208; KELLEGHAN SI, 1993, AM J INFECT CONTROL, V21, P322, DOI 10.1016/0196-6553(93)90390-P; Kirton OC, 1997, CHEST, V112, P1055, DOI 10.1378/chest.112.4.1055; KLEIN BS, 1989, NEW ENGL J MED, V320, P1714, DOI 10.1056/NEJM198906293202603; Kollef MH, 1997, AM J RESP CRIT CARE, V156, P466, DOI 10.1164/ajrccm.156.2.9612083; KOLLEF MH, 1995, CHEST, V108, P1655, DOI 10.1378/chest.108.6.1655; Kollef MH, 1997, AM J RESP CRIT CARE, V156, P1040, DOI 10.1164/ajrccm.156.4.9701046; Kollef MH, 1998, CHEST, V113, P759, DOI 10.1378/chest.113.3.759; Kollef MH, 1998, CHEST, V113, P412, DOI 10.1378/chest.113.2.412; Kollef MH, 1998, CHEST, V113, P267, DOI 10.1378/chest.113.2.267; LEU HS, 1989, AM J EPIDEMIOL, V129, P1258, DOI 10.1093/oxfordjournals.aje.a115245; Luna CM, 1997, CHEST, V111, P676, DOI 10.1378/chest.111.3.676; MAHER DW, 1994, ANN INTERN MED, V121, P492, DOI 10.7326/0003-4819-121-7-199410010-00004; Mitchell PLR, 1997, J CLIN ONCOL, V15, P1163, DOI 10.1200/JCO.1997.15.3.1163; NIEDERMAN MS, 1990, CHEST, V97, P170, DOI 10.1378/chest.97.1.170; NIEDERMAN MS, 1989, CHEST, V95, P155, DOI 10.1378/chest.95.1.155; Niederman MS, 1997, CLIN INFECT DIS, V24, P320, DOI 10.1093/clinids/24.3.320; Papazian L, 1996, AM J RESP CRIT CARE, V154, P91, DOI 10.1164/ajrccm.154.1.8680705; PINGLETON SK, 1992, CHEST, V102, pS553, DOI 10.1378/chest.102.5_Supplement_1.553S; PIZZO PA, 1990, J HOSP INFECT, V15, P41, DOI 10.1016/0195-6701(90)90078-3; RELLO J, 1993, CHEST, V104, P1230, DOI 10.1378/chest.104.4.1230; Rello J, 1997, AM J RESP CRIT CARE, V156, P196, DOI 10.1164/ajrccm.156.1.9607030; Rello J, 1996, AM J RESP CRIT CARE, V154, P111, DOI 10.1164/ajrccm.154.1.8680665; ROUBY JJ, 1994, AM J RESP CRIT CARE, V150, P776, DOI 10.1164/ajrccm.150.3.8087352; RUMBAK MJ, 1995, CRIT CARE MED, V23, P1200, DOI 10.1097/00003246-199507000-00008; Russell AD, 1997, J APPL MICROBIOL, V83, P155, DOI 10.1046/j.1365-2672.1997.00198.x; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; TABLAN OC, 1994, INFECT CONT HOSP EP, V15, P588, DOI 10.1086/646989; TABLAN OC, 1998, INFECT CONT HOSP EP, V19, P304; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; TORRES A, 1995, AM J RESP CRIT CARE, V152, P137, DOI 10.1164/ajrccm.152.1.7599812; VALLES J, 1995, ANN INTERN MED, V122, P179, DOI 10.7326/0003-4819-122-3-199502010-00004	54	284	307	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1999	340	8					627	634		10.1056/NEJM199902253400807	http://dx.doi.org/10.1056/NEJM199902253400807			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	169NP	10029648				2022-12-28	WOS:000078755700007
J	Glass, C; Soni, B				Glass, C; Soni, B			ABC of sexual health - Sexual problems of disabled patients	BRITISH MEDICAL JOURNAL			English	Article									Southport Dist Gen Hosp, NW Reg Spinal Injuries Unit, Southport, England		Glass, C (corresponding author), Southport Dist Gen Hosp, NW Reg Spinal Injuries Unit, Southport, England.								0	24	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1999	318	7182					518	+		10.1136/bmj.318.7182.518	http://dx.doi.org/10.1136/bmj.318.7182.518			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QT	10024264	Green Published			2022-12-28	WOS:000078818100032
J	Hughes, JMB				Hughes, JMB			A memorable patient - 67 years on the national health	BRITISH MEDICAL JOURNAL			English	Article									Hammersmith Hosp, London, England	Imperial College London	Hughes, JMB (corresponding author), Hammersmith Hosp, London, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1999	318	7182					511	511		10.1136/bmj.318.7182.511	http://dx.doi.org/10.1136/bmj.318.7182.511			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QT	10024261	Green Published			2022-12-28	WOS:000078818100029
J	Bernstein, MP; Sandford, SA; Allamandola, LJ; Gillette, JS; Clemett, SJ; Zare, RN				Bernstein, MP; Sandford, SA; Allamandola, LJ; Gillette, JS; Clemett, SJ; Zare, RN			UV irradiation of polycyclic aromatic hydrocarbons in ices: Production of alcohols, quinones, and ethers	SCIENCE			English	Article							INTERPLANETARY DUST PARTICLES; INFRARED-SPECTROSCOPY; ABSORPTION FEATURES; MICRON SPECTRA; DENSE CLOUDS; INTERSTELLAR; MOLECULES; METEORITES; ANALOGS	Polycyclic aromatic hydrocarbons (PAHs) in water ice were exposed to ultraviolet (UV) radiation under astrophysical conditions, and the products were analyzed by infrared spectroscopy and mass spectrometry. Peripheral carbon atoms were oxidized, producing aromatic alcohols, ketones; and ethers, and reduced, producing partially hydrogenated aromatic hydrocarbons, molecules that account for the interstellar 3.4-micrometer emission feature. These classes of compounds are all present in carbonaceous meteorites. Hydrogen and deuterium atoms exchange readily between the PAHs and the ice, which may explain the deuterium enrichments found in certain meteoritic molecules. This work has important implications for extraterrestrial organics in biogenesis.	NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; SETI Inst, Mountain View, CA 94043 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Stanford University	Bernstein, MP (corresponding author), NASA, Ames Res Ctr, Mail Stop 245-6, Moffett Field, CA 94035 USA.	mbernstein@mail.arc.nasa.gov	Zare, Richard N./A-8410-2009	Zare, Richard/0000-0001-5266-4253				ALLAMANDOLA LJ, 1987, SCIENCE, V237, P56, DOI 10.1126/science.237.4810.56; ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; ALLAMANDOLA LJ, 1998, ASTRON ASTROPHYS, V339, P194; ALLAMANDOLA LJ, 1997, IAU C, V161, P23; Bernstein MP, 1996, ASTROPHYS J, V472, pL127, DOI 10.1086/310376; BERNSTEIN MP, 1995, ASTROPHYS J, V454, P327, DOI 10.1086/176485; Brooke TY, 1996, ASTROPHYS J, V459, P209, DOI 10.1086/176883; BROOKE TY, IN PRESS ASTROPHYS J; Clemett SJ, 1997, IAU SYMP, P305, DOI 10.1017/S0074180900009451; CLEMETT SJ, 1993, SCIENCE, V262, P721, DOI 10.1126/science.262.5134.721; CRONIN JR, 1993, GEOCHIM COSMOCHIM AC, V57, P4745, DOI 10.1016/0016-7037(93)90197-5; CRONIN JR, 1993, NATO ADV SCI INST SE, V416, P209; DALGARNO A, 1984, ASTROPHYS J, V287, pL47, DOI 10.1086/184395; Deamer DW, 1997, MICROBIOL MOL BIOL R, V61, P239, DOI 10.1128/.61.2.239-261.1997; Gerakines PA, 1996, ASTRON ASTROPHYS, V312, P289; HAHN JH, 1988, SCIENCE, V239, P1523, DOI 10.1126/science.239.4847.1523; HUDGINS DM, 1995, J PHYS CHEM-US, V99, P3033, DOI 10.1021/j100010a011; Irvine WM, 1998, ORIGINS LIFE EVOL B, V28, P365, DOI 10.1023/A:1006574110907; KERRIDGE JF, 1987, GEOCHIM COSMOCHIM AC, V51, P2527, DOI 10.1016/0016-7037(87)90303-6; McDonald GD, 1996, ICARUS, V122, P107, DOI 10.1006/icar.1996.0112; MCKEEGAN KD, 1985, GEOCHIM COSMOCHIM AC, V49, P1971, DOI 10.1016/0016-7037(85)90091-2; MENDOZAGOMEZ CX, 1995, ASTRON ASTROPHYS, V295, P479; MESSENGER S, 1995, METEORITICS, V30, P546; MESSENGER S, 1996, LPS, V27, P867; MOORE MH, 1983, ICARUS, V54, P388, DOI 10.1016/0019-1035(83)90236-1; MOREELS G, 1994, ASTRON ASTROPHYS, V282, P643; PRASAD SS, 1983, ASTROPHYS J, V267, P603, DOI 10.1086/160896; PUGET JL, 1989, ANNU REV ASTRON ASTR, V27, P161; Sandford SA, 1996, METEORIT PLANET SCI, V31, P449, DOI 10.1111/j.1945-5100.1996.tb02088.x; SANDFORD SA, 1993, ASTROPHYS J, V417, P815, DOI 10.1086/173362; SELLGREN K, 1995, ASTROPHYS J, V449, pL69, DOI 10.1086/309627; Sloan GC, 1997, ASTROPHYS J, V474, P735, DOI 10.1086/303484; STERNBERG A, 1987, ASTROPHYS J, V320, P676, DOI 10.1086/165585; STRAZZULLA G, 1995, PLANET SPACE SCI, V43, P1247, DOI 10.1016/0032-0633(95)00040-C; TEGLER SC, 1993, ASTROPHYS J, V411, P260, DOI 10.1086/172825; TIELENS AGGM, 1983, ASTRON ASTROPHYS, V119, P177; TIELENS AGGM, 1984, ASTROPHYS J, V287, P697, DOI 10.1086/162728; TIELENS AGGM, 1992, IAU SYMP, V150, P91; WARNECK P, 1962, APPL OPTICS, V1, P721, DOI 10.1364/AO.1.000721; Wexler AS, 1967, APPL SPECTROSC REV, V1, P29, DOI DOI 10.1080/05704926708547581; WHITTET DCB, 1988, MON NOT R ASTRON SOC, V233, P321, DOI 10.1093/mnras/233.2.321	41	319	325	5	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1135	1138		10.1126/science.283.5405.1135	http://dx.doi.org/10.1126/science.283.5405.1135			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024233				2022-12-28	WOS:000078738400042
J	Jenny, C; Hymel, KP; Ritzen, A; Reinert, SE; Hay, TC				Jenny, C; Hymel, KP; Ritzen, A; Reinert, SE; Hay, TC			Analysis of missed cases of abusive head trauma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SHAKEN BABY SYNDROME; CHILD-ABUSE; SHAKING; INJURY	Context Abusive head trauma (AHT) is a dangerous form of child abuse that can be difficult to diagnose in young children. Objectives To determine how frequently AHT was previously missed by physicians in a group of abused children with head injuries and to determine factors associated with the unrecognized diagnosis. Design Retrospective chart review of cases of head trauma presenting between January 1, 1990, and December 31, 1995. Setting Academic children's hospital. Patients One hundred seventy-three children younger than 3 years with head injuries caused by abuse. Main Outcome Measures Characteristics of head-injured children in whom diagnosis of AHT was unrecognized and the consequences of the missed diagnoses. Results Fifty-four (31.2%) of 173 abused children with head injuries had been seen by physicians after AHT and the diagnosis was not recognized. The mean time to correct diagnosis among these children was 7 days (range, 0-189 days). Abusive head trauma was more likely to be unrecognized in very young white children from intact families and in children without respiratory compromise or seizures. In 7 of the children with unrecognized AHT, misinterpretation of radiological studies contributed to the delay in diagnosis. Fifteen children (27.8%) were reinjured after the missed diagnosis. Twenty-two (40.7%) experienced medical complications related to the missed diagnosis. Four of 5 deaths in the group with unrecognized AHT might have been prevented by earlier recognition of abuse. Conclusion Although diagnosing head trauma can be difficult in the absence of a history, it is important to consider inflicted head trauma in infants and young children presenting with nonspecific clinical signs.	Brown Univ, Sch Med, Dept Pediat, Providence, RI 02912 USA; Lifespan Med Comp, Providence, RI USA; Natl Naval Med Ctr, Dept Pediat, Bethesda, MD USA; Univ Oregon, Hlth Sci Ctr, Dept Pediat, Portland, OR USA; Univ Colorado, Sch Med, Dept Radiol, Denver, CO USA	Brown University; Walter Reed National Military Medical Center; University of Oregon; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Jenny, C (corresponding author), Hasbo Childrens Hosp, MOC-140,593 Eddy St, Providence, RI 02903 USA.			Hymel, Kent/0000-0002-1422-182X				ALEXANDER R, 1990, AM J DIS CHILD, V144, P724, DOI 10.1001/archpedi.1990.02150300124032; ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; BENZEL EC, 1989, SOUTHERN MED J, V82, P1347, DOI 10.1097/00007611-198911000-00005; Bureau of the Census, 1991, 1990 CENS POP HOUS S; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; DIAMOND P, 1994, PEDIATR EMERG CARE, V10, P83, DOI 10.1097/00006565-199404000-00005; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HOSMER DW, 1989, APPL LOGISTIC REGRES; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; JACKSON G, 1972, BRIT MED J, V2, P756, DOI 10.1136/bmj.2.5816.756; KORTBEEK LHTS, 1979, CLIN NEUROL NEUROSUR, V81, P265, DOI 10.1016/0303-8467(79)90031-3; Levitt CJ, 1994, CHILD ABUSE MED DIAG, P1; ONEILL JA, 1973, J TRAUMA, V13, P332, DOI 10.1097/00005373-197304000-00012; RESURRECCION EC, 1972, ANGIOLOGY, V23, P105, DOI 10.1177/000331977202300206; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; SMITH WL, 1992, PEDIATRICS, V89, P332; SPEAR RM, 1992, AM J DIS CHILD, V146, P1415, DOI 10.1001/archpedi.1992.02160240025007; STARLING SP, 1995, PEDIATRICS, V95, P259; WEDGEWOOD J, 1990, PRACTITIONER, V234, P598	22	705	709	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1999	281	7					621	626		10.1001/jama.281.7.621	http://dx.doi.org/10.1001/jama.281.7.621			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	165YA	10029123	Bronze			2022-12-28	WOS:000078548400032
J	Fanto, M; Mlodzik, M				Fanto, M; Mlodzik, M			Asymmetric Notch activation specifies photoreceptors R3 and R4 and planar polarity in the Drosophila eye	NATURE			English	Article							CELL FATES; TISSUE POLARITY; EXPRESSION; GENE; RECEPTOR; COMPLEX; MEMBER	Planar polarity is seen in epidermally derived structures throughout the animal kingdom(1,2). In the Drosophila eye, planar polarity is reflected in the mirror-symmetric arrangement of ommatidia (eye units) across the dorsoventral midline or equator; ommatidia on the dorsal and ventral sides of the equator exhibit opposite chirality(3-5). Photoreceptors R3 and R4 are essential in the establishment of the polarity of ommatidia(6-11). The R3 cell is thought to receive the polarizing signal, through the receptor Frizzled (Fz), before or at higher levels then the R4 cell, generating a difference between neighbouring R3 and R4 cells(6,7,9,10). Both loss-of-function and overexpression of Fz in the R3/R4 pair result in polarity defects and loss of mirror-image symmetry(6,7,9,10,12). Here we identify Notch and Delta (Dl) as dominant enhancers of the phenotypes produced by overexpression of fz and dishevelled (dsh), which encodes a signalling component downstream of Fz, and we show that Dl-mediated activation of Notch is required for establishment of ommatidial polarity. Whereas fz signalling is required to specify R3, Notch signalling induces the R4 fate. Our data indicate that Dl is a transcriptional target of Fz/Dsh signalling in R3, and activates Notch in the neighbouring R4 precursor. This two-tiered mechanism explains how small differences in the level and/or timing of Fz activation reliably generate a binary cell-fate decision, leading to specification of R3 and R4 and ommatidial chirality.	European Mol Biol Lab, Dev Biol Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Mlodzik, M (corresponding author), European Mol Biol Lab, Dev Biol Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Fanto, Manolis/C-5618-2009					ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Baker NE, 1996, CURR BIOL, V6, P1290, DOI 10.1016/S0960-9822(02)70715-X; BAKER NE, 1995, MECH DEVELOP, V49, P173, DOI 10.1016/0925-4773(94)00314-D; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; Chen CWJ, 1997, DEV BIOL, V188, P181, DOI 10.1006/dbio.1997.8643; Cho KO, 1998, NATURE, V396, P272, DOI 10.1038/24394; Dominguez M, 1998, NATURE, V396, P276, DOI 10.1038/24402; Fanto M, 1998, MECH DEVELOP, V74, P51, DOI 10.1016/S0925-4773(98)00063-X; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GUBB D, 1993, DEVELOPMENT, P269; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; Papayannopoulos V, 1998, SCIENCE, V281, P2031, DOI 10.1126/science.281.5385.2031; PARKS AL, 1995, MECH DEVELOP, V50, P201, DOI 10.1016/0925-4773(94)00336-L; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; THEISEN H, 1994, DEVELOPMENT, V120, P347; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; Tomlinson A, 1997, DEVELOPMENT, V124, P4515; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; Wolff T, 1998, DEVELOPMENT, V125, P1149; Wolff Tanya, 1993, P1277; ZHENG L, 1995, DEVELOPMENT, V121, P3045	29	172	172	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 11	1999	397	6719					523	526		10.1038/17389	http://dx.doi.org/10.1038/17389			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KN	10028968				2022-12-28	WOS:000078574900050
J	Mayers, D				Mayers, D			Maintenance antiretroviral treatment in HIV infection - Abstract and commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ZIDOVUDINE		Henry Ford Hosp, Div Infect Dis, Detroit, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital	Mayers, D (corresponding author), Henry Ford Hosp, Div Infect Dis, Detroit, MI 48202 USA.							Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hall DB, 1998, AIDS, V12, pF41, DOI 10.1097/00002030-199807000-00001; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; HAVLIR DV, 1998, 2 INT WORKSH HIV DRU; MCLEAN AR, 1992, AIDS, V6, P71, DOI 10.1097/00002030-199201000-00009; MCLEAN AR, 1998, 2 INT WORKSH HIV DRU; Pialoux G, 1998, NEW ENGL J MED, V339, P1269, DOI 10.1056/NEJM199810293391802; Reijers MHE, 1998, LANCET, V352, P185, DOI 10.1016/S0140-6736(98)06193-5	8	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1999	281	6					497	498		10.1001/jama.281.6.497	http://dx.doi.org/10.1001/jama.281.6.497			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164FQ	10022089				2022-12-28	WOS:000078452900003
J	Kambach, C; Walke, S; Young, R; Avis, JM; de la Fortelle, E; Raker, VA; Luhrmann, R; Li, J; Nagai, K				Kambach, C; Walke, S; Young, R; Avis, JM; de la Fortelle, E; Raker, VA; Luhrmann, R; Li, J; Nagai, K			Crystal structures of two Sm protein complexes and their implications for the assembly of the spliceosomal snRNPs	CELL			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEINS; YEAST TFIIA/TBP/DNA COMPLEX; ELECTRON-MICROSCOPY; CORE PROTEIN; U SNRNPS; IN-VITRO; RNA; BINDING; DOMAIN; CAP	The U1, U2, U4/U6, and U5 small nuclear ribonucleoprotein particles (snRNPs) involved in pre-mRNA splicing contain seven Sm proteins (B/B', D-1, D-2, D-3, E, F, and G) in common, which assemble around the Sm site present in four of the major spliceosomal small nuclear RNAs (snRNAs). These proteins share a common sequence motif in two segments, Sm1 and Sm2, separated by a short variable linker. Crystal structures of two Sm protein complexes, D3B and D1D2, show that these proteins have a common fold containing an N-terminal helix followed by a strongly bent five-stranded antiparallel beta sheet, and the D1D2 and D3B dimers superpose closely in their core regions, including the dimer interfaces. The crystal structures suggest that the seven Sm proteins could form a closed ring and the snRNAs may be bound in the positively charged central hole.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany	MRC Laboratory Molecular Biology; Philipps University Marburg	Nagai, K (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	kn@mrc-imb.cam.ac.uk						Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; Baserga S., 1993, RNA WORLD, P359; Bordonne R, 1996, GENE, V176, P111, DOI 10.1016/0378-1119(96)00230-2; Camasses A, 1998, MOL CELL BIOL, V18, P1956, DOI 10.1128/MCB.18.4.1956; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CECH TR, 1985, CELL, V43, P713; CHU JL, 1991, GENE, V97, P311; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dodson EJ, 1997, METHOD ENZYMOL, V277, P620, DOI 10.1016/S0076-6879(97)77034-4; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FEENEY RJ, 1989, J BIOL CHEM, V264, P5776; FISCHER U, 1993, EMBO J, V12, P573, DOI 10.1002/j.1460-2075.1993.tb05689.x; FISHER DE, 1985, CELL, V42, P751, DOI 10.1016/0092-8674(85)90271-5; FRANK DN, 1994, MOL CELL BIOL, V14, P2180, DOI 10.1128/MCB.14.3.2180; Fury MG, 1997, EXP CELL RES, V237, P63, DOI 10.1006/excr.1997.3750; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; Hartmuth K, 1999, J MOL BIOL, V285, P133, DOI 10.1006/jmbi.1998.2300; HEINRICHS V, 1992, J MOL BIOL, V227, P15, DOI 10.1016/0022-2836(92)90678-D; HERMANN H, 1995, EMBO J, V14, P2076, DOI 10.1002/j.1460-2075.1995.tb07199.x; Huber J, 1998, EMBO J, V17, P4114, DOI 10.1093/emboj/17.14.4114; IKEMURA T, 1982, J MOL BIOL, V158, P573, DOI 10.1016/0022-2836(82)90250-9; JONES TA, 1994, MANUAL; KASTNER B, 1990, P NATL ACAD SCI USA, V87, P1710, DOI 10.1073/pnas.87.5.1710; KASTNER B, 1992, J CELL BIOL, V116, P839, DOI 10.1083/jcb.116.4.839; LEHMEIER T, 1994, P NATL ACAD SCI USA, V91, P12317, DOI 10.1073/pnas.91.25.12317; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; Lo Conte L, 1999, J MOL BIOL, V285, P2177; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; Moore M., 1993, RNA WORLD, P303; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NAGAI K, 1994, RNA PROTEIN INTERACT, P150; NELISSEN RLH, 1994, EMBO J, V13, P4113, DOI 10.1002/j.1460-2075.1994.tb06729.x; Newman AJ, 1997, EMBO J, V16, P5797, DOI 10.1093/emboj/16.19.5797; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Palacios I, 1997, EMBO J, V16, P6783, DOI 10.1093/emboj/16.22.6783; Plessel G, 1997, J MOL BIOL, V265, P87, DOI 10.1006/jmbi.1996.0713; PLESSEL G, 1994, MOL CELL BIOL, V14, P4160, DOI 10.1128/MCB.14.6.4160; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SHELDRICK GM, 1991, ISOMORPHOUS REPLACEM, P23; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Tarn WY, 1997, TRENDS BIOCHEM SCI, V22, P132, DOI 10.1016/S0968-0004(97)01018-9; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; VANDAM A, 1989, EMBO J, V8, P3853, DOI 10.1002/j.1460-2075.1989.tb08563.x; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9	57	371	385	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 5	1999	96	3					375	387		10.1016/S0092-8674(00)80550-4	http://dx.doi.org/10.1016/S0092-8674(00)80550-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025403	Bronze			2022-12-28	WOS:000078514600010
J	Wei, M; Gibbons, LW; Mitchell, TL; Kampert, JB; Lee, CD; Blair, SN				Wei, M; Gibbons, LW; Mitchell, TL; Kampert, JB; Lee, CD; Blair, SN			The association between cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes mellitus in men	ANNALS OF INTERNAL MEDICINE			English	Article						diabetes mellitus, non-insulin-dependent; physical fitness; blood glucose; age factors; body mass index	ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; MEXICAN-AMERICANS; RISK-FACTORS; CARDIOVASCULAR-DISEASE; EXERCISE; NIDDM; WOMEN; HYPERGLYCEMIA; HYPERTENSION	Background: Several studies show an inverse association between, self-reported physical activity and type 2 diabetes. It is not known whether physical activity or cardiorespiratory fitness is associated with the onset of objectively determined impaired fasting glucose and type 2 diabetes. Objective: To determine whether cardiorespiratory fitness, an objective marker of physical activity, is associated with risk for impaired fasting glucose and type 2 diabetes. Design: Population-based prospective study. Setting: Preventive medicine clinic. Patients: 8633 nondiabetic men (of whom 7511 did not have impaired fasting glucose) who were examined at least twice. Measurements: Cardiorespiratory fitness (determined by a maximal exercise test on a treadmill), fasting plasma glucose level, and other clinical and personal characteristics and incidence of impaired tasting glucose and type 2 diabetes. Results: During an average follow-up of 6 years, 249 patients developed type 2 diabetes and 593 patients developed impaired fasting glucose. After age, cigarette smoking, alcohol consumption, and parental diabetes were considered, men in the low-fitness group (the least fit 20% of the cohort) at baseline had a 1.9-fold risk (95% CI, 1.5- to 2.4-fold) for impaired fasting glucose and a 3.7-fold risk (CI, 2.4- to 5.8-fold) for diabetes compared with those in the high-fitness group (the most fit 40% of the cohort). The risk for impaired fasting glucose was elevated in older men and those with a higher body mass index. Age, body mass index, blood pressure, triglyceride level, and a history of parental diabetes were also directly related to risk for type 2 diabetes. Conclusions: Low cardiorespiratory fitness was associated with increased risk for impaired fasting glucose and type 2 diabetes. A sedentary lifestyle may contribute to the progression from normal fasting glucose to impaired fasting glucose and diabetes. Risk for type 2 diabetes was elevated in older persons and those with higher body mass index, blood pressure, and triglyceride levels and a parental history of diabetes.	Cooper Inst Aerob Res, Dallas, TX 75230 USA; Cooper Clin, Dallas, TX 75230 USA	Cooper Institute; Cooper Institute	Wei, M (corresponding author), Cooper Inst Aerob Res, 12330 Preston Rd, Dallas, TX 75230 USA.	mwei@cooperinst.org			NATIONAL INSTITUTE ON AGING [R01AG006945, R37AG006945] Funding Source: NIH RePORTER; NIA NIH HHS [AG06945] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM COLL SPORTS ME, 1990, MED SCI SPORTS EXERC, V20, P265; BALKE B, 1959, U S Armed Forces Med J, V10, P675; Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205; BLAIR SN, 1984, JAMA-J AM MED ASSOC, V252, P487, DOI 10.1001/jama.252.4.487; BLAIR SN, 1989, AM J EPIDEMIOL, V129, P1145, DOI 10.1093/oxfordjournals.aje.a115236; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BOGARDUS C, 1984, DIABETES, V33, P311, DOI 10.2337/diabetes.33.4.311; Bouchard C., 1994, PHYSICAL ACTIVITY FI, P106; BURCHFIEL CM, 1995, AM J EPIDEMIOL, V141, P360, DOI 10.1093/aje/141.4.360; CHARLES MA, 1991, DIABETES, V40, P796, DOI 10.2337/diabetes.40.7.796; Charles MA, 1996, LANCET, V348, P1657, DOI 10.1016/S0140-6736(05)65719-4; Eriksson KF, 1996, DIABETOLOGIA, V39, P573, DOI 10.1007/BF00403304; Gavin JR, 1997, DIABETES CARE, V20, P1183; Ghosh S, 1996, DIABETES, V45, P1, DOI 10.2337/diabetes.45.1.1; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; Host HH, 1998, J APPL PHYSIOL, V84, P798, DOI 10.1152/jappl.1998.84.3.798; KLEIN R, 1995, DIABETES CARE, V18, P258, DOI 10.2337/diacare.18.2.258; LAPORTE RE, 1995, DIABETES AM, P37; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; LIPTON RB, 1993, AM J EPIDEMIOL, V138, P826, DOI 10.1093/oxfordjournals.aje.a116786; Lowe LP, 1997, DIABETES CARE, V20, P163, DOI 10.2337/diacare.20.2.163; Lynch J, 1996, ARCH INTERN MED, V156, P1307, DOI 10.1001/archinte.156.12.1307; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; Mayer-Davis EJ, 1998, JAMA-J AM MED ASSOC, V279, P669, DOI 10.1001/jama.279.9.669; McCance DR, 1997, DIABETOLOGIA, V40, P247, DOI 10.1007/s001250050671; MONTERROSA AE, 1995, DIABETES CARE, V18, P448, DOI 10.2337/diacare.18.4.448; Nyholm B, 1996, DIABETOLOGIA, V39, P813, DOI 10.1007/s001250050515; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PERRY IJ, 1995, BRIT MED J, V310, P560, DOI 10.1136/bmj.310.6979.560; Perseghin G, 1996, NEW ENGL J MED, V335, P1357, DOI 10.1056/NEJM199610313351804; POLLOCK ML, 1976, AM HEART J, V92, P39, DOI 10.1016/S0002-8703(76)80401-2; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; *SAS I, 1996, SAS PROC GUID VERS 6; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Wei M, 1996, AM J EPIDEMIOL, V144, P1058, DOI 10.1093/oxfordjournals.aje.a008878; Wei M, 1998, DIABETES CARE, V21, P1167, DOI 10.2337/diacare.21.7.1167; Wei M, 1997, J CLIN EPIDEMIOL, V50, P1137, DOI 10.1016/S0895-4356(97)00150-9; Wei M, 1997, OBES RES, V5, P16, DOI 10.1002/j.1550-8528.1997.tb00278.x; WEI M, 1998, CVD PREV, V1, P123; WILSON JD, 1992, WILLIAMS TXB ENDOCRI, P1255; WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801	45	299	307	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	1999	130	2					89	+		10.7326/0003-4819-130-2-199901190-00002	http://dx.doi.org/10.7326/0003-4819-130-2-199901190-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158KG	10068380				2022-12-28	WOS:000078114200001
J	Raju, TNJ				Raju, TNJ			The Nobel chronicles	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNJ (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 9	1999	353	9147					157	157		10.1016/S0140-6736(05)76205-X	http://dx.doi.org/10.1016/S0140-6736(05)76205-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023935				2022-12-28	WOS:000078087200069
J	Stein, K; Allen, N				Stein, K; Allen, N			Cross sectional survey of cervical cancer screening in women with learning disability	BRITISH MEDICAL JOURNAL			English	Article									Southampton & SW Hants Hlth Author, Southampton SO16 4GX, Hants, England		Stein, K (corresponding author), Univ Southampton, Inst Hlth Res & Dev, Boldrewood, Southampton SO15 2GS, Hants, England.							ALLEN N, 1994, ANN REPORT DIRECTOR; BEAIL N, 1995, J INTELL DISABIL RES, V39, P382, DOI 10.1111/j.1365-2788.1995.tb00542.x; HAIRE AR, 1992, BR J FAM PLAN, V17, P120; Reid D, 1995, BR J LEARN DISABIL, V23, P56; *ROYAL COLL GEN PR, 1990, 47 RCGP	5	22	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					641	641		10.1136/bmj.318.7184.641	http://dx.doi.org/10.1136/bmj.318.7184.641			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066206	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000079089200029
J	Collerson, KD; Kamber, BS				Collerson, KD; Kamber, BS			Evolution of the continents and the atmosphere inferred from Th-U-Nb systematics of the depleted mantle	SCIENCE			English	Article							ABITIBI GREENSTONE-BELT; OCEANIC-CRUST; ISOTOPIC DATA; RIVER WATER; ISLAND-ARC; SM-ND; GEOCHEMISTRY; BASALTS; EARTH; PB	Temporal evolution of depleted mantle thorium-uranium-niobium systematics constrain the amount of continental crust present through Earth's history (through the niobium/thorium ratio) and date formation of a globally oxidizing atmosphere and hydrosphere at approximately 2.0 billion years ago (through the niobium/uranium ratio). increase in the niobium/thorium ratio shows involvement of hydrated lithosphere in differentiation of Earth since approximately 3.8 billion years ago. After approximately 2.0 billion years ago, the decreasing mantle thorium/uranium ratio portrays mainly preferential recycling of uranium in an oxidizing atmosphere and hydrosphere. Net growth rate of continental crust has varied over time, and continents are still growing today.	Univ Queensland, Dept Earth Sci, Brisbane, Qld 4072, Australia	University of Queensland	Collerson, KD (corresponding author), Univ Queensland, Dept Earth Sci, Brisbane, Qld 4072, Australia.		Kamber, Balz S/A-1823-2008	Kamber, Balz S/0000-0002-8720-0608				ALLEGRE CJ, 1989, EARTH PLANET SC LETT, V96, P61, DOI 10.1016/0012-821X(89)90124-6; ANDERSSON PS, 1995, EARTH PLANET SC LETT, V130, P217, DOI 10.1016/0012-821X(94)00262-W; ARMSTRONG RL, 1981, PHILOS T R SOC A, V301, P443, DOI 10.1098/rsta.1981.0122; ARNDT NT, 1994, CHEM GEOL, V118, P9, DOI 10.1016/0009-2541(94)90167-8; ASMEROM Y, 1993, EARTH PLANET SC LETT, V115, P245, DOI 10.1016/0012-821X(93)90225-X; Ayer JA, 1997, PRECAMBRIAN RES, V81, P155, DOI 10.1016/S0301-9268(96)00033-2; Ayers J, 1998, CONTRIB MINERAL PETR, V132, P390, DOI 10.1007/s004100050431; BRENAN JM, 1994, EARTH PLANET SC LETT, V128, P327, DOI 10.1016/0012-821X(94)90154-6; COLLERSON KD, UNPUB; CONDIE KC, 1993, CHEM GEOL, V104, P1, DOI 10.1016/0009-2541(93)90140-E; DOSTAL J, 1994, PRECAMBRIAN RES, V65, P55, DOI 10.1016/0301-9268(94)90099-X; Dostal J, 1997, J GEOL, V105, P545, DOI 10.1086/515956; DOSTAL J, 1994, GEOL MAG, V131, P243, DOI 10.1017/S0016756800010761; DUNCAN IJ, 1985, J GEODYN, V2, P1, DOI 10.1016/0264-3707(85)90029-8; Fan J, 1997, GEOCHIM COSMOCHIM AC, V61, P4723, DOI 10.1016/S0016-7037(97)00269-X; GALER SJG, 1985, NATURE, V316, P778, DOI 10.1038/316778a0; GOLDSTEIN SL, 1984, EARTH PLANET SC LETT, V70, P221, DOI 10.1016/0012-821X(84)90007-4; Gutzmer J, 1998, GEOLOGY, V26, P263, DOI 10.1130/0091-7613(1998)026<0263:ELAPEF>2.3.CO;2; HOFMANN AW, 1986, EARTH PLANET SC LETT, V79, P33, DOI 10.1016/0012-821X(86)90038-5; HOFMANN AW, 1988, EARTH PLANET SC LETT, V90, P297, DOI 10.1016/0012-821X(88)90132-X; ISLEY AE, 1995, J GEOL, V103, P169, DOI 10.1086/629734; JOCHUM KP, 1991, EARTH PLANET SC LETT, V107, P272, DOI 10.1016/0012-821X(91)90076-T; Kamber BS, 1998, CHEM GEOL, V150, P19, DOI 10.1016/S0009-2541(98)00059-X; Keppie JD, 1998, GEOL MAG, V135, P171, DOI 10.1017/S0016756898008322; Kramers JD, 1997, CHEM GEOL, V139, P75, DOI 10.1016/S0009-2541(97)00027-2; Kramers JD, 1998, SCHWEIZ MINER PETROG, V78, P169; LAHAYE Y, 1995, CHEM GEOL, V126, P43, DOI 10.1016/0009-2541(95)00102-1; Lee KS, 1998, PRECAMBRIAN RES, V89, P47, DOI 10.1016/S0301-9268(97)00077-6; Leybourne MI, 1997, J PETROL, V38, P1541, DOI 10.1093/petrology/38.11.1541; Mahoney JJ, 1998, J PETROL, V39, P1285, DOI 10.1093/petrology/39.7.1285; Mathieu D, 1995, EARTH PLANET SC LETT, V136, P703, DOI 10.1016/0012-821X(95)00199-M; MCCULLOCH MT, 1993, EARTH PLANET SC LETT, V115, P89, DOI 10.1016/0012-821X(93)90215-U; Nagler TF, 1998, PRECAMBRIAN RES, V91, P233, DOI 10.1016/S0301-9268(98)00051-5; Ohta H, 1996, LITHOS, V37, P199, DOI 10.1016/0024-4937(95)00037-2; Peltonen P, 1996, J PETROL, V37, P1359, DOI 10.1093/petrology/37.6.1359; Puchtel IS, 1998, CONTRIB MINERAL PETR, V130, P134, DOI 10.1007/s004100050355; PYLE DG, 1995, J GEOPHYS RES-SOL EA, V100, P22261, DOI 10.1029/95JB01424; REYMER A, 1984, TECTONICS, V3, P63, DOI 10.1029/TC003i001p00063; Stalder R, 1998, GEOCHIM COSMOCHIM AC, V62, P1781, DOI 10.1016/S0016-7037(98)00101-X; STAUDIGEL H, 1995, EARTH PLANET SC LETT, V130, P169, DOI 10.1016/0012-821X(94)00263-X; STERN RA, 1995, GEOCHIM COSMOCHIM AC, V59, P3131, DOI 10.1016/0016-7037(95)00202-B; Sylvester PJ, 1997, SCIENCE, V275, P521, DOI 10.1126/science.275.5299.521; TAYLOR SR, 1995, REV GEOPHYS, V33, P241, DOI 10.1029/95RG00262; Tomlinson KY, 1998, PRECAMBRIAN RES, V89, P59, DOI 10.1016/S0301-9268(97)00078-8; WILSON AH, 1989, EARTH PLANET SC LETT, V96, P89, DOI 10.1016/0012-821X(89)90125-8; XIE Q, 1993, GEOCHIM COSMOCHIM AC, V57, P4111, DOI 10.1016/0016-7037(93)90357-3; ZARTMAN RE, 1988, GEOCHIM COSMOCHIM AC, V52, P1327, DOI 10.1016/0016-7037(88)90204-9; ZIMMER M, 1995, CHEM GEOL, V123, P29, DOI 10.1016/0009-2541(95)00018-H	48	178	189	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	1999	283	5407					1519	1522		10.1126/science.283.5407.1519	http://dx.doi.org/10.1126/science.283.5407.1519			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066171				2022-12-28	WOS:000078959200043
J	Inouye, SK; Bogardus, ST; Charpentier, PA; Leo-Summers, L; Acampora, D; Holford, TR; Cooney, LW				Inouye, SK; Bogardus, ST; Charpentier, PA; Leo-Summers, L; Acampora, D; Holford, TR; Cooney, LW			A multicomponent intervention to prevent delirium in hospitalized older patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CLINICAL-TRIAL; ACUTE CONFUSIONAL STATES; ELDERLY MEDICAL PATIENTS; MINI-MENTAL STATE; PREDICTIVE MODEL; PROGNOSIS; SELECTION; FRACTURES; RECOVERY; PROGRAM	Background Since in hospitalized older patients delirium is associated with poor outcomes, we evaluated the effectiveness of a multicomponent strategy for the prevention of delirium. Methods We studied 852 patients 70 years of age or older who had been admitted to the general-medicine service at a teaching hospital. Patients from one intervention unit and two usual-care units were enrolled by means of a prospective matching strategy. The intervention consisted of standardized protocols for the management of six risk factors for delirium: cognitive impairment, sleep deprivation, immobility, visual impairment, hearing impairment, and dehydration. Delirium, the primary outcome, was assessed daily until discharge. Results Delirium developed in 9.9 percent of the intervention group, as compared with 15.0 percent of the usual-care group (matched odds ratio, 0.60; 95 percent confidence interval, 0.39 to 0.92). The total number of days with delirium (105 vs. 161, P=0.02) and the total number of episodes (62 vs. 90, P=0.03) were significantly lower in the intervention group. However, the severity of delirium and recurrence rates were not significantly different. The overall rate of adherence to the intervention was 87 percent, and the total number of targeted risk factors per patient was significantly reduced. Intervention was associated with significant improvement in the degree of cognitive impairment among patients with cognitive impairment at admission and with a significant reduction in the rate of use of sleep medications among all patients. Among the other risk factors, there were trends toward improvement in immobility, visual impairment, and hearing impairment. Conclusions The risk-factor intervention strategy that we studied resulted in significant reductions in the number and duration of episodes of delirium in hospitalized older patients. The intervention had no significant effect on the severity of delirium or on recurrence rates; this finding suggests that primary prevention of delirium is probably the most effective treatment strategy. (N Engl J Med 1999;340:669-76.) (C) 1999, Massachusetts Medical Society.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06504 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06504 USA	Yale University; Yale University	Inouye, SK (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 20 York St,Tompkins 15, New Haven, CT 06504 USA.		Inouye, Sharon/R-7216-2019		NATIONAL INSTITUTE ON AGING [R01AG012551] Funding Source: NIH RePORTER; NIA NIH HHS [R01AG12551] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*ADM AG, 1995, PROF OLD AM; Beresin E V, 1988, J Geriatr Psychiatry Neurol, V1, P127, DOI 10.1177/089198878800100302; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BUDD S, 1974, NURS RES, V23, P341; CHARPENTIER PA, 1995, GERONTOLOGIST, V35, P181; CHATHAM MA, 1978, HEART LUNG, V7, P995; COLE MG, 1994, CAN MED ASSOC J, V151, P965; COLE MG, 1993, CAN MED ASSOC J, V149, P41; COLE MG, 1991, J AM GERIATR SOC, V39, P1183, DOI 10.1111/j.1532-5415.1991.tb03572.x; CUMMINGS JL, 1985, CLIN NEUROPSYCHIATRY, P9; Elie M, 1998, J GEN INTERN MED, V13, P204, DOI 10.1046/j.1525-1497.1998.00047.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANCIS J, 1990, J GEN INTERN MED, V5, P65, DOI 10.1007/BF02602312; GREENLAND S, 1989, AM J EPIDEMIOL, V130, P1066, DOI 10.1093/oxfordjournals.aje.a115409; GUSTAFSON Y, 1991, J AM GERIATR SOC, V39, P655, DOI 10.1111/j.1532-5415.1991.tb03618.x; HALL JP, 1988, MED J AUSTRALIA, V148, P271; HOBBS FB, 1996, CURRENT POPULATI P23, V190; HOGAN DB, 1987, CAN MED ASSOC J, V136, P713; HOLFORD TR, 1989, AM J EPIDEMIOL, V130, P1247, DOI 10.1093/oxfordjournals.aje.a115453; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; INOUYE SK, 1994, AM J MED, V97, P278, DOI 10.1016/0002-9343(94)90011-6; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Inouye SK, 1998, J GEN INTERN MED, V13, P234, DOI 10.1046/j.1525-1497.1998.00073.x; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LAYNE OL, 1971, NEW ENGL J MED, V284, P518, DOI 10.1056/NEJM197103112841003; LYNN HS, 1992, BIOMETRICS, V48, P397, DOI 10.2307/2532299; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; Makuch RW, 1998, STAT MED, V17, P1517, DOI 10.1002/(SICI)1097-0258(19980715)17:13<1517::AID-SIM859>3.0.CO;2-0; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Nagley S J, 1986, J Gerontol Nurs, V12, P27; OWENS JF, 1982, NURS RES, V31, P60; RIIS J, 1983, ACTA ANAESTH SCAND, V27, P44, DOI 10.1111/j.1399-6576.1983.tb01903.x; Rizzo JA, 1996, MED CARE, V34, P954, DOI 10.1097/00005650-199609000-00007; RUBENSTEIN LZ, 1984, NEW ENGL J MED, V311, P1664, DOI 10.1056/NEJM198412273112604; RUMMANS TA, 1995, MAYO CLIN PROC, V70, P989, DOI 10.4065/70.10.989; SCHINDLER BA, 1989, GEN HOSP PSYCHIAT, V11, P358, DOI 10.1016/0163-8343(89)90124-2; UHLMANN RF, 1987, J GERONTOL, V42, P33, DOI 10.1093/geronj/42.1.33; *US BUR CENS, 1996, STAT ABSTR US 1996, P116; Wanich C K, 1992, Image J Nurs Sch, V24, P201; WILLIAMS MA, 1985, RES NURS HEALTH, V8, P329, DOI 10.1002/nur.4770080405; WILLIAMSRUSSO P, 1992, J AM GERIATR SOC, V40, P759, DOI 10.1111/j.1532-5415.1992.tb01846.x	45	1704	1753	3	98	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1999	340	9					669	676		10.1056/NEJM199903043400901	http://dx.doi.org/10.1056/NEJM199903043400901			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	172ZB	10053175	Green Published			2022-12-28	WOS:000078955200001
J	Tuomilehto, J; Rastenyte, D; Birkenhager, WH; Thijs, L; Antikainen, R; Bulpitt, CJ; Fletcher, AE; Forette, F; Goldhaber, A; Palatini, P; Sarti, C; Fagard, R; Staessen, JA; Arabidze, GG; Carrageta, M; Celis, H; Kocemba, J; Leonetti, G; Nachev, C; O'Brien, ET; Ritz, E; Rodicio, JL; Rosenfeld, J; Heyrman, J; Stibbe, G; Van den Haute, H; Yodfat, Y; De Cort, P; Hubner, GE				Tuomilehto, J; Rastenyte, D; Birkenhager, WH; Thijs, L; Antikainen, R; Bulpitt, CJ; Fletcher, AE; Forette, F; Goldhaber, A; Palatini, P; Sarti, C; Fagard, R; Staessen, JA; Arabidze, GG; Carrageta, M; Celis, H; Kocemba, J; Leonetti, G; Nachev, C; O'Brien, ET; Ritz, E; Rodicio, JL; Rosenfeld, J; Heyrman, J; Stibbe, G; Van den Haute, H; Yodfat, Y; De Cort, P; Hubner, GE		Systolic Hypertension Europe Trial Inv	Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NITRENDIPINE; ANTAGONISTS; INSULIN; MORTALITY	Background Recent reports suggest that calcium-channel blockers may be harmful in patients with diabetes and hypertension. We previously reported that antihypertensive treatment with the calcium-channel blocker nitrendipine reduced the risk of cardiovascular events. In this post hoc analysis, we compared the outcome of treatment with nitrendipine in diabetic and nondiabetic patients. Methods After stratification according to center, sex, and presence or absence of previous cardiovascular complications, 4695 patients (age, greater than or equal to 60 years) with systolic blood pressure of 160 to 219 mm Hg and diastolic pressure below 95 mm Hg were randomly assigned to receive active treatment or placebo. Active treatment consisted of nitrendipine (10 to 40 mg per day) with the possible addition or substitution of enalapril (5 to 20 mg per day) or hydrochlorothiazide (12.5 to 25 mg per day) or both, titrated to reduce the systolic blood pressure by at least 20 mm Hg and to less than 150 mm Hg. In the control group, matching placebo tablets were administered similarly. Results At randomization, 492 patients (10.5 percent) had diabetes. After a median follow-up of two years, the systolic and diastolic blood pressures in the placebo and active-treatment groups differed by 8.6 and 3.9 mm Hg, respectively, among the diabetic patients. Among the 4203 patients without diabetes, systolic and diastolic pressures differed by 10.3 and 4.5 mm Hg, respectively, in the two groups. After adjustment for possible confounders, active treatment was found to have reduced overall mortality by 55 percent (from 45.1 deaths per 1000 patients to 26.4 deaths per 1000 patients), mortality from cardiovascular disease by 76 percent, all cardiovascular events combined by 69 percent, fatal and nonfatal strokes by 73 percent, and all cardiac events combined by 63 percent in the group of patients with diabetes. Among the nondiabetic patients, active treatment decreased all cardiovascular events combined by 26 percent and fatal and nonfatal strokes by 38 percent. In the group of patients receiving active treatment, reductions in overall mortality, mortality from cardiovascular disease, and all cardiovascular events were significantly larger among the diabetic patients than among the nondiabetic patients (P=0.04, P=0.02, and P=0.01, respectively). Conclusions Nitrendipine-based antihypertensive therapy is particularly beneficial in older patients with diabetes and isolated systolic hypertension. Thus, our findings do not support the hypothesis that the use of long-acting calcium-channel blockers may be harmful in diabetic patients. (N Engl J Med 1999;340:677-84) (C) 1999, Massachusetts Medical Society.	Katholieke Univ Leuven, Dept Mol & Cardiovasc Res, Hypertens & Cardiovasc Rehabil Unit, B-3000 Leuven, Belgium; Inst Cardiol, Kaunas, Lithuania; Natl Publ Hlth Inst, Helsinki, Finland; Erasmus Univ, Rotterdam, Netherlands; Oulu Univ Hosp, Dept Internal Med, Oulu, Finland; Hosp Oulu, Ctr Hlth, Oulu, Finland; Hammersmith Hosp, Imperial Coll, London, England; London Sch Hyg & Trop Med, London WC1, England; Hop Broca, Paris, France; Inst Clin Med, Padua, Italy	KU Leuven; Finland National Institute for Health & Welfare; Erasmus University Rotterdam; University of Oulu; Imperial College London; University of London; London School of Hygiene & Tropical Medicine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Broca - APHP; UDICE-French Research Universities; Universite Paris Cite	Staessen, JA (corresponding author), Katholieke Univ Leuven, Dept Mol & Cardiovasc Res, Hypertens & Cardiovasc Rehabil Unit, Campus Gasthuisberg,Herestr 49, B-3000 Leuven, Belgium.	jan.staessen@med.kuleuven.ac.be	Staessen, Jan A/A-1065-2011	Staessen, Jan A/0000-0002-3026-1637; Thijs, Lutgarde/0000-0002-8108-2356				Alderman M, 1998, LANCET, V351, P216, DOI 10.1016/S0140-6736(05)78175-7; Alderman MH, 1997, LANCET, V349, P594, DOI 10.1016/S0140-6736(96)08359-6; AMERY A, 1988, J HYPERTENS, V6, P925, DOI 10.1097/00004872-198811000-00012; Amery A, 1991, Aging (Milano), V3, P287; [Anonymous], 1994, World Health Organ Tech Rep Ser, V844, P1; [Anonymous], 1991, JAMA, V265, P3255; Berkels R., 1996, Pharmaceutical and Pharmacological Letters, V6, P75; BORHANI NO, 1996, JAMA-J AM MED ASSOC, V276, P783; Byington RP, 1997, LANCET, V350, P1075, DOI 10.1016/S0140-6736(05)70455-4; Curb JD, 1997, JAMA-J AM MED ASSOC, V277, P1356; *DECL HELS, 1990, B PAN AM HLTH ORG, V24, P606; EPSTEIN M, 1992, ARCH INTERN MED, V152, P1573; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GIUGLIANO D, 1993, AM J HYPERTENS, V6, P927, DOI 10.1093/ajh/6.11.927; GOA KL, 1987, DRUGS, V33, P123, DOI 10.2165/00003495-198733020-00003; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; LEVER AF, 1995, J HYPERTENS, V13, P571, DOI 10.1097/00004872-199506000-00001; Pahor M, 1998, LANCET, V351, P689, DOI 10.1016/S0140-6736(05)78489-0; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; Pahor M, 1998, DIABETES CARE, V21, P193, DOI 10.2337/diacare.21.1.193; Ricciardelli B, 1997, CURR THER RES CLIN E, V58, P180, DOI 10.1016/S0011-393X(97)80013-6; Sowers JR, 1997, AM J CARDIOL, V79, P24, DOI 10.1016/S0002-9149(97)89421-0; Staessen J, 1997, LANCET, V350, P1636; Staessen JA, 1998, ARCH INTERN MED, V158, P1681, DOI 10.1001/archinte.158.15.1681; Staessen JA, 1998, HYPERTENSION, V32, P410, DOI 10.1161/01.HYP.32.3.410; Staessen JA, 1997, HYPERTENSION, V29, P659, DOI 10.1161/01.HYP.29.2.659; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Taddei S, 1997, HYPERTENSION, V30, P1606, DOI 10.1161/01.HYP.30.6.1606; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597	30	636	662	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1999	340	9					677	684		10.1056/NEJM199903043400902	http://dx.doi.org/10.1056/NEJM199903043400902			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172ZB	10053176				2022-12-28	WOS:000078955200002
J	McGovern, MM; Benach, MO; Wallenstein, S; Desnick, RJ; Keenlyside, R				McGovern, MM; Benach, MO; Wallenstein, S; Desnick, RJ; Keenlyside, R			Quality assurance in molecular genetic testing laboratories	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER; BRCA1	Context Specific regulation of laboratories performing molecular genetic tests may be needed to ensure standards and quality assurance (QA) and safeguard patient rights to informed consent and confidentiality. However, comprehensive analysis of current practices of such laboratories, important for assessing the need for regulation and its impact on access to testing, has not been conducted. Objective To collect and analyze data regarding availability of clinical molecular genetic testing, including personnel standards and laboratory practices, Design A mail survey in June 1997 of molecular genetic testing laboratory directors and assignment of a QA score based on responses to genetic testing process items. Setting Hospital-based, independent, and research-based molecular genetic testing laboratories in the United States. Participants Directors of molecular genetic testing laboratories (n = 245; response rate, 74.9%), Main Outcome Measure Laboratory process QA score, using the American College of Medical Genetics Laboratory Practice Committee standards. Results The 245 responding laboratories reported availability of testing for 94 disorders, Personnel qualifications varied, although all directors had doctoral degrees. The mean QA score was 90% (range, 44%-100%) with 36 laboratories (15%) scoring lower than 70%. Higher scores were associated with test menu size of more than 4 tests (P = .01), performance of more than 30 analyses annually (P = .01), director having a PhD vs MD degree (P = .002), director board certification (P = .03), independent (P < .001) and hospital (P = .01) laboratories vs research laboratory, participation in proficiency testing (P < .001), and Clinical Laboratory Improvement Amendment certification (P = .006). Seventy percent of laboratories provided access to genetic counseling, 69% had a confidentiality policy, and 45% required informed consent prior to testing. Conclusion The finding that a number of laboratories had QA scores that may reflect suboptimal laboratory practices suggests that both personnel qualification and laboratory practice standards are most in need of improvement to ensure quality in clinical molecular genetic testing laboratories.	Mt Sinai Sch Med, Dept Human Genet, New York, NY USA; Mt Sinai Sch Med, Dept Pediat, New York, NY USA; Mt Sinai Sch Med, Dept Biomath, New York, NY USA; Ctr Dis Control & Prevent, Div Lab Syst, Publ Hlth Practice Program Off, Atlanta, GA USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Centers for Disease Control & Prevention - USA	McGovern, MM (corresponding author), CUNY, Mt Sinai Med Ctr, Box 1497,100th St & 5th Ave, New York, NY 10029 USA.				ATSDR CDC HHS [TS-218] Funding Source: Medline	ATSDR CDC HHS		*AM COLL HUM GEN L, 1993, STAND GUID CLIN GEN; Bernstein T, 1994, RADON RENTAL HOUSING; *CHILDR HOSP REG M, 1999, HELIX DIR; FUKIMARA FK, 1990, NEW ENGL J MED, V322, P61; Holtzman NA, 1997, PROMOTING SAFE EFFEC; HUDSON KL, 1995, SCIENCE, V270, P391, DOI 10.1126/science.270.5235.391; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Krynetski EY, 1998, AM J HUM GENET, V63, P11, DOI 10.1086/301941; Larkin M, 1998, LANCET, V351, P1937, DOI 10.1016/S0140-6736(05)78625-6; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Szabo CI, 1997, AM J HUM GENET, V60, P1013; UDoHaH Services, 1992, FED REGISTER, V57, P7002; *US C, 1992, PUBL US C OFF TECHN; VERMA RS, 1992, GENOMICS, V14, P113, DOI 10.1016/S0888-7543(05)80291-5; WATSON MS, 1995, DIAGN MOL PATHOL, V4, P233, DOI 10.1097/00019606-199512000-00001; Yankowitz J, 1997, AM J OBSTET GYNECOL, V176, P1107, DOI 10.1016/S0002-9378(97)70411-3; 1995, FED REG, V42, P888; 1995, FED REG, V42, P892	18	62	67	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					835	840		10.1001/jama.281.9.835	http://dx.doi.org/10.1001/jama.281.9.835			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10071006	Bronze			2022-12-28	WOS:000078804300035
J	Nightingale, SL				Nightingale, SL			Celecoxib for arthritis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					786	786		10.1001/jama.281.9.786	http://dx.doi.org/10.1001/jama.281.9.786			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10070983				2022-12-28	WOS:000078804300006
J	Dries, DL; Exner, DV; Gersh, BJ; Cooper, HA; Carson, PE; Domanski, MJ				Dries, DL; Exner, DV; Gersh, BJ; Cooper, HA; Carson, PE; Domanski, MJ			Racial differences in the outcome of left ventricular dysfunction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-FAILURE; CARVEDILOL	Background Population-based studies have found that black patients with congestive heart failure have a higher mortality rate than white patients with the same condition. This finding has been attributed to differences in the severity, causes, and management of heart failure, the prevalence of coexisting conditions, and socioeconomic factors. Although these factors probably account for some of the higher mortality due to congestive heart failure among blacks, we hypothesized that racial differences in the natural history of left ventricular dysfunction might also have a role. Methods Using data from the Studies of Left Ventricular Dysfunction (SOLVD) prevention and treatment trials, in which all patients received standardized therapy and follow-up, we conducted a retrospective analysis of the outcomes of asymptomatic and symptomatic left ventricular systolic dysfunction among black and white participants. The mean (+/-SD) follow-up was 34.2+/-14.0 months in the prevention trial and 32.3+/-14.8 months in the treatment trial among the black and white participants. Results The overall mortality rates in the prevention trial were 8.1 per 100 person-years for blacks and 5.1 per 100 person years for whites. In the treatment trial, the rates were 16.7 per 100 person-years and 13.4 per 100 person-years, respectively. After adjustment for age, coexisting conditions, severity and causes of heart failure, and use of medications, blacks had a higher risk of death from all causes in both the SOLVD prevention trial (relative risk, 1.36; 95 percent confidence interval, 1.06 to 1.74; P=0.02) and the treatment trial (relative risk, 1.25; 95 percent confidence interval, 1.04 to 1.50; P=0.02). In both trials blacks were also at higher risk for death due to pump failure and for the combined end point of death from any cause or hospitalization for heart failure, our two predefined indicators of the progression of left ventricular systolic dysfunction. Conclusions Blacks with mild-to-moderate left ventricular systolic dysfunction appear to be at higher risk for progression of heart failure and death from any cause than similarly treated whites. These results suggest that there may be racial differences in the outcome of asymptomatic and symptomatic left ventricular systolic dysfunction. (N Engl J Med 1999;340:609-16.) (C)1999, Massachusetts Medical Society.	NHLBI, Clin Trials Sci Res Grp, Div Epidemiol & Clin Applicat, Rockledge Ctr 2, Bethesda, MD 20892 USA; Georgetown Univ Hosp, Div Cardiol, Washington, DC 20007 USA; Dept Vet Affairs, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Georgetown University	Dries, DL (corresponding author), NHLBI, Clin Trials Sci Res Grp, Div Epidemiol & Clin Applicat, Rockledge Ctr 2, 6701 Rockledge Dr,Rm 8149, Bethesda, MD 20892 USA.	ddries@aol.com	E, D/AAH-1638-2020		NHLBI NIH HHS [TA-HL-1002] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AHCPR, 1994, AHCPR PUBL; ALEXANDER M, 1995, JAMA-J AM MED ASSOC, V274, P1037, DOI 10.1001/jama.274.13.1037; Benedict CR, 1996, CIRCULATION, V94, P690, DOI 10.1161/01.CIR.94.4.690; Chatterjee K, 1996, CIRCULATION, V94, P2689, DOI 10.1161/01.CIR.94.11.2689; Colucci WS, 1996, CIRCULATION, V94, P2800, DOI 10.1161/01.CIR.94.11.2800; GHALI JK, 1988, ARCH INTERN MED, V148, P2013, DOI 10.1001/archinte.148.9.2013; Gillum RF, 1996, NEW ENGL J MED, V335, P1597, DOI 10.1056/NEJM199611213352110; GILLUM RF, 1987, AM HEART J, V113, P1043, DOI 10.1016/0002-8703(87)90077-9; MATERSON BJ, 1994, NEW ENGL J MED, V330, P1689, DOI 10.1056/NEJM199406093302316; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2344; Packer M, 1996, CIRCULATION, V94, P2793, DOI 10.1161/01.CIR.94.11.2793; PAPPAS G, 1993, NEW ENGL J MED, V329, P1139; Philbin EF, 1998, AM J CARDIOL, V82, P76, DOI 10.1016/S0002-9149(98)00233-1; SOLVD Investigators, 1990, AM J CARDIOL, V66, P1026; WEIR MR, 1995, HYPERTENSION, V26, P124, DOI 10.1161/01.HYP.26.1.124; WILLIAMS DR, 1990, SOC PSYCHOL QUART, V53, P81, DOI 10.2307/2786672; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; YUSUF S, 1990, AM J CARDIOL, V66, P315; 1994, MMWR MORB MORTAL WKL, V43, P77	20	266	270	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1999	340	8					609	616		10.1056/NEJM199902253400804	http://dx.doi.org/10.1056/NEJM199902253400804			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	169NP	10029645				2022-12-28	WOS:000078755700004
J	Jazwinska, A; Kirov, N; Wieschaus, E; Roth, S; Rushlow, C				Jazwinska, A; Kirov, N; Wieschaus, E; Roth, S; Rushlow, C			The Drosophila gene brinker reveals a novel mechanism of Dpp target gene regulation	CELL			English	Article							DORSAL-VENTRAL PATTERN; ORGANIZING ACTIVITY; MORPHOGEN GRADIENT; SIGNALING PATHWAY; TUMOR-SUPPRESSOR; WING DEVELOPMENT; PROTEIN; EMBRYO; RECEPTOR; HEDGEHOG	decapentaplegic (dpp), a Drosophila member of the TGF beta family of secreted molecules, functions as a long-range morphogen in patterning of the embryo and the adult appendages. Dpp signals via the SMAD proteins Mad and Medea. Here we show that in the absence of brinker (brk), Mad is not required for the activation of Dpp target genes that depend on low levels of Dpp. brk encodes a novel protein with features of a transcriptional repressor. brk itself is negatively regulated by Dpp. Dpp signaling might relieve brk's repression of low-level target genes either by transcriptional repression of brk or by antagonizing a repressor function of brk at the target gene promoters.	Max Planck Inst Entwicklungsbiol, D-72076 Tubingen, Germany; NYU, Dept Biol, New York, NY 10003 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Max Planck Society; New York University; Princeton University	Roth, S (corresponding author), Max Planck Inst Entwicklungsbiol, Spemannstr 35-2, D-72076 Tubingen, Germany.	roth@bio.tuebingen.mpg.de; rushlow@is.nyu.edu	Jazwinska, Anna/M-8705-2016; Roth, Siegfried/E-8241-2010	Jazwinska, Anna/0000-0003-3881-9284; Roth, Siegfried/0000-0001-5772-3558				ARORA K, 1992, DEVELOPMENT, V114, P1003; ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; Biehs B, 1996, GENE DEV, V10, P2922, DOI 10.1101/gad.10.22.2922; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Burke R, 1996, DEVELOPMENT, V122, P2261; Campbell G, 1999, CELL, V96, P553, DOI 10.1016/S0092-8674(00)80659-5; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Das P, 1998, DEVELOPMENT, V125, P1519; De Celis JF, 1998, INT J DEV BIOL, V42, P335; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dosch R, 1997, DEVELOPMENT, V124, P2325; Ferguson EL, 1996, CURR OPIN GENET DEV, V6, P424, DOI 10.1016/S0959-437X(96)80063-3; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; Haerry TE, 1998, DEVELOPMENT, V125, P3977; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1998, CURR TOP MICROBIOL, V228, P235; Hudson JB, 1998, DEVELOPMENT, V125, P1407; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; KALDERON D, 1995, CURR BIOL, V5, P580, DOI 10.1016/S0960-9822(95)00114-X; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; Lecuit T, 1998, DEVELOPMENT, V125, P4901; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Patterson GI, 1997, GENE DEV, V11, P2679, DOI 10.1101/gad.11.20.2679; RAFTERY LA, 1995, GENETICS, V139, P241; ROBERTS DB, 1998, DROSOPHILA, V191; Rushlow C., 1996, ADV DEV BIO, V4, P27, DOI 10.1016/s1566-3116(08)60016-x; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Singer MA, 1997, DEVELOPMENT, V124, P79; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TERRACOL R, 1994, GENETICS, V138, P165; TOWER J, 1993, GENETICS, V133, P347; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; WHARTON KA, 1993, DEVELOPMENT, V117, P807; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wilson PA, 1997, DEVELOPMENT, V124, P3177; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; XU T, 1993, DEVELOPMENT, V117, P1223; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; ZECCA M, 1995, DEVELOPMENT, V121, P2265	62	225	232	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 19	1999	96	4					563	573		10.1016/S0092-8674(00)80660-1	http://dx.doi.org/10.1016/S0092-8674(00)80660-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	168XN	10052458	hybrid			2022-12-28	WOS:000078718600007
J	Simmen, MW; Leitgeb, S; Charlton, J; Jones, SJM; Harris, BR; Clark, VH; Bird, A				Simmen, MW; Leitgeb, S; Charlton, J; Jones, SJM; Harris, BR; Clark, VH; Bird, A			Nonmethylated transposable elements and methylated genes in a chordate genome	SCIENCE			English	Article							TRANSCRIPTIONAL INTERFERENCE; GLOBIN GENE; DNA METHYLATION; PROMOTER; UPSTREAM; REPEATS; CPG; INACTIVATION; RNA	The genome of the invertebrate chordate Ciona intestinalis was found to be a stable mosaic of methylated and nonmethylated domains. Multiple copies of an apparently active long terminal repeat retrotransposon and a long interspersed element are nonmethylated and a Large fraction of abundant short interspersed elements are also methylation free. Genes, by contrast, are predominantly methylated. These data are incompatible with the genome defense model which proposes that DNA methylation in animals is primarily targeted to endogenous transposable elements. Cytosine methylation in this urochordate may be preferentially directed to genes.	Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Sanger Ctr, Cambridge CB10 1SA, England	University of Edinburgh; Wellcome Trust Sanger Institute	Simmen, MW (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Kings Bldg, Edinburgh EH9 3JR, Midlothian, Scotland.		Jones, Steven J/C-3621-2009	Jones, Steven J/0000-0003-3394-2208; Bird, Adrian/0000-0002-8600-0372	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADHYA S, 1982, CELL, V29, P939, DOI 10.1016/0092-8674(82)90456-1; ALLAN M, 1983, CELL, V35, P187; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; [Anonymous], UNPUB; Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; Bird A, 1997, TRENDS GENET, V13, P469, DOI 10.1016/S0168-9525(97)01310-3; BIRD AP, 1979, CELL, V17, P889, DOI 10.1016/0092-8674(79)90329-5; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; Boeke J. D., 1997, P343; BRODERS F, 1990, P NATL ACAD SCI USA, V87, P503, DOI 10.1073/pnas.87.2.503; CALABI F, 1985, EMBO J, V4, P667, DOI 10.1002/j.1460-2075.1985.tb03681.x; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; CORBIN V, 1989, NATURE, V337, P279, DOI 10.1038/337279a0; CULLEN BR, 1984, NATURE, V307, P241, DOI 10.1038/307241a0; ELLEDGE SJ, 1989, GENE DEV, V3, P185, DOI 10.1101/gad.3.2.185; FREEDMAN T, 1993, GENETICS, V135, P357; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Goyon C, 1996, NUCLEIC ACIDS RES, V24, P3348, DOI 10.1093/nar/24.17.3348; Greger IH, 1998, NUCLEIC ACIDS RES, V26, P1294, DOI 10.1093/nar/26.5.1294; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; KRICKER MC, 1992, P NATL ACAD SCI USA, V89, P1075, DOI 10.1073/pnas.89.3.1075; LEY TJ, 1983, BIOCHEM BIOPH RES CO, V112, P1041, DOI 10.1016/0006-291X(83)91723-0; Moore T, 1997, P NATL ACAD SCI USA, V94, P12509, DOI 10.1073/pnas.94.23.12509; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; Regev A, 1998, MOL BIOL EVOL, V15, P880, DOI 10.1093/oxfordjournals.molbev.a025992; ROSSIGNOL JL, 1994, EXPERIENTIA, V50, P307, DOI 10.1007/BF01924014; SELKER EU, 1988, P NATL ACAD SCI USA, V85, P6870, DOI 10.1073/pnas.85.18.6870; Selker EU, 1997, TRENDS GENET, V13, P296, DOI 10.1016/S0168-9525(97)01201-8; Simmen MW, 1998, P NATL ACAD SCI USA, V95, P4437, DOI 10.1073/pnas.95.8.4437; SONNHAMMER ELL, 1994, COMPUT APPL BIOSCI, V10, P301; TORNALETTI S, 1995, ONCOGENE, V10, P1493; Tweedie S, 1997, MOL CELL BIOL, V17, P1469, DOI 10.1128/MCB.17.3.1469; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; WHITTAKER PA, 1981, NUCLEIC ACIDS RES, V9, P801, DOI 10.1093/nar/9.4.801; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	35	110	114	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1164	1167		10.1126/science.283.5405.1164	http://dx.doi.org/10.1126/science.283.5405.1164			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024242				2022-12-28	WOS:000078738400051
J	Finlay, IG; Wyatt, P				Finlay, IG; Wyatt, P			Randomised cross-over study of patient-held records in oncology and palliative care	LANCET			English	Article									Univ Wales, Coll Med, Marie Curie Canc Care & Velindre NHS Trust, Cardiff CF4 7XL, S Glam, Wales	Cardiff University	Finlay, IG (corresponding author), Univ Wales, Coll Med, Marie Curie Canc Care & Velindre NHS Trust, Cardiff CF4 7XL, S Glam, Wales.							BOSCH A, 1990, PATIENTENVOORLICHTIN, P12; Calman K., 1995, POLICY FRAMEWORK COM; Fierman AH, 1996, ARCH PEDIAT ADOL MED, V150, P863, DOI 10.1001/archpedi.1996.02170330089015; Finlay I, 1998, PALLIATIVE MED, V12, P397, DOI 10.1191/026921698666540505; Neame R, 1997, BRIT MED J, V314, P573, DOI 10.1136/bmj.314.7080.573	5	16	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 13	1999	353	9152					558	559		10.1016/S0140-6736(98)05814-0	http://dx.doi.org/10.1016/S0140-6736(98)05814-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028990				2022-12-28	WOS:000078670200019
J	Shin, E				Shin, E			Star material	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1999	281	6					493	493		10.1001/jama.281.6.493	http://dx.doi.org/10.1001/jama.281.6.493			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164FQ	10022087				2022-12-28	WOS:000078452900001
J	Chakravarti, D; Ogryzko, V; Kao, HY; Nash, A; Chen, HW; Nakatani, Y; Evans, RM				Chakravarti, D; Ogryzko, V; Kao, HY; Nash, A; Chen, HW; Nakatani, Y; Evans, RM			A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity	CELL			English	Article							STEROID-RECEPTOR COACTIVATOR-1; HISTONE ACETYLTRANSFERASE; TRANSCRIPTIONAL ADAPTER; RNA-POLYMERASE; CELL-CYCLE; ACTIVATION; ACETYLATION; BINDING; CBP; PROTEINS	Nucleosomal histone modification is believed to be a critical step in the activation of RNA polymerase II-dependent transcription. p300/CBP and PCAF histone acetyltransferases (HATs) are coactivators for several transcription factors, including nuclear hormone receptors, p53, and Stat1 alpha, and participate in transcription by forming an activation complex and by promoting histone acetylation. The adenoviral E1A oncoprotein represses transcriptional signaling by binding to p300/CBP and displacing PCAF and p/CIP proteins from the complex. Here, we show that E1A directly represses the HAT activity of both p300/CBP and PCAF in vitro and p300-dependent transcription in vivo. Additionally, E1A inhibits nucleosomal histone modifications by the PCAF complex and blocks p53 acetylation. These results demonstrate the modulation of HAT activity as a novel mechanism of transcriptional regulation.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA	Salk Institute; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Howard Hughes Medical Institute; Salk Institute	Chakravarti, D (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Evans, Ronald/AAF-4001-2019; Ogryzko, Vasily/M-6665-2015	Evans, Ronald/0000-0002-9986-5965; Ogryzko, Vasily/0000-0002-8548-1389; Chakravarti, Debabrata/0000-0001-8446-8599				ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; DYSON N, 1992, CANCER SURV, V12, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STURHL K, 1998, GENE DEV, V12, P599; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	44	297	306	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 5	1999	96	3					393	403		10.1016/S0092-8674(00)80552-8	http://dx.doi.org/10.1016/S0092-8674(00)80552-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025405	hybrid			2022-12-28	WOS:000078514600012
J	Klein, DS				Klein, DS			What happened in Laramie	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Klein, DS (corresponding author), 3116 Willet Dr, Laramie, WY 82070 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 2	1999	130	3					235	236		10.7326/0003-4819-130-3-199902020-00030	http://dx.doi.org/10.7326/0003-4819-130-3-199902020-00030			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	162PD	10049204				2022-12-28	WOS:000078355000010
J	Whittle, HC; Aaby, P; Samb, B; Jensen, H; Bennett, J; Simondon, F				Whittle, HC; Aaby, P; Samb, B; Jensen, H; Bennett, J; Simondon, F			Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa	LANCET			English	Article							RURAL SENEGAL; MORTALITY; EFFICACY; IMMUNIZATION; COVERAGE; EXPOSURE; DURATION; ANTIBODY; GAMBIA; RATES	Background Despite a high coverage with measles vaccines in parts of west Africa, epidemics of measles occur with reduced severity in an increasing proportion of older children who have been vaccinated. We examined the effect of exposure to natural measles on immunity in vaccinated children. Methods Our study was carried out in 1992 during an epidemic of measles in Niakhar, a rural area of Senegal with about 27 000 inhabitants who mostly live in compounds that include several households; within each household people live in different huts. Vaccine coverage in Niakhar was 81% at the time of our study. We measured haemagglutinin-inhibiting antibody at exposure and twice thereafter (after 4-5 weeks and at 6 months) in 36 vaccinated and 87 unvaccinated children. The frequency of measles and subclinical measles-defined as a four-fold or greater rise in antibody titre without clinical signs or symptoms-was related to intensity of exposure according to whether the index case was in the same hut, household, or compound. Findings Clinical measles occurred in 20 (56%) of 36 unvaccinated children and in one (1%) of 87 vaccinated children. Subclinical measles occurred in 39 (45%) of 86 vaccinated children who were exposed to measles and in four (25%) of 16 unvaccinated children. The frequency was inversely related to pre-exposure antibody concentration (p<0.001 for trend) and directly related to intensity of exposure (p=0.002 for trend), Antibody concentrations in subclinical cases increased on average by 45-fold and remained raised for at least 6 months. Interpretation Increased antibody titre after subclinical measles may be common in vaccinated children in West Africa where the intensity of exposure is high. As measles vaccination coverage increases, the circulation of wild measles will decrease, and vaccine-induced antibody is less likely to be boosted. Thus, new epidemics, albeit milder in form, may occur in vaccinated areas which should be recognised in campaigns to eradicate measles.	MRC Labs, Banjul, Gambia; ORSTOM, Dakar, Senegal; Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol, DK-2300 Copenhagen, Denmark; INSERM, U13, Paris, France; Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA USA	MRC Laboratory Molecular Biology; Institut de Recherche pour le Developpement (IRD); Aarhus University; Statens Serum Institut; Institut National de la Sante et de la Recherche Medicale (Inserm); Emory University; Rollins School Public Health	Whittle, HC (corresponding author), MRC Labs, POB 273, Banjul, Gambia.			Aaby, Peter/0000-0001-8331-1389; Simondon, Francois/0000-0003-0395-1314				AABY P, 1990, J INFECT DIS, V162, P1043, DOI 10.1093/infdis/162.5.1043; AABY P, 1984, AM J EPIDEMIOL, V120, P49, DOI 10.1093/oxfordjournals.aje.a113874; Anders JF, 1996, PEDIATR INFECT DIS J, V15, P62, DOI 10.1097/00006454-199601000-00014; BENNETT J, IN PRESS INT J EPIDE; BIN D, 1991, B WORLD HEALTH ORGAN, V69, P415; CHABNAZARIAN A, 1992, POPULATION SANTE NIA; CHEN RT, 1990, J INFECT DIS, V162, P1036, DOI 10.1093/infdis/162.5.1036; CISSE B, IN PRESS AM J EPIDEM; COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0; deQuadros CA, 1996, JAMA-J AM MED ASSOC, V275, P224, DOI 10.1001/jama.275.3.224; FORSTER SO, 1971, AFR J MED SCI, V2, P151; GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; GUSTAFSON TL, 1987, NEW ENGL J MED, V316, P771, DOI 10.1056/NEJM198703263161303; KRUGMAN S, 1983, REV INFECT DIS, V5, P477; MARKOWITZ LE, 1990, PEDIATR INFECT DIS J, V9, P101, DOI 10.1097/00006454-199002000-00008; McMurray D N, 1979, Bull Pan Am Health Organ, V13, P52; MULHOLLAND K, 1995, LANCET, V345, P305, DOI 10.1016/S0140-6736(95)90282-1; NORRBY E, 1995, CURR TOP MICROBIOL, V191, P167; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; Outlaw MC, 1997, VIRUS RES, V48, P125, DOI 10.1016/S0168-1702(96)01434-7; Panum, 1940, OBSERVATIONS MADE EP; RIMA BK, 1995, J GEN VIROL, V76, P1173, DOI 10.1099/0022-1317-76-5-1173; SAMB B, 1995, PEDIATR INFECT DIS J, V14, P203, DOI 10.1097/00006454-199503000-00007; SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6; Samb B, 1997, AM J EPIDEMIOL, V145, P51, DOI 10.1093/oxfordjournals.aje.a009031; STETLER HC, 1986, PEDIATRICS, V77, P471; WHITTLE H, 1988, LANCET, V2, P811; WHITTLE HC, 1998, LANCET, V351, P866; WHITTLE HC, IN PRESS PEDIAT INFE	30	101	105	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 9	1999	353	9147					98	102		10.1016/S0140-6736(98)02364-2	http://dx.doi.org/10.1016/S0140-6736(98)02364-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023894				2022-12-28	WOS:000078087200010
J	Power, R; French, R; Connelly, J; George, S; Hawes, D; Hinton, T; Klee, H; Robinson, D; Senior, J; Timms, P; Warner, D				Power, R; French, R; Connelly, J; George, S; Hawes, D; Hinton, T; Klee, H; Robinson, D; Senior, J; Timms, P; Warner, D			Health, health promotion, and homelessness	BRITISH MEDICAL JOURNAL			English	Article							PUBLIC-HEALTH; PEOPLE		UCL Royal Free & Univ Coll Med Sch, Dept Sexually Transmitted Dis, London WC1E 6AU, England; Nuffield Inst Hlth, Leeds LS2 9PL, W Yorkshire, England; Univ Southampton, Hlth Care Res Unit, Southampton SO16 6YD, Hants, England; Hlth Act Homeless People, London E8 3DL, England; Manchester Metropolitan Univ, Fac Community Studies & Educ, Manchester N13 0JA, Lancs, England; Sheffield Hallam Univ, Ctr Reg Econ & Social Res, Sheffield S1 1UB, S Yorkshire, England; N Yorkshire Specialist Hlth Promot Serv, Dept Hlth Studies, York YO3 7BY, N Yorkshire, England; United Med & Dent Sch Guys & St Thomas Hosp, London SE1 9RT, England; Homeless Network, London SW1H 0QS, England; Univ Bristol, Bristol BS8 4EA, Avon, England	University of London; University College London; UCL Medical School; University of Leeds; University of Southampton; Manchester Metropolitan University; Sheffield Hallam University; University of Sheffield; University of London; King's College London; University of Bristol	Power, R (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Sexually Transmitted Dis, London WC1E 6AU, England.	rpower@gum.ucl.nc.uk						ARBLASTER L, 1993, HLTH HOUSING SOCIAL; Breakey WR, 1997, AM J PUBLIC HEALTH, V87, P153, DOI 10.2105/AJPH.87.2.153; BURROWS L, 1992, HOMES COST LESS HOME; CHAMBERLAIN S, 1997, BIG ISSUE, V208, P21; Connelly J, 1996, BRIT MED J, V312, P262; CONNELLY J, 1994, HOMELESSNESS ILL HLT; *DEP HLTH, 1998, OUR HLTH NAT CONTR H; *DEPT HLTH, 1997, CM3807; FISHER N, 1994, BRIT MED J, V308, P27, DOI 10.1136/bmj.308.6920.27; GEORGE SL, 1991, BRIT MED J, V302, P1387, DOI 10.1136/bmj.302.6789.1387; Gill B., 1996, PREVALENCE PSYCHIAT; HINTON T, 1997, ICING CAKE REV HLTH; KLEE H, 1991, J COMMUNITY APPL SOC, V1, P143, DOI 10.1002/casp.2450010208; MOORE J, 1995, FACES HOMELESSNESS L, P238; Murray R B, 1996, J Psychosoc Nurs Ment Health Serv, V34, P16; NORTH C, 1997, USE ACCIDENT EMERGEN; PIEARCE N, 1996, HLTH HOMELESSNESS LO; Reid P, 1999, HEALTH SOC CARE COMM, V7, P17, DOI 10.1046/j.1365-2524.1999.00152.x; Robinson D, 1998, HOUSING STUD, V13, P23, DOI 10.1080/02673039883470; RODERICK P, 1991, BRIT MED J, V302, P157, DOI 10.1136/bmj.302.6769.157; ROGER A, 1997, INEQUALITIES HLTH HL; *ROYAL COLL GEN PR, 1993, STAT HOM GEN PRACT; SHANKS N, 1992, POLICY POLIT, V20, P35, DOI 10.1332/030557392782454060; SMITH SJ, 1994, PUBLIC HEALTH, V108, P175, DOI 10.1016/S0033-3506(94)80115-0; SMITH SJ, 1990, SOC SCI MED, V31, P753, DOI 10.1016/0277-9536(90)90170-W; Stitt Sean, 1994, Nutrition and Health (Bicester), V9, P275; STLAWRENCE JS, 1995, AIDS EDUC PREV, V7, P22; WARWICK I, 1995, IT MATTERS DEV HIV A; WHITTAKER D, 1996, SATELLITE CLIN DELIV; WILLIAMS S, 1995, REV PRIMARY CARE PRO; WILLIAMS S, 1989, HLTH CARE SINGLE HOM, P267; WRIGHT J, 1998, HLTH NEEDS ASSESSMEN	32	36	36	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					590	592		10.1136/bmj.318.7183.590	http://dx.doi.org/10.1136/bmj.318.7183.590			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	173DQ	10037643	Green Published			2022-12-28	WOS:000078966300037
J	Buck, E; Li, JR; Chen, YB; Weng, GZ; Scarlata, S; Iyengar, R				Buck, E; Li, JR; Chen, YB; Weng, GZ; Scarlata, S; Iyengar, R			Resolution of a signal transfer region from a general binding domain in G beta for stimulation of phospholipase C-beta 2	SCIENCE			English	Article							OPIOID RECEPTOR ANTAGONISTS; MESSAGE-ADDRESS CONCEPT; SUBUNIT; DESIGN; GAMMA	Signaling by guanine nucleotide-binding proteins (G proteins) involves sequential protein-protein interactions. G protein-beta gamma subunit (G beta gamma) interactions with phospholipase C-beta 2 (PLC-beta 2) were studied to determine if all G beta contacts are required for signaling. A peptide encoding G beta amino acid residues 86 to 105 stimulated PLC-beta 2. Six residues (96 to 101) within this sequence could transfer signals and thus constitute a core signal transfer region. Another peptide, encoding G beta amino acid residues 115 to 135, did not substantially stimulate PLC-beta 2 by itself but inhibited G beta gamma stimulation, indicating that residues 115 to 135 constitute a general binding domain. Resolution of signal transfer regions from general binding domains indicates that all protein-protein contacts are not required for signal transfer and that it may be feasible to synthesize agonists and antagonists that regulate intracellular signal flaw.	CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11729 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Iyengar, R (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol, Box 1215, New York, NY 10029 USA.	iyengar@msvax.mssm.edu			NIDDK NIH HHS [DK-38761] Funding Source: Medline; NIGMS NIH HHS [GM-43125, GM-54508] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054508] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Chen YB, 1997, P NATL ACAD SCI USA, V94, P2711, DOI 10.1073/pnas.94.6.2711; DEVIVO M, 1994, METHOD ENZYMOL, V238, P131; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; PORTOGHESE PS, 1989, TRENDS PHARMACOL SCI, V10, P230, DOI 10.1016/0165-6147(89)90267-8; PORTOGHESE PS, 1990, J MED CHEM, V33, P1714, DOI 10.1021/jm00168a028; Runnels LW, 1996, BIOCHEMISTRY-US, V35, P16824, DOI 10.1021/bi961606w; Runnels LW, 1998, BIOCHEMISTRY-US, V37, P15563, DOI 10.1021/bi9811258; SCHWYZER R, 1980, PROC R SOC SER B-BIO, V210, P5, DOI 10.1098/rspb.1980.0115; Weng GZ, 1996, J BIOL CHEM, V271, P26445, DOI 10.1074/jbc.271.43.26445; Yan K, 1997, J BIOL CHEM, V272, P2056	14	33	34	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1332	1335		10.1126/science.283.5406.1332	http://dx.doi.org/10.1126/science.283.5406.1332			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037604				2022-12-28	WOS:000078839900043
J	Strong, JP; Malcom, GT; McMahan, CA; Tracy, RE; Newman, WP; Herderick, EE; Cornhill, JF				Strong, JP; Malcom, GT; McMahan, CA; Tracy, RE; Newman, WP; Herderick, EE; Cornhill, JF			Prevalence and extent of atherosclerosis in adolescents and young adults - Implications for prevention from the pathobiological determinants of atherosclerosis in youth study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; NATURAL-HISTORY; CORONARY-DISEASE; FATTY STREAKS; LESIONS; LIPIDS; MORPHOLOGY; TRACKING; SOLDIERS; PLAQUE	Context Atherosclerosis, the underlying cause of coronary heart disease, has been shown to be present even in young adults. Objective To document the extent and severity of atherosclerosis in adolescents and young adults in the United States. Design and Setting The Pathobiological Determinants of Atherosclerosis in Youth a multi-institutional autopsy study conducted in US medical centers. Subjects A total of 2876 study subjects, between 15 and 34 years old, black and white, men and women, who died of external causes and underwent autopsy between June 1, 1987, and August 31, 1994. Main Outcome Measures Extent, prevalence, and topography of atherosclerotic lesions. Results Intimal lesions appeared in all the aortas and more than half of the right coronary arteries of the youngest age group (15-19 years) and increased in prevalence and extent with age through the oldest age group (30-34 years). Fatty streaks were more extensive in black subjects than in white subjects, but raised lesions did not differ between blacks and whites. Raised lesions in the aortas of women and men were similar, but raised lesions in the right coronary arteries of women were less than those of men. The prevalence of total lesions was lower in the right coronary artery than in the aorta, but the proportion of raised lesions among total lesions was higher in the right coronary artery than in the aorta. Conclusions Atherosclerosis begins in youth. Fatty streaks and clinically significant raised lesions increase rapidly in prevalence and extent during the 15- to 34-year age span. Primary prevention of atherosclerosis, as contrasted with primary prevention of clinically manifest atherosclerotic disease, must begin in childhood or adolescence.	Louisiana State Univ, Med Ctr, Dept Pathol, New Orleans, LA 70112 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX USA; Ohio State Univ, Ctr Biomed Engn, Columbus, OH 43210 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA	Louisiana State University System; University of Texas System; University of Texas Health San Antonio; University System of Ohio; Ohio State University; Cleveland Clinic Foundation	Strong, JP (corresponding author), Louisiana State Univ, Med Ctr, Dept Pathol, Box P5-1,1901 Perdido St, New Orleans, LA 70112 USA.	jstron@lsumc.edu	tracy, richard/L-6072-2019		NHLBI NIH HHS [HL-33728, HL-33765, HL-33733] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R10HL033733, R10HL033728, R10HL033765] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOCAN TMA, 1986, AM J PATHOL, V123, P413; BOCAN TMA, 1985, AM J PATHOL, V120, P193; Burke AP, 1997, NEW ENGL J MED, V336, P1276, DOI 10.1056/NEJM199705013361802; CLARKE WR, 1978, CIRCULATION, V58, P626, DOI 10.1161/01.CIR.58.4.626; CORNHILL JF, 1995, WIEN KLIN WOCHENSCHR, V107, P540; CORNHILL JF, 1990, MG ATHEROSC, V15, P13; CORNHILL JF, 1993, AM J CARDIOL; Draper NR., 1998, APPL REGRESSION ANAL, DOI [10.1002/9781118625590, DOI 10.1002/9781118625590]; ENOS WF, 1986, JAMA-J AM MED ASSOC, V256, P2859, DOI 10.1001/jama.256.20.2859; ENOS WF, 1953, JAMA-J AM MED ASSOC, V152, P1090, DOI 10.1001/jama.1953.03690120006002; FREEDMAN DS, 1988, CIRCULATION, V77, P856, DOI 10.1161/01.CIR.77.4.856; GEER JC, 1968, LAB INVEST, V18, P565; GUYTON JR, 1994, ARTERIOSCLER THROMB, V14, P1305, DOI 10.1161/01.ATV.14.8.1305; GUZMAN MA, 1968, LAB INVEST, V18, P479; HATA Y, 1974, AM J PATHOL, V75, P423; HOLMAN RL, 1958, AM J PATHOL, V34, P209; HOLMAN RL, 1961, AM J CLIN NUTR, V9, P565, DOI 10.1093/ajcn/9.5.565; KATZ S S, 1976, Journal of Clinical Investigation, V58, P200; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; Klotz O, 1912, J PATHOL BACTERIOL, V16, P211; LABARTHE DR, 1978, INTERDISCIPL SCI REV, V3, P225; MCGILL HC, 1995, ARTERIOSCL THROM VAS, V15, P2222, DOI 10.1161/01.ATV.15.12.2222; McGill HC, 1998, ARTERIOSCL THROM VAS, V18, P1108, DOI 10.1161/01.ATV.18.7.1108; McGill HC, 1997, ARTERIOSCL THROM VAS, V17, P95, DOI 10.1161/01.ATV.17.1.95; MCGILL HC, 1995, ARTERIOSCL THROM VAS, V15, P431, DOI 10.1161/01.ATV.15.4.431; MCGILL HC, 1968, LAB INVEST, V18, P560; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; MCGILL HC, 1968, GEOGRAPHIC PATHOLOGY; Monckeberg J., 1915, ZENTRALBL HERZ GEFAS, V7, P7; MONTENEGRO MR, 1968, LAB INVEST, V18, P586; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; NEWMAN WP, 1988, MODERN PATHOL, V1, P109; ROBERTSON WILLIAM B., 1963, EXPTL AND MOLECULAR PATHOL SUPPL, V1, P28; SALTYSALTYKOW S, 1915, AERTZE, V45, P1047; SOLBERG LA, 1983, ARTERIOSCLEROSIS, V3, P187, DOI 10.1161/01.ATV.3.3.187; SPRECHER DL, 1984, AM J CARDIOL, V54, P20, DOI 10.1016/0002-9149(84)90298-4; STARY HC, 1989, ARTERIOSCLEROSIS, V9, pI19; STARY HC, 1990, EUR HEART J, V11, P3, DOI 10.1093/eurheartj/11.suppl_E.3; STRONG JACK P., 1963, EXPTL AND MOLECULAR PATHOL SUPPL, V1, P15; STRONG JP, 1984, AM HEART J, V108, P747, DOI 10.1016/0002-8703(84)90668-9; STRONG JP, 1995, CLIN CHEM, V41, P134; STRONG JP, 1992, ARCH PATHOL LAB MED, V116, P1268; STRONG JP, 1986, JAMA-J AM MED ASSOC, V256, P2863, DOI 10.1001/jama.256.20.2863; STRONG JP, 1979, LANCET, V2, P1294; STRONG JP, 1962, AM J PATHOL, V40, P37; TEJADA C, 1968, LAB INVEST, V18, P509; WEBBER LS, 1991, AM J EPIDEMIOL, V133, P884, DOI 10.1093/oxfordjournals.aje.a115968; WISSLER RW, 1993, ARTERIOSCLER THROMB, V13, P1291; WISSLER RW, 1991, ANN NY ACAD SCI, V623, P26, DOI 10.1111/j.1749-6632.1991.tb43716.x; WISSLER RW, 1996, SYNDROMES ATHEROSCLE, P65; WISSLER RW, 1996, ATHEROSCLEROSIS CORO, P475; Zeek P, 1930, ARCH PATHOL, V10, P417; Zinserling WD, 1925, VIRCHOWS ARCH A, V255, P677, DOI 10.1007/BF01891708	53	599	638	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1999	281	8					727	735		10.1001/jama.281.8.727	http://dx.doi.org/10.1001/jama.281.8.727			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BD	10052443	Bronze			2022-12-28	WOS:000078669900032
J	Chae, CU; Pfeffer, MA; Glynn, RJ; Mitchell, GF; Taylor, JO; Hennekens, CH				Chae, CU; Pfeffer, MA; Glynn, RJ; Mitchell, GF; Taylor, JO; Hennekens, CH			Increased pulse pressure and risk of heart failure in the elderly	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYSTOLIC BLOOD-PRESSURE; AGE-RELATED-CHANGES; MYOCARDIAL-INFARCTION; ARTERIAL DISTENSIBILITY; NORMOTENSIVE SUBJECTS; AORTIC COMPLIANCE; WAVE VELOCITY; HYPERTENSION; ATHEROSCLEROSIS; PROGRESSION	Context Arterial stiffness increases with age, Thus, pulse pressure, an index of arterial stiffening, may predict congestive heart failure (CHF) in the elderly. Objective To study prospectively the association between pulse pressure and risk of CHF, Design Prospective cohort study. Setting The community-based East Boston Senior Health Project, East Boston, Mass. Patients A total of 1621 men and women (mean [SD] age, 77.9 [5.0] years) free of CHF who had blood pressure measurements taken in 1988-1989 and were followed up for 3.8 years. Main Outcome Measure Incidence of CHF as ascertained by hospital discharge diagnosis (n = 208) and death certificates (n = 13), Results After controlling for age, sex, mean arterial pressure, history of coronary heart disease, diabetes mellitus, atrial fibrillation, valvular heart disease, and antihypertensive medication use, pulse pressure was an independent predictor of CHF. For each 10-mm Hg elevation in pulse pressure, there was a 14% increase in risk of CHF (95% confidence interval, 1.05-1.24; P = .003). Those in the highest tertile of pulse pressure (>67 mm Hg) had a 55% increased risk of CHF (P = .02) compared with those in the lowest (<54 mm Hg). Pulse pressure was more predictive than systolic blood pressure alone and was independent of diastolic blood pressure. Conclusion Pulse pressure, an easily measurable correlate of pulsatile hemodynamic load, is an independent predictor of risk of CHF in this elderly cohort.	Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Div Cardiovasc, Dept Med, Boston, MA 02215 USA; Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; E Boston Neighborhood Hlth Ctr, E Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Chae, CU (corresponding author), Brigham & Womens Hosp, Div Prevent Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.				NHLBI NIH HHS [HL-07575] Funding Source: Medline; NIA NIH HHS [N01AG02107] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AVOLIO AP, 1986, ARTERIOSCLEROSIS, V6, P166, DOI 10.1161/01.ATV.6.2.166; Ayanian JZ, 1998, HEALTH AFFAIR, V17, P194, DOI 10.1377/hlthaff.17.6.194; Benetos A, 1997, HYPERTENSION, V30, P1410, DOI 10.1161/01.HYP.30.6.1410; BUCKBERG GD, 1972, CIRC RES, V30, P67, DOI 10.1161/01.RES.30.1.67; Cornoni-Huntley J., 1986, ESTABLISHED POPULATI; DARNE B, 1989, HYPERTENSION, V13, P392, DOI 10.1161/01.HYP.13.4.392; DZAU VJ, 1988, CIRCULATION, V77, P947, DOI 10.1161/01.CIR.77.5.947; FANG J, 1995, J HYPERTENS, V13, P413; FARRAR DJ, 1991, CIRCULATION, V83, P1754, DOI 10.1161/01.CIR.83.5.1754; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; Franklin SS, 1997, CIRCULATION, V96, P308; FRANKLIN SS, 1994, AM HEART J, V128, P793, DOI 10.1016/0002-8703(94)90278-X; GARDIN JM, 1997, HYPERTENSION, V29, P195; GIRERD X, 1991, AM HEART J, V122, P1210, DOI 10.1016/0002-8703(91)90941-A; GLYNN RJ, 1993, AM J EPIDEMIOL, V138, P365, DOI 10.1093/oxfordjournals.aje.a116869; HIRAI T, 1989, CIRCULATION, V80, P78, DOI 10.1161/01.CIR.80.1.78; *HYP DET FOLL UP P, 1977, JAMA-J AM MED ASSOC, V237, P2385; KANNEL WB, 1994, BRIT HEART J, V72, P3; Kass DA, 1996, CIRCULATION, V93, P1533, DOI 10.1161/01.CIR.93.8.1533; KELLY R, 1989, CIRCULATION, V80, P1652, DOI 10.1161/01.CIR.80.6.1652; KELLY RP, 1992, CIRC RES, V71, P490, DOI 10.1161/01.RES.71.3.490; Kohno F, 1996, CIRCULATION, V93, P2080, DOI 10.1161/01.CIR.93.11.2080; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; LATSON TW, 1988, CIRC RES, V62, P884, DOI 10.1161/01.RES.62.5.884; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; LYON RT, 1987, J VASC SURG, V5, P59, DOI 10.1067/mva.1987.avs0050059; MADHAVAN S, 1994, HYPERTENSION, V23, P395, DOI 10.1161/01.HYP.23.3.395; MILNOR WR, 1975, CIRC RES, V36, P565, DOI 10.1161/01.RES.36.5.565; Mitchell GF, 1997, CIRCULATION, V96, P4254; Mitchell GF, 1996, CIRCULATION, V94, P2923, DOI 10.1161/01.CIR.94.11.2923; *NAT HEART LUNG BL, 1996, CONG HEART FAIL US N; OROURKE MF, 1982, ATERIAL FUNCTION HLT; SABA PS, 1993, J AM COLL CARDIOL, V22, P1873, DOI 10.1016/0735-1097(93)90772-S; SAEKI A, 1995, CIRC RES, V76, P132, DOI 10.1161/01.RES.76.1.132; SCHLATMANN TJM, 1977, AM J CARDIOL, V39, P13, DOI 10.1016/S0002-9149(77)80004-0; Smulyan H, 1997, J AM COLL CARDIOL, V29, P1407, DOI 10.1016/S0735-1097(97)00081-8; TING CT, 1986, J CLIN INVEST, V78, P1462, DOI 10.1172/JCI112737; URSCHEL CW, 1968, AM J PHYSIOL, V214, P298, DOI 10.1152/ajplegacy.1968.214.2.298; WATANABE H, 1993, J AM COLL CARDIOL, V21, P1497, DOI 10.1016/0735-1097(93)90330-4; WITTEMAN JCM, 1994, LANCET, V343, P504, DOI 10.1016/S0140-6736(94)91459-1	41	406	432	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1999	281	7					634	639		10.1001/jama.281.7.634	http://dx.doi.org/10.1001/jama.281.7.634			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	165YA	10029125	Bronze			2022-12-28	WOS:000078548400034
J	Freese, RB				Freese, RB			The Park Nicollet experience in establishing a hospitalist system	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	National Policy Conference on the Hospitalist Movement	DEC 05-06, 1997	SAN FRANCISCO, CA					A hospitalist system was developed at Park Nicollet Clinic in 1993, was implemented in 1994, and remains in existence today. It was established without knowledge of any other similar program in the United States. Internists and family practitioners were given the choice to continue to care for hospitalized patients or to become totally office based. The new system has met with good patient acceptance along with increased physician satisfaction and retention. This paper describes some key aspects of the institution of the system in a multispecialty group that includes both family practitioners and internists.	Healthsyst Minnesota, Nicollet Clin, St Louis Pk, MN 55416 USA		Freese, RB (corresponding author), Healthsyst Minnesota, Nicollet Clin, 3800 Pk Nicollet Blvd, St Louis Pk, MN 55416 USA.	freesr@hsmnet.com						Wachter RM, 1999, ANN INTERN MED, V130, P338, DOI 10.7326/0003-4819-130-4-199902161-00002; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713; Wheeler D, 1993, UNDERSTANDING VARIAT	3	71	71	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	2				350	354		10.7326/0003-4819-130-4-199902161-00004	http://dx.doi.org/10.7326/0003-4819-130-4-199902161-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	166QB	10068404				2022-12-28	WOS:000078587500004
J	Pretre, R; Turina, MI				Pretre, R; Turina, MI			Laser to the heart: magic but costly, or only costly?	LANCET			English	Editorial Material							REVASCULARIZATION; DISEASE		Univ Zurich Hosp, Dept Cardiovasc Surg, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Pretre, R (corresponding author), Univ Zurich Hosp, Dept Cardiovasc Surg, CH-8091 Zurich, Switzerland.							Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Cooley DA, 1996, J THORAC CARDIOV SUR, V111, P791, DOI 10.1016/S0022-5223(96)70339-2; FRAZIER OH, 1995, CIRCULATION, V92, P58, DOI 10.1161/01.CIR.92.9.58; Horvath KA, 1997, J THORAC CARDIOV SUR, V113, P645, DOI 10.1016/S0022-5223(97)70221-6; Kwong KF, 1997, J THORAC CARDIOV SUR, V114, P883, DOI 10.1016/S0022-5223(97)70001-1; Malekan R, 1998, CIRCULATION, V98, pII62; March R J, 1999, Semin Thorac Cardiovasc Surg, V11, P12; Mueller XM, 1998, EUR J CARDIO-THORAC, V13, P170, DOI 10.1016/S1010-7940(97)00308-4; Nagele H, 1998, EUR HEART J, V19, P1525, DOI 10.1053/euhj.1998.1152; Vincent JG, 1997, EUR J CARDIO-THORAC, V11, P888, DOI 10.1016/S1010-7940(97)01203-7	10	16	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 13	1999	353	9152					512	513		10.1016/S0140-6736(99)90015-6	http://dx.doi.org/10.1016/S0140-6736(99)90015-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028973				2022-12-28	WOS:000078670200002
J	Buckley, CD; Pilling, D; Henriquez, NV; Parsonage, G; Threlfall, K; Scheel-Toellner, D; Simmons, DL; Albar, AN; Lord, JM; Salmon, M				Buckley, CD; Pilling, D; Henriquez, NV; Parsonage, G; Threlfall, K; Scheel-Toellner, D; Simmons, DL; Albar, AN; Lord, JM; Salmon, M			RGD peptides induce apoptosis by direct caspase-3 activation	NATURE			English	Article							CELL-DEATH; ADHESION; PROTEOLYSIS; INHIBITION; INTEGRINS; PROTEIN; CED-4	Synthetic peptides containing the arginine-glycine-aspartate (RGD) motif have been used extensively as inhibitors of integrin-ligand interactions in studies of cell adhesion, migration, growth and differentiation(1-3), because the RGD motif is an integrin-recognition motif found in many ligands. Here we report that RGD-containing peptides are able to directly induce apoptosis without any requirement for integrin-mediated cell clustering or signals. We show that RGD-containing peptides enter cells and directly induce autoprocessing and enzymatic activity of pro-caspase-3, a pro-apoptotic protein. Using the breast carcinoma cell line MCF-7, which has a functional deletion of the caspase-3 gene, we confirm that caspase-3 is required for RGD-mediated cell death, In addition to an RGD motif, pro-caspase-3 also contains a potential RGD-binding motif, aspartate-aspartate-methionine (DDM)(4), near the site of processing to produce the p12 and p17 subunits(5). On the basis of the ability of RGD-DDX interactions to trigger integrin activation(6), we suggest that RGD peptides induce apoptosis by triggering conformational changes that promote pro-caspase-3 autoprocessing and activation. These findings provide an alternative molecular explanation for the potent pro-apoptotic properties of RGD peptides in models of angiogenesis, inflammation and cancer metastasis(7-9).	Univ Birmingham, Div Immun & Infect, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Inst Canc Studies, MRC, Ctr Immune Regulat, Birmingham B15 2TT, W Midlands, England; SmithKline Beecham Pharmaceut, Dept Neurosci, Harlow CM19 5AW, Essex, England; Royal Free Hosp, Dept Clin Immunol, London NW3 2PF, England; Univ Coll, Sch Med, London NW3 2PF, England	University of Birmingham; University of Birmingham; GlaxoSmithKline; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; UCL Medical School	Salmon, M (corresponding author), Univ Birmingham, Div Immun & Infect, Birmingham B15 2TT, W Midlands, England.	M.Salmon@bham.ac.uk	Buckley, Christopher/AAN-6378-2021; Henriquez, Nico/C-3758-2008	Buckley, Christopher/0000-0001-6924-6402; Lord, Janet/0000-0003-1030-6786; Pilling, Darrell/0000-0002-7413-2773	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOUCAUT JC, 1984, J CELL BIOL, V99, P1822, DOI 10.1083/jcb.99.5.1822; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; Jacobson MD, 1997, TRENDS CELL BIOL, V7, P467, DOI 10.1016/S0962-8924(97)01182-3; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LWEBUGAMUKASA JS, 1994, AM J RESP CELL MOL, V10, P347, DOI 10.1165/ajrcmb.10.4.8136151; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; McGill G, 1997, J CELL BIOL, V138, P901, DOI 10.1083/jcb.138.4.901; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Salmon M, 1997, J CLIN INVEST, V99, P439, DOI 10.1172/JCI119178; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	30	383	422	0	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 11	1999	397	6719					534	539		10.1038/17409	http://dx.doi.org/10.1038/17409			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KN	10028971				2022-12-28	WOS:000078574900053
J	Chalmers, I; Altman, DG				Chalmers, I; Altman, DG			How can medical journals help prevent poor medical research? Some opportunities presented by electronic publishing	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED TRIALS; CONSORT STATEMENT; PROTOCOL REVIEWS; CLINICAL-TRIALS; METAANALYSIS; METHODOLOGY; QUALITY; PLACEBO; SEPSIS; RISK		UK Cochrane Ctr, NHS Res & Dev Programme, Oxford OX2 7LG, England; Inst Hlth Sci, Imperial Canc Res Fund, Med Stat Grp, Ctr Stat Med, Oxford, England	Cochrane Centre; University of Oxford	Chalmers, I (corresponding author), UK Cochrane Ctr, NHS Res & Dev Programme, Summertown Pavill,Middle Way, Oxford OX2 7LG, England.							Adams RJ, 1998, CONTROL CLIN TRIALS, V19, P110, DOI 10.1016/S0197-2456(97)00099-8; Altman DG, 1996, BRIT MED J, V313, P570; ALTMAN DG, 1994, BRIT MED J, V308, P283, DOI 10.1136/bmj.308.6924.283; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BERO L, 1997, C PEER REV GLOB COMM; BOWIE C, 1998, BRIT MED J, V316, P175; BUTTERWORTH I, 1998, IMPACT ELECT PUBLISH; Chalmers I, 1995, SYSTEMATIC REV; Chollar S, 1998, ANN INTERN MED, V128, P701, DOI 10.7326/0003-4819-128-8-199804150-00038; Delamothe T, 1998, BMJ-BRIT MED J, V316, P1109, DOI 10.1136/bmj.316.7138.1109; Delamothe T, 1996, BRIT MED J, V312, P1241, DOI 10.1136/bmj.312.7041.1241; *DEP HLTH, 1998, DAT CD ROM; DOWNS JR, 1995, AM J CARDIOL, V75, P1130; Erbel R, 1997, J INTERV CARDIOL, V10, P271, DOI 10.1111/j.1540-8183.1997.tb00041.x; Foss A, 1997, BRIT MED J, V314, P1691, DOI 10.1136/bmj.314.7095.1691a; GIAMMONA M, 1984, CLIN RES, V31, P472; GUEYFFIER F, 1995, THERAPIE, V50, P353; GUEYFFIER F, 1997, ITAL J NEUROL SCI, V18, P119; HOBSLEY M, 1988, THEOR SURG, V3, P132; Horton R, 1997, LANCET, V349, P6, DOI 10.1016/S0140-6736(05)62158-7; Hotopf M, 1997, J EPIDEMIOL COMMUN H, V51, P354, DOI 10.1136/jech.51.4.354; Jadad AR, 1998, JAMA-J AM MED ASSOC, V280, P278, DOI 10.1001/jama.280.3.278; Kirwan JR, 1997, J RHEUMATOL, V24, P822; KUPFERSMID J, 1988, AM PSYCHOL, V43, P635, DOI 10.1037/0003-066X.43.8.635; Lewis Michael A., 1996, Pharmacoepidemiology and Drug Safety, V5, P43; LORENZ W, 1994, LANCET, V343, P933, DOI 10.1016/S0140-6736(94)90063-9; LORENZ W, 1994, THEOR SURG, V9, P10; LORENZ W, 1988, THEOR SURG, V3, P55; McConnell J, 1998, BRIT MED J, V316, P1907; MCGUIGAN SM, 1995, BRIT J PSYCHIAT, V167, P683, DOI 10.1192/bjp.167.5.683; McNamee D, 1997, LANCET, V350, P6, DOI 10.1016/S0140-6736(05)66237-X; *MED RES COUNC, 1998, MRC GUID GOOD CLIN P; Meinert CL, 1998, JAMA-J AM MED ASSOC, V279, P1487, DOI 10.1001/jama.279.18.1487; Moher D, 1998, JAMA-J AM MED ASSOC, V279, P1489, DOI 10.1001/jama.279.18.1489; NEWCOMBE RG, 1987, BRIT MED J, V295, P656, DOI 10.1136/bmj.295.6599.656; PILZ G, 1993, THEOR SURG, V8, P61; RELMAN AS, 1990, NEW ENGL J MED, V323, P1355; REMY W, 1995, ALLERGOLOGIE, V18, P246; Savulescu J, 1996, BMJ-BRIT MED J, V313, P1390, DOI 10.1136/bmj.313.7069.1390; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schulz KF, 1995, ONLINE J CURR C 0826; SIEGEL JP, 1990, NEW ENGL J MED, V323, P1355; Silverman WA, 1996, LANCET, V347, P171, DOI 10.1016/S0140-6736(96)90347-5; SIMES RJ, 1995, AM J CARDIOL, V76, pC122; SMITH GD, 1994, BRIT MED J, V308, P1519, DOI 10.1136/bmj.308.6943.1519; Smith R, 1999, BRIT MED J, V318, P142, DOI 10.1136/bmj.318.7177.142; Soares K, 1996, LANCET, V347, P1696, DOI 10.1016/S0140-6736(96)91525-1; Spitzer WO, 1996, BRIT MED J, V312, P83; Spitzer WO, 1993, PHARMACOEPIDEM DR S, V2, P21; Tramer MR, 1997, BMJ-BRIT MED J, V315, P635, DOI 10.1136/bmj.315.7109.635; Tsubono Y, 1997, JPN J CANCER RES, V88, P344, DOI 10.1111/j.1349-7006.1997.tb00387.x; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WEISS DJ, 1989, APPL PSYCH MEAS, V13, P1, DOI 10.1177/014662168901300101; WHO Int Soc Hyperten Blood Press Lower, 1998, J HYPERTENS, V16, P127; WILKINSON SL, 1998, ELECT PUBLISHING TAK; 1997, BMJ, V314, P1691; 1999, COCHRANE LIBRARY	57	81	83	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 6	1999	353	9151					490	493		10.1016/S0140-6736(98)07618-1	http://dx.doi.org/10.1016/S0140-6736(98)07618-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JQ	9989737				2022-12-28	WOS:000078572800046
J	Hamamori, Y; Sartorelli, V; Ogryzko, V; Puri, PL; Wu, HY; Wang, JYJ; Nakatani, Y; Kedes, L				Hamamori, Y; Sartorelli, V; Ogryzko, V; Puri, PL; Wu, HY; Wang, JYJ; Nakatani, Y; Kedes, L			Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A	CELL			English	Article							LOOP-HELIX PROTEIN; TRANSCRIPTION FACTORS; MUSCLE DIFFERENTIATION; GENE-TRANSCRIPTION; DEVELOPING SOMITES; GROWTH-FACTOR; CELL-CYCLE; MYOD; COACTIVATOR; ACETYLATION	Histone acetyltransferases (HAT) play a critical role in transcriptional control by relieving repressive effects of chromatin, and yet how HATs themselves are regulated remains largely unknown. Here, it is shown that Twist directly binds two independent HAT domains of acetyltransferases, p300 and p300/CBP-associated factor (PCAF), and directly regulates their HAT activities. The N terminus of Twist is a primary domain interacting with both acetyltransferases, and the same domain is required for inhibition of p300-dependent transcription by Twist. Adenovirus E1A protein mimics the effects of Twist by inhibiting the HAT activities of p300 and PCAF. These findings establish a cogent argument for considering the HAT domains as a direct target for acetyltransferase regulation by both a cellular transcription factor and a viral oncoprotein.	Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Inst Med Genet, Los Angeles, CA 90033 USA; NICHHD, Lab Mol Growth Regulat, Bethesda, MD 20892 USA; Univ Calif San Diego, Ctr Mol Genet, Dept Biol, La Jolla, CA 92093 USA; Univ Rome La Sapienza, Policlin Umberto I, Inst Clin Med 1, Fdn Andrea Cesalpino,Lab Gene Express, I-00161 Rome, Italy	University of Southern California; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of California System; University of California San Diego; Sapienza University Rome; University Hospital Sapienza Rome	Hamamori, Y (corresponding author), Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Inst Med Genet, Los Angeles, CA 90033 USA.		Ogryzko, Vasily/M-6665-2015	Ogryzko, Vasily/0000-0002-8548-1389; Puri, Pier Lorenzo/0000-0003-4964-0095; Sartorelli, Vittorio/0000-0002-9284-3675	NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER; NCI NIH HHS [CA58320, R01 CA058320] Funding Source: Medline; Telethon [1072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Telethon(Fondazione Telethon)		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERLINGIERI MT, 1993, ONCOGENE, V8, P249; BOULUKOS KE, 1993, ONCOGENE, V8, P237; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CARUSO M, 1993, ONCOGENE, V8, P267; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Coleman CS, 1996, BIOCHEM J, V316, P697, DOI 10.1042/bj3160697; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; Dallas PB, 1998, MOL CELL BIOL, V18, P3596, DOI 10.1128/MCB.18.6.3596; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; FUCHTBAUER EM, 1995, DEV DYNAM, V204, P316; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1997, MOL CELL BIOL, V17, P6563, DOI 10.1128/MCB.17.11.6563; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lu L, 1996, J BIOL CHEM, V271, P18920, DOI 10.1074/jbc.271.31.18920; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; MARUYAMA K, 1987, ONCOGENE, V1, P361; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MURRAY SS, 1992, J BONE MINER RES, V7, P1131; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Pullner A, 1996, J BIOL CHEM, V271, P31452, DOI 10.1074/jbc.271.49.31452; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; StanfieldOakley SA, 1996, J MOL BIOL, V256, P503, DOI 10.1006/jmbi.1996.0104; STOETZEL C, 1995, MECH DEVELOP, V51, P251, DOI 10.1016/0925-4773(95)00369-X; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; WADE PA, 1997, CURR BIOL, V7, P82; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	55	317	326	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 5	1999	96	3					405	413		10.1016/S0092-8674(00)80553-X	http://dx.doi.org/10.1016/S0092-8674(00)80553-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025406	Bronze			2022-12-28	WOS:000078514600013
J	Ostermeier, C; Brunger, AT				Ostermeier, C; Brunger, AT			Structural basis of Rab effector specificity: Crystal structure of the small G protein Rab3A complexed with the effector domain of Rabphilin-3A	CELL			English	Article							SYNAPTIC-VESICLE FUSION; MACROMOLECULAR STRUCTURES; PHOSPHOLIPID-BINDING; ADENYLYL-CYCLASE; GTP HYDROLYSIS; MECHANISM; DIFFRACTION; RESOLUTION; TRANSPORT; ALPHA	The small G protein Rab3A plays an important role in the regulation of neurotransmitter release. The crystal structure of activated Rab3A/GTP/Mg2+ bound to the effector domain of rabphilin-3A was solved to 2.6 Angstrom resolution. Rabphilin-3A contacts Rab3A in two distinct areas. The first interface involves the Rab3A switch I and switch II regions, which are sensitive to the nucleotide-binding state of Rab3A. The second interface consists of a deep pocket in Rab3A that interacts with a SGAWFF structural element of rabphilin-3A. Sequence and structure analysis, and biochemical data suggest that this pocket, or Rab complementarity-determining region (RabCDR), establishes a specific interaction between each nab protein and its effecters. RabCDRs could be major determinants of effector specificity during vesicle trafficking and fusion.	Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Yale University	Brunger, AT (corresponding author), Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA.	brunger@laplace.csb.yale.edu		Brunger, Axel/0000-0001-5121-2036				BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; Chung SH, 1998, J BIOL CHEM, V273, P10240, DOI 10.1074/jbc.273.17.10240; Conner S, 1998, DEV BIOL, V203, P334, DOI 10.1006/dbio.1998.9057; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DUMAS JJ, 1998, IN PRESS STRUCTURE; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FYKSE EM, 1995, J NEUROSCI, V15, P2385, DOI 10.1523/JNEUROSCI.15-03-02385.1995; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; Gill GN, 1995, STRUCTURE, V3, P1285, DOI 10.1016/S0969-2126(01)00265-9; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; Johnson JD, 1997, MOL CELL BIOL, V17, P3488, DOI 10.1128/MCB.17.7.3488; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATO M, 1994, BIOCHEM BIOPH RES CO, V205, P1776, DOI 10.1006/bbrc.1994.2875; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; Kotake K, 1997, J BIOL CHEM, V272, P29407, DOI 10.1074/jbc.272.47.29407; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEAHY DJ, 1994, PROTEINS, V19, P48, DOI 10.1002/prot.340190107; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; MCKLEMAN CJ, 1996, MOL CELL BIOL, V16, P4985; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Neu M, 1997, PROTEINS, V27, P204, DOI 10.1002/(SICI)1097-0134(199702)27:2<204::AID-PROT6>3.0.CO;2-F; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Pannu NS, 1998, ACTA CRYSTALLOGR D, V54, P1285, DOI 10.1107/S0907444998004119; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; PerezAlvarado GC, 1996, J MOL BIOL, V257, P153, DOI 10.1006/jmbi.1996.0153; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PHILLIPS JC, 1980, ACTA CRYSTALLOGR A, V36, P856, DOI 10.1107/S0567739480001817; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; *POV RAY TEAM, 1998, POV RAY PERS VIS RAY; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Schmeichel KL, 1998, BIOCHEM J, V331, P885, DOI 10.1042/bj3310885; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; Sigler PB, 1996, ALFRED BENZON SYMP S, V39, P17; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sprang SR, 1997, CURR OPIN STRUC BIOL, V7, P849, DOI 10.1016/S0959-440X(97)80157-1; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; TONG L, 1989, SCIENCE, V245, P244, DOI 10.1126/science.2665078; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wiedemann C, 1998, NATURE, V394, P426, DOI 10.1038/28752; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; YONG K, 1990, ACTA CRYSTALLOGR A, V46, P41	85	282	292	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 5	1999	96	3					363	374		10.1016/S0092-8674(00)80549-8	http://dx.doi.org/10.1016/S0092-8674(00)80549-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025402	hybrid			2022-12-28	WOS:000078514600009
J	Harrison, PJ				Harrison, PJ			Brains at risk of schizophrenia	LANCET			English	Editorial Material							TWINS DISCORDANT; NEUROPATHOLOGY; ABNORMALITIES; SIZE		Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England	University of Oxford	Harrison, PJ (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.			Harrison, Paul/0000-0002-6719-1126				Callicott JH, 1998, BIOL PSYCHIAT, V44, P941, DOI 10.1016/S0006-3223(98)00264-9; CANNON TD, 1993, ARCH GEN PSYCHIAT, V50, P551; HARRISON PJ, 1995, NEURODEGENERATION, V4, P1, DOI 10.1006/neur.1995.0001; Lawrie SM, 1998, BRIT J PSYCHIAT, V172, P110, DOI 10.1192/bjp.172.2.110; Nelson MD, 1998, ARCH GEN PSYCHIAT, V55, P433, DOI 10.1001/archpsyc.55.5.433; REVELEY AM, 1982, LANCET, V1, P540; Sharma T, 1998, BRIT J PSYCHIAT, V173, P132, DOI 10.1192/bjp.173.2.132; Silverman JM, 1998, BIOL PSYCHIAT, V43, P97, DOI 10.1016/S0006-3223(97)00247-3; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; Ward KE, 1996, SCHIZOPHR RES, V22, P197, DOI 10.1016/S0920-9964(96)00076-X; WEINBERGER DR, 1995, LANCET, V346, P552, DOI 10.1016/S0140-6736(95)91386-6	11	16	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 2	1999	353	9146					3	4		10.1016/S0140-6736(05)74878-9	http://dx.doi.org/10.1016/S0140-6736(05)74878-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023939				2022-12-28	WOS:000077934800004
J	Ball, K				Ball, K			Anthony Dominic Abdullah - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					673	673		10.1136/bmj.318.7184.673	http://dx.doi.org/10.1136/bmj.318.7184.673			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066227	Green Published			2022-12-28	WOS:000079089200062
J	Adashi, EY; Hennebold, JD				Adashi, EY; Hennebold, JD			Single-gene mutations resulting in reproductive dysfunction in women	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LUTEINIZING-HORMONE-RECEPTOR; MCCUNE-ALBRIGHT SYNDROME; FOLLICLE-STIMULATING-HORMONE; LIPOID ADRENAL-HYPERPLASIA; ACUTE REGULATORY PROTEIN; PLACENTAL AROMATASE DEFICIENCY; LIMITED PRECOCIOUS PUBERTY; KALLMANNS-SYNDROME; HYPERGONADOTROPIC HYPOGONADISM; OVARIAN FAILURE		Univ Utah, Hlth Sci Ctr, Dept Obstet & Gynecol, Div Reprod Sci, Salt Lake City, UT 84108 USA	Utah System of Higher Education; University of Utah	Adashi, EY (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Obstet & Gynecol, Div Reprod Sci, 546 Chipeta Way,Rm 109, Salt Lake City, UT 84108 USA.			Hennebold, Jon/0000-0002-6760-3733				Adashi EY, 1996, REPROD ENDOCRINOLOGY, P211; Aittomaki K, 1996, J CLIN ENDOCR METAB, V81, P3722, DOI 10.1210/jc.81.10.3722; AITTOMAKI K, 1995, CELL, V82, P959, DOI 10.1016/0092-8674(95)90275-9; Andersson S, 1996, J CLIN ENDOCR METAB, V81, P130, DOI 10.1210/jc.81.1.130; BICK D, 1992, NEW ENGL J MED, V326, P1752, DOI 10.1056/NEJM199206253262606; BONGIOVANNI AM, 1962, J CLIN INVEST, V41, P2086, DOI 10.1172/JCI104666; Bose HS, 1997, J CLIN ENDOCR METAB, V82, P1511, DOI 10.1210/jc.82.5.1511; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; BOULOUX PMG, 1992, J ENDOCRINOL, V133, P323, DOI 10.1677/joe.0.1330323; Bulun SE, 1996, J CLIN ENDOCR METAB, V81, P867, DOI 10.1210/jc.81.3.867; COMITE F, 1984, NEW ENGL J MED, V311, P1032, DOI 10.1056/NEJM198410183111607; CONTE FA, 1994, J CLIN ENDOCR METAB, V78, P1287, DOI 10.1210/jc.78.6.1287; deRoux N, 1997, NEW ENGL J MED, V337, P1597, DOI 10.1056/NEJM199711273372205; Evans WS, 1996, REPROD ENDOCRINOLOGY, P181; FEUILLAN PP, 1991, J CLIN ENDOCR METAB, V73, P1370, DOI 10.1210/jcem-73-6-1370; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; Fujieda K, 1997, J CLIN INVEST, V99, P1265, DOI 10.1172/JCI119284; GUIOLI S, 1992, NAT GENET, V1, P337, DOI 10.1038/ng0892-337; HAPPLE R, 1986, CLIN GENET, V29, P321; HARADA N, 1992, AM J HUM GENET, V51, P666; HARADA N, 1992, J BIOL CHEM, V267, P4781; HARDELIN JP, 1993, J CLIN ENDOCR METAB, V76, P827, DOI 10.1210/jc.76.4.827; HOTCHKISS J, 1996, REPROD ENDOCRINOLOGY, P123; ISSELBACHER KURT J., 1966, P178; KAUFMAN FR, 1989, ACTA ENDOCRINOL-COP, V120, P129, DOI 10.1530/acta.0.1200129; KAUFMAN FR, 1981, NEW ENGL J MED, V304, P994, DOI 10.1056/NEJM198104233041702; KAUFMAN FR, 1986, J INHERIT METAB DIS, V9, P140, DOI 10.1007/BF01799450; KOSUGI S, 1995, HUM MOL GENET, V4, P183, DOI 10.1093/hmg/4.2.183; Kotlar TJ, 1997, J CLIN ENDOCR METAB, V82, P1020, DOI 10.1210/jc.82.4.1020; KREMER H, 1995, NAT GENET, V9, P160, DOI 10.1038/ng0295-160; KREMER H, 1993, HUM MOL GENET, V2, P1779, DOI 10.1093/hmg/2.11.1779; Latronico AC, 1996, NEW ENGL J MED, V334, P507, DOI 10.1056/NEJM199602223340805; LATRONICO AC, 1995, J CLIN ENDOCR METAB, V80, P2490, DOI 10.1210/jc.80.8.2490; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; Layman LC, 1997, NEW ENGL J MED, V337, P607, DOI 10.1056/NEJM199708283370905; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LEMLI L, 1977, J PEDIATR-US, V91, P947, DOI 10.1016/S0022-3476(77)80898-6; LEVY HL, 1984, NEW ENGL J MED, V310, P50; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MALLIN SR, 1969, ANN INTERN MED, V70, P69, DOI 10.7326/0003-4819-70-1-69; MATTHEWS CH, 1993, NAT GENET, V5, P83, DOI 10.1038/ng0993-83; McKusick V.A., 1992, MENDELIAN INHERITANC; MORISHIMA A, 1995, J CLIN ENDOCR METAB, V80, P3689, DOI 10.1210/jc.80.12.3689; Mullis PE, 1997, J CLIN ENDOCR METAB, V82, P1739, DOI 10.1210/jc.82.6.1739; Nakae J, 1997, HUM MOL GENET, V6, P571, DOI 10.1093/hmg/6.4.571; New M I, 1997, Curr Ther Endocrinol Metab, V6, P179; NEW MI, 1996, REPROD ENDOCRINOLOGY, P1555; Newfield RS, 1997, ANN NY ACAD SCI, V816, P219, DOI 10.1111/j.1749-6632.1997.tb52145.x; Nilsson C, 1997, FERTIL STERIL, V67, P998, DOI 10.1016/S0015-0282(97)81430-6; Okuyama E, 1997, J CLIN ENDOCR METAB, V82, P2337, DOI 10.1210/jc.82.7.2337; Pang SY, 1997, ENDOCRIN METAB CLIN, V26, P853, DOI 10.1016/S0889-8529(05)70285-1; Penning TM, 1997, ENDOCR REV, V18, P281, DOI 10.1210/er.18.3.281; PETIT C, 1993, TRENDS ENDOCRIN MET, V4, P8, DOI 10.1016/1043-2760(93)90057-L; Quinton R, 1996, J CLIN ENDOCR METAB, V81, P3010, DOI 10.1210/jc.81.8.3010; RABIN D, 1972, NEW ENGL J MED, V287, P1313, DOI 10.1056/NEJM197212282872602; RABINOWITZ D, 1979, NEW ENGL J MED, V300, P126, DOI 10.1056/NEJM197901183000306; RHEAUME E, 1991, MOL ENDOCRINOL, V5, P1147, DOI 10.1210/mend-5-8-1147; Rosler A, 1996, J CLIN ENDOCR METAB, V81, P1827, DOI 10.1210/jc.81.5.1827; ROSLER A, 1993, J STEROID BIOCHEM, V45, P99, DOI 10.1016/0960-0760(93)90128-J; SANCHEZ R, 1994, J CLIN ENDOCR METAB, V78, P561, DOI 10.1210/jc.78.3.561; SCHWANZELFUKUDA M, 1989, NATURE, V338, P161, DOI 10.1038/338161a0; SCHWINDINGER WF, 1992, P NATL ACAD SCI USA, V89, P5152, DOI 10.1073/pnas.89.11.5152; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SHOZU M, 1991, J CLIN ENDOCR METAB, V72, P560, DOI 10.1210/jcem-72-3-560; Spiegel AM, 1996, J CLIN ENDOCR METAB, V81, P2434, DOI 10.1210/jc.81.7.2434; SPITZ IM, 1974, NEW ENGL J MED, V290, P10, DOI 10.1056/NEJM197401032900103; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; Toledo SPA, 1996, J CLIN ENDOCR METAB, V81, P3850, DOI 10.1210/jc.81.11.3850; Waldstreicher J, 1996, J CLIN ENDOCR METAB, V81, P4388, DOI 10.1210/jc.81.12.4388; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; ZERAH M, 1994, J CLIN ENDOCR METAB, V79, P1811, DOI 10.1210/jc.79.6.1811; Zhang Y, 1996, J CLIN ENDOCR METAB, V81, P3594, DOI 10.1210/jc.81.10.3594; ZHAO HF, 1991, J BIOL CHEM, V266, P583; ZUBER MX, 1988, P NATL ACAD SCI USA, V85, P699, DOI 10.1073/pnas.85.3.699	75	18	19	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1999	340	9					709	718		10.1056/NEJM199903043400907	http://dx.doi.org/10.1056/NEJM199903043400907			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172ZB	10053181				2022-12-28	WOS:000078955200007
J	Moller, H; Skakkebaek, NE				Moller, H; Skakkebaek, NE			Risk of testicular cancer in subfertile men: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SEMEN QUALITY; EUROPEAN COUNTRIES; BIRTH COHORT; SPERMATOGENESIS; CRYPTORCHIDISM; DISORDERS; DENMARK; TESTIS	Objective To evaluate the association between subfertility in men and the subsequent risk of testicular cancer. Design Population based case-control study. Setting The Danish population Participants Cases were identified in the Danish Cancer Registry; controls were randomly selected from the Danish population with the computerised Danish Central Population Register. Men were interviewed by telephone; 514 men with cancer and 720 controls participated. Outcome measure Occurrence of testicular cancer. Results A reduced risk of testicular cancer was associated with paternity (relative risk 0.63; 95% confidence interval 0.47 to 085). In men who before the diagnosis of testicular cancer had a lower number of children than expected on the basis of their age, the relative risk was 1.98 (1.43 to 2.75). There was no corresponding protective effect associated with a higher number of children than expected. The associations were similar for seminoma and non-seminoma and were not influenced by adjustment for potential confounding factors. Conclusion These data are consistent with the hypothesis that male subfertility and testicular cancer share important aetiological factors.	Danish Natl Res Fdn, Ctr Res Hlth & Social Stat, DK-2100 Copenhagen O, Denmark; Natl Univ Hosp, Dept Growth & Reprod, Copenhagen, Denmark	Danmarks Grundforskningsfond	Moller, H (corresponding author), Danish Natl Res Fdn, Ctr Res Hlth & Social Stat, Sejrogade 11, DK-2100 Copenhagen O, Denmark.	cerefo@inet.uni2.dk		Moller, Henrik/0000-0001-8200-5929				ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; Akre O, 1996, J NATL CANCER I, V88, P883, DOI 10.1093/jnci/88.13.883; Armstrong BK, 1992, MONOGRAPHS EPIDEMIOL, V21; AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; BENDVOLD E, 1989, INT J FERTIL, V34, P401; Bergstrom R, 1996, J NATL CANCER I, V88, P727, DOI 10.1093/jnci/88.11.727; BERTHELSEN JG, 1983, FERTIL STERIL, V39, P68; BOSTOFTE E, 1983, INT J FERTIL, V28, P91; Breslow NE, 1980, IARC SCI PUBL, P5; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; COLEMAN MP, 1993, IARC SCI PUBL, V121, P521; FORMAN D, 1994, BRIT MED J, V308, P1393, DOI 10.1136/bmj.308.6941.1393; FORMAN D, 1994, CANCER SURV, V20, P323; HANSEN PV, 1989, J NATL CANCER I, V81, P1246, DOI 10.1093/jnci/81.16.1246; HENDERSON BE, 1979, INT J CANCER, V23, P598, DOI 10.1002/ijc.2910230503; HO GT, 1992, J UROLOGY, V148, P821, DOI 10.1016/S0022-5347(17)36732-0; Irvine S, 1996, BMJ-BRIT MED J, V312, P467, DOI 10.1136/bmj.312.7029.467; MACMAHON B, 1970, B WORLD HEALTH ORGAN, V43, P209; Moller H, 1996, CANCER CAUSE CONTROL, V7, P264, DOI 10.1007/BF00051302; MOLLER H, 1993, EUR UROL, V23, P8; Moller H, 1997, CANCER CAUSE CONTROL, V8, P904, DOI 10.1023/A:1018472530653; Moller H, 1996, INT J CANCER, V66, P287, DOI 10.1002/(SICI)1097-0215(19960503)66:3<287::AID-IJC2>3.0.CO;2-V; Pajarinen J, 1997, BRIT MED J, V314, P13, DOI 10.1136/bmj.314.7073.13; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; Storm H H, 1991, IARC Sci Publ, P220	26	208	210	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 27	1999	318	7183					559	562		10.1136/bmj.318.7183.559	http://dx.doi.org/10.1136/bmj.318.7183.559			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037628	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000078966300020
J	O'Donnell, CA; McConnachie, A; Moffat, K; Drummond, N; Wilson, P; Ross, S				O'Donnell, CA; McConnachie, A; Moffat, K; Drummond, N; Wilson, P; Ross, S			Cross sectional study of social variation in use of an out of hours patient transport service	BRITISH MEDICAL JOURNAL			English	Article									Univ Glasgow, Woodside Hlth Ctr, Dept Gen Practice, Glasgow G20 7LR, Lanark, Scotland; Univ Glasgow, Publ Hlth Res Unit, Glasgow G12 8RZ, Lanark, Scotland	University of Glasgow; University of Glasgow	O'Donnell, CA (corresponding author), Univ Glasgow, Dept Gen Practice, Glasgow G12 0RR, Lanark, Scotland.			O'Donnell, Kate/0000-0002-5368-3779				Carlisle R, 1998, BRIT MED J, V316, P520, DOI 10.1136/bmj.316.7130.520; Carstairs V., 1991, DEPRIVATION HLTH SCO; Hallam L, 1997, BMJ-BRIT MED J, V314, P157, DOI 10.1136/bmj.314.7075.157; PITTS J, 1990, BRIT MED J, V300, P1113, DOI 10.1136/bmj.300.6732.1113; [No title captured]	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					566	567		10.1136/bmj.318.7183.566	http://dx.doi.org/10.1136/bmj.318.7183.566			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037631	Green Published			2022-12-28	WOS:000078966300026
J	Mortensen, PB; Pedersen, CB; Westergaard, T; Wohlfahrt, J; Ewald, H; Mors, O; Andersen, PK; Melbye, M				Mortensen, PB; Pedersen, CB; Westergaard, T; Wohlfahrt, J; Ewald, H; Mors, O; Andersen, PK; Melbye, M			Effects of family history and place and season of birth on the risk of schizophrenia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISORDERS; WINTER	Background Although a family history of schizophrenia is the best-established risk factor for schizophrenia, environmental factors such as the place and season of birth may also be important. Methods Using data from the Civil Registration System in Denmark, we established a population-based cohort of 1.75 million persons whose mothers were Danish women born between 1935 and 1978. We linked this cohort to the Danish Psychiatric Central Register and identified 2669 cases of schizophrenia among cohort members and additional cases among their parents. Results The respective relative risks of schizophrenia for persons with a mother, father, or sibling who had schizophrenia were 9.31 (95 percent confidence interval, 7.24 to 11.96), 7.20 (95 percent confidence interval, 5.10 to 10.16), and 6.99 (95 percent confidence interval, 5.38 to 9.09), as compared with persons with no affected parents or siblings. The risk of schizophrenia was associated with the degree of urbanization of the place of birth (relative risk for the capital vs. rural areas, 2.40; 95 percent confidence interval, 2.13 to 2.70). The risk was also significantly associated with the season of birth; it was highest for births in February and March and lowest for births in August and September. The population attributable risk was 5.5 percent for a history of schizophrenia in a parent or sibling, 34.6 percent for urban place of birth, and 10.5 percent for the season of birth. Conclusions Although a history of schizophrenia in a parent or sibling is associated with the highest relative risk of having the disease, the place and season of birth account for many more cases on a population basis. (N Engl J Med 1999;340:603-8.) (C)1999, Massachusetts Medical Society.	Aarhus Univ Hosp, Hosp Psychiat, Inst Basic Psychiat Res, Dept Psychiat Demog, DK-8240 Risskov, Denmark; Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark	Aarhus University; Aarhus University; Statens Serum Institut	Mortensen, PB (corresponding author), Aarhus Univ Hosp, Hosp Psychiat, Inst Basic Psychiat Res, Dept Psychiat Demog, Skovagervej 2, DK-8240 Risskov, Denmark.	ph.phl.pbm@aaa.dk	Pedersen, Carsten Bøcker/B-8441-2013; Mortensen, Preben B/D-2358-2015	Pedersen, Carsten Bøcker/0000-0003-2077-8533; Mortensen, Preben B/0000-0002-5230-9865; Mors, Ole/0000-0002-5660-0393; melbye, mads/0000-0001-8264-6785				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; BARR CE, 1990, ARCH GEN PSYCHIAT, V47, P869; BRESLOW NE, 1996, STAT APPL, V8, P23; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; COTTER D, 1996, NEUROSCI INTELL UNIT, P17; EATON WW, 1988, HDB SCHIZOPHRENIA, V3, P169; Geddes JR, 1995, BRIT J PSYCHIAT, V167, P786, DOI 10.1192/bjp.167.6.786; GOLDSTEIN JM, 1990, BRIT J PSYCHIAT, V156, P819, DOI 10.1192/bjp.156.6.819; Gottesman I.I., 1991, SCHIZOPHRENIA GENESI; GOTTESMAN II, 1989, ARCH GEN PSYCHIAT, V46, P867; Hettema John M., 1996, British Journal of Psychiatry, V168, P205, DOI 10.1192/bjp.168.2.205; Hills, 1993, STAT MODELS EPIDEMIO; JABLENSKY A, 1995, BAILLIERES CLIN PSYC, V1, P283; KENDLER KS, 1995, BRIT J PSYCHIAT, V167, P184, DOI 10.1192/bjp.167.2.184; KENDLER KS, 1995, ARCH GEN PSYCHIAT, V52, P895; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P527; KENDLER KS, 1993, SCHIZOPHRENIA BULL, V19, P261, DOI 10.1093/schbul/19.2.261; KENDLER KS, 1990, PSYCHOL MED, V20, P311, DOI 10.1017/S0033291700017621; LEWIS G, 1992, LANCET, V340, P137, DOI 10.1016/0140-6736(92)93213-7; LEWIS MS, 1989, SCHIZOPHRENIA BULL, V15, P59, DOI 10.1093/schbul/15.1.59; Malig C, 1996, INT I VITAL REGISTRA, V66, P1; MCNEIL TF, 1995, EPIDEMIOL REV, V17, P107, DOI 10.1093/oxfordjournals.epirev.a036165; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; MUNKJORGENSEN P, 1995, THESIS ARHUS U ARHUS; OCALLAGHAN E, 1991, BRIT J PSYCHIAT, V158, P764, DOI 10.1192/bjp.158.6.764; *SAS I INC, 1996, SAS STAT SOFTW CHANG, P23; TAKEI N, 1995, J EPIDEMIOL COMMUN H, V49, P106, DOI 10.1136/jech.49.1.106; TORREY EF, 1990, SCHIZOPHRENIA BULL, V16, P591, DOI 10.1093/schbul/16.4.591; WESSELY S, 1991, BRIT J PSYCHIAT, V159, P795, DOI 10.1192/bjp.159.6.795; Westergaard T, 1997, J NATL CANCER I, V89, P939, DOI 10.1093/jnci/89.13.939; *WHO, 1967, MAN INT STAT CLASS D, V1; World Health Organization, 1974, GLOSS MENT DIS GUID	33	545	556	0	44	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1999	340	8					603	608		10.1056/NEJM199902253400803	http://dx.doi.org/10.1056/NEJM199902253400803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	169NP	10029644				2022-12-28	WOS:000078755700003
J	O'Connell, DL; Henry, D; Tomlins, R				O'Connell, DL; Henry, D; Tomlins, R			Randomised controlled trial of effect of feedback on general practitioners' prescribing in Australia	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONTINUING MEDICAL-EDUCATION; CLINICAL-PRACTICE; BEHAVIOR; INTERVENTIONS; COSTS	Objective To evaluate the effect on general practitioners' prescribing of feedback on their levels of prescribing. Design Randomised controlled trial. Setting General practice in rural Australia. Participants 2440 full time recognised general practitioners practising in non-urban areas. Intervention Two sets of graphical displays (6 months apart) of their prescribing rates for 2 years, relative to those of their peers, were posted to participants. Data were provided for five main drug groups and were accompanied by educational newsletters. The control group received no information on their prescribing. Main outcome measures Prescribing rates in the intervention and control groups for the five main drug groups, total prescribing and potential substitute prescribing and ordering before and after the interventions. Results The intervention and control groups had similar baseline characteristics (age, sex, patient mix, practices). Median prescribing rates for the two groups were almost identical before and after the interventions. Any changes in prescribing observed in the intervention group were also seen in the control group. There was no evidence that feedback reduced the variability in prescribing nor did it differentially affect the very high or very low prescribers. Conclusions The form of feedback evaluated here-mailed, unsolicited, centralised, government sponsored, and based on aggregate data-had no impact on die prescribing levels of general practitioners.	Univ Newcastle, Fac Med & Hlth Sci, Discipline Clin Pharmacol, Newcastle, NSW 2308, Australia; Hlth Insurance Commiss, Profess Review Div, Tuggeranong, ACT, Australia	University of Newcastle	O'Connell, DL (corresponding author), Newcastle Mater Hosp, Discipline Clin Pharmacol, Level 5,Clin Sci Bldg, Waratah, NSW 2298, Australia.	doconnel@mail.newcastle.edu.au	Henry, David/AAU-4650-2020; Henry, David/AAJ-4332-2020	Henry, David/0000-0001-7169-7704; Henry, David/0000-0003-2934-2242				Andersen JF, 1996, CAN MED ASSOC J, V154, P31; ANDERSON FA, 1994, ARCH INTERN MED, V154, P669, DOI 10.1001/archinte.154.6.669; AXTADAM P, 1993, MED CARE, V31, P784, DOI 10.1097/00005650-199309000-00003; DRUMMOND MF, 1992, HEALTH AFFAIR, V11, P191, DOI 10.1377/hlthaff.11.4.191; GEHLBACH SH, 1984, MED CARE, V22, P193, DOI 10.1097/00005650-198403000-00002; GULLION DS, 1988, J CONTIN EDUC HEALTH, V8, P239; HAAIJERRUSKAMP FM, 1991, DRUGS MONEY PROBLEM; HERSHEY CO, 1986, MED CARE, V24, P472, DOI 10.1097/00005650-198606000-00002; Hill SR, 1997, MED J AUSTRALIA, V167, P6, DOI 10.5694/j.1326-5377.1997.tb138752.x; Majeed A, 1997, BRIT MED J, V315, P1515, DOI 10.1136/bmj.315.7121.1515; MEYER TJ, 1991, J GEN INTERN MED, V6, P133, DOI 10.1007/BF02598309; MITCHELL MW, 1985, J ROY COLL PHYS LOND, V19, P251; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; SCHECTMAN JM, 1995, MED CARE, V33, P139; STEELE MA, 1989, DICP ANN PHARMAC, V23, P497, DOI 10.1177/106002808902300612; THOMSON MA, 1998, COCHRANE COLLABORATI; Wensing M, 1994, Int J Qual Health Care, V6, P115	18	99	101	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 20	1999	318	7182					507	+		10.1136/bmj.318.7182.507	http://dx.doi.org/10.1136/bmj.318.7182.507			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QT	10024260	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000078818100028
J	Ito, N; Rubin, GM				Ito, N; Rubin, GM			Gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle	CELL			English	Article							TSC2 GENE; PROTEIN; MELANOGASTER; EYE; DIFFERENTIATION; IDENTIFICATION; REPLICATION; PROGRESSION; TRANSITION; OMMATIDIUM	Tuberous sclerosis complex (TSC) is an autosomal dominant disorder leading to the widespread development of benign tumors that often contain giant cells. We show that the Drosophila gene gigas encodes a homolog of TSC2, a gene mutated in half of TSC patients. Clones of gigas mutant cells induced in imaginal discs differentiate normally to produce adult structures. However, the cells in these clones are enlarged and repeat S phase without entering M phase. Our results suggest that the TSC disorder may result from an underlying defect in cell cycle control. We have also identified a Drosophila homolog of TSC1.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Rubin, GM (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.	gerry@fruitfly.berkeley.edu		Rubin, Gerald/0000-0001-8762-8703	NIGMS NIH HHS [GM33135] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033135, R37GM033135] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Braet F, 1997, J MICROSC-OXFORD, V186, P84, DOI 10.1046/j.1365-2818.1997.1940755.x; CANAL I, 1994, EUR J NEUROSCI, V6, P1423, DOI 10.1111/j.1460-9568.1994.tb01004.x; CHOU TB, 1993, DEVELOPMENT, V119, P1359; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; FAIN MJ, 1982, DEV BIOL, V92, P247, DOI 10.1016/0012-1606(82)90169-5; FEN S, 1997, DEVELOPMENT, V124, P1497; FERRUS A, 1976, NATURE, V260, P425, DOI 10.1038/260425a0; GATEFF E, 1994, INT J DEV BIOL, V38, P565; Gomez MR, 1988, TUBEROUS SCLEROSIS; Hayashi S, 1996, DEVELOPMENT, V122, P1051; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; HENSKE EP, 1995, GENE CHROMOSOME CANC, V13, P295, DOI 10.1002/gcc.2870130411; JOHNSON WG, 1991, ANN NY ACAD SCI, V615, P211; Karim FD, 1996, GENETICS, V143, P315; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; Kimmerly W, 1996, GENOME RES, V6, P414, DOI 10.1101/gr.6.5.414; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; Kylsten P, 1997, DEV BIOL, V192, P509, DOI 10.1006/dbio.1997.8770; Maheshwar MM, 1996, HUM MOL GENET, V5, P131, DOI 10.1093/hmg/5.1.131; MAKI C, 1989, GENE, V79, P289, DOI 10.1016/0378-1119(89)90211-4; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NELLIST M, 1993, CELL, V75, P1305; Neufeld TP, 1998, GENETICS, V148, P277; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; PIRROTTA V, 1998, GENE DEV, V2, P1839; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SIMPSON P, 1981, DEV BIOL, V85, P299, DOI 10.1016/0012-1606(81)90261-X; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; SU TT, 1995, CELL, V81, P825, DOI 10.1016/0092-8674(95)90000-4; Su TT, 1998, CURR BIOL, V8, pR687, DOI 10.1016/S0960-9822(98)70436-1; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; Thomas BJ, 1997, GENE DEV, V11, P1289, DOI 10.1101/gad.11.10.1289; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; Tsuchiya H, 1996, CANCER RES, V56, P429; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; VINCENT JP, 1994, DEV BIOL, V164, P328, DOI 10.1006/dbio.1994.1203; Weigmann K, 1997, DEVELOPMENT, V124, P3555; Wienecke R, 1996, ONCOGENE, V13, P913; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wilson PJ, 1996, HUM MOL GENET, V5, P249, DOI 10.1093/hmg/5.2.249; WINBERG ML, 1992, DEVELOPMENT, V115, P903; Wolff Tanya, 1993, P1277; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; XU T, 1993, DEVELOPMENT, V117, P1223; [No title captured]	55	211	213	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 19	1999	96	4					529	539		10.1016/S0092-8674(00)80657-1	http://dx.doi.org/10.1016/S0092-8674(00)80657-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	168XN	10052455	Bronze			2022-12-28	WOS:000078718600004
J	Nishida, S; Johnston, A				Nishida, S; Johnston, A			Influence of motion signals on the perceived position of spatial pattern	NATURE			English	Article							MONKEY VISUAL-CORTEX; ATTENTION SHIFT; AREAS V5; EXTRAPOLATION; ORGANIZATION; CONNECTIONS; MOVEMENT	After adaptation of the visual system to motion of a pattern in a particular direction, a static pattern appears to move in the opposite direction-the motion aftereffect (MAE)(1,2). It is thought that the MAE is not accompanied by a shift in perceived spatial position af the pattern bring viewed(3,4), providing psychophysical evidence for a dissociation of the neural processing of motion and position that complements anatomical and physiological evidence of functional specialization in primate and human visual cortex(5-7). However, here we measure the perceived orientation of a static windmill pattern after adaptation to rotary motion and find a gradual shift in orientation in the direction of the illusory rotation, though at a rate much lower than the apparent rotation speed. The orientation shift, which started to decline within a few seconds, could persist longer than the MAE, and disappeared when the MAE was nulled by physical motion of the windmill pattern. Our results indicate that the representation of the position of spatial pattern is dynamically updated by neurons involved in the analysis of motion.	UCL, Dept Psychol, London WC1E 6BT, England; UCL, Inst Cognit Neurosci, London WC1E 6BT, England; NTT, Commun Sci Labs, Human & Informat Sci Res Lab, Atsugi, Kanagawa 2430198, Japan	University of London; University College London; University of London; University College London; Nippon Telegraph & Telephone Corporation	Johnston, A (corresponding author), UCL, Dept Psychol, Gower St, London WC1E 6BT, England.	a.johnston@ucl.ac.uk	Johnston, Alan/B-5393-2008	Johnston, Alan/0000-0001-9026-1199				ANSTIS SM, 1995, ARTFUL EYE, P232; BALDO MVC, 1995, NATURE, V378, P565, DOI 10.1038/378565a0; DEVALOIS RL, 1991, VISION RES, V31, P1619, DOI 10.1016/0042-6989(91)90138-U; Gregory R.L., 1966, EYE BRAIN; KHURANA B, 1995, NATURE, V378, P566, DOI 10.1038/378566a0; LIVINGSTONE MS, 1987, J NEUROSCI, V7, P3416; Mather G., 1998, MOTION AFTEREFFECT M; MERIGAN WH, 1993, ANNU REV NEUROSCI, V16, P369, DOI 10.1146/annurev.ne.16.030193.002101; NAKAYAMA K, 1985, VISION RES, V25, P625, DOI 10.1016/0042-6989(85)90171-3; NIJHAWAN R, 1994, NATURE, V370, P256, DOI 10.1038/370256b0; RAMACHANDRAN VS, 1990, PERCEPTION, V19, P611, DOI 10.1068/p190611; SHIPP S, 1989, EUR J NEUROSCI, V1, P309, DOI 10.1111/j.1460-9568.1989.tb00798.x; SHIPP S, 1989, EUR J NEUROSCI, V1, P333, DOI 10.1111/j.1460-9568.1989.tb00799.x; Snowden RJ, 1998, PERCEPTION, V27, P49; SPIGEL IM, 1960, J PSYCHOL, V50, P209, DOI 10.1080/00223980.1960.9916438; Wohlgemuth A., 1911, AFTER EFFECT SEEN MO, V1; Zeki S., 1993, VISION BRAIN; ZEKI SM, 1974, J PHYSIOL-LONDON, V236, P549, DOI 10.1113/jphysiol.1974.sp010452; ZIHL J, 1983, BRAIN, V106, P313, DOI 10.1093/brain/106.2.313	19	147	147	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 18	1999	397	6720					610	612		10.1038/17600	http://dx.doi.org/10.1038/17600			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GE	10050853				2022-12-28	WOS:000078738500048
J	Craig, DE; Hartka, L; Likosky, WH; Caplan, WM; Litsky, P; Smithey, J				Craig, DE; Hartka, L; Likosky, WH; Caplan, WM; Litsky, P; Smithey, J			Implementation of a hospitalist system in a large health maintenance organization: The Kaiser Permanente experience	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	National Policy Conference on the Hospitalist Movement	DEC 05-06, 1997	SAN FRANCISCO, CA					This paper presents preliminary quality and utilization data from a hospitalist system that is being implemented at Kaiser Permanente, a large health maintenance organization with 16 hospitals in northern California. Hospitalist programs, which are staffed by clinicians highly skilled in caring for inpatients, are being launched with the aim of delivering high-quality, efficient medical care in an increasingly competitive health care delivery environment. This paper also describes, in some detail, the process of implementation at one hospital. Challenges to implementation included 1) overcoming the reluctance of clinic physicians to relinquish inpatient care responsibilities, 2) developing sustainable work schedules, 3) creating effective channels of communication between staff in inpatient and outpatient settings, and 4) designing appropriate compensation scales for hospitalists. Mean length of stay, patient-day rates, admission rates, consultation request rates, costs, and readmission rates were examined for patients discharged from adult medicine services at all 16 hospitals between 1 January 1994 and 30 June 1997. These preliminary resource utilization data seem promising, but further analysis is needed to assess how hospitalist programs may affect clinical quality of care, costs, and patient and provider satisfaction.	So Calif Permanente Med Grp, Dept Qual & Utilizat, Oakland, CA 94612 USA; Kaiser Permanente Med Ctr, Dept Med, Santa Clara, CA 95051 USA; So Calif Permanente Med Grp, Operat Dev, Oakland, CA 94612 USA; So Calif Permanente Med Grp, Operat Support Serv, Oakland, CA 94612 USA	Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; Kaiser Permanente; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups	Likosky, WH (corresponding author), So Calif Permanente Med Grp, Dept Qual & Utilizat, 1800 Harrison St,Suite 410, Oakland, CA 94612 USA.	bill.likosky@ncal.kaiperm.org						CAPLAN WM, 1997, PERMANENTE J, V1, P37; Freese RB, 1999, ANN INTERN MED, V130, P350, DOI 10.7326/0003-4819-130-4-199902161-00004; Kahn HA, 1989, STAT METHODS EPIDEMI; *KAIS PERM INF TEC, 1996, ADT CABS ENH PHAS 1; *PERM MED GROUP, 1997, HOSP BAS SPEC SUGG D; *PERM MED GROUP DE, 1997, POP RISK UT; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713; WACHTER RM, 1997, P EM ROL HOSP AM HLT, P227; 1997, INTERSTUDY COMPETI 3; 1997, FED REG, V62, P45970	10	76	76	3	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	2				355	359		10.7326/0003-4819-130-4-199902161-00005	http://dx.doi.org/10.7326/0003-4819-130-4-199902161-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	166QB	10068405				2022-12-28	WOS:000078587500005
J	Parker, RM; Williams, MV; Weiss, BD; Baker, DW; Davis, TC; Doak, CC; Doak, LG; Hein, K; Meade, CD; Nurss, J; Schwartzberg, JG; Somers, SA; Davis, RM; Riggs, JA; Champion, HC; Howe, JP; Altman, RD; Deitchman, SD; Genel, M; Karlan, MS; Khan, MK; Nielsen, NH; Williams, MA; Young, DC; Schwartzberg, J; Bresolin, LB; Dickinson, BD				Parker, RM; Williams, MV; Weiss, BD; Baker, DW; Davis, TC; Doak, CC; Doak, LG; Hein, K; Meade, CD; Nurss, J; Schwartzberg, JG; Somers, SA; Davis, RM; Riggs, JA; Champion, HC; Howe, JP; Altman, RD; Deitchman, SD; Genel, M; Karlan, MS; Khan, MK; Nielsen, NH; Williams, MA; Young, DC; Schwartzberg, J; Bresolin, LB; Dickinson, BD		Amer Med Assoc	Health literacy - Report of the Council on Scientific Affairs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							READING-ABILITY; CONSENT FORMS; DISCHARGE INSTRUCTIONS; DIABETES EDUCATION; INFORMED CONSENT; EMERGENCY; COMPREHENSION; COMMUNICATION; READABILITY; PAMPHLETS	Context Patients with the greatest health care needs may have the least ability to read and comprehend information needed to function successfully as patients. Objective To examine the scope and consequences of poor hearth literacy in the United States, characterize its implications for patients and physicians, and identify policy and research issues. Participants The 12 members of the Ad Hoc Committee on Health Literacy, American Medical Association Council on Scientific Affairs, were selected by a key informant process as experts in the field of health literacy from a variety of backgrounds in clinical medicine, medical and health services research, medical education, psychology, adult literacy, nursing, and health education. Evidence Literature review using the MEDLINE database for January 1966 through October 1, 1996, searching Medical Subject Heading (MeSH) reading combined with text words health or literacy in the title, abstract, or MeSH. A subsequent search using reading as a search term identified articles published between 1993 and August 1998. Authors of relevant published abstracts were asked to provide manuscripts. Experts in health services research, health education, and medical law identified proprietary and other unpublished references. Consensus Process Consensus among committee members was reached through review of 216 published articles and additional unpublished manuscripts and telephone and Internet conferencing. All committee members approved the final report. Conclusions Patients with inadequate health literacy have a complex array of communications difficulties, which may interact to influence health outcome. These patients report worse health status and have less understanding about their medical conditions and treatment. Preliminary studies indicate inadequate health literacy may increase the risk of hospitalization. Professional and public awareness of the health literacy issue must be increased, beginning with education of medical students and physicians and improved patient-physician communication skills. Future research should focus on optimal methods of screening patients to identify those with poor health literacy, effective health education techniques, outcomes and costs associated with poor health literacy, and the causal pathway of how poor health literacy influences health.	Amer Med Assoc, Council Sci Affairs, Chicago, IL 60610 USA	American Medical Association	Bresolin, LB (corresponding author), Amer Med Assoc, Council Sci Affairs, 515 N State St, Chicago, IL 60610 USA.	Linda_Bresolin@ama-assn.org	Parker, Ruth M/S-4583-2017; Weiss, Barry/AIB-2395-2022; Williams, Michael A./O-4075-2019	Parker, Ruth M/0000-0001-9685-6396; Williams, Michael A./0000-0002-7284-8014				BAKER D, IN PRESS J GEN INTER; Baker DW, 1997, AM J PUBLIC HEALTH, V87, P1027, DOI 10.2105/AJPH.87.6.1027; Baker DW, 1996, ARCH FAM MED, V5, P329, DOI 10.1001/archfami.5.6.329; BAKER DW, IN PRESS PATIENT ED; Bennett CL, 1998, J CLIN ONCOL, V16, P3101, DOI 10.1200/JCO.1998.16.9.3101; BOYLE CM, 1970, BMJ-BRIT MED J, V2, P286, DOI 10.1136/bmj.2.5704.286; Braddock CH, 1997, J GEN INTERN MED, V12, P339, DOI 10.1046/j.1525-1497.1997.00057.x; BRANDES WL, 1996, LITERACY HLTH LAW; CASSILETH BR, 1980, NEW ENGL J MED, V302, P896, DOI 10.1056/NEJM198004173021605; Cole R, 1979, Health Educ J, V38, P111, DOI 10.1177/001789697903800403; Davidoff F, 1997, ANN INTERN MED, V127, P483, DOI 10.7326/0003-4819-127-6-199709150-00011; Davis T C, 1993, Fam Med, V25, P391; Davis T C, 1991, Fam Med, V23, P433; Davis TC, 1998, JNCI-J NATL CANCER I, V90, P668, DOI 10.1093/jnci/90.9.668; Davis TC, 1998, PATIENT EDUC COUNS, V33, P25, DOI 10.1016/S0738-3991(97)00053-0; Davis TC, 1996, CANCER-AM CANCER SOC, V78, P1912, DOI 10.1002/(SICI)1097-0142(19961101)78:9<1912::AID-CNCR11>3.0.CO;2-0; DAVIS TC, 1993, INT J ADDICT, V28, P571, DOI 10.3109/10826089309039648; DAVIS TC, 1994, PEDIATRICS, V93, P460; Davis TC, 1996, PEDIATRICS, V97, P804; Davis TC, 1998, J GEN INTERN MED, V13, P230, DOI 10.1046/j.1525-1497.1998.00072.x; Doak CC, 1996, TEACHING PATIENTS LO; DOAK LG, 1991, TEACHING PATIENTS LO; Dowe MC, 1997, APPL NURS RES, V10, P86, DOI 10.1016/S0897-1897(97)80151-6; ESREY SA, 1988, AM J EPIDEMIOL, V127, P1079, DOI 10.1093/oxfordjournals.aje.a114884; FELDMAN JJ, 1989, AM J EPIDEMIOL, V129, P919, DOI 10.1093/oxfordjournals.aje.a115225; FOEGE AT, 1982, POPULATION STUDIES, V36, P441; GARBER AM, 1989, PATHWAYS HLTH ROLE S, P271; Glazer HR, 1996, PATIENT EDUC COUNS, V27, P185, DOI 10.1016/0738-3991(95)00834-9; Gottfredson LS, 1997, INTELLIGENCE, V24, P79, DOI 10.1016/S0160-2896(97)90014-3; GROSSE RN, 1989, ANNU REV PUBL HEALTH, V10, P281; GROSSMAN SA, 1994, J CLIN ONCOL, V12, P2211, DOI 10.1200/JCO.1994.12.10.2211; GURALNIK JM, 1993, NEW ENGL J MED, V329, P110, DOI 10.1056/NEJM199307083290208; JOLLY BT, 1995, ANN EMERG MED, V26, P443, DOI 10.1016/S0196-0644(95)70112-5; JOLLY BT, 1993, ANN EMERG MED, V22, P573, DOI 10.1016/S0196-0644(05)81944-4; KIRSCH IS, 1993, ADULT LIT AM 1 LOOK; Kitagawa EM, 1973, DIFFERENTIAL MORTALI; Knowles M.S., 1973, ADULT LEARNER NEGLEC; LEDBETTER C, 1990, Health Care for Women International, V11, P295; LOVERDE ME, 1989, J GEN INTERN MED, V4, P410, DOI 10.1007/BF02599693; Meade C D, 1992, Oncol Nurs Forum, V19, P51; MORROW GR, 1980, JAMA-J AM MED ASSOC, V244, P56, DOI 10.1001/jama.244.1.56; MULROW C, 1987, J GEN INTERN MED, V2, P215, DOI 10.1007/BF02596442; *NAT ASTHM ED PREV, 1997, 2 US DEP HHS NAT HEA; *NAT COMM QUAL ASS, 1995, NCQA REV GUID ACCR M; OVERLAND JE, 1993, DIABETIC MED, V10, P847, DOI 10.1111/j.1464-5491.1993.tb00178.x; Parikh NS, 1996, PATIENT EDUC COUNS, V27, P33, DOI 10.1016/0738-3991(95)00787-3; PARKER RM, 1995, J GEN INTERN MED, V10, P537, DOI 10.1007/BF02640361; *PAT FAM ED, 1996, ACCR MAN HOSP; PLIMPTON S, 1994, PUBLIC HEALTH REP, V109, P86; POWERS RD, 1988, ANN EMERG MED, V17, P124, DOI 10.1016/S0196-0644(88)80295-6; RUDD RE, 1994, HEALTH EDUC QUART, V21, P313, DOI 10.1177/109019819402100304; SPANDORFER JM, 1995, ANN EMERG MED, V25, P71, DOI 10.1016/S0196-0644(95)70358-6; STEDMAN LC, 1991, LIT US READERS READI, P75; U. S. Department of Health and Human Services, 1998, HLTH PEOPL 2010 OBJ; *US DEP HHS, 1994, CLEAR SIMPL DEV EFF; Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008; Wallerstein N, 1992, Am J Health Promot, V6, P197; WEISS B, 1999, 20 COMMON PROBLEMS P, P498; Weiss B D, 1992, J Am Board Fam Pract, V5, P257; Weiss B D, 1994, J Health Care Poor Underserved, V5, P99; WEISS BD, 1995, PATIENT EDUC COUNS, V25, P109, DOI 10.1016/0738-3991(95)00710-H; Weiss BD, 1998, J FAM PRACTICE, V46, P168; Weiss BD, 1997, NEW ENGL J MED, V337, P272, DOI 10.1056/NEJM199707243370411; WELLS JA, 1994, PATIENT EDUC COUNS, V24, P249, DOI 10.1016/0738-3991(94)90068-X; WILLIAMS MV, 1995, JAMA-J AM MED ASSOC, V274, P1677; Williams MV, 1998, CHEST, V114, P1008, DOI 10.1378/chest.114.4.1008; Williams MV, 1998, ARCH INTERN MED, V158, P166, DOI 10.1001/archinte.158.2.166; Young Daniel R, 1990, IRB, V12, P1, DOI 10.2307/3564107; 1996, FED REG, V60, P44182; 1995, MMWR MORB MORTAL WKL, V43, P894; 1996, FED REG, V60, P44252	71	975	985	1	166	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1999	281	6					552	557						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	164FQ	10022112				2022-12-28	WOS:000078452900034
J	Kulkarni, RN; Bruning, JC; Winnay, JN; Postic, C; Magnuson, MA; Kahn, CR				Kulkarni, RN; Bruning, JC; Winnay, JN; Postic, C; Magnuson, MA; Kahn, CR			Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes	CELL			English	Article							MOLECULAR MECHANISMS; TARGETED DISRUPTION; FEEDBACK INHIBITION; GLUCOSE-TOLERANCE; ISLET CELLS; B-CELL; RESISTANCE; MELLITUS; GENE; MICE	Dysfunction of the pancreatic beta cell is an important defect in the pathogenesis of type 2 diabetes, although its exact relationship to the insulin resistance is unclear. To determine whether insulin signaling has a functional role in the beta cell we have used the Cre-loxP system to specifically inactivate the insulin receptor gene in the beta cells. The resultant mice exhibit a selective loss of insulin secretion in response to glucose and a progressive impairment of glucose tolerance. These data indicate an important functional role for the insulin receptor in glucose sensing by the pancreatic beta cell and suggest that defects in insulin signaling at the level of the beta cell may contribute to the observed alterations in insulin secretion in type 2 diabetes.	Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Vanderbilt University	Kahn, CR (corresponding author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	kahnr@joslab.harvard.edu	Postic, Catherine/P-2271-2017; Kahn, Ronald/AAY-2435-2021; Magnuson, Mark/AAY-7172-2021; Magnuson, Mark A/B-1335-2009	Postic, Catherine/0000-0002-1875-6960; Kahn, Ronald/0000-0002-7583-9228; Magnuson, Mark/0000-0002-8824-6499; Magnuson, Mark A/0000-0002-8824-6499	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031036, R37DK031036, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK 36836, DK31036] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; AMMON HPT, 1991, J ENDOCRINOL, V128, P27, DOI 10.1677/joe.0.1280027; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGOUD GM, 1987, DIABETES, V36, P959, DOI 10.2337/diabetes.36.8.959; BOGARDUS C, 1984, J CLIN INVEST, V74, P1238, DOI 10.1172/JCI111533; BONNERWEIR S, 1989, DIABETES, V38, P49, DOI 10.2337/diabetes.38.1.49; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; CERASI E, 1972, DIABETES, V21, P224, DOI 10.2337/diab.21.4.224; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; Efendic S, 1988, Adv Exp Med Biol, V246, P167; ELAHI D, 1982, NEW ENGL J MED, V306, P1196, DOI 10.1056/NEJM198205203062002; FAJANS SS, 1989, DIABETES METAB REV, V5, P579, DOI 10.1002/dmr.5610050705; FLIER JS, 1975, SCIENCE, V190, P63, DOI 10.1126/science.170678; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; GILLIES MC, 1990, METABOLISM, V39, P1253, DOI 10.1016/0026-0495(90)90179-G; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HALES CN, 1994, DIABETOLOGIA, V37, pS162, DOI 10.1007/BF00400840; Harbeck MC, 1996, DIABETES, V45, P711, DOI 10.2337/diabetes.45.6.711; IVERSEN J, 1971, DIABETES, V20, P1; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; Josefsen K, 1996, J ENDOCRINOL, V149, P145, DOI 10.1677/joe.0.1490145; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Kulkarni RN, 1997, J CLIN INVEST, V100, P2729, DOI 10.1172/JCI119818; LEAHY JL, 1990, ENDOCRINOLOGY, V126, P1593, DOI 10.1210/endo-126-3-1593; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MCRAE JR, 1981, METABOLISM, V30, P1065, DOI 10.1016/0026-0495(81)90049-4; METZGER D, 1995, P NATL ACAD SCI USA, V92, P6991, DOI 10.1073/pnas.92.15.6991; NESHER R, 1987, EUR J CLIN INVEST, V17, P266, DOI 10.1111/j.1365-2362.1987.tb01247.x; OLEFSKY JM, 1995, AM J CLIN NUTR, V61, p980S, DOI 10.1093/ajcn/61.4.980S; OMEARA NM, 1993, J CLIN INVEST, V92, P262, DOI 10.1172/JCI116560; ORAHILLY S, 1988, NEW ENGL J MED, V318, P1225, DOI 10.1056/NEJM198805123181902; PATEL YC, 1982, SCIENCE, V217, P1155, DOI 10.1126/science.6126003; PFEIFER MA, 1982, DIABETES, V31, P154, DOI 10.2337/diabetes.31.2.154; Pictet R., 1972, HDB PHYSL, P25; Poitout V, 1996, ANNU REV MED, V47, P69; POLONSKY KS, 1995, DIABETES, V44, P705, DOI 10.2337/diabetes.44.6.705; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; REAVEN GM, 1993, J CLIN ENDOCR METAB, V76, P44, DOI 10.1210/jc.76.1.44; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; TEMPLE RC, 1989, LANCET, V1, P293, DOI 10.1016/S0140-6736(89)91306-8; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; TRENT DF, 1984, DIABETES, V33, P170, DOI 10.2337/diabetes.33.2.170; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; TURNER RC, 1988, BAILLIERE CLIN ENDOC, V2, P327, DOI 10.1016/S0950-351X(88)80035-1; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; VAGUE P, 1982, METABOLISM, V31, P139, DOI 10.1016/0026-0495(82)90125-1; VANSCHRAVENDIJK CFH, 1987, ENDOCRINOLOGY, V121, P1784, DOI 10.1210/endo-121-5-1784; VANSCHRAVENDIJK CFH, 1985, ENDOCRINOLOGY, V117, P841; Velloso LA, 1995, FEBS LETT, V377, P353, DOI 10.1016/0014-5793(95)01370-9; VERSPOHL EJ, 1980, J CLIN INVEST, V65, P1230, DOI 10.1172/JCI109778; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; Weinhaus AJ, 1997, DIABETOLOGIA, V40, P374, DOI 10.1007/s001250050690; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wurst W., 1993, Gene targeting: a practical approach., P33	66	894	950	1	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 5	1999	96	3					329	339		10.1016/S0092-8674(00)80546-2	http://dx.doi.org/10.1016/S0092-8674(00)80546-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025399	Bronze			2022-12-28	WOS:000078514600006
J	Levine, C; Zuckerman, C				Levine, C; Zuckerman, C			The trouble with families: Toward an ethic of accommodation	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							MALPRACTICE; CONSENT	Although some clinicians are extraordinarily sensitive to the legitimate roles of patients' families in medical crises, a persistent tendency to equate families with trouble is evident in both the literature and the practice of medicine. Some negative presumptions about families derive from western medicine's almost exclusive focus on the individual patient in codes of ethics, training, and practice. Modern bioethics has reinforced this individualistic approach. Physicians' primary responsibilities are unequivocally to their patients, but a complete understanding of the patient's personhood must include consideration of the significant persons who help define the patient's core identity. One source of tension between professionals and families lies in differing perceptions of the roles that family members should play and how they should play them. Members of a family may act as advocates, provide or manage care, serve as trusted companions on the journey through illness and death, and make decisions on behalf of an incompetent patient. Each role presents potential conflicts. Other sources of conflict include disagreement within a family; challenges to physician authority; fear of litigation; and differing religious, ethnic, or cultural traditions. An ethic of accommodation emphasizes the need to negotiate care plans that do not compromise patients' basic interests but that recognize the capacities and limitations of family members. Family caregivers want understandable and timely information, better training, compassionate recognition of their anxiety, guidance in defining their roles and responsibilities, and support for the setting of fair limits on their sacrifices. Health care professionals can better meet these needs through education and skills acquisition, the establishment of partnerships with families, and regular dialogue and communication.	Beth Israel Deaconess Med Ctr, Ctr Eth Med, New York, NY 10003 USA	Harvard University; Beth Israel Deaconess Medical Center	Levine, C (corresponding author), United Hosp Fund, Families & Hlth Care Project, 350 5th Ave,23rd Floor, New York, NY 10118 USA.							ALMAGOR RC, 1996, ANN REV LAW ETHICS; BECKMAN HB, 1994, ARCH INTERN MED, V154, P1365, DOI 10.1001/archinte.154.12.1365; Butler D J, 1998, Fam Med, V30, P356; COLLOPY B, 1990, HASTINGS CENT REP, V20, pS1; DILL AEP, 1995, SOC SCI MED, V41, P1289, DOI 10.1016/0277-9536(95)00211-O; DUBLER NN, 1995, KENNEDY INST ETHIC J, V5, P289; HICKSON GB, 1994, JAMA-J AM MED ASSOC, V272, P1583, DOI 10.1001/jama.272.20.1583; Kuczewski MG, 1996, HASTINGS CENT REP, V26, P30, DOI 10.2307/3528574; Levine C., 1998, ROUGH CROSSINGS FAMI; Pearlman R A, 1992, J Clin Ethics, V3, P114; PLETCHER LC, 1993, PARENT PROFESSIONAL; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SIEGLER M, 1982, ARCH INTERN MED, V142, P1899, DOI 10.1001/archinte.142.10.1899; Sulmasy DP, 1998, ANN INTERN MED, V128, P621, DOI 10.7326/0003-4819-128-8-199804150-00002; TOMLINSON T, 1990, GERONTOLOGIST, V30, P54, DOI 10.1093/geront/30.1.54; ZUCKERMAN C, 1999, END LIFE CARE DECISI, P8; ZWEIBEL NR, 1989, GERONTOLOGIST, V29, P615, DOI 10.1093/geront/29.5.615	17	92	94	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	1999	130	2					148	152		10.7326/0003-4819-130-2-199901190-00010	http://dx.doi.org/10.7326/0003-4819-130-2-199901190-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	158KG	10068362				2022-12-28	WOS:000078114200009
J	Glazener, CMA; Ramsay, CR; Campbell, MK; Booth, P; Duffty, P; Lloyd, DJ; McDonald, A; Reid, JA				Glazener, CMA; Ramsay, CR; Campbell, MK; Booth, P; Duffty, P; Lloyd, DJ; McDonald, A; Reid, JA			Neonatal examination and screening trial (NEST): a randomised, controlled, switchback trial of alternative policies for low risk infants	BRITISH MEDICAL JOURNAL			English	Article							CONGENITAL DISLOCATION; HIP	Objective To evaluate the effectiveness of one rather than two hospital neonatal examinations in detection of abnormalities. Design Randomised controlled switchback trial. Setting Postnatal wards in a teaching hospital in north east Scotland. Participants All infants delivered at the hospital between March 1993 and February 1995. Intervention A policy of one neonatal screening examination compared with a policy of two. Main outcome measures Congenital conditions diagnosed in hospital; results of community health assessments at 8 weeks and 8 months; outpatient referrals; inpatient admissions; use of general practioner services; focused analysis of outcomes for suspected hip and heart abnormalities. Results 4835 babies were allocated to receive one screening examination (one screen policy) and 4877 to receive two (two screen policy). More congenital conditions were suspected at discharge among babies examined twice (9.9 v 8.3 diagnoses per 100 babies; 95% confidence interval for difference 0.3 to 2.7). There was no no overall significant difference between the groups in use of community, outpatient, or inpatient resources or in health care received. Although more babies who were examined twice attended orthopaedic outpatient clinics (340 (7%) v 289 (6%)), particularly for suspected congenital dislocation of the hip (176 (3.6/100 babies) v 137 (2.8/100 babies); difference - 0.8; - 1.5 to 0.1), there was no significant difference in the number of babies who required active management (12 (0.2%) v 15 (0.3%)). Conclusions Despite more suspected abnormalities, there was no evidence of net health gain from a policy of two hospital neonatal examinations, Adoption of a single examination policy would save resources both during the postnatal hospital stay and through fewer outpatient consultations.	Hlth Serv Res Unit, Aberdeen AB25 2ZD, Scotland; Aberdeen Matern Hosp, Aberdeen AB25 2ZL, Scotland	University of Aberdeen; University of Aberdeen	Glazener, CMA (corresponding author), Hlth Serv Res Unit, Polwarth Bldg, Aberdeen AB25 2ZD, Scotland.		Ramsay, Craig/AAD-8249-2021; Campbell, Marion/ABB-7063-2020	Ramsay, Craig/0000-0003-4043-7349; Campbell, Marion/0000-0001-5386-4097				ABUHARB M, 1994, ARCH DIS CHILD, V71, P179; BARLOW TG, 1962, J BONE JOINT SURG BR, V44, P292, DOI 10.1302/0301-620X.44B2.292; BRADLEY J, 1987, J BONE JOINT SURG BR, V69, P257, DOI 10.1302/0301-620X.69B2.3818757; CARTLIDGE PHT, 1992, ARCH DIS CHILD, V67, P1421, DOI 10.1136/adc.67.12.1421; Cochran WG, 1957, EXPT DESIGNS; Daly L. E., 1991, INTERPRETATION USES; Godward S, 1998, LANCET, V351, P1149, DOI 10.1016/S0140-6736(97)10466-4; HALL DMB, 1989, HLTH ALL CHILDREN PR; HUGHES AP, 1991, BRIT MED J, V302, P1209, DOI 10.1136/bmj.302.6786.1209-c; KALAMCHI A, 1980, J BONE JOINT SURG AM, V62, P876, DOI 10.2106/00004623-198062060-00002; MANNING DJ, 1991, BRIT MED J, V302, P1209; *MAT SERV ADV COMM, 1985, MAT CAR ACT 3; MOSS GD, 1991, BRIT MED J, V302, P878, DOI 10.1136/bmj.302.6781.878; Robinson R, 1998, BMJ-BRIT MED J, V316, P1	14	30	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					627	631		10.1136/bmj.318.7184.627	http://dx.doi.org/10.1136/bmj.318.7184.627			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066201	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000079089200022
J	Farinella, P; Vokrouhlicky, D				Farinella, P; Vokrouhlicky, D			Semimajor axis mobility of asteroidal fragments	SCIENCE			English	Article							ORDINARY CHONDRITES; EARTH; RADIATION; EVOLUTION; VELOCITY; HISTORY; SYSTEM; GASPRA; BELT	The semimajor axes of asteroids up to about 20 kilometers in diameter drift as a result of the Yarkovsky effect, a subtle nongravitational mechanism related to radiation pressure recoil on spinning objects that orbit the sun. Over the collisional lifetimes of these objects (typically, 10 to 1000 million years), orbital semimajor axes can be moved by a few hundredths of an astronomical unit for bodies between 1 and 10 kilometers in mean radius. This has implications for the delivery of multikilometer near-Earth asteroids, because the Yarkovsky drift drives many small main-belt asteroids into the resonances that transport them to the Mars-crossing state and eventually to near-Earth space. Recent work has shown that, without such a drift, the Mars-crossing population would be depleted over about 100 million years, a time scale much smaller than the age of the solar system. Moreover, the Yarkovsky semimajor axis mobility may spread in an observable way the tight semimajor axis clustering of small asteroids produced as a consequence of disruptive collisions.	Univ Trieste, Dipartimento Astron, I-34131 Trieste, Italy; Charles Univ, Inst Astron, CZ-18000 Prague 8, Czech Republic	University of Trieste; Charles University Prague	Farinella, P (corresponding author), Univ Trieste, Dipartimento Astron, Via Tiepolo 11, I-34131 Trieste, Italy.		Vokrouhlický, David/Q-4359-2017	Vokrouhlický, David/0000-0002-6034-5452				AFONSO GB, 1995, PLANET SPACE SCI, V43, P787, DOI 10.1016/0032-0633(94)00171-M; BAGATIN AC, 1994, PLANET SPACE SCI, V42, P1079, DOI 10.1016/0032-0633(94)90008-6; Binzel R.P., 1989, ASTEROIDS, P416; BROUWER D, 1961, METHODS CELESTIAL ME, pCH16; BURNS JA, 1979, ICARUS, V40, P1, DOI 10.1016/0019-1035(79)90050-2; Caffee M.W., 1988, METEOR EARLY SOLAR S, P205; Ceplecha Z, 1996, ASTRON ASTROPHYS, V311, P329; CHAPMAN CR, 1989, ASTEROIDS, V2, P386; Davis DR, 1996, ICARUS, V120, P220, DOI 10.1006/icar.1996.0047; DAVIS DR, 1989, ASTEROIDS, V2, P805; DOHNANYI JS, 1969, J GEOPHYS RES, V74, P2531, DOI 10.1029/JB074i010p02531; Farinella P, 1998, ICARUS, V132, P378, DOI 10.1006/icar.1997.5872; FARINELLA P, 1992, ASTRON ASTROPHYS, V257, P329; Farinella P, 1996, PLANET SPACE SCI, V44, P1551, DOI 10.1016/S0032-0633(96)00073-6; GIBLIN I, 1994, ICARUS, V110, P203, DOI 10.1006/icar.1994.1117; Giblin I, 1998, PLANET SPACE SCI, V46, P921, DOI 10.1016/S0032-0633(98)00016-6; Giblin I, 1998, ICARUS, V134, P77, DOI 10.1006/icar.1998.5937; GREENBERG R, 1994, ICARUS, V107, P84, DOI 10.1006/icar.1994.1008; HARTMANN WK, IN PRESS METEORIT PL; Knezevic Z, 1997, PLANET SPACE SCI, V45, P1581, DOI 10.1016/S0032-0633(97)00117-7; Langseth M. G., 1973, LUNAR PLANETARY SCI, P4; MARTI K, 1992, ANNU REV EARTH PL SC, V20, P221, DOI 10.1146/annurev.ea.20.050192.001253; Menichella M, 1996, EARTH MOON PLANETS, V72, P133, DOI 10.1007/BF00117512; Migliorini F, 1998, SCIENCE, V281, P2022, DOI 10.1126/science.281.5385.2022; MILANI A, 1995, ICARUS, V115, P209, DOI 10.1006/icar.1995.1090; Milani A., 1987, NONGRAVITATIONAL PER; Morbidelli A, 1998, METEORIT PLANET SCI, V33, P999, DOI 10.1111/j.1945-5100.1998.tb01707.x; MORBIDELLI A, IN PRESS ICARUS; NAKAMURA A, 1991, ICARUS, V92, P132, DOI 10.1016/0019-1035(91)90040-Z; NAKAMURA AM, 1994, PLANET SPACE SCI, V42, P1043, DOI 10.1016/0032-0633(94)90005-1; NAKAMURA T, 1994, ASTR SOC P, V63, P52; Opik E.J., 1951, P R IRISH ACAD A, V54, P165; PETERSON C, 1976, ICARUS, V29, P91, DOI 10.1016/0019-1035(76)90105-6; PRAVEC P, 1998, IAU CIRC, V6941, P2; Presley MA, 1997, J GEOPHYS RES-PLANET, V102, P6551, DOI 10.1029/96JE03303; RABINOWITZ DL, 1993, ASTROPHYS J, V407, P412, DOI 10.1086/172524; Radzievskii V.V., 1952, AZH, V29, P162; Rubincam DP, 1998, J GEOPHYS RES-PLANET, V103, P1725, DOI 10.1029/97JE03034; RUBINCAM DP, 1995, J GEOPHYS RES-PLANET, V100, P1585, DOI 10.1029/94JE02411; RUBINCAM DP, 1987, J GEOPHYS RES-SOLID, V92, P1287, DOI 10.1029/JB092iB02p01287; Slabinski VJ, 1997, CELEST MECH DYN ASTR, V66, P131, DOI 10.1007/BF00054962; Vokrouhlicky D, 1998, ASTRON ASTROPHYS, V335, P1093; Vokrouhlicky D, 1998, ASTRON J, V116, P2032, DOI 10.1086/300565; Vokrouhlicky D, 1998, ASTRON ASTROPHYS, V335, P351; WECHSLER AE, 1972, THERMAL CHARACTERIST, P215; WETHERILL GW, 1980, METEORITICS, V15, P386; YOMOGIDA K, 1983, J GEOPHYS RES, V88, P9513, DOI 10.1029/JB088iB11p09513; ZAPPALA V, 1995, ICARUS, V116, P291, DOI 10.1006/icar.1995.1127	49	131	131	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	1999	283	5407					1507	1510		10.1126/science.283.5407.1507	http://dx.doi.org/10.1126/science.283.5407.1507			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066167				2022-12-28	WOS:000078959200039
J	Ghoname, ESA; Craig, WF; White, PF; Ahmed, HE; Hamza, MA; Henderson, BN; Gajraj, NM; Huber, PJ; Gatchel, RJ				Ghoname, ESA; Craig, WF; White, PF; Ahmed, HE; Hamza, MA; Henderson, BN; Gajraj, NM; Huber, PJ; Gatchel, RJ			Percutaneous electrical nerve stimulation for low back pain - A randomized crossover study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPINAL MANIPULATION; CONTROLLED TRIAL; EXERCISE; TENS; ELECTROACUPUNCTURE; REHABILITATION; MEDICINE; PROGRAM; MODEL	Context Low back pain (LBP) contributes to considerable disability and lost wages in the United States. Commonly used opioid and nonopioid analgesic drugs produce adverse effects and are of limited long-term benefit in the management of this patient population. Objective To compare the effectiveness of a novel nonpharmacologic pain therapy, percutaneous electrical nerve stimulation (PENS), with transcutaneous electrical nerve stimulation (TENS) and flexion-extension exercise therapies in patients with long-term LBP. Design A randomized, single-blinded, sham-controlled, crossover study from March 1997 to December 1997. Setting An ambulatory pain management center at a university medical center. Patients Twenty-nine men and 31 women with LBP secondary to degenerative disk disease. Interventions Four therapeutic modalities (sham-PENS, PENS, TENS, and exercise therapies) were each administered for a period of 30 minutes 3 times a week for 3 weeks. Main Outcome Measures Pretreatment and posttreatment visual analog scale (VAS) scores for pain, physical activity, and quality of sleep; daily analgesic medication usage; a global patient assessment questionnaire; and Health Status Survey Short Form (SF-36). Results PENS was significantly more effective in decreasing VAS pain scores after each treatment than sham-PENS, TENS, and exercise therapies (after-treatment mean +/- SD VAS for pain, 3.4 +/- 1.4 cm, 5.5 +/- 1.9 cm, 5.6 +/- 1.9 cm, and 6.4 +/- 1.9 cm, respectively). The average +/- SD daily oral intake of nonopioid analgesics (2.6 +/- 1.4 pills per day) was decreased to 1.3 +/- 1.0 pills per day with PENS (P < .008) compared with 2.5 +/- 1.1, 2.2 +/- 1.0, and 2.6 +/- 1.2 pills per day with sham-PENS, TENS, and exercise, respectively. Compared with the other 3 modalities, 91 % of the patients reported that PENS was the most effective in decreasing their LBP. The PENS therapy was also significantly more effective in improving physical activity, quality of sleep, and sense of well-being (P < .05 for each). The SF-36 survey confirmed that PENS improved posttreatment function more than sham-PENS, TENS, and exercise. Conclusions In this sham-controlled study, PENS was more effective than TENS or exercise therapy in providing short-term pain relief and improved physical function in patients with long-term LBP.	Univ Texas, SW Med Ctr, Dept Anesthesiol & Pain Management, Eugene McDermott Ctr Pain Management, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Surg, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	White, PF (corresponding author), Univ Texas, SW Med Ctr, Dept Anesthesiol & Pain Management, Eugene McDermott Ctr Pain Management, 5161 Harry Hines Blvd,Suite CS 2-202, Dallas, TX 75235 USA.	pwhite@mednet.swmed.edu						Ahmed HE, 1998, ANESTH ANALG, V87, P911, DOI 10.1097/00000539-199810000-00031; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Faas A, 1996, SPINE, V21, P2874, DOI 10.1097/00007632-199612150-00016; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; HADLER NM, 1987, SPINE, V12, P703, DOI 10.1097/00007632-198709000-00012; Hadler NM, 1997, NEW ENGL J MED, V337, P341, DOI 10.1056/NEJM199707313370511; HERMAN E, 1994, SPINE, V19, P561, DOI 10.1097/00007632-199403000-00012; KRAUS H, 1983, AM FAM PHYSICIAN, V28, P153; LAITINEN J, 1976, American Journal of Chinese Medicine, V4, P169, DOI 10.1142/S0192415X76000214; LEHMANN TR, 1986, PAIN, V26, P277, DOI 10.1016/0304-3959(86)90057-6; LIAO SJ, 1992, ACUPUNCTURE ELECTRO, V17, P249, DOI 10.3727/036012992816357666; MANNICHE C, 1991, PAIN, V47, P53, DOI 10.1016/0304-3959(91)90011-L; MANNICHE C, 1995, DAN MED BULL, V42, P301; MARCHAND S, 1993, PAIN, V54, P99, DOI 10.1016/0304-3959(93)90104-W; MELZACK R, 1983, PHYS THER, V63, P489, DOI 10.1093/ptj/63.4.489; Moore SR, 1997, ARCH PHYS MED REHAB, V78, P55, DOI 10.1016/S0003-9993(97)90010-1; Romita VV, 1997, BRAIN RES BULL, V42, P289, DOI 10.1016/S0361-9230(96)00264-X; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; Sun R, 1997, ANESTH ANALG, V84, pS339; THOMPSON A, 1973, THOMPSONS MANEUVER N; TWOMEY L, 1995, SPINE, V20, P615, DOI 10.1097/00007632-199503010-00021; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002; WALSH DM, 1995, PAIN, V61, P39, DOI 10.1016/0304-3959(94)00147-7; Ware J.E, 1994, PHYS MENTAL HLTH SUM; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Watcha MF, 1997, ANESTHESIOLOGY, V86, P1170, DOI 10.1097/00000542-199705000-00021; [No title captured]	28	130	147	1	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					818	823		10.1001/jama.281.9.818	http://dx.doi.org/10.1001/jama.281.9.818			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10071003				2022-12-28	WOS:000078804300032
J	Lowe, MD; Harcombe, AA; Grace, AA; Petch, MC				Lowe, MD; Harcombe, AA; Grace, AA; Petch, MC			Restrictive-constrictive heart failure masquerading as liver disease	BRITISH MEDICAL JOURNAL			English	Article							BUDD-CHIARI SYNDROME; PERICARDITIS; CARDIOMYOPATHY		Papworth Hosp, Dept Cardiol, Cambridge CB3 8RE, England	Papworth Hospital	Petch, MC (corresponding author), Papworth Hosp, Dept Cardiol, Cambridge CB3 8RE, England.							ARORA A, 1991, J CLIN GASTROENTEROL, V13, P178, DOI 10.1097/00004836-199104000-00012; ARORA A, 1993, AM J GASTROENTEROL, V88, P430; BLAKE S, 1983, AM HEART J, V106, P432, DOI 10.1016/0002-8703(83)90226-0; CAMERON J, 1987, AM HEART J, V113, P354, DOI 10.1016/0002-8703(87)90278-X; FOWLER NO, 1982, AM J CARDIOL, V50, P1014, DOI 10.1016/0002-9149(82)90410-6; HANCOCK EW, 1971, CIRCULATION, V43, P183, DOI 10.1161/01.CIR.43.2.183; HILL RW, 1956, P STAFF M MAYO CLIN, V31, P627; HIRSCHMANN JV, 1978, AM HEART J, V96, P110, DOI 10.1016/0002-8703(78)90133-3; IDRISS FS, 1974, ARCH SURG-CHICAGO, V109, P223; KIRSCH M, 1992, SOUTH MED J, V85, P1151, DOI 10.1097/00007611-199211000-00023; KLEIN AL, 1993, J AM COLL CARDIOL, V22, P1935, DOI 10.1016/0735-1097(93)90782-V; Kushwaha SS, 1997, NEW ENGL J MED, V336, P267, DOI 10.1056/NEJM199701233360407; Lorell BH, 1997, HEART DIS TXB CARDIO; Lowe MD, 1997, LANCET, V350, P1000, DOI 10.1016/S0140-6736(97)06302-2; MANGA P, 1984, BRIT HEART J, V52, P465; MASUI T, 1992, RADIOLOGY, V182, P369, DOI 10.1148/radiology.182.2.1732952; ROBERTS SH, 1978, DIG DIS, V23, P844; SOLANO FX, 1986, AM J MED, V80, P113, DOI 10.1016/0002-9343(86)90058-6; TOBKES AI, 1995, DIGEST DIS, V13, P267, DOI 10.1159/000171507; VAITKUS PT, 1991, AM HEART J, V122, P1431, DOI 10.1016/0002-8703(91)90587-8; WOOD P, 1961, AM J CARDIOL, V7, P48, DOI 10.1016/0002-9149(61)90422-2	21	15	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					585	586		10.1136/bmj.318.7183.585	http://dx.doi.org/10.1136/bmj.318.7183.585			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037641	Green Published			2022-12-28	WOS:000078966300035
J	Clayton, DD; Liu, WH; Dalgarno, A				Clayton, DD; Liu, WH; Dalgarno, A			Condensation of carbon in radioactive supernova gas	SCIENCE			English	Article							RADIATIVE ASSOCIATION; INTERSTELLAR CLOUDS; MURCHISON METEORITE; LARGE HYDROCARBONS; PRESOLAR GRAPHITE; CLUSTERS; MATTER; ORIGIN; GRAINS	Chemistry resulting in the formation of Large carbon-bearing molecules and dust in the interior of an expanding supernova was explored, and the equations governing their abundances were solved numerically, Carbon dust condenses from initially gaseous carbon and oxygen atoms because energetic electrons produced by radioactivity in the supernova cause dissociation of the carbon monoxide molecules, which would otherwise form and Limit the supply of carbon atoms, The resulting free carbon atoms enable carbon dust to grow faster by carbon association than the rate at which the dust can be destroyed by oxidation. The origin of presolar micrometer-sized carbon solids that are found in meteorites is thereby altered.	Clemson Univ, Dept Phys & Astron, Clemson, SC 29634 USA; Oak Ridge Natl Lab, Div Phys, Oak Ridge, TN 37831 USA; Univ Tennessee, Dept Phys, Knoxville, TN 37996 USA; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA	Clemson University; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution	Clayton, DD (corresponding author), Clemson Univ, Dept Phys & Astron, Clemson, SC 29634 USA.							Amari S, 1997, AIP CONF PROC, P287, DOI 10.1063/1.53330; Andreazza CM, 1997, MON NOT R ASTRON SOC, V287, P287, DOI 10.1093/mnras/287.2.287; BATES DR, 1983, ASTROPHYS J, V267, pL121, DOI 10.1086/184015; BERNATOWICZ T, 1997, ASTROPHYSICAL IMPLIC, P391; Bernatowicz TJ, 1996, ASTROPHYS J, V472, P760, DOI 10.1086/178105; Bernatowicz TJ, 1997, PHYS TODAY, V50, P26, DOI 10.1063/1.882049; Bettens RPA, 1997, ASTROPHYS J, V478, P585, DOI 10.1086/303834; BETTENS RPA, 1995, INT J MASS SPECTROM, V149, P321, DOI 10.1016/0168-1176(95)04266-N; Bettens RPA, 1996, ASTROPHYS J, V468, P686, DOI 10.1086/177726; BETTENS RPA, 1995, ASTROPHYS J, V443, P664, DOI 10.1086/175558; Choi BG, 1998, SCIENCE, V282, P1284, DOI 10.1126/science.282.5392.1284; Clayton D. D., 1981, P LUNAR PLANET SCI, V12B, P1781; CLAYTON DD, 1976, ASTROPHYS SPACE SCI, V42, P463, DOI 10.1007/BF01225970; CLAYTON DD, 1975, NATURE, V257, P36, DOI 10.1038/257036b0; Clayton DD, 1997, ASTROPHYS SPACE SCI, V251, P355, DOI 10.1023/A:1000799831553; CLAYTON DD, 1978, MOON PLANETS, V19, P109, DOI 10.1007/BF00896983; CLAYTON DD, 1991, ASTROPHYS J, V375, P221, DOI 10.1086/170184; Clayton DD, 1998, METEORIT PLANET SCI, V33, pA32; CLAYTON DD, 1998, LUNAR PLANET SCI, V29; FREED KF, 1982, ASTROPHYS J, V263, P718, DOI 10.1086/160543; HERBST E, 1991, MON NOT R ASTRON SOC, V253, P341, DOI 10.1093/mnras/253.2.341; HERBST E, 1994, MON NOT R ASTRON SOC, V268, P335, DOI 10.1093/mnras/268.2.335; Hoppe P, 1996, SCIENCE, V272, P1314, DOI 10.1126/science.272.5266.1314; LIU WH, 1995, ASTROPHYS J, V454, P472, DOI 10.1086/176498; LODDERS K, 1995, METEORITICS, V30, P661, DOI 10.1111/j.1945-5100.1995.tb01164.x; Lodders K, 1997, ASTROPHYS J, V484, pL71, DOI 10.1086/310757; LUCY LB, 1989, IAU C, V120, P164; MEZZACAPPA A, 1998, STELLAR EVOLUTION ST, P3; Nittler LR, 1996, ASTROPHYS J, V462, pL31, DOI 10.1088/1538-4357/462/1/L31; SHARP CM, 1995, GEOCHIM COSMOCHIM AC, V59, P1633, DOI 10.1016/0016-7037(95)00069-C; Terzieva R, 1998, ASTROPHYS J, V501, P207, DOI 10.1086/305811; Van Orden A, 1998, CHEM REV, V98, P2313, DOI 10.1021/cr970086n; WEAVER TA, 1993, PHYS REP, V227, P65, DOI 10.1016/0370-1573(93)90058-L; Woon DE, 1996, ASTROPHYS J, V465, P795, DOI 10.1086/177463	34	112	112	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1290	1292		10.1126/science.283.5406.1290	http://dx.doi.org/10.1126/science.283.5406.1290			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037591	Green Published			2022-12-28	WOS:000078839900030
J	Ulloa, L; Doody, J; Massague, J				Ulloa, L; Doody, J; Massague, J			Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway	NATURE			English	Article							FACTOR-BETA; SIGNALING PATHWAYS; SMAD PROTEINS; IFN-GAMMA; CELLS; EXPRESSION; RECEPTORS; IDENTIFICATION; TRANSDUCTION; ANTAGONIST	Transforming growth factor-beta (TGF-beta) and interferon-gamma (IFN-gamma) have opposite effects on diverse cellular functions(1-5), but the basis for this antagonism is not known(6). TGF-beta signals through a receptor serine kinase that phosphorylates and activates the transcription factors Smads 2 and 3 (refs 7, 8), whereas the IFN-gamma receptor and its associated protein tyrosine kinase Jak1 mediate phosphorylation and activation of the transcription factor Stat1 (refs 6, 9, 10). Here we present a basis for the integration of TGF-beta and IFN-gamma signals. IFN-gamma inhibits the TGF beta-induced phosphorylation of Smad3 and its attendant events, namely, the association of Smad3 with Smad4, the accumulation of Smad3 in the nucleus, and the activation of TGF beta-responsive genes. Acting through Jak1 and Stat1, IFN-gamma induces the expression of Smad7, an antagonistic SMAD(11,12), which prevents the interaction of Smad3 with the TGF-beta receptor. The results indicate a mechanism of transmodulation between the STAT and SMAD signal-transduction pathways.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.		Ulloa, Luis/AAE-8751-2019	Ulloa, Luis/0000-0002-7702-7549; Massague, Joan/0000-0001-9324-8408				BAUVOIS B, 1992, J IMMUNOL, V148, P3912; CACAMO J, 1994, MOL CELL BIOL, V14, P3810; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CZARNIECKI CW, 1988, J IMMUNOL, V140, P4217; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; KUMAR R, 1990, J BIOL CHEM, V265, P4578; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEE K, 1987, EXP CELL RES, V173, P156, DOI 10.1016/0014-4827(87)90341-7; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHMITT E, 1994, EUR J IMMUNOL, V24, P793, DOI 10.1002/eji.1830240403; Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364; Spittler A, 1997, IMMUNOLOGY, V90, P286, DOI 10.1046/j.1365-2567.1997.00148.x; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tu GC, 1998, J BIOL CHEM, V273, P25125, DOI 10.1074/jbc.273.39.25125; Xiao BG, 1996, CLIN EXP IMMUNOL, V103, P475; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	30	677	729	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 25	1999	397	6721					710	713		10.1038/17826	http://dx.doi.org/10.1038/17826			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AP	10067896				2022-12-28	WOS:000078840100054
J	Jeelani, NUO; Jaspan, T; Punt, JAG				Jeelani, NUO; Jaspan, T; Punt, JAG			Lesson of the week - Tethered cord syndrome after myelomeningocoele repair	BRITISH MEDICAL JOURNAL			English	Article							SPINA-BIFIDA; ADULTS		Univ Nottingham Hosp, Dept Paediat Neurosurg, Nottingham NG7 2UH, England; Univ Nottingham Hosp, Dept Neuroradiol, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Punt, JAG (corresponding author), Univ Nottingham Hosp, Dept Paediat Neurosurg, Nottingham NG7 2UH, England.			Jeelani, Noor ul Owase/0000-0002-3240-681X				Bell WO, 1996, PEDIATR NEUROSURG, V24, P134, DOI 10.1159/000121029; FILLER AG, 1995, BRIT J NEUROSURG, V9, P659; GUTHKELCH AN, 1986, DEV MED CHILD NEUROL, V28, P525; HOLLAND MB, 1983, Z KINDERCHIR, V38, P113; MCCARTHY GT, 1991, BRIT MED J, V302, P65, DOI 10.1136/bmj.302.6768.65; MCCLONE DG, 1989, PAEDIAT NEUROSURGERY, P53; Murphy M, 1996, ARCH DIS CHILD-FETAL, V75, pF133, DOI 10.1136/fn.75.2.F133; PANG D, 1982, J NEUROSURG, V57, P32, DOI 10.3171/jns.1982.57.1.0032; SCHNEIDER SJ, 1993, NEUROSURGERY, V32, P214, DOI 10.1227/00006123-199302000-00010; TAMAKI N, 1988, J NEUROSURG, V69, P393, DOI 10.3171/jns.1988.69.3.0393; WILDEN JN, 1989, J NEUROSURG, V70, P815	11	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1999	318	7182					516	517		10.1136/bmj.318.7182.516	http://dx.doi.org/10.1136/bmj.318.7182.516			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QT	10024263	Green Published			2022-12-28	WOS:000078818100031
J	Vedhara, K; Cox, NKM; Wilcock, GK; Perks, P; Hunt, M; Anderson, S; Lightman, SL; Shanks, NM				Vedhara, K; Cox, NKM; Wilcock, GK; Perks, P; Hunt, M; Anderson, S; Lightman, SL; Shanks, NM			Chronic stress in elderly carers of dementia patients and antibody response to influenza vaccination	LANCET			English	Article							KILLER-CELL ACTIVITY; IMMUNE-RESPONSE; CORTISOL-LEVELS; OLDER ADULTS; VIRUS; MEN; CAREGIVERS; DISTRESS; BURDEN	Background There are many reports of psychological morbidity in spousal carers of patients with dementia. The consequences of this increased stress on the immune system are unclear. We investigated whether antibody responses to influenza vaccination differed between carers and a control group, and the relation of the antibody response to the hypothalamic-pituitary-adrenal (HPA) axis. Methods 50 spousal carers of dementia patients, median age 73 years (IQR 66-77), and 67 controls (68 years [66-71]) of similar socioeconomic status were enrolled. Anxiety and depression were measured by the Savage Aged Personality Screening Scale and stress by the Global Measure of Perceived Stress scale. Principal-component analysis was used to yield a summary score of emotional distress from these two scales. Salivary cortisol concentrations were measured over a single day at three times (0800-100, 1100-1300, and 2000-2200). Participants received a trivalent influenza vaccine and IgG antibody titres to each strain were measured on days 0, 7, 14, and 28. Findings Mean scores of emotional distress were significantly higher in carers at each time point than in controls (all p < 0.0003). Mean (SD) salivary cortisol concentrations, calculated as area under the curve (AUC), were higher in carers than controls at all three assessments (6 months 16.0 [8.0] vs 11.2 [4.4], p = 0.0001; respectively). Eight (16%) of 50 carers and 26 (39%) of 67 controls had a four-fold increase in at least one of the IgG titres (p = 0.007). There was an inverse relation between AUC cortisol and IgG antibody titre to the Nanchang strain that was significant on day 14 (r = -0.216, p = 0.039). Interpretation Elderly carers of spouses with dementia have increased activation of the hypothalamic-pituary-adrenal axis and a poor antibody response to influenza vaccine. Carers may be more vulnerable to infectious disease than the population of a similar age.	Univ Bristol, Dept Expt Psychol, Bristol BS8 1TN, Avon, England; Univ Bristol, Dept Med, Bristol BS8 1TN, Avon, England; Frenchay Hosp, Dept Care Elderly, Bristol BS16 1LE, Avon, England	University of Bristol; University of Bristol	Vedhara, K (corresponding author), Univ Bristol, Dept Expt Psychol, 8 Woodland Rd, Bristol BS8 1TN, Avon, England.		vedhara, kavita/G-3565-2010	Vedhara, Kavita/0000-0002-9940-7534				Braithwaite V, 1996, RES AGING, V18, P139, DOI 10.1177/0164027596182001; BRANTLEY PJ, 1988, J CONSULT CLIN PSYCH, V56, P549, DOI 10.1037/0022-006X.56.4.549; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Esterling BA, 1996, PSYCHOSOM MED, V58, P264, DOI 10.1097/00006842-199605000-00010; GLASER R, 1994, PSYCHONEUROENDOCRINO, V19, P765, DOI 10.1016/0306-4530(94)90023-X; GLASER R, 1993, BEHAV NEUROSCI, V107, P252; Ironson G, 1994, Int J Behav Med, V1, P90, DOI 10.1207/s15327558ijbm0101_6; Irwin M, 1997, ANN BEHAV MED, V19, P83, DOI 10.1007/BF02883324; IRWIN M, 1988, BIOL PSYCHIAT, V24, P173, DOI 10.1016/0006-3223(88)90272-7; KIECOLTGLASER JK, 1987, PSYCHOSOM MED, V49, P523, DOI 10.1097/00006842-198709000-00008; KIECOLTGLASER JK, 1984, PSYCHOSOM MED, V46, P15, DOI 10.1097/00006842-198401000-00004; KiecoltGlaser JK, 1996, P NATL ACAD SCI USA, V93, P3043, DOI 10.1073/pnas.93.7.3043; KIRSCHBAUM C, 1995, PSYCHOSOM MED, V57, P468, DOI 10.1097/00006842-199509000-00009; LEVINE M, 1987, J AM GERIATR SOC, V35, P609, DOI 10.1111/j.1532-5415.1987.tb04335.x; Murray JM, 1997, AGING MENT HEALTH, V1, P256, DOI 10.1080/13607869757155; Rose R.M., 1980, PSYCHIAT CLIN N AM, V3, P251, DOI [DOI 10.1016/S0193-953X(18)30965-1, https://doi.org/10.1016/S0193-953X(18)30965-1]; SAVAGE D, 1993, SAVAGE AGED PERSONAL; SAVAGE D, 1990, SAVAGE PERSONALITY S; SAVAGE D, 1997, SCREENING PERSONALIT; SHIMADA M, 1995, HORM RES, V44, P213, DOI 10.1159/000184628; Vedhara K, 1997, J PSYCHOSOM RES, V42, P379, DOI 10.1016/S0022-3999(96)00351-0; WALLSTEN SM, 1993, INT J AGING HUM DEV, V37, P55, DOI 10.2190/FB4J-MNDK-YNTH-3XJP; Waltrowicz W, 1996, AUST J AGEING, V15, P115, DOI 10.1111/j.1741-6612.1996.tb00007.x	23	340	347	2	71	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 20	1999	353	9153					627	631		10.1016/S0140-6736(98)06098-X	http://dx.doi.org/10.1016/S0140-6736(98)06098-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	170QU	10030328				2022-12-28	WOS:000078818200012
J	Bhattacharya, SK; Ramchandani, S; Cervoni, N; Szyf, M				Bhattacharya, SK; Ramchandani, S; Cervoni, N; Szyf, M			A mammalian protein with specific demethylase activity for mCpG DNA	NATURE			English	Article							MOUSE EMBRYO; METHYLATION; METHYLTRANSFERASE; 5-METHYLCYTOSINE; GLYCOSYLASE; CELLS	DNA-methylation patterns are important for regulating genome functions, and are determined by the enzymatic processes of methylation and demethylation. The demethylating enzyme has now been identified: a mammalian complementary DNA encodes a methyl-CpG-binding domain, bears a demethylase activity that transforms methylated cytosine bases to cytosine, and demethylates a plasmid when the cDNA is translated or transiently transfected into human embryonal kidney cells in vitro. The discovery of this DNA demethylase should provide a basis for the molecular and developmental analysis of the role of DNA methylation and demethylation.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.	mszyf@pharma.mcgill.ca	Bhattacharya, Sanjoy K/B-2001-2008					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; Corpet F, 1998, NUCLEIC ACIDS RES, V26, P323, DOI 10.1093/nar/26.1.323; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; HENRICH B, 1998, MOL CELL BIOL, V18, P6538; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; JOST JP, 1995, J BIOL CHEM, V270, P9734, DOI 10.1074/jbc.270.17.9734; KAFRI T, 1993, P NATL ACAD SCI USA, V90, P10558, DOI 10.1073/pnas.90.22.10558; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MONK M, 1987, DEVELOPMENT, V99, P371; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; NUR I, 1985, J BACTERIOL, V164, P19, DOI 10.1128/JB.164.1.19-24.1985; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; RAZIN A, 1986, P NATL ACAD SCI USA, V83, P2827, DOI 10.1073/pnas.83.9.2827; Rost B, 1996, METHOD ENZYMOL, V266, P525; SIEGFRIED Z, 1997, CURR BIOL, V7, P305; Swisher JFA, 1998, NUCLEIC ACIDS RES, V26, P5573, DOI 10.1093/nar/26.24.5573; SZYF M, 1995, J BIOL CHEM, V270, P12690, DOI 10.1074/jbc.270.21.12690; SZYF M, 1994, TRENDS PHARMACOL SCI, V7, P233; VAIRAPANDI M, 1993, NUCLEIC ACIDS RES, V21, P5323, DOI 10.1093/nar/21.23.5323; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4	28	529	563	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 18	1999	397	6720					579	583		10.1038/17533	http://dx.doi.org/10.1038/17533			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GE	10050851				2022-12-28	WOS:000078738500038
J	Milstein, A				Milstein, A			An employer's perspective on hospitalists as a source of improved health care value	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	National Policy Conference on the Hospitalist Movement	DEC 05-06, 1997	SAN FRANCISCO, CA					The probable perspective of large employers toward the phenomenon of hospitalists can be derived by examining the four essential elements of health care va rue to employers. Current hospital care in the United States is thought to offer substantial opportunities for improvement, and the impact of hospitalist programs on an employer's sense of health care value is predicted to be favorable. This prediction, however, should be validated through outcomes research before it is widely propagated. If innovations as promising as hospitalist programs are to occur in ambulatory care, employers and other health care purchasers must be proactive in identifying and rewarding them.	Univ Calif San Francisco, San Francisco, CA 94143 USA; William M Mercer Inc, Pacific Business Grp Hlth, San Francisco, CA USA	University of California System; University of California San Francisco	Milstein, A (corresponding author), 2750 Broadway, San Francisco, CA 94115 USA.							*AF HIGG CO, 1996, NAT SURV EMPL SPONS; ANDERSON RE, 1989, JAMA-J AM MED ASSOC, V261, P1610, DOI 10.1001/jama.261.11.1610; BERKOWITZ M, 1997, FULL COSTS DISABILIT; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Brook RH, 1997, JAMA-J AM MED ASSOC, V278, P1612, DOI 10.1001/jama.278.19.1612; Cleary P D, 1993, Qual Manag Health Care, V2, P31; *DARTM MED SCH CTR, 1996, DARTM ATL HLTH CAR U; Freese RB, 1999, ANN INTERN MED, V130, P350, DOI 10.7326/0003-4819-130-4-199902161-00004; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; Hibbard JH, 1997, HEALTH AFFAIR, V16, P172, DOI 10.1377/hlthaff.16.6.172; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LO B, 1995, JAMA-J AM MED ASSOC, V274, P1634, DOI 10.1001/jama.274.20.1634; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MILSTEIN AM, 1998, ROSENTHAL LECT; Nichols L, 1998, AM J CLIN PATHOL, V110, P210; Peyrot M, 1993, J Health Care Mark, V13, P24; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; Wachter RM, 1998, JAMA-J AM MED ASSOC, V279, P1560, DOI 10.1001/jama.279.19.1560; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713; *WASH BUS GROUP HL, 1995, ORG SYST CAR WORK BR	20	7	7	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	2				360	363		10.7326/0003-4819-130-4-199902161-00006	http://dx.doi.org/10.7326/0003-4819-130-4-199902161-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	166QB	10068406				2022-12-28	WOS:000078587500006
J	Leape, LL; Hilborne, LH; Bell, R; Kamberg, C; Brook, RH				Leape, LL; Hilborne, LH; Bell, R; Kamberg, C; Brook, RH			Underuse of cardiac procedures: Do women, ethnic minorities, and the uninsured fail to receive needed revascularization?	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-ARTERY DISEASE; NEW-YORK-STATE; ACUTE MYOCARDIAL-INFARCTION; BYPASS GRAFT-SURGERY; OF-VETERANS-AFFAIRS; RACIAL-DIFFERENCES; SURGICAL-PROCEDURES; HEART-DISEASE; GENDER BIAS; ANGIOGRAPHY	Background: Women, ethnic minorities, and uninsured persons receive fewer cardiac procedures than affluent white male patients do, but rates of use are crude indicators of quality. The important question is, Do women, minorities, and the uninsured fail to receive cardiac procedures when they need them? Objective: To measure receipt of necessary coronary artery bypass graft (CABG) surgery and percutaneous transluminal coronary angioplasty (PTCA) overall; by patient sex, ethnicity, and payer status; and by availability of onsite revascularization. Design: Retrospective, randomized medical record review. Setting: 13 of the 24 hospitals in New York City that provide coronary angiography. Patients: 631 patients who had coronary angiography in 1992 and met the RAND expert panel criteria for necessary revascularization. Measurements: The percentage of patients who had CABG surgery or PTCA was measured, as were variations in use rates by sex, ethnic group, insurance status, and availability of on-site revascularization. Clinical and laboratory data were retrieved from medical records to identify patients who met the panel criteria for necessary revascularization. Receipt of revascularization was determined from state reports, medical records, and information provided by cardiologists. Results: Overall, 74% (95% CI, 71% to 77%) of patients who met the panel criteria for necessary revascularization had CABG surgery or PTCA (underuse rate, 26%). No differences were found in use rates by patient sex, ethnic group, or payer status, but hospitals that provided on-site revascularization had higher use rates (76% [CI, 74% to 79%]) than hospitals that did not provide it (59% [CI, 56% to 65%]) (P < 0.01). In hospitals that did not provide onsite revascularization, uninsured patients were less likely to have revascularization recommended to them (52% [CI, 32% to 78%]); rates of recommendation for patients with private insurance, Medicare, and Medicaid were 82%, 91%, and 75%, respectively (P = 0.026). Conclusions: Although revascularization procedures are substantially underused, no variations in rate of use by sex, ethnic group, or payer status were seen among patients treated in hospitals that provide CABG surgery and PTCA. However, underuse was significantly greater in hospitals that do not provide these procedures, particularly among uninsured persons.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Rand Corp, Santa Monica, CA 90407 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA	Harvard University; Harvard T.H. Chan School of Public Health; RAND Corporation; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Leape, LL (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.							AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; BROOK RH, 1988, LANCET, V1, P750; CARLISLE DM, 1995, AM J PUBLIC HEALTH, V85, P352, DOI 10.2105/AJPH.85.3.352; CARLISLE DM, IN PRESS AM J MED; CHASSIN MR, 1986, INDICATIONS SELECTED; CORNELIUS LJ, 1991, J NATL MED ASSOC, V83, P617; Efron B., 1994, MONOGRAPHS STAT APPL; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; GITTELSOHN AM, 1991, AM J PUBLIC HEALTH, V81, P1435, DOI 10.2105/AJPH.81.11.1435; Graubard B I, 1996, Stat Methods Med Res, V5, P263, DOI 10.1177/096228029600500304; HANNAN EL, 1991, MED CARE, V29, P430, DOI 10.1097/00005650-199105000-00004; HILBORNE LH, 1993, JAMA-J AM MED ASSOC, V269, P761, DOI 10.1001/jama.269.6.761; HILBORNE LH, 1991, PERCUTANEOUS TRANSLU; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; KRAVITZ RL, 1995, JAMA-J AM MED ASSOC, V274, P632, DOI 10.1001/jama.274.8.632; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; LANGE RA, 1993, NEW ENGL J MED, V328, P726, DOI 10.1056/NEJM199303113281010; Leape LL, 1996, ANN INTERN MED, V125, P8, DOI 10.7326/0003-4819-125-1-199607010-00003; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; LEAPE LL, 1991, CORONARY ARTERY BYPA; LITTLE RJA, 1982, AM STAT, V36, P38, DOI 10.2307/2684091; Mort EA, 1996, MED CARE, V34, P783, DOI 10.1097/00005650-199608000-00006; MORT EA, 1994, ARCH INTERN MED, V154, P761, DOI 10.1001/archinte.154.7.761; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; Schecter AD, 1996, AM J CARDIOL, V78, P996, DOI 10.1016/S0002-9149(96)00523-1; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; SHAW LJ, 1994, ANN INTERN MED, V120, P559, DOI 10.7326/0003-4819-120-7-199404010-00005; SKELELLE PG, 1998, NEW ENGL J MED, V338, P1888; *STAT CORP, 1997, STAT REF MAN REL 5; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907	38	114	115	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 2	1999	130	3					183	+		10.7326/0003-4819-130-3-199902020-00003	http://dx.doi.org/10.7326/0003-4819-130-3-199902020-00003			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	162PD	10049196				2022-12-28	WOS:000078355000002
J	Tichelli, A; Socie, G; Henry-Amar, M; Marsh, J; Passweg, J; Schrezenmeier, H; McCann, S; Hows, J; Ljungman, P; Marin, P; Raghavachar, A; Locasciulli, A; Gratwohl, A; Bacigalupo, A				Tichelli, A; Socie, G; Henry-Amar, M; Marsh, J; Passweg, J; Schrezenmeier, H; McCann, S; Hows, J; Ljungman, P; Marin, P; Raghavachar, A; Locasciulli, A; Gratwohl, A; Bacigalupo, A		European Grp Blood MarrowTransplantation	Effectiveness of immunosuppressive therapy in older patients with aplastic anemia	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; SAA WORKING PARTY; ANTILYMPHOCYTE GLOBULIN ALG; COLONY-STIMULATING-FACTOR; TERM FOLLOW-UP; ANTITHYMOCYTE GLOBULIN; RANDOMIZED TRIAL; METHYLPREDNISOLONE; CYCLOSPORINE; EVOLUTION	Background: Immunosuppressive therapy has been used for successful treatment of severe aplastic anemia, but little information is available on outcome in older patients. Objective: To evaluate outcome in patients older than 50 years of age who received immunosuppressive therapy for aplastic anemia. Design: Retrospective cohort study. Setting: 56 centers of the European Group for Blood and Marrow Transplantation (EBMT). Patients: 810 patients with aplastic anemia reported between 1974 and 1997. Patients were evaluated according to age group: 60 years of age or older (n = 127), 50 to 59 years of age (n = 115), and 20 to 49 years of age (n = 568; reference group). Intervention: Antilymphocyte globulin, cyclosporine, or both. Measurements: Survival, cause of death, response to treatment, relapse rate, and risk for late complications were analyzed in all patients and by age group. Results: The 5-year survival rate was 57% (95% CI, 46% to 66%) in patients 50 to 59 years of age and 50% (CI, 39% to 60%) in patients 60 years of age or older compared with 72% (CI, 68% to 76%) in patients younger than 50 years of age (P < 0.001). Response to therapy, relapse rate, and risk for clonal complications were similar in all three age groups (P > 0.2). Age was significantly associated with an increased risk for death (relative risk compared with patients 20 to 49 years of age, 1.80 [CI, 1.29 to 2.52] for patients 50 to 59 yea rs of age and 2.57 [CI, 1.87 to 3.53] for patients greater than or equal to 60 years of age), mainly because of bleeding or infection (P = 0.02). Response to immunosuppressive therapy in all patients at 12 months was 62% (CI, 58% to 66%); no difference was seen among the age groups in multivariate analysis (P > 0.2). Sixty-six of the 379 responding patients (17%) subsequently had relapse. The risk for clonal disorders at 10 years was 20% (CI, 15% to 27%). Conclusions: Response to immunosuppression in aplastic anemia is independent of age, but treatment is associated with increased mortality in older patients.	Kantonsspital, Dept Zent Lab, Hamatol Lab, CH-4031 Basel, Switzerland; Hop St Louis, Bone Marrow Transplant Unit, F-75475 Paris 10, France; Ctr Francois Baclesse, F-14076 Caen 5, France; Univ London St Georges Hosp, Div Haematol, London SW17 0RE, England; Univ Ulm, Innere Med Abt, D-89081 Ulm, Germany; Univ Ireland Trinity Coll, St James Hosp, Dublin 8, Ireland; Southmead Hlth Serv, Dept Transplantat Sci, Bristol BS10 5NB, Avon, England; Huddinge Hosp, Dept Med, S-14186 Huddinge, Sweden; Farreras Valenti, Postgrad Sch Haematol, E-08036 Barcelona, Spain; Osped San Gerardo, Pediat Clin, I-20052 Monza, Italy; Osped San Martino Genova, Div Ematol, Ctr Trapianti Midollo Osseo, I-16132 Genoa, Italy	Kantonsspital Aarau AG (KSA); University of Basel; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Centre Francois Baclesse; St Georges University London; Ulm University; Trinity College Dublin; San Gerardo Hospital; University of Genoa; IRCCS AOU San Martino IST	Tichelli, A (corresponding author), Kantonsspital, Dept Zent Lab, Hamatol Lab, Petersgraben 4, CH-4031 Basel, Switzerland.		passweg, jakob/AAG-3911-2020; Henry-Amar, Michel/S-9358-2019; Ljungman, Per/M-4946-2019	Passweg, Jakob R/0000-0001-7092-3351; Henry-Amar, Michel/0000-0002-9357-6476				BACIGALUPO A, 1993, BRIT J HAEMATOL, V83, P145, DOI 10.1111/j.1365-2141.1993.tb04645.x; BACIGALUPO A, 1995, BLOOD, V85, P1348, DOI 10.1182/blood.V85.5.1348.bloodjournal8551348; BACIGALUPO A, 1988, BRIT J HAEMATOL, V70, P177, DOI 10.1111/j.1365-2141.1988.tb02460.x; CAMITTA B, 1983, BLOOD, V62, P883; CHAMPLIN RE, 1985, BLOOD, V66, P184, DOI 10.1182/blood.V66.1.184.184; Deeg HJ, 1998, BLOOD, V91, P3637; DEPLANQUE MM, 1988, BRIT J HAEMATOL, V70, P55; DEPLANQUE MM, 1989, BRIT J HAEMATOL, V73, P121; Doney K, 1997, ANN INTERN MED, V126, P107, DOI 10.7326/0003-4819-126-2-199701150-00003; DONEY K, 1992, BLOOD, V79, P2566; FRICKHOFEN N, 1991, NEW ENGL J MED, V324, P1297, DOI 10.1056/NEJM199105093241901; GLUCKMAN E, 1992, BLOOD, V79, P269; GLUCKMAN E, 1992, BLOOD, V79, P2540; KLINGEMANN HG, 1986, BLOOD, V67, P770; MARSH JCW, 1987, BLOOD, V70, P1046; MARSH JCW, 1991, BRIT J HAEMATOL, V77, P447; NAJEAN Y, 1990, BLOOD, V76, P2222; NISSEN C, 1993, BRIT J HAEMATOL, V83, P319, DOI 10.1111/j.1365-2141.1993.tb08288.x; Ohara A, 1997, BLOOD, V90, P1009, DOI 10.1182/blood.V90.3.1009.1009_1009_1013; Orazi A, 1997, AM J CLIN PATHOL, V107, P268, DOI 10.1093/ajcp/107.3.268; PAQUETTE RL, 1995, BLOOD, V85, P283, DOI 10.1182/blood.V85.1.283.bloodjournal851283; Passweg JR, 1997, BLOOD, V90, P858; Reiter E, 1997, BONE MARROW TRANSPL, V19, P1191, DOI 10.1038/sj.bmt.1700819; SCHREZENMEIER H, 1993, BRIT J HAEMATOL, V85, P371, DOI 10.1111/j.1365-2141.1993.tb03181.x; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; SPECK B, 1986, EXP HEMATOL, V14, P126; Storb R, 1997, BLOOD, V89, P3890, DOI 10.1182/blood.V89.10.3890.3890_3890_3890; TICHELLI A, 1994, LEUKEMIA LYMPHOMA, V12, P167, DOI 10.3109/10428199409059587; TICHELLI A, 1988, BRIT J HAEMATOL, V69, P413, DOI 10.1111/j.1365-2141.1988.tb02382.x; Yamazaki E, 1997, BLOOD CELL MOL DIS, V23, P213, DOI 10.1006/bcmd.1997.0138; YOUNG N, 1988, BLOOD, V72, P1861; YOUNG NS, 1995, BLOOD, V85, P3367, DOI 10.1182/blood.V85.12.3367.bloodjournal85123367; YOUNG NS, 1992, BLOOD, V79, P1385, DOI 10.1182/blood.V79.6.1385.bloodjournal7961385	33	72	80	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 2	1999	130	3					193	+		10.7326/0003-4819-130-3-199902020-00004	http://dx.doi.org/10.7326/0003-4819-130-3-199902020-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	162PD	10049197				2022-12-28	WOS:000078355000003
J	Amato, R				Amato, R			Modest effect of interferon alfa on metastatic renal-cell carcinoma	LANCET			English	Editorial Material							VINBLASTINE		MD Anderson Canc Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Amato, R (corresponding author), MD Anderson Canc Ctr, Houston, TX 77030 USA.							*AM CANC SOC, 1998 CANC STAT; FOSSA SD, 1992, ANN ONCOL, V3, P301, DOI 10.1093/oxfordjournals.annonc.a058185; KROWN SE, 1987, CANCER, V59, P647, DOI 10.1002/1097-0142(19870201)59:3+<647::AID-CNCR2820591313>3.0.CO;2-#; MINASIAN LM, 1993, J CLIN ONCOL, V11, P1368, DOI 10.1200/JCO.1993.11.7.1368; NANUS DM, 1990, CANCER RES, V50, P4190; NEIDHART JA, 1991, J CLIN ONCOL, V9, P832, DOI 10.1200/JCO.1991.9.5.832; WIRTH MP, 1993, UROL CLIN N AM, V20, P283	7	14	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 2	1999	353	9146					6	7		10.1016/S0140-6736(05)74876-5	http://dx.doi.org/10.1016/S0140-6736(05)74876-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023941				2022-12-28	WOS:000077934800006
J	Reis, A				Reis, A			Genetics and B-cell leukaemia	LANCET			English	Editorial Material							ATAXIA-TELANGIECTASIA; BREAST-CANCER; ATM GENE; MUTATIONS; LEUKEMIA		Max Delbruck Ctr Mol Med, Mol Genet & Mikrosatellitenzentrum, D-13122 Berlin, Germany; Humboldt Univ, Charite, Inst Human Genet, D-13122 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Reis, A (corresponding author), Max Delbruck Ctr Mol Med, Mol Genet & Mikrosatellitenzentrum, D-13122 Berlin, Germany.							Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Concannon P, 1997, HUM MUTAT, V10, P100, DOI 10.1002/(SICI)1098-1004(1997)10:2<100::AID-HUMU2>3.0.CO;2-O; Cordone I, 1998, BLOOD, V91, P4342, DOI 10.1182/blood.V91.11.4342.411k39_4342_4349; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Lens D, 1997, BRIT J HAEMATOL, V99, P848, DOI 10.1046/j.1365-2141.1997.4723278.x; Stilgenbauer S, 1996, P NATL ACAD SCI USA, V93, P11837, DOI 10.1073/pnas.93.21.11837; Stilgenbauer S, 1997, NAT MED, V3, P1155, DOI 10.1038/nm1097-1155; Swift M, 1997, LANCET, V350, P740, DOI 10.1016/S0140-6736(05)63548-9; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96	9	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 2	1999	353	9146					3	3		10.1016/S0140-6736(05)74879-0	http://dx.doi.org/10.1016/S0140-6736(05)74879-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023938				2022-12-28	WOS:000077934800003
J	Truog, RD; Robinson, W; Randolph, A; Morris, A				Truog, RD; Robinson, W; Randolph, A; Morris, A			Is informed consent always necessary for randomized, controlled trials?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Childrens Hosp, Boston, MA 02115 USA; Univ Utah, Sch Med, Salt Lake City, UT 84143 USA	Harvard University; Boston Children's Hospital; Utah System of Higher Education; University of Utah	Truog, RD (corresponding author), Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.							[Anonymous], 1996, Fed Regist, V61, P51498; APPELBAUM P, 1987, INFORMED CONSENT LEG; BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P148; BEECHER HK, 1966, NEW ENGL J MED, V274, P1354, DOI 10.1056/NEJM196606162742405; BREWIN TB, 1982, LANCET, V2, P919; CURRAN WJ, 1973, NEW ENGL J MED, V289, P730, DOI 10.1056/NEJM197310042891406; Ellenberg SS, 1997, CONTROL CLIN TRIALS, V18, P628, DOI 10.1016/S0197-2456(96)00130-4; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; GOLDBERG HI, 1991, MED CARE, V29, pJS41; LANTOS J, 1993, CANCER, V72, P2811, DOI 10.1002/1097-0142(19931101)72:9+<2811::AID-CNCR2820721507>3.0.CO;2-G; LAVELLEJONES C, 1993, BRIT MED J, V306, P885, DOI 10.1136/bmj.306.6882.885; LEVINE RJ, 1995, JAMA-J AM MED ASSOC, V273, P1300, DOI 10.1001/jama.273.16.1300; MODI N, 1993, BRIT MED J, V307, P1495, DOI 10.1136/bmj.307.6917.1495-b; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; Shuster E, 1997, NEW ENGL J MED, V337, P1436, DOI 10.1056/NEJM199711133372006; SMITHELLS RW, 1975, POSTGRAD MED J, V51, P39; Snowdon C, 1997, SOC SCI MED, V45, P1337, DOI 10.1016/S0277-9536(97)00063-4; TARNOWSKI KJ, 1990, PEDIATRICS, V85, P58; Tobias JS, 1997, BRIT MED J, V314, P1111, DOI 10.1136/bmj.314.7087.1111; WMA (World Medical Association), 1964, J AMER MED ASSOC, V189, P33, DOI [10.1001/jama.1964.03070130073046, DOI 10.1001/JAMA.1964.03070130073046]; *WORLD MED ASS DEC, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038	22	146	146	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 11	1999	340	10					804	807		10.1056/NEJM199903113401013	http://dx.doi.org/10.1056/NEJM199903113401013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	174KJ	10072420				2022-12-28	WOS:000079034100013
J	Limburg, J; Vrettos, JS; Liable-Sands, LM; Rheingold, AL; Crabtree, RH; Brudvig, GW				Limburg, J; Vrettos, JS; Liable-Sands, LM; Rheingold, AL; Crabtree, RH; Brudvig, GW			A functional model for O-O bond formation by the O-2-evolving complex in photosystem II	SCIENCE			English	Article							PHOTOSYNTHETIC OXYGEN EVOLUTION; WATER-OXIDATION; MANGANESE CLUSTER; EVOLVING COMPLEX; EPOXIDATION; DIOXYGEN; RELEVANT; PLANTS; DIMER; ION	The formation of molecular oxygen from water in photosynthesis is catalyzed by photosystem II at an active site containing four manganese ions that are arranged in di-mu-oxo dimanganese units (where mu is a bridging mode). The complex [H2O(terpy)Mn(O)(2)Mn(terpy)OH2](NO3)(3) (terpy is 2,2':6',2 "-terpyridine), which was synthesized and structurally characterized, contains a di-mu-oxo manganese dimer and catalyzes the conversion of sodium hypochlorite to molecular oxygen. Oxygen-18 isotope labeling showed that water is the source of the oxygen atoms in the molecular oxygen evolved, and so this system is a functional model for photosynthetic water oxidation.	Yale Univ, Dept Chem, New Haven, CT 06520 USA; Univ Delaware, Dept Chem, Crystallog Lab, Newark, DE 19716 USA	Yale University; University of Delaware	Crabtree, RH (corresponding author), Yale Univ, Dept Chem, POB 208107, New Haven, CT 06520 USA.	robert.crabtree@yale.edu; gary.bruvig@yale.edu	Rheingold, Arnold/U-4735-2019	Rheingold, Arnold/0000-0003-4472-8127	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032715] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32715] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldwin MJ, 1996, J AM CHEM SOC, V118, P11325, DOI 10.1021/ja9626906; Bernadou J, 1998, CHEM COMMUN, P2167, DOI 10.1039/a802734j; BERNADOU J, 1994, J AM CHEM SOC, V116, P9375, DOI 10.1021/ja00099a083; Blomberg MRA, 1997, J AM CHEM SOC, V119, P8285, DOI 10.1021/ja9642323; BRITT RD, 1996, ADV PHOTOSYNTH, V4, P137; BRUICE TC, 1983, J AM CHEM SOC, V105, P2452, DOI 10.1021/ja00346a057; COLLINS TJ, 1989, J AM CHEM SOC, V111, P4511, DOI 10.1021/ja00194a063; COLLINS TJ, 1990, J AM CHEM SOC, V112, P899, DOI 10.1021/ja00158a077; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DINER BA, 1996, ADV PHOTOSYNTHESIS, V4, P214; Finney NS, 1997, ANGEW CHEM INT EDIT, V36, P1720, DOI 10.1002/anie.199717201; GAMELIN DR, 1994, J AM CHEM SOC, V116, P2392, DOI 10.1021/ja00085a019; GERSTEN SW, 1982, J AM CHEM SOC, V104, P4029, DOI 10.1021/ja00378a053; GESELOWITZ D, 1990, INORG CHEM, V29, P3894, DOI 10.1021/ic00344a048; GILCHRIST ML, 1995, P NATL ACAD SCI USA, V92, P9545, DOI 10.1073/pnas.92.21.9545; Groves JT, 1997, J AM CHEM SOC, V119, P6269, DOI 10.1021/ja962605u; GROVES JT, 1988, J AM CHEM SOC, V110, P8628, DOI 10.1021/ja00234a009; Halfen JA, 1996, SCIENCE, V271, P1397, DOI 10.1126/science.271.5254.1397; Hoganson CW, 1997, SCIENCE, V277, P1953, DOI 10.1126/science.277.5334.1953; HURST JK, 1992, INORG CHEM, V31, P1010, DOI 10.1021/ic00032a017; Limburg J, 1997, J AM CHEM SOC, V119, P2761, DOI 10.1021/ja963899m; LIMBURG J, IN PRESS J CHEM S DA; LIMBURG J, IN PRESS BIOMIMETIC; MACDONNELL FM, 1994, J AM CHEM SOC, V116, P7431, DOI 10.1021/ja00095a066; MANCHANDA R, 1995, COORDIN CHEM REV, V144, P1, DOI 10.1016/0010-8545(95)01147-H; MESSINGER J, 1995, P NATL ACAD SCI USA, V92, P3209, DOI 10.1073/pnas.92.8.3209; NARUTA Y, 1994, ANGEW CHEM INT EDIT, V33, P1839, DOI 10.1002/anie.199418391; Pecoraro VL, 1998, PURE APPL CHEM, V70, P925, DOI 10.1351/pac199870040925; RANDALL DW, 1995, J AM CHEM SOC, V117, P11780, DOI 10.1021/ja00152a021; Ruttinger W, 1997, CHEM REV, V97, P1, DOI 10.1021/cr950201z; Siegbahn PEM, 1999, J AM CHEM SOC, V121, P117, DOI 10.1021/ja982290d; THORP HH, 1991, NEW J CHEM, V15, P479; Tommos C, 1998, CURR OPIN CHEM BIOL, V2, P244, DOI 10.1016/S1367-5931(98)80066-5; Yachandra VK, 1996, CHEM REV, V96, P2927, DOI 10.1021/cr950052k; YACHANDRA VK, 1993, SCIENCE, V260, P675, DOI 10.1126/science.8480177	35	618	623	3	161	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 5	1999	283	5407					1524	1527		10.1126/science.283.5407.1524	http://dx.doi.org/10.1126/science.283.5407.1524			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066173				2022-12-28	WOS:000078959200045
J	Oberstar, JV				Oberstar, JV			Physician-legislators: Physicians practicing public service	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Univ Minnesota, Sch Med, Duluth, MN 55812 USA	University of Minnesota System; University of Minnesota Duluth	Oberstar, JV (corresponding author), Univ Minnesota, Sch Med, Duluth, MN 55812 USA.							FRIST WH, 1998, TODAYS INTERNIST, V39, P21; MCDERMOTT JA, 1998, BIOGRAPHY J MCDERMOT; PINS K, 1995, DES MOINES REGI 0101, pA1	3	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					862	862		10.1001/jama.281.9.862	http://dx.doi.org/10.1001/jama.281.9.862			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10071014	Bronze			2022-12-28	WOS:000078804300044
J	Dixon, J; Inglis, S; Klein, R				Dixon, J; Inglis, S; Klein, R			Is the English NHS underfunded?	BRITISH MEDICAL JOURNAL			English	Article									Kings Fund, London W1M 0AN, England; Univ Aberdeen, Sch Med, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Dixon, J (corresponding author), Kings Fund, London W1M 0AN, England.							Appleby J, 1992, FINANCING HLTH CARE; *CLIN STAND ADV GR, 1996, DISTR EL SURG; COLE P, 1985, 385 U AB HLTH EC RES; *DEP HLTH, 1996, GOV EXP PLANS 1996 7; *DEP HLTH, 1997, HLTH PERS SOC SERV S; *DEP HLTH, 1997, SCOTT HLTH STAT 1996; *DEP HLTH SOC SERV, 1996, HOSP STAT 1 APR 1995; DOWDS L, 1997, SOCIAL ATTITUDES NO; *FOR COMM DEP SECR, 1995, SERV SCOTL NEEDS GOV; Hazell R., 1998, DEVOLUTION HLTH; *HLTH DEP, 1997, HLTH STAT WAL 1996; Hunter D. J., 1987, COMMUNITY CARE BRITA; Hunter DJ, 1982, J PUBLIC POLICY, V2, P263; KLEIN R, 1983, HLTH WELFARE STATES; MAYNARD A, 1980, LANCET, V1, P85; Mossialos E, 1997, HEALTH ECON, V6, P109, DOI 10.1002/(SICI)1099-1050(199703)6:2<109::AID-HEC251>3.0.CO;2-L; MULLIGAN JA, 1997, HLTH CARE UK 1996 7; *NHS, 1997, NHS SUMM ACC NO IR 1; *NHS, 1997, NHS SUMM ACC WAL 199; *NHS, 1997, NHS SUMM ACC ENGL 19; *NHS, 1997, NHS SUMM ACC SCOTL 1; *OFF NAT STAT, 1997, MORT STAT GEN REV RE; *SOC SURV DIV OFF, 1996, LIV BRIT RES 1994 GE, P60; *TREAS COMM, 1997, 2 TREAS COMM; *WELSH OFF, 1997, GOV EXP PLANS 1997 8	25	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1999	318	7182					522	+		10.1136/bmj.318.7182.522	http://dx.doi.org/10.1136/bmj.318.7182.522			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QT	10024266	Green Published			2022-12-28	WOS:000078818100034
J	Lavendar, E				Lavendar, E			A memorable patient - Repeating the tests	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1999	318	7182					526	526		10.1136/bmj.318.7182.526	http://dx.doi.org/10.1136/bmj.318.7182.526			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QT	10024267	Green Published			2022-12-28	WOS:000078818100035
J	Campbell, G; Tomlinson, A				Campbell, G; Tomlinson, A			Transducing the Dpp morphogen gradient in the wing of Drosophila: Regulation of Dpp targets by brinker	CELL			English	Article							OPTOMOTOR-BLIND; DNA-BINDING; GENE; PROTEIN; RECEPTORS; EXPRESSION; PATTERN; MELANOGASTER; DOWNSTREAM; MECHANISMS	Dpp, a TGF beta, organizes pattern in the Drosophila wing by acting as a graded morphogen, activating different targets above distinct threshold concentrations. Like other TGF beta s, Dpp appears to induce transcription directly via activation of a SMAD, Mad. However, here we demonstrate that Dpp can also control gene expression indirectly by downregulating the expression of the brinker gene, which encodes a putative transcription factor that functions to repress Dpp targets. The medial-to-lateral Dpp gradient along the anterior-posterior axis is complemented by a lateral-to-medial gradient of Drinker, and the presence of these two opposing gradients may function to allow cells to detect small differences in Dpp concentration and respond by activating different target genes.	Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, Dept Genet & Dev, New York, NY 10032 USA	Columbia University	Campbell, G (corresponding author), Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.	camp+@pitt.edu		Campbell, Gerard/0000-0002-7631-4394				BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; Chen YJ, 1998, DEVELOPMENT, V125, P1759; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; Ferguson EL, 1996, CURR OPIN GENET DEV, V6, P424, DOI 10.1016/S0959-437X(96)80063-3; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Haerry TE, 1998, DEVELOPMENT, V125, P3977; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HARTL DL, 1994, P NATL ACAD SCI USA, V91, P6824, DOI 10.1073/pnas.91.15.6824; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Jazwinska A, 1999, CELL, V96, P563, DOI 10.1016/S0092-8674(00)80660-1; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Khalsa O, 1998, DEVELOPMENT, V125, P2723; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; Kuhnlein RP, 1997, MECH DEVELOP, V66, P107, DOI 10.1016/S0925-4773(97)00103-2; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Lecuit T, 1998, DEVELOPMENT, V125, P4901; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Neumann CJ, 1996, DEVELOPMENT, V122, P3477; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; Nguyen M, 1998, CELL, V95, P495, DOI 10.1016/S0092-8674(00)81617-7; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; PFLUGFELDER GO, 1992, BIOCHEM BIOPH RES CO, V186, P918, DOI 10.1016/0006-291X(92)90833-7; RiveraPomar R, 1996, TRENDS GENET, V12, P478, DOI 10.1016/0168-9525(96)10044-5; ROBERTSON HM, 1988, GENETICS, V118, P461; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; WILLIAMS JA, 1990, MOL GEN GENET, V221, P8, DOI 10.1007/BF00280361; XU T, 1993, DEVELOPMENT, V117, P1223; Yu K, 1996, DEVELOPMENT, V122, P4033; ZECCA M, 1995, DEVELOPMENT, V121, P2265	43	233	241	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 19	1999	96	4					553	562		10.1016/S0092-8674(00)80659-5	http://dx.doi.org/10.1016/S0092-8674(00)80659-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	168XN	10052457	hybrid			2022-12-28	WOS:000078718600006
J	O'Connor, GT; Quinton, HB; Traven, ND; Ramunno, LD; Dodds, TA; Marciniak, TA; Wennberg, JE				O'Connor, GT; Quinton, HB; Traven, ND; Ramunno, LD; Dodds, TA; Marciniak, TA; Wennberg, JE			Geographic variation in the treatment of acute myocardial infarction - The cooperative cardiovascular project	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; HEALTH-CARE; PRACTICE GUIDELINES; CLINICAL-TRIALS; HEART-DISEASE; TASK-FORCE; MANAGEMENT; IMPROVEMENT; MEDICARE; MASSACHUSETTS	Context. Quality indicators for the treatment of acute myocardial infarction include pharmacologic therapy, reperfusion, and smoking cessation advice, but these therapies may not be administered to all patients who could benefit from them. Objective To assess geographic variation in adherence to quality indicators for treatment of acute myocardial infarction, Design Inception cohort using data from the Health Care Financing Administration Cooperative Cardiovascular Project. Setting Acute care hospitals in the United States. Patients A total of 186 800 Medicare beneficiaries hospitalized for treatment of confirmed acute myocardial infarction from February 1994 through July 1995. Main Outcome Measures Adherence to quality indicators for pharmacologic therapy, reperfusion, and smoking cessation advice for patients judged to be ideal candidates for these therapies. The mean rates of adherence to these quality indicators for the entire United States were determined, and the 20th and 80th percentiles of the age- and sex-adjusted rates for each of 306 hospital referral regions were contrasted (mean rate [20th-80th percentiles]), Results Aspirin was used frequently both during hospitalization (86.2% [82.6% 90.1%]) and at discharge (77.8% [72.5%-83.9%]). Calcium channel blockers were with held from most patients with impaired left Ventricular function (81.9% [73.6%-90.8%]). Lower rates were seen in the use of angiotensin-converting enzyme inhibitors at discharge (59.3% [49.2%-69.2%]); reperfusion, using thrombolytic therapy or coronary angioplasty. (67.2% [59.8%-75.1%]); prescription of beta-blockers at discharge (49.5% [35.8%-61.5%]); and for smoking cessation advice (41.9% [32.8%-51.3%]). Conclusions Substantial geographic Variation exists in the treatment of patients with acute myocardial infarction, and these gaps between knowledge and practice have important consequences. Therapies with proven benefit for AMI are underused despite strong evidence that their use will result in better patient outcomes.	Dartmouth Med Sch, Ctr Evaluat Clin Sci, Hanover, NH 03755 USA; NE Hlth Care Qual Fdn, Dover, NH USA; Hlth Care Financing Adm, Dept Hlth & Human Serv, Baltimore, MD USA	Dartmouth College	O'Connor, GT (corresponding author), Dartmouth Med Sch, Ctr Evaluat Clin Sci, 330 Strasenburgh Hall, Hanover, NH 03755 USA.	gerald.t.oconnor@dartmouth.edu						*AM HEART ASS, 1996, HEART STROK FACTS 19, P1; [Anonymous], 1988, BRIT MED J, V296, P320; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BATALDEN PB, 1994, JOINT COMM J QUAL IM, V20, P167, DOI 10.1016/S1070-3241(16)30059-1; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; CORNFIELD J, 1960, B INT STATIST INST, V38, P97; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; Hennekens CH, 1996, NEW ENGL J MED, V335, P1660, DOI 10.1056/NEJM199611283352207; Huff ED, 1997, J CLIN EPIDEMIOL, V50, P1395, DOI 10.1016/S0895-4356(97)00218-7; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; Kanigel Robert, 1997, 1 BEST WAY FW TAYLOR; LAMBERTHUBER DA, 1994, CLIN PERFORMANCE QUA, V2, P219; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LEE TH, 1997, HEART DIS TXB CARDIO, P1939; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; NELSON EC, 1994, HLTH CARE FORUM J, V34, P25; PILOTE L, 1995, NEW ENGL J MED, V333, P565, DOI 10.1056/NEJM199508313330907; Rogers E., 2003, DIFFUSION INNOVATION, VFifth; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Soumerai SB, 1998, JAMA-J AM MED ASSOC, V279, P1358, DOI 10.1001/jama.279.17.1358; *STAT CORP, 1997, STAT COMP PROGR REL; Tukey J. W., 1977, EXPLORATORY DATA ANA; TUNIS SR, 1994, ANN INTERN MED, V120, P956, DOI 10.7326/0003-4819-120-11-199406010-00008; *US DEP HHS, 1988, INT CLASS DIS 9 REV; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; Wennberg J. E., 1996, DARTMOUTH ATLAS HLTH; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; ZYZANSKI SJ, 1994, J FAM PRACTICE, V39, P140	37	259	262	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1999	281	7					627	633		10.1001/jama.281.7.627	http://dx.doi.org/10.1001/jama.281.7.627			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	165YA	10029124	Bronze			2022-12-28	WOS:000078548400033
J	Ko, CW; Sekijima, JH; Lee, SP				Ko, CW; Sekijima, JH; Lee, SP			Biliary sludge	ANNALS OF INTERNAL MEDICINE			English	Review							TOTAL PARENTERAL-NUTRITION; SOMATOSTATIN ANALOG OCTREOTIDE; GALLBLADDER MOTILITY INVITRO; BONE-MARROW TRANSPLANT; SHOCK-WAVE LITHOTRIPSY; LONG-TERM TREATMENT; LOW-CALORIE DIET; GALLSTONE FORMATION; BILE COMPOSITION; MICROSCOPIC EXAMINATION	Biliary sludge was first described with the advent of ultrasonography in the 1970s. It is defined as a mixture of particulate matter and bile that occurs when solutes in bile precipitate. Its composition varies, but cholesterol monohydrate crystals, calcium bilirubinate, and other calcium salts are the most common components. The clinical course of biliary sludge varies, and complete resolution, a waxing and waning course, and progression to gallstones are all possible outcomes. Biliary sludge may cause complications, including biliary colic, acute pancreatitis, and acute cholecystitis. Clinical conditions and events associated with the formation of biliary sludge include rapid weight loss, pregnancy, ceftriaxone therapy, octreotide therapy, and bone marrow or solid organ transplantation. Sludge may be diagnosed on ultrasonography or bile microscopy, and the optimal diagnostic method depends on the clinical setting. This paper proposes a protocol for the microscopic diagnosis of sludge. There are no proven methods for the prevention of sludge formation, even in high-risk patients, and patients should not be routinely monitored for the development of sludge. Asymptomatic patients with sludge can be managed expectantly. If patients with sludge develop symptoms or complications, cholecystectomy should be considered as the definitive therapy. Further studies of the pathogenesis, natural history, and clinical associations of biliary sludge will be essential to our understanding of gallstones and other biliary tract abnormalities.	Vet Affairs Puget Sound Hlth Care Syst, Gastroenterol Sect, Seattle, WA 98108 USA; Univ Washington, Seattle, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle	Lee, SP (corresponding author), Vet Affairs Puget Sound Hlth Care Syst, Gastroenterol Sect, Mailstop 111GI-A,1660 S Columbian Way, Seattle, WA 98108 USA.	splee@u.washington.edu	Neoptolemos, John P/G-4488-2010; Lee, Sum Ping/C-4333-2009; masjedizadeh, abdolrahim/Q-8337-2017	masjedizadeh, abdolrahim/0000-0002-2536-3567	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041678, R01DK046890] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 46890, DK 41678] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHRENDT S A, 1991, Gastroenterology, V100, pA307; AHRENDT S A, 1990, Gastroenterology, V98, pA242; AHRENDT SA, 1991, AM J SURG, V161, P177, DOI 10.1016/0002-9610(91)90381-M; ALLEN B, 1981, AM J SURG, V141, P51, DOI 10.1016/0002-9610(81)90011-8; ARIAS IM, 1993, GASTROENTEROLOGY, V104, P1558, DOI 10.1016/0016-5085(93)90371-I; BINMOELLER KF, 1992, DIGEST DIS SCI, V37, P773, DOI 10.1007/BF01296438; BOHME M, 1994, GASTROENTEROLOGY, V107, P255; BOLONDI L, 1985, GUT, V26, P734, DOI 10.1136/gut.26.7.734; BOONYAPISIT ST, 1978, GASTROENTEROLOGY, V74, P70; BROOMFIELD PH, 1988, J ENGL J MED, V319, P567; BURCKART GJ, 1988, TRANSPLANT P, V20, P841; BUSCAIL L, 1992, DIGEST DIS SCI, V37, P116, DOI 10.1007/BF01308353; CAHALANE MJ, 1988, SEMIN LIVER DIS, V8, P317, DOI 10.1055/s-2008-1040553; CANO N, 1986, GASTROENTEROLOGY, V91, P313, DOI 10.1016/0016-5085(86)90562-7; CAREY MC, 1988, GASTROENTEROLOGY, V95, P508, DOI 10.1016/0016-5085(88)90513-6; CATNACH SM, 1993, GUT, V34, P270, DOI 10.1136/gut.34.2.270; CONRAD MR, 1979, AM J ROENTGENOL, V132, P967, DOI 10.2214/ajr.132.6.967; Dahan P, 1996, GUT, V38, P277, DOI 10.1136/gut.38.2.277; DAVIS M, 1986, DIGEST DIS SCI, V31, P513, DOI 10.1007/BF01320317; DELCHIER JC, 1986, HEPATOLOGY, V6, P118, DOI 10.1002/hep.1840060123; DILL JE, 1995, ENDOSCOPY, V27, P424, DOI 10.1055/s-2007-1005734; DOTY JE, 1984, JPEN-PARENTER ENTER, V8, P263, DOI 10.1177/0148607184008003263; ETTESTAD PJ, 1995, J INFECT DIS, V171, P356, DOI 10.1093/infdis/171.2.356; EVERSON GT, 1991, J CLIN INVEST, V87, P237, DOI 10.1172/JCI114977; EVERSON GT, 1988, J LIPID RES, V29, P68; EVERSON GT, 1993, HEPATOLOGY, V17, P159, DOI 10.1002/hep.1840170126; EVERSON RB, 1982, GASTROENTEROLOGY, V82, P4; EZZAT S, 1992, ANN INTERN MED, V117, P711, DOI 10.7326/0003-4819-117-9-711; FEUERSTEIN IM, 1990, J COMPUT ASSIST TOMO, V14, P325, DOI 10.1097/00004728-199003000-00037; FILLY RA, 1980, J CLIN ULTRASOUND, V8, P193, DOI 10.1002/jcu.1870080302; FRICK MP, 1984, AM J GASTROENTEROL, V79, P122; GAFA M, 1987, SURG GYNECOL OBSTET, V165, P413; Gatica M, 1997, GASTROENTEROLOGY, V112, pA505; GRIER JF, 1994, AM J GASTROENTEROL, V89, P617; HO YC, 1988, DIGEST DIS SCI, V33, P335; HOLAN KR, 1979, GASTROENTEROLOGY, V77, P611; HOY MK, 1994, AM J CLIN NUTR, V60, P249, DOI 10.1093/ajcn/60.2.249; HUSSAINI SH, 1994, GASTROENTEROLOGY, V107, P1503, DOI 10.1016/0016-5085(94)90556-8; INOUE K, 1992, ANN SURG, V215, P19, DOI 10.1097/00000658-199201000-00002; JACOBS RF, 1988, PEDIATR INFECT DIS J, V7, P434, DOI 10.1097/00006454-198806000-00018; JACOBSON AF, 1993, AM J GASTROENTEROL, V88, P1044; JANOWITZ P, 1994, HEPATOLOGY, V20, P291, DOI 10.1016/0270-9139(94)90176-7; JOHNSTON DE, 1993, NEW ENGL J MED, V328, P412, DOI 10.1056/NEJM199302113280608; JUNIPER K, 1957, GASTROENTEROLOGY, V32, P175; KADMON M, 1993, GASTROENTEROLOGY, V104, P1507, DOI 10.1016/0016-5085(93)90363-H; KAMINSKI DL, 1984, GASTROENTEROLOGY, V86, P1628; KIM YS, 1992, J GASTROEN HEPATOL, V7, P618, DOI 10.1111/j.1440-1746.1992.tb01496.x; KINGSTON RD, 1975, BRIT J SURG, V62, P231, DOI 10.1002/bjs.1800620314; Ko CW, 1996, AM J GASTROENTEROL, V91, P1207; Kossoff D, 1998, GASTROENTEROLOGY, V114, pA527, DOI 10.1016/S0016-5085(98)82138-0; LEE SP, 1992, NEW ENGL J MED, V326, P589, DOI 10.1056/NEJM199202273260902; LEE SP, 1988, GASTROENTEROLOGY, V94, P170, DOI 10.1016/0016-5085(88)90626-9; LEE SP, 1994, HEPATOLOGY, V20, P523, DOI 10.1016/0270-9139(94)90205-4; LEE SP, 1986, GASTROENTEROLOGY, V90, P677, DOI 10.1016/0016-5085(86)91123-6; LEE SP, 1990, HEPATOLOGY, V12, pS200; LEWIS MH, 1982, ANN SURG, V195, P97, DOI 10.1097/00000658-198201001-00014; LITTLE JM, 1991, LANCET, V337, P1135, DOI 10.1016/0140-6736(91)92796-5; LITTLEWOOD JD, 1991, EQUINE VET J, V23, P70, DOI 10.1111/j.2042-3306.1991.tb02719.x; LORBER MI, 1987, TRANSPLANTATION, V43, P35, DOI 10.1097/00007890-198701000-00009; LUK AS, 1993, BIOCHEMISTRY-US, V32, P6965, DOI 10.1021/bi00078a022; MAGNUSSON I, 1989, GASTROENTEROLOGY, V96, P206, DOI 10.1016/0016-5085(89)90782-8; MARINGHINI A, 1987, J HEPATOL, V5, P218, DOI 10.1016/S0168-8278(87)80576-7; MARINGHINI A, 1993, ANN INTERN MED, V119, P116, DOI 10.7326/0003-4819-119-2-199307150-00004; MARKS JW, 1991, GASTROENTEROLOGY, V101, P214, DOI 10.1016/0016-5085(91)90480-9; MARZIO L, 1988, DIGEST DIS SCI, V33, P4, DOI 10.1007/BF01536623; MESSING B, 1983, GASTROENTEROLOGY, V84, P1012; Mittelstaedt CA, 1987, ABDOMINAL ULTRASOUND; MOSER AJ, 1995, GASTROENTEROLOGY, V108, P1547, DOI 10.1016/0016-5085(95)90705-X; MOSKOVITZ M, 1986, AM J GASTROENTEROL, V81, P329; MULLER EL, 1986, J SURG RES, V40, P55, DOI 10.1016/0022-4804(86)90145-9; MURRAY FE, 1992, GUT, V33, P1123, DOI 10.1136/gut.33.8.1123; NEOPTOLEMOS JP, 1988, BRIT J SURG, V75, P450, DOI 10.1002/bjs.1800750517; NEWMAN CB, 1995, J CLIN ENDOCR METAB, V80, P2768, DOI 10.1210/jc.80.9.2768; NYBERG B, 1990, ACTA CHIR SCAND, P1; OHARA N, 1990, J CLIN GASTROENTEROL, V12, P291, DOI 10.1097/00004836-199006000-00011; PARK HZ, 1991, GASTROENTEROLOGY, V100, P1665, DOI 10.1016/0016-5085(91)90667-A; PAUMGARTNER G, 1991, LANCET, V338, P1117, DOI 10.1016/0140-6736(91)91972-W; PETERSEIM DS, 1995, J HEART LUNG TRANSPL, V14, P623; PITT HA, 1983, AM J SURG, V145, P106, DOI 10.1016/0002-9610(83)90175-7; REBNER M, 1985, AM J ROENTGENOL, V145, P237, DOI 10.2214/ajr.145.2.237; REDFERN JS, 1995, AM J GASTROENTEROL, V90, P1042; REUBEN A, 1986, EUR J CLIN INVEST, V16, P133, DOI 10.1111/j.1365-2362.1986.tb01320.x; RODA E, 1992, GASTROENTEROLOGY, V102, P372, DOI 10.1016/0016-5085(92)91833-P; ROS E, 1991, GASTROENTEROLOGY, V101, P1701, DOI 10.1016/0016-5085(91)90410-M; ROS E, 1987, GUT, V28, P1500, DOI 10.1136/gut.28.11.1500; RUBIN M, 1992, GUT, V33, P1400, DOI 10.1136/gut.33.10.1400; RYAN JP, 1982, GASTROENTEROLOGY, V83, P81; SACKMANN M, 1991, ANN INTERN MED, V114, P290, DOI 10.7326/0003-4819-114-4-290; SACKMANN M, 1988, NEW ENGL J MED, V318, P393, DOI 10.1056/NEJM198802183180701; SACKMANN M, 1987, ANN INTERN MED, V107, P347, DOI 10.7326/0003-4819-107-2-347; SAUERBRUCH T, 1986, NEW ENGL J MED, V314, P818, DOI 10.1056/NEJM198603273141304; SCHAAD UB, 1986, PEDIATR INFECT DIS J, V5, P708, DOI 10.1097/00006454-198611000-00026; SCHAAD UB, 1988, LANCET, V2, P1411; SCHADE RR, 1993, TRANSPLANT P S1, V15, P2575; SCHARSCHMIDT BF, 1993, GASTROINTESTINAL DIS, P1730; SCHLIERF G, 1981, DIGESTION, V21, P44, DOI 10.1159/000198519; SHIFFMAN ML, 1991, AM J GASTROENTEROL, V86, P1000; SHIFFMAN ML, 1990, GASTROENTEROLOGY, V99, P1772, DOI 10.1016/0016-5085(90)90486-K; SHIFFMAN ML, 1992, GASTROENTEROLOGY, V103, P214, DOI 10.1016/0016-5085(92)91115-K; SHIFFMAN ML, 1995, ANN INTERN MED, V122, P899, DOI 10.7326/0003-4819-122-12-199506150-00002; SITZMANN JV, 1990, SURG GYNECOL OBSTET, V170, P25; SORENSEN TIA, 1977, SCAND J GASTROENTERO, V12, P449, DOI 10.3109/00365527709181686; SPIVAK W, 1987, BIOCHEM J, V242, P323, DOI 10.1042/bj2420323; STECK TB, 1991, J HEART LUNG TRANSPL, V10, P1029; STONE B, 1988, TRANSPLANT P, V20, P841; STONE BG, 1992, HEPATOLOGY, V15, P795, DOI 10.1002/hep.1840150508; TEEFEY SA, 1994, ABDOM IMAGING, V19, P57, DOI 10.1007/BF02165864; TINT GS, 1992, GASTROENTEROLOGY, V102, P2042, DOI 10.1016/0016-5085(92)90330-2; VANCE ML, 1991, ARCH INTERN MED, V151, P1573; VANLIESSUM PA, 1989, J CLIN ENDOCR METAB, V69, P557, DOI 10.1210/jcem-69-3-557; Vega KJ, 1996, ANN INTERN MED, V124, P980, DOI 10.7326/0003-4819-124-11-199606010-00005; WISE L, 1978, ANN SURG, V187, P57, DOI 10.1097/00000658-197801000-00011; XIA Y, 1990, GASTROENTEROLOGY, V99, P454, DOI 10.1016/0016-5085(90)91029-6	113	117	123	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	1				301	311		10.7326/0003-4819-130-4-199902160-00016	http://dx.doi.org/10.7326/0003-4819-130-4-199902160-00016			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166PY	10068389				2022-12-28	WOS:000078587200008
J	Sobecks, NW; Justice, AC; Hinze, S; Chirayath, HT; Lasek, RJ; Chren, MM; Aucott, J; Juknialis, B; Fortinsky, R; Youngner, S; Landefeld, CS				Sobecks, NW; Justice, AC; Hinze, S; Chirayath, HT; Lasek, RJ; Chren, MM; Aucott, J; Juknialis, B; Fortinsky, R; Youngner, S; Landefeld, CS			When doctors marry doctors: A survey exploring the professional and family lives of young physicians	ANNALS OF INTERNAL MEDICINE			English	Article							FEMALE PHYSICIANS; PRACTICE PATTERNS; WOMEN PHYSICIANS; SEX-DIFFERENCES; CAREER; MEDICINE; INCOMES; GENDER; MEN; COUPLES	Background: Soon, half of all physicians may be married to other physicians (that is, in dual-doctor families). Little is known about how marriage to another physician affects physicians themselves. Objective: To learn how physicians in dual-doctor families differ from other physicians in their professional and family lives and in their perceptions of career and family. Design: Cross-sectional survey. Setting: Two medical schools in Ohio. Participants: A random sample of physicians from the classes of 1980 to 1990. Measurements: Responses to a questionnaire on hours worked, income, number of children, child-rearing arrangements, and perceptions about work and family. Results: Of 2000 eligible physicians, 1208 responded (752 men and 456 women). Twenty-two percent of male physicians and 44% of female physicians were married to physicians (P < 0.002). Men and women in dual-doctor families differed (P < 0.001) from other married physicians in key aspects of their professional and family lives: They earned less money, less often felt that their career took precedence over their spouse's career, and more often played a major role in child-rearing. These differences were greater for female physicians than for male physicians. Men and women in dual-doctor families were similar to other physicians in the frequency with which they achieved career goa Is and goats for their children and with which they felt conflict between professional and family roles. Marriage to another physician had distinct benefits (P < 0.001) for both men and women, including more frequent enjoyment from shared work interests and higher family incomes. Conclusions: Men and women in dual-doctor families differed from other physicians in many aspects of their professional and family lives, but they achieved their career and family goals as frequently. These differences reflect personal choices that will increasingly affect the profession as more physicians marry physicians.	Vet Affairs Med Ctr, Div Geriatr 111G, San Francisco, CA 94121 USA; Vet Affairs Med Ctr 111G, Dept Dermatol, San Francisco, CA 94121 USA; Univ Hosp Cleveland, Vet Affairs Med Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Sociol, Cleveland, OH 44106 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University Hospitals of Cleveland; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University; University of California System; University of California San Francisco	Landefeld, CS (corresponding author), Vet Affairs Med Ctr, Div Geriatr 111G, 4150 Clement St, San Francisco, CA 94121 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001962] Funding Source: NIH RePORTER; NIAMS NIH HHS [K08AR01962] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baker LC, 1996, NEW ENGL J MED, V334, P960, DOI 10.1056/NEJM199604113341506; BELKIN L, 1985, NY TIMES        0616, P45; BOBULA JD, 1980, J MED EDUC, V55, P826; Brotherton S E, 1993, J Am Med Womens Assoc (1972), V48, P175; CARR P, 1992, J GEN INTERN MED, V7, P418, DOI 10.1007/BF02599159; Carr PL, 1998, ANN INTERN MED, V129, P532, DOI 10.7326/0003-4819-129-7-199810010-00004; COHEN AB, 1990, HEALTH AFFAIR, V9, P138, DOI 10.1377/hlthaff.9.4.138; DIAL TH, 1994, AM J PSYCHIAT, V151, P96; EISENBERG C, 1989, NEW ENGL J MED, V321, P1542, DOI 10.1056/NEJM198911303212210; FLETCHER RH, 1993, ANN INTERN MED, V119, P628, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00014; Gabbard GO, 1988, MED MARRIAGES; GRANT L, 1990, J MARRIAGE FAM, V52, P39, DOI 10.2307/352836; HERTZ R, 1986, MORE EQUAL OTHERS WO; HOJAT M, 1990, ACAD MED, V65, P755, DOI 10.1097/00001888-199012000-00011; IZRAELI DN, 1994, SOCIOL QUART, V35, P69, DOI 10.1111/j.1533-8525.1994.tb00399.x; Johnson C A, 1992, Fam Med, V24, P205; Johnson C A, 1991, J Am Med Womens Assoc (1972), V46, P155; JOHNSON CA, 1991, J AM MED WOMEN ASSOC, V46, P163; Kaplan SH, 1996, NEW ENGL J MED, V335, P1282, DOI 10.1056/NEJM199610243351706; Laine C, 1998, ANN INTERN MED, V129, P579, DOI 10.7326/0003-4819-129-7-199810010-00013; LANGWELL KM, 1982, J HUM RESOUR, V17, P261, DOI 10.2307/145472; LEVINSON W, 1989, NEW ENGL J MED, V321, P1511, DOI 10.1056/NEJM198911303212205; LORBER J, 1983, J MED EDUC, V58, P447; MENAGHAN E, 1991, CONT FAMILIES LOOKIN; MITCHELL JB, 1984, INQUIRY-J HEALTH CAR, V21, P361; MYERS MF, 1994, DOCTORS MARRIAGES LO; NADELSON CC, 1988, MODERN PERSPECTIVES; OGLE KS, 1986, J FAM PRACTICE, V23, P357; OHSFELDT RL, 1986, J HEALTH ECON, V5, P335, DOI 10.1016/0167-6296(86)90008-1; Pfifferling J H, 1984, Fam Community Health, V6, P68; RELMAN AS, 1989, NEW ENGL J MED, V321, P550; RELMAN AS, 1980, NEW ENGL J MED, V302, P1252, DOI 10.1056/NEJM198005293022209; SILBERGER AB, 1987, HEALTH AFFAIR, V6, P104, DOI 10.1377/hlthaff.6.4.104; STANLEY SC, 1986, J FAM ISSUES, V7, P3, DOI 10.1177/019251386007001001; TESCH BJ, 1992, ACAD MED, V67, P542, DOI 10.1097/00001888-199208000-00014; UHLENBERG P, 1990, SOC SCI MED, V30, P373, DOI 10.1016/0277-9536(90)90192-U; WARD AWM, 1982, BRIT MED J, V284, P31, DOI 10.1136/bmj.284.6308.31; Warde C, 1996, J GEN INTERN MED, V11, P729, DOI 10.1007/BF02598986; WEISMAN CS, 1987, J HEALTH SOC BEHAV, V28, P247, DOI 10.2307/2136844	39	60	63	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	1				312	319		10.7326/0003-4819-130-4-199902160-00017	http://dx.doi.org/10.7326/0003-4819-130-4-199902160-00017			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	166PY	10068390				2022-12-28	WOS:000078587200009
J	Raju, TNK				Raju, TNK			The Nobel Chronicles	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 13	1999	353	9152					598	598		10.1016/S0140-6736(05)75665-8	http://dx.doi.org/10.1016/S0140-6736(05)75665-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10029019				2022-12-28	WOS:000078670200068
J	Holmich, P; Uhrskou, P; Ulnits, L; Kanstrup, IL; Nielsen, MB; Bjerg, AM; Krogsgaard, K				Holmich, P; Uhrskou, P; Ulnits, L; Kanstrup, IL; Nielsen, MB; Bjerg, AM; Krogsgaard, K			Effectiveness of active physical training as treatment for long-standing adductor-related groin pain in athletes: randomised trial	LANCET			English	Article							INJURIES; TENDON; SOCCER	Background Groin pain is common among athletes. A major cause of long-standing problems is adductor-related groin pain. The purpose of this randomised clinical trial was to compare an active training programme (AT) with physiotherapy treatment without active training (PT) in the treatment of adductor-related groin pain in athletes. Methods 68 athletes with long-standing (median 40 weeks) adductor-related groin pain-after examination according to a standardised protocol-were randomly assigned to AT or PT. The treatment period was 8-12 weeks. 4 months after the end of treatment a standardised examination was done. The examining physician was unaware of the treatment allocation. The ultimate outcome measure was full return to sports at the same level without groin pain. Analyses were by intention to treat. Findings 23 patients in the AT group and four in the PT group returned to sports without groin pain (odds ratio, multiple-logistic-regression analysis, 12.7 [95% CI 3.4-47.2]). The subjective global assessments of the effect of the treatments showed a significant (p = 0.006) linear trend towards a better effect in the AT group. A per-protocol analysis did not show appreciably different results. Interpretation AT with a programme aimed at improving strength and coordination of the muscles acting on the pelvis, in particular the adductor muscles, is very effective in the treatment of athletes with long-standing adductor-related groin pain, The potential preventive value of a short programme based upon the principles of AT should be assessed in future, randomised, clinical trials.	Amager Univ Hosp, Dept Orthopaed Surg, Clin Sports Med, DK-2300 Copenhagen S, Denmark; Herlev Univ Hosp, Dept Rheumatol, Herlev, Denmark; Herlev Univ Hosp, Dept Clin Physiol, Herlev, Denmark; Glostrup Univ Hosp, Dept Radiol, Glostrup, Denmark; Univ Copenhagen, Inst Prevent Med, Ctr Clin Intervent Res, Copenhagen Trial Unit, Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; University of Copenhagen	Holmich, P (corresponding author), Amager Univ Hosp, Dept Orthopaed Surg, Clin Sports Med, DK-2300 Copenhagen S, Denmark.		Nielsen, Michael Bachmann/U-2749-2018	Nielsen, Michael Bachmann/0000-0002-9380-1688; Krogsgaard, Kim/0000-0002-7153-9287; Holmich, Per/0000-0003-2098-0272				AKERMARK C, 1992, AM J SPORT MED, V20, P640, DOI 10.1177/036354659202000604; BALDUINI FC, 1988, CLIN SPORT MED, V7, P349; Bradshaw C, 1997, AM J SPORT MED, V25, P402, DOI 10.1177/036354659702500322; EKSTRAND J, 1983, MED SCI SPORT EXER, V15, P267, DOI 10.1249/00005768-198315030-00014; EKSTRAND J, 1982, THESIS U LINKOPING S; ENGSTROM B, 1990, AM J SPORT MED, V18, P101, DOI 10.1177/036354659001800118; GARRETT WE, 1987, AM J SPORT MED, V15, P448, DOI 10.1177/036354658701500504; Hackney R G, 1993, Br J Sports Med, V27, P58; HASSELMAN CT, 1995, PHYSICIAN SPORTSMED, V23, P53, DOI 10.1080/00913847.1995.11947813; Holmich P, 1997, SPORTS MED ARTHROSC, V5, P285; HOLMICH P, 1998, SCAND J MED SCI SPOR, V8, P331; HOLMICH P, 1998, SCAND J MED SCI SPOR, V8, P332; HOLT MA, 1995, AM J SPORT MED, V23, P601, DOI 10.1177/036354659502300515; KALEBO P, 1992, AM J SPORT MED, V20, P634, DOI 10.1177/036354659202000603; KARLSSON J, 1994, SPORTS MED, V17, P141, DOI 10.2165/00007256-199417020-00006; Lovell G, 1995, Aust J Sci Med Sport, V27, P76; MALYCHA P, 1992, AUST NZ J SURG, V62, P123; MANNICHE C, 1988, LANCET, V2, P1473; MARTENS MA, 1987, AM J SPORT MED, V15, P353, DOI 10.1177/036354658701500410; MOLLER MHL, 1985, INT J SPORTS MED, V6, P50, DOI 10.1055/s-2008-1025813; Morrenhof JW, 1989, STABILISATION HUMAN; NIELSEN AB, 1989, AM J SPORT MED, V17, P803, DOI 10.1177/036354658901700614; Renstrom P, 1980, Br J Sports Med, V14, P30; RENSTROM PAF, 1994, CLIN PRACTICE SPORTS, P97; SWAIN R, 1995, PHYSICIAN SPORTSMED, V23, P55; TAYLOR DC, 1991, AM J SPORT MED, V19, P239, DOI 10.1177/036354659101900306; TAYLOR DC, 1990, AM J SPORT MED, V18, P300, DOI 10.1177/036354659001800314; TROPP H, 1985, THESIS U SWEDEN LINK; WIKTORSSONMOLLER M, 1983, AM J SPORT MED, V11, P249, DOI 10.1177/036354658301100412	29	275	277	0	121	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 6	1999	353	9151					439	443		10.1016/S0140-6736(98)03340-6	http://dx.doi.org/10.1016/S0140-6736(98)03340-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JQ	9989713				2022-12-28	WOS:000078572800009
J	De Backer, G; De Bacquer, D				De Backer, G; De Bacquer, D			Lifetime-risk prediction: a complicated business	LANCET			English	Editorial Material									State Univ Ghent, Dept Publ Hlth, B-9000 Ghent, Belgium	Ghent University	De Backer, G (corresponding author), State Univ Ghent, Dept Publ Hlth, B-9000 Ghent, Belgium.		De Bacquer, Dirk/HGU-3191-2022; De Backer, Guy/AAI-4607-2021					de Backer G, 1998, ATHEROSCLEROSIS, V137, pS1, DOI 10.1016/S0021-9150(97)00310-9; Marmot M, 1992, CORONARY HEART DIS E; MENOTTI A, 1995, INT J EPIDEMIOL, V24, P515, DOI 10.1093/ije/24.3.515; ROSE G, 1990, LANCET, V33, P275	4	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 9	1999	353	9147					82	83		10.1016/S0140-6736(98)00404-8	http://dx.doi.org/10.1016/S0140-6736(98)00404-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023886				2022-12-28	WOS:000078087200002
J	Shaw, PJ				Shaw, PJ			Stiff-man syndrome and its variants	LANCET			English	Editorial Material							AUTOANTIBODIES; RIGIDITY		Univ Newcastle Upon Tyne, Royal Victoria Infirm, Dept Med Neurol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK	Shaw, PJ (corresponding author), Univ Newcastle Upon Tyne, Royal Victoria Infirm, Dept Med Neurol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.		Shaw, Pamela J/A-5215-2009; Shaw, Pamela J/A-7620-2010	Shaw, Pamela/0000-0002-8925-2567				Barker RA, 1998, J NEUROL NEUROSUR PS, V65, P633, DOI 10.1136/jnnp.65.5.633; BLUM P, 1991, MOVEMENT DISORD, V6, P12, DOI 10.1002/mds.870060104; FOLLI F, 1993, NEW ENGL J MED, V328, P546, DOI 10.1056/NEJM199302253280805; LEIGH PN, 1980, J NEUROL NEUROSUR PS, V43, P1125, DOI 10.1136/jnnp.43.12.1125; Marsden CD, 1994, MOVEMENT DISORD, V3, P373; MOERSCH FP, 1956, P STAFF M MAYO CLIN, V31, P421; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; WHITELEY AM, 1976, BRAIN, V99, P27, DOI 10.1093/brain/99.1.27	8	31	31	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 9	1999	353	9147					86	87		10.1016/S0140-6736(05)76151-1	http://dx.doi.org/10.1016/S0140-6736(05)76151-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023890				2022-12-28	WOS:000078087200006
J	Chavasse, DC; Shler, RP; Murphy, OA; Huttly, SRA; Cousens, SN; Akhtar, T				Chavasse, DC; Shler, RP; Murphy, OA; Huttly, SRA; Cousens, SN; Akhtar, T			Impact of fly control on childhood diarrhoea in Pakistan: community-randomised trial	LANCET			English	Article							HOUSEFLIES MUSCA-DOMESTICA; SHIGELLOSIS; PREVENTION; DISEASE	Background Several million children are killed each year by diarrhoeal diseases; preventive strategies appropriate for developing countries are vital. Despite strong circumstantial evidence that flies are vectors of diarrhoeal diseases, no convincing studies of the impact of fly control on diarrhoea incidence in developing countries have been reported. We undertook a randomised study of the effect of insecticide spraying on diarrhoea incidence. Methods Six study villages were randomly assigned to two groups. Flies were controlled through insecticide application in group A in 1995 and in group B in 1996. In 1997 the effectiveness of baited fly traps was tested in group A villages. Diarrhoea episodes were monitored in children under 5 years through mothers' reports during weekly visits by a health visitor. Fly density was monitored by use of sticky fly-papers hung in sentinel compounds. Findings During the fly seasons (March-June) of both 1995 and 1996, insecticide application practically eliminated the fly population in the treated villages. The incidence of diarrhoea was lower in the sprayed villages than in the unsprayed villages in both 1995 (mean episodes per child-year 6.3 vs 7.1) and 1996 (4.4 vs 6.5); the reduction in incidence was 23% (95% CI 11-33, p=0.007). At times other than the fly season there was no evidence of a difference in diarrhoea morbidity between sprayed and unsprayed villages. Fly density data for 1997 indicate the ineffectiveness of baited traps in this setting. Interpretation Fly control can have an impact on diarrhoea incidence similar to, or greater than, that of the interventions currently recommended by WHO for inclusion in diarrhoeal disease control programmes in developing countries. This important finding needs confirmation in other settings in developing countries. Technologies and practices that interrupt disease transmission by flies need to be developed and promoted.	London Sch Hyg & Trop Med, London WC1, England; Khyber Med Coll, Pakistan Med Res Council, Peshawar, Pakistan	University of London; London School of Hygiene & Tropical Medicine; Pakistan Medical Research Council	Chavasse, DC (corresponding author), Populat Serv Int, 1120 19th St NW,Suite 600, Washington, DC 20036 USA.							BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705; Chavasse D, 1996, SOC SCI MED, V43, P1289, DOI 10.1016/0277-9536(95)00409-2; CHAVASSE DC, 1994, LANCET, V344, P1231, DOI 10.1016/S0140-6736(94)90547-9; CHAVASSE DC, 1997, WHOCTDWHOPES972, P28; CHAVASSE DC, 1997, WHOEOS9712; COHEN D, 1991, LANCET, V337, P993, DOI 10.1016/0140-6736(91)92657-N; Esrey S.A., 1991, WHOCDD9137; Feachem R. G., 1986, Health Policy and Planning, V1, P109, DOI 10.1093/heapol/1.2.109; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; Huttly SRA, 1997, B WORLD HEALTH ORGAN, V75, P163; LEVINE OS, 1991, REV INFECT DIS, V13, P688; SCUDDER HI, 1947, PUBLIC HEALTH REP, V62, P681, DOI 10.2307/4586121; THOMSON MC, 1995, OXFAM PRACTICAL HLTH, V10; WATT J, 1948, PUBLIC HEALTH REP, V63, P1319, DOI 10.2307/4586723; WRIGHT CE, 1991, AM J EPIDEMIOL, V134, P887, DOI 10.1093/oxfordjournals.aje.a116163; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	16	95	102	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 2	1999	353	9146					22	25		10.1016/S0140-6736(98)03366-2	http://dx.doi.org/10.1016/S0140-6736(98)03366-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023946				2022-12-28	WOS:000077934800012
J	White, M				White, M			A patient who changed my practice - Footsteps and faces	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					632	632		10.1136/bmj.318.7184.632	http://dx.doi.org/10.1136/bmj.318.7184.632			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066202	Green Published			2022-12-28	WOS:000079089200024
J	Yki-Jarvinen, H; Ryysy, L; Nikkila, K; Tulokas, T; Vanamo, R; Heikkila, M				Yki-Jarvinen, H; Ryysy, L; Nikkila, K; Tulokas, T; Vanamo, R; Heikkila, M			Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							SECONDARY FAILURE; SULFONYLUREA; THERAPY; METAANALYSIS; EFFICACY; FOLLOW	Background: Compared with other insulin regimens, combination therapy with oral hypoglycemic agents and bedtime insulin produces similar improvement in glycemic control but induces less weight gain. Objective: To determine whether bedtime insulin regimens differ with respect to their effects on weight gain in patients with type 2 diabetes. Design: Randomized, controlled trial. Setting: Four outpatient clinics at central hospitals. Patients: 96 patients (mean age, 58 +/- 1 years; mean body mass index, 29 +/- 1 kg/m(2)) whose type 2 diabetes was poorly controlled with sulfonylurea therapy (mean glycosylated hemoglobin value, 9.9% +/- 0.2%; mean fasting plasma glucose level, 11.9 +/- 0.3 mmol/L [214 +/- 5 mg/dL]). Intervention: Random assignment to 1 year of treatment with bedtime intermediate-acting insulin plus glyburide (10.5 mg) and placebo, metformin (2 g) and placebo, glyburide and metformin, or a second injection of intermediate-acting insulin in the morning. Patients were taught to adjust the bedtime insulin dose on the basis of fasting glucose measurements. Measurements: Body weight, biochemical and symptomatic hypoglycemias, and indices of glycemic control. Results: At 1 year, body weight remained unchanged in patients receiving bedtime insulin plus metformin (mean change, 0.9 +/- 1.2 kg; P < 0.001 compared with all other groups) but increased by 3.9 +/- 0.7 kg, 3.6 +/- 1.2 kg, and 4.6 +/- 1.0 kg in patients receiving bedtime insulin plus glyburide, those receiving bedtime insulin plus both oral drugs, and those receiving bedtime and morning insulin, respectively. The greatest decrease in the glycosylated hemoglobin value was observed in the bedtime insulin and metformin group (from 9.7% +/- 0.4% to 7.2% +/- 0.2% [difference, -2.5 +/- 0.4 percentage points] at 1 year; P < 0.001 compared with 0 months and P < 0.05 compared with other groups). This group also had significantly fewer symptomatic and biochemical cases of hypoglycemia (P < 0.05) than the other groups. Conclusions: Combination therapy with bedtime insulin plus metformin prevents weight gain. This regimen also seems superior to other bedtime insulin regimens with respect to improvement in glycemic control and frequency of hypoglycemia.	Kymenlaakso Cent Hosp, FIN-48210 Kotka, Finland; Jorvi Hosp, FIN-02740 Espoo, Finland; Lapland Cent Hosp, FIN-96101 Rovaniemi, Finland; S Carelian Cent Hosp, FIN-53130 Lappeenranta, Finland; Orion, FIN-02101 Espoo, Finland; Univ Helsinki, Dept Med, FIN-00029 Helsinki, Finland	University of Helsinki	Yki-Jarvinen, H (corresponding author), Univ Helsinki, Dept Med, Haartmaninkatu 4,Box 340, FIN-00029 Helsinki, Finland.							ABRAIRA C, 1995, DIABETES CARE, V18, P1113, DOI 10.2337/diacare.18.8.1113; BRUCE DG, 1987, MED J AUSTRALIA, V146, P240, DOI 10.5694/j.1326-5377.1987.tb120229.x; DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902; DESBUQUOIS B, 1971, J CLIN ENDOCR METAB, V33, P732, DOI 10.1210/jcem-33-5-732; GIDEZ LJ, 1998, NIH PUBLICATION, P328; GUTNIAK M, 1987, DIABETES CARE, V10, P545, DOI 10.2337/diacare.10.5.545; Johnson JL, 1996, ARCH INTERN MED, V156, P259, DOI 10.1001/archinte.156.3.259; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; MAKIMATTILA S, IN PRESS DIABETOLOGI; PETERS AL, 1991, ANN INTERN MED, V115, P45, DOI 10.7326/0003-4819-115-1-45; PUGH JA, 1992, DIABETES CARE, V15, P953, DOI 10.2337/diacare.15.8.953; QUATRARO A, 1986, DIABETES METAB, V12, P315; Saudek CD, 1996, JAMA-J AM MED ASSOC, V276, P1322, DOI 10.1001/jama.276.16.1322; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; United Kingdom Prospective Diabetes Study (UKPDS), 1995, BMJ-BRIT MED J, V310, P83, DOI DOI 10.1136/BMJ.310.6972.83; Wright AD, 1998, DIABETES CARE, V21, P87; Yki-Jarvinen H, 1997, J CLIN ENDOCR METAB, V82, P4037, DOI 10.1210/jc.82.12.4037; YKIJARVINEN H, 1992, NEW ENGL J MED, V327, P1426, DOI 10.1056/NEJM199211123272005	21	289	311	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	1999	130	5					389	+		10.7326/0003-4819-130-5-199903020-00002	http://dx.doi.org/10.7326/0003-4819-130-5-199903020-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172AA	10068412				2022-12-28	WOS:000078898100001
J	Henderson, DA				Henderson, DA			Biological terrorism - The looming threat of bioterrorism	SCIENCE			English	Review							WEAPONS; OUTBREAK; WARFARE; FUTURE		Johns Hopkins Univ, Sch Publ Hlth, Johns Hopkins Ctr Civilian Biodef Studies, Baltimore, MD 21202 USA	Johns Hopkins University	Henderson, DA (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Johns Hopkins Ctr Civilian Biodef Studies, Suite 850,Candler Bldg,111 Market Pl, Baltimore, MD 21202 USA.							Christopher GW, 1997, JAMA-J AM MED ASSOC, V278, P412, DOI 10.1001/jama.278.5.412; Danzig R, 1997, JAMA-J AM MED ASSOC, V278, P431, DOI 10.1001/jama.278.5.431; Departments of the Army Navy and Air Force, 1996, NATO HDB MED ASP NBC; Henderson DA, 1998, EMERG INFECT DIS, V4, P488, DOI 10.3201/eid0403.980340; Jezek Z, 1988, HUMAN MONKEYPOX; Kadlec RP, 1997, JAMA-J AM MED ASSOC, V278, P351, DOI 10.1001/jama.278.5.351; LEITENBERG M, 1993, BIOLOGICALS, V21, P187, DOI 10.1006/biol.1993.1074; LEITENBERG M, 1997, ASIAN PERSPECT, V21, P7; MESELSON M, 1994, SCIENCE, V266, P1202, DOI 10.1126/science.7973702; MILLER J, 1998, NY TIMES        1011, pA12; MILLER J, 1998, NY TIMES        1208, pA1; MILLER SH, 1985, BOSTON GLOBE    1212, P62; PATRICK WC, 1998, UNPUB ANAL BOTULINUM; PRESTON R, 1998, NEW YORKER, V74, P52; TOTOK TJ, 1997, JAMA-J AM MED ASSOC, V278, P389; TUCKER JB, 1997, JAMA-J AM MED ASSOC, V278, P369; *US HR, 1998, DEP DEF ROL FED RESP; VOROBJEV AA, 1994, WORK GROUP BIOL WEAP; WEHRLE PF, 1970, B WORLD HEALTH ORGAN, V43, P669; WHO Group of Consultants, 1970, HLTH ASP CHEM BIOL W; WUDUNN S, 1998, NY TIMES        0410, pA1; Zilinskas RA, 1997, JAMA-J AM MED ASSOC, V278, P418, DOI 10.1001/jama.278.5.418	22	347	361	5	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1279	1282		10.1126/science.283.5406.1279	http://dx.doi.org/10.1126/science.283.5406.1279			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037590	Green Published			2022-12-28	WOS:000078839900029
J	Raju, TNK				Raju, TNK			The Nobel chronicles - 1939: Gerhard Domagk(1895-1964)	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	12	12	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 20	1999	353	9153					681	681		10.1016/S0140-6736(05)75485-4	http://dx.doi.org/10.1016/S0140-6736(05)75485-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QU	10030374				2022-12-28	WOS:000078818200075
J	Perez, F; Diamantopoulos, GS; Stalder, R; Kreis, TE				Perez, F; Diamantopoulos, GS; Stalder, R; Kreis, TE			CLIP-170 highlights growing microtubule ends in vivo	CELL			English	Article							DYNAMIC INSTABILITY; GOLGI-APPARATUS; MITOTIC SPINDLE; LIVING CELLS; IN-VIVO; STABILIZE MICROTUBULES; BINDING PROTEIN; XENOPUS EGGS; HELA-CELLS; PLUS-END	A chimera with the green fluorescent protein (GFP) has been constructed to visualize the dynamic properties of the endosome-microtubule linker protein CLIP170 (GFP-CLIP170). GFP-CLIP170 binds in stretches along a subset of microtubule ends. These fluorescent stretches appear to move with the growing tips of microtubules at 0.15-0.4 mu m/s, comparable to microtubule elongation in vivo. Analysis of speckles along dynamic GFP-CLIP170 stretches suggests that CLIP170 treadmills on growing microtubule ends, rather than being continuously transported toward these ends. Drugs affecting microtubule dynamics rapidly inhibit movement of GFP-CLIP170 dashes. We propose that GFP-CLIP170 highlights growing microtubule ends by specifically recognizing the structure of a segment of newly polymerized tubulin.	Univ Geneva, Dept Cell Biol Sci 3, CH-1204 Geneva, Switzerland	University of Geneva	Perez, F (corresponding author), Univ Geneva, Dept Cell Biol Sci 3, CH-1204 Geneva, Switzerland.	franck.perez@cellbio.unige.ch	Perez, Franck/A-1558-2014	Perez, Franck/0000-0002-9129-9401				ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; Andersen SSL, 1997, J CELL BIOL, V139, P975, DOI 10.1083/jcb.139.4.975; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bloom GS, 1998, J CELL BIOL, V140, P1277, DOI 10.1083/jcb.140.6.1277; CAPLOW M, 1992, Current Opinion in Cell Biology, V4, P58, DOI 10.1016/0955-0674(92)90059-L; Caplow M, 1996, MOL BIOL CELL, V7, P663, DOI 10.1091/mbc.7.4.663; CARLIER MF, 1981, BIOCHEMISTRY-US, V20, P1918, DOI 10.1021/bi00510a030; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; CHAPIN SJ, 1995, BIOCHEMISTRY-US, V34, P2289, DOI 10.1021/bi00007a025; Charrasse S, 1998, J CELL SCI, V111, P1371; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DHAMODHARAN R, 1995, J CELL SCI, V108, P1679; Diamantopoulos GS, 1999, J CELL BIOL, V144, P99, DOI 10.1083/jcb.144.1.99; DRECHSEL DN, 1994, CURR BIOL, V4, P1053, DOI 10.1016/S0960-9822(00)00243-8; Dujardin D, 1998, J CELL BIOL, V141, P849, DOI 10.1083/jcb.141.4.849; GARD DL, 1987, J CELL BIOL, V105, P2203, DOI 10.1083/jcb.105.5.2203; GEIGER B, 1982, J CELL BIOL, V95, P137, DOI 10.1083/jcb.95.1.137; Goodson HV, 1997, CURR OPIN CELL BIOL, V9, P18, DOI 10.1016/S0955-0674(97)80147-0; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KREIS TE, 1987, EMBO J, V6, P2597, DOI 10.1002/j.1460-2075.1987.tb02550.x; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KUPFER A, 1982, P NATL ACAD SCI-BIOL, V79, P2603, DOI 10.1073/pnas.79.8.2603; Lewis SA, 1997, TRENDS CELL BIOL, V7, P479, DOI 10.1016/S0962-8924(97)01168-9; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; Mata J, 1997, CELL, V89, P939, DOI 10.1016/S0092-8674(00)80279-2; MIMIN AA, 1997, J CELL SCI, V110, P2495; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PIERRE P, 1994, J CELL SCI, V107, P1909; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; RICKARD JE, 1991, J BIOL CHEM, V266, P17597; RICKARD JE, 1990, J CELL BIOL, V110, P1623, DOI 10.1083/jcb.110.5.1623; Rickard JE, 1996, TRENDS CELL BIOL, V6, P178, DOI 10.1016/0962-8924(96)10017-9; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; Severin FF, 1997, NATURE, V388, P888, DOI 10.1038/42270; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; SIMON JR, 1990, J CELL SCI, V96, P571; Tian GL, 1997, J CELL BIOL, V138, P821, DOI 10.1083/jcb.138.4.821; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; VALE RD, 1999, IN PRESS GUIDEBOOK C; VASQUEZ RJ, 1994, J CELL BIOL, V127, P985, DOI 10.1083/jcb.127.4.985; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; Waterman-Storer CM, 1998, BIOPHYS J, V75, P2059, DOI 10.1016/S0006-3495(98)77648-9; Waterman-Storer CM, 1998, CURR BIOL, V8, P798, DOI 10.1016/S0960-9822(98)70321-5; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; WATERMANSTORER CM, 1995, J CELL BIOL, V130, P1161, DOI 10.1083/jcb.130.5.1161; WatermanStorer CM, 1997, J CELL BIOL, V139, P417, DOI 10.1083/jcb.139.2.417; Wilson Leslie, 1994, V13, P59	60	310	315	1	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 19	1999	96	4					517	527		10.1016/S0092-8674(00)80656-X	http://dx.doi.org/10.1016/S0092-8674(00)80656-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	168XN	10052454	Bronze			2022-12-28	WOS:000078718600003
J	Christoforidis, S; McBride, HM; Burgoyne, RD; Zerial, M				Christoforidis, S; McBride, HM; Burgoyne, RD; Zerial, M			The Rab5 effector EEA1 is a core component of endosome docking	NATURE			English	Article							VESICLE TRANSPORT; SNARE ACTIVATION; YEAST VACUOLES; ALPHA-SNAP; PROTEIN; FUSION; NSF; ER	Intracellular membrane docking and fusion requires the interplay between soluble factors and SNAREs. The SNARE hypothesis' postulates that pairing between a vesicular v-SNARE and a target membrane z-SNARE is the primary molecular interaction underlying the specificity of vesicle targeting as well as lipid bilayer fusion. This proposal is supported by recent studies using a minimal artificial system(2). However, several observations demonstrate that SNAREs function at multiple transport steps and can pair promiscuously, questioning the role of SNAREs in conveying vesicle targeting(3-6). Moreover, other proteins have been shown to be important in membrane docking or tethering(7-9). Therefore, if the minimal machinery is defined as the set of proteins sufficient to reproduce in vitro the fidelity of vesicle targeting, docking and fusion as in vivo, then SNAREs are not sufficient to specify vesicle targeting. Endosome fusion also requires cytosolic factors and is regulated by the small GTPase Rab5 (refs 10-20). Here we show that Rab5-interacting soluble proteins can completely substitute for cytosol in an in vivo endosome-fusion assay, and that the Rab5 effector EEA1 is the only factor necessary to confer minimal fusion activity. Rab5 and other associated proteins seem to act upstream of EEA1, implying that Ra65 effecters comprise both regulatory molecules and mechanical components of the membrane transport machinery. We further show that EEA1 mediates endosome docking and, together with SNAREs, leads to membrane fusion.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	European Molecular Biology Laboratory (EMBL); Max Planck Society; University of Liverpool	Zerial, M (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Burgoyne, Robert/C-6706-2008; Burgoyne, Robert D/P-6641-2019; McBride, Heidi M./ABD-5774-2021; McBride, Heidi M/C-1162-2008	Burgoyne, Robert/0000-0002-9219-0387; Burgoyne, Robert D/0000-0002-9219-0387; McBride, Heidi M./0000-0003-4666-2280; McBride, Heidi M/0000-0003-4666-2280; Christoforidis, Savvas/0000-0002-0210-0713				Barlowe C, 1997, J CELL BIOL, V139, P1097, DOI 10.1083/jcb.139.5.1097; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Colombo MI, 1997, J BIOL CHEM, V272, P7707, DOI 10.1074/jbc.272.12.7707; Colombo MI, 1996, J BIOL CHEM, V271, P18810, DOI 10.1074/jbc.271.31.18810; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Gournier H, 1998, EMBO J, V17, P1930, DOI 10.1093/emboj/17.7.1930; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Robinson LJ, 1998, CURR OPIN CELL BIOL, V10, P483, DOI 10.1016/S0955-0674(98)80063-X; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; VanRheenen SM, 1998, J CELL BIOL, V141, P1107, DOI 10.1083/jcb.141.5.1107; vonMollard GF, 1997, J CELL BIOL, V137, P1511, DOI 10.1083/jcb.137.7.1511; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wiedemann C, 1998, NATURE, V394, P426, DOI 10.1038/28752	30	631	641	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 18	1999	397	6720					621	625		10.1038/17618	http://dx.doi.org/10.1038/17618			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GE	10050856				2022-12-28	WOS:000078738500051
J	Lindenauer, PK; Pantilat, SZ; Katz, PP; Wachter, RM				Lindenauer, PK; Pantilat, SZ; Katz, PP; Wachter, RM			Hospitalists and the practice of inpatient medicine: Results of a survey of the National Association of Inpatient Physicians	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	National Policy Conference on the Hospitalist Movement	DEC 05-06, 1997	SAN FRANCISCO, CA				CARE	The number of hospital-based physicians, or hospitalists, in the United States has grown rapidly, yet no published data have characterized hospitalists or their practices. A self-administered questionnaire was used to describe 1) the features of hospitalists, 2) the hospitals in which they practice, and 3) the practice of inpatient medicine. The questionnaire contained 48 questions that covered four domains: demographic information about the respondent, the clinical and nonclinical workload and responsibilities of the respondent, organizational and financial aspects of the respondent's practice, and the respondent's satisfaction and his or her perception of the reaction of other physicians and nurses to the hospitalist system. The overall response rate was 57%. Data are reported on 372 surveys. Respondents were young and most were men, and only 48% had practiced hospital-based medicine for more than 2 years. Eighty-nine percent of respondents were internists; of these, 51% were generalists and 38% were subspecialists. Most hospitalists limited their practices to the inpatient setting, but 37% practiced outpatient general internal medicine or subspecialty medicine in a limited capacity. In addition to providing care for inpatients, 90% of hospitalists were engaged in consultative medicine. Quality assurance and practice guideline development were the most frequently reported nonclinical activities (53% and 46%, respectively). Small group practices (31%) and staff-model health maintenance organizations (25%) were the most common practice settings, and 78% of participants were reimbursed through salary. Financial incentives were common (43 %) but modest. Accurate information about hospitalists and their practices will be important to clinicians, educators, researchers, and policymakers as the hospitalist movement continues to grow.	Tufts Univ, Sch Med, Off Clin Practice Evaluat & Management, Springfield, MA 01199 USA; Tufts Univ, Sch Med, Dept Med, Baystate Med Ctr, Springfield, MA 01199 USA; Univ Calif San Francisco, Div Gen Internal Med, Dept Med, Program Med Eth, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA	Tufts University; Baystate Medical Center; Tufts University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lindenauer, PK (corresponding author), Tufts Univ, Sch Med, Off Clin Practice Evaluat & Management, 759 Chestnut St,P-5928, Springfield, MA 01199 USA.	lindenauer@bhs.org						Ayanian JZ, 1997, ARCH INTERN MED, V157, P2570, DOI 10.1001/archinte.157.22.2570; BELLET P, IN PRESS PEDIATRICS; BOODMAN S, 1998, WASHINGTON POST 0127, P1; BOSCHERT S, 1998, INTERNAL MED NE 0115, P6; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; *CTR HLTH POL RES, 1997, SOC CHAR MED PRACT; Diamond HS, 1998, ANN INTERN MED, V129, P197, DOI 10.7326/0003-4819-129-3-199808010-00006; Fitzgerald F T, 1998, Hospitalist, V1, P5; GESENWAY D, 1998, ACP OBSERVER     FEB, P2; Gipe B, 1997, Mod Healthc, V27, P25; Henry L A, 1997, Fam Pract Manag, V4, P54; HENRY LA, 1997, FAMILY PRACTICE MANA, V4, P65; HENRY LA, 1997, FAMILY PRACTICE MANA, V4, P58; JEFFREY NA, 1997, WALL STREET J   0520, pB1; LINDENAUER PK, 1997, NEW MED, V1, P245; SEIDMAN B, 1998, PHYSICIANS CHARACTER; Wachter RM, 1998, JAMA-J AM MED ASSOC, V279, P1560, DOI 10.1001/jama.279.19.1560; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713	18	95	96	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	2				343	349		10.7326/0003-4819-130-4-199902161-00003	http://dx.doi.org/10.7326/0003-4819-130-4-199902161-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	166QB	10068403				2022-12-28	WOS:000078587500003
J	Moss-Morris, R; Petrie, KJ				Moss-Morris, R; Petrie, KJ			Link between psychiatric dysfunction and dizziness	LANCET			English	Editorial Material							CHRONIC FATIGUE SYNDROME; BACK-PAIN; DISTRESS		Univ Auckland, Fac Med & Hlth Sci, Dept Psychiat & Behav Sci, Auckland, New Zealand	University of Auckland	Moss-Morris, R (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Dept Psychiat & Behav Sci, Private Bag 92 019, Auckland, New Zealand.			Moss-Morris, Rona/0000-0002-2927-3446				Brandt TH, 1998, J NEUROL NEUROSUR PS, V65, P619, DOI 10.1136/jnnp.65.5.619; Croft PR, 1995, SPINE, V20, P2731, DOI 10.1097/00007632-199512150-00015; Fry AM, 1996, J PSYCHOSOM RES, V41, P415, DOI 10.1016/S0022-3999(96)00190-0; HUDSON JI, 1994, BAILLIERE CLIN RHEUM, V8, P839, DOI 10.1016/S0950-3579(05)80051-2; INGRAM RE, 1990, PSYCHOL BULL, V107, P156, DOI 10.1037/0033-2909.107.2.156; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; MossMorris R, 1996, J NEUROL NEUROSUR PS, V60, P474, DOI 10.1136/jnnp.60.5.474; PENNEBAKER JW, 1982, PSYCHOL PHYSICAL SYM; WATSON D, 1989, PSYCHOL REV, V96, P234, DOI 10.1037/0033-295X.96.2.234; WEINMAN J, 1997, J PSYCHOSOM RES, V42, P116; WESSELY S, 1995, LANCET, V345, P1333, DOI 10.1016/S0140-6736(95)92537-6; Yardley L, 1998, J NEUROL NEUROSUR PS, V65, P679, DOI 10.1136/jnnp.65.5.679	12	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 13	1999	353	9152					515	516		10.1016/S0140-6736(98)00348-1	http://dx.doi.org/10.1016/S0140-6736(98)00348-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028975				2022-12-28	WOS:000078670200004
J	Cooper, MTD; Bray, SJ				Cooper, MTD; Bray, SJ			Frizzled regulation of Notch signalling polarizes cell fate in the Drosophila eye	NATURE			English	Article							SIGNALING PATHWAY; DELTA-EXPRESSION; ENHANCER; COMPLEX; GENE; WINGLESS; SUBSET	The Drosophila eye, a paradigm for epithelial organization, is highly polarized with mirror-image symmetry about the equator. The R3 and R4 photoreceptors in each ommatidium are vital in this polarity; they adopt asymmetrical positions in adult ommatidia and are the site of action for several essential genes(1-5). Two such genes are frizzled (fz) and dishevelled (dsh), the products of which are components of a signalling pathway required in R3, and which are thought to be activated by a diffusible signal(3,6-10). Here we show that the transmembrane receptor Notch is required downstream of dsh in R3/R4 for them to adopt distinct fates, By using an enhancer for the Notch target gene Enhancer of split m delta, we show that Notch becomes activated specifically in R4, We propose that Fz/Dsh promotes activity of the Notch ligand Delta and inhibits Notch receptor activity in R3, creating a difference in Notch signalling capacity between R3 and R4. Subsequent feedback in the Notch pathway ensures that this difference becomes amplified. This interplay between Fz/Dsh and Notch indicates that polarity is established through local comparisons between two cells and explains how a signal from one position (for example, the equator in the eye) could be interpreted by all ommatidia in the field.	Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England	University of Cambridge	Bray, SJ (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.			Bray, Sarah/0000-0002-1642-599X				Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Baker NE, 1996, CURR BIOL, V6, P1290, DOI 10.1016/S0960-9822(02)70715-X; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; Chen CWJ, 1997, DEV BIOL, V188, P181, DOI 10.1006/dbio.1997.8643; Choi KW, 1996, P NATL ACAD SCI USA, V93, P5737, DOI 10.1073/pnas.93.12.5737; deCelis JF, 1996, DEVELOPMENT, V122, P2719; Eastman DS, 1997, MOL CELL BIOL, V17, P5620, DOI 10.1128/MCB.17.9.5620; Fanto M, 1998, MECH DEVELOP, V74, P51, DOI 10.1016/S0925-4773(98)00063-X; FEHON RG, 1994, DEVELOPMENT, V120, P545; FISCHERVIZE JA, 1992, DEVELOPMENT, V115, P89; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Gubb D, 1998, INT J DEV BIOL, V42, P369; HIGASHIJIMA SI, 1992, GENE DEV, V6, P50, DOI 10.1101/gad.6.1.50; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; Klein T, 1997, DEV BIOL, V189, P123, DOI 10.1006/dbio.1997.8564; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; PARKS AL, 1995, MECH DEVELOP, V50, P201, DOI 10.1016/0925-4773(94)00336-L; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791; THEISEN H, 1994, DEVELOPMENT, V120, P347; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; Wehrli M, 1998, DEVELOPMENT, V125, P1421; Wolff T, 1998, DEVELOPMENT, V125, P1149; Wolff Tanya, 1993, P1277; ZHENG L, 1995, DEVELOPMENT, V121, P3045	30	196	198	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 11	1999	397	6719					526	530		10.1038/17395	http://dx.doi.org/10.1038/17395			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KN	10028969				2022-12-28	WOS:000078574900051
J	Schneider, EL				Schneider, EL			Demographics - Aging in the third millennium	SCIENCE			English	Editorial Material									Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Leonard Davis Sch Gerontol, Los Angeles, CA 90089 USA	University of Southern California	Schneider, EL (corresponding author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Leonard Davis Sch Gerontol, Los Angeles, CA 90089 USA.	eschneid@usc.edu						*AARP, 1997, PROF OLD AM; Crimmins EM, 1997, J GERONTOL B-PSYCHOL, V52, pS59, DOI 10.1093/geronb/52B.2.S59; *HCFA, 1998, HIGHL NAT HLTH EXP P; HOLMES OW, 1891, DEACONS MASTERPIECE; Lee R, 1997, DEMOGRAPHY, V34, P67, DOI 10.2307/2061660; LUBITZ J, 1995, NEW ENGL J MED, V332, P999, DOI 10.1056/NEJM199504133321506; *NAT CTR HLTH STAT, 1998, 1995 VIT STAT US A, V2, P14; NELSON TM, 1993, INT J AGING HUM DEV, V36, P239, DOI 10.2190/TAG8-9WA4-YX0M-9T17; OUSLANDER JG, 1997, MED CARE NURSING HOM; OWSLEY C, 1991, PSYCHOL AGING, V6, P403, DOI 10.1037/0882-7974.6.3.403; REGNIER V, 1996, CRITICAL ISSUES ASSI; Singer BH, 1998, P NATL ACAD SCI USA, V95, P15618, DOI 10.1073/pnas.95.26.15618; Smith S, 1998, HEALTH AFFAIR, V17, P128, DOI 10.1377/hlthaff.17.5.128; U.S. Census Bureau, 1967, TABLE 4 YEARS SCH CO; Wachter KW, 1997, PHILOS T R SOC B, V352, P1811, DOI 10.1098/rstb.1997.0166	15	70	71	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1999	283	5403					796	797		10.1126/science.283.5403.796	http://dx.doi.org/10.1126/science.283.5403.796			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	165AT	10049123				2022-12-28	WOS:000078496800025
J	Kefalides, P				Kefalides, P			Solid organ transplantation. 2: Ethical considerations	ANNALS OF INTERNAL MEDICINE			English	Article																			0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	1999	130	2					169	170		10.7326/0003-4819-130-2-199901190-00101	http://dx.doi.org/10.7326/0003-4819-130-2-199901190-00101			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158KG	10068378				2022-12-28	WOS:000078114200028
J	Scott, DL; Gishen, P				Scott, DL; Gishen, P			Radiological assessment of hip osteoarthritis	LANCET			English	Editorial Material							ARTHROPLASTY; PROGRESSION		Kings Coll Hosp London, Dept Rheumatol, London SE22 8PT, England	King's College Hospital NHS Foundation Trust; King's College Hospital	Scott, DL (corresponding author), Kings Coll Hosp London, Dept Rheumatol, London SE22 8PT, England.							Auleley GR, 1998, ANN RHEUM DIS, V57, P519, DOI 10.1136/ard.57.9.519; Chang RW, 1996, JAMA-J AM MED ASSOC, V275, P858, DOI 10.1001/jama.275.11.858; CONROZIER T, 1995, OSTEOARTHR CARTILAGE, V3, P81; Cooper C, 1998, AM J EPIDEMIOL, V147, P516; DANIELSSON L, 1997, CLIN ORTHOP RELAT R, V20, P107; Dougados M, 1996, ANN RHEUM DIS, V55, P356, DOI 10.1136/ard.55.6.356; Fox KM, 1996, J RHEUMATOL, V23, P693; HANSSON G, 1993, ACTA RADIOL, V34, P117; Hirsch R, 1998, ARTHRITIS RHEUM, V41, P361, DOI 10.1002/1529-0131(199802)41:2<361::AID-ART21>3.3.CO;2-U; HUSKISSON EC, 1995, J RHEUMATOL, V22, P1941; LEDINGHAM J, 1993, ANN RHEUM DIS, V52, P263, DOI 10.1136/ard.52.4.263; Odding E, 1998, ANN RHEUM DIS, V57, P203, DOI 10.1136/ard.57.4.203; Petersson IF, 1996, ANN RHEUM DIS, V55, P659, DOI 10.1136/ard.55.9.659; RAVAUD P, HIP RADIOGRAPHY; Theiler R, 1996, OSTEOARTHR CARTILAGE, V4, P35, DOI 10.1016/S1063-4584(96)80005-7	15	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 9	1999	353	9147					87	88		10.1016/S0140-6736(05)76152-3	http://dx.doi.org/10.1016/S0140-6736(05)76152-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023891				2022-12-28	WOS:000078087200007
J	Skelton, JR; Hobbs, FDR				Skelton, JR; Hobbs, FDR			Concordancing: use of language-based research in medical communication	LANCET			English	Article								Background The available literature on medical communication reports almost exclusively on observational, qualitative studies. We aimed to apply a novel approach to the analysis of doctor-patient consultation by means of computer concordancing. This methodology, established in linguistic research but rarely applied to professional language, allows both the quantitative and qualitative study of language. Methods We analysed the language of 40 doctors and their patients during 373 complete primary-care consultations. We examined the use of jargon by doctors, the language of power and absence of power, and ways in which language was used to diminish the potential threat of the presenting disorder. Findings There was no evidence that the doctors used medical jargon. Some doctors used language associated with social power, and some patients used language associated with absence of power. There was substantial evidence that the doctors used language to express emotions leg, anxiety), to diminish threats leg, words such as "little"), and to reassure patients. Interpretation Concordancing is a valuable resource to study the consultation. The finding that doctors do not use jargon suggests that they are aware of the need to avoid it, but it does not follow that they are easily understood by patients. The use of some elements of the language of power may imply that consultations may be less democratic than is appropriate. The language of emotion and diminution is a major part of the primary-care doctor's repertoire and denotes a therapeutic use of language.	Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Skelton, JR (corresponding author), Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.	j.r.skelton@bham.ac.uk		hobbs, richard/0000-0001-7976-7172				ATKINSON JM, 1984, STRUCTURES SOCIAL A; Chomsky Noam., 1965, ASPECTS THEORY SYNTA; Church K., 1991, LEXICAL ACQUISITION, P115; COX J, 1993, BRIT MED J, V306, P1043, DOI 10.1136/bmj.306.6884.1043; FISHER S, 1983, SOCIAL ORG DOCTOR PA; HOEY M., 1983, SURFACE DISCOURSE; KRAAN HF, 1987, MAASTRICHT HIST TAKI; Marinker M, 1997, MED EDUC, V31, P293, DOI 10.1111/j.1365-2923.1997.tb02928.x; Mishler EG, 1984, DISCOURSE MED DIALEC; Shuy R W, 1976, Prim Care, V3, P365; SIMPSON M, 1991, BRIT MED J, V303, P1385, DOI 10.1136/bmj.303.6814.1385; Sinclair J. McH., 1987, LOOKING ACCOUNT COBU; STILES WB, 1989, MED CARE, V27, P212, DOI 10.1097/00005650-198902000-00011; Stubbs M., 1995, FUNCT LANG, V2, P23, DOI [DOI 10.1075/F0L.2.1.03STU, 10.1075/fol.2.1.03stu]; WEST C, 1983, ROUTINE COMPLICATION; Woods Anthony, 1986, STAT LANGUAGE STUDIE	16	41	41	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 9	1999	353	9147					108	111		10.1016/S0140-6736(98)02469-6	http://dx.doi.org/10.1016/S0140-6736(98)02469-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023896				2022-12-28	WOS:000078087200012
J	Cornu, C; Cano, A; Pornel, B; Melis, GB; Boissel, JP				Cornu, C; Cano, A; Pornel, B; Melis, GB; Boissel, JP		EUTERP Pilot Study Grp	Could institutional clinical trials exist in Europe?	LANCET			English	Editorial Material									Univ Valencia, Dept Pediat, Valencia, Spain; Univ Lyon 1, Serv Pharmacol EA643, F-69365 Lyon, France; Brussels Menopause Ctr, Brussels, Belgium; Univ Cagliari, Ist Ginecol Ostetricia & Fisiopatol Reprod Umana, Cagliari, Italy	University of Valencia; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Cagliari	Cornu, C (corresponding author), 162 Ave Lacassagne,BP3041, F-69394 Lyon 03, France.								0	14	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 2	1999	353	9146					63	64		10.1016/S0140-6736(98)07611-9	http://dx.doi.org/10.1016/S0140-6736(98)07611-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023967				2022-12-28	WOS:000077934800046
J	Cousens, SN; Linsell, L; Smith, PG; Chandrakumar, M; Wilesmith, JW; Knight, RSG; Zeidler, M; Stewart, G; Will, RG				Cousens, SN; Linsell, L; Smith, PG; Chandrakumar, M; Wilesmith, JW; Knight, RSG; Zeidler, M; Stewart, G; Will, RG			Geographical distribution of variant CJD in the UK (excluding Northern Ireland)	LANCET			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; DISEASE; BSE	Background The agent that causes variant Creutzfeldt-Jakob disease (variant CJD) is indistinguishable from the causative agent of bovine spongiform encephalopathy (BSE). The transmission route by which human beings are infected has not been established. One hypothesis is that cases of variant CJD have resulted from exposure to the BSE agent via rendering plants involved in the production of meat and bone meal, the main vehicle of the BSE epidemic. Methods We identified cases of variant CJD through the National CJD Surveillance Unit, and obtained lifetime residential histories of cases by interviewing a relative. The addresses of all rendering plants in the UK (excluding Northern Ireland) in production in 1988 were available from a survey done in that year. We calculated the distance between each case's place of residence on Jan 1, 1988, and the nearest rendering plant from postcode data, and used data from the 1991 UK census to estimate the population living within various distances of rendering plants. We compared the observed number of cases of variant CJD within a particular distance of a rendering plant with the number expected if there is no association between residential proximity to a rendering plant and the risk of developing variant CJD. Findings Up to Aug 31, 1998, 26 cases of variant CJD with onset in the UK (Northern ireland not included) had been identified. The observed and expected numbers of variant CJD cases living within a specified distance of any rendering plant up to 50 km were almost the same. Two plants in the county of Kent each had four cases within 50 km in 1988, significantly more cases than expected (plant A, 1.04 expected; plant B, 0.74 expected). Multiple significance tests were done, so some tests would be expected to appear significant by chance alone. Computer simulations suggested that the observation of four cases of variant CJD living in an area with a population of 1.5 million (the size of Kent) is not unexpected. Interpretation There is no evidence that people with variant CJD tended to live closer than the population as a whole to rendering plants in the 1980s. The reported cluster of variant CJD cases in Kent is most probably a chance finding.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; E Kent Hlth Author, Dover, Kent, England; Western Gen Hosp, Natl Creutzfeldt Jakob Dis Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of London; London School of Hygiene & Tropical Medicine; University of Edinburgh	Cousens, SN (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.		smith, peter/ABH-9627-2020	smith, peter/0000-0003-0080-7560				Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; *DNV TECHN, 1997, RISKS DISP BSE INF C; *DNV TECHN, 1997, RISKS BURN REND PROD; *DNV TECHN, 1997, THRUXT MILL REND PLA; GAGE P, 1998, J APPL MICROBIOL, V84, P467; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; HILLS M, 1989, J ROY STAT SOC A STA, V152, P353, DOI 10.2307/2983132; *NAT CJD SURV UN L, 1997, CREUTZF JAK DIS SURV; WATKINS A, 1996, GUARDIAN        0611; WILESMITH JW, 1992, VET REC, V130, P90, DOI 10.1136/vr.130.5.90; WILESMITH JW, 1991, VET REC, V128, P199, DOI 10.1136/vr.128.9.199; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; YOUNG R, 1997, TIMES           0826	13	31	31	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 2	1999	353	9146					18	21		10.1016/S0140-6736(98)08062-3	http://dx.doi.org/10.1016/S0140-6736(98)08062-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023945				2022-12-28	WOS:000077934800011
J	Raju, TNK				Raju, TNK			The Nobel Chronicles - 1932: Charles Scott Sherrington (1857-1952), Edgar Douglas Adrian (1889-1977)	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	1	2	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 2	1999	353	9146					76	76		10.1016/S0140-6736(05)74826-1	http://dx.doi.org/10.1016/S0140-6736(05)74826-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023985				2022-12-28	WOS:000077934800068
J	Beecham, L				Beecham, L			Consultants' leader meets health minister	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					675	675						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066228				2022-12-28	WOS:000079089200077
J	Gandhi, MM; Dawkins, KD				Gandhi, MM; Dawkins, KD			Intracoronary stents	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CORONARY-ARTERY DISEASE; ACUTE MYOCARDIAL-INFARCTION; CLINICAL FOLLOW-UP; BALLOON ANGIOPLASTY; THROMBOLYTIC THERAPY; MEDICAL THERAPY; PLACEMENT; IMPLANTATION; RESTENOSIS; VESSEL		Southampton Univ Hosp, Wessex Cardiothorac Ctr, Southampton SO16 6YD, Hants, England	University of Southampton	Gandhi, MM (corresponding author), Southampton Univ Hosp, Wessex Cardiothorac Ctr, Southampton SO16 6YD, Hants, England.							Bailey SR, 1997, PROG CARDIOVASC DIS, V40, P183, DOI 10.1016/S0033-0620(97)80008-4; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Folland ED, 1997, J AM COLL CARDIOL, V29, P1505, DOI 10.1016/S0735-1097(97)00097-1; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; GRUNTZIG AR, 1979, NEW ENGL J MED, V301, P61, DOI 10.1056/NEJM197907123010201; Kimura T, 1996, NEW ENGL J MED, V334, P561, DOI 10.1056/NEJM199602293340903; Klugherz BD, 1996, J AM COLL CARDIOL, V27, P1185, DOI 10.1016/0735-1097(95)00574-9; Lange RA, 1996, NEW ENGL J MED, V335, P1311; Leon MB, 1998, NEW ENGL J MED, V339, P1665, DOI 10.1056/NEJM199812033392303; Macaya C, 1996, J AM COLL CARDIOL, V27, P255, DOI 10.1016/0735-1097(95)00473-4; Moussa I, 1997, J AM COLL CARDIOL, V29, P6, DOI 10.1016/S0735-1097(96)00452-4; Moussa I, 1997, CIRCULATION, V96, P3873; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; *PART RAND INT TRE, 1997, LANCET, V350, P461; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; Savage MP, 1997, NEW ENGL J MED, V337, P740, DOI 10.1056/NEJM199709113371103; Schneider DB, 1997, CIRCULATION, V95, P308; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Schwartz L, 1997, LANCET, V350, P113, DOI 10.1016/S0140-6736(05)61815-6; Serruys PW, 1998, LANCET, V352, P673, DOI 10.1016/S0140-6736(97)11128-X; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SERRUYS PW, 1997, HDB CORONARY STENTS; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; Stone GW, 1998, J INVASIVE CARDIOL, V10, p16A; Teirstein PS, 1997, NEW ENGL J MED, V336, P1697, DOI 10.1056/NEJM199706123362402; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; Versaci F, 1997, NEW ENGL J MED, V336, P817, DOI 10.1056/NEJM199703203361201	28	6	6	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 6	1999	318	7184					650	653		10.1136/bmj.318.7184.650	http://dx.doi.org/10.1136/bmj.318.7184.650			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066211	Green Published			2022-12-28	WOS:000079089200032
J	Kahn, CN				Kahn, CN			Patients' rights proposals: The insurers' perspective	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Hlth Insurance Assoc Amer, Washington, DC 20004 USA		Kahn, CN (corresponding author), Hlth Insurance Assoc Amer, Washington, DC 20004 USA.							*AM ASS HLTH PLANS, 1998, DISP MAN CAR MYTHS; *HLTH CAR ADV BOAR, 1998, IMP MAN CAR HLTH CAR; *HLTH EC PRACT BAR, 1998, IMP 4 LEG PROV MAN C; *HLTH INS ASS AM, 1998, SOURC BOOK HLTH INS; JENSEN G, 1999, MANDATED BENEFIT LAW; MAJILCHTOTH C, 1995, MONITORING ATTITUDES; *NAT RES CORP, 1998, SAT REP CARD 1998	7	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					858	858						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10071011				2022-12-28	WOS:000078804300041
J	Read, J				Read, J			Sexual problems associated with infertility, pregnancy, and ageing	BRITISH MEDICAL JOURNAL			English	Review																		ADLER N, 1991, INFERTILITY PERSPECT; BANCROFT J, 1989, HUMAN SEXUALITY ITS, P282; BRECHER EM, 1984, LOVE SEX AGEING CONS; GUANOTRUJILLO B, 1987, HLTH CARE WOM INT, V5, P339; KAPLAN HS, 1993, NEW INJECTION TREATM, P142; MILLS JL, 1981, LANCET, V2, P136, DOI 10.1016/S0140-6736(81)90311-1; READ J, 1995, COUNSELLING FERTILIT; REAMY K J, 1985, Journal of Psychosomatic Obstetrics and Gynecology, V4, P263, DOI 10.3109/01674828509016728; Savage W, 1984, Midwife Health Visit Community Nurse, V20, P398	9	23	25	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					587	589		10.1136/bmj.318.7183.587	http://dx.doi.org/10.1136/bmj.318.7183.587			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037642	Green Published			2022-12-28	WOS:000078966300036
J	Blichert-Toft, J; Albarede, F; Kornprobst, J				Blichert-Toft, J; Albarede, F; Kornprobst, J			Lu-Hf isotope systematics of garnet pyroxenites from Beni Bousera, Morocco: Implications for basalt origin	SCIENCE			English	Article							OCEAN-RIDGE BASALTS; UPPER MANTLE; ULTRAMAFIC COMPLEX; PERIDOTITE MASSIF; TRACE-ELEMENT; NORTH MOROCCO; CONSTRAINTS; RONDA	Six garnet pyroxenites from Beni Bousera. Morocco, yield a mean Lutetium-hafnium age of 25 +/- 1 million years ago and show a wide range in hafnium isotope compositions (epsilon(Hf) = -9 to +42 25 million years ago), which exceeds that of known basalts (0 to +25), Therefore, primary melts of garnet pyroxenites cannot be the source of basalts. The upper mantle may be an aggregate of pyroxenites that were Left by the melting of oceanic crust at subduction zones and peridotites that were contaminated by the percolation of melts from these pyroxenites. As a consequence, the concept of geochemical heterogeneities as passive tracers is inadequate, Measured Lutetium-hafnium partitioning of natural minerals requires a reassessment of some experimental work relevant to mantle melting in the presence of garnet.	Ecole Normale Super Lyon, F-69364 Lyon 7, France; CNRS, F-69364 Lyon, France; Observ Phys Globe Clermont Ferrand, CNRS, Unite Mixte Rech Magmas & Volcans, F-63038 Clermont Ferrand, France	Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA)	Blichert-Toft, J (corresponding author), Ecole Normale Super Lyon, 46 Allee Italie, F-69364 Lyon 7, France.		Albarede, Francis/A-8871-2011; Blichert-Toft, Janne/C-8280-2012	Albarede, Francis/0000-0003-1994-1428; Blichert-Toft, Janne/0000-0002-4932-4079				ALLEGRE CJ, 1986, NATURE, V323, P123, DOI 10.1038/323123a0; BlichertToft J, 1997, CONTRIB MINERAL PETR, V127, P248, DOI 10.1007/s004100050278; Blundy JD, 1998, EARTH PLANET SC LETT, V160, P493, DOI 10.1016/S0012-821X(98)00106-X; Bourdon B, 1996, NATURE, V384, P231, DOI 10.1038/384231a0; Duchene S, 1997, NATURE, V387, P586, DOI 10.1038/42446; GJATA K, 1992, B SOC GEOL FR, V163, P469; Hauri EH, 1997, EARTH PLANET SC LETT, V153, P1, DOI 10.1016/S0012-821X(97)00157-X; Hirschmann MM, 1996, CONTRIB MINERAL PETR, V124, P185, DOI 10.1007/s004100050184; Javoy M., 1980, C INT CNRS, V272, P279; KORNPROBST J, 1990, J PETROL, V31, P717, DOI 10.1093/petrology/31.3.717; KORNPROBST J, 1969, CONTRIB MINERAL PETR, V23, P283, DOI 10.1007/BF00371425; Kornprobst J, 1974, NOTES M MOIRES SERV, V256, P1; Kumar N, 1996, GEOCHIM COSMOCHIM AC, V60, P1429, DOI 10.1016/0016-7037(95)00443-2; LASSITER JC, 1998, MINERAL MAG A, V62, P856; LATOURRETTE TZ, 1993, SCIENCE, V261, P739, DOI 10.1126/science.261.5122.739; LOOMIS TP, 1975, AM J SCI, V275, P1, DOI 10.2475/ajs.275.1.1; LOUBET M, 1982, NATURE, V298, P809, DOI 10.1038/298809a0; Lundstrom CC, 1998, EARTH PLANET SC LETT, V157, P151, DOI 10.1016/S0012-821X(98)00038-7; MCKENZIE D, 1991, J PETROL, V32, P1021, DOI 10.1093/petrology/32.5.1021; PEARSON DG, 1993, J PETROL, V34, P125, DOI 10.1093/petrology/34.1.125; PEARSON DG, 1991, EARTH PLANET SC LETT, V102, P289, DOI 10.1016/0012-821X(91)90024-C; REISBERG L, 1989, EARTH PLANET SC LETT, V96, P161, DOI 10.1016/0012-821X(89)90130-1; REISBERG L, 1986, EARTH PLANET SC LETT, V81, P29, DOI 10.1016/0012-821X(86)90098-1; RICARD Y, 1989, J GEOPHYS RES-SOLID, V94, P17543, DOI 10.1029/JB094iB12p17543; ROYBARMAN M, 1995, EARTH PLANET SC LETT, V129, P145, DOI 10.1016/0012-821X(94)00238-T; SALTERS VJM, 1989, NATURE, V342, P420, DOI 10.1038/342420a0; SALTERS VJM, 1995, EARTH PLANET SC LETT, V129, P13, DOI 10.1016/0012-821X(94)00234-P; SLODKEVITCH VV, 1982, MIN SOC USSR, V1, P13; VANWESTRENEN W, IN PRESS AM MINERAL; Vergely P, 1998, CR ACAD SCI II A, V326, P717, DOI 10.1016/S1251-8050(98)80183-3; WOOD DA, 1979, GEOLOGY, V7, P499, DOI 10.1130/0091-7613(1979)7<499:AVVSUM>2.0.CO;2; ZINDLER A, 1984, EARTH PLANET SC LETT, V70, P175, DOI 10.1016/0012-821X(84)90004-9; ZINDLER A, 1986, ANNU REV EARTH PL SC, V14, P493, DOI 10.1146/annurev.ea.14.050186.002425	33	133	136	2	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1303	1306		10.1126/science.283.5406.1303	http://dx.doi.org/10.1126/science.283.5406.1303			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037596				2022-12-28	WOS:000078839900035
J	Robinson, NJ; Procter, CM; Connolly, EL; Guerinot, ML				Robinson, NJ; Procter, CM; Connolly, EL; Guerinot, ML			A ferric-chelate reductase for iron uptake from soils	NATURE			English	Article							RESPIRATORY BURST OXIDASE; ARABIDOPSIS-THALIANA; GENE FAMILY; SACCHAROMYCES-CEREVISIAE; EVOLUTION; PROTEIN; CLONES; CELLS	Iron deficiency afflicts more than three billion people worldwide(1), and plants are the principal source of iron in most diets. Low availability of iron often limits plant growth because iron forms insoluble ferric oxides, leaving only a small, organically complexed fraction in soil solutions(2). The enzyme ferric-chelate reductase is required for most plants to acquire soluble iron. Here we report the isolation of the FRO2 gene, which is expressed in iron-deficient roots of Arabidopsis. FRO2 belongs to a superfamily of flavocytochromes that transport electrons across membranes. It possesses intramembranous binding sites for haem and cytoplasmic binding sites for nucleotide cofactors that donate and transfer electrons. We show that FRO2 is allelic to the frd1 mutations that impair the activity of ferric-chelate reductase(3). There is a nonsense mutation within the first exon of FRO2 in frd1-1 and a missense mutation within FRO2 in frd1-3. Introduction of functional FRO2 complements the frd1-1 phenotype in transgenic plants. The isolation of FRO2 has implications for the generation of crops with improved nutritional quality and increased growth in iron-deficient soils.	Newcastle Univ, Sch Med, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA	Newcastle University - UK; Dartmouth College	Robinson, NJ (corresponding author), Newcastle Univ, Sch Med, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	n.j.robinson@ncl.ac.uk; mary.lou.guerinot@dartmouth.edu	Robinson, Nigel J/J-6363-2012; Connolly, Erin L/B-7648-2013	Robinson, Nigel J/0000-0001-5586-1092; 				BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BIENFAIT HF, 1985, J BIOENERG BIOMEMBR, V17, P73, DOI 10.1007/BF00744199; BRUGGEMANN W, 1993, PLANTA, V190, P151, DOI 10.1007/BF00196606; CHANEY RL, 1972, PLANT PHYSIOL, V50, P208, DOI 10.1104/pp.50.2.208; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; Eide D, 1997, CH MICROBIOL SER, P342; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Finegold AA, 1996, J BIOL CHEM, V271, P31021, DOI 10.1074/jbc.271.49.31021; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Groom QJ, 1996, PLANT J, V10, P515, DOI 10.1046/j.1365-313X.1996.10030515.x; Grusak MA, 1996, PLANT PHYSIOL, V110, P329, DOI 10.1104/pp.110.1.329; GUERINOT ML, 1994, PLANT PHYSIOL, V104, P815, DOI 10.1104/pp.104.3.815; Keller T, 1998, PLANT CELL, V10, P255, DOI 10.1105/tpc.10.2.255; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; McDowell JM, 1996, GENETICS, V142, P587; MILPETZ F, 1995, TRENDS BIOCHEM SCI, V20, P204, DOI 10.1016/S0968-0004(00)89009-X; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; PETERMAN TK, 1991, MOL GEN GENET, V230, P145, DOI 10.1007/BF00290662; Robinson NJ, 1997, PLANT SOIL, V196, P245, DOI 10.1023/A:1004258225806; ROGERS SG, 1988, METHOD ENZYMOL, V253, P253; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; Torres MA, 1998, PLANT J, V14, P365, DOI 10.1046/j.1365-313X.1998.00136.x; VOYTAS DF, 1990, GENETICS, V126, P713; Yi Y, 1996, PLANT J, V10, P835, DOI 10.1046/j.1365-313X.1996.10050835.x	28	876	950	10	174	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 25	1999	397	6721					694	697		10.1038/17800	http://dx.doi.org/10.1038/17800			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AP	10067892				2022-12-28	WOS:000078840100050
J	Pyke, D				Pyke, D			Alexander Macdougal Cooke - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																		COOKE AGR, PUBLICATION LIST	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1999	318	7182					540	540		10.1136/bmj.318.7182.540	http://dx.doi.org/10.1136/bmj.318.7182.540			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QT	10024283	Green Published			2022-12-28	WOS:000078818100062
J	Shulman, CE; Dorman, EK; Cutts, F; Kawuondo, K; Bulmer, JN; Peshu, N; Marsh, K				Shulman, CE; Dorman, EK; Cutts, F; Kawuondo, K; Bulmer, JN; Peshu, N; Marsh, K			Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial	LANCET			English	Article							PLASMODIUM-FALCIPARUM TRANSMISSION; PLACENTAL MALARIA; MATERNAL MORTALITY; COASTAL KENYA; BED NETS; CHEMOPROPHYLAXIS; PRIMIGRAVIDAE; INFECTION; CHILDREN; EFFICACY	Background In areas of endemic transmission, malaria in pregnancy is associated with severe maternal anaemia and low-birthweight babies, We studied the efficacy of intermittent treatment doses of sulphadoxine-pyrimethamine In preventing malaria and severe anaemia in pregnancy in a double-blind placebo-controlled trial among primigravid women living in Kilifi District, Kenya. Methods Between January, 1996, and April, 1997, 1264 primigravid women were recruited when they attended: for antenatal care, and randomly assigned sulphadoxine-pyrimethamine (640) or placebo (624). Women received one, two, or three doses of study medication depending an the duration of gestation at enrolment. Primary outcome measures were severe anaemia (haemoglobin <8 g/dL) and malaria parasitaemia, assessed at 34 weeks of gestation. Analyses were based on intention to treat among women who had study blood tests at 34 weeks, Findings 30 (5.3%) of 567 women in the sulphadoxine- pyrimethamine group and 199 (35.3%) of 564 in the placebo group had peripheral parasitaemia (protecive efficacy 85% [95% CI 78-90], p < 0.0001). 82 (14.5%) and 134 (23.7%) had severe anaemia (protective efficacy 39% [22-52], p<0.0001). Even women who booked late and received only one dose of sulphadoxine-pyrimethamine benefited significantly from the intervention. The effects were, seen both in women who owned insecticide-treated bednets and in women who did not. Interpretation intermittent presumptive treatment with sulphadoxine-pyrimethamine is an effective, practicable strategy to decrease the risk of severe anaemia in primigravidae living in malarious areas.	Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Matrnal & Child Epidemiol Unit, London WC1E 7HT, England; Kenya Med Res Inst, Ctr Geog Med Res, Kilifi, Kenya; Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England; Univ Newcastle, Royal Victoria Infirm, Dept Pathol, Newcastle Upon Tyne, Tyne & Wear, England	University of London; London School of Hygiene & Tropical Medicine; Kenya Medical Research Institute; University of Oxford; Newcastle University - UK	Shulman, CE (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Matrnal & Child Epidemiol Unit, Keppel St, London WC1E 7HT, England.	c.shulman@lshtm.ac.uk		Shulman, Caroline/0000-0002-7744-2101	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; ARMON PJ, 1979, T ROY SOC TROP MED H, V73, P284, DOI 10.1016/0035-9203(79)90083-X; BJORKMAN A, 1991, B WORLD HEALTH ORGAN, V69, P297; BOERMA JT, 1989, STUD FAMILY PLANN, V20, P245, DOI 10.2307/1966761; BRABIN B, 1991, APPL FIELD RES MALAR, V1; BULMER JN, 1993, HISTOPATHOLOGY, V22, P211, DOI 10.1111/j.1365-2559.1993.tb00110.x; BULMER JN, 1993, HISTOPATHOLOGY, V22, P219, DOI 10.1111/j.1365-2559.1993.tb00111.x; DAlessandro U, 1996, T ROY SOC TROP MED H, V90, P487, DOI 10.1016/S0035-9203(96)90289-8; DESCOWITZ RS, 1992, ANN TROP MED PARASIT, V86, P95; DOLAN G, 1993, T ROY SOC TROP MED H, V87, P620, DOI 10.1016/0035-9203(93)90262-O; FLEMING AF, 1986, ANN TROP MED PARASIT, V80, P211, DOI 10.1080/00034983.1986.11812006; GILLES HM, 1969, ANN TROP MED PARASIT, V63, P245, DOI 10.1080/00034983.1969.11686625; GREENWOOD BM, 1989, T ROY SOC TROP MED H, V83, P589, DOI 10.1016/0035-9203(89)90362-3; GULMEZOGLU AM, 1998, COCHRANE LIB; HEYMANN DL, 1990, T ROY SOC TROP MED H, V84, P496, DOI 10.1016/0035-9203(90)90011-3; KIRUMBI LW, 1996, PREVALENCE FACTORS A; MacLeod J, 1998, TROP MED INT HEALTH, V3, P130, DOI 10.1046/j.1365-3156.1998.00174.x; MBOGO CNM, 1995, AM J TROP MED HYG, V52, P201, DOI 10.4269/ajtmh.1995.52.201; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; MCDERMOTT JM, 1988, T ROY SOC TROP MED H, V82, P520, DOI 10.1016/0035-9203(88)90491-9; MTIMAVALYE LAR, 1980, E AFR MED J, V57, P111; MUTABINGWA TK, 1993, TROP GEOGR MED, V45, P49; Nevill CG, 1996, TROP MED INT HEALTH, V1, P139; PARRY JV, 1989, AIDS, V3, P173, DOI 10.1097/00002030-198903000-00008; PhillipsHoward PA, 1996, DRUG SAFETY, V14, P131, DOI 10.2165/00002018-199614030-00001; SCHULTZ LJ, 1994, AM J TROP MED HYG, V51, P515, DOI 10.4269/ajtmh.1994.51.515; Shulman CE, 1998, TROP MED INT HEALTH, V3, P197; Shulman CE, 1996, T ROY SOC TROP MED H, V90, P535, DOI 10.1016/S0035-9203(96)90312-0; SNOW RW, 1993, T ROY SOC TROP MED H, V87, P386, DOI 10.1016/0035-9203(93)90007-D; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; Steketee RW, 1996, AM J TROP MED HYG, V55, P33, DOI 10.4269/ajtmh.1996.55.33; STEKETEE RW, 1988, ANN TROP MED PARASIT, V82, P113, DOI 10.1080/00034983.1988.11812217; WALKER PC, 1987, CLIN PHARMACOKINET, V13, P26, DOI 10.2165/00003088-198713010-00002	33	286	288	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 20	1999	353	9153					632	636		10.1016/S0140-6736(98)07318-8	http://dx.doi.org/10.1016/S0140-6736(98)07318-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QU	10030329				2022-12-28	WOS:000078818200013
J	Chuang, PT; McMahon, AP				Chuang, PT; McMahon, AP			Vertebrate Hedgehog signalling modulated by induction of a Hedgehog-binding protein	NATURE			English	Article							SONIC-HEDGEHOG; SIGNALING PATHWAY; GENE; RECEPTOR; CARTILAGE; POLARITY; MICE	The Hedgehog signalling pathway is essential for the development of diverse tissues during embryogenesis(1). Signalling is activated by binding: of Hedgehog protein to the multipass membrane protein Patched (Ptc)(2,3). We have now identified a novel component in the vertebrate signalling pathway, which we name Hip (for Hedgehog-interacting protein) because of its ability to bind Hedgehog proteins. Hip encodes a membrane glycoprotein that binds to all three mammalian Hedgehog proteins with an affinity comparable to that of Ptc-1. Hip-expressing cells are located next to cells that express each Hedgehog gene. Hip expression is induced by ectopic Hedgehog signalling and is lost in Hedgehog mutants. Thus, Hip, like Ptc-1, is a general transcriptional target of Hedgehog signalling. Overexpression of Hip in cartilage, where Indian hedgehog (Ihh) controls growth(4), leads to a shortened skeleton that resembles that seen when Ihh function is lost (B. St-Jacques, M. Hammerschmidt & A.P.M., in preparation). Our findings support a model in which Hip attenuates Hedgehog signalling as a result of binding to Hedgehog proteins: a negative regulatory feedback loop established in this way could thus modulate the responses to any Hedgehog signal.	Harvard Univ, Biolabs, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Chuang, PT (corresponding author), Harvard Univ, Biolabs, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.		McMahon, Andrew P/ABE-7520-2020					Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Brown DD, 1996, P NATL ACAD SCI USA, V93, P1924, DOI 10.1073/pnas.93.5.1924; CHEAH KSE, 1991, DEVELOPMENT, V111, P945; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Epstein DJ, 1996, DEVELOPMENT, V122, P2885; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hogan B, 1994, MANIPULATING MOUSE E; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; JESSELL TM, 1992, HARVEY LECT, V86, P87; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Muskavitch M.A.T., 1990, Current Topics in Developmental Biology, V24, P289, DOI 10.1016/S0070-2153(08)60091-5; NAKATA K, 1993, P NATL ACAD SCI USA, V90, P2870, DOI 10.1073/pnas.90.7.2870; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; Schneider D, 1996, GENE, V177, P243, DOI 10.1016/0378-1119(96)00310-1; Schwabe JWR, 1998, TRENDS GENET, V14, P229, DOI 10.1016/S0168-9525(98)01477-2; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Tabin CJ, 1997, TRENDS CELL BIOL, V7, P442, DOI 10.1016/S0962-8924(97)01159-8; von Heijne G, 1990, CURR OPIN CELL BIOL, V2, P604, DOI 10.1016/0955-0674(90)90100-S; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; Yang Y, 1997, DEVELOPMENT, V124, P4393	29	598	621	3	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 18	1999	397	6720					617	621		10.1038/17611	http://dx.doi.org/10.1038/17611			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GE	10050855				2022-12-28	WOS:000078738500050
J	Aranda-Michel, J; Koehler, A; Bejarano, PA; Poulos, JE; Luxon, BA; Khan, CM; Ee, LC; Balistreri, WF; Weber, FL				Aranda-Michel, J; Koehler, A; Bejarano, PA; Poulos, JE; Luxon, BA; Khan, CM; Ee, LC; Balistreri, WF; Weber, FL			Nefazodone-induced liver failure: Report of three cases	ANNALS OF INTERNAL MEDICINE			English	Article							ANTIDEPRESSANT DRUG; PHARMACOLOGY	Background: Liver failure is a rare but devastating result of drug toxicity. Objective: To describe three cases of subfulminant liver failure that were probably caused by nefazodone, a new antidepressant that is a synthetically derived phenylpiperazine. Design: Case series. Setting: Two university medical centers and a children's hospital. Patients: Three women 16 to 57 years of age. Intervention: Two patients underwent liver transplantation; the third was listed for transplantation but subsequently improved. Measurement: Liver biopsy. Results: Nefazodone was administered for 14 to 28 weeks before the onset of symptoms. The duration of jaundice before onset of encephalopathy ranged from 4 to 6 weeks. All cases of liver failure had similar histologic appearance, with prominent necrosis in the centrolobular areas (zone 3). One patient had successful liver transplantation, one underwent transplantation but died, and one improved without transplantation. The temporal onset of disease after the start of nefazodone therapy suggested severe hepatocellular injury caused by the drug. Conclusions: Because nefazodone seems to cause severe hepatocellular injury in an idiosyncratic manner, routine liver chemistries should be performed before starting nefazodone therapy and patients should be monitored regularly. Therapy should be discontinued if liver enzyme concentrations become abnormal.	Univ Cincinnati, Med Ctr, Div Digest Dis, Liver Unit, Cincinnati, OH 45267 USA; Childrens Hosp, Med Ctr, Div Pediat Gastroenterol & Nutr, Cincinnati, OH 45229 USA; St Louis Univ, Div Gastroenterol & Hepatol, St Louis, MO 63110 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Saint Louis University	Weber, FL (corresponding author), Univ Cincinnati, Med Ctr, Div Digest Dis, Liver Unit, 231 Bethesda Ave,ML 595, Cincinnati, OH 45267 USA.							BARBHAIYA RH, 1995, CLIN PHARMACOL THER, V58, P390, DOI 10.1016/0009-9236(95)90051-9; BENHAMOU JP, 1991, ACUTE LIVER FAILURE, P6; FONTAINE R, 1993, CLIN NEUROPHARMACOL, V16, pS45; HUYBRECHTS I, 1991, CLIN THER, V13, P100; MADDREY WC, 1975, GASTROENTEROLOGY, V68, P351; MAYOL RF, 1994, DRUG METAB DISPOS, V22, P304; Robinson DS, 1996, J CLIN PSYCHIAT, V57, P31; SHARPLEY AL, 1992, BIOL PSYCHIAT, V31, P1070, DOI 10.1016/0006-3223(92)90101-5; STRICKER BH, 1992, DRUG INDUCED HEPATIC, P429; TAYLOR DP, 1995, J CLIN PSYCHIAT, V56, P3; Williams R, 1996, SEMIN LIVER DIS, V16, P343, DOI 10.1055/s-2007-1007247	11	63	64	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	1				285	288		10.7326/0003-4819-130-4-199902160-00013	http://dx.doi.org/10.7326/0003-4819-130-4-199902160-00013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166PY	10068386				2022-12-28	WOS:000078587200005
J	Krishna, S; Taylor, AM; Supanaranond, W; Pukrittayakamee, S; ter Kuile, F; Tawfiq, KM; Holloway, PAH; White, NJ				Krishna, S; Taylor, AM; Supanaranond, W; Pukrittayakamee, S; ter Kuile, F; Tawfiq, KM; Holloway, PAH; White, NJ			Thiamine deficiency and malaria in adults from southeast Asia	LANCET			English	Article							ERYTHROCYTE TRANSKETOLASE ACTIVITY; PLASMODIUM-FALCIPARUM; PARACETAMOL; FEVER	Background Thiamine deficiency (beriberi) is common in some parts of southeast Asia. Acute thiamine deficiency can mimic many complications of malaria, such as encephalopathy and lactic acidosis. We examined the incidence of thiamine deficiency in adults admitted to hospital with malaria in Thailand. Methods For this prospective study, we recruited consecutive patients with malaria or other febrile illness who presented to Paholpolpayuhasena Hospital, Kanchanaburi, Thailand, between May and July, 1.992. We used the activation coefficient (a) for transketolase activity in erythrocytes to measure thiamine deficiency (defined as alpha>1.31) in patients with severe and uncomplicated malaria and in controls (patients' relatives and healthy volunteers). To exclude the possibility of interference in the assays, transketolase activity was also measured in erythrocytes used to culture parasites. Findings 12 (52%) of 23 patients with severe malaria and ten (19%) of 54 patients with uncomplicated malaria had ct values above the normal range (p<0.0001 and p=0.0014, respectively, compared with controls), which indicated severe thiamine deficiency. Thiamine deficiency was more severe in patients with cerebral malaria than in those with uncomplicated malaria and the controls (p=0.008). Interpretation In adults admitted to hospital in Thailand, thiamine deficiency commonly complicates acute falciparum malaria, particularly in severe infections, and could contribute to dysfunction of the central nervous system.	Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand; John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England; John Radcliffe Hosp, Dept Clin Biochem, Oxford OX3 9DU, England	Mahidol University; University of Oxford; University of Oxford	Krishna, S (corresponding author), St George Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England.		Kuile, Feiko ter/ABD-6681-2020; White, Nicholas J/I-4629-2012; White, Nick/AAC-6527-2019	Kuile, Feiko ter/0000-0003-3663-5617; White, Nick/0000-0002-1897-1978; Krishna, Sanjeev/0000-0003-0066-0634	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1990, Trans R Soc Trop Med Hyg, V84 Suppl 2, P1; BAINES M, 1988, ANN CLIN BIOCHEM, V25, P698, DOI 10.1177/000456328802500617; BAYOUMI RA, 1976, CLIN CHEM, V22, P327; BRIN M, 1960, J NUTR, V71, P273, DOI 10.1093/jn/71.3.273; HERVE C, 1995, CLIN CHIM ACTA, V234, P91, DOI 10.1016/0009-8981(94)05980-7; KRISHNA S, 1993, BRIT J CLIN PHARMACO, V36, P585, DOI 10.1111/j.1365-2125.1993.tb00419.x; KRISHNA S, 1995, T ROY SOC TROP MED H, V89, P197, DOI 10.1016/0035-9203(95)90494-8; KRISHNA S, 1995, T ROY SOC TROP MED H, V89, P507, DOI 10.1016/0035-9203(95)90087-X; Krishna S, 1996, BRIT J CLIN PHARMACO, V41, P29, DOI 10.1111/j.1365-2125.1996.tb00155.x; MCCONACHIE I, 1988, INTENS CARE MED, V14, P628; MOUNT JN, 1987, ANN CLIN BIOCHEM, V24, P41, DOI 10.1177/000456328702400106; Newton CRJC, 1998, PHARMACOL THERAPEUT, V79, P1, DOI 10.1016/S0163-7258(98)00008-4; SAUBERLICH HE, 1967, AM J CLIN NUTR, V20, P528, DOI 10.1093/ajcn/20.6.528; Schaal KP., 1996, OXFORD TXB MED, V1, P680; SMEETS EHJ, 1971, CLIN CHIM ACTA, V33, P379, DOI 10.1016/0009-8981(71)90496-7; TERKUILE F, 1993, EXP PARASITOL, V76, P85, DOI 10.1006/expr.1993.1010; VICTOR M, 1989, WERNICKEKORSAKOFF SY; VIMOKESANT SL, 1975, AM J CLIN NUTR, V28, P1458, DOI 10.1093/ajcn/28.12.1458; WHITE NJ, 1992, ADV PARASIT, V31, P83, DOI 10.1016/S0065-308X(08)60021-4	19	49	51	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 13	1999	353	9152					546	549		10.1016/S0140-6736(98)06316-8	http://dx.doi.org/10.1016/S0140-6736(98)06316-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028983				2022-12-28	WOS:000078670200012
J	Steele, EK; Lewis, SEM; McClure, N				Steele, EK; Lewis, SEM; McClure, N			Science versus clinical adventurism in treatment of azoospermia	LANCET			English	Editorial Material							TESTICULAR SPERMATOZOA; CONSEQUENCES; INJECTION		Queens Univ Belfast, Inst Clin Sci, Dept Obstet & Gynaecol, Belfast BT12 6BJ, Antrim, North Ireland	Queens University Belfast	Steele, EK (corresponding author), Queens Univ Belfast, Inst Clin Sci, Dept Obstet & Gynaecol, Belfast BT12 6BJ, Antrim, North Ireland.		Lewis, Sheena E M/ABI-8338-2020					BRAUDE P, 1988, NATURE, V332, P459, DOI 10.1038/332459a0; De Croo I, 1998, HUM REPROD, V13, P1893, DOI 10.1093/humrep/13.7.1893; Dohle GR, 1998, HUM REPROD, V13, P620, DOI 10.1093/humrep/13.3.620; Friedler S, 1997, FERTIL STERIL, V68, P892, DOI 10.1016/S0015-0282(97)00358-0; GENESCA A, 1992, HUM GENET, V89, P181; Hewitson L, 1997, INT J ANDROL, V20, P35; Hull MGR, 1998, HUM REPROD, V13, P1825, DOI 10.1093/humrep/13.7.1825; Jurisicova A, 1998, MOL HUM REPROD, V4, P139, DOI 10.1093/molehr/4.2.139; Madgar I, 1998, FERTIL STERIL, V69, P1080, DOI 10.1016/S0015-0282(98)00076-4; Manning M, 1998, LANCET, V352, P37, DOI 10.1016/S0140-6736(05)79518-0; Schlegel PN, 1997, HUM REPROD, V12, P1688, DOI 10.1093/humrep/12.8.1688; SILBER SJ, 1995, HUM REPROD, V10, P2031, DOI 10.1093/oxfordjournals.humrep.a136231; Steele EK, 1998, HUM REPROD, V13, P132; Steele EK, 1998, HUM REPROD, V13, P131; Tycko B, 1997, J ANDROL, V18, P480; Verheyen G, 1995, HUM REPROD, V10, P2956, DOI 10.1093/oxfordjournals.humrep.a135828	16	11	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 13	1999	353	9152					516	517		10.1016/S0140-6736(98)00312-2	http://dx.doi.org/10.1016/S0140-6736(98)00312-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028976				2022-12-28	WOS:000078670200005
J	Gazmararian, JA; Baker, DW; Williams, MV; Parker, RM; Scott, TL; Green, DC; Fehrenbach, SN; Ren, JL; Koplan, JP				Gazmararian, JA; Baker, DW; Williams, MV; Parker, RM; Scott, TL; Green, DC; Fehrenbach, SN; Ren, JL; Koplan, JP			Health literacy among Medicare enrollees in a managed care organization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFORMED CONSENT FORMS; DISCHARGE INSTRUCTIONS; PATIENT LITERACY; EMERGENCY; READABILITY; SURVEILLANCE; SKILLS; OLDER; READ	Context Elderly patients may have limited ability to read and comprehend medical information pertinent to their health, Objective To determine the prevalence of low functional health literacy among community-dwelling Medicare enrollees in a national managed care organization. Design Cross-sectional survey. Setting Four Prudential HealthCare plans (Cleveland, Ohio; Houston, Tex; south Florida; Tampa, Fla). Participants A total of 3260 new Medicare enrollees aged 65 years or older were interviewed in person between June and December 1997 (853 in Cleveland, 498 in Houston, 975 in south Florida, 934 in Tampa); 2956 spoke English and 304 spoke Spanish as their native language. Main Outcome Measure Functional health literacy as measured by the Short Test of Functional Health Literacy in Adults. Results Overall, 33.9% of English-speaking and 53.9% of Spanish-speaking respondents had inadequate or marginal health literacy. The prevalence of inadequate or marginal functional health literacy among English speakers ranged from 26.8% to 44.0%. In multivariate analysis, study location, race/language, age, years of school completed, occupation, and cognitive impairment were significantly associated with inadequate or marginal literacy. Reading ability declined dramatically with age, even after adjusting for years of school completed and cognitive impairment, The adjusted odds ratio for having inadequate or marginal health literacy was 8.62 (95% confidence interval, 5.55-13.38) for enrollees aged 85 years or older compared with individuals aged 65 to 69 years. Conclusions Elderly managed care enrollees may not have the literacy skills necessary to function adequately in the health care environment. Low health literacy may impair elderly patients' understanding of health messages and limit their ability to care for their medical problems.	Prudential Ctr Hlth Care Res, Atlanta, GA 30339 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Metrohlth Med Ctr, Dept Med, Cleveland, OH USA; Metrohlth Med Ctr, Dept Epidemiol, Cleveland, OH USA; Metrohlth Med Ctr, Dept Biostat, Cleveland, OH USA	Emory University; Case Western Reserve University; MetroHealth System; MetroHealth System; MetroHealth System	Gazmararian, JA (corresponding author), Prudential Ctr Hlth Care Res, 2859 Paces Ferry Rd,Suite 820, Atlanta, GA 30339 USA.		Parker, Ruth M/S-4583-2017	Parker, Ruth M/0000-0001-9685-6396; Williams, Mark V/0000-0001-6107-0457				ANSCHER MS, 1991, SOUTHERN MED J, V84, P209, DOI 10.1097/00007611-199102000-00014; Baker DW, 1998, J GEN INTERN MED, V13, P791, DOI 10.1046/j.1525-1497.1998.00242.x; Baker DW, 1996, ARCH FAM MED, V5, P329, DOI 10.1001/archfami.5.6.329; BAKER DW, IN PRESS PATIENT ED; BAKER MT, 1983, JAMA-J AM MED ASSOC, V250, P2646, DOI 10.1001/jama.250.19.2646; Barnett E, 1997, AM J PUBLIC HEALTH, V87, P1521, DOI 10.2105/AJPH.87.9.1521; BENSON V, 1998, VITAL HLTH STAT, V10, P199; Callahan CM, 1998, J GEN INTERN MED, V13, P746, DOI 10.1046/j.1525-1497.1998.00226.x; Doak CC, 1996, TEACHING PATIENTS LO; FOSTEIN MF, 1975, J PSYCHIATR RES, V12, P189; GROSSMAN SA, 1994, J CLIN ONCOL, V12, P2211, DOI 10.1200/JCO.1994.12.10.2211; GRUNDNER TM, 1980, NEW ENGL J MED, V302, P900, DOI 10.1056/NEJM198004173021606; HERZOG AR, 1988, J GERONTOL, V43, pS200, DOI 10.1093/geronj/43.6.S200; JOLLY BT, 1993, ANN EMERG MED, V22, P573, DOI 10.1016/S0196-0644(05)81944-4; KIRSCH IS, 1993, ADULT LIT AM 1 LOOK; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; LAUBACH R, 1977, USING READABILITY FO; LOVERDE ME, 1989, J GEN INTERN MED, V4, P410, DOI 10.1007/BF02599693; Meade C D, 1992, Oncol Nurs Forum, V19, P51; MORLEY G, 1997, FUNCTIONAL HLTH LIT; MORROW GR, 1980, JAMA-J AM MED ASSOC, V244, P56, DOI 10.1001/jama.244.1.56; MURPHY PW, 1993, EDUC GERONTOL, V19, P311, DOI 10.1080/0360127930190403; Parikh NS, 1996, PATIENT EDUC COUNS, V27, P33, DOI 10.1016/0738-3991(95)00787-3; PARKER RM, 1995, J GEN INTERN MED, V10, P537, DOI 10.1007/BF02640361; PETTERSON T, 1994, DIABETIC MED, V11, P111, DOI 10.1111/j.1464-5491.1994.tb00239.x; POWERS RD, 1988, ANN EMERG MED, V17, P124, DOI 10.1016/S0196-0644(88)80295-6; REMINGTON PL, 1988, PUBLIC HEALTH REP, V103, P366; *SAS I INC, 1989, SAS STAT US GUID VER, V1; SHAH BV, 1997, SUDAN USERS MANUAL R; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; SPANDORFER JM, 1995, ANN EMERG MED, V25, P71, DOI 10.1016/S0196-0644(95)70358-6; STEDMAN LC, 1991, LIT US READERS READI, P75; Taylor WL, 1953, JOURNALISM QUART, V30, P415, DOI 10.1177/107769905303000401; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; U. S. Bureau of the Census, 1996, STAT ABSTR US; Unutzer J, 1997, JAMA-J AM MED ASSOC, V277, P1618, DOI 10.1001/jama.277.20.1618; WARE JE, 1994, SF36 PHYSICAL MENTAL; WEISS BD, 1995, PATIENT EDUC COUNS, V25, P109, DOI 10.1016/0738-3991(95)00710-H; Williams DM, 1996, AM J EMERG MED, V14, P19, DOI 10.1016/S0735-6757(96)90006-6; WILLIAMS MV, 1995, JAMA-J AM MED ASSOC, V274, P1677; Williams MV, 1998, CHEST, V114, P1008, DOI 10.1378/chest.114.4.1008; Williams MV, 1998, ARCH INTERN MED, V158, P166, DOI 10.1001/archinte.158.2.166; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; PC DEMOGRAPHICS LAKE	44	557	566	2	41	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1999	281	6					545	551		10.1001/jama.281.6.545	http://dx.doi.org/10.1001/jama.281.6.545			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	164FQ	10022111	Bronze			2022-12-28	WOS:000078452900033
J	Hamel, MB; Teno, JM; Goldman, L; Lynn, J; Davis, RB; Galanos, AN; Desbiens, N; Connors, AF; Wenger, N; Phillips, RS				Hamel, MB; Teno, JM; Goldman, L; Lynn, J; Davis, RB; Galanos, AN; Desbiens, N; Connors, AF; Wenger, N; Phillips, RS		SUPPORT Investigators	Patient age and decisions to withhold life-sustaining treatments from seriously ill, hospitalized adults	ANNALS OF INTERNAL MEDICINE			English	Article						age factors; life support care; decision making; health care rationing; health resources	ACUTE MYOCARDIAL-INFARCTION; CARDIOPULMONARY-RESUSCITATION; PATIENTS PREFERENCES; CARE; PATTERNS; SURVIVAL; SUPPORT; TRENDS; WORK; OLD	Background: Patient age may influence decisions to withhold life-sustaining treatments, independent of patients' preferences for or ability to benefit from such treatments. Controversy exists about the appropriateness of using age as a criterion for making treatment decisions. Objective: To determine the effect of age on decisions to withhold life-sustaining therapies. Design: Prospective cohort study. Setting: Five medical centers participating in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT). Patients: 9105 hospitalized adults who had one of nine illnesses associated with an average 6-month mortality rate of 50%. Measurements: Outcomes were the presence and timing of decisions to withhold ventilator support, surgery, and dialysis. Adjustment was made for sociodemographic characteristics, prognoses, baseline function, patients' preferences for life-extending care, and physicians' understanding of patients' preferences for life-extending care. Results: The median patient age was 63 years; 44% of patients were women, and 53% survived to 180 days. In adjusted analyses, older age was associated with higher rates of withholding each of the three life-sustaining treatments studied. For ventilator support, the rate of decisions to withhold therapy increased 15% with each decade of age (hazard ratio, 1.15 [95% CI, 1.12 to 1.19]); for surgery, the increase per decade was 19% (hazard ratio, 1.19 [CI, 1.12 to 1.27]); and for dialysis, the increase per decade was 12% (hazard ratio, 1.12 [CI, 1.06 to 1.19]). Physicians underestimated older patients' preferences for life-extending care; adjustment for this underestimation resulted in an attenuation of the association between age and decisions to withhold treatments. Conclusion: Even after adjustment for differences in patients' prognoses and preferences, older age was associated with higher rates of decisions to withhold ventilator support, surgery, and dialysis.	Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Brown Univ, Ctr Gerontol & Hlth Care Res, Providence, RI 02912 USA; Univ Calif San Francisco, Dept Med, Sch Med, San Francisco, CA 94143 USA; George Washington Univ, Washington, DC USA; Duke Univ, Med Ctr, Durham, NC USA; Univ Tennessee, Coll Med, Chattanooga, TN USA; Univ Virginia, Sch Med, Charlottesville, VA 22908 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA	Harvard University; Beth Israel Deaconess Medical Center; Brown University; University of California System; University of California San Francisco; George Washington University; Duke University; University of Tennessee System; University of Tennessee Health Science Center; University of Virginia; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Hamel, MB (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave, Boston, MA 02215 USA.			Connors, Alfred F./0000-0001-7123-3360	NIA NIH HHS [K08 AG0075-02] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLISON PD, 1995, SURVIVAL ANAL USING, P165; [Anonymous], 1995, JAMA-J AM MED ASSOC, V274, P1541; AVORN J, 1984, NEW ENGL J MED, V310, P1294, DOI 10.1056/NEJM198405173102005; Baker R, 1993, Health Care Anal, V1, P139, DOI 10.1007/BF02197107; BEARDEN DM, 1993, J AM GERIATR SOC, V41, P1075, DOI 10.1111/j.1532-5415.1993.tb06455.x; Bowling A, 1996, BRIT MED J, V312, P670; BRENNAN TA, 1988, JAMA-J AM MED ASSOC, V260, P803, DOI 10.1001/jama.260.6.803; BUTLER RN, 1969, GERONTOLOGIST, V9, P243, DOI 10.1093/geront/9.4_Part_1.243; CALLAHAN D, 1986, DAEDALUS-US, V115, P247; CALLAHAN D, 1990, NEUROSURGERY, V27, P160, DOI 10.1227/00006123-199007000-00028; Callahan D., 1987, MED GOALS AGEING SOC; CASSEL CK, 1991, TOO OLD HLTH CARE CO; COLLETT D, 1994, MODELLING SURVIVAL D, P95; Daniels N, 1984, Bus Health, V1, P29; Dougherty C J, 1991, Health Prog, V72, P32; EVANS JG, 1991, BRIT MED J, V303, P869, DOI 10.1136/bmj.303.6807.869; FLEMING C, 1991, AM J PUBLIC HEALTH, V81, P1121, DOI 10.2105/AJPH.81.9.1121; FRANKL D, 1989, AM J MED, V86, P645, DOI 10.1016/0002-9343(89)90436-1; GEIGER DL, 1978, GERONTOLOGIST, V18, P591, DOI 10.1093/geront/18.6.591; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; GURWITZ JH, 1991, AM J EPIDEMIOL, V134, P948, DOI 10.1093/oxfordjournals.aje.a116179; Hakim RB, 1996, ANN INTERN MED, V125, P284, DOI 10.7326/0003-4819-125-4-199608150-00005; Hamel MB, 1996, J AM GERIATR SOC, V44, P1043, DOI 10.1111/j.1532-5415.1996.tb02935.x; *HAST CTR, 1987, GUID TERM LIF SUST T; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; JECKER NS, 1989, J AM GERIATR SOC, V37, P1067, DOI 10.1111/j.1532-5415.1989.tb06923.x; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LANDEFELD CS, 1990, J CLIN EPIDEMIOL, V43, pS37, DOI 10.1016/0895-4356(90)90216-C; LUBITZ J, 1995, NEW ENGL J MED, V332, P999, DOI 10.1056/NEJM199504133321506; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; LYNN J, 1990, J CLIN EPIDEMIOL, V43, pS1, DOI 10.1016/0895-4356(90)90211-7; McKenzie JK, 1998, AM J KIDNEY DIS, V31, P12, DOI 10.1053/ajkd.1998.v31.pm9428446; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; NAYLOR CD, 1992, J GEN INTERN MED, V7, P492, DOI 10.1007/BF02599450; Phillips RS, 1996, AM J MED, V100, P128, DOI 10.1016/S0002-9343(97)89450-8; PHILLIPS RS, 1990, J CLIN EPIDEMIOL, V43, pS33, DOI 10.1016/0895-4356(90)90215-B; Prottas J, 1983, Health Care Financ Rev, V4, P91; SPENCE DL, 1968, J AM GERIATR SOC, V16, P976, DOI 10.1111/j.1532-5415.1968.tb02727.x; Stone CJ, 1985, P STAT COMP SECT AM, P45; TUNIS SR, 1993, ARCH INTERN MED, V153, P991, DOI 10.1001/archinte.153.8.991; *US, 1983, PRES COMM STUD ETH P; VEATCH RM, 1988, HASTINGS CENT REP, V18, P34, DOI 10.2307/3563234; WETLE T, 1987, JAMA-J AM MED ASSOC, V258, P516, DOI 10.1001/jama.1987.03400040114035; WONG JB, 1993, NEW ENGL J MED, V328, P971, DOI 10.1056/NEJM199304013281319; YARZEBSKI J, 1994, CHEST, V105, P1003, DOI 10.1378/chest.105.4.1003	47	201	204	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	1999	130	2					116	+		10.7326/0003-4819-130-2-199901190-00005	http://dx.doi.org/10.7326/0003-4819-130-2-199901190-00005			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	158KG	10068357				2022-12-28	WOS:000078114200004
J	Decosas, J				Decosas, J			Developing health in Africa	LANCET			English	Article																			0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 9	1999	353	9147					143	144		10.1016/S0140-6736(98)11454-X	http://dx.doi.org/10.1016/S0140-6736(98)11454-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023917				2022-12-28	WOS:000078087200045
J	Stapleton, A				Stapleton, A			Prevention of recurrent urinary-tract infections in women	LANCET			English	Editorial Material							UROPATHOGENIC ESCHERICHIA-COLI; CYTOKINE RESPONSES; EPITHELIAL-CELLS; RISK-FACTORS		Univ Washington, Dept Med, Div Infect Dis, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Stapleton, A (corresponding author), Univ Washington, Dept Med, Div Infect Dis, Seattle, WA 98195 USA.		Stapleton, Ann E/N-2428-2015	Stapleton, Ann E/0000-0003-0130-8659				Brumfitt W, 1998, J ANTIMICROB CHEMOTH, V42, P363, DOI 10.1093/jac/42.3.363; FOXMAN B, 1990, AM J PUBLIC HEALTH, V80, P331, DOI 10.2105/AJPH.80.3.331; FOXMAN B, 1995, J INFECT DIS, V171, P1514, DOI 10.1093/infdis/171.6.1514; Gupta K, 1998, J INFECT DIS, V178, P446, DOI 10.1086/515635; HEDGES SR, 1995, TRENDS MICROBIOL, V3, P266, DOI 10.1016/S0966-842X(00)88941-6; Hedlund M, 1996, J EXP MED, V183, P1037, DOI 10.1084/jem.183.3.1037; HOOTON TM, 1991, JAMA-J AM MED ASSOC, V265, P64, DOI 10.1001/jama.265.1.64; Hooton TM, 1996, NEW ENGL J MED, V335, P468, DOI 10.1056/NEJM199608153350703; JOHNSON JR, 1991, CLIN MICROBIOL REV, V4, P80, DOI 10.1128/CMR.4.1.80-128.1991; Langermann S, 1997, SCIENCE, V276, P607, DOI 10.1126/science.276.5312.607; LEFFLER H, 1981, INFECT IMMUN, V34, P920, DOI 10.1128/IAI.34.3.920-929.1981; RAZ R, 1993, NEW ENGL J MED, V329, P753, DOI 10.1056/NEJM199309093291102; SCHAEFFER AJ, 1981, NEW ENGL J MED, V304, P1062, DOI 10.1056/NEJM198104303041802; SMITH S, 1996, CLIN INFECT DIS, V25, P63; STAPLETON A, 1992, J CLIN INVEST, V90, P965, DOI 10.1172/JCI115973; Stapleton A, 1997, INFECT DIS CLIN N AM, V11, P719, DOI 10.1016/S0891-5520(05)70382-2; Stapleton AE, 1998, INFECT IMMUN, V66, P3856, DOI 10.1128/IAI.66.8.3856-3861.1998; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Zopf D, 1996, LANCET, V347, P1017, DOI 10.1016/S0140-6736(96)90150-6	19	21	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 2	1999	353	9146					7	8		10.1016/S0140-6736(05)74875-3	http://dx.doi.org/10.1016/S0140-6736(05)74875-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023942				2022-12-28	WOS:000077934800007
J	Steinhubl, SR; Tan, WA; Foody, JM; Topol, EJ				Steinhubl, SR; Tan, WA; Foody, JM; Topol, EJ		EPISTENT Investigators	Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context Thrombotic thrombocytopenic purpura (TTP) is a rare and often fatal disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, mental status changes, and renal dysfunction. Ticlopidine hydrochloride is 1 of several drugs that have been associated with this disorder and is currently used routinely in the approximately 500 000 patients per year in the United States who undergo a percutaneous coronary intervention involving a stent. Objectives To determine the incidence and describe the clinical course of TTP due to ticlopidine therapy following stenting. Design Retrospective analysis of cohort of all patients undergoing coronary stenting at the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) study sites. Setting Sixty-three centers throughout the United States and Canada. Patients A total of 43 322 patients who underwent a percutaneous coronary intervention and received a coronary stent during a 1-year period from 1996 to 1997. Main Outcome Measures Cases of TTP following stenting during the 1-year period to determine the incidence of TTP due to ticlopidine therapy following coronary stenting. Additional cases were collected from these and other centers across North America to further describe the clinical presentation and course of TTP due to ticlopidine therapy following stenting. Results Nine cases of TTP following stenting were recognized at the 63 centers during the specified period, giving an incidence of 1 case per 4814 patients treated (0.02%; 95% confidence interval, 1 case per 2533 to 1 case per 10541 patients treated). Ten additional cases of TTP related to ticlopidine therapy following stenting were identified from other centers, were identified from the primary centers outside the predefined period, or involved a noncoronary stent. Four patients (21%) received ticlopidine far 2 weeks or fewer, 14 patients (74%) for 2 to 4 weeks, and 1 patient (5%) for 8 weeks. The mean time of ticlopidine treatment prior to TTP diagnosis was 22 days (range, 5-60 days). The overall mortality rate was 21% (4/19), with all 4 deaths occurring in patients not treated with plasmapheresis, whereas there were no deaths among the 13 patients who received plasmapheresis, Conclusion The findings of a TTP incidence of 0.02% in our cohort of ticlopidine-treated patients following coronary stenting suggests that TTP occurs much more commonly in this population than the estimated incidence of 0.0004% in the general population. The mortality rate for this rare complication exceeds 20%, Limiting ticlopidine therapy to 2 weeks after stenting does not prevent the development of TTP. Rapid diagnosis and treatment that includes plasmapheresis are critical for improved survival.	Wilford Hall USAF Med Ctr, Dept Cardiol, Lackland AFB, TX 78236 USA; Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA	United States Department of Defense; United States Air Force; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Steinhubl, SR (corresponding author), Wilford Hall USAF Med Ctr, Dept Cardiol, 2200 Bergquist Dr, Lackland AFB, TX 78236 USA.	steinhubl@whmc.af.mil		Topol, Eric/0000-0002-1478-4729				Ariyoshi K, 1997, AM J HEMATOL, V54, P175; Bennett CL, 1998, ANN INTERN MED, V128, P541, DOI 10.7326/0003-4819-128-7-199804010-00004; BERKOWITZ LR, 1979, JAMA-J AM MED ASSOC, V241, P1709, DOI 10.1001/jama.241.16.1709; Chang JC, 1996, AM J HEMATOL, V53, P11, DOI 10.1002/(SICI)1096-8652(199609)53:1<11::AID-AJH3>3.0.CO;2-8; ELLIE E, 1992, STROKE, V23, P922, DOI 10.1161/01.STR.23.6.922; FURFAN M, 1998, NEW ENGL J MED, V339, P1578; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; KOVACS MJ, 1993, ANN PHARMACOTHER, V27, P1060, DOI 10.1177/106002809302700910; Kupfer Y, 1997, NEW ENGL J MED, V337, P1245, DOI 10.1056/NEJM199710233371717; MOAKE JL, 1989, AM J MED, V87, pN9; PAGE Y, 1991, LANCET, V337, P774, DOI 10.1016/0140-6736(91)91383-6; Rice L, 1998, BLOOD, V92, p706A; RIDOLFI RL, 1981, MEDICINE, V60, P413, DOI 10.1097/00005792-198111000-00003; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; SCHROR K, 1993, PLATELETS, V4, P252, DOI 10.3109/09537109309013225; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; Topol EJ, 1998, CIRCULATION, V98, P1802, DOI 10.1161/01.CIR.98.17.1802; TOROK TJ, 1995, AM J HEMATOL, V50, P84, DOI 10.1002/ajh.2830500203; Tsai HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203	19	171	175	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					806	810		10.1001/jama.281.9.806	http://dx.doi.org/10.1001/jama.281.9.806			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10071001	Bronze			2022-12-28	WOS:000078804300030
J	Costigan, DJ				Costigan, DJ			Trying to let go	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Costigan, DJ (corresponding author), 10007 Kennerly Rd, St Louis, MO 63128 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	1999	130	5					446	446		10.7326/0003-4819-130-5-199903020-00006	http://dx.doi.org/10.7326/0003-4819-130-5-199903020-00006			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172AA	10068422				2022-12-28	WOS:000078898100011
J	Pesek, CA; Cooley, R; Narkiewicz, K; Dyken, M; Weintraub, NL; Somers, VK				Pesek, CA; Cooley, R; Narkiewicz, K; Dyken, M; Weintraub, NL; Somers, VK			Theophylline therapy for near-fatal Cheyne-Stokes respiration - A case report	ANNALS OF INTERNAL MEDICINE			English	Article							NEUROPATHY; APNEA	Background: Cheyne-Stokes respiration is characterized by periodic breathing that alternates with hypopnea or apnea. Objective: To describe the effect of theophylline on near-fatal Cheyne-Stokes respiration. Design: Case report. Setting: Tertiary referral center. Patient: A 48-year-old diabetic woman with a history of three cardiorespiratory arrests, a normal coronary arteriogram, normal left ventricular function, and severe Cheyne-Stokes respiration. Measurements: Oxygen saturation, intra-arterial blood pressure, central Venous pressure, chest wall movement, electrocardiography, electromyography, electroencephalography, electro-oculography, minute ventilation, arterial blood gases, and serum theophylline levels. Results: After intravenous administration of 1.2 mg of theophylline at 0.6 mg/kg per hour (serum level, 5.6 mu g/mL), both Cheyne-Stokes respiration and oxygen desaturation were markedly attenuated. After infusion of 2.4 mg of theophylline (serum level, 11.6 mu g/mL), Cheyne-Stokes respiration resolved completely. No change was seen with placebo. Cheyne-Stokes respiration did not recur during outpatient treatment with oral theophylline. Conclusion: Theophylline may be a rapid and effective therapy for life-threatening Cheyne-Stokes respiration.	Univ Iowa, Coll Med, Dept Internal Med, Div Cardiovasc, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Internal Med, Ctr Cardiovasc, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Neurol, Sleep Disorder Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Somers, VK (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, Div Cardiovasc, 200 Hawkins Dr, Iowa City, IA 52242 USA.			Dyken, Mark/0000-0002-6252-581X; Narkiewicz, Krzysztof/0000-0001-5949-5018; Weintraub, Neal/0000-0002-5138-3705	FOGARTY INTERNATIONAL CENTER [F05TW005200] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009264] Funding Source: NIH RePORTER; FIC NIH HHS [3F5 TW05200] Funding Source: Medline; NHLBI NIH HHS [HL9264-06, HL07121] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CALVERLEY PMA, 1982, CLIN SCI, V63, P17, DOI 10.1042/cs0630017; CHEYNE J, 1881, DUBLIN HOSP REP, V2, P216; DOWELL AR, 1971, ARCH INTERN MED, V127, P712, DOI 10.1001/archinte.127.4.712; DOWELL AR, 1965, NEW ENGL J MED, V273, P1447, DOI 10.1056/NEJM196512302732702; HOMMA I, 1981, CLIN SCI, V61, P599, DOI 10.1042/cs0610599; Javaheri S, 1996, NEW ENGL J MED, V335, P562, DOI 10.1056/NEJM199608223350805; Javaheri S, 1996, SLEEP, V19, pS229; JAVAHERI S, 1998, J APPL PHYS, V64, P1837; LAHIRI S, 1983, RESP PHYSIOL, V52, P281, DOI 10.1016/0034-5687(83)90086-5; MARSIS OAS, 1937, LANCET, V2, P437; RADULOVACKI M, 1985, SLEEP NEUROTRANSMITT, P221; RIGATTO H, 1972, PEDIATRICS, V50, P202; SNYDER SH, 1984, J PSYCHIAT RES, V18, P91, DOI 10.1016/0022-3956(84)90001-3; STOKES W, 1854, DIS HEART AORTA, P185	14	14	14	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	1999	130	5					427	430		10.7326/0003-4819-130-5-199903020-00014	http://dx.doi.org/10.7326/0003-4819-130-5-199903020-00014			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172AA	10068417				2022-12-28	WOS:000078898100006
J	Weingarten, S				Weingarten, S			Using practice guideline compendiums to provide better preventive care	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-PRACTICE GUIDELINES; HEALTH-CARE; SYSTEMATIC REVIEWS; CRITICAL-APPRAISAL; MEDICAL LITERATURE; USERS GUIDES; RECOMMENDATIONS; PERFORMANCE; MANAGEMENT; ADOPTION		Cedars Sinai Hlth Syst, Beverly Hills, CA 90211 USA	Cedars Sinai Medical Center	Weingarten, S (corresponding author), Cedars Sinai Hlth Syst, 200 N Robertson,Suite 205, Beverly Hills, CA 90211 USA.	weingarten@csmc.edu						*AM MED ASS, 1999, CLIN PRACT GUID DIR; Balas EA, 1996, J GEN INTERN MED, V11, P584, DOI 10.1007/BF02599025; Balas EA, 1997, JAMA-J AM MED ASSOC, V278, P152, DOI 10.1001/jama.278.2.152; BASINSKI ASH, 1995, CAN MED ASSOC J, V153, P1575; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BERWICK DM, 1994, JAMA-J AM MED ASSOC, V272, P797, DOI 10.1001/jama.272.10.797; Bradley LR, 1997, MED CARE, V35, P86, DOI 10.1097/00005650-199701000-00008; Buchan IE, 1997, INT J MED INFORM, V47, P39, DOI 10.1016/S1386-5056(97)00084-1; Canadian Task Force on the Periodic Health Examination, 1994, CAN GUID CLIN PREV H; CHALMERS I, 1994, BMJ-BRIT MED J, V309, P862, DOI 10.1136/bmj.309.6958.862; Cook DJ, 1997, ANN INTERN MED, V127, P210, DOI 10.7326/0003-4819-127-3-199708010-00006; Davis DA, 1997, CAN MED ASSOC J, V157, P408; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; Eagle KA, 1997, J AM COLL CARDIOL, V29, P1141; ELLRODT AG, 1995, ANN INTERN MED, V122, P277, DOI 10.7326/0003-4819-122-4-199502150-00007; Ellrodt G, 1997, JAMA-J AM MED ASSOC, V278, P1687, DOI 10.1001/jama.278.20.1687; Field MJ., 1992, GUIDELINES CLIN PRAC; Field MJ, 1990, CLIN PRACTICE GUIDEL; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Grol R, 1997, BRIT MED J, V315, P418, DOI 10.1136/bmj.315.7105.418; HAYNES RB, 1987, ARCH INTERN MED, V147, P1297, DOI 10.1001/archinte.147.7.1297; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; Hornberger J, 1997, ANN INTERN MED, V127, P697, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00053; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; KATTLOVE H, 1995, JAMA-J AM MED ASSOC, V273, P142, DOI 10.1001/jama.273.2.142; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; Lobach DF, 1997, AM J MED, V102, P89, DOI 10.1016/S0002-9343(96)00382-8; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; PATTERSON C, 1995, LANCET, V345, P1611, DOI 10.1016/S0140-6736(95)90119-1; SAFRAN C, 1995, LANCET, V346, P341, DOI 10.1016/S0140-6736(95)92226-1; Schneider EC, 1998, WESTERN J MED, V168, P311; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; Spoeri RK, 1997, ANN INTERN MED, V127, P726, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00058; *US DEP HHS, 1998, CLIN HDB PREV SERV P; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; WEINGARTEN S, 1995, J GEN INTERN MED, V10, P138, DOI 10.1007/BF02599668; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630; Zelingher J, 1996, M D COMPUT, V13, P204	41	28	29	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	1999	130	5					454	458		10.7326/0003-4819-130-5-199903020-00023	http://dx.doi.org/10.7326/0003-4819-130-5-199903020-00023			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172AA	10068430				2022-12-28	WOS:000078898100021
J	Jones, L				Jones, L			Genetically modified foods	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Campden & Chorleywood Food Res Assoc, Chipping Campden GL55 6LD, Glos, England		Jones, L (corresponding author), Campden & Chorleywood Food Res Assoc, Chipping Campden GL55 6LD, Glos, England.	Leighton@campden.co.uk						*ADV COMM NOV FOOD, 1991, GUID ASS NOV FOOD PR, V38; *ADV COMM NOV FOOD, 1994, REP US ANT RES MARK; ALLEN AH, 1996, FOOD PRODUCT DES MAY, P80; ANDERSON A, 1998, NEW SCI         1031; BACHEM CWB, 1994, BIO-TECHNOL, V12, P1101, DOI 10.1038/nbt1194-1101; Border P., 1998, GENETICALLY MODIFIED; Burke D, 1998, BRIT MED J, V316, P1845; BURKE D, 1997, 19 ANN COMPD DAY LEC; Coghlan A, 1998, NEW SCI, V159, P5; COGHLAN A, 1995, NEW SCI, P23; Henninghausen L, 1997, NAT BIOTECHNOL, V15, P945, DOI 10.1038/nbt1097-945; *I GROC DISTR, 1997, COMM LAB GUID GEN MO; JONES L, 1997, B CHIPPING CAMPDEN, V1; Jones RFC, 1996, EUR J PEDIATR SURG, V6, P5, DOI 10.1055/s-2008-1071027; KIERNAN V, 1996, NEW SCI         0921, P6; MACKENZIE D, 1998, NEW SCI         1017, P13; Rossiter L., 1997, BIOTECHNOLOGY FACTFI	17	18	20	47	147	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 27	1999	318	7183					581	584		10.1136/bmj.318.7183.581	http://dx.doi.org/10.1136/bmj.318.7183.581			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037638	Green Published			2022-12-28	WOS:000078966300033
J	Treasure, T				Treasure, T			There's nothing really new	BRITISH MEDICAL JOURNAL			English	Article									St George Hosp, London, England	St Georges University London	Treasure, T (corresponding author), St George Hosp, London, England.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					580	580		10.1136/bmj.318.7183.580	http://dx.doi.org/10.1136/bmj.318.7183.580			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037637	Green Published			2022-12-28	WOS:000078966300032
J	Zimmermann, S; Wixforth, A; Kotthaus, JP; Wegscheider, W; Bichler, M				Zimmermann, S; Wixforth, A; Kotthaus, JP; Wegscheider, W; Bichler, M			A semiconductor-based photonic memory cell	SCIENCE			English	Article							LIGHT	Photonic signals were efficiently stored in a semiconductor-based memory cell. The incident photons were converted to electron-hole pairs that were locally stored in a quantum well that was Laterally modulated by a field-effect tunable electrostatic superlattice. At Large superlattice potential amplitudes, these pairs were stored for a time that was at least five orders of magnitude Longer than their natural Lifetime. At an arbitrarily chosen time, they were released in a short and intense flash of incoherent light, which was triggered by flattening the superlattice amplitude.	Univ Munich, Sekt Phys, D-80539 Munich, Germany; Univ Munich, Ctr Nanosci, D-80539 Munich, Germany; Tech Univ Munich, Walter Schottky Inst, D-85748 Garching, Germany	University of Munich; University of Munich; Technical University of Munich	Wixforth, A (corresponding author), Univ Munich, Sekt Phys, Geschwister Scholl Pl 1, D-80539 Munich, Germany.		Kotthaus, Jorg P/A-7674-2010; Wegscheider, Werner H/D-1493-2010; Wixforth, Achim/H-5417-2011					DOHLER GH, 1981, PHYS REV LETT, V47, P864, DOI 10.1103/PhysRevLett.47.864; FELDMANN J, 1987, PHYS REV LETT, V59, P2337, DOI 10.1103/PhysRevLett.59.2337; Gmachl C, 1998, SCIENCE, V280, P1556, DOI 10.1126/science.280.5369.1556; MILLY PCD, 1985, ADV WATER RESOUR, V8, P32, DOI 10.1016/0309-1708(85)90078-8; Mukherjee B., 1997, OPTICAL COMMUNICATIO; Rocke C, 1997, PHYS REV LETT, V78, P4099, DOI 10.1103/PhysRevLett.78.4099; RUFENACHT M, 1997, APPL PHYS LETT, V70, P9; SCHMELLER A, 1994, APPL PHYS LETT, V64, P330, DOI 10.1063/1.111166; SCHMELLER A, 1995, PHYSICS SEMICONDUCTO, P1727; Welker M, 1997, APPL PHYS LETT, V71, P3561, DOI 10.1063/1.120391; Wiersma DS, 1997, NATURE, V390, P671, DOI 10.1038/37757; Zimmermann S, 1998, APPL PHYS LETT, V73, P154, DOI 10.1063/1.121740; Zimmermann S, 1997, PHYS REV B, V56, P13414, DOI 10.1103/PhysRevB.56.13414	13	76	77	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1292	1295		10.1126/science.283.5406.1292	http://dx.doi.org/10.1126/science.283.5406.1292			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037592	Green Submitted			2022-12-28	WOS:000078839900031
J	Schulman, KA; Berlin, JA; Harless, W; Kerner, JF; Sistrunk, S; Gersh, BJ; Dube, R; Taleghani, CK; Burke, JE; Williams, S; Eisenberg, JM; Escarce, JJ				Schulman, KA; Berlin, JA; Harless, W; Kerner, JF; Sistrunk, S; Gersh, BJ; Dube, R; Taleghani, CK; Burke, JE; Williams, S; Eisenberg, JM; Escarce, JJ			The effect of race and sex on physicians' recommendations for cardiac catheterization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; ACUTE MYOCARDIAL-INFARCTION; IN-HOSPITAL MORTALITY; OF-VETERANS-AFFAIRS; RACIAL-DIFFERENCES; REVASCULARIZATION PROCEDURES; CARDIOVASCULAR PROCEDURES; RHEUMATOID-ARTHRITIS; REFERRAL PATTERNS; CLINICAL JUDGMENT	Background Epidemiologic studies have reported differences in the use of cardiovascular procedures according to the race and sex of the patient. Whether the differences stem from differences in the recommendations of physicians remains uncertain. Methods We developed a computerized survey instrument to assess physicians' recommendations for managing chest pain. Actors portrayed patients with particular characteristics in scripted interviews about their symptoms. A total of 720 physicians at two national meetings of organizations of primary care physicians participated in the survey. Each physician viewed a recorded interview and was given other data about a hypothetical patient. He or she then made recommendations about that patient's care. We used multivariate logistic-regression analysis to assess the effects of the race and sex of the patients on treatment recommendations, while controlling for the physicians' assessment of the probability of coronary artery disease as well as for the age of the patient, the level of coronary risk, the type of chest pain, and the results of an exercise stress test. Results The physicians' mean (+/-SD) estimates of the probability of coronary artery disease were tower for women (probability, 64.1+/-19.3 percent, vs. 69.2+/-18.2 percent for men; P<0.001), younger patients (63.8+/-19.5 percent for patients who were 55 years old, vs. 69.5+/-17.9 percent for patients who were 70 years old; P<0.001), and patients with non-anginal pain (58.3+/-19.0 percent, vs. 64.4+/-18.3 percent for patients with possible angina and 77.1+/-14.0 percent for those with definite angina; P<0.001). Logistic-regression analysis indicated that women (odds ratio, 0.60; 95 percent confidence interval, 0.4 to 0.9; P=0.02) and blacks (odds ratio, 0.60; 95 percent confidence interval, 0.4 to 0.9; P=0.02) were less likely to be referred for cardiac catheterization than men and whites, respectively. Analysis of race-sex interactions showed that black women were significantly less likely to be referred for catheterization than white men (odds ratio, 0.4; 95 percent confidence interval, 0.2 to 0.7; P=0.004). Conclusions Our findings suggest that the race and sex of a patient independently influence how physicians manage chest pain. (N Engl J Med 1999;340:618-26.) (C)1999, Massachusetts Medical Society.	Georgetown Univ, Med Ctr, Clin Econ Res Unit, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Div Gen Internal Med, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Div Cardiol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA; Interact Drama, Bethesda, MD USA; RAND Hlth Program, Santa Monica, CA USA	Georgetown University; Georgetown University; Georgetown University; Georgetown University; Georgetown University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; RAND Corporation	Schulman, KA (corresponding author), Georgetown Univ, Med Ctr, Clin Econ Res Unit, 2233 Wisconsin Ave NW,Suite 440, Washington, DC 20007 USA.			Kerner, Jon/0000-0002-8792-3830	AHRQ HHS [HS07315] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Abbott RD, 1987, NIH PUBLICATION, V87-2703; ADES PA, 1992, AM J CARDIOL, V69, P1422, DOI 10.1016/0002-9149(92)90894-5; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BEERY TA, 1995, HEART LUNG, V24, P427, DOI 10.1016/S0147-9563(95)80020-4; BEGG MD, 1993, J AM STAT ASSOC, V88, P166, DOI 10.2307/2290710; BELL MR, 1993, JAMA-J AM MED ASSOC, V269, P2091, DOI 10.1001/jama.269.16.2091; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; BLUSTEIN J, 1995, AM J PUBLIC HEALTH, V85, P345, DOI 10.2105/AJPH.85.3.345; Carlisle DM, 1997, AM J PUBLIC HEALTH, V87, P263, DOI 10.2105/AJPH.87.2.263; DEVINE PG, 1989, J PERS SOC PSYCHOL, V56, P5, DOI 10.1037/0022-3514.56.5.680; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; DIAMOND GA, 1983, J AM COLL CARDIOL, V1, P474; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; Ferguson JA, 1997, J AM COLL CARDIOL, V30, P1707, DOI 10.1016/S0735-1097(97)00365-3; GILES WH, 1995, ARCH INTERN MED, V155, P318, DOI 10.1001/archinte.155.3.318; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; JONES TV, 1990, J CLIN EPIDEMIOL, V43, P805, DOI 10.1016/0895-4356(90)90241-G; KIMMEL SE, 1995, J AM COLL CARDIOL, V26, P931, DOI 10.1016/0735-1097(95)00294-4; KIRWAN JR, 1983, ANN RHEUM DIS, V42, P644, DOI 10.1136/ard.42.6.644; KIRWAN JR, 1983, J RHEUMATOL, V10, P901; Laouri M, 1997, J AM COLL CARDIOL, V29, P891, DOI 10.1016/S0735-1097(96)00434-2; LOOP FD, 1983, J AM COLL CARDIOL, V1, P383, DOI 10.1016/S0735-1097(83)80064-3; MARK DB, 1994, NEW ENGL J MED, V330, P1101, DOI 10.1056/NEJM199404213301601; MAYNARD C, 1991, AM J CARDIOL, V67, P18, DOI 10.1016/0002-9149(91)90092-Y; MCNUTT RA, 1992, MED DECIS MAKING, V12, P342; Newby LK, 1996, J AM COLL CARDIOL, V27, P1646; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; PRYOR DB, 1983, AM J MED, V75, P771, DOI 10.1016/0002-9343(83)90406-0; SCHULMAN KA, 1992, MED DECIS MAKING, V12, P109, DOI 10.1177/0272989X9201200203; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; WIGTON RS, 1990, ACAD MED, V65, pS5, DOI 10.1097/00001888-199009000-00017	40	1362	1367	0	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1999	340	8					618	626		10.1056/NEJM199902253400806	http://dx.doi.org/10.1056/NEJM199902253400806			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	169NP	10029647				2022-12-28	WOS:000078755700006
J	Makadon, HJ				Makadon, HJ			An asymptomatic 41-year-old man with HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							IMMUNODEFICIENCY-VIRUS INFECTION; CONTROLLED TRIAL; ANTIRETROVIRAL THERAPY; CUBIC MILLIMETER; CELL COUNTS; ZIDOVUDINE; AIDS; PREVENTION; INDINAVIR; SURVIVAL		Beth Israel Deaconess Med Ctr, Div Gen Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Makadon, HJ (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med, 330 Brookline Ave,LY318, Boston, MA 02215 USA.							ALBOUKER J, 1993, LANCET, V341, P889; *AM MED ASS, 1996, PHYS GUID HIV PREV; BARTLETT J, 1998, 1998 MED MANAGEMENT; Bryan CS., 1997, OSLER INSPIRATIONS G; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P861; CONDRA JH, 1997, SCI MED, V4, P7; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; DEAN M, 1996, NATURE, V382, P722; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FRANCE D, 1998, NY TIMES D      1006, P10; GREEN J, 1996, NY TIMES MAGAZI 0915, P38; GREEN J, 1996, NY TIMES MAGAZI 0915, P84; GREEN J, 1996, NY TIMES MAGAZI 0915, P55; GREEN J, 1996, NY TIMES MAGAZI 0915, P46; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Haidet P., 1998, JGIM, V13, P105; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; MAKADON HJ, 1995, ANN INTERN MED, V123, P715, DOI 10.7326/0003-4819-123-9-199511010-00010; MANNING DT, 1989, J FAM PRACTICE, V29, P173; *NIH, 1998, MMWR-MORBID MORTAL W, V47, P4; Odets W, 1995, SHADOW EPIDEMIC BEIN; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Rabkin J G, 1997, GMHC Treat Issues, V11, P6; Rofes Eric, 1996, REVIVING TRIBE REGEN; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; STASZEWKI S, 1998, 12 INT C AIDS JUN 28; Stein MD, 1998, ARCH INTERN MED, V158, P253, DOI 10.1001/archinte.158.3.253; STRYKER J, 1995, JAMA-J AM MED ASSOC, V273, P1143, DOI 10.1001/jama.273.14.1143; *US DEP HHS, 1998, MMWR-MORBID MORTAL W, V47, P43; VOLBERDING PA, 1989, NEW ENGL J MED, V321, P947; 1989, DAEDALUS S, V118; 1997, MED LETT DRUGS THER, V39, P111	37	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1999	281	8					739	744		10.1001/jama.281.8.739	http://dx.doi.org/10.1001/jama.281.8.739			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BD	10052445				2022-12-28	WOS:000078669900034
J	Bardhan, KD; Muller-Lissner, S; Bigard, MA; Porro, GB; Ponce, J; Hosie, J; Scott, M; Weir, DG; Gillon, KRW; Peacock, RA; Fulton, C				Bardhan, KD; Muller-Lissner, S; Bigard, MA; Porro, GB; Ponce, J; Hosie, J; Scott, M; Weir, DG; Gillon, KRW; Peacock, RA; Fulton, C		European Study Grp	Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine	BRITISH MEDICAL JOURNAL			English	Article							LONG-TERM TREATMENT; LANSOPRAZOLE 15 MG; MAINTENANCE TREATMENT; PROGNOSTIC FACTORS; ESOPHAGITIS; TRIAL; PREVENTION; RELAPSE	Objective To assess intermittent treatment over 12 months in patients wit symptomatic gastro-oesophageal reflux disease. Design Randomised, multicentre, double blind, controlled study. Patients with heartburn and normal endoscopy results or mild erosive changes received omeprazole 10 mg or 20 mg daily or ranitidine 150 mg twice daily for 2 weeks. Patients remaining symptomatic had omeprazole 10 mg or ranitidine dose doubled for another 2 weeks while omeprazole 20 mg was continued for 2 weeks. patients who were symptomatic or mildly symptomatic were followed up for 12 months. Recurrences of moderate or severe heartburn during follow up were treated with the dose which was successful for initial symptom control. Setting Hospitals and primary care practices between 1994 and 1996. Subjects 677 patients with gastro-oesophageal reflux disease. Main outcome measures Total time off active treatment, time to failure of intermittent treatment, and outcomes ranked from best to worst. Results 704 patients were randomised, 677 were eligible for analyses; 318 reached the end of the study with intermittent treatment without recourse to maintenance antisecretory drugs. The median number of days off active treatment during follow up was 142 for the entire study (281 for the 526 patients who reached a treatment related end point). Thus, about half the patients did not require treatment for at least 6 months, and this was similar in all three treatment groups. According to outcome, 378 (72%) patients were in the best outcome ranks (no relapse or one (or more) relapse but in remission until 12 months); 630 (93%) had three or fewer relapses in the intermittent treatment phase. Omeprazole 20 mg provided faster relief of heartburn. The results were similar in patients with erosive and non-erosive disease. Conclusions Intermittent treatment is effective in managing symptoms of heartburn in half of patients with uncomplicated gastro-oesophageal reflux disease. It is simple and applicable in general practice, where most patients are seen.	Rotherham Gen Hosp NHS Trust, Rotherham S60 2UD, S Yorkshire, England; Pk Klin Weissensee, D-13086 Berlin, Germany; Hosp Brabois, F-54500 Vandoeuvre Nancy, France; Osped L Sacco, I-20157 Milan, Italy; CS La Fe Valencia, Serv Digest, Valencia 46009, Spain; Great Western Med Ctr, Glasgow G13 2SW, Lanark, Scotland; Med Ctr, Glasgow G14 0XT, Lanark, Scotland; St James Hosp, Dublin 8, Ireland; Astra Clin Res Unit, Edinburgh EH7 4HG, Midlothian, Scotland; Astra Hassle AB, S-43183 Molndal, Sweden	CHU de Nancy; University of Milan; Luigi Sacco Hospital; Trinity College Dublin; AstraZeneca	Bardhan, KD (corresponding author), Rotherham Gen Hosp NHS Trust, Rotherham S60 2UD, S Yorkshire, England.	kdbardhan@d-morton.demon.co.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altman DG, 1996, BRIT MED J, V313, P570; Armstrong D, 1996, GASTROENTEROLOGY, V111, P85, DOI 10.1053/gast.1996.v111.pm8698230; Baldi F, 1996, GASTROENTEROLOGY, V110, pA55; Bardhan KD, 1998, GUT, V43, P458, DOI 10.1136/gut.43.4.458; Bardhan KD, 1997, GUT, V41, pA203; BATE CM, 1995, GUT, V36, P492, DOI 10.1136/gut.36.4.492; Carlsson R, 1997, ALIMENT PHARM THER, V11, P473, DOI 10.1046/j.1365-2036.1997.00167.x; DENT J, 1994, GUT, V35, P590, DOI 10.1136/gut.35.5.590; Gough AL, 1996, ALIMENT PHARM THERAP, V10, P529, DOI 10.1046/j.1365-2036.1996.14156000.x; HALLERBACK B, 1994, GASTROENTEROLOGY, V107, P1305, DOI 10.1016/0016-5085(94)90531-2; Harris RA, 1997, AM J MED, V102, P78, DOI 10.1016/S0002-9343(96)00301-4; HATLEBAKK JG, 1995, GASTROENTEROLOGY, V108, pA111, DOI 10.1016/0016-5085(95)23106-4; Hungin APS, 1997, GASTROENTEROLOGY, V112, pA19; Lambert R, 1997, ALIMENT PHARM THER, V11, P651, DOI 10.1046/j.1365-2036.1997.00181.x; LAURSEN LS, 1995, SCAND J GASTROENTERO, V30, P839, DOI 10.3109/00365529509101589; LIND T, 1996, GASTROENTEROLOGY, V110, pA178; POYNARD T, 1995, GASTROENTEROLOGY, V108, pA195, DOI 10.1016/0016-5085(95)23441-1; Robinson M, 1996, ANN INTERN MED, V124, P859, DOI 10.7326/0003-4819-124-10-199605150-00001; SANDMARK S, 1988, SCAND J GASTROENTERO, V23, P625, DOI 10.3109/00365528809093923; SONTAG SJ, 1993, ALIMENT PHARM THERAP, V7, P293; TYTGAT GNJ, 1995, ALIMENT PHARM THERAP, V9, P271; VIGNERI S, 1995, NEW ENGL J MED, V333, P1106, DOI 10.1056/NEJM199510263331703; ZEITOUN P, 1989, HEPATO-GASTROENTEROL, V36, P279	23	105	107	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1999	318	7182					502	+		10.1136/bmj.318.7182.502	http://dx.doi.org/10.1136/bmj.318.7182.502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QT	10024259	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000078818100027
J	Okada, Y; Hirokawa, N				Okada, Y; Hirokawa, N			A processive single-headed motor: Kinesin superfamily protein KIF1A	SCIENCE			English	Article							STIMULATED ATP HYDROLYSIS; MICROTUBULE INTERACTION; MOLECULES; MECHANISM; MOVEMENT; DOMAINS; NECK; MICROSCOPY; KINETICS; MYOSIN	A single kinesin molecule can move "processively" along a microtubule for more than 1 micrometer before detaching from it. The prevailing explanation far this processive movement is the "walking model," which envisions that each of two motor domains (heads) of the kinesin molecule binds coordinately to the microtubule. This implies that each kinesin molecule must have two heads to "walk" and that a single-headed kinesin could not move processively. Here, a motor-domain construct of KIF1A, a single-headed kinesin superfamily protein, was shown to move processively along the microtubule for more than 1 micrometer. The movement along the microtubules was stochastic and fitted a biased Brownian-movement model.	Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Tokyo 1130033, Japan	University of Tokyo	Hirokawa, N (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Hongo, Tokyo 1130033, Japan.		Okada, Yasushi/N-5067-2015	Okada, Yasushi/0000-0003-2601-3689				Amos LA, 1997, CURR OPIN CELL BIOL, V9, P4, DOI 10.1016/S0955-0674(97)80145-7; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; Chandrasekhar S, 1943, REV MOD PHYS, V15, P0001, DOI 10.1103/RevModPhys.15.1; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Inoue Y, 1997, P NATL ACAD SCI USA, V94, P7275, DOI 10.1073/pnas.94.14.7275; Jiang W, 1997, J BIOL CHEM, V272, P7626, DOI 10.1074/jbc.272.12.7626; Jiang W, 1997, J BIOL CHEM, V272, P5616, DOI 10.1074/jbc.272.9.5616; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; NAKATA T, 1993, BIOPHYS J, V65, P2504, DOI 10.1016/S0006-3495(93)81304-3; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SVOBODA K, 1994, P NATL ACAD SCI USA, V91, P11782, DOI 10.1073/pnas.91.25.11782; Tokunaga M, 1997, BIOCHEM BIOPH RES CO, V235, P47, DOI 10.1006/bbrc.1997.6732; Tripet B, 1997, J BIOL CHEM, V272, P8946; Tucker C, 1997, J BIOL CHEM, V272, P9481; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; VALE RD, 1989, CELL, V59, P915, DOI 10.1016/0092-8674(89)90614-4; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	34	349	355	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1152	1157		10.1126/science.283.5405.1152	http://dx.doi.org/10.1126/science.283.5405.1152			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024239				2022-12-28	WOS:000078738400048
J	Sieradzki, K; Roberts, RB; Haber, SW; Tomasz, A				Sieradzki, K; Roberts, RB; Haber, SW; Tomasz, A			The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITALS		Rockefeller Univ, Microbiol Lab, New York, NY 10021 USA; Cornell Univ, Med Ctr, New York Hosp, New York, NY 10021 USA; United Hosp, Med Ctr, Port Chester, NY USA	Rockefeller University; Cornell University; NewYork-Presbyterian Hospital	Tomasz, A (corresponding author), Rockefeller Univ, Microbiol Lab, 1230 York Ave, New York, NY 10021 USA.	tomasz@rocvax.rockefeller.edu		Tomasz, Alexander/0000-0003-1520-1983				[Anonymous], 1997, MMWR-MORBID MORTAL W, V46, P813; deLencastre H, 1996, MICROB DRUG RESIST, V2, P343, DOI 10.1089/mdr.1996.2.343; DELENCASTRE H, 1994, ANTIMICROB AGENTS CH, V38, P2590, DOI 10.1128/AAC.38.11.2590; Hiramatsu K, 1997, LANCET, V350, P1670, DOI 10.1016/S0140-6736(97)07324-8; NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195; Roberts RB, 1998, J INFECT DIS, V178, P164, DOI 10.1086/515610; Sieradzki K, 1997, J ANTIMICROB CHEMOTH, V39, P47, DOI 10.1093/jac/39.suppl_1.47; Sieradzki K, 1998, ANTIMICROB AGENTS CH, V42, P100, DOI 10.1128/AAC.42.1.100; Sieradzki K, 1997, J BACTERIOL, V179, P2557, DOI 10.1128/jb.179.8.2557-2566.1997; Tenover FC, 1998, J CLIN MICROBIOL, V36, P1020, DOI 10.1128/JCM.36.4.1020-1027.1998; Tenover FC, 1998, J CLIN MICROBIOL, V36, P2167, DOI 10.1128/JCM.36.7.2167-2167.1998; TOMASZ A, 1964, J CELL BIOL, V22, P453, DOI 10.1083/jcb.22.2.453; 1997, MMWR MORB MORTAL WKL, V46, P851; 1997, MMWR MORB MORTAL WKL, V46, P765	14	477	502	1	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1999	340	7					517	523		10.1056/NEJM199902183400704	http://dx.doi.org/10.1056/NEJM199902183400704			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168FD	10021472				2022-12-28	WOS:000078680100004
J	Wood, ER; Dudchenko, PA; Eichenbaum, H				Wood, ER; Dudchenko, PA; Eichenbaum, H			The global record of memory in hippocampal neuronal activity	NATURE			English	Article							UNIT-ACTIVITY; SAMPLE PERFORMANCE; RECOGNITION MEMORY; DELAYED-NONMATCH; RATS; TASK; RESPONSES	In humans the hippocampal region of the brain is crucial for declarative(1) or episodic(2) memory for a broad range of materials. In contrast, there has been controversy over whether the hippocampus mediates a similarly general memory function in other species, or whether it is dedicated to spatial memory processing(3-6). Evidence for the spatial view is derived principally from the observations of 'place cells'-hippocampal neurons that fire whenever the animal is in a particular location in its environment(7,8), or when it perceives a specific stimulus or per forms a specific behaviour in a particular place(3,4). We trained rats to perform the same recognition memory task in several distinct locations in a rich spatial environment and found that the activity of many hippocampal neurons was related consistently to perceptual, behavioural or cognitive events, regardless of the location where these events occurred. These results indicate that nonspatial events are fundamental elements of hippocampal representation, and support the view that, across species, the hippocampus has a broad role in information processing associated with memory.	Boston Univ, Dept Psychol, Lab Cognit Neurobiol, Boston, MA 02215 USA	Boston University	Eichenbaum, H (corresponding author), Boston Univ, Dept Psychol, Lab Cognit Neurobiol, 64 Cummington St, Boston, MA 02215 USA.	hbe@bu.edu						BERGER TW, 1983, J NEUROPHYSIOL, V50, P1197, DOI 10.1152/jn.1983.50.5.1197; Bunsey M, 1996, NATURE, V379, P255, DOI 10.1038/379255a0; Cohen N. J., 1993, MEMORY AMNESIA HIPPO; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; Deadwyler SA, 1996, J NEUROSCI, V16, P354; EICHENBAUM H, 1987, J NEUROSCI, V7, P716; Gothard KM, 1996, J NEUROSCI, V16, P8027; Gothard KM, 1996, J NEUROSCI, V16, P823; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; Morris RGM, 1997, PHILOS T ROY SOC B, V352, P1489, DOI 10.1098/rstb.1997.0136; MULLER RU, 1987, J NEUROSCI, V7, P1935; Nadel L., 1991, Hippocampus, V1, P221, DOI 10.1002/hipo.450010302; NADEL L., 1991, HIPPOCAMPUS, V1, P230; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKeefe J, 1996, NATURE, V381, P425, DOI 10.1038/381425a0; OTTO T, 1992, HIPPOCAMPUS, V2, P323, DOI 10.1002/hipo.450020310; RANCK JB, 1973, EXP NEUROL, V41, P462, DOI 10.1016/0014-4886(73)90290-2; ROLLS ET, 1993, EXP BRAIN RES, V93, P299; SAKURAI Y, 1994, J NEUROSCI, V14, P2606; Tanila H, 1997, J NEUROSCI, V17, P5155; VarghaKhadem F, 1997, SCIENCE, V277, P376, DOI 10.1126/science.277.5324.376; Weiss C, 1996, HIPPOCAMPUS, V6, P192, DOI 10.1002/(SICI)1098-1063(1996)6:2<192::AID-HIPO9>3.0.CO;2-R; WIBLE CG, 1986, BRAIN RES, V399, P97, DOI 10.1016/0006-8993(86)90604-9; WIENER SI, 1989, J NEUROSCI, V9, P2737; WILSON FAW, 1990, BEHAV BRAIN RES, V40, P7, DOI 10.1016/0166-4328(90)90038-G; YOUNG BJ, 1994, J NEUROSCI, V14, P6553	27	490	494	2	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 18	1999	397	6720					613	616		10.1038/17605	http://dx.doi.org/10.1038/17605			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GE	10050854				2022-12-28	WOS:000078738500049
J	Rich-Edwards, JW; Colditz, GA; Stampfer, MJ; Willett, WC; Gillman, MW; Hennekens, CH; Speizer, FE; Manson, JE				Rich-Edwards, JW; Colditz, GA; Stampfer, MJ; Willett, WC; Gillman, MW; Hennekens, CH; Speizer, FE; Manson, JE			Birthweight and the risk for type 2 diabetes mellitus in adult women	ANNALS OF INTERNAL MEDICINE			English	Article						birth weight; diabetes mellitus, non-insulin-dependent; infant, low birth weight; body weight; diabetes, gestational	IMPAIRED GLUCOSE-TOLERANCE; LOW-PROTEIN-DIET; BIRTH-WEIGHT; FETAL GROWTH; CARDIOVASCULAR-DISEASE; THRIFTY PHENOTYPE; HEART-DISEASE; HYPERTENSION; LIFE; HISTORY	Background: Previous reports have suggested an association between birthweight and type 2 diabetes mellitus. Objective: To investigate the association between birthweight and type 2 diabetes in a large cohort of adult women, taking into account potential explanatory factors in childhood and adult life. Design: Cohort study. Birthweight was ascertained at the end of follow-up. Setting: The Nurses' Health Study, a cohort of 121701 U.S. women born from 1921 to 1946 who have been followed since 1976. Participants: 69526 women in the Nurses' Health Study who were free of diabetes at baseline and reported their own birthweight on the 1992 questionnaire. Measurement: 2123 cases of confirmed type 2 diabetes diagnosed from 1976 to 1992. Results: Low birthweight was associated with increased risk for type 2 diabetes. Age-adjusted relative risks suggested a reverse J-shape association between birthweight and risk for type 2 diabetes. However, after adjustment for adult body mass index and maternal history of diabetes, an inverse association across the entire range of birthweight became apparent; compared with the reference group, relative risks by ascending birthweight category were 1.83 (95% CI, 1.55 to 2.16) for birthweight less than 5.0 Ib, 1.76 (CI, 1.49 to 2.07) for birthweight 5.0 to 5.5 Ib, 1.23 (CI, 1.11 to 1.37) for birthweight 5.6 to 7.0 Ib, 0.95 (Ct, 0.82 to 1.10) for birthweight 8.6 to 10.0 Ib, and 0.83 (CI, 0.63 to 1.07) for birthweight of more than 10 lb (P for trend < 0.001). Adjustment for ethnicity, childhood socioeconomic status, and adult lifestyle factors did not substantially alter this association. The association between birthweight and risk for type 2 diabetes was strongest among women whose mothers had no history of diabetes. Conclusions: Birthweight is inversely associated with risk for type 2 diabetes during adulthood. Examination of prenatal nutrition and other potential in utero determinants of both birthweight and risk for type 2 diabetes may yield new means to prevent type 2 diabetes.			Rich-Edwards, JW (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356] Funding Source: Medline; NIDDK NIH HHS [DK36798] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALCOLADO JC, 1991, BRIT MED J, V302, P1178, DOI 10.1136/bmj.302.6786.1178; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Curhan GC, 1996, CIRCULATION, V94, P1310, DOI 10.1161/01.CIR.94.6.1310; Curhan GC, 1996, CIRCULATION, V94, P3246, DOI 10.1161/01.CIR.94.12.3246; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DAHRI S, 1991, DIABETES, V40, P115, DOI 10.2337/diab.40.2.S115; DAHRI S, 1995, P NUTR SOC, V54, P345, DOI 10.1079/PNS19950003; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; FALL CHD, 1995, BRIT MED J, V310, P17, DOI 10.1136/bmj.310.6971.17; Forrester TE, 1996, BRIT MED J, V312, P156; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HARRIS M, 1979, DIABETES, V28, P1039; Kleinbaum D, 1988, APPL REGRESSION ANAL; LANGFORD K, 1994, EUR J CLIN INVEST, V24, P851, DOI 10.1111/j.1365-2362.1994.tb02030.x; LAW CM, 1995, DIABETIC MED, V12, P24, DOI 10.1111/j.1464-5491.1995.tb02057.x; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MCCANCE DR, 1994, BRIT MED J, V308, P942, DOI 10.1136/bmj.308.6934.942; Michels KB, 1996, LANCET, V348, P1542, DOI 10.1016/S0140-6736(96)03102-9; MITCHELL BD, 1993, DIABETES CARE, V16, P1262, DOI 10.2337/diacare.16.9.1262; NEEL JV, 1962, AM J HUM GENET, V14, P353; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; PETTITT DJ, 1988, DIABETES, V37, P622, DOI 10.2337/diabetes.37.5.622; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; ROBINSON S, 1992, DIABETOLOGIA, V35, P444, DOI 10.1007/BF02342441; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; STAMPFER MJ, 1988, AM J EPIDEMIOL, V128, P549, DOI 10.1093/oxfordjournals.aje.a115002; Troy LM, 1996, INT J EPIDEMIOL, V25, P122, DOI 10.1093/ije/25.1.122; VANASSCHE FA, 1975, CARBOHYD METABOL, P68; YAJNIK CS, 1995, DIABETIC MED, V12, P330, DOI 10.1111/j.1464-5491.1995.tb00487.x	33	346	359	0	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	1				278	+		10.7326/0003-4819-130-4_Part_1-199902160-00005	http://dx.doi.org/10.7326/0003-4819-130-4_Part_1-199902160-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166PY	10068385				2022-12-28	WOS:000078587200004
J	Dimitrakopoulos, AN; Kordossis, T; Hatzakis, A; Moutsopoulos, HM				Dimitrakopoulos, AN; Kordossis, T; Hatzakis, A; Moutsopoulos, HM			Mixed cryoglobulinemia in HIV-1 infection: The role of HIV-1	ANNALS OF INTERNAL MEDICINE			English	Article							HEPATITIS-C VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; RED FINGERS SYNDROME; LYMPHOMA; RNA	Background: Cryoglobulins are associated with chronic infections. Objective: To investigate the prevalence of mixed cryoglobulinemia in patients with HIV-1 infection, the clinical spectrum of cryoglobulinemia in these patients, and the possible role of HIV-1 in cryoglobulin formation. Design: Prospective cohort study. Setting: Laiko Hospital, Athens, Greece. Patients: 89 patients with HIV-1 infection. Measurements: Serum and cryoglobulins were evaluated for antibodies to HIV and hepatitis C virus (HCV), HIV-1, and HCV viral load. Results: Mixed cryoglobulins were detected in 24 patients with HIV-1 infection (27% [95% CI, 18% to 36%]). The HIV-1 viral load was higher in cryoglobulin-positive patients (median, 38.25 x 10(3) copies/mL [25th, 75th percentiles: 13.8 x 10(3) copies/mL, 78.55 x 10(3) copies/mL]) than in cryoglobulin-negative patients (median, 5.3 x 10(3) copies/mL [25th, 75th percentiles: 0.7 x 10(3) copies/mL, 27.2 x 10(3) copies/mL]) (P = 0.001). Antibodies to HIV were detected in all cryoprecipitates, and HIV-1 RNA sequences were identified in 22 of the 23 cryoprecipitates examined. Nine cryoglobulin-positive patients (38% [CI, 19% to 54%]) had clinical manifestations compatible with cryoglobulinemia. Conclusions: Mixed cryoglobulinemia is common in patients with HIV-1 infection.	Natl & Kapodistrian Univ, Sch Med, Dept Pathophysiol, Athens 11527, Greece; Natl & Kapodistrian Univ, Sch Med, Dept Hyg & Epidemiol, Athens 11527, Greece	Athens Medical School; National & Kapodistrian University of Athens; Athens Medical School; National & Kapodistrian University of Athens	Moutsopoulos, HM (corresponding author), Natl & Kapodistrian Univ, Sch Med, Dept Pathophysiol, 75 Mikras Asias St, Athens 11527, Greece.							Battegay M, 1996, LANCET, V348, P763, DOI 10.1016/S0140-6736(05)65682-6; BROUET JC, 1974, AM J MED, V57, P775, DOI 10.1016/0002-9343(74)90852-3; DAgati V, 1997, J AM SOC NEPHROL, V8, P138; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; ELLAURIE M, 1990, AIDS RES HUM RETROV, V6, P1437, DOI 10.1089/aid.1990.6.1437; GOREVIC PD, 1980, AM J MED, V69, P287, DOI 10.1016/0002-9343(80)90390-3; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LELOSTEC Z, 1994, AIDS, V8, P1351, DOI 10.1097/00002030-199409000-00026; MATSUDA J, 1994, CLIN INFECT DIS, V18, P832, DOI 10.1093/clinids/18.5.832; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MELTZER M, 1966, AM J MED, V40, P837, DOI 10.1016/0002-9343(66)90200-2; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; PAPADOPOULOS NM, 1985, CLIN IMMUNOL IMMUNOP, V35, P43, DOI 10.1016/0090-1229(85)90076-5; Pechere M, 1996, LANCET, V348, P196, DOI 10.1016/S0140-6736(05)66142-9; Straus DJ, 1997, MED CLIN N AM, V81, P495, DOI 10.1016/S0025-7125(05)70528-9; STRICKER RB, 1992, NEUROLOGY, V42, P2103, DOI 10.1212/WNL.42.11.2103; TAILLAN B, 1993, CLIN EXP RHEUMATOL, V11, P350; Tzioufas AG, 1996, ARTHRITIS RHEUM, V39, P767, DOI 10.1002/art.1780390508; Zignego AL, 1997, ARCH VIROL, V142, P545, DOI 10.1007/s007050050100	19	47	48	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 2	1999	130	3					226	230		10.7326/0003-4819-130-3-199902020-00027	http://dx.doi.org/10.7326/0003-4819-130-3-199902020-00027			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	162PD	10049201				2022-12-28	WOS:000078355000007
J	Campbell, SM; Wernick, R				Campbell, SM; Wernick, R			Update in rheumatology	ANNALS OF INTERNAL MEDICINE			English	Bibliography									Vet Affairs Med Ctr, Portland, OR 97202 USA; Prov Portland Med Ctr, Portland, OR 97213 USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University	Campbell, SM (corresponding author), Vet Affairs Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97202 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	1999	130	2					135	142		10.7326/0003-4819-130-2-199901190-00008	http://dx.doi.org/10.7326/0003-4819-130-2-199901190-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158KG	10068360				2022-12-28	WOS:000078114200007
J	Gahrton, G				Gahrton, G			Treatment of multiple myeloma	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION		Huddinge Hosp, Dept Med, SE-14186 Huddinge, Sweden; Huddinge Hosp, Dept Haematol, SE-14186 Huddinge, Sweden; Karolinska Inst, SE-14186 Huddinge, Sweden	Karolinska Institutet	Gahrton, G (corresponding author), Huddinge Hosp, Dept Med, SE-14186 Huddinge, Sweden.							ALEXANIAN R, 1969, J AMER MED ASSOC, V208, P1680, DOI 10.1001/jama.208.9.1680; Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892; Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204; Bjorkstrand B, 1996, BLOOD, V88, P4711, DOI 10.1182/blood.V88.12.4711.bloodjournal88124711; Bjorkstrand B, 1998, BONE MARROW TRANSPL, V21, pS208; Dilber MS, 1996, BLOOD, V88, P2192, DOI 10.1182/blood.V88.6.2192.bloodjournal8862192; GAHRTON G, 1991, NEW ENGL J MED, V325, P1267, DOI 10.1056/NEJM199110313251802; Goldman JM, 1998, BONE MARROW TRANSPL, V21, P1, DOI 10.1038/sj.bmt.1701089; LUDWIG H, 1995, ANN ONCOL, V6, P467, DOI 10.1093/oxfordjournals.annonc.a059217; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; SAMSON D, 1996, MULTIPLE MYELOMA, P108; Treon S P, 1998, Curr Opin Hematol, V5, P42; Treon SP, 1998, BLOOD, V92, P1749, DOI 10.1182/blood.V92.5.1749.417k38_1749_1757; Turner JG, 1998, HUM GENE THER, V9, P1121, DOI 10.1089/hum.1998.9.8-1121	14	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 9	1999	353	9147					85	86		10.1016/S0140-6736(05)76150-X	http://dx.doi.org/10.1016/S0140-6736(05)76150-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023889				2022-12-28	WOS:000078087200005
J	Hateboer, N; Dijk, MAV; Bogdanova, N; Coto, E; Saggar-Malik, AK; San Millan, JL; Torra, R; Breuning, M; Ravine, D				Hateboer, N; Dijk, MAV; Bogdanova, N; Coto, E; Saggar-Malik, AK; San Millan, JL; Torra, R; Breuning, M; Ravine, D		European PDK1-PDK2 Study Grp	Comparison of phenotypes of polycystic kidney disease types 1 and 2	LANCET			English	Article							RENAL-FAILURE; CLINICAL-FEATURES; HETEROGENEITY; PROGRESSION; PROGNOSIS; FAMILIES; PKD2; INSUFFICIENCY; ENCODES; PROTEIN	Background Although autosomal dominant polycystic kidney disease type 2 (PKD2) is known to have a milder clinical phenotype than PKD1, neither disorder has been compared with an unaffected control population in terms of survival. We report the findings;of a multicentre survey that aimed to define more precisely;Phe survival and clinical expression of PKD1 and PKD2. Methods Clinical data from 333 people with PKD1 (31 families) were compared with data from 291 people with PKD2(31 families) and 398 geographically matched controls. Survival analysis was used to compare age-at-event data. Differences in the prevalence of complications were assessed by logistic regression. Findings Median age at death or onset of end-stage renal disease, was 53.0 years (95% CI 51.2-54.8) in individuals with PKD1, 69.1 years (66.9-71.3) in those with PKD2, and 78.0 years (73.8-82.2) in controls. Women with PKD2 had a significantly longer median survival than men (71.0 [67.4-74.8] vs 67.3 [64.9-69.7] years), but no sex influence was apparent in PKD1. Age at presentation with kidney failure was later in PKD2 than in PKD1 (median age 74.0 [67.2-80.8] vs 54.3 [52.7-55.9] years). PKD2 patients were less likely to have hypertension (odds ratio 0.25 [95% CI 0.15-0.42]), a history of urinary-tract infection (0.50 [0.31-0.83]), or haematuria (0.59 [0.35-0.98]). Interpretation Although PKD2 is clinically milder than PKD1, it has a deleterious impact on overall life expectancy and cannot be regarded as a benign disorder.	Univ Wales Hosp, Inst Med Genet, Cardiff CF4 4XN, S Glam, Wales; Acad Hosp Leiden, Leiden, Netherlands; Univ Munster, Inst Human Genet, D-4400 Munster, Germany; Univ Oviedo, Hosp Cent Asturias, Inst Reine Sofia Invest Nefrol, E-33080 Oviedo, Spain; Univ London St Georges Hosp, Sch Med, Med Genet Unit, London SW17 0RE, England; Hosp Ramon & Cajal, Unidad Genet Mol, E-28034 Madrid, Spain; Hosp Clin Barcelona, Serv Nefrol, Barcelona, Spain; Leiden Univ, Afdeling Anthropogenet, Leiden, Netherlands	Cardiff University; Leiden University; Leiden University Medical Center (LUMC); University of Munster; Central University Hospital Asturias; University of Oviedo; St Georges University London; Hospital Universitario Ramon y Cajal; University of Barcelona; Hospital Clinic de Barcelona; Leiden University; Leiden University - Excl LUMC	Hateboer, N (corresponding author), Univ Wales Hosp, Inst Med Genet, Hlth Pk, Cardiff CF4 4XN, S Glam, Wales.	hateboer@cardiff.ac.uk	San-Millán, José L./F-9944-2015; Torra, Roser/A-9983-2008; Breuning, Martijn H/E-3429-2010; Ravine, David/A-6797-2008	Torra, Roser/0000-0001-8714-2332; 				BEAR JC, 1992, AM J MED GENET, V43, P548, DOI 10.1002/ajmg.1320430309; BRAZY PC, 1989, KIDNEY INT, V35, P670, DOI 10.1038/ki.1989.37; COTO E, 1995, J MED GENET, V32, P442, DOI 10.1136/jmg.32.6.442; DALGAARD O Z, 1957, Acta Med Scand Suppl, V328, P1; DAOUST MC, 1995, GENOMICS, V25, P733, DOI 10.1016/0888-7543(95)80020-M; FLORIJN KW, 1995, AM J KIDNEY DIS, V25, P370, DOI 10.1016/0272-6386(95)90096-9; GABOW PA, 1992, AM J KIDNEY DIS, V20, P140, DOI 10.1016/S0272-6386(12)80541-5; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; GABOW PA, 1992, KIDNEY INT, V41, P1311, DOI 10.1038/ki.1992.195; Gonzalo A, 1996, NEPHRON, V72, P225, DOI 10.1159/000188846; GRETZ N, 1989, AM J KIDNEY DIS, V14, P178, DOI 10.1016/S0272-6386(89)80068-X; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; KANNEL WB, 1976, STROKE, V7, P327, DOI 10.1161/01.STR.7.4.327; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; NAROD S, 1991, CLIN GENET, V39, P125; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; RAVINE D, 1994, LANCET, V343, P824, DOI 10.1016/S0140-6736(94)92026-5; RAVINE D, 1992, LANCET, V340, P1330, DOI 10.1016/0140-6736(92)92503-8; Sandhu S, 1997, KIDNEY INT, V51, P1535, DOI 10.1038/ki.1997.211; SANMILLAN JL, 1995, AM J HUM GENET, V56, P248; Simon P, 1996, NEPHROLOGIE, V17, P123; STEWART JH, 1994, AM J KIDNEY DIS, V24, P181, DOI 10.1016/S0272-6386(12)80179-X; Torra R, 1996, J AM SOC NEPHROL, V7, P2142; VANDERMEY AGL, 1989, LANCET, V2, P1291; WARD CJ, 1994, CELL, V77, P881; ZEIER M, 1994, NEPHROL DIAL TRANSPL, V9, P1734; ZERRES K, 1993, J MED GENET, V30, P583, DOI 10.1136/jmg.30.7.583	29	409	433	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 9	1999	353	9147					103	107		10.1016/S0140-6736(98)03495-3	http://dx.doi.org/10.1016/S0140-6736(98)03495-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023895				2022-12-28	WOS:000078087200011
J	Kandela, P				Kandela, P			Male midwives	LANCET			English	Editorial Material											Kandela, P (corresponding author), 29 Greenlands Rd, Staines TW18 4LR, Middx, England.							CARLISLE A, 1827, LANCEY          0505, P146; 1827, LANCET          0512, P177	2	0	0	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 2	1999	353	9146					79	79		10.1016/S0140-6736(05)74822-4	http://dx.doi.org/10.1016/S0140-6736(05)74822-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023987				2022-12-28	WOS:000077934800069
J	Beecham, L				Beecham, L			Helping to learn about medicine	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					675	675						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066228				2022-12-28	WOS:000079089200076
J	Beecham, L				Beecham, L			New owner takes over BMA's taxation service	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					675	675						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066228				2022-12-28	WOS:000079089200078
J	Keane, FM; Munn, SE; du Vivier, AWP; Taylor, NF; Higgins, EM				Keane, FM; Munn, SE; du Vivier, AWP; Taylor, NF; Higgins, EM			Analysis of Chinese herbal creams prescribed for dermatological conditions	BRITISH MEDICAL JOURNAL			English	Article							ECZEMA	Objective To determine whether Chinese herbal creams used for the treatment of dermatological conditions contain steroids. Design 11 herbal creams obtained from patients attending general and paediatric dermatology outpatient clinics were analysed with high resolution gas chromatography and mass spectrometry Setting Departments of dermatology and clinical biochemistry Main outcome measure Presence of steroid. Results Eight creams contained dexamethasone at a mean concentration of 456 mu g/g (range 64 to 1500 mu g/g). All were applied to areas of sensitive skin such as face and flexures. Conclusion Greater regulation needs to be imposed on Chinese herbalists to prevent illegal and inappropriate prescribing of potent steroids.	Univ London Kings Coll Hosp, Dept Dermatol, London SE5 9RS, England; Univ London Kings Coll Hosp, Dept Clin Biochem, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Keane, FM (corresponding author), Univ London Kings Coll Hosp, Dept Dermatol, London SE5 9RS, England.							ALLEN BR, 1990, LANCET, V336, P177, DOI 10.1016/0140-6736(90)91696-8; HUGHES JR, 1994, BRIT J DERMATOL, V130, P261, DOI 10.1111/j.1365-2133.1994.tb02916.x; KANE JA, 1995, GUT, V36, P146, DOI 10.1136/gut.36.1.146; MACGREGOR FB, 1989, BRIT MED J, V299, P1156, DOI 10.1136/bmj.299.6708.1156; ODRISCOLL J, 1992, BRIT J DERMATOL, V127, P543, DOI 10.1111/j.1365-2133.1992.tb14859.x; SHEEHAN MP, 1992, BRIT J DERMATOL, V126, P179, DOI 10.1111/j.1365-2133.1992.tb07817.x; SHEEHAN MP, 1992, LANCET, V340, P13, DOI 10.1016/0140-6736(92)92424-E	7	77	79	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					563	564		10.1136/bmj.318.7183.563	http://dx.doi.org/10.1136/bmj.318.7183.563			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037629	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000078966300024
J	Beecham, L				Beecham, L			GMC advises doctors on seeking consent	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					553	553		10.1136/bmj.318.7183.553a	http://dx.doi.org/10.1136/bmj.318.7183.553a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037614				2022-12-28	WOS:000078966300007
